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Synopsis
Purpose of Project: Gut dysfunction in children in resource-poor environments is well
documented. The precipitant of this dysfunction is unknown. However, infections, nonspecific
inflammation, malabsorption, and leakiness of mucosa are frequently incriminated as processes
that underlie this dysfunction. Major consequences of this dysfunction have been postulated, the
most critical of which is poor growth, especially stunting. The study of gut dysfunction in children
would have as its ultimate goal the prevention of growth consequences. In this project, we have
collated literature published between 2000 and 2010, with the purpose of guiding near-term
research into the causes and pathophysiology of enteric dysfunction. In particular, we have
attempted to identify biomarkers with which to detect this dysfunction.
Rationale for seeking biomarkers: Theoretically, tissue from the small bowel, the organ of
greatest interest, could shed light on the underlying pathophysiology. However, analyzing this
tissue poses challenges. These challenges include the practicalities of gaining access to this
organ, incomplete confidence regarding sampling strategies to pursue, risk of sampling error,
and the yet-to-be-determined value of the information that would be obtained. Thus, the more
readily obtained and potentially more informative biomarkers found in stool or blood could
feasibly advance the field.
Methods: A systematic literature review was performed by trained research analysts, two
physicians, and two epidemiologists. Materials were collated in a master, highly inclusive
database of publications relevant to environmental enteric dysfunction (EED) in children in
resource-poor settings. This process was undertaken for two reasons. First, because search
terms sensitive and specific for “enteropathy” and “enteric dysfunction” are not well indexed in
literature databases (including PubMed), we had to create a resource with which to find data
related to biomarkers. Second, the project was built to address multiple and different inquiries
xi

related to the topic. Development of an internal library was the most efficient preparation for
multiple interrogations, including those seeking to identify publications relevant to the following
systematic review question, which is a main focus of this book:
What biomarkers or diagnostic tests have been used to identify, or have been shown to
be associated with, mucosal dysfunction of the small intestine or host inflammation in
children less than five years of age from developing-country settings?
Findings: 67,903 unique references were obtained from PubMed, Embase, Global Health and
World Health Organization (WHO) Regional Libraries (1980-2010). 9,675 of these publications
met EED Library inclusion criteria and 374 between 2000 and 2010 were potentially relevant to
the systematic review question. Of these, 77 met the review inclusion criteria.
Each relevant publication was thoroughly and systematically reviewed and summarized in
evidence table format. Biomarkers were categorized as being relevant to one of eight processes
that could underlie, be associated with, or reflect enteric function/dysfunction in children: (1)
absorption; (2) porosity/permeability; (3) digestion; (4) intestinal inflammation and/or intestinal
immune activation; (5) systemic inflammation and/or systemic immune activation; (6) microbial
drivers; (7) nonspecific intestinal injury, and (8) non-small intestinal organ function. A metaanalysis of pooled data from these publications was not possible because of the heterogeneity
of study populations and methods, non-standardized information portrayal, scant attempts to
correlate biomarkers to intestinal pathology (and where this was attempted, correlation was
lacking), small population sizes, and limited relation of biomarkers with outcomes of interest,
i.e., stunting. However, the data do strongly suggest the presence of broad categories of
intestinal dysfunction, and imply a high prevalence of poorly functioning guts, in children in
resource-poor environments. It is quite likely that a panel of biomarkers reflecting multiple
physiologic derangements might predict intestinal injury.

xii

Conclusions: Our novel search and EED construction methodology effectively identified a
diffusely defined and poorly indexed (in the literature)—but nevertheless important—public
health problem. Our EED Library format permits efficient information retrieval for multiple EEDrelated inquiries and the methodology can be applied to other health issues that face similar
definition and search/retrieval issues.
Using this comprehensive data collation and extraction system, we found no evidence of a
globally applicable, simple, single-purpose biomarker that reliably correlates with intestinal
dysfunction in children or to growth faltering mediated by such a lesion. The studies that are
available were often not performed with this goal in mind. However, there is a large body of
evidence that enteric dysfunction in children is highly prevalent in resource-poor settings, and
that this dysfunction could be an important, and potentially remediable, cause of stunting.
Therefore, we urge that future research on biomarkers in human populations be pursued. We
also urge that future work adheres to the following principles:
1. Assess function-related candidate biomarkers.
2. Relate the biomarker data to consequential outcomes.
3. Rigorously describe the study design and methodology underlying the data produced.
4. Provide robust data repositories. Employ best practices publication guidelines, such as
those endorsed by the Consolidated Standards of Reporting Trials (CONSORT) system
including the Standards for Reporting of Diagnostic Accuracy (STARD) Initiative.
5. Consider indices of enteric dysfunction, incorporating “stacking” multiple biomarkers
representing diverse pathophysiologic processes, potentially also including nonlaboratory test derived clinical characteristics.
6. Explore invasive, field-adaptable, host assessments (e.g., saliva, transcutaneous), even
if technology needs to be developed or adapted.
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Chapter 1. Environmental Enteric
Dysfunction (EED) Background
1.1 EED History and Overview
For many years it has been known that the digestive system, and in particular the small
bowel, of people who reside in poor regions do not function well. The first English language
description of this disorder was written by William Hillary in the mid-1700s. His case series of
malabsorption in European expatriates in Barbados [2] (reviewed by Booth [3]) also reported
glossitis (most likely caused by concomitant folate deficiency) and diarrhea. Over a century
later, Patrick Manson re-described this disorder, again focusing on expatriates in the Dutch
West Indies, and used the term tropical “Sprouw,” from a Dutch word describing what was
almost certainly celiac disease (gluten-sensitive enteropathy) in Europe [4]. The onset of this
malady in previously healthy Europeans residing in the tropics, and reports of epidemic
malabsorption in Allied troops in Southern Asia during the Second World War [5, 6], gave rise to
the concept of gut lesions caused by “environmental” factors. Therefore, this enteropathy was
modeled as an acquired, likely infectious, problem [7]. This acquired/environmental concept was
reinforced by secular variances in the incidence of tropical malabsorption syndromes,
alternately referred to as tropical enteropathy (TE), in areas previously endemic for this disorder
[8, 9].
The early descriptions of tropical enteropathy did not define the true extent of the
problem. Most notably, these initial reports focused on adults. The realization that children were
affected by what was probably the same disorder was delayed. Second, while various causes of
this intestinal dysfunction have been postulated, the definitive cause or causes remain(s)
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elusive. Indeed, interest and investigation into the problem itself waxes and wanes with
discoveries of new enteric pathogens. This has implications for our systematic review of the
problem. For example, giardiasis would be a lead candidate as a cause of tropical enteropathy
in view of the chronicity of the illnesses it can cause, and the ability of Giardia to injure the
mucosa of the small bowel. However, Giardia lamblia was not widely accepted as a human
pathogen until the 1970s. Hence, prior investigations would have discounted this agent as being
a cause of enteropathy. Third, there have been regional differences in the reported incidence of
tropical enteropathy. Early communications suggested that individuals in Africa were seemingly
less affected than were individuals in other areas, and that many cases of adult malabsorption
were attributed to biliary and pancreatic disorders [10]. However, more recent reports suggest
that Africans are, indeed, susceptible to tropical enteropathy [11-15]. Also, diagnosis in early
studies was made by varying methodologies, including those based on response to empiric
treatments (antibiotics, antiparasitics, micronutrients) and repatriation to countries in which
tropical enteropathy is not endemic; it is often unclear from which intervention(s) responders
benefitted. Finally, enteric dysfunction in resource-poor settings has often eluded, and continues
to elude, useful definition. Instead, we are forced to rely on histopathologic findings from the
small bowel, and these findings are variably specific. These abnormalities include villous
blunting, increased crypt:villous ratios, and presence of intraepithelial lymphocytes (IEL).
However, the reliance on biopsies skews disease detection and data acquisition towards adults
who more frequently undergo invasive testing [16]. These definitional issues continue to hinder
advancement in the field, and to impose challenges in identifying useful biomarkers.
The nomenclature used to describe the entity of interest has shifted in response to
ongoing efforts to better understand and describe the disease. As early as 1984, the term
“environmental enteropathy” was used synonymously with “tropical enteropathy” [17], although
not commonly until 2004 [18]. Most recently, "environmental enteric dysfunction" (EED) has
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been suggested as nomenclature for the entity of interest [16]. We adopt this term in this book
as it provides specificity with regards to the origin of intestinal dysfunction (i.e., environmental
opposed to genetic or other factors) and focuses on functional alterations of consequence [19].
The term EED refers to functional shortcomings of the gut with and/or without histological
correlates, and obviates the need to rely on the histology inferred by the term “enteropathy" 1.
We acknowledge that EED might differ in disease burden, etiology, and effects in children and
adults in different regions. However, independent of case definition or underlying criteria,
suboptimal intestinal function in children in resource-poor environments is common, and it is
important to determine its true incidence, spectrum of host injury, mechanisms of
pathophysiology, diagnostic ascertainment, clinical consequences, and mitigation via
interventions whether prevention or treatment. Therefore, it is now time to measure the extent of
this dysfunction and its consequences. To do so, we need to consider the technology that will
be required to investigate the problem.

1.2 An Old Problem Requiring New Knowledge
There is a compelling need for research on enteric dysfunction in children in resourcepoor environments, but scientific advancement in the field has been, in fact, quite modest. The
Web of Science (formerly ISI Web of Knowledge) demonstrates a paucity of publications related
to EED (Figure 1).

1

Strictly speaking, the “-pathy” suffix is from the Greek word for disease or suffering, but in many
connotations refers to histopathologically defined disorders.

3

Figure 1. List of plausibly relevant literature from 1980 to 2010.
A search of Thomson Reuters Web of Science™ ALL Databases Collection 1 on 27 August
2014, spanning 1980-2010 and using any of the following search terms: "tropical enteropathy",
"environmental enteropathy", "tropical sprue", "environmental enteric dysfunction", "tropical
malabsorption syndrome", or "tropical malabsorption." Topic was used for the query, with the
phrase enclosed in quotation marks. Search filters for language or document type were not
applied.
25
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The lack of progress on EED contrasts with recent dramatic advances in mortality
reduction caused by acute enteric infections. The annual number of deaths attributed to
diarrhea among children under five years of age fell from an estimated 4.6 million in 1980 [20] to
about 700,000 in 2011 [21]. Most of the mortality reduction in the latter two decades of the past
century was likely a result of refinements in, and/or increased use of, oral rehydration

1

Searches were conducted using the Thomson Reuters Web of Science™ ALL Databases Collection and
reflect only the data as indexed by the database. Publication data may be incomplete. The Thomson
Reuters Web of Science™ ALL Databases Collection consisted of Inspec® (1898-present), MEDLINE®
(1950-present), SciELO Citation Index (1997-present), Science Citation Index Expanded (1970-present),
Social Sciences Citation Index (1970-present) and Art & Humanities Citation Index (1975-present).
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2010

therapy(ORT) [22, 23]. Globally, current ORT coverage rates are moderate and have stabilized
over the past decade [24]; more recent reductions in diarrhea-related mortality likely stem from
general improvements in socioeconomic development, nutrition, and water/sanitation
infrastructure [25]. Coverage rates for access to improved water sources, particularly in urban
settings, are on track to meet international development goals [26]. However, access to
adequate quantities of water, water of sufficient quality for drinking, and improved sanitation
facilities are limited and only slowly improving [26-28]; the same lack of progress applies to
hand hygiene prevalences [29]. Improved water sources, sanitation, and hygiene can avert 58%
of childhood diarrhea-related deaths in low- and middle-income countries [27]. A 34% reduction
in risk of diarrheal disease has been demonstrated with interventions to improve water quality,
and a 28% reduction in diarrheal disease has been observed with improvements in sanitation,
particularly sewer interventions [30]. Promotion of hand hygiene with soap is estimated to
contribute to a 23% reduction in diarrheal disease risk [29].
Treatment with zinc can reduce the duration and severity of acute episodes of diarrhea
and reduce the risk of future episodes [31-33]. Since 2004, zinc has been a recommended
therapeutic for children suffering from diarrheal episodes in resource-limited settings. Safe and
effective rotavirus vaccines are now available and recommended for widespread use [34-36].
Coverage rates for these relatively “new” interventions are low, but their implementation is
accelerating. Major advances might also be on the horizon in the form of effective cholera,
typhoid, Shigella, and enterotoxigenic Escherichia coli (ETEC) vaccines [37-39].
Despite reductions in mortality risk associated with acute diarrhea, enteric infections
remain prevalent. Over 1.7 billion episodes of diarrhea occur among children under five years of
age each year [21] and incidence rates have not changed markedly in the past several decades
[40]. Repeated episodes of infection in the developing gut are probably deleterious [41].
Expanded implementation of prevention and treatment measures could further diminish diarrhea
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mortality and could additionally reduce morbidity and disease burden. However, these advances
against acute enteric infections now raise the relative importance of chronic intestinal
dysfunction as a hindrance to optimal childhood health [42].
However, this problem is much more complex: emphasis on acute enteric infection fails
to address the consequences of recurrent, persistent, and chronic diarrhea, as well as the longterm consequences of diarrhea on stunting and on disability-adjusted life years. Also, a new
variety of agents, in particular enteroaggregative Escherichia coli, and Cryptosporidia spp.,
which each require special technologies to identify, have recently and repeatedly been
associated with persistent diarrhea and stunting. Additionally, several epidemiologic studies
suggested that the frequency of episodes of acute diarrhea impairs long-term health in
populations outside Brazil [18, 43, 44]. In view of the successes of oral rehydration and the
rotavirus vaccine, it was reasonable to assume that the problem of enteric infections in children
would be solved. Moreover, simple infrastructural management strategies, particularly the
provision of appropriate village waste containment facilities [45] were determined to be
important protective measures against chronic diarrhea. We now recognize that enteric
inflammation is a determinant of stunting and long-term gastrointestinal dysfunction, even
independent of the presence of the more easily enumerable episodes of diarrhea [45].
The renewed interest in EED is aptly timed for many different reasons. As noted above,
we are in an era in which we know how to treat and prevent acute diarrhea. Therefore, chronic
intestinal injury and inflammation now pose larger proportional threats to population and
childhood well-being. Also, translational research has created new proteomic, metabolomic, and
genomic technology with which to study human pathophysiology. The value of re-examining and
expanding diagnostic capabilities is two-fold. First, such efforts will shed light on incidence rates
within communities and assess factors associated with differences in disease rates in various
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populations. Second, such tools might accurately identify children at risk of developing EED,
who have EED (at its various clinical stages), and as a way to monitor treatment for EED.
We recognize that other priorities compete with EED for resources in the field of child
health. First, there is the imperative to continue to reduce mortality from acute diarrhea. Indeed,
the Child Health and Nutrition Research Initiative of the Global Forum for Health Research
methodology de-emphasized research on chronic enteric conditions in favor of implementing
available strategies to continue to reduce acute childhood diarrhea mortality [46, 47]. That
analysis was weighted towards interventions that could be implemented by 2015 to meet
Millennium Development Goals. EED intervention studies require longer investigation periods
than do disorders with known etiologies and outcomes that are apparent in the short term. For
example, the pathophysiology of EED is not well understood, technologies sufficient to assess
the process in individual hosts or within populations are not broadly available, and interventions
to mitigate consequences of clinical importance are not yet established. Work to understand and
control EED should be viewed as complementing, rather than competing with, continued efforts
to reduce the burden of acute enteric illnesses. It was with this concept in mind that we
embarked on our review of the EED literature, with a goal of providing a platform on which
future EED efforts, especially those related to biomarkers and diagnostics, could be built.

1.3 Pathophysiologic Processes and Consequences
of EED
The gut is an organ that is central to health and development. Healthy intestinal
functioning optimizes childhood physical and intellectual well-being and development, and
enables children to achieve adult stature. Several lines of evidence indicate that suboptimal
functioning of the human gut, manifesting as EED, leads to poor health for children in resourcepoor settings. First, investigators in Fortaleza, Brazil have demonstrated that episodes of
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recurrent or persistent diarrhea are major determinants of childhood growth impairment [48],
and subsequent reduced growth and intellectual capacity at school entrance [49, 50]. These
investigations were seminal because they provided a new metric for calculating the burden of
enteric-related disease other than counting deaths or numbers of episodes of loose stools. This
is also important because stunting can be associated with subclinical intestinal inflammation [15,
51].
Multiple aspects of intestinal pathophysiology contribute to poor health, growth and
development (Figure 2) and physiologic derangements in these processes are deleterious
(Figure 3). First, injured intestinal mucosa absorbs nutrients poorly [52] and represents one
potential EED-mediated growth-failure pathway [15, 53]. Chronic intestinal inflammation is very
common in the tropics [54] and can damage intestinal epithelial integrity and disrupt tight
junctions, resulting in intestinal permeability defects. Multiple studies demonstrate increased
intestinal porosity in children in the tropics [15, 44, 55-58]. Increased intestinal permeability can,
in turn, lead to translocation or the nonphysiologic uptake of intestinal luminal contents,
including microbes and microbial products, into the bloodstream [59]. Microbial translocation
can, in turn, mediate systemic inflammation as can chronic intestinal inflammation. Stunting is
often associated with subclinical intestinal inflammation [15, 51]. Systemic inflammation can
penalize growth by interrupting bone growth potential, release of growth hormone binding
proteins at the level of the liver [60], suppressing appetite, and increasing metabolic
requirements [61]. Such mechanistic attribution remains hypothetical at this juncture.

8

Figure 2. The vicious cycle of intestinal dysfunction, infectious disease susceptibility,
poor growth, and development.
NCDs= non-communicable diseases. WaSH=water, sanitation and hygiene. EED=
environmental enteric dysfunction.

Adapted from Denno DM [62], Guerrant RL, et al. [63] and Mata L [64].
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Figure 3. EED-related pathophysiological processes result in stunting and/or growth
shortfall.
Growth can be affected by disturbances in a variety of intestinal and other physiologic
processes resulting from EED. GH=growth hormone.

The first several years of childhood represent a critical period that influences life-long
nutritional and health status and human potential [65]. Stunting is an especially important cause
of adverse consequences in resource-poor regions, and stunting that occurs in the first two
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years of life is particularly consequential [48, 66-72]. Childhood stunting is associated with
cognitive impairment, poor school performance, and reduced adult capacity [73-76]. Clinical
complications of childhood stunting also include predisposition to obesity and diabetes and
other chronic diseases in later adulthood—a double burden increasingly afflicting populations in
resource-limited settings [65]. Moreover, undernutrition contributes to over one-third of
childhood deaths [77].
Poor nutrition among girls can have a particularly profound effect on future reproductive
and fetal/neonatal health. For example, maternal stunting can be a risk factor for obstructed
labor, stillbirth, and neonatal mortality [78]. Furthermore, maternal anthropometry also
influences future generational growth, morbidity and mortality [79].
Dysfunctional guts can hinder the efficacy of oral vaccinations and absorption of
medications. This may pose a threat to oral enteric vaccine strategies and absorption of
medications for chronic infections such as tuberculosis and HIV/AIDS [80]. Indeed, failure of oral
polio vaccine to induce protective immunity in children at risk is a major challenge to disease
eradication [81].
Increasing dietary nutrient provision does not necessarily or completely resolve growth
failure in resource-poor settings [82]. Gut function is an important antecedent to healthy human
growth and development. Strategies are needed to ascertain gut inflammation, increased
permeability, and decreased absorption. Strategies are also needed to measure and address
the persistence, progression, and resolution of these types of dysfunction. Chronic intestinal
inflammation and inability to absorb nutrients may be the most actionable manifestations of
enteric dysfunction in children. Intervention studies to mitigate EED will require appropriate,
robust and reproducible methods to identify children with intestinal dysfunction, ideally before
penalties to growth and development accrue.
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A coordinated effort to control EED in children in resource-poor regions could markedly
reduce childhood undernutrition, poor development, and mortality. In the past decade, we have
seen an explosion in our understanding and abilities to diagnose an analogous disorder, i.e.,
celiac disease, which has histopathologic similarities to EED. We have learned the genetic and
environmental, i.e., dietary, risk factors for celiac disease, and also determined that this disorder
is not confined to individuals of northern European ancestry, as previously thought.
Furthermore, the diagnosis and management of celiac disease, including partial mitigation of
growth consequences, has advanced, at least in high-income countries. Similar data are
emerging regarding the more challenging disorders of inflammatory bowel disease, i.e., Crohn’s
disease and ulcerative colitis [83]. We can apply lessons learned from these chronic intestinal
inflammatory states to the study of EED.
There is reason to be optimistic about renewed research and development relevant to
EED. Emerging technologies can interrogate human processes and microbial populations to an
extent not predicted even a few years ago. These technologies can shed new light on EED, an
entity that has traditionally required tissue for diagnosis.

1.4 The Role of Biomarkers and Diagnostics in EED
Much as pioneering studies on mechanisms of intestinal secretion in cholera [84] formed
the basis for giving oral rehydration solution to children with diarrhea worldwide, it is critical to
identify the mechanisms underlying intestinal dysfunction in children in resource-poor areas.
Beyond searches for specific etiologic pathogens or nutritional deficiencies, biomarkers and
diagnostics will need to be broadly considered in favor of pursuing a better understanding of
EED as a disorder. “Discovery” efforts will be needed to generate sufficient information to move
forward.
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Broad-based research is urgently needed to invigorate the field. For example, multidimensional assessments of individuals and populations will be necessary to measure intestinal
dysfunction, and identify factors that precipitate and perpetuate EED. We believe that the utility
of biomarkers in EED needs to extend beyond the concept of diagnostics. Diagnostics, as most
commonly used to assess the human gut, usually seek specific pathogens, or belong to a
limited panel of tests of gut inflammation and/or absorptive function. It is likely that rigorous and
systematic analyses of EED require a better understanding of the microbial population in the gut
and detailed assessments of intestinal inflammation, absorption, permeability, translocation, and
subsequent systemic inflammatory cascade as well as the precipitants and consequences of
EED, such as nutrient deficiencies. As such, we sought to systematically search, review and
portray the existing diagnostics/biomarkers literature related to EED as a basis of knowledge to
leverage further investigation.

1.5 Scientific Basis for this Review
In view of increasing understanding of the role of gut health and function in promoting
overall health and development in childhood and beyond, it is logical to catalyze efforts to
accurately identify and predict children with EED and to refine the sensitivity and specificity of
promising biomarkers. While a single marker with optimal operating characteristics would be a
welcome tool, it is unlikely that a single test can be used worldwide to detect and predict EED
with the necessary precision. A panel of tests, perhaps in conjunction with clinical
characteristics, may be necessary, akin to the Jones criteria used to diagnose acute rheumatic
fever.
Currently, there is no consensus on the best way to measure intestinal function either
invasively or noninvasively. Additionally, there is no evidence that the entities of interest, i.e.,
intestinal inflammation and/or poor function associated with stunting, are caused by a single
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etiology or that a common pathogenesis underlies all cases. Also, we do not know if intestinal
inflammation precedes growth failure, if the disorder might actually begin in utero, or if any
therapies can reliably and uniformly restore linear growth. Nonetheless, there is now consensus
that stunted children are not only at risk for unhealthy consequences during childhood, they are
more likely than their non-stunted peers to develop chronic disorders that extend into adulthood,
including obesity, type II diabetes, and hypertension [85, 86]. Clearly there is a need to reassess
whether existing markers of intestinal dysfunction can better define the disorder of interest, and
anticipate its development in children. We therefore attempted to first identify the current state of
the knowledge, then delineate gaps in that knowledge, and, finally, sought to determine which
tests might have the most utility.
Table 1. Spectrum of etiologies, outcomes, and biomarkers/diagnostics in EED.
These lists of causes, results, and techniques to identify EED were used to define manuscripts
of potential interest in the list generated by the search terms.
Potential drivers (causes) of EED

Pathogens, food insecurity, immune activation, specific
nutrient deficiencies, environmental hygiene

Potential consequences of EED

Recurrent diarrhea, persistent diarrhea, intestinal
inflammation with and without diarrhea, stunting

Possible biomarkers/diagnostics of
EED

Biopsies, sugar clearance tests (measuring absorption
and permeability of the gut), breath hydrogen tests,
nutrient challenge tests, fecal analyses for leakage or
non-absorption, serologic analyses for inflammation or
evidence of gut permeability
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Chapter 2. Methodology: Building the EED
Library and Undertaking a Systematic
Review of EED Biomarkers/Diagnostics
2.1 EED: A Broad Field, Many Unanswered
Questions
First, in collaboration with experts in the field, we developed a set of questions that
would be of primary importance to better understand and control EED. The scope was broad
and included environmental, nutritional, and other factors that might underlie EED, as well as
information related to EED pathogenesis. We framed these questions within six “topic areas”
(Table 2). We used these questions to guide our systematic literature search, seeking to identify
all references that could contribute to answering them. Prior to searching the literature for
relevant EED references, a search of the Cochrane Database of Systematic Reviews found no
Cochrane Reviews related to EED.
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Table 2. Topic areas and questions.
The left column lists inclusive but circumscribed areas of relevance to EED, and the right
column presents questions relevant to each topic area. These formed the basis for the literature
search terms (Appendix 1).
Topic area

Questions

I. Epidemiology
of EED

What is the burden of disease represented by EED?
What is the prevalence of EED (including as measured by tests of gut
dysfunction or inflammation)?
1. What proportion of stunted/malnourished children have EED (as

measured by gut dysfunction/inflammation or infection with specific
microbes or identifiable microbial populations) or have a past history
of EED?
2. Other
II. EED,
malnutrition as
an outcome.
Associations,
risk factors,
protective
factors, causes
of acquisition of
EED,
malnutrition

What exposures/variables are associated with EED (including as measured
by tests of gut dysfunction or inflammation) or malnutrition/stunting? What
are the effect sizes (e.g., relative risk (RR), odd ratio (OR)) of the
associations? What are the causal pathways/mechanisms? Exclude
exposures related to food security/caloric density. Include:
3. Is infection with specific enteric pathogens (e.g., subsets of

4.
5.
6.

7.

8.
9.

10.
11.

12.
13.

diarrheagenic E. coli, Cryptosporidium, Giardia) associated with EED
or malnutrition/stunting?
Are recurrent acute enteric infections/recurrent episodes of diarrhea
associated with EED or malnutrition/stunting?
Are persistent or chronic enteric infections/persistent diarrheal
episodes associated with EED or malnutrition/stunting?
Is exposure to/ingestion of fecal microbial populations (e.g., in
settings with lack of access to improved sanitation) associated with
EED or malnutrition/stunting?
Are other diseases/conditions including infections not predominantly
enteric in origin/manifestation (e.g., HIV, tuberculosis, malaria)
associated with EED or malnutrition/stunting?
Are environmental (e.g., water, sanitation, hygiene) factors
associated with EED or malnutrition/stunting?
Are social (e.g., socioeconomic status (SES), household
characteristics) or geographic (e.g., rural/urban) factors associated
with EED or malnutrition/stunting?
Are genetic factors associated with EED or malnutrition/stunting?
Are specific foods or nutrients (e.g., micronutrients (MNs), lack of
specific foods or nutrients, or specific feeding practices associated
with EED or malnutrition/stunting?
Are maternal factors (e.g., anemia in pregnancy, maternal short
stature) associated with EED or malnutrition/stunting?
Is low birth weight (LBW) or small for gestational age (SGA)
associated with EED or malnutrition/stunting?
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Topic area

Questions
14. Are microbially contaminated foods/lack of food safety or
contaminated bottles, feeding utensils, etc. associated with EED or
malnutrition/stunting?
15. Is malnutrition a risk factor for EED?
16. Other

III. EED as an
exposure.

What outcomes are associated with EED (including as measured by gut
dysfunction or inflammation or infection with specific microbes or identifiable
microbial populations)?

EED
association
with, risk factor
for, a cause of
subsequent
other child
health
problems.

17. Is EED a risk factor for malnutrition/stunting?
18. Is EED a risk factor for MN deficiencies—either multiple deficiencies

19.
20.
21.
22.
23.

IV.
Assessment,
biomarkers, and
diagnostics of
EED or
malnutrition

or isolated deficiencies (including zinc, vitamin A, iron, vitamin D,
folate, vitamin B12)?
Is EED a risk factor for overnutrition (including overweight and
obesity), especially later in childhood/adulthood?
Is EED a risk factor for subsequent enteric infections/diarrheal illness,
either in general or as caused by specific pathogens?
Is EED a risk factor for decreased oral vaccine efficacy or oral drug
efficacy?
Is EED a risk factor for diminished cognitive function or
developmental delay?
Other

24. What diagnostic tools or biomarkers are available to assess for EED

or malnutrition1? What biomarkers are manifest during the EED
clinical state that could be utilized to develop a diagnostic test?
Subquestions:
24a. How sensitive and specific is the test/biomarker in identifying the
child with EED compared to villous blunting with crypt hyperplasia on
histologic examination of small bowel biopsy intestinal biopsy? In the
absence of comparison to histology, how does the test/marker
compare to other diagnostic tests of gut function/dysfunction
including permeability, inflammation, or nutrient uptake?
24b. Does the marker or diagnostic allow grading of disease severity
or gut dysfunction?
24c. Is the diagnostic or biomarker field-friendly?
24d. What are the costs associated with the diagnostic/marker?
25. Other

V. EED Clinical
course, pathophysiology

26. What is the clinical course of EED (e.g., clinical symptoms, signs and

laboratory findings)? What are the underlying mechanisms/pathways
of these clinical changes?
27. What nutritional changes/abnormalities occur in EED including
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Topic area

Questions
energy metabolism, MN uptake, bioavailability and metabolism?
28. What gut pathophysiology, histology or cellular changes are found in
EED?
29. Other

VI. EED,
malnutrition
interventions—
prevention and
treatment

What interventions can prevent, treat or mitigate EED (including as
measured by tests of gut dysfunction or inflammation) or
stunting/malnutrition? What is the effect2 of interventions in reducing
prevalence of EED or malnutrition among children (compared to no
intervention or placebo intervention)? What is the effect of interventions on
treating or mitigating the impact of EED (outcomes could include diminished
gut inflammation, diminished microbial content in host guts, improved gut
function) or stunting/malnutrition (outcomes could include improved linear
growth or weight gain) among individual children? For each treatment
intervention identified, what is the effect in impacting outcomes compared to
no intervention or placebo intervention3?
Exclude interventions related to increased calorie intake or food security.
Interventions include:
Population-based interventions among asymptomatic children in
developing-country settings:
30. Zinc, vitamin A, folic acid, vitamin B12 supplementation or

31.
32.

33.
34.
35.
36.
37.

38.
39.

fortification4 (or supplementation or fortification with other MNs or with
multiple MNs)
Interventions related to breastfeeding
Nutritional interventions such as introduction of or increased
consumption of certain foods, including weaning or complementary
foods
Feeding practices (e.g., responsive feeding practices among
caretakers)
Improved food safety (e.g., boiling eating utensils, improved food
storage and reheating)
Improved water, sanitation, hygiene
Prebiotics, probiotics
Maternal interventions (e.g., prenatal iron/folate supplements in
pregnancy and examination of impact on EED or malnutrition in
offspring)
Health services interventions (e.g., implementation of growth
monitoring programs, cash transfers in return for care-seeking)
Other

Interventions to prevent EED implemented among children in
developing-country settings with specific symptoms (e.g., diarrhea):
40. Zinc, vitamin A, folic acid, vitamin B12, or other MNs (e.g., for

treatment of diarrhea)
41. Prebiotics, probiotics (e.g., for treatment diarrhea)
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Topic area

Questions
42. Management/treatment of other conditions (e.g., antitubercular
agents, tuberculosis, antiretrovirals for HIV, antimalarials to treat
malaria infections, intermittent preventive treatment of malaria)
43. Other
Among children identified/diagnosed as having EED or malnutrition:
44. Treatment with specific MNs including: iron, zinc, vitamin A, vitamin
D, folic acid, vitamin B12
45. Treatment with multiple MN preparations (e.g., Sprinkles)
46. Treatment with antibiotics
47. Treatment with probiotics
48. Nutritional interventions such as introduction or increased
consumption of specific foods; ready-to-use therapeutic or
supplementary foods; related nutritional therapeutics
49. Feeding practices (e.g., responsive feeding practices among
caretakers)
50. Other

1

Not including measures of physical growth (e.g., height, weight, mid upper arm circumference), indices
calculated from measures of physical growth (e.g., body surface area), or use of growth charts or growth
standards.
2
Including any potential harms identified with the intervention. Furthermore, cost information should be
captured where available.
3
Where possible, also identify the best stage in the EED clinical spectrum in which to intervene and at
which stage does therapeutic effect have the greatest impact on outcomes compared to other stages?
4
Supplementation defined as administration of MNs to a population subgroup based on age or other life
cycle factors. E.g., prenatal vitamins, giving 6-36 month-olds vitamin A capsule every six months.
Fortification defined as adding MNs to food staples such as the addition of folate to flour.

A “wide-net” broadly inclusive systematic search strategy was considered necessary at
project inception in order to capture sufficient references of relevance for four reasons: (1) a
wide scope and breadth of questions were deemed of interest for potential systematic
investigation; (2) we believed that there would likely be modified or derivative questions after the
initial review was performed; (3) EED has a broad, indistinct, and historically variable definition;
and (4) specific search terms for EED, ED or even enteropathy do not exist in the medical and
health databases. Because the effort involved in searching for articles solely related to one EED
systematic review question would only be marginally more compared to searching more broadly
for articles to address a wide range of EED-related questions, we opted for an infrastructure that
could produce a systematic review product efficiently and expediently.
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2.2 Constructing a Systematic Search Strategy:
Optimizing Sensitivity
We devised a systematic and comprehensive search, extraction, and analysis strategy.
Our overall procedure is depicted in Figure 4. We now describe the process components.
The first step was the construction of a comprehensive, systematic search strategy. We
developed individual search strategies for each database with the assistance of a research
librarian at the World Health Organization in Geneva. We devised a two-step search strategy
that was extensive due to the broadly defined nature of EED and the lack of robust indexing of
search terms across databases (as described above) (Appendix 1). In the first step, we used
broad terms to capture all references related to EED, including similar or identical disorders
(‘tropical enteropathy’, ‘environmental enteropathy’, ‘tropical sprue’, ‘tropical malabsorption
syndrome’, and ‘malabsorption’, ’enteropathy’, or ‘intestinal dysfunction’ in the tropics). At first
pass, we included any age group and any setting (e.g., returned travelers), because these
publications could conceivably contain data that provide some understanding of aspects of
EED. We were also interested in other enteropathies among children under five years of age
in developing countries, such as celiac disease or Crohn’s disease, because these disorders
might have been misdiagnosed EED, or because tests employed could be relevant to EED in
children at risk in resource-poor areas of the world.
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Figure 4. EED systematic review processes flow chart.
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As the second step, we identified references about malnutrition or nutritional status (as
measured by anthropometrics) among children under five years of age in developing countries.
The goal was to identify scenarios where EED is an intermediary: nutritional status as an
outcome of enteric dysfunction, biochemical or radiologic biomarkers/diagnostics of nutritional
status, or interventions to prevent or treat malnutrition. For nutritional outcomes, we limited our
search to effects on anthropometric indices (e.g., height-for-age, weight-for-age, weight-forheight, mid-upper arm circumference, and growth velocity). We excluded articles strictly about
prevalence or incidence of malnutrition (i.e., containing no information about risk factors
associated with nutritional status), articles about non-EED outcomes of malnutrition/nutritional
status, and articles examining the utility of anthropometric measures.
Next, we constructed search strategies to query the most relevant medical and health
databases: PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase
(http://www.embase.com/), Global Health (database published by Centre for Agriculture and
Biosciences International (CABI)), and the WHO regional databases. We included Global Health
and the WHO databases because of their higher proportions of articles from resource-poor
regions, which are often not published in journals that are indexed in PubMed and Embase.
Additionally, the WHO regional databases contain much “gray” literature from government and
nongovernmental organizations that could have been of relevance.
To ensure that our search adequately identified relevant references, we developed a test
set of references obtained by identifying 20 key EED references in collaboration with two
external advisors with content expertise (Appendix 2).
We sought to retain as many relevant references in our search results as possible, while
minimizing extraneous and irrelevant information. To maintain specificity, we filtered the
references for data from developing countries, tropical settings, or indigenous populations.
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However, universal use of this filter resulted in test EED references being missed. We were,
however, able to use the filter on the malnutrition search strategy without losing relevant
articles. We were able to apply another filter to restrict malnutrition articles to those related to
children. We did not restrict language or year of publication. After these modifications to our
search strategy, 18 of the 20 test references were captured. To detect the remaining two
articles, we would have needed to use a strategy that yielded a ten-fold increase in the number
of articles returned in the search. On further scrutiny, this problem was caused by a lack of
sensitive index terms for one article [87] and lack of child terms for the other [57] (Appendix 2).
We accepted this compromise, recognizing that the “snowball” technique (described below)
would increase our search sensitivity.
With our approach, we were able to interrogate the literature on a topic that is both
poorly defined and poorly indexed. Our comprehensive, rigorously evaluated, and reproducible
methodology can be utilized as a systematic search model approach for other topics that are
similarly broad and/or diffusely defined or cataloged, for which standard systematic search
techniques would be insufficient and imprecise.

2.3 Reference Volume Mitigation
The systematic search, completed June 2010, identified a total of 85,334 references
(after identifying and removing references that were duplicated within the four databases that
were searched), dating back to 1910 (discussed further in Results section). This overwhelming
volume of potentially relevant literature was unexpected, and we briefly considered using only
references from recent review articles on the topic. This was not possible, however, because no
previous systematic reviews had been published with which to identify biomarkers that could be
used to prevent and treat, or to guide rehabilitation from, intestinal dysfunction in children in
resource-limited countries. Some reviews [8, 45, 88-93] either focused on adults or on narrow
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components of the problems, and not diagnostic strategies. Hence, this “look back” literature
review strategy would not have yielded the information we were seeking.
We next considered two options relevant to processing the ca. 85,000 titles. The first
option was to scrutinize this very long list with only one or two questions in mind, and vote on
each as presumptive “include” or “exclude” related only to the limited inquiry, and ignore all
irrelevant topic areas and corresponding questions (“limited-use scrutiny”). The second option
was to build an EED Library with references with notation of its relevance to any of the potential
topic area(s) and questions (“future use scrutiny”). The third option was to scrutinize each
reference, and then note the relevance only at the topic level, and not identify the specific
questions that each reference might address. Table 3 summarizes the advantages and
disadvantages of each approach.
After careful consideration, we decided to use a “modified future use” approach, i.e.,
examine each reference for its relevance to each of the six target areas, but not drill down to the
question level. However, we left questions available to the analysts as guides to the potential
utility of each document. We recognized that this approach entailed more analyst labor, i.e.,
approximately 200 additional person hours (assuming two readings of each listing) compared to
the first strategy in Table 3 (these estimates are limited to the review of the reference lists).
However, the hours of effort per question potentially answered would be considerably fewer,
when considering that the comprehensive scoring would encompass topic areas that include a
total of 49 potentially useful questions.
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Table 3. Summary of analysis options.
Advantages and disadvantages of comprehensive versus targeted analysis of literature
produced by search terms are portrayed.
Strategy

Advantages

Disadvantages

1. Targeted (“single use”)
scrutiny of 85,000
references (focus on only
1 or 2 possible uses
of/questions for
database)

Reduced time per reference,
based on an estimate of 0.75
hour for 1 analyst to scrutinize
200 references, and all
references are independently
reviewed by two analysts, for
a total of 637 person hours

Cannot be used for more than
a very limited number of
questions (estimated 2 at
most)

2. Broad (“future use”)
scrutiny (focus on all
possible topic areas, and
denote particular
questions)

Diminishes need to repeat
scrutiny of references, and
generates candidate
documents for all potential
topic areas and questions

Extended time per reference
compared to strategy 1
(based on an estimate of 1.75
hours for 1 analyst to
scrutinize 200 references, and
all references are reviewed by
two analysts), for a total of
1488 hours

3. Broad (“modified future
use”) scrutiny (focus on
all possible topic areas,
but do not denote
particular questions)

Diminishes need to repeat
scrutiny of references, and
generates candidate
documents for all potential
topic areas, but not questions

Extended time per reference
compared to strategy 1
(based on an estimate of 1.25
hours for 1 analyst to
scrutinize 200 references, and
all references are reviewed by
two analysts), for a total of
1,063 person hours

2.4 Building the EED Library
The initial list of approximately 85,000 references from the processes described above
contained the following information from the databases searched: title, authors, journal, and to
varying extents, abstracts. We exported the references from PubMed, EMBASE and Global
Health into EndNote software (ca. 81,000); this was not possible with the references from the
WHO Regional libraries (ca. 4,000) because of the format in which these references were
exported from the search engine.
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References from all of these sources were reviewed by research analyst (RA) pairs
comprised of individuals trained in epidemiology or nutritional sciences, and who received
extensive training in our protocol for inclusion/exclusion of studies.
Per standard systematic review methodology, each reference (title, keywords, and
abstract when available) was reviewed by two analysts to determine inclusion status for the
EED Library. Dual review reduces bias and inaccuracies in the systematic review process. The
principal investigators (DMD and PIT) initially piloted the Library inclusion process, until 100%
concordance was achieved upon independent review of 1,300 consecutive references. A series
of training sessions to convey the goals of the project, along with a protocol with which to
determine inclusion of a reference in the EED Library, were provided to the team of RAs. Verbal
and written instructions were conveyed to the analysts (Table 4), and a schematic regarding
articles to include, and under what category, was also provided (Figure 5).
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Table 4. Summary of EED Library inclusion/exclusion instructions to research analysts.
Each analyst was instructed in the scope of interest of the EED Library, and how to code, tag
and label data related to each reference included in the EED Library.

A reference was included if it pertained to any of the following conditions:
•
•
•
•
•
•

Environmental Enteric Dysfunction
Tropical Enteropathy
Tropical Sprue
Environmental Enteropathy
Tropical Malabsorption Syndrome
Malabsorption/Enteropathy/Enteric Dysfunction in resource-limited settings

Any age group and any setting (e.g., travelers) were eligible for this filter step.
References about other enteropathies were included only if among children under five in
developing countries (e.g., celiac disease, inflammatory bowel disease (IBD)).
Nutrition-related articles were included if:
•
•
•

Malnutrition or nutritional status (as measured by anthropometrics) among children
under five in developing country was an outcome
The study pertained to biochemical diagnostics or biomarkers or radiographic or
other imaging among children under five in a developing country
The study used interventions to prevent or treat malnutrition, even if the outcome
was something other than change in nutritional status or prevalence of malnutrition.
Interventions were eligible only if they started among children under five years,
even if outcomes were measured at a later age.

A separate category of inclusion captured relevant reviews; this was defined broadly to include
review articles, meta-analyses, editorials, commentaries, compendia or conference
proceedings, letters, books, or book chapters.

Exclusions:
•
•
•

prevalence, incidence, etc. of malnutrition if there was no information about factors
(other than caloric insufficiency/food insecurity) associated with nutritional status
outcomes specifically due to malnutrition/nutritional status
the utilization of anthropometric measures
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Further delineation of relevance to our systematic review
Topic areas:
I. Epidemiology of EED
II. EED or malnutrition as an outcome
Any associations, risk factors, protective factors, causes of acquisition of EED,
malnutrition (except for food insecurity/inadequate calories associated with malnutrition).
III. EED as an exposure
EED as an association with, risk factor for, or cause of subsequent other child health
problems.
IV. Assessment, biomarkers, and diagnostics of EED or malnutrition
V. EED clinical course, pathophysiology
VI. EED or malnutrition interventions
Relevant studies included in the EED Library:
•
•
•

•

Exposures, risk factors, protective factors, host factors, prevention or treatment
interventions (other than those related to caloric density or food security), and their
impact on EED or malnutrition outcomes.
Diagnostic tests or biomarkers related to, or to assess for, EED or malnutrition.
Interventions (other than those related to caloric density or food security) to prevent or
treat malnutrition in children under five years, even if the outcome was something other
than change in prevalence of malnutrition or change in nutritional status of individual
children. Outcomes could include, for example, change in case fatality rate. Outcomes
measured beyond five years were also included.
Prevalence, clinical course, and pathophysiology of EED.

References we excluded from the EED Library:
•

•
•

Malnutrition as a risk factor for other morbidities/outcomes (e.g., malnutrition as a risk
factor for pneumonia, stunting as a risk factor for obesity or mortality in adulthood,
malnutrition as a risk factor for childhood mortality) unless the outcome was EED (e.g.,
malnutrition as a risk factor for poor intestinal function was included)
Malnutrition prevalence studies--unless they also examined risk factors for malnutrition
or were intervention studies where change in prevalence of malnutrition is an outcome.
Measures/indices of physical growth such as growth charts or use of new indices
calculated based on height, weight, or other physical measurements.
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Figure 5. EED Library inclusion schematic.
Analysts used this as a guide in determining which references should be included in the EED
Library.

Feedback on nuances of the inclusion protocol was communicated to the analysts on a
regular basis for the duration of the project. Table 5 contains samples of such guidance.
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Table 5. Additional EED Library inclusion/exclusion guidance and tips.
The EED category was intentionally defined broadly. The term environmental enteric
dysfunction (EED) has several potential equivalents in the literature, including tropical
enteropathy, environmental enteropathy, tropical sprue, and tropical malabsorption syndrome.
We also included references about enteric dysfunction and any other enteropathy impacting
children in developing countries. These enteric conditions included kwashiorkor enteropathy,
HIV enteropathy, tuberculosis enteropathy, celiac disease, inflammatory bowel disease, and
other enteropathies, assuming they occurred in a developing-country setting.
References were included even if our outcomes of interest were not the study's primary focus.
If the title or abstract clearly indicated that the outcome was acute diarrhea, acute gastroenteritis
or an acute enteric infection, we excluded it. If the reference noted they specifically examined
persistent or chronic diarrhea as an outcome, it was included. Even if the main outcome studied
was acute diarrhea, the reference was included if it examined EED or persistent/chronic
diarrhea as a "minor" outcome. If an outcome of "diarrhea" was not specified as either acute or
persistent/chronic, we assumed the article referred to acute diarrhea and we excluded it.
References about acute diarrhea were included when they examined the impact of acute
diarrheal illness or acute gastroenteritis on EED or malnutrition.
References about children with IBD or celiac disease originating in a developing country were
included (but excluded if the study was conducted in a developed country). Even though the
origin of IBD and celiac disease is distinct from EED, we included it from developing-country
settings for two reasons:
a. Celiac disease or IBD in developing countries may truly be misdiagnosed EED, a fact
we will be better able to judge when reading the study methodology.
b. We are attempting to look at enteric dysfunction in developing settings more broadly
and with fresh perspectives, to allow new observations of underlying patterns.
While enteropathy is not always a manifestation of tuberculosis, HIV, or kwashiorkor, if a study
in a developing country discussed enteric dysfunction or enteropathy related to these
conditions, we included it.
We excluded studies that reported prevalence of infection with a specific pathogen. If a study
examined a pathogen's association with EED or other outcomes of interest as previously
specified, then we included it.
We focused on small intestine pathology; therefore, we excluded studies looking at
gastric/colonic pathology unless they also examined outcomes pertaining to the small intestine.
References about gastrointestinal problems that are not EED-related were excluded; a nonexhaustive list of commonly encountered conditions not included in our review includes:
•
•
•
•
•

Appendicitis
Blind loop syndrome
Colonic atresia
Duodenal atresia
Dyspepsia
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•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Hemolytic uremic syndrome
Henoch-Schonlein purpura
Hirschsprung's disease
Intestinal obstruction
Intussusception
Irritable bowel syndrome
Malrotation
Necrotizing enterocolitis
Perirectal abscess
Peritonitis
Primary bile acid malabsorption
Pseudomembranous colitis
Rectal prolapse
Short bowel syndrome
Volvulus

We included studies examining potential risk/protective factors for stunting, wasting or other
forms of malnutrition, except those related to food security or caloric density. We excluded
studies where any type of malnutrition was considered the exposure, unless EED was an
outcome.
Articles examining factors associated with anthropometric/growth outcomes were included even
if not related to malnutrition. We did not include articles that solely examined the outcomes of
overweight and obesity (unless related to EED), but studies of changes in growth status among
children under five in developing countries were included. We excluded anthropometric data
collected for the purpose of evaluating national statistics (e.g., in relation to WHO child growth
standards) and studies of malnutrition or nutritional status prevalence unless the studies also
looked at risk or protective factors associated with EED.
Growth outcomes among children with common chronic infectious diseases such as HIV or
hepatitis were considered outcomes of interest.
We included any potential risk or protective factors for EED, malnutrition, or other outcomes of
interest, even if they are not necessarily directly related to gut dysfunction, e.g., poverty,
domestic violence, maternal anemia, small for gestational age (SGA), or low birth weight (LBW).
We excluded studies where SGA or LBW was the study outcome, however.
We included genetic risk factors for EED, malnutrition, or another related outcome of interest as
long the study was conducted in a developing-country setting.
Many studies contain relevant information about children under five even though they are not
restricted to— or even focusing on— that age group. If any children under five were included,
we included the reference.
If a relevant study was conducted in a year when the study country was on the developing
country list, it was included.
We excluded case reports (or in vitro lab or animal model studies) even if relevant to EED.
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The analysts were provided guidelines on inclusion and exclusion criteria. They were
further instructed to: include only references from work performed in low- and middle-income
countries (per World Bank definitions during the time that the data in the reference were
collected) or among marginalized or indigenous populations in developed countries (e.g.,
Aboriginal Australian children) [94, 95]; to include references related to EED or conditions
identical to or very consistent with EED (e.g., environmental enteropathy, tropical enteropathy,
persistent diarrhea) among any age group in a setting of interest, and references related to
other enteropathies or to nutritional conditions of interest among children under five years of age
in a setting of interest.
The refinements in the inclusion/exclusion instructions regarding other enteropathies
were implemented because there is accumulating evidence that celiac disease is not confined
to individuals of northern European descent residing in industrialized countries, but is instead a
worldwide problem, including in regions in which EED is endemic, such as South Asia [96].
Second, there is increasing recognition of inflammatory bowel diseases (i.e., Crohn’s disease
and ulcerative colitis) in these regions [97], though most cases of intestinal inflammation in
these populations are not related to idiopathic inflammatory bowel diseases in children under
five years of age. Third, we wished to include references on malnutrition and nutritional status
where EED could act as an intermediary while excluding references that examined other
aspects of malnutrition. For example, while food insecurity commonly affects populations at risk
for EED, studies of nutritional deficits by themselves, including surveys of such deficiencies,
were designated to be beyond the scope of our project. In another example, iron deficiency can
be caused by a multitude of factors including defective absorptive capacity in the small bowel.
To capture only the references relating to intestinal absorptive function, we excluded references
if iron deficiency was studied outside the context of intestinal uptake assessment or another
process related to EED.
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Progressing in reverse chronological order, virtually all references between 1980 and
2010 were evaluated as to whether or not they should be included or excluded from the EED
Library, or whether or not additional information from the full text (particularly when the abstract
was not initially available from the medical/health databases searched) was needed to make the
determination. If included in the Library, references were assigned tags as to whether the
reference contained information about: 1) enteropathy or enteric function/dysfunction, 2)
nutritional status or malnutrition, and/or 3) enteric microbes. By using the topic areas and tags,
we could then formulate queries to apply to our EED Library to identify articles potentially
relevant to specific review questions that are contained in Table 2 or identified in the future.
Additionally, topic areas (Table 2) covered in each reference were noted, as well as an
indication whether the reference was a review or otherwise did not present primary data.
Each reference published between 1980 and 2010 was reviewed for inclusion by two
analysts according to the written guidelines and instructions. A principal investigator or lead
analyst reviewed all references for which the analysts were discordant on Library inclusion, topic
area, or other determinations, and provided final decisions. Furthermore, to verify that
systematic errors did not occur in the exclusion of references, a random subset of references
excluded by both analysts was scrutinized by a lead analyst. Percent error rate for this subset
was calculated.
The kappa statistic was used to evaluate reliability of individual analyst responses
against final inclusion/exclusion determinations. Interpretation of kappa was performed using
the following guidelines as described by Koepsell and Weiss [98]: agreement of >0.80 was
deemed excellent, 0.61-0.80 substantial, 0.41-0.60 moderate, 0.21-0.40 fair, 0.00-0.20 slight,
and <0.00 poor.
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Chapter 3. EED Library as a Basis for
Systematic Reviews
3.1 Defining Systematic Review Question Priorities
Evidence related to any topic area and addressing questions raised in Table 2 has
potential to move the EED field forward. While an argument could be made to pursue any of the
topic areas/questions, we had to define a starting question to address and had to develop a
prioritization scheme given the importance of many of the topic areas/questions. Descriptive
epidemiology (topic area I in Table 2), for example, would certainly be useful to gauge the scope
of the problem, but would probably not produce useful recommendations. We considered
developing a review that considered EED as a dependent variable (i.e., an outcome) of
processes and risk factors (topic area II in Table 2). Such a characterization might be used to
develop preventive interventions for EED. We next formulated a model of EED as an event that
causes many injuries in the host (topic area III in Table 2), such as stunting and micronutrient
deficiencies. A review based on this model could be considered an analysis of its consequences
by focusing on host injuries and population impact. Biomarkers of EED as a subject for review
(topic area IV in Table 2) could provide a compendium of tools that could be used to detect
EED, and possibly to shed light on its origin. Consideration was additionally given to reporting
the clinical course and pathophysiology of EED (topic area V in Table 2), to summarize the state
of knowledge about cellular and organ processes that underlie its disease course. Finally, we
considered reviewing existing treatment or prevention interventions for EED (topic area VI in
Table 2).
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To provide direction for our initial efforts, we decided that it was important to select areas
in which a sufficient body of data is likely to exist. An additional attribute for a useful review is
that the resulting analysis can be used for disease control.
With these considerations in mind, we narrowed the set to four lead questions:
1.

What is the evidence that EED is caused by (an) identifiable pathogen(s),
microbial populations, environmental or other identifiable factors?

2.

What is the evidence that EED can be prevented by any interventions?

3.

What is the evidence that EED can be noninvasively diagnosed?

4.

What is the evidence regarding efficacy/effectiveness of treatment
interventions for EED?

Based on deliberations amongst the co-authors, and engagement with the Bill & Melinda
Gates Foundation, as well as discussions at the Gut Integrity Workshop held in Seattle,
Washington in December 2010, we focused on noninvasive diagnosis of EED as a priority
systematic review question.
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3.2 Determining Relevance to the Systematic
Review
We carefully considered the specifics of the review question and framed the question for
consistency with the Population Intervention Comparison Outcome (PICO) framework for
systematic review questions [99]:
What biomarkers or diagnostic tests 1 have been used to identify or have been shown to
be associated with mucosal dysfunction of the small intestine 2 or host inflammation 3 in
children under five years of age from developing-country settings 4?
For the purpose of this systematic review question, dysfunction was defined as
manifestation of increased small intestinal permeability, decreased absorption of nutrients,
enteric inflammation, or abnormal enterocyte metabolism or cell function. These conditions
could be present in children with environmental enteric dysfunction based on histology or
persistent diarrhea or those with malnutrition, or who were clinically asymptomatic. Evaluation of
asymptomatic or “normal” subjects without overt clinical evidence of enteric dysfunction or those
with acute diarrhea was of interest as long as they were evaluated for tests of mucosal small
intestinal dysfunction (e.g., endoscopy, histology, or markers of permeability or absorption from
serum, urine, or stool) or they were being tested in the same study as children with persistent
diarrhea. Gastrointestinal dysfunction or enteropathy related to celiac disease, cow's milk
protein allergy (CMPA), inflammatory bowel disease, or cystic fibrosis, as well as primary

1

Assessments of host biological materials or imaging assessments (e.g. radiologic) of the host.
Including increased small intestinal permeability, decreased absorption of nutrients, enteric
inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g.
environmental enteric dysfunction (EED) based on histology or persistent diarrhea) or children with
malnutrition or clinically asymptomatic children.
3
Laboratory confirmed generalized or tissue inflammation, but not necessarily specifically measuring gutspecific inflammation, e.g. C-reactive protein (CRP), IL-6.
4
Defined as low or middle income country as determined by World Bank or among marginalized or
indigenous populations in a developed country.
2
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immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable
immunodeficiency, IgA deficiency, IgG subclass deficiency) were excluded from this systematic
review.
Studies that used tests or markers specifically related to small intestinal mucosal
function (except for the aforementioned excluded specific enteropathies) among children under
five years of age from a developing country setting were included. These tests include biopsy,
tests of nutrient absorption (e.g., iron absorption), tests of gut permeability and/or absorption
(e.g., D-xylose, lactulose:mannitol ratio [L:M]), and stool markers (e.g., fecal fat, reducing
substances). Articles describing tests or markers of systemic inflammation that can be affected
by mucosal intestinal function (e.g., IL-6, C-reactive protein (CRP), blood counts) were also
included as long as they were conducted: a) among children with EED or enteric dysfunction
consistent with EED (e.g., those with persistent diarrhea and without an excluded enteropathy),
b) among acute diarrhea or asymptomatic patients in a study that compared results to subjects
with a small intestinal mucosal disorder of interest, or c) in association with a test of mucosal
small intestinal function. Articles that were limited to tests of micronutrient status, celiac or
CMPA disease-specific tests, or tests for specific pathogens were excluded from the systematic
review.
We decided to restrict this analysis to articles published between 2000 and 2010 in the
interest of producing an expedited analysis of a well-defined literature set. We retain the ability
to apply this methodology to the literature identified for prior intervals. We also performed an
assessment of 10 references chosen at random that were published between 1990 and 1999 to
determine the scope of additional information that an analysis of the literature prior to our
restricted time block might provide (Appendix 3). Of the 10 articles, only one had a sample size
of 100 or more subjects under five years of age. Overall, these articles do not lend substantial or
novel data to content already derived from the 2000-2010 analysis.
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We acknowledge that delving back to prior decades could provide additional informative
data. This is especially true because much study regarding EED occurred in the 1970s and
1980s and waned in the subsequent decades, and because technology is not evolving rapidly in
this field. However, secular trends in socioeconomic, environmental, nutritional, and disease
conditions as well as improvements in laboratory, epidemiologic, and biostatical methods
complicate comparison of data across studies from different time periods. Also, earlier studies
focused on adults.
The team included analysts knowledgeable in German, French, Spanish, Italian, and
Portuguese; thus, we were able to thoroughly dissect articles in these languages. References in
other languages were excluded as we were not able to translate other languages in detail
sufficient for the purposes of thorough extraction and analysis.
A summary of inclusion/exclusion criteria and of the instructions given to analysts is
provided in Table 6.
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Table 6. Guidelines for systematic review inclusion/exclusion determination and data
extraction.
Biomarkers and Diagnostics Systematic Review Question:
What biomarkers or diagnostic tests1 have been used to identify or have been shown to be
associated with mucosal dysfunction2 of the small intestine or host inflammation3 in children
under five years of age from developing-country settings4?
1

Assessments of host biological materials or imaging (e.g., radiologic) assessments of the host.
Dysfunction can be related to increased small intestinal permeability, decreased absorption of
nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those
with enteropathy (e.g., EED based on histology, persistent diarrhea) or children with malnutrition
or clinically asymptomatic children.
3
Laboratory-confirmed generalized or tissue inflammation, but not necessarily specifically
measuring gut-specific inflammation (e.g. CRP, IL-6).
4
Developing-country setting is defined as a low- or middle-income country (as classified by
World Bank) or among indigenous populations in a developed country.
2

Excludable conditions (non-EED enteropathies)
Celiac disease, IBD, CMPA, cystic fibrosis (CF) (diagnosed by abnormal sweat test), as well as
primary immunodeficiency disorders (e.g., X-Linked agammaglobulinemia, common variable
immunodeficiency, IgA deficiency, IgG subclass deficiency) were not conditions of interest for
this review unless the following circumstances existed:
1.
The study had controls or other subjects of interest who underwent diagnostic tests that
are of interest to us (see "Category I Tests," below).
2.
The condition (i.e., celiac disease, CMPA, IBD) did not meet our systematic review
criteria for defining or diagnosing that condition. In other words, these disorders may have been
incorrectly diagnosed and could actually have been an enteric dysfunction of interest.
Asymptomatic children and children with acute diarrhea:
Evaluation of asymptomatic or ‘normal’ subjects without overt clinical evidence of enteropathy or
those with acute diarrhea was pertinent to our review as long as the included tests of mucosal
small intestinal dysfunction (e.g., endoscopy, histology, or serum, urine, or stool markers of
permeability or absorption). We were not interested in asymptomatic children or those with
acute diarrhea if tested for only systemic markers, unless they were tested in the same study as
children with EED or persistent diarrhea (PD). We were interested in the comparison of
systemic tests in patients who are asymptomatic and/or have acute diarrhea vs. PD. For
example, if a systemic marker was measured in subjects who were asymptomatic or had acute
diarrhea, we did not include these data. However, if these tests were also performed in a PD
group, then we included the data from all of these subjects— acute diarrhea, PD, and
asymptomatic subjects— taking care to separate findings by these categories.
We did not include references about children who presented with abdominal pain, vomiting,
anemia, rectal bleeding, gastroesophageal reflux, etc., unless they reported to have also had
EED, tropical enteropathy (TE), environmental enteropathy (EE), PD, malabsorption, or other
symptoms suggesting small intestinal mucosal dysfunction.
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Tests to Include:
Tests specific to intestinal dysfunction: We included biomarkers and diagnostic tests specifically
related to small intestinal mucosal function if other inclusion criteria were met (i.e., age under 5,
developing-country setting, etc.). We included these types of tests:
•
•
•

Endoscopy
Intestinal biopsy or lavage
Lactose/sucrose load test

Tests of nutrient absorption (not static blood levels; see Excludable Diagnostic Tests, below),
such as the following:
•
•
•
•

B12 absorption
Iron absorption
Calcium absorption
13
C sucrose or hydrogen breath test (HBT)

Urine markers of gut permeability or absorption:
•
•
•
•
•
•
•
•
•
•
•

D-xylose
Creatinine, fraction excretion
Lactulose, fraction excretion
Sucrose, fraction excretion
Sucralose, fraction excretion
Mannitol, fraction excretion
L:M (lactulose:mannitol) ratio
Sucrose:lactulose ratio
Sucralose:lactulose ratio
Urea:creatinine ratio
Lactose:creatinine ratio

Any stool markers (except those testing for specific micro-organisms; see Excludable Diagnostic
Tests, below), such as the following:
•
•
•
•
•
•
•
•
•
•
•

Alpha-1-antitrypsin
Calprotectin
Fecal fat
Lactoferrin
Neopterin
Myeloperoxidase
pH
Reducing substances
Leukocytes (i.e., white blood cells (WBCs) by microscopy
Occult blood testing (including guiac)
Red blood cells (RBCs) by microscopy

Systemic, Non-specific Tests: Many biomarkers and diagnostic tests, including the below list of
systemic markers of inflammation, can be impacted by mucosal intestinal function, but they can
also be impacted by other non-gastrointestinal disorders.

40

For these tests, we only included if one or more of the following conditions were met:
1. They were conducted among patients with a mucosal small intestinal disorder of interest
(e.g., EED, PD, or among asymptomatic or acute diarrhea subjects in a study that also
examined subjects with mucosal small intestinal disorder of interest).
2. The tests were reported in relation to a test of mucosal small intestinal function (see list
above).
Examples of systemic, non-specific tests are the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Hemoglobin (HGB), hematocrit (HCT) (blood cell counts)
Total serum proteins and other serum proteins such as albumin, pre-albumin
Serum lipids and lipoproteins
Liver function tests (e.g., alanine transaminase)
Urine sodium (Na)
Urine pH
Systemic inflammatory markers such as:
C-reactive protein (CRP)
Erythrocyte sedimentation rate (ESR)
Tumor necrosis factor (TNF)
Interleukin-6 (IL-6)
Interferon-gamma (IFN-gamma)
Alpha-1-acid glycoprotein (AGP)
Serum immunoglobulins
Immune cell subsets
Ferritin

Algorithm for our inclusion/exclusion decisions on tests/markers:
1.
Was the test performed on children under five years in a developing-country setting? If
no, exclude. If yes, continue.
2.

Is the test on the list of excludable tests? If yes, exclude. If no, continue.

3.
Is the test potentially related to small intestinal mucosal function? If no, exclude. If yes,
continue.
4.
Is the test specific for small intestinal mucosal function? If yes, include and extract data.
If no, continue.
5.
Is the test a more general test that could be related to dysfunction of other organ
systems? If no, exclude. If yes, continue.
6.
Was the test assessed among children with mucosal small intestinal dysfunction or
among children who have been assessed for mucosal small intestinal dysfunction? If no,
exclude. If yes, include and extract data.
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3.3 Acquisition of References and Copyright Fair
Use Compliance
References potentially relevant to the systematic review were determined by querying
the EED Library Access database. The query identified references tagged as explicitly EEDrelated and relevant to or possibly relevant to topic area IV (i.e., diagnostic tests and
biomarkers).
Starting in reverse chronological order, full texts of references that were identified as
potentially relevant to the systematic review were obtained as Portable Document Format files
(PDFs) and deposited into a central repository on Google Drive.
We maintained compliance with Fair Use obligations of U.S. Copyright Law,
watermarking all PDFs and making the Google Drive repository available only to team
members. Furthermore, analysts who performed data extraction indicated their compliance with
fair use when logging into the data entry system, via a checkbox that stated “I agree to use this
article according to US copyright law.”

3.4 Documenting Relevance to the Systematic
Review
Two principal investigators (DMD, PIT) and/or lead analysts (ZCN, KMV) reviewed
discordant decisions made by research analysts (RAs) to determine relevance of references to
the systematic review according to written guidelines (Table 6). In addition, a subset of
concordant decisions (with an emphasis on excluded references) was reviewed for quality
control.
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After the systematic search of the EED Library, we employed the "snowball technique" to
identify further articles relevant to the systematic review. The snowball technique involves
review of bibliographies of references determined as relevant to the systematic review, and
cited articles were cross-checked against the EED Library. If not already included in the Library,
the article was evaluated for inclusion in the Library and the systematic review.

3.5 Data Extraction for the Systematic Review
For data extraction, presentation, and analysis, we utilized the REDCap (Research
Electronic Data Capture) system (http://project-redcap.org/). REDCap is a secure, web-based
application for construction and management of online surveys and databases from multiple
users [100]. A sample REDCap template for data extracted from systematic review references
can be found in Appendix 4.
After inclusion/exclusion decisions for the review were finalized, six analysts extracted
data from studies into REDCap. The analysts were provided written guidelines on the type of
data to be extracted (Table 6). Conference call training sessions were employed to reinforce
guidelines and to address questions. Analysts were instructed to extract data on relevant facets
including: study objectives, outcome of relevance to review question, setting, study design,
subject description, case definition for subjects of interest, age groups and age range, study
population, sample size for review question, biomarkers or diagnostic tests, test conditions and
specifications, and results, as well as provide their impression of the evidence quality and a
study synopsis. Extracted data were reviewed for accuracy and completeness by lead analysts,
who made edits as needed and provided feedback to the RAs to increase efficiency and
accuracy.
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We exported specific fields of data from REDCap, facilitating analyses and data
presentation in evidence table format. From these characterizations, we portrayed the spectrum
of responses in quantitative and free-text formats as needed.
It is important to note that the EED Library, with references from PubMed, EMBASE,
Global Health, and WHO Regional databases that were published between 1980 and 2010,
remains available for research relevant to enteric dysfunction in children in resource-poor
environments.

3.6 EED Library: Search Results Overview
The systematic search of PubMed, Embase, WHO Regional, and Global Health
databases yielded 85,334 references of potential relevance to the EED Library. 17,431
references that were published before 1980 have not been assessed for inclusion in the Library.
67,903 references published between 1980 and 2010 are depicted in Figure 6. A small portion
of this set was not reviewed because full text was necessary for determination, but was not
available (i.e., we were unable to retrieve 89 articles published between 2000 and 2010).
66,541 references were dual-reviewed against EED Library inclusion criteria with 9,669
admitted to the project Library. Fifteen percent of those included were reviews, commentaries,
abstract proceedings, books, or editorials, and the remainder were references with primary data.
To conserve project resources, approximately 1,350 articles from the original systematic search
that were published before 2000 were not reviewed for library inclusion.
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Figure 6. Flowchart of project procedure results.

3.7 Quality Control
Accuracy and completeness in coding inclusion/exclusion and labels, tags, and topic
areas by analysts were closely monitored. Means for the percent of inaccurate exclusion and
inclusion and for kappa statistics were weighted based on the number of reference
spreadsheets reviewed by each analyst. The overall inaccurate exclusion and inclusion rates
were 2.2% and 2.7%, respectively. The kappa average for the group of analysts was 0.76,
which is considered to be in the "substantial concordance" range [98]. In addition, 1,200
references that were concordantly excluded by two analysts were reviewed by a lead analyst;
the exclusion error rate for these references was 0.5% (Table 7).
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Table 7. Accuracy rates for inclusion and exclusion.
Concordance/discordance between analysts and study investigators on an evaluation set of
12,000 references. Analysts who completed only a limited number of references are not
included.

Analyst

Inaccurate
Exclude
(%)

Inaccurate
Include (%)

Kappa
(mean)

Number of
references
analyzed
for quality
control

A

5.2

3.4

0.46

1800

B

0.9

3.2

0.83

11400

C

2.9

0.9

0.78

2000

D

1.9

2.9

0.78

7800

E

2.9

1.3

0.74

6400

F

5.8

6.4

0.50

600

G

6.4

3.7

0.61

200

H

2.9

3.3

0.75

600

I

4.2

6.5

0.67

800

J

3.3

0.7

0.79

600

Weighted
average
inaccurate
exclude
2.2

Weighted
average
inaccurate
include
2.7

Weighted
average
kappa

Concordant
exclusion
error rate

0.76

0.5 %

Group
metrics:

3.8 EED Library Status
Twenty percent of all of the references derived from our initial systematic search of the
PubMed, Embase, and Global Health databases were published between 2006 and 2010. The
discordance between the abundance of references that we found in our search and the paucity
of references found in the ISI query suggest that relevant literature is indexed with search terms
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that are neither sensitive nor specific. The inclusive approach using terms that broadened the
scope of papers identified was therefore warranted, even though such broadening obligated the
inclusion of over 85,000 references.
Furthermore, careful documentation of our search terms allows reproducibility despite
the complex nature of our strategy. The search strategy can be replicated and resultant
references run through our project procedures to update the Library at any time. In addition, the
search strategy designed for this project can be modified if related searches are needed.
The EED Library, as derived from PubMed, EMBASE, Global Health and WHO Regional
databases and published between 1980 and 2010, was designed to be a resource for scientists,
public health and clinical practitioners working on a variety of EED investigations. In fact, we
have interrogated our EED Library for several groups of researchers in the field:
1.

2.

3.
4.
5.

Dr. David Rudnick at Washington University in St. Louis requested assistance in
his work on liver function and growth in resource-limited settings, and we queried
the database as regards the role of aflatoxin and growth as reflected in the
literature.
We provided a list of references from the last decade that reported use of
biopsies among children in resource-limited settings to Dr. James Lavery‘s team
in Toronto to assist in their examination of ethical considerations of invasive and
noninvasive assessments of what they termed "tropical enteropathy/enteric
enteropathy."
We provided data from our database to Dr. Gerald Keusch’s team (which
includes co-authors Drs. Denno and Tarr) who were building a working definition
of EED.
The master evidence table was made available to all of the participants of the Bill
and Melinda Gates Foundation Grand Challenges Gut Function Biomarker
Shaping Meeting in London in June 2012.
We performed a pilot project for the Bill and Melinda Gates Foundation to
determine the number of studies in the EED database that involved interventions.
We further determined how many of these were clinical trials vs. treatment
studies, categorized the interventions, and tallied the number of studies per
category.

The EED Library can be searched using the codes, labels and tags that our Research
Analyst team assigned to EED Library records. Continued assembly of literature post-2010
would add value if the database is to be further utilized to address other queries.
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Chapter 4. Systematic Review of EED
Biomarkers/Diagnostic Tests: Results
Synopsis
4.1 Biomarkers and Diagnostics Systematic Search
Results
The query of our EED Library to identify references potentially relevant to the systematic
review produced 361 citations for the time period between 2000 and 2010. The "snowball"
technique identified 13 additional potentially relevant publications that were not found through
the original systematic search. Thirty-three of the 374 potentially relevant publications were in
languages other than those that we included for this review—English, French, German, Italian,
Portuguese, and Spanish (Table 8).
Table 8. Breakdown of publications in excluded languages of potential relevance to the
systematic review.

Language
Arabic
Chinese
Croatian
Czech
Norwegian
Polish
Russian
Turkish
Totals

Number potentially relevant
1
3
2
2
1
14
9
1
33

Number sufficiently reviewed
and excluded for reasons other
than language
0
1
2
1
0
10
6
1
21
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However, we were able to determine (via translation and/or English language abstract)
that 21 of the 33 did not meet our other systematic review inclusion criteria. We were unable to
sufficiently translate the remaining 12 papers to determine their relevance or, if they were
relevant, to extract data. These papers were in Arabic (n=1), Chinese (n=2), Czech (n=1),
Norwegian (n=1), Polish (n=4), and Russian (n=3). Two-hundred and fifty publications were
eliminated for various reasons, including their focus on celiac disease, cow’s milk protein
allergy, or inflammatory bowel disease; lack of at least three subjects of interest under five years
of age; or they did not assess biomarkers or diagnostic tests related to small intestinal function
or inflammation. One potentially relevant article was thought to be pertinent to the systematic
review based on the abstract, and another article required full text for further determination;
however, the full texts for these two articles could not be found.
An additional 12 references were highly considered for inclusion, but ultimately excluded
from the review for reasons including insufficient subjects in the specified age range, inadequate
relevant data on appropriately-aged subjects, or uncertainty about the setting in which the study
was performed (Appendix 5).
We identified 20 review articles with content that addressed or discussed material of
relevance to our systematic review question (Appendix 6); however, we identified no systematic
review that had been conducted on biomarkers or diagnostic tests related to EED.
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4.2 Characteristics of References Included in the
Systematic Review
The remaining 77 references included in the systematic review (Table 9) describe
research that was performed in 22 different countries. Figure 7 maps the sites where the studies
were performed.
Table 9. Articles pertinent to the systematic review.
These were determined to be the publications of interest between 2000 and 2010.
Alcantara CS, et al. Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with
experimental and Brazilian children with acquired cryptosporidiosis. 2003. [101]
Alves GM, et al. Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian
children. 2002. [102]
Amadi B, et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with
kwashiorkor but not marasmus. 2009. [103]
Azim T, et al. Immune response of Bangladeshi children with AD who subsequently have persistent diarrhea.
2000. [104]
Bhatnagar S, et al. Celiac disease with mild to moderate histological changes is a common cause of chronic
diarrhea in Indian children. 2005. [105]
Bitarakwate E, et al. Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea
management unit of Mulago Hospital, Uganda. 2003. [106]
Bukhari AS, et al. DNA damage and plasma homocysteine levels are associated with serum metabolites and
mineral constituents' profiles in children with persistent diarrhea. 2010. [107]
Bushen OY, et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of
Cryptosporidium hominis and Cryptosporidium parvum. 2007. [108]
Bustos M, et al. Disaccharidase deficiency in Bolivian children with persistent diarrhea. 2003. [109]
Campbell DI, et al. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy:
association with growth failure, Giardia lamblia, and intestinal permeability. 2004. [15]
Campbell DI, et al. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier
function, leading to endotoxemia and systemic inflammation. 2003. [110]
Campbell DI, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with
nutritional status and small bowel function. 2003. [111]
Campbell DI, et al. Age-related association of small intestinal mucosal enteropathy with nutritional status in
rural Gambian children. 2002. [112]
Chen P, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort
data from northeastern Brazil. 2003. [113]
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Clark TD, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virusinfected children in Uganda. 2002. [114]
Darboe MK, et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard
WHO protocol in Gambian mothers and infants: a randomised controlled trial. 2007. [115]
Dini E, et al. Sudan III and steatocrit in the detection of fecal fat in malnourished children. 2002. [116]
El Mouzan MI, et al. Endoscopic duodenal biopsy in children. 2006. [117]
Fagundes-Neto U, et al. Studies of the small bowel surface by scanning electron microscopy in infants with
persistent diarrhea. 2000. [118]
Filteau SM, et al. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of
infants of HIV-infected South African women. 2001. [119]
Galpin L, et al. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical
enteropathy. 2005. [120]
Gandolfi L, et al. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it
celiac disease? 2001. [121]
Goto R, et al. Impact of anti-Giardia and anthelminthic treatment on infant growth and intestinal permeability in
rural Bangladesh: a randomised double-blind controlled study. 2008. [122]
Goto R, et al. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth
faltering in rural Bangladesh. 2008. [123]
Goto R, et al. Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices
and Giardia lamblia infection. 2002. [124]
Haase A, et al. Dual sugar permeability testing in diarrheal disease. 2000. [125]
Hafeez A, et al. An audit of pediatric upper gastrointestinal endoscopies. 2000. [126]
Jain S, et al. Fecal occult blood screening in children with severe malnutrition. 2007. [127]
Kapoor L, et al. Giardiasis--clinical and diagnostic perspective. 2001. [128]
Kapoor S, et al. Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: A novel experience.
2002. [129]
Kirkpatrick BD, et al. Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young
Haitian children. 2006. [130]
Kirkpatrick BD, et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory
response. 2006. [131]
Kirkpatrick BD, et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian
children. 2002. [132]
Kohli A, et al. Giardia duodenalis assemblage, clinical presentation and markers of intestinal inflammation in
Brazilian children. 2008. [133]
Kukuruzovic R, et al. Increased nitric oxide production in AD is associated with abnormal gut permeability,
hypokalemia and malnutrition in tropical Australian aboriginal children. 2003. [43]
Kukuruzovic R, et al. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. 2002. [134]
Kukuruzovic R, et al. Small bowel intestinal permeability in Australian aboriginal children. 2002. [58]
Laadhar L, et al. Determination of anti-transglutaminase antibodies in the diagnosis of celiac disease in
children: results of a five year prospective study. 2004. [135]
Leite CA, et al. Functional, microbiological and morphological intestinal findings among human
immunodeficiency virus infected children. 2006. [136]
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Lima AA, et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and
specific Giardia spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled
trial. 2010. [137]
Lima AA, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine
supplemented enteral formula. 2005. [138]
Lima NL, et al. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral
formula. 2007. [139]
Long KZ, et al. The effect of vitamin A supplementation on the intestinal immune response in Mexican children
is modified by pathogen infections and diarrhea. 2006. [140]
López de Romaña D, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming
wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. 2005. [141]
Mahmud MA, et al. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhea
among infants in a rural community of Egypt. 2001. [142]
Mahmud MA, et al. Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated
risk factors. 2001. [143]
Manary ML, et al. Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet. 2002.
[144]
Mishra OP, et al. Endoscopic and histopathological evaluation of preschool children with chronic diarrhea.
2001. [145]
Mittal SK, et al. Tropical Sprue in North Indian Children. 2001. [146]
Moya-Camarena SY, et al. Effects of asymptomatic Giardia intestinalis infection on carbohydrate absorption in
well-nourished Mexican children. 2002. [147]
Murphy JL, et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. 2002.
[148]
Murphy JL, et al. Gastrointestinal handling and metabolic disposal of 13C-labelled tripalmitin during
rehabilitation from childhood malnutrition. 2001. [149]
Nichols B, et al. Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition. 2000.
[53]
Northrop-Clewes CA, et al. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology,
growth, and biochemical status. 2001. [150]
Panter-Brick C, et al. Pathways leading to early growth faltering: An investigation into the importance of
mucosal damage and immunostimulation in different socio-economic groups in Nepal. 2009. [151]
Perin NM, et al. Intestinal absorption of D-xylose in children infected with the human immunodeficiency virus.
2001. [152]
Pires AL, et al. Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and
malnourished children with persistent diarrhea. 2003. [153]
Poddar U, et al. Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of
developing countries? 2008. [154]
Poddar U, et al. Celiac disease in India: Are they true cases of celiac disease? 2002. [155]
Quadro L, et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins. 2000. [156]
Rabbani GH, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in
Bangladeshi children with persistent diarrhea. 2004. [157]

52

Rabbani GH, et al. Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or
shigellosis. 2001. [158]
Ritchie BK, et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health.
2009. [159]
Rollins NC, et al. Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants
of HIV-infected South African women. 2001. [160]
Rollins NC, et al. Vitamin A supplementation of South African children with diarrhea: optimum timing for
improving biochemical and clinical recovery and subsequent vitamin A status. 2000. [161]
Samie A, et al. Cryptosporidium species: preliminary descriptions of the prevalence and genotype distribution
among school children and hospital patients in the Venda region, Limpopo Province, South Africa. 2006. [162]
Sarker SA, et al. Helicobacter pylori infection, iron absorption, and gastric acid secretion in Bangladeshi
children. 2004. [163]
Sheng XY, et al. Major variables of zinc homeostasis in Chinese toddlers. 2006. [164]
Sherwani K, et al. Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - A western UP
experience. 2008. [165]
Soliman SM, et al. Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on
nutritional status. 2003. [166]
Tassara O, et al. Gastrointestinal diseases in children infected with the human immunodeficiency virus. 2003.
[167]
Thurnham DI, et al. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. 2000. [168]
Trehan I, et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in
the treatment of tropical enteropathy. 2009. [13]
Vieira MM, et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil. 2008.
[169]
Williams EA, et al. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering
Gambian infants. 2007. [170]
Willumsen JF, et al. Subclinical mastitis as a risk factor for mother-infant HIV transmission. 2000. [171]
Zhang Y, et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and
Cryptosporidium. 2000. [172]

53

Figure 7. Geographic mapping of study sites
Number of studies by country included in the systematic review.
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*One of the studies attributed only to The Gambia in this map had two study locations: The Gambia and India.

Aggregated characteristics of the included studies are presented in Table 10. Details of
the data from each article are reported in the Evidence Table of all studies included in the
review (Appendix 7 ). Data are also presented in individual Evidence Tables based on category
of biomarker (Evidence Tables 1-8). It is important to note that we only include data from articles
that pertain to our review question. No identified study was explicitly designed to assess the
accuracy of the diagnostic tests or biomarkers that they employed among children in
developing-country settings. While this does not detract from their intrinsic value, it does pose
an additional challenge to our goal of evaluating diagnostics for EED. For example, we did not
find data pertaining specifically to standard measures of diagnostic test evaluation, such as
positive or negative predictive values, or receiver operating characteristic curves. We assessed
the use of the biomarkers as they were employed and extracted data relevant to the markers
themselves, even if these data were not the primary focus of the studies.
Table 10. Overview of studies.
Characteristics of studies are provided and demonstrate broad-based nature of current and
recent data.
Study sites by WHO regions, countries: Number of studies
WPRO: China (1), Australia (5)
AMRO: Brazil (16), Haiti (3), Mexico (2), Peru (2),
Venezuela (1), Chile (1), Bolivia (1), Jamaica (2)
AFRO: Zambia (1), Malawi (3), The Gambia (6),
South Africa (5), Uganda (2)
EMRO: Saudi Arabia (1), Pakistan (2), Egypt (3), Tunisia (1)
SEARO: India (10), Bangladesh (7), Nepal (2)
Publication year: Number of studies
2000:10
2001:12
2002:13
2003:10
2004:4
2005:4

2006:7
2007:5
2008:7
2009:3
2010:2

Language of Publication: Number of studies
French: 1
Portuguese: 2
Spanish: 3
English: 71
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Study durations: Time period for subject enrollment
Median: 502 days
Range: 28 days – 17 years
Not specified: 27 studies
Publication Lag: Time from study enrollment to publication
Median: 4 years
Range: 1 year – 15 years
Not specified: 37 studies
Study setting: Number of studies
Urban: 49
Peri-urban: 5
Rural: 16
1
Urban slum : 7
Study designs: Number of studies
Case-controls: 25
Longitudinal cohort: 14
Randomized controlled trial: 16
Cross-sectional: 12
Case-series: 10
Sample size of subjects of interest: Number of subjects in all studies combined
Total: 7730
Interquartile Range: 104
Median: 75
Range: 3-318
Age range of subjects investigated in all studies combined
Range: birth-88 years
Subjects of interest to this review under five years of age: Number of subjects all studies combined
2

Total: 5419
Interquartile range: 119
Median: 71
Range: 3-306
Presenting conditions of study subjects of interest at the time of recruitment: Number of studies

3

Acute Diarrhea: 27
Persistent Diarrhea: 30
Infection with specific enteric pathogens: 28
Cryptosporidium (8)
Giardia (11)
Helminths (4)
Helicobacter pylori (3)
Other (13)
Malnutrition: 45
Infected with HIV or Tuberculosis: 9
Healthy / asymptomatic: 40
Other: 18
1

This comprises any study noted as being conducted in a slum, shantytown, or urban squatter settlement.
Excluding 22 studies that do not specify subjects <4 and 5 years.
3
Number >77 because some studies included more than one condition or test.
2
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Types of specimens and biomarkers reported: Number of studies
Blood (25)
Hemoglobin: 10
Albumin: 9
Immunoglobulins: 7
Lactulose:rhamnose ratio (L:R): 5
α-1-acid glycoprotein: 4
CRP: 5
Red blood cell indices (e.g., Mean
corpuscular volume): 4
WBC: 4
Total protein: 3
D-xylose: 2
Transferrin (saturation): 2
α-1-antichymotrypsin: 2
Cytokines: 1
Immune function assays: 1
Mannose-binding lectin: 1
Nitric oxide: 1
Oxidative stress markers, DNA
damage to lymphocytes, liver
enzymes, thyroid hormones: 1
Radiolabeled iron challenge: 1
Breath (4)
13
C lipid breath test: 1
13
C sucrose breath test: 1
Hydrogen breath test
Lactose: 2
Lactulose: 1
Xylose: 1

4

Urine (32)
5
Lactulose:mannitol (L:M): 25
Radiolabeled zinc or lipid
challenge: 3
Neopterin: 2
Nitric oxide: 2
6
Sucrose:lactulose ratio: 2
D-xylose: 1
7
Lactose:lactulose ratio: 1
Lactulose:rhamnose (L:R): 1
8
Sucralose:lactulose ratio: 1
Stool (24)
Lactoferrin: 9
Leukocytes: 4
Cytokines: 5
Fecal fat: 3
Radiolabeled zinc or lipid
challenge: 4
Reducing substances: 4
Occult blood/RBCs by
microscopy: 3
IgE: 2
Neopterin: 1

Small intestinal aspirates (2)
Concentrations of
immunoglobulins (Ig) IgA, IgG,
and IgM: 1
Microbial concentrations: 1
Small intestinal endoscopic gross
visualization (4)
Small intestinal tissue (18)
Histopathology: 17
Disaccharidases: 2
Protein and inflammatory
markers: 2
Messenger RNA abundances: 1
Site not specified (2)
D-xylose: 2

For studies that included small intestinal biopsy, characteristics specific to biopsy results:
Total subjects of interest: 996
Subjects of interest under five years of age: 8 studies specified
(n=311), 10 did not specify
Site of small intestinal biopsy: Number of studies
- Duodenum: 11
- Jejunum or ileum: 4
- Not specified: 3
Esophagus or stomach also biopsied: 1
Large intestine or rectum also biopsied: 2
4

Number >77 because some studies included more than one condition or test.
18 of the 25 studies include fractional excretion of the individual components.
6
Includes fractional excretion of the individual components.
7
Includes fractional excretion of the individual components; there was also one study that measured lactose
excretion individually without relationship to another sugar.
8
Includes fractional excretion of the individual components.
5
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Comparison of biomarkers to histopathology: Number of studies
Yes: 3 studies compared extra-intestinal tissue markers to
9
10
histopathology: D-xylose (2) ; Fecal fat (1); L:M (1)
Yes: 3 studies compared endoscopic visualization or intestinal
tissue markers to histopathology: Intestinal maltase activity and
various intestinal mRNA abundances (1), endoscopic gross
visualization (1), scanning electron microscopy (compared to
light microscopy) (1)
No: 71 studies
Comparison of extra-intestinal tissue biomarkers to other extra-intestinal tissue biomarkers: Number of
studies
11

Yes: 12 studies comparing:
L:M vs. albumin (1), Immunoglobulins (2), Alpha-1-acid
glycoprotein AGP (1), Endotoxin and IgG endotoxin core
antibody (1) Fecal neopterin (1); Lactose and Lactose:lactulose
(1)
Serum L:R vs. urinary L:R (1), sucrose breath test (1), urinary
nitric oxide (1), serum lactose (1), reducing substances (1), red
cell indices (1)
Fecal lactoferrin vs. TNF-α receptor I (1), Urinary
lactose:creatinine vs. hemoglobin (1); Urinary nitrites vs. stool
reducing substances (1); Serum nitrites vs. WBC (1)
No: 65 studies

We calculated that in the 77 papers analyzed, a total of 5,410 children under five years
of age were studied for any biomarker plausibly related to EED, and an additional 2,311 children
were studied, among whom the number of subjects aged under five years could not be
determined (Table 10). More than 50 different biomarkers were studied. These biomarkers were
obtained by study of urine, stool, blood, breath, and intestinal tissue. Eighteen studies examined
the histopathology of biopsied intestinal tissue, but only three studies compared intestinal
histopathology to non-intestinal tissue biomarkers (D-xylose; fecal fat; urinary L:M [111, 136,
155]). One additional study compared results of intestinal tissue markers (maltase activity and
intestinal mRNA abundances for various markers) to histopathology [53]. Notably, few small
9

One study compared D-xylose as well as fecal fat.
This study compared the lactulose:mannitol ratio (L:M) to morphometric analysis of biopsy tissue.
11
Number of comparisons listed is >12 because some studies included more than one comparison.
10
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bowel biopsies (the “gold standard” diagnostic) among children under five years of age in
developing-country settings are included in this cohort of studies from the past eleven years.
Indeed, small bowel biopsies from only 311 children under five years of age in eight studies
were reported, and an additional 685 children in 10 other studies had small bowel biopsies but
the number of those who were under five years of age could not be determined.
We were also interested in the lag time between study enrollment and publication, and
examined a subset of the first 24 articles relevant to the systematic review. Table 11 provides
intervals between enrollment, study start and close, study duration, and year of publication for a
subset of the first 24 articles that we reviewed. There were, in general, long delays in cohort
enrollment and dissemination of primary data (up to 19 years, and often over a decade).
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Table 11. Study timing analysis.
Dates of publication, enrollment, and performance of a subset of publications. Seven of 24
studies did not specify study time interval.
Publication
Year

Study enrollment years

Range of study intervals

Aug 1994-May 1995
30 days – date not specified
1993-2002
2006

Not specified

1991-2002

9 months – date not specified
15 months – date not specified
Not specified
1991-2001
Sept 2001-October 2004

2007

July 2003-November 2004

2001-2004

5 years – date not specified
June 2003-February 2004
June 2003-April 2004
2008

Jan 2000-Dec 2002

1989-2004

Not specified
Aug 1989-Apr 1993 (current study 2004)
July 2000-Aug 2001
3 days- date not specified
Date not specified

2009

2005 – 7 months

1998-2007

Sept 2007
1998-2000
2010

June 2000-Aug 2004

2000-2004

Not specified
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4.3 Classification of Biomarkers and Diagnostic
Tests
The “job description” of the small bowel can be reduced to a circumscribed set of tasks:
break down specific nutrients using enzymes in the intestinal lining or by micellization of
lipophilic substances; extract nutrients from food; exclude the food components that have no
nutritive value and propel them distally for elimination; retain (i.e., not leak into the gut)
molecules used (and often synthesized) by the host; and resist microbial breach of the barrier.
Hence, the intestinal mucosa serves as a specialized transporting organ as well as a physical,
physiologic, and antimicrobial interface between the host and the environment which in this
case consists of ingested food and water, but also other potentially highly contaminated
materials (e.g., soil) [173], given the oral-motor activities of infants and toddlers. The cells and
submucosa that line the small bowel are, therefore, critical for assimilation of nutrients,
maintenance of structural integrity, and protection against microbial assault. In injury,
substances are absorbed by barrier breach rather than by physiologic transport or diffusion.
We strove to take an unbiased and uniform approach to classifying the EED markers.
Our classification system was blinded to the assertions of study authors regarding marker
category; however we did find that investigators’ categorizations were largely consistent with
ours. Our classification system was based on the primary function/dysfunction that the test is
likely to measure or the underlying pathophysiology and pathogenesis that the test may likely
reflect. For example, the amount of D-xylose that is absorbed after an oral challenge is believed
to reflect gut absorptive capacity, and D-xylose uptake from the challenge, measured either in
the blood or urine, is therefore classified as a test of gut absorption. We also aimed to
unambiguously place a marker in one group based on best fit when possible, though we
recognize that markers might detect derangements of multiple functions. For example, the
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presence of lactose in the blood or urine likely indicates a loss of lactase enzyme in the
intestinal brush border, and thus can be a marker of abnormal digestion or nonspecific intestinal
injury. However, for lactose to traverse the mucosa and gain access to the systemic circulation,
a porosity defect is needed. Hence, we chose to place this marker in the permeability category.
Finally, we recognize that many tests reflect nonspecific injury and processes, which
cannot be so easily binned into mechanistic or pathophysiologic categories. For example, while
measures of surface area on a biopsy provide a general impression of absorptive capacity, we
categorize histopathology as a measure of nonspecific injury, as the visualization of tissue
portrays a general picture of derangements in architecture without specifying function.
With these factors in mind, we formulated eight test categories, classified in Table 12,
and constructed evidence tables based on these classifications.
Table 12. Classification framework for biomarkers of intestinal function/dysfunction and
inflammation.
Evidence
Table

Type of Functional Measure

1

Absorption

2

Porosity/permeability (with or without assessment of absorption)

3

Digestion

4

Intestinal inflammation and/or intestinal immune activation

5

Systemic inflammation and/or systemic immune activation

6

Microbial drivers

7

Nonspecific intestinal injury

8

Non-small intestine organ function
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Chapter 5. Systematic Review Results by
Biomarker Classifications
5.1 Markers of Absorption and Permeability:
Overview
Tests of gut permeability and of absorption often overlap in concept, and are frequently
performed simultaneously. For this reason, it is appropriate to provide background in tandem.
Proper functioning of the intestine depends on sufficient absorptive surface area and
maintaining the barrier function and structural integrity of the lining of this organ. Absorptive
surface is a function of individual villous surface area, as depicted in the photos below [3], and
of gut length, which is probably not compromised in post-natally-acquired enteropathic
syndromes. Absorption depends on the ability of various cellular mechanisms to assimilate
nutrients from food that is ingested, using processes that rely on specialized pumps, pathways,
and degradation. Integrity reflects
sieve size, and presumably passive
diffusion of large molecules across
non-intact epithelia. To varying
extents, these functionalities are
hindered in EED, celiac disease, and
small bowel Crohn’s disease, among
other disorders.
To perform its functions, the
Microvilli of the small bowel, as seen with a magifying lens
[3]. Normal finger-like projections are presented in the top
panel. Enteropathy is characterized by flattened villi (bottom
panel). Reproduced from Gut, Booth, C.C., Vol. 5, p. 46,
1964 with permission from BMJ Publishing Group Ltd.
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intestinal epithelium utilizes a layer of

highly specialized columnar epithelial cells connected by the apical junctional complex of tight
junctions and adherens junctions. Theoretically, specific molecules can be chosen strategically
to interrogate these various attributes. For example, breaches in integrity that enable passive
diffusion into the host could be measured by ingesting a substance that is not found in the diet,
and measuring its concentration in the blood or urine. Another detection strategy would be to
use a molecule that is easily absorbed in health and disease, but where absorption is limited
only by mucosal surface availability, and, similarly, measure this tracer in urine and blood. The
optimal challenge substances would resist digestion in the gut, be nontoxic, and be easily
measured. Ideally, one attribute (surface area) can and should be measured in parallel with the
other (specific uptake). Lastly, it might be difficult to separate one function (i.e., permeability)
from the other (absorption); therefore these two processes are discussed in tandem in this
section.

5.1.1 Sugars as Tracers of Intestinal Function
Historically, sugars have served well as tracers of intestinal function. These substances
are nontoxic, easily detected in blood or urine, and, most importantly, neither made, nor
degraded, by the host, so their presence in the body reflects gut uptake. Most of these sugars
are assayed after ingestion of a load. Some of these sugars are “endomolecular,” i.e.,
consumed as part of a normal diet, but most are “xenomolecular,” i.e., foreign to natural diets,
not metabolically necessary for the host, and absorbed without the benefit of specific
transporters. Because they are foreign to the human diet, their use as a marker of intestinal
function requires administration of a load to assay presence in body fluids. Moreover, depending
on their size and the physiology of their assimilation, these sugars can be used to probe either
amalgamated function, or specific processes or lesions (see Table 13).
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Table 13. Sugar probes.

Sugar

Molecular
weight

D-xylose

150.13

Lactose

Lactulose

1

Molecular structure

Endo- vs.
Xeno1
molecular

Primary function
assessed when found
in blood and/or urine /
Other comments

Chemical (IUPAC) name

Formula

[174]

D-xylose

HOCH2
(CH
(OH))3CHO

Xenomolecular

Measure of small bowel
(perhaps primarily
jejunal) absorptive
capacity. Sugar
synthesized by wood.

342.3

[175]

β-D-galactopyranosyl-(1→4)D-glucose

C12H22O11

Endomolecular

Measure of small bowel
permeability, although
might also reflect lactase
deficiency.

342.30

[176]

4-0-β-D-galactopyranosyl-Dfructofuranose

C12H22-011

Xenomolecular

Measure of small bowel
permeability. Usually
normalized to mannitol.

We use the term xenomolecular for probes that would not be ingested in a normal dietary environment, while endomolecular probes are common
and/or necessary dietary constituents. Therefore, endomolecular probes or their breakdown products are typical constituents in body analytes.

Table 13. Sugar probes.

Sugar

Molecular
weight

Mannitol

182.17

Rhamnose 164.16

Sucralose

397.64

Sucrose

342.30

Molecular structure

Endo- vs.
Xeno1
molecular

Primary function
assessed when found
in blood and/or urine /
Other comments

Chemical (IUPAC) name

Formula

[177]

(2R,3R,4R,5R)-Hexan1,2,3,4,5,6-hexol

C6H14O6

Xenomolecular

Measure of total small
bowel absorptive
capacity.

[178]

2R,3R,4R,5R,6S)-6methyloxane-2,3,4,5-tetrol

C6H12O5 ·
H2O

Xenomolecular

Has been used in lieu of
mannitol as a measure of
total small bowel
absorptive capacity.

1,6-Dichloro-1,6-dideoxy-β-Dfructofuranosyl-4-chloro-4deoxy-α-D-galactopyranoside

C12H19-Cl3O8

Xenomolecular

Measure of colonic
permeability. Active
R
ingredient in Splenda .

Structural α-D-glucopyranosyl(1→2)-β-D-fructofuranoside

C12H22-O11

Endomolecular

Measure of gastric
permeability.

[179]

[180]

An early sugar that was employed as an indicator of intestinal function was D-xylose
[181, 182], a pentose, which remains a standard for single sugar absorption testing worldwide.
Humans do not synthesize D-xylose isomerase. Following an enteral challenge, the molecule is
eliminated intact by renal clearance, after circulating in the blood. It is largely passively
absorbed in the small bowel. The mechanism of clearance is glomerular filtration without
demonstrated tubular reabsorption or renal tubular excretion. Hence, uptake of D-xylose can be
assayed by seeking the peak in the serum or by collecting urine for assay. The assay for Dxylose currently relies on isotopic or photometric assays [183]. Its main limitation is that a single
sugar cannot differentiate loss of absorptive function from loss of absorptive area (e.g., due to
shortened bowel length). Other single sugars that indicate absorptive function include mannitol
and rhamnose. Sugars that are not absorbed by an intact healthy gastrointestinal tract better
reflect porosity including lactose and lactulose in the small intestine, sucrose in the stomach,
and sucralose in the large intestine.
The second class of sugar absorption tests utilizes two sugars. One sugar reflects total
small bowel absorptive capacity, and is most often mannitol or, occasionally, rhamnose. This
"denominator" sugar requires no specific uptake mechanisms or host attributes except for
available surface area. The “numerator” sugar in these dual tests is most often lactulose
although lactose, sucrose, and sucralose have also been used. These large molecules enter the
host by passive diffusion in the presence of alterations of the integrity of the small bowel
(lactulose and lactose), stomach (sucrose), or colon (sucralose).
Dual sugar tests have additional advantages. A single molecule might be affected by
factors that are not related to the permeability process, e.g., rates of gastric emptying and
intestinal transit, bacterial degradation, or the sufficiency of urine collection. In contrast, a ratio
of excretion of two molecules is not susceptible to these factors, because such processes act on
both molecules similarly, and the ratio is the key retained metric. However, absolute values
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might be low in these situations, and dynamic ranges for uptake are not well established.
Finally, in adults, some data suggest that the use of hyperosmolar fluids (i.e., lactulose and
mannitol) might affect absorption via solvent drag [184]. For purposes of comparison, the four
grams of lactulose and one gram of mannitol dissolved in five milliliters of water, a commonly
employed formulation [185] produces a solution that is 4,629 mOsm/kg as compared to normal
plasma osmolality of 270-285 mOsm/kg.
Variations on the challenge and recover motif used in the classic sugar absorption
studies warrant discussion. Some studies use indirect assessments of uptake. For example,
non-absorbed D-xylose can be metabolized by microbes in the bacteria-rich colon, and possibly
also in small bowel bacterial overgrowth, and measured as exhaled carbon dioxide.
We reviewed 36 studies that assessed small intestinal absorption or permeability using
sugars as absorbed probes. Three studies measured lactose, an endomolecular sugar, either in
the serum (n=1) or urine (n=2) among breastfeeding children. Of the 36 studies, 35 assessed
malabsorption/permeability deficits by administering xenomolecular sugar challenges using
lactulose, mannitol, rhamnose, or xylose (including one study each that also measured serum
and urinary lactose). We reviewed five studies that reported xenomolecular probe results
of single-only sugar tests, and 30 studies that reported results of dual sugar tests. The dual
sugar tests included urinary L:M (n=25 studies), urinary or serum L:R (n=5), and urinary
lactose:lactulose (n=1). The single sugar assay was used in six studies: urinary lactose (n=1)
and D-xylose (two using serum measures, one using urine as a substrate, and two in which the
body fluid from which the sugar was measured was not reported).

5.1.2 Endomolecular Nutrients as Tracers of Intestinal Function
Essential nutrients that are absorbed by healthy small intestine provide another
opportunity to assess gut absorptive function. These types of marker assessments can provide
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especially valuable information regarding the role of derangement of gut function among
children with nutrient deficiencies, i.e., how much of the deficiency is because of lack of intake
rather than malabsorption. Since these molecules are naturally found in body analytes, load
administration requires tagging such as with the use of radiolabeled molecules, quantification of
which can then be assessed in breath, blood, urine, and/or stool as surrogate markers of
absorptive capacity. We reviewed six studies that utilized such methodologies including
assessments of zinc (n=3), lipid (n=2) and iron (n=1) absorption.
We present in Evidence Tables 1 and 2 data from publications that utilized markers of
absorption and permeability, respectively. Evidence Table 1 depicts data related to the
systematic review from the articles that reported results of markers that were principally related
to absorptive functions (such as D-xylose and fecal fat). Evidence Table 2 contains data on
markers related to porosity or permeability. However, tests of gut permeability are often
assessed simultaneously with markers of absorption. For example, the lactulose:mannitol ratio
(L:M) and lactulose:rhamnose ratio (L:R) are often described as tests of permeability; however,
by their nature they do include measures of absorption (via mannitol and rhamnose,
respectively). For this reason, we present markers of permeability with or without concomitant
assessment of absorption in Evidence Table 2. We identified 44 publications that assessed
small intestinal absorption (13 studies) or permeability (primarily, sometimes also with some
assessment of absorption based on dual sugar testing; 31 studies) in children in resource-poor
settings.

5.2 Markers of Absorption
Data regarding markers of absorption are presented in Evidence Table 1.
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Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest
2002
Dini E et al.

Location and
Target Population

Caracas, Venezuela Case-control

6 mo-9 yr olds with
recruited from an
Sudan III and
outpatient nutrition
steatocrit in the
center and welldetection of fecal fat nourished controls.
in malnourished
children
Fecal fat by four
different testing
methods as a
marker of
malabsorption
among children with
varying nutritional
status and wellnourished controls

Design and
Sample Size

n=129;
n=99 cases:
• 30 with
subclinical
malnutrition
• 34 with mild
malnutrition
• 30 with
moderate
malnutrition
• 5 with severe
malnutrition
n=30 controls

Biomarker

Results

Stool Test:
Fecal fat, by method:
• Sudan III
classic
• Sudan III
modified
• Steatocrit
classic
• Steatocrit acid

Conclusion

Proportions testing positive for A majority of children
fecal fat ranged from 33%-41% studied tested negative
overall, depending on test
for fecal fat.
method used.
The highest percent
The proportion testing positive testing positive was in
varied by nutritional status
those with severe
across testing methods:
malnutrition, followed by
those with subclinical• 80%-100% of severely
malnourished subjects had a moderate malnutrition.
Controls had the lowest
positive test
• Similar proportions of subjects percent testing positive.
Each subject
underwent testing for with subclinical, mild or
moderate malnutrition tested Subjects with enteric
all four methods.
parasites or those
positive, ranging from 30%experiencing diarrhea at
47%
time of testing excreted
• 13%-27% of controls tested
fat significantly more
positive
These differences appeared to often than uninfected
children without
be significant, but statistical
diarrhea, although the
comparison results were not
magnitude of difference
entirely clear.
was not reported.
Fecal fat did not vary based on
There was some
quantity of fat intake.
variation between the
different testing
By all four methods, a high
methods, for example
percentage of children with
parasites tested positive (~60%) their relationship with a
history of diarrhea in the
compared to children without
year prior to testing.
parasites (25%).
Associations were observed
between infection with Giardia
lamblia or Blastocystis hominis
and fecal fat (p<0.05); this held
true across diagnostic methods.
The presence of diarrhea at time
of testing was positively
associated with fecal fat by all
test methods (p<0.02 for all
except steatocrit classic,

Comments
Spanish language
article.
Control recruitment
strategy was not
well described.
Proportions positive
for fecal fat by
history of diarrhea
(current or
previous) were not
provided.
Authors reported
percent agreement
between tests but
did not report
results of statistical
testing of these
estimates.
Test results varied
by subject
characteristics;
however,
assessments
adjusting for
potential
confounding were
not reported.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

There was a high
prevalence (100%) of
abnormal D-xylose
results among HIVinfected children,
regardless of diarrhea
status.

Portuguese
language article.

p=0.06).
The relationship between fecal
fat and history of diarrhea in the
year prior to testing varied by
test method:
• Sudan III classic: p=0.134
• Sudan III modified: p<0.001
• Steatocrit classic: p=0.14
• Steatocrit acid: p=0.015

2006

Sao Paulo, Brazil

Cohort

n=11;
5 mo-12 yr old
(median 24 mo) HIVn=5 patients with
Functional,
infected subjects
current or recent
microbiological and recruited from a
morphological
hospital and clinic. episode of
diarrhea
intestinal findings
among human
All subjects had
n=6 patients with
immunodeficiency
some degree of
no diarrhea in the
virus infected
protein-energy
30 days
children
malnutrition.
preceding
enrollment
Small intestinal and
rectal biopsy to
assess morphology
and D-xylose as a
marker of
malabsorption
among HIV-infected
children
Leite CA et al.

Blood Test:
D-xylose
(9 tested)

Agreement between all four
methods was 72%. Agreement
between at least three was
91.5%.
100% had low D-xylose
absorption:
• Mean: 15.6 mg/dL
• SD: 5
• Range: 8.9-24.4
• Median: 14.2

D-xylose <25 mg/dL
was defined as
Biopsy of small
indicative of
intestine by tethered
malabsorption. This
capsule or
Small intestinal biopsy:
value is higher than
endoscopy:
• 100% had some degree of
what some
All patients also had
Histopathology
villous atrophy based on a I-IV cellular infiltration of the references have
grading system:
noted as a cut-point
(10 tested)
lamina propria and
[186]
varying degrees of
• Grade I: 3
Investigators used
villous atrophy.
• Grade I/II: 2
Rectal biopsy:
a well-articulated
• Grade II: 1
Histopathology
There
was
no
correlation
system of grading
• Grade II/III: 1
between
D-xylose
and
villous atrophy.
(6 tested)
• Grade III/IV: 1
degree
of
villous
atrophy
• 2 samples were too
Results were not
on biopsy.
superficial to assess
presented by
• Intraepithelial lymphocytes
diarrhea status,
were increased in half of the
perhaps due to
biopsies.
small sample size.
• Lymphocytic and
polymorphonuclear (PMN)
infiltration of the lamina
propria were present in 10/10
and 7/10 biopsies,
respectively.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Rectal biopsy:
• 100% had normal architecture
Lymphocytic and PMN infiltration
were present in 6/6 and 4/6,
respectively.
2005
Lima, Peru
RCT
Urine Test:
Mean zinc parameters (SD) at Despite a reduction in
Zinc excretion to
initial assessment:
FAZ with increasing
measure fractional • FAZ:
López de Romaña D 3-4 yr olds residing n=41;
fortification, TAZ
absorption of zinc
et al.
in a poor community (31 completed
increased as more zinc
• Group 1: 0.34 (0.11)
(FAZ) and total
at the periphery of both initial and
was consumed and with
• Group 2: 0.24 (0.05)
absorbed zinc (TAZ)
follow-up
Longitudinal
Lima with stunting
increasing
• Group 3: 0.13 (0.04)
absorption assay following
measurements of
and moderate
concentrations of zinc
• TAZ (mg/d):
radiolabeled zinc
at 2 mo)
zinc absorption in
anemia as a
fortification.
• Group 1: 0.71 (0.18)
administration
Peruvian children
surrogate risk factor
• Group 2: 1.11 (0.21)
Authors speculate that
consuming wheat
for zinc deficiency. Group 1:
• Group 3: 1.34 (0.47)
n=14 received
reduction in FAZ with
products fortified
wheat flour with
increasing fortification
with iron only or iron
Neither mean FAZ nor TAZ
iron fortification
could be due to factors
and 1 of 2 amounts
changed significantly at
only
of zinc
subsequent assessments in any such as saturation
(10 completed
kinetics.
treatment group.
follow-up)
Zinc absorption
Authors described a
among stunted,
In both the initial and
Group 2:
anemic children
subsequent assays, mean TAZ unexpected finding:
n=12 received
subjects consuming
receiving zinc as
from zinc-fortified meals
wheat flour with
more zinc from the zincwell as iron and/or
increased with increasing
iron and 3mg
fortified breakfast
iron/zinc-fortified
amounts of fortification (p<
zinc/100g flour
foods
0.001). However mean FAZ was and lunch meals
(9 completed
inversely related to zinc intake absorbed less zinc from
follow-up)
the unfortified
from these meals (p<0.001).
dinners during the initial
Group 3:
absorption assay.
Non-fortified dinner FAZ and
n=15 wheat flour
TAZ were significantly lower in
with iron and 9mg
the group receiving the most
zinc/100g flour
zinc-supplementation at the
(12 completed
initial assay (p=0.015 and
follow-up)
p=0.012, respectively) despite
no difference in zinc intakes
from the unfortified dinner by
treatment group. This
relationship between groups was
not observed at the second
assay; however, a significant
decrease of 16% in mean FAZ

Comments

Intestinal function
could play a role in
zinc (or other
micronutrient)
absorption; such
factors were not
explored in this
study.
The principal aim of
this study was to
determine
appropriate extent
of zinc fortification
of a staple food in a
specific community;
we present only
results relevant to
this review.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest

2002

Location and
Target Population

Design and
Sample Size

Results

Conclusion

Comments

and TAZ from the unfortified
dinners was observed between
initial and subsequent assays
(p<0.001).

Blantyre, Malawi

Case-series

n=10
2–5 yr olds (mean
age 43.6 mo, SD
Zinc homeostasis in 7.7) from rural area
Malawian children
attending
consuming a high- immunization clinic.
phytate, maizebased diet
There was a high
prevalence of
Zinc absorption in a stunting and low
sample of 10
plasma zinc in this
asymptomatic
series.
children
Manary ML et al.

Biomarker

Mean plasma zinc
concentrations did not differ
between treatment groups
throughout the study period. The
proportion with low fasting
plasma zinc concentrations
(<65μg/dL) was lower at the end
of the study (3.3% vs. 20.5%
initially, p=0.046).
Stool Test:
Mean (SD):
EFZ was higher than
Authors note that
Endogenous fecal • FAZ: 0.24 (0.04)
would be expected for a the lack of
zinc (EFZ)
• TAZ (mg/d): 1.30 (0.33)
zinc deficient cohort, and comparable
• EFZ (mg/d): 1.15 (0.33)
EFZ was not correlated data from children
with TAZ as would have of the age range in
Urine Test:
Language in the discussion
this study limits
been expected. While
Zinc excretion to
section strongly suggests, but
data interpretation.
high-phytate diets
measure fractional does not explicitly state, that
They also provide
leading to poor zinc
absorption (FAZ)
TAZ and EFZ were not
absorption might explain results per body
and total absorption correlated. Correlation analysis these findings, the
weight due to
(TAZ) following
for these parameters was not
presumed
authors note that in a
radiolabeled zinc
reported.
previous study (among a relationship; validity
administration
somewhat older age
of such measures
has not been
group) there were no
established.
differences in EFZ
among children
consuming high- or low- Authors comment
phytate diets [187]. They that the methods
note that such
used for calculating
absorption
perturbations in EFZ
have also been reported measures are
sensitive and
in children with
accurate, but quite
enteropathy due to
cystic fibrosis [188] and difficult to conduct,
especially among
suggest that a similar
process could be going children.
on in these Malawian
children due to TE.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest
2001

Location and
Target Population

Design and
Sample Size

New Delhi,
India

Case-series

n=94;
(38 with repeat
0-15 yr old
biopsies)
Tropical sprue in
gastroenterology
north Indian children clinic patients with
<5 yr old: n=44
PD.
D-xylose and
duodenal biopsy as Those with abnormal
morphology on
markers of TS
biopsy, abnormal Dxylose test, and
clinical response to
antibiotics were
diagnosed as having
TS.
Mittal SK et al.

Those with abnormal
morphology and
response to glutenfree diet were
diagnosed with CD.
We include data on
these subjects for
comparative
reasons.

2002

Hermosillo, Sonora, Case-control
Mexico
n=13;
Moya-Camarena SY
3-6 yr olds in a
et al.
<5 yr old:
periurban setting
Effects of
attending preschool n=5
asymptomatic
centers meeting
Giardia intestinalis inclusion criteria of n=7
infection on
no GI symptoms, no asymptomatic
carbohydrate
antibiotics in the
cases infected
1

D-xylose results were expressed as % of dose administered.

Biomarker

Results

Conclusion

Comments

Duodenal biopsy,
36 (38.3%) were diagnosed with More than half of the GI Biopsy results were
method not specified: TS including 14/44 (31.8%) who clinic patients with PD
not provided for
Histopathology
were under 5 years of age.
patients without TS
had some degree of
or CD.
villous atrophy.
18 (19.1%) were diagnosed with
Blood Tests:
CD.
More than one-third and It was unclear if
there were patients
almost one-fifth of
• Hemoglobin
Degree of villous atrophy among subjects were diagnosed with abnormal D• D-xylose*
TS vs. CD patients:
with TS and CD,
xylose and
• Mild in 8/36 (22.2%) vs. 0
histology who did
respectively.
• Moderate in 23/36 (63.9%) vs.
not respond to
* Not specified
4/18
(22.2%)
By
study
diagnostic
antibiotic therapy
whether from urine or
•
Severe
in
5/36
(13.9%)
vs.
and therefore were
definition,
all
TS
patients
serum, and units of
improved with treatment. not diagnosed with
14/18 (77.8%)
measurement not
Among those who had TS.
provided.
Mean hemoglobin concentration repeat biopsies, almost
(range) among TS patients was three-quarters showed Cut-off points used
8.3 g/dL (5.5-11) and did not
to define abnormal
normalization of
differ from values of those with histology, while 23% had D-xylose tests were
CD.
partial improvement and not provided.
1 patient had worsened
Among the 22 TS patients,
pathology.
repeat biopsies showed:
• 16 with normalization
• 5 with improvement
• 1 worsened despite marked
clinical improvement

Breath Tests*:
• Lactose HBT
• D-Xylose HBT**
Urine Test:
,1
D-xylose**
* Reported as parts

The D-xylose test was abnormal
in all TS patients by diagnostic
definition.
Mean lactose HBT (SE):
• Cases pre-treatment: 3.6
(0.75) ppm
• Cases post-treatment: -0.85
(0.75) ppm (p<0.05 compared
to pre-treatment)
• Controls: 0.19 (0.81) ppm
(p<0.05 compared to pretreatment cases)

Lactose HBT
concentrations were
normal according to
established cut-points
among all subjects.

Statistical methods
might not have
been adequate to
account for intrasubject correlation
when comparing
However, lactose HBT the same group of
was significantly higher subjects (cases)
among cases compared before and after
to controls and there
treatment.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest
absorption in wellnourished Mexican
children

Location and
Target Population

Design and
Sample Size

preceding 3 wk, and only with G.
intestinalis
no SBBO by
lactulose HBT and
n=6 controls
Indican test.
without Giardia

Biomarker

Results

Conclusion

per million (ppm)
Mean xylose HBT (SE):
was also a significant
post-substrate
• Cases pre-treatment: 2.2
decrease in lactose HBT
ingestion after
(0.69) ppm for infected group among cases after
• Cases post-treatment: -4.16 treatment. The clinical
subtraction of
Lactose hydrogen
(0.69) ppm (p<0.05 compared relevance of such mildly
baseline, prebreath test (HBT) as
to pre-treatment)
elevated HBT results in
substrate H2
concentrations. A
• Controls: 1.13 (0.74) ppm (NS asymptomatically
a marker of lactose
Cases were
positive HBT is
compared to pre-treatment
absorption, and
infected children is
evaluated before considered to be a
cases)
xylose breath test
unclear.
and urinary excretion
and 3 wk after
rise of >20ppm in
as markers of xylose
treatment with
breath H2 above
Mean urinary excretion of xylose Results did not
tinidazole. Post- baseline H2
(SE) among cases pre-treatment demonstrate xylose
absorption in welltreatment stools concentration.
and post- treatment was 34% (3) malabsorption by either
nourished children
were verified for
and 46% (11), respectively (NS), urinary or breath
with asymptomatic
absence of
** Investigators did well above cut-offs indicative of measures among any
giardiasis and nonparasites.
not specify the xylose malabsorption.
infected controls
group. While urinary
enantiomer used,
results did not differ
however test
before and after
functionality
treatment, case xylose
characteristics lead
HBT was significantly
us to assume that it
lower after treatment;
was the dextrorotary
again the clinical
(D) enantiomer.
significance of such
results is not apparent.
2002
Kingston, Jamaica Case-series
Stool Tests:
Median total stool excretion of High concentrations of
13
13
C in phase 1 was 9% (range:
C (compared to
• Total and
13
n=24
1%-29%) and did not vary
Murphy JL et al.
5-23 mo olds
healthy UK children)
fractionated C
between TG groups.
admitted to the
[190] were observed in
following
13
Maldigestion and
Tropical Metabolism Subjects were
ingestion of one Median C excretion dropped half of the subjects at
13
33%-99% in phase 2 and 86%- admission, reflecting
malabsorption of
Research Unit of the divided into 3
of three C
groups of 8
95% in phase 3 compared to
dietary lipid during University of the
impaired digestion or
labeled
children, each
severe childhood
West Indies with
absorption.
triglycerides (TG): phase 1 (p<0.05 each).
malnutrition
severe malnutrition. group receiving a trilaurin, triolein,
different labeled
Over the study period, there
The differences in stool
or trilinolein*
13
13
Stool recovery of
triglyceride.
were significant associations
C were wide but not as
• C stool assay
between total lipid and the
extreme as in a previous
radiolabeled
following
13
Data were
amount of C labeled TGs in
study by same
products as markers
administration of
collected in three labeled fatty acid
stool for some groups, but not
investigators (also
of lipid digestion and
13
separate phases
examined in this review)
absorption, and bile
C glycocholate** for others.
as described
using a different TG
salt deconjugation
13
above in JL
Median C in TG and FA was (tripalmitin) substrate
as a marker of
Murphy et al.
similar across TG groups in all [149].
SBBO among
* To assess fat
children with severe
2001 [149].
excretion as a % of phases. 13C FA recovery was

Comments
Investigators
wished to exclude
children with SBBO.
As such, inclusion
criteria restricted
participants to
those with
adequate
production of H2
following ingestion
of lactulose and
with minimal urinary
indoxyl sulfate
excretion. The
number of children
excluded due to
failure to meet
these criteria was
not reported.

Authors state that
the study was not
powered to
compare the
different TGs, but
they contend that
medium chain
trilaurin did not
appear to be
processed
differently than the
longer chain TGs
triolein and
trilinolein.
Authors did not
describe the
method used to
assign subjects to

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest
malnutrition

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

dose administered.
Also assessed
13
proportion of C in
triglyceride (TG) and
fatty acid (FA)
fractions to
distinguish excretion
caused impaired
digestion (presence
of TG) vs. poor
absorption (presence
of FA).

similar and reduced by ~2/3
13
compared to Phase 1. C TG
was not detectable in Phases 2
or 3. Statistical comparisons
between phases were not
reported.

13

different TG groups.

C excretion did not
significantly differ
between TG groups and
declined with improving
clinical course.

While it was noted
that some subjects
had positive stool
cultures, details
Similar to their previous were not provided
13
C after radiolabeled
study, significantly more on the nature of the
13
glycocholate administration was C in stool was
enteric infections.
detected in stool at quantities
recovered as FA than
considered to be in excess of
TG, reflecting impaired
the 7% recovery of dose
absorption over poor
administered upper limit of
lipid digestion/
** To assess bile salt normal in U.S. adults in [189]:
hydrolysis. Unlike in their
previous study, there
deconjugation in the • Phase 1: 13/24 (54%)
• Phase 2: 5/24 (20.8%)
was evidence of SBBO
bowel caused by
Phase 3: 3/24 (12.5%)
as measured postSBBO; conducted
13
ingestion of C
after the TG
glycocholate.
assessment and a 3
day washout period.
2001
Kingston, Jamaica Case-series
Stool Tests:
Mean fecal fat (SD):
Mean fecal fat was not Statistical methods
• Phase 1: 2.4 g/day (3.6) or
elevated compared to
might be
• Fecal fat*
7-23 mo olds with
n=8
Murphy JL et al.
5.9% (9.4) of dietary lipid
published norms [191, inappropriate for a
• Total and
13
malnutrition admitted
intake
192], during any study small sample.
fractionated C
Gastrointestinal
to the University of
• Phase 2: 1.7 (0.9) g/day, or
phase.
assay after
Data were
All subjects were
handling and
the West Indies.
3.3% (2.4) of intake
administration of
metabolic disposal of
collected in three 13C tripalmitin
• Phase 3: 0.9 (0.6) g/day, or
There was wide variation treated with
13
C-labelled
separate phases
in fecal fat at
antibiotics including
1.4% (0.7) of intake
(TP)**
13
(each lasting 9
•
Differences
between
phases
metronidazole for
tripalmitin during
presentation,
and
wide
• C assay after
13
days):
C
presumptive SBBO;
were
not
statistically
rehabilitation from
variations
in
stool
administration of
1. Within 48 hours 13C glycocholate
across subjects. Authors this might have
significant.
childhood
of admission
indicate that this is the affected GCA
malnutrition
(GCA)***
13
2. During early
Total excretion of C in stool
first such assessment in testing.
also varied widely across
Fecal fat, stool
rehabilitation
malnourished children;
Breath Tests:
13
3. During late
patients (0%-44%) and did not previous studies on
recovery of
• CO2 after
differ between study phases.
healthy children from the
rehabilitation
radiolabeled
administration of
13
UK demonstrated
products, and breath
C glycocholate
13
Correlation
between
fecal
fat
average excretion of 6%
tests as markers of
(GCA)*** or C
13
and
C
(r=0.48;
p<0.05)
was
[190].
lipid digestion and
TP****
observed.
absorption and bile
The majority of excreted
salt deconjugation
* In 72 hour stool
13
C was in the form of
as a marker of
collection (measured Lack of lipid digestion and
FA rather than TG.
SBBO among
as total grams and as absorption were assessed by

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
children with severe
malnutrition

Design and
Sample Size

Biomarker
% of dietary fat
intake).

Results

measuring TG and FA fractions,
13
respectively. Mean C TG
recovery (SD) (% of
administered dose), number of
** To assess fat
excretion as a % of patients excreting TG:
dose administered. • Phase 1: 0.7% (1.6), n=3
• Phase 2: 0.9% (2.8), n=1
Also assessed
13
proportion of C in • Phase 3: no recovery from
triglyceride (TG) and
any subjects, differences
fatty acid (FA)
between phases were NS
fractions to
13
distinguish excretion C FA fraction in stool declined
caused by impaired during rehabilitation.
13
digestion (presence Mean C FA recovery (SD):
• Phase 1: 6.0% (7.3)
of TG) vs. poor
absorption (presence • Phase 2: 4.8% (3.7)
• Phase 3: 3.3% (3.8),
of FA).
differences between phases
were NS
*** To assess bile
salt deconjugation in
the bowel caused by Mean FA values were ~9x (NS),
5x (p<0.001), and 3x (p<0.05)
SBBO; conducted
higher than mean TG values in
after the TG
assessment and a 3 Phases 1, 2, and 3, respectively.
day washout period.
Following administration of
13
**** Expressed as a labeled TP, absorbed C label
by breath analysis was ~5%
percentage of
absorbed label (dose (range 0%-21.2%) and similar
administered - label across study phases.
recovered in stool) to
assess oxidation for Following the administration of
acute energy needs. labeled GCA, there was either
13
no or minimal recovery of C in
13
stool and CO2 on breath (as %
of dose administered) in all
phases.

Conclusion
Authors interpreted this
to reflect failure of lipid
absorption in the face of
adequate digestion/
hydrolysis. Each form
(FA and TG) was found
in decreasing values as
the study phases
progressed, suggesting
improved digestion and
absorption, although
results did not differ
significantly.
Fecal fat was correlated
with concentrations of
13
C in stool.
There was no evidence
of SBBO or bile acid
malabsorption.
13

CO2 excretion following
13
administration of C TP
was minimal, suggesting
a propensity for
deposition in adipose
tissues rather than
oxidation for immediate
energy needs. The
authors report that this
breath test has not been
widely used, but that
healthy UK children
have breath excretion
values from 15%-43%
[190], compared to a
mean of 5% and range
0%-21% in this cohort;
the latter findings were
more similar to results
from kwashiorkor
13
patients where Clabeled oleic acid was

Comments

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

2000

Sao Paulo, Brazil

Case-control

Nichols B et al.

Cases were children n=33;
(mean age 9.9 mo,
SD 8.1) hospitalized n=24 cases
with malnutrition
refractory to dietary n=9 controls
rehabilitation.

Contribution of
villous atrophy to
reduced intestinal
maltase in infants
with malnutrition
Jejunal biopsy,
maltase activity, and
enzyme messenger
RNAs among
malnourished and
well-nourished
children. Assessed
association between
maltase and villous
atrophy and other
mucosal intestinal
markers indicative of
loss of enterocytes
and enterocytic
function.

Controls were
children (mean age
3.6 mo, SD 1.0) with
HAZ and WAZ
scores >-2 and
normal intestinal
mucosa on biopsy,
hospitalized for
Kasai procedure for
biliary atresia.

Subjects were
matched on
height and
weight; ages
differed within
matched sets.

Biomarker

Results

Conclusion

Comments

used as substrate [193].
Mean villous atrophy score (SD): The malnourished
Tissue from
• Cases: 2.6 (0.8)
children had significantly patients requiring
• Controls: 1.2 (0.5), p=0.006) greater villous atrophy
intestinal resection
as part of their
than the younger
WAZ score was correlated with controls.
biliary atresia
villous atrophy (r=0.65, p- value
management
not reported).
Among the subset tested provides an
for mRNA messages,
opportunity to
13/25 [sic] cases and 0/5
maltase activity as well assess presumably
controls had subnormal (defined as the mRNA
“normal” intestinal
as <94U/g protein) of maltase
architecture.
abundances for MGA,
activity; mean maltase was 34% villin and SGLT were
However, unless
lower among cases (p=0.11).
significantly correlated they mocked up ex
vivo mucosal
Maltase activity did not appear with case status and
to decrease with WAZ score
biopsies in these
were correlated with
(further details not provided).
controls, resections
villous atrophy.
will have lower
However, in sub-analyses
While maltase deficiency proportions of
among those samples with an
has been reported in
villous to
adequate β-actin, a
submucosa tissue
malnutrition in other
housekeeping gene message, studies, authors assert compared to cases’
(n=10 cases, n=9 controls),
samples derived
that these are the first
cases’ findings expressed as a results that directly
from mucosal
mean percent of controls' (SD) support the hypothesis biopsies. While this
included:
probably doesn’t
that reductions in
• Villous length (reciprocal of
maltase activity are due affect histology, it
atrophy score): 38.9 (41.6),
to villous atrophy. This might affect
enterocyte
p=0.004
study also nicely
• Maltase activity: 37.1 (23.2), correlates mRNA
functional assays
p=0.001
relative abundance with and mRNA
• MGA mRNA: 45.1 (36.4),
determination, as
function.
transmural tissue
p=0.016
• Villin mRNA: 52.5 (22.6),
will bring in more
diverse populations
p=0.003
• SGLT mRNA: 66.6 (23.1),
of cells; only some
* Mucosal atrophy
of them might have
p=0.057
was scored on a
• β-actin: 88.2 (15.8), p=0.189
transcripts of
scale of 1 (absence
interest. However,
of atrophy compared
Both villous length and maltase
the bias is likely in a
to an organ donor) to
activity in a subset of cases
direction that would
4 (similar to children
were less than 40% of control
reduce effect size.
with active CD).
values.

Jejunal capsule
biopsy:
• Histopathology*
• Maltase activity
• Intestinal
messenger RNA
(mRNA)
abundances:
• Maltaseglucoamylase
(MGA)
• Sucraseisomaltase (SI)
• Villin, a
structural
protein
expressed
only in
enterocytes
• Sodiumactivated
luminal
glucosegalactose
transporter 1
(SGLT), a
functional
protein
expressed
only in
enterocytes
• β-actin

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker
Histology among
controls was on
surgically resected
tissue.

Results

Conclusion

It was unclear if
control inclusion
criteria included
absence of atrophy
or if all potential
controls lacked
atrophy.

MGA, villin, and SGLT mRNA
abundances were correlated
with villous atrophy score
(r=0.73), (r=0.76), and (r=0.54),
respectively (p-values not
1
reported) .
MGA mRNA abundance was
correlated with maltase activity
(r=0.32).

2001

Florianopolis, Brazil Cross-sectional

18 mo-14 yr old HIV- n=104
infected children with
Intestinal absorption GI and non-GI
Perin NM et al.

1

Blood Test:
D-xylose

Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin.

Prevalence of an abnormal Dxylose result was 7.7%.
Mean D-xylose (SD, range):
42.8mg/dL (14.4mg/dL, 16-73

Comments

Statistical methods
might not have
adequately taken
into account the
small sample size
and matching
scheme.

D-xylose showed
substantial variation
across individuals.

Subsets of subjects
were investigated
for various tests.
For example, 10
cases had mRNA
analyses based on
β-actin adequacy.
Another instance of
selected testing
was the subset of
22 and 15 cases
that had WAZ score
to histology and
mRNA correlation
analyses,
respectively.
Rationale for subset
selection was not
thoroughly
described.
Portuguese
language article.
D-xylose <25 mg/dL
was defined as

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
of D-xylose in
symptoms of HIV
children infected with infection recruited
the human
from a pediatric
immunodeficiency
AIDS center.
virus

Design and
Sample Size

Comments
indicative of
malabsorption.

Of the 8 children with abnormal
results, 1 had diarrhea. Of 19
with diarrhea, 1 had an
abnormal result.

Chandigarh, India

Poddar U et al.

n=47
18 mo-14 yr olds
with PD, FTT, or
pallor from a hospital
pediatric
gastroenterology
unit.
Subjects with normal
crypt:villous ratio on
biopsy were of
interest for this
review.

Conclusion

D-xylose was not associated
with age.

2002

Duodenal biopsy, Dxylose, and fecal fat
in children with
symptoms of CD but
normal mucosal
biopsy results

Results
mg/dL)

D-xylose as a
marker of intestinal
absorption among
HIV-infected children
with and without GI
symptoms

Celiac disease in
India: Are they true
cases of celiac
disease?

Biomarker

Case-control

Of those with abnormal results,
50% had Cryptosporidium
infection. Of the 33 subjects with
Cryptosporidium infection, 4 had
abnormal D-xylose results.
Endoscopic duodenal 38% had chronic inflammatory Among controls with
biopsy:
cell infiltrates in the lamina
normal mucosal
Histopathology
propria.
architecture by biopsy,
more than one-third had
55% had abnormal D-xylose
PD.
Stool Tests:
concentrations.
D-xylose and fecal fat
• Fecal fat*
20% had abnormal fecal fat test. might not correlate well
• D-xylose**
with duodenal biopsy
No results beyond proportion
results.
positive were reported for any of
* In 72-hour stool
the above markers.
collection.
** Not specified
whether from urine or
serum, and units of
measurement not
provided.

Relationships
between fecal fat,
D-xylose and
biopsy results were
not reported.
While 38% of
controls had PD,
results for the
markers studied
were not stratified
by PD for this
group.
Seven children with
biopsies consistent
with CD did not
respond to glutenfree diet and were
excluded from the
study.
Cut-off points used
to define abnormal
D-xylose tests were
not provided.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.
Reference and
Study Outcomes of
Diagnostic Interest
2004

Location and
Target Population

Design and
Sample Size

Dhaka, Bangladesh Case-control

Biomarker

Results

Blood Test:
Iron (absorption
test)

2-5 yr old apparently n=25:
healthy children from
Helicobacter pylori a periurban setting, n=13 cases
infected with H.
infection, iron
screened for iron
pylori
deficiency and H.
absorption, and
pylori.
gastric acid
n=12 controls not
secretion in
infected with H.
Bangladeshi children
pylori
Iron absorption
among children with
iron deficiency
anemia with and
without H. pylori
infection
2006
Xi-Chou (town) &
Cross-sectional Stool Test:
Endogenous fecal
Yun-Nan (province),
zinc (EFZ)
n=43
Sheng XY et al.
China
Sarker SA et al.

19-25 mo olds
Major variables of
zinc homeostasis in recruited from a
remote small town
Chinese toddlers
and 2 surrounding
Differences in zinc rural villages.
absorption in healthy
toddlers with a high 48% of children had
prevalence of zinc plasma zinc
concentrations below
deficiency.
2.5th percentile.
Dietary zinc intake
was low.

Conclusion

Comments

Mean iron absorption from
ferrous (Fe) sulfate and Fe
fumarate:
• Uninfected children: 15.6%
and 5.4%, (p<0.001)
• Infected children before
treatment: 19.7% and 5.3%,
(p<0.0001)
• Infected children after
treatment: 22.5% and 6.4%,
(p<0.0001)
• H. pylori treatment did not
significantly affect absorption
(Fe sulfate or fumarate),
p=0.3

Iron absorption from Fe
fumarate was
significantly lower than
from Fe sulfate.

Data on iron
absorption among
2-5 yr olds are
limited, making
comparison of
results from this
study setting
difficult.

Mean (SD):
• FAZ: 0.35 (0.12)
• AZ (mg/d): 0.63 (0.24)
• EFZ (mg/d): 0.67 (0.23)

Zinc absorption was
lower than physiologic
requirements and EFZ
was higher than
expected.

1

Results do not support
the hypothesis that H.
pylori infection
influences absorption of
water-soluble (Fe
sulfate) or non-watersoluble (Fe fumarate)
iron compounds.

Urine Test:
The quantity of absorbed zinc
Zinc excretion to
was lower than physiologic
The authors note that
measure fractional requirements.
the results are difficult to
absorption of zinc
explain and specifically
(FAZ) and total
There was no statistically
state that they do not
absorbed zinc (TAZ) significant difference in any
think (though without
following
laboratory value between the
clear justification) that
radiolabeled zinc
town and village groups.
enteropathy is prevalent
administration
in the population and
Zinc absorption was ~80% of
therefore could not be a
estimated physiologic
contributing factor.
requirement and equivalent to
the amount of endogenous zinc
There was a high
excreted via the intestine; it was
prevalence of
expected that absorbed zinc
stunting among the
would exceed excreted zinc
subjects.
[144, 187, 194, 195]
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
1

Geometric mean.

Evidence Table 1. Markers of absorption.
Biomarkers in bold are primarily markers of malabsorption.

Reference and
Location and
Design and
Study Outcomes of
Biomarker
Results
Conclusion
Target Population
Sample Size
Diagnostic Interest
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Comments

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

Thirteen studies used markers of intestinal absorption among children in resourcelimited settings. The range of markers included urinary, breath and serum markers of sugar
absorption, fecal fat as a marker of lipid absorption, measures of endomolecular absorption, and
presence of messenger RNAs in intestinal tissue as markers of intestinal surface area, and, by
inference, absorptive capacity.

5.2.1 D-Xylose
While single molecule tests have disadvantages compared with dual molecule tests, as
discussed above, the D-xylose test has been commonly used to assess malabsorption in
developing settings. There has been further criticism of this test, including its potential hepatic
metabolism of the sugar [196] and jejunal absorption [197].
D-Xylose was the most commonly reported measure of small bowel absorption in the
literature that we reviewed and was employed in five studies. It was assessed either in serum
(n=2) [136, 152] or urine (n=1) [147], although in two studies the substrate from which D-xylose
was measured was not reported [146, 155]. Although one of these reports did not specify the
xylose enantiomer [147], test functionality characteristics led us to assume it was the
dextrorotary (D) enantiomer, as was used in the other studies. This study, in addition to
assessment of urinary excretion of the sugar, also measured hydrogen excretion in breath
before and after administration of the xylose. Three of the studies [136, 146, 147] provided
demographic information stratified by age group and together included 58 children under five
years of age. However, none of the studies presented D-xylose data by age group. Overall, the
five studies included D-xylose results for 267 children up to the age of 14 years.
Two of the studies investigated the association of D-xylose with degree of villous atrophy
on biopsy. One of these studies performed D-xylose tests in children with symptoms of celiac
disease and normal architecture on duodenal biopsy, although approximately one-third had
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chronic inflammatory cell infiltrates in the lamina propria [155]. This publication reported
abnormal D-xylose results in 55% of these subjects (but did not provide information on the
range of normal and abnormal concentrations, sampling site, or units of measure of D-xylose).
Their results suggested that the D-xylose test might not correlate well with intestinal
histopathology, especially crypt:villous architecture. The other study was among HIV-infected
children with protein-energy malnutrition in Brazil [136]. All subjects’ tissue had cellular
infiltration of the lamina propria and varying degrees of villous atrophy on biopsy, and all
subjects also had abnormally low D-xylose absorption (based on authors’ reported cutoff value
of <25 mg/dL). However, there was no correlation between the proportion of serum D-xylose
absorption and the degree of villous atrophy on biopsy.
Another Brazilian study used the same definition of normal range for serum D-xylose
among HIV-infected children with and without gastrointestinal symptoms. Eight percent of the
children had D-xylose below the “normal” range in their blood following challenge [152]. The
authors also examined the relationships between D-xylose absorption and history of diarrhea
and Cryptosporidium infection. Of the eight children with abnormal D-xylose, one had diarrhea,
and of 19 subjects with diarrhea, one had an abnormal result for D-xylose. Among subjects with
abnormal results, 50% had Cryptosporidium infection, and of the 33 with Cryptosporidium
infection (many of whom did not have diarrhea), four had an abnormal D-xylose test. They did
not report statistical testing of association, but these clinical factors do not appear to be
associated with D-xylose absorption in this cohort.
Moya-Camarena et al. performed urinary D-xylose and xylose breath hydrogen tests in
well-nourished children with asymptomatic Giardia intestinalis infection and healthy controls
recruited from preschool centers [147]. Results did not demonstrate any disturbance in urinary
xylose absorption among infected cases or healthy controls. Urinary results did not differ before
and after treatment for Giardia. Breath hydrogen levels decreased significantly with treatment,
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indicating improvement. The clinical and physiologic implications of this difference, in the face of
hydrogen breath test results well within the range of normal, are not apparent. The investigators
did not report on the relationship between breath and urinary D-xylose results.
Finally, Mittal et al. used the D-xylose absorption test as part of their diagnostic criteria
for tropical sprue among gastroenterology clinic patients presenting with persistent diarrhea. By
definition, all of the children had abnormal xylose absorption results; however, information about
the D-xylose dose, units of measure, cutoff point for normal, and even the identity of the
sampled fluid (urine or serum) were not provided [146].
Methods of test performance and cutoff points were often not described adequately to
enable comparing results across studies. For example, in two instances D-xylose abnormal cut
points were specifically defined as <25 mg/dL [136, 152], This is higher than some references
suggest as a cutoff point among infants and children [186]. Insufficient data were reported in
these two studies for readers to assess how the proportion of those with D-xylose malabsorption
might have shifted with differing cut points. In two other studies D-xylose results were only
reported as normal or abnormal without defining a cutoff point [146, 155].

5.2.2 Endomolecular Challenge Absorption Tests
Six studies assessed absorption after administering labelled endomolecules (zinc (n=3),
iron (n=1), and lipids (n=2)). These investigations rely on challenge with the molecule of interest,
which is generally a stable isotope, and measure urinary excretion as an indicator of absorption,
or fecal excretion, as an indicator of non-absorption. When examining stool, it is important to
note that the fecal concentration could potentially represent uptake and subsequent excretion by
the host. In one Peruvian study, there appeared to be saturation kinetics at high doses of zinc,
and zinc dosing early in the day was related to diminished absorption of this divalent cation from
unfortified foods later in the day [141]. Manary et al. identified an unexpectedly high fractional
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excretion of the challenge zinc in children in Malawi [144]. In China, Sheng et al. demonstrated
unexpectedly high fractional excretion of zinc in stool, and inferred diminished uptake of this
nutrient, but also speculated that their population of children were not suffering from enteropathy
[164]. Murphy et al. used 13C labeled triglycerides (TG) as trilaurin, triolein, or trilinolein, and
determined that in a group of Jamaican children, many of whom had bacterial overgrowth, the
uptake of challenge lipids was impaired, but that the defect was not related to impaired intestinal
lipolysis [148] Earlier, Murphy et al. demonstrated that during acute malnutrition, there is
impaired lipid uptake from the gut, and that this defect improved during rehabilitation [149].
Unlike in the cohort in their later study, small bowel bacterial overgrowth was not an issue in this
cohort. Sarker et al. studied labeled iron uptake in children with and without Helicobacter pylori
infection, and found no evidence for diminished uptake among the infected children [163].
Similarly, treatment of the H. pylori infection did not improve uptake. They inferred that this
gastric infection did not play a role in diminished uptake of iron by children in Bangladesh, but
did note that there are limited data on the physiology of normal iron uptake in children in the age
group studied (2-5 year olds).

5.2.3 Enterocyte-specific Proteins
Nichols et al. assessed intestinal tissue markers of digestion (see Evidence Table 3) as
well as two markers of absorption: intestinal messenger RNA (mRNA) abundances of villin and
sodium-activated luminal glucose-galactose transporter 1 transcripts [53]. These are structural
proteins expressed only in enterocytes. mRNAs for these proteins are found in reduced
quantities if intestinal surface area is diminished and hence reflect absorptive capacity. Nichols
et al. compared the mRNA abundances in intestinal biopsies of children with refractory
malnutrition to values found in controls that were neither stunted nor wasted, and found a
reduction of more than 50% in mRNA abundances for both proteins among cases. It is
important to note that the controls were children with biliary atresia who, as part of their
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management for the condition, underwent intestinal resection. Without having performed an ex
vivo mucosal biopsy in the control subjects, it is not possible to rule out a lower ratio of villous to
submucosa tissue present in resected tissue which might affect mRNA determinations, as
transmural tissue can be expected to contain a more diverse population of cells, only some of
which might contain the transcripts of interest. However, the bias, if any, is likely in the direction
that would reduce effect size.

5.2.4 Fecal Fat
Data on fecal fat was reported in three studies as a marker of malabsorption, including
one study that measured the fat by four different methods, with a high degree of consistency in
results across techniques [116]. That study, conducted among children with varying nutritional
status in Venezuela, and another study conducted in India among children with symptoms
consistent with and being evaluated for celiac disease [155], reported results as percent of
subjects that tested positive while another study of severely malnourished Jamaican children
[149] presented results as mean fecal fat excretion in grams per day and as percent of intake;
hence, the results of this third study could not be compared to the other two. Positive results
among the Venezuelan children varied from 13-27% (depending on laboratory method) among
well-nourished children to 80-100% (again, depending on method) among the most severely
malnourished children [116], while the Indian study detected fat in the stools of 20% of the
children [155].
The Jamaican study found the fecal fat results to correlate with recovery of radiolabeled
lipids in the stool after administration of 13C tripalmitin. The Indian study found that 55% of
subjects with symptoms of celiac disease but a negative serologic evaluation for that disorder
had abnormal D-xylose absorption (although the authors did not report the units of measure,
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cutoff point of normal-abnormal results, or whether or not they measured the sugar in the urine
or serum) and 20% had abnormal fecal fat results; correlation testing was not reported.

5.2.5 Summary of Markers of Absorption
The assessed markers demonstrated normal and abnormal enteric function, depending
on the marker and the study. The proportion of abnormal urinary D-xylose excretion results
ranged from none among well-nourished children with asymptomatic Giardia intestinalis
infection and healthy controls [147] to 100% among HIV-infected children in Brazil with proteinenergy malnutrition [136]. Endomolecular markers also yielded varying results in different study
populations. Apparent malabsorption was observed based on lipid uptake in a cohort of
Jamaican children, some of whom had small bowel bacterial overgrowth [149]. In contrast, a
study of iron uptake among children with and without Helicobacter pylori infection found no
evidence of impaired absorption [163]. Malnourished children had reduced absorptive capacity
relative to controls as inferred from reduced abundance of messenger RNA in biopsies for
enterocyte-specific proteins [53]. Similarly malnourished children showed absorptive
derangement by fecal fat test, with a notably higher proportion of positive tests than among wellnourished children [116].
Two of the fecal fat studies were the only ones that assessed more than one marker that
is primarily a measure of absorptive capacity. The Jamaican study was the only one that
reported testing for correlation between these tests of absorption [149]. Several studies
compared the relationship of markers of absorption to biopsy. D-xylose [136, 146, 155] and
fecal fat [155] corresponded poorly with histopathology. The papers suggested that there was
only a short interval between the performance of these tests and the biopsies, but the exact
length of time was not provided. Abundance of messenger RNA for two enterocyte-specific
proteins, villin and sodium-activated luminal glucose-galactose transporter 1, did correlate with
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villous atrophy in a study examining biopsy-derived markers [53]. None of the studies compared
markers of absorption to other types of markers of enteric dysfunction (i.e., other than to biopsy
or other measures of absorptive function).
Only one study reported data on an absorption marker in relation to the presence of
diarrhea, finding no apparent association with D-xylose absorption, although this was not
analyzed statistically [152]. None of the studies examined the association between absorption
markers and growth outcomes. A Peruvian study was the only one to report an absorption
marker as a clinical endpoint of an intervention trial, in this case a randomized, controlled trial of
zinc supplementation [141]. It was also the only study to measure intra-individual longitudinal
change outside of the context of intervention or convalescence. These investigators assessed
zinc absorption longitudinally in controls without zinc supplementation and observed no change
in absorption of this pentose sugar.
These absorption tests showed a range of logistical challenges for deployment in
resource-limited settings. When methods were described, the D-xylose test was conducted by
colorimetric or spectrophotometric means, whereas the tests of endomolecules involved more
complex laboratory methods and the intestinal tissue markers, requiring biopsy, were most
technically complicated and invasive. The D-xylose studies generally did not cite reference
standards or compare their results to those from other studies. Two studies compared their fecal
fat results to those in other published studies [116, 149]. One of these studies also conducted a
lipid breath test and compared results to those previously published [149]. All of the zinc
absorption studies discussed results in relation to expected values based on reference indices
and other studies of zinc homeostasis [141, 144, 164]. In the iron absorption study, authors
cited a lack of data available in the literature for subjects of similar age for comparison [163].
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5.3 Markers of Permeability
Data regarding markers of permeability are presented in Evidence Table 2. As discussed
above, many of the tests that assess permeability also entail a test component that assesses
absorptive function.
Thirty-one studies assessed markers of intestinal permeability. All but one of these
included assessments of dual sugar tests as either lactulose:mannitol (L:M) (n=25) or
lactulose:rhamnose (L:R) (n=5); the other reported measures of lactose in the urine as
lactose:creatinine. Two studies reporting L:M test results also reported other markers of
permeability, either urinary lactose and lactose:lactulose or plasma endotoxin and IgG
endotoxin-core antibody.
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Evidence Table 2. Markers of permeability.

This category includes markers with dual assessment of absorption and permeability. Biomarkers in bold are primarily markers of permeability (with or without dual
assessment of absorption).
Reference and Study
Location and
Design and
Outcomes of
Biomarker
Results
Conclusion
Comments
Target Population Sample Size
Diagnostic Interest
2004
Keneba, Gambia Cohort
Stool Test:
Mean neopterin concentration was L:M and mean fecal Study population
Neopterin
negatively correlated with long-term neopterin
might have some
2 mo olds from
n=72
height (r=-0.29, p<0.009) and weight concentration were overlap with that of
Campbell DI et al.
(r=-0.36, p<0.007) gain, but not with not correlated.
Campbell et al. also
rural area followed
Urine Tests:
giardiasis.
included in this
Intestinal inflammation until 15 mo of age. Subjects were
1
evaluated with
review [110].
Mean L:M in the
measured by fecal
• Lactulose
2
twice-weekly
Mean L:M (CI): 0.31 (0.26, 0.34).
Gambian children
neopterin in Gambian
• Mannitol
questionnaire to • L:M
was substantially
children with
determine
Mean excretion of lactulose (CI):
higher than normal
enteropathy:
diarrhea
0.20 (0.18, 0.23).
values in children in
association with
growth failure, Giardia
morbidity, clinic
the UK. These high
lamblia, and intestinal
assessments of
Mean excretion of mannitol (CI): 3.0 L:M ratios appear to
growth, and
(2.8, 3.2).
be driven by
permeability
screening
mannitol excretion.
Fecal neopterin and
laboratory tests
Mean L:M was negatively correlated
every 2 mo.
with long-term height gain (r value
L:M as markers of
not provided, p<0.0001), but was not
intestinal inflammation
correlated with presence of Giardia.
and permeability,
respectively, and their
L:M and fecal neopterin were not
correlation with growth
status and Giardia
correlated (p=0.11).
recovery in the stool
2003
Keneba, The
Cohort
Urine Tests:
At 8 wk of age:
Mean L:M ratios
Presence of malaria
4
3
Gambia
• Mean L:M: 0.169 (CI: 0.145,
were elevated at 8 parasites was
• Lactulose
n=71
Campbell DI et al.
0.198; range: 0.058-0.657)
weeks of age, and assessed by blood
(53 tested)
•
Mean
lactulose
recovery:
0.202
All 2-11 mo olds
more than doubled smear at each
• Mannitol
study visit; the only
(SD=0.159;
range:
0.009-0.640)
were recruited
Growth faltering in
in the first year of
(52 tested)
•
Mean
mannitol
recovery:
3.80
parameter
rural Gambian infants from this rural
life.
• L:M
associated with
(SD=2.35; range: 0.52-8.58)
village and
is associated with
(52 tested)
malaria was CRP.
Many markers of
followed up to 14
impaired small
L:M more than doubled between 12 inflammation and
mo of age.
intestinal barrier
wk-1 yr of age (r=0.44, p<0.001) and endotoxin release
Authors did not
function, leading to
Blood tests:
was driven by both increasing
report investigating
were significantly
endotoxemia and
• Albumin
lactulose
(r=0.18,
p<0.001)
and
relationships
correlated
with
L:M
systemic inflammation
• CBC
decreasing
mannitol
(r=-0.14,
between certain
and
lactulose
• C-reactive
p<0.01)
excretion
with
age.
serum parameters
recovery.
L:M as a marker of
protein (CRP)
1

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.
3
For lactulose and mannitol results, excretion measurement was not specified.
4
Geometric mean.
2

Evidence Table 2. Markers of permeability.

Reference and Study
Location and
Design and
Outcomes of
Target Population Sample Size
Diagnostic Interest
intestinal permeability
and its relationship
with various
inflammatory markers
and endotoxin

Biomarker

Results

Conclusion

• IgA
• IgM
• IgG
• Plasma endotoxin
• IgG endotoxin-core
antibody

WAZ and HAZ scores were
negatively correlated with L:M (r=0.41, p<0.001), and primarily driven
by lactulose excretion (r=-0.39,
p<0.001).

Poor growth was
significantly
correlated with L:M
ratios, primarily due
to lactulose
excretion.

Laboratory values were consistent
with chronic, low level
immunostimulation:
• 50% of platelet and 39% of
leukocyte counts were elevated,
especially mean lymphocyte
counts which were almost twice
expected values [198].
1
• While the mean CRP was within
the normal range, 25% of values
were above the upper limit of
normal (5 mg/L), and 17% were
>10 mg/L [198].
• Mean IgG, IgA and IgM
concentrations were near normal
at 8 wk of age, but increased
rapidly; all three were elevated
above expected values in all other
age groups [198, 199]
2
• Mean free plasma endotoxin
concentration was twice the upper
limit of normal [200] and IgG
endotoxin-core antibody
concentrations were also elevated
[198]
• However, mean albumin
concentrations (and
concentrations within SD) were
generally within normal range
[198].
L:M was correlated with
IgG and IgA (r=0.41 and 0.41,
1
2

Geometric mean.
Geometric mean.

Comments
(blood counts, CRP
concentrations) and
L:M.
Authors postulate
that while general
markers of
inflammation
cannot
be specifically
ascribed to a gut
source, endotoxin
and its related core
antibody are
potentially a direct
measure of
intestinal
inflammation due to
gut gram negatives
as a primary source
of endotoxin
release among
subjects without
sources of extraintestinal gram
negative infection.
Study population
might have overlap
with that of
Campbell et al.
2004 also included
in this review [15].

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

Comments

respectively, p<0.001), and IgM
(r=0.28, p<0.02).
IgG and IgA were also correlated
with lactulose recovery (r=0.26 and
0.25, respectively, p<0.02).
IgG endotoxin core antibody
concentration was correlated with
L:M and driven by lactulose
recovery, (r=0.35, p<0.005 for both).
Endotoxin concentrations were
correlated with lactulose recovery
(r=0.36, p<0.02) only.
2003
Fajara and
Case-control
Endoscopic
Crypt-hyperplasia and villous
All Gambian
Sibanar, The
small bowel biopsy, atrophy were observed among all
subjects had
n=40 cases:
site not specified:
Gambian subjects, and the degree of evidence of
Campbell DI et al.
Gambia
• Group 1: n=4
• Histopathology
histopathology did not differ among enteropathy with
• Group 2: n=11 • Morphometric
cases with differing nutritional status, crypt-hyperplasia
6 mo-3 yr old
Chronic T cellnor was there a correlation with
(7 with diarrhea) assessment by
mediated enteropathy hospital- and
and villous atrophy,
computer analysis* diarrhea.
clinic-based cases • Group 3: n=25
in rural west African
and mean IELs >2
• Intestinal tissue
(18 with
children: relationship from rural
SD above UK
1
IEL means were ~3-fold higher in norms, independent
cytokines and
diarrhea)
with nutritional status communities.
immune markers: Gambian than UK children.
and small bowel
of nutritional status
n=34 with case
Case groups
function
and diarrhea history.
• CD-3
tissue samples
Median CD3, CD4, CD8, CD19, and
based on
• CD-4
CD25 cell counts were significantly Elevation of cellsufficient for
differences in
• CD-8
L:M as a marker of
higher (2-5x higher) among each
cytokine
mediated intestinal
nutritional status:
• CD-19
case
group
compared
to
the
UK
intestinal permeability, 1. WAZ score >-2, immunomarkers and
• CD-25
controls.
with GI
small bowl biopsy with
reactivity tests:
mucosal
• HLA-DR
complaints other • Group 1: n=3
assessment of
proinflammatory
• Perforin
than diarrhea
• Group 2: n=8
IEL, γδ, syndecan-1, HLA-DR, and cytokines was
intestinal immune
• γδ T-cell
2. Grade I protein • Group 3: n=23
perforin were detected among the
markers, and
present across the 3
receptor
Gambian children in varying degrees Gambian groups,
energy
computerized
• Syndecan-1
but were not reported for UK
malnutrition
morphometric analysis
variably correlated
• TNF-α
controls. Syndecan, CD3, and CD8 with nutritional
(PEM) (WAZ
among rural Gambian
• IFN-γ
displayed a gradient proportional to status.
score -2 to -4)
children with differing
•
TGF-β
malnutrition severity.
degrees of malnutrition and
• IL-10
and compared to wellL:M ratios were
unresponsive to
All Gambian groups showed higher elevated in all
nourished UK children
nutritional
supplements,
lamina propria cytokineGambian groups,
1

These figures are presumed to represent IEL means; however, this was not explicitly stated.

Statistical
methodology was
not sufficiently
detailed to
determine what was
compared (e.g. type
of central tendency
measure and
variance
calculations for L:M
not stated).
Duration of diarrhea
not specified, but
assumed to be
persistent.
Mucosal
lymphocyte
densities, cytokine
immuno-reactivity,
and L:M results
were not stratified
by history of
diarrhea.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size
with or without
diarrhea
3. Grade II PEM
(WAZ score <-4)
with or without
diarrhea

Biomarker

Results

Conclusion

Urine Tests:
2
• Lactulose
• Mannitol
• L:M

immunoreactive mononuclear cell
2
density (~200-450/mm ) than UK
2
controls (30-80/mm ).

without apparent
correlation to host
nutritional status.

Among subjects with elevated
cytokines, similar densities were
seen for both pro-inflammatory (IFN* Biopsy involved
γ and TNF-α) and putative regulatory
morphometric
(IL-10 and TGF-β) cytokines.
assessment by
computer analysis of Epithelial expression of TGF-β was
villous height, crypt also enhanced compared to UK
controls, but subjects with poorer
depth, villous:crypt
nutritional status had lower densities
ratio, and
of mucosal TGF-β+ cells, with
intraepithelial
median densities of 420 and 250
lymphocyte (IEL)
2
cells/mm in the grade I and grade II
density (per 100
PEM groups, respectively.
epithelial cells).

Controls from UK*
who were well
nourished children
with GI complaints
other than diarrhea
and with normal
endoscopy results
were also studied.

* UK subjects are
presented in this
table due to
comparisons of
interest made in
the review.
However we do
not include these
subjects in the
sample size for
this review.

2002
Campbell DI et al.
Age-related
association of small
1

Keneba, The
Gambia and
surrounding
villages
2-60 yr olds

1

L:M values :
• Group 1: 0.53 (0.4-1.3)
• Group 2: 0.47 (0.02-2.20)
• Group 3: 0.73 (0.14-2.2)
• Not assessed among the UK
controls
Nutritional status was not associated
with L:M, recoveries of lactulose or
mannitol.

Cohort
n=162;
<5 yr old:
n=26

Urine Tests:
2
• Lactulose
• Mannitol
• L:M

L:M was correlated with mucosal B
lymphocyte density (r=0.57, p<0.05),
IEL (r=0.51, p<0.02), and perforin+
IEL (r=-0.64, p<0.03).
3
Mean L:M (SE) in 2-5 yr old group: Mean L:M in
0.353 (0.022).
asymptomatic 2 to 5
yr olds was high and
Mean lactulose and mannitol %
decreased
recovery was ~0.45 and ~0.65,
significantly with
respectively.
increasing age, but

Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.
Lactulose and mannitol results were expressed as % of dose administered.
3
Type of mean not specified.
2

Comments

Subjects were free
from diarrhea
symptoms for at
least one week
prior to urinary
assessments.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
intestinal mucosal
enteropathy with
nutritional status in
rural Gambian children

Location and
Design and
Target Population Sample Size
randomly selected (23 were refrom rural
assessed)
communities.

L:M and urinary
lactulose and mannitol
recovery as a marker
of intestinal
permeability and its
association with
nutritional status at
varying ages. Also
assessed correlation
of change in L:M with
nutritional status at 3.5
mo re-visit.

Biomarker

Results

L:M was highest in 2-5 yr age group
and decreased with increasing age
(up to age 20) (p<0.001), but never
fell within referenced UK normal
ranges [201].

In contrast, although mannitol
excretion slightly decreased with
age, this trend did not reach
statistical significance. In fact,
excretion proportions were at all
times ½ - ⅓ of expected UK values
[201].

There was a small improvement in
mean L:M (SE) between the two
study time points from 0.198 (0.018)
to 0.172 (0.010) (p=0.026 for change
in L:M), driven by an improvement in
mannitol recovery with no change in
lactulose excretion.
Indices of intestinal permeability
within subjects showed a high

Reported results were adjusted for age, sex, and visit.

never fell within
expected range of
values.

Comments

The authors sought
correlation between
the mean L:M of the
two visits and
Among all age
groups, L:M showed ∆BMIZ, ∆HAZ and
∆WAZ scores, but
significant intraMost of the improvement in L:M was subject correlation statistical
driven by a reduction in lactulose
calculations were
between tests
excretion (p<0.001), which fell within conducted 3.5
not provided.
expected UK ranges by age 10 yr. months apart.

L:M was inversely correlated with
1
HAZ score (r=-0.31, p<0.001), but
not with WAZ or body mass index
(BMI) Z- scores. The correlation with
HAZ score was mainly due to the
higher lactulose excretion in subjects
with poorer HAZ scores (r=-0.22,
p=0.001) and held across all age
groups.

1

Conclusion

Among all age
groups, L:M was
significantly
inversely correlated
with HAZ score,
primarily driven by
lactulose excretion.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

2003
Chen P et al.
Association of vitamin
A and zinc status with
altered intestinal
permeability: analyses
of cohort data from
northeastern Brazil
L:M as a marker of
intestinal permeability
pre- and post-vitamin
A and zinc
supplementation
among children with
history of PD or low
WAZ score

1
2

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

Comments

degree of correlation between the
two visits:
• Lactulose: r=0.55, p<0.001
• Mannitol: r=0.24, p<0.05
• L:M: r=0.66, p<0.001

Goncalves Dias
Cohort
favela in Fortaleza,
Brazil
n=75 with presupplement L:M
2-97 mo olds
and retinol
recruited from an concentrations
urban shantytown. measured:
• 51 with presupplement
circulating zinc
concentrations
measured
• 20 with postintervention*
longitudinal
follow-up of
subset with
history of PD or
low WAZ score

Urine Tests:
1
• Lactulose
• Mannitol
• L:M

For lactulose and mannitol results, excretion measurement was not specified.
Type of mean not specified.

Change in measures between visits
(analysis not stratified by age):
• Mean L:M (SD):
• Visit 1: -1.62 (0.66)
• Visit 2: -1.76 (0.55),
(p=0.026)
• Mean mannitol recovery (SD):
• Visit 1: 5.25 (2.69)
• Visit 2: 6.28 (3.03),
(p=0.006)
• Mean lactulose recovery (SD):
• Visit 1: 0.28 (0.20)
• Visit 2: 0.29 (0.18),
NS (p-value not specified)
Baseline mean (SD):
2
• L:M : 0.29 (0.16)
• Lactulose: 0.54 (0.29)
• Mannitol: 2.07 (0.88)

Supplementation of Longitudinal data
vitamin A and zinc were not reported
stratifying on
resulted in
underlying condition
significant
improvements in L:M (i.e. PD history vs.
L:M was not correlated with age. L:M among the cohort of WAZ score).
was inversely correlated with retinol children with a
(r=-0.55, p<0.0005), including after history of PD or low Follow-up data on
L:M were not
WAZ score who
adjustment for zinc concentration
provided for the
received postand stratification on retinol
children with normal
supplementation
concentrations.
assessment. Less WAZ score or no
Retinol was correlated with mannitol than one-third of the history of PD.
(r=0.28, p=0.017) and lactulose (r=- subjects had postUnclear how long
intervention L:M
0.22, p<0.063) excretion.
after
assessments.
supplementation
Lactulose, mannitol and their
the L:M testing was
combined ratio were not correlated
done.
with zinc concentrations.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

* These subjects
received a single
oral dose of
vitamin A and a 2wk course of daily
zinc supplements.

2007

Keneba, The
Gambia

RCT

n=197
Subjects recruited
at birth from rural n=99 received
Effectiveness of an
high dose vitamin
early supplementation community. Age
scheme of high-dose range during study A protocol
was 0-12 mo.
vitamin A versus
n=98 received
standard WHO
standard dose
protocol in Gambian
vitamin A protocol
mothers and infants: a
randomised controlled
trial
Darboe MK et al.

L:M as a marker of
intestinal epithelial
integrity among infants
receiving high-dose
vitamin A or standard
vitamin A protocol
2001
Durban,
South Africa
Filteau SM et al.
Pregnant, HIVThe effect of antenatal infected women
vitamin A and (beta)- between 28-32 wk
carotene
gestation recruited
supplementation on
from antenatal
gut integrity of infants clinic. Infants were
1

RCT
n=238
n=119 received
vitamin A
supplements
(26 with HIV
infection)

Urine Test:
L:M

Conclusion

L:M improved after supplementation
for the cohort of 20 children followed
longitudinally with PD or low WAZ
score:
L:M mean (SD):
• Pre-treatment: 0.28 (0.12)
• Post-treatment: 0.19 (0.07)
However, lactulose and mannitol
excretion did not change
significantly.
1
Mean L:M and proportion with
values >0.30 among those receiving
standard doses of vitamin A, by age:
• 2 mo: 0.195, 12%
• 5 mo: 0.197, 13%
• 7 mo: 0.212, 22%
• 9 mo: 0.286, 30%
• 12 mo: 0.322, 34%

Comments
Postsupplementation
L:M results in the
text of the
publication differed
somewhat from
what was reported
in the publication
table.

L:M values rose by
~50% from age 2
mo to 1 yr and were
not affected by
dosing of vitamin A.

The L:M normal
cutoff was defined
higher than for most
other L:M studies,
as 0.30. This was
derived from the
mean plus 2 SD
from a study of UK
infants [202].

Mean L:M differed between the two
groups only at 7 mo (0.276 in highdose vitamin A group, p=0.014),
although there was no difference in
percentages with L:M >0.30.

Urine Tests:
2
• Lactulose
• Mannitol
• L:M
Subjects tested:
• 1 wk:
• Treatment:

Geometric mean.
For lactulose and mannitol results, excretion measurement was not specified.
3
Geometric mean.
2

Results

3

Mean L:M (CI) at 1 wk among
Mean L:M overall
Specific sugar
infants without reports of illness was was within normal
excretion was
0.12 (0.08, 0.17). L:M did not change range. However,
normalized to
with increasing age and did not
urinary creatinine to
mean L:M for
significantly increase with reported placebo-treated,
control for variation
morbidity.
HIV-infected infants in renal function.
by 14 weeks was
While a history of ever having been significantly elevated
breastfed was an important
to almost 0.5.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
of HIV-infected South
African women

L:M as a marker of
intestinal permeability
among infants of HIVinfected mothers
enrolled in a vitamin A
trial

Location and
Design and
Target Population Sample Size
followed until 14
wk of age.

Biomarker

Results

Conclusion
2

n=104
contributor to L:M at 1 wk (ΔR =0.22,
n=119 received
• Placebo: n=104 p=0.008), a significant effect was not While HIV infection
1
placebo
seen at 6 and 14 weeks . Current
did not affect
• 6 wk:
(29 with HIV
feeding
status
had
a
modest
effect
mannitol excretion, it
• Treatment:
2
infection)
on
L:M
only
at
14
wk
(ΔR
=0.06,
was associated with
n=100
p=0.04).
increased lactulose
• Placebo: n=105
excretion.
• 14 wk:
Treatment
Birth
weight
contributed
significantly
• Treatment: n=99
2
involved maternal
• Placebo: n=95 at 1 wk (ΔR =0.07, p=0.02), but
vitamin A
current weight did not contribute
supplements
significantly to L:M at any time point.
during pregnancy
and at delivery.
HIV infection status by 14 wk was
the major factor contributing to L:M
2
at 6 wk (ΔR =0.22, p=0.008) and 14
2
wk (ΔR =0.21, p=0.01).
Maternal HIV viral load during
pregnancy was not consistently
significantly correlated with infant
L:M. Maternal lymphocyte counts
and plasma retinol concentrations
were not associated with infant L:M.
While maternal vitamin A
supplementation had no effect on
L:M of uninfected infants, it
appeared to prevent the increase in
2
L:M of HIV-infected infants :
Mean L:M (CI):
• Uninfected:
• Vitamin A group: 0.11 (0.08,
0.15)
• Placebo group: 0.09 (0.06,
0.12)
• HIV-infected:
• Vitamin A group: 0.17 (0.13,
0.23)
• Placebo group: 0.50 (0.37,
0.68)

1
2

Reported results were adjusted for confounding variables, unless otherwise noted.
Reported results were adjusted for confounding variables included an interaction with HIV infection.

Comments

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

2005

Location and
Design and
Target Population Sample Size

Biomarker

Mwenye, Malawi

RCT

P-values are from reported results that were adjusted for confounding variables.
Lactulose, mannitol, and sucrose results were expressed as % of dose administered.
3
Arithmetic mean.
2

Conclusion

Comments

A high baseline
prevalence of
abnormal L:M was
observed, with no
change after
intervention.

Difficult to interpret
sucrose tests
because there are
limited data on
laboratory values
for these tests in
young children.

Mannitol was not affected by vitamin
A. HIV infection was not consistently
significantly associated with mannitol
across age groups.

Urine Tests:
2
• Lactulose
n=164;
Galpin L et al.
36-60 mo olds
• Mannitol
recruited from a
• Sucrose (SUC)
Effect of Lactobacillus rural community, n=81 received
• L:M
GG on intestinal
excluding children Lactobacillus GG • SUC:L
integrity in Malawian with severe acute (80 completed the
study)
children at risk of
malnutrition or
tropical enteropathy
severe chronic
n=83 received
illnesses.
placebo
L:M and sucrose:
(81 completed the
lactulose ratio (SUC:L) Subjects were
as markers of
considered at risk study)
intestinal and gastric for EED due to
permeability,
residence in a
respectively, in
location with high Subjects received
30-days of
asymptomatic children prevalence of
Lactobacillus GG
presumed at risk of
EED.
or placebo. Only
EED
Presumed that if the 161 subjects
SBBO is etiology who completed
for EED, treatment the study had
with Lactobacillus repeat testing.
will result in
improved gut
integrity.
2008
Dhamrai Upazila, RCT
Urine Test:
Bangladesh
1

Results

Lactulose also did not consistently
differ between treatment groups or
by HIV-status, although vitamin A
prevention of increase in lactulose
among HIV-infected infants neared
1
significance at 14 wk (p=0.058) .
At enrollment:
• 73% had L:M >0.10
• 40% had L:M >0.20
3
• Mean L:M (SD):
• Treatment: 0.18 (0.16)
• Placebo: 0.22 (0.20)
• Mean lactulose (SD) in treatment
group: 0.25 (0.17)
• Mean mannitol (SD) in treatment
group: 8.0 (4.5)
• Mean SUC:L (SD):
• Treatment: 0.58 (0.64)
• Placebo: 0.60 (0.64)

High mannitol
excretion (relative to
UK norms) drove the
abnormal L:M.

There was little
effect on SUC:L with
intervention; sucrose
Mean excretion of sucrose (SD)
excretion increased
increased from 0.057 (0.042) to
in both treatment
0.078 (0.058) in the treatment group and control groups.
(p=0.01), but similar results were
observed in the placebo group.
Otherwise there were no changes in
lactulose, mannitol, L:M, or SUC:L
after treatment or placebo.

1

Mean L:M (SD) at baseline was
High L:M ratios
0.18 (0.24) in treatment groups, with overall with

High L:M ratios
were defined as

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
Goto R et al.

Location and
Design and
Target Population Sample Size

3-15 mo olds from
Impact of anti-Giardia a rural area were
and anthelminthic
enrolled and
treatment on infant
followed in a 9-mo
growth and intestinal trial.
permeability in rural
Bangladesh: a
There was a high
randomised doubleprevalence of
blind controlled study malnutrition in the
study population.
L:M as a marker of
intestinal permeability,
IgG as a marker of
chronic immune
stimulation, and α-1acid glycoprotein as an
acute phase reactant
among children
undergoing antiparasitic presumptive
treatment vs. placebo.
Also assessed
markers’ associations
with growth
parameters.

n=222*

Biomarker

Results

Conclusion

no significant difference in placebo substantial seasonal
group or in testing post-intervention. and within-infant
n=75 received
variability.
anti-Giardia and Blood Tests:
Proportion with elevated L:M at any
anthelminthic
study time point varied between
Interventions did not
• α-1-acid
treatment
impact L:M or serum
glycoprotein (AGP) 58%-74%. >57% consistently
elevated L:M ratios.
immune markers.
• IgG
n=59 received
• Albumin
anti-Giardia
Seasonal variation in L:M was
There was
treatment only
observed (p <0.001), with highest
improvement in
mean values in the monsoon
weight with better
n=88 received
season.
L:M values, the
placebo
degree to which this
L:M was associated with ∆WAZ and occurred was not
∆WHZ scores at 24 weeks (p=0.001 reported.
* Those who fully
and p<0.001, respectively, point
participated and
estimates not provided.)
for whom data
were analyzed
Serum immune marker values were
are included in
similar in all groups and did not
this review.
change substantially with
interventions.
• L:M

Comments
greater than the
upper CI for UK
infants.
Same study
population as
reported by this
group in another
study also included
in this review [123].

AGP concentrations were negatively
associated with ∆WAZ score at 24
weeks (p=0.004, point estimate not
provided), and were associated with
∆WHZ score at 12 weeks but not at
24 weeks.
2
2008
Dhamrai Upazila, Longitudinal data Urine Test:
Mean L:M: 0.15
Mean L:M was
Helminthiasis
Bangladesh
extracted from an L:M
elevated. L:M was prevalence was
RCT [122].
L:M showed a decreasing trend with not associated with very low; testing for
Goto R et al.
age (p=0.003), and was associated any of the tested
association with
3-15 mo olds from
Impact of intestinal
Blood Tests:
with female gender (p=0.004), HAZ serum markers of
markers was not
a rural area were n=298
score (p=0.039), and WAZ score
permeability,
enrolled and
inflammation or with performed.
• α-1-acid
inflammation status
followed in a 9-mo
glycoprotein (AGP) (p=0.019), but not with giardiasis or giardiasis.
and parasitic infections trial.
Urine and blood • IgG
any of the serum immune markers.
Giardiasis was
on infant growth
samples were
IgG
rose
with
defined as
• Albumin
IgG, AGP, and albumin were
increasing age at the presence of a
faltering in rural
There was a high collected every 3 • Hemoglobin
Giardia-specific IgM
mo and
associated with giardiasis, but
rate expected
Bangladesh
prevalence of
1
2

Geometric mean.
Geometric mean.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

malnutrition in the
L:M as a marker of
study population.
intestinal permeability,
IgG as a marker of
chronic immune
stimulation, and α-1acid glycoprotein as an
acute phase reactant.
Also assessed
laboratory values’
associations with
giardiasis and growth
parameters.

anthropometric
measurements
were collected
monthly.

2002

Kathmandu, Nepal Cross-sectional

Goto R et al.

0-5 yr olds (mean n=210
age 3.8 yr) from
two urban squatter
settlements.

Poor intestinal
permeability in mildly
stunted Nepali
children: Associations
with weaning practices
and Giardia lamblia
infection
L:M as a marker of
intestinal permeability,
and assessment of
association with
giardiasis,
helminthiasis,
nutritional practices,
and growth status.
1

37% and 33% of
subjects were
stunted and
underweight,
respectively.

Biomarker

hemoglobin was not.

Conclusion

(compared to UK
norms) [199] but at
Mean circulating albumin
higher
concentration was normal for age
concentrations
[203]. Compared to UK age-matched across all ages.
reference [199], rate of rise in IgG
with increasing age was similar, but
concentrations were consistently
~3g/L higher.

Urine Tests:
1
• Lactulose
• Mannitol
2
• Lactose
(168 tested)
• L:M
(158 tested)
• Lactose:lactulose
ratio
(157 tested)

Comments
response.
Same study
population as
reported by this
group in another
study also included
in this review [122].

Cut-off values
representing
elevated
concentrations
have not been
determined for
AGP. UK norms for
10 mo olds-adults
are 0.88 g/L mean
(0.21 SD) [204].
L:M:
L:M ratios were high Low lactase activity
overall.
was defined as
• 92% had values >UK norms
3
lactose:lactulose
• Mean L:M (SD, range): 0.26 (0.21,
ratio >0.4.
Wide individual
0.04-1.71).
• Giardia-infected versus uninfected variation was
Specific L:M data
observed in L:M
means: 0.43 vs. 0.25, p=0.014
by WAZ and HAZ
ratios.
scores were not
The duration of ingestion of solid
L:M was associated reported, although
foods (with or without concurrent
authors state that
breastfeeding) was not associated with giardiasis but
L:M was not
not
helminthiasis.
with L:M in multivariate analysis.
associated with
Urinary lactose
“growth status.”
L:M was correlated with longer
concentrations and
duration of breastfeeding (r=0.27,
p<0.019). Specifically, children who lactose:lactulose
breastfed for >2 yr had higher L:M ratios were
significantly higher in
ratios than children who breastfed
for shorter times (data not provided). breastfed subjects
than in those that
were not breastfed,
L:M was not associated with:
IgG was not associated with growth
parameters. Albumin was associated
with HAZ score only (p=0.016). AGP
was inversely associated with HAZ
(p=0.011) and WAZ (p=0.005)
scores.

Lactulose and mannitol results were expressed as % of dose administered.
Lactose results were expressed in mg/L.
3
Geometric mean.
2

Results

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

• History of diarrhea in the week
preceding testing
• Helminthiasis
• Age
• WAZ or HAZ scores

despite similar
intestinal
permeability values.

Comments

There were some
unexpected findings:
the duration of
Lactulose excretion ranged from
breastfeeding, and
0.02–15.00. Mannitol excretion
not the timing of
ranged from 0.5–15.00.
introduction of solid
foods, was
47% showed low lactase activity.
Lactose values and lactose:lactulose correlated with L:M,
2
ratios decreased with age (R =28%, and the correlation
p<0.0001), but were not associated was direct, not
with sex, ethnicity, and location nor inverse. Authors
speculate that this
were they associated with L:M.
could be due to
1
higher mean age of
Mean urinary lactose
their cohort
concentrations (mg/L) by feeding
compared to another
mode:
study that
• Breastfed: 172.5
demonstrated
• Non-breastfed: 44.5, p<0.0001
beneficial effect of
corrected for infant age
duration of
2
breastfeeding on
Mean lactose:lactulose ratio by
reduced L:M in
feeding mode:
Guatemala [205].
• Breastfed: 2.76
• Non-breastfed: 0.31,
p<0.0001 corrected for infant age

2000

Darwin, Australia

Haase A et al.

Cases were >4 mo n=264;
olds admitted to
n=150 cases with Urine Test:
Royal Darwin

Dual sugar
1

Geometric mean.
Geometric mean.
3
Geometric mean.
2

Case-control

Blood Test:
L:R

Mean L:M by feeding mode:
• Breastfed: 0.23
Non-breastfed: 0.28, non-significant,
p-value not specified
Among the subset with both blood
and urine specimens:
• Urine L:R:
3
• Mean (CI):
• Cases: 12.4 (9.3, 16.5)

Children with
diarrhea had
significantly higher
L:R ratios by both
blood and urine

Authors used data
from non-diarrheal
controls from their
clinical practice to
derive cut-points for

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
permeability testing in
diarrheal disease

Location and
Design and
Target Population Sample Size

Hospital with
AD
diarrhea. Controls
n=114 controls
were patients
Lactulose:rhamnose admitted with non- with no diarrhea
ratio (L:R) as a marker GI illness.
of intestinal
permeability in children More than 75% of
with or without
cases and controls
diarrhea. Also directly were Aboriginal.
compared blood and
urine methods of L:R
testing in a subset of
subjects.

1

Geometric mean.
Geometric mean.
3
Geometric mean.
2

Biomarker

Results

Conclusion

Comments

testing compared
L:R ratios used in
with controls without this study:
GI illness.
• Blood L:R:
Among cases:
• Low= <7
There was
• 24 had both blood
• Intermediate=
substantial
and urine L:R
7-12.5
agreement between
• 98 had blood L:R
• High= >12.5
urine and blood L:R • Urinary L:R:
only
tests in the same
• 28 had urine L:R
• Low= <10
subjects.
only
• Intermediate=
10-18
Urine has been an
Among controls:
• High= >18
established
• 25 had both blood
substrate for sugar
and urine L:R
Controls were
excretion
• 36 had blood L:R
significantly older
assessment as an
only
than the cases, but
indication of
• 53 had urine L:R
authors suggest
Among subjects with only urine
intestinal
only
that age differences
tested:
permeability.
2
do not impact L:R
Mean urine L:R (CI):
However, timed
A total of 49 subjects
test performance.
• Cases: 15.7 (12.6, 19.6)
collection of urine is
were tested with both
• Controls: 6.7 (5.7, 8.0), p<0.0001 not a trivial task,
blood and urine L:R
Numbers of
especially among
methods to allow
subjects do not
Among subjects with only blood
female children, and
direct comparison of
always match up
tested:
contamination with
values.
3
(e.g. numerator in
Mean blood L:R (CI):
stool is problematic,
test failure rate
• Cases: 12.8 (10.3, 16.0)
especially in children
calculations does
• Controls: 3.7 (2.8, 4.9), p<0.0001 with diarrhea.
not match other
However, the much
such reported
Even though blood L:R was
lower concentrations
numbers).
consistently lower than urine L:R by of probe sugars in
a geometric mean (CI) of 1.09 (1.02, blood compared to
Analyses of those
1.16), there was strong correlation urine had posed a
subjects who had
between L:R ratios in blood and
challenge to
both blood and
urine as measured by:
sensitive detection in
urine testing were
• Concordance correlation coefficient blood. High
conducted on
performance liquid
for agreement (CI) of 0.76 (0.64,
combined cases
chromatography
0.88)
and controls.
• Kappa statistic (CI) of 0.71 (0.51, (HPLC) methods, as Analyses of those
L:R

• Controls: 6.7 (5.0, 8.8),
p=0.004
• Distribution across ratios:
• Low: n=31
• Intermediate: n=9
• High: n=9
• Blood L:R:
1
• Mean (CI):
• Cases: 9.4 (6.7, 13.1)
• Controls: 5.9 (4.4, 7.8),
p=0.04
• Distribution across ratios:
• Low: n=27
• Intermediate: n=11
• High: n=11

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

Comments

0.92) (when L:R ratios are divided
into 3 ordered categories)
• Sensitivity and specificity of blood
tests of 81% (25/31) and 89%
(16/18), respectively, when using
the urine testing as the standard.

used in this study,
now provide a more
sensitive method of
assessing blood
specimens.

with and without
diarrhea would
have been of
interest. One would
expect children with
diarrhea to have
higher rates of urine
test failure due to
contamination with
stool and to have
higher failure rates
using either
analytes due to
higher rates of
emesis.

The failure rate* for serum L:R
testing (20/197, 10%) was lower
than for urine testing (86/234, 37%)
(p<0.0001).
* Defined as emesis with
rhamnose/lactulose oral challenge
(same dose for urine and serum
testing), urine leakage or
contamination with stool, or plasma
quantity from blood draw of
insufficient quantity for analysis.

2003

Darwin,
Australia

Case-control

Urine Test:
Nitric Oxide (NO)*

n=318;
1-6 yr old
Increased nitric oxide Aboriginal and
n=169 cases with Blood Tests:
AD
production in acute
non-Aboriginal
• L:R
diarrhea is associated hospital inpatients. (154 Aboriginal) • Mean corpuscular
with abnormal gut
volume (MCV)
Kukuruzovic R et al.

The failure rate of
L:R blood testing
was significantly
lower than that of
urine testing.

Spot blood testing
might be more
feasible than timed
urine collections,
but HPLC might not
be feasible in
resource-poor
settings.

This study appears
to report on the
same population as
two other studies in
this review which
also assessed
serum L:R as a
marker of intestinal
permeability [43,
58].
NO among Aboriginal children with NO2 + NO3:Cr ratio, Positive stool RS
diarrhea was >3x higher than any
as a measure of
was defined as
other group and >5x higher than in endogenous nitric
>0.5%.
non-Aboriginal controls.
oxide production,
Abnormal L:R was
was used as a
• NO was >3x and >2x higher
defined as >7.6; no
marker of gut
among Aboriginal than nonreference or
Aboriginal children in the diarrhea permeability and
(p<0.001) and no infections groups inflammation, with derivation was

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
permeability,
hypokalemia and
malnutrition in tropical
Australian aboriginal
children

Location and
Design and
Target Population Sample Size

Subjects were
n=149 controls:
grouped as
• 73 with non-GI
follows:
infections (49
1. Children with
Aboriginal)
AD
• 76 with no
2. Children with no infections (29
diarrhea but with Aboriginal)
Nitric oxide (NO) as a
non-GI
marker of intestinal
infectious
permeability and
conditions
inflammation, and
3. Children without
lactulose:rhamnose
ratio (L:R) as a marker GI or infectious
conditions
of intestinal
permeability and the
relationship between
NO and L:R, growth
parameters, mean
corpuscular volume
(as a surrogate of iron
deficiency), and stool
reducing substances
among children with
and without diarrhea

Biomarker

Results

Stool Test:
Reducing substances
(RS)**
(169 cases tested)
•

Reported results appear to have been adjusted for age and race.
Reported results were adjusted for age and race.
3
Reported results among children with diarrhea were adjusted for age and race.
2

Comments

(p<0.001), respectively, but there an attempt to identify provided for this
was no difference between them in how much more it
cut-point.
the non-GI infections group.
reflects as response
NO was >3x and ~2x higher in the to inflammation from Study population
appears to be the
GI vs. non-GI
diarrhea compared to the no
same as in another
infections.
infections group among
* NO is an unstable
Kukuruzovic, et al.
Aboriginals (p<0.001) and nonstudy also included
free radical and is
Aboriginals (p<0.03), respectively. Among nonconverted to nitrite
• NO was virtually the same among Aboriginal controls, in this review which
NO production was assessed serum
and nitrate. Urine
the Aboriginal non-GI infections
lactulose:rhamnose
nitrate (NO3)+ nitrite
and no infections groups, as well the same among
(NO2) was expressed as among the non-Aboriginal
those with diarrhea as a marker of
as a ratio with urine
intestinal
and non-GI
diarrhea and non-GI infections
permeability [58].
creatinine (NO2 +
infections (and
groups.
NO3:Cr) in order to
higher compared to
account for
112/152 (74%) and 31/169 (18%) of controls). NO was
differences in urine children with AD had abnormal L:R highest by far
1
concentration.
among Aboriginal
ratios and positive stool RS,
children with
respectively.
** Measured only
diarrhea compared
among children with NO and L:R were measured at
to any other group.
Authors suggest that
profuse diarrhea.
“convalescence” on Day 5 among
high basal
those with diarrhea: the mean
concentrations of
improvement in NO was 21.7%
NO among
compared with 54.6% for L:R
Aboriginal children
(p=0.01).
due to (clinically
NO and L:R were correlated (n=193, silent) enteropathy
1
could explain the
r=0.37, p<0.001) ; the correlation
concentrations seen
was stronger for lactulose (effect
among Aboriginal
ratio=1.47, p<0.001) than for
controls in this
rhamnose (effect ratio=0.80,
2
study.
p=0.02 ).
NO was not correlated with stool
3
RS or MCV, but was correlated with
lower WAZ score (effect ratio=0.88,
p=0.05).

1

Conclusion

NO appeared to
decrease
significantly more
slowly than L:R
among children

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

2002

Darwin, Australia

Kukuruzovic RH et al. Inpatient
Aboriginal children
Milk formulas in acute <3 yr old with AD
gastroenteritis and
and/or WAZ score
malnutrition: a
<-2.
randomized trial
60% of subjects
Lactulose:rhamnose had low WAZ
ratio (L:R) as a marker score and 90%
of intestinal
had diarrhea.
permeability among
children with diarrhea
and/or malnutrition
treated with milk
formulas of varying
composition and
osmolality

2002

Darwin, Australia

Kukuruzovic RH et al. Cases were
Aboriginal and
1
2

RCT
n=177;

Biomarker

Blood Test:
L:R

n=60 received
De-Lact formula

L:R testing was
repeated in 150
subjects at day 5:
n=65 received O- • De-Lact: n=48
Lac formula
• O-Lac: n=52
• Alfaré: n=50
n=52 received
Alfaré formula
Subjects were
treated with one
of three lowlactose formulas:
• De-Lact, lowosmolality
lactose-free
formula
• O-Lac, lactosefree formula
• Alfaré, partially
hydrolyzed
formula
Case-control

Blood Tests:
• Lactose
n=375 admissions • Lactulose 2
for 306 children; • Rhamnose

Geometric mean.
Lactulose and rhamnose results were expressed as % of dose administered.

Results

Conclusion

recovering from
diarrhea.
NO was found to
correlate with L:R.
NO was more
strongly correlated
with lactulose than
rhamnose.
1
Baseline mean L:R (CI) in De-Lact Authors noted that
group was 14.9 (10.4, 21.5), with no treatment with all of
difference between groups.
the low-lactose
formulas studied
The mean improvement* in L:R (CI) resulted in improved
was 13.0 (9.3, 16.6) with some
L:R among this
significant differences between the population at risk for
various formulas:
enteropathy and
• De-Lact: 18.6 (10.6, 26.6)
growth failure.
• O-Lac: 12.0 (7.5, 16.6), p=0.15
Improvement was
compared to De-Lact
most marked with
• Alfaré: 8.5 (2.1, 14.9), p=0.049
the low osmolality
compared to De-Lact
formula, De-Lact.
* Improvement in L:R was calculated
as baseline L:R minus repeat L:R.

27/75 (36%) of Aboriginal controls
and 0 non-Aboriginal controls had
abnormal L:R ratios.

Comments

Reported results
did not appear to be
harmonized with
the method
described for
calculating
improvement in
L:R.
Fully breastfed
children were
excluded.
The study did not
include a control
arm (of standard
care) to which
change in L:R could
be compared.

Authors reiterate
the advantages of
serum over timed
urine collection for
assessment of L:R
as discussed in
another publication
in this review [125].
Mean L:R ratios of Positive stool RS
Aboriginal children was defined as
were approximately >0.5%.
double those of non-

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
Small bowel intestinal
permeability in
Australian Aboriginal
children

Location and
Design and
Target Population Sample Size

non-Aboriginal
children admitted n=285 case
admissions for
to hospital with
diarrhea. Controls AD (264
Aboriginal)
were Aboriginal
Serum lactulose:
and non-Aboriginal
rhamnose ratio (L:R), children admitted n=90 control
admissions with
without GI
serum lactose, and
no diarrhea (74
illnesses.
stool reducing
Aboriginal)
substances as
markers of intestinal
permeability among
Aboriginal and nonAboriginal children
with and without
diarrhea

1

Biomarker

Results
1

Mean L:R at baseline:
Cases:
• Aboriginal: 16.4
• Non-Aboriginal: 7.9, p=0.002
compared to Aboriginal cases
Controls:
• Aboriginal: 4.6
Stool Test:
Reducing substances • Non-Aboriginal: 2.5, p=0.02
compared to Aboriginal controls
(RS)*

Conclusion

Comments

Abnormal L:R was
defined as >5.6,
derived from 2 SD
above the
arithmetic mean for
non-Aboriginal
controls in this
study. The rationale
for the choice of 2
SD above the
2
Mean improvement in L:R (CI) at
arithmetic, instead
day
5
among
those
with
repeat
of the geometric,
Mean
L:R
L:R testing was
testing:
mean is not clear.
significantly
repeated on day 5 for
•
Aboriginal
cases:
14.6
(11.2,
18.0)
Proportions of
improved
over
5
a subset of Aboriginal
• Aboriginal controls: -0.63 (-4.0,
cases with
days among
subjects:
abnormal
Aboriginal cases.
• 174/264 admissions 2.7)
Children with severe concentrations
for acute diarrhea
3
Mean lactulose recovery :
diarrhea had higher were not reported.
• 25/74 control
• Cases day 1: 0.085 (0.070–0.103) mean L:R.
admissions
• Cases day 5: 0.039 (0.033–0.046)
Analysis included
• Controls: 0.024 (0.019–0.029)
Higher case L:R was data for 69 children
All 3 values significantly differed
driven more by high with repeat
* Measured only
from
one
another.
lactulose than by low admissions; this
among children with
rhamnose.
might violate
profuse diarrhea
Mean
rhamnose
recovery:
Similarly,
independence
when “clinically
indicated." Number • Cases day 1: 0.479 (0.424–0.542) improvement in L:R assumptions for
tested not provided. • Cases day 5: 0.555 (0.498–0.616) among cases was their statistical
• Controls: 0.585 (0.500–0.685)
analysis methods.
primarily due to
These values did not significantly
decreased lactulose.
differ from one another.
Repeat L:R testing
Stool RS and serum was conducted on
Confidence intervals (CIs) in the
lactose were found controls of both
authors' graphical representation of in approximately
racial groups, but
mean L:R at admission did not
among cases it was
one-quarter and
overlap, and the difference in means one-third of
only conducted on
was particularly evident between
Aboriginal cases.
Aboriginal cases,
Aboriginal and non-Aboriginal
respectively. The
subjects.
This study appears
latter was weakly
associated with
to report on the
• L:R
• Hemoglobin
• Mean corpuscular
volume (MCV)

Aboriginal children
both among those
with and without
diarrhea, consistent
with authors’
suggestion that
clinically silent
enteropathy is
prevalent among
Aboriginal children.

Geometric mean.
Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated.
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577.
3
Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.
2

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Factors associated with L:R among increased lactulose.
1
cases were :
• Acidosis (p=0.007)
• Hypokalemia (p=0.035)
• Diarrhea severity (p=0.001)
Age and malnutrition were not
associated with L:R.
38% and 27% of Aboriginal cases
had positive serum lactose and stool
RS, respectively. 12% of Aboriginal
and non-Aboriginal controls
combined had lactosemia.

2010

Fortaleza, Brazil

Lima AA et al.

2 mo-9 yr olds
n=79;
(mean 43 mo) from
an impoverished n=40 received
urban community, placebo
Stool Tests:
(tocopherol)
eligible if HAZ
• Lactoferrin
score was
• Cytokines:
<median for their n=39 received
• IFN-γ
vitamin A (retinyl
community.
• TNF-α
palmitate)
• IL-4
Subjects were
• IL-10
screened for
Subjects were
intestinal
treated every 4
parasites, and
mo.
longitudinal
anthropometrics
were assessed.

Effects of vitamin A
supplementation on
intestinal barrier
function, growth, total
parasitic, and specific
Giardia spp infections
in Brazilian children: a
prospective
randomized, doubleblind, placebocontrolled trial
L:M as a marker of
intestinal barrier
function, and stool
1

RCT

Urine Tests:
3
• Lactulose
• Mannitol
• L:M

Reported results were adjusted for confounding variables, unless otherwise noted.
Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.
3
For lactulose and mannitol results, excretion measurement was not specified.
2

Conclusion

Comments
same population as
in the Kukuruzovic,
et al. 2003
reference also
included in this
review, which
assessed nitric
oxide excretion
[43].
Authors reiterate
the advantages of
serum over timed
urine collection for
assessment of L:R,
as discussed in
another publication
in this review [125].

Presence of lactosemia was
associated with L:R, adjusted
2
relative risk (CI)=1.06 (1.03, 1.10) .
Stool RS, anemia, and MCV were
not associated with L:R.
Median L:M at baseline was 0.089. Frequency of stool Authors did not
There was no significant change in lactoferrin varied
report testing for
L:M at 4 mo follow-up within either between 23%-32%. associations
treatment group.
between urinary
While vitamin A
markers of
No significant difference in L:M was supplementation
intestinal
observed between treatment groups. was associated with permeability and
concentrations of
reduced lactulose
Both median lactulose and mannitol excretion, it was also fecal cytokines, or
excretions decreased at 4 mo follow- associated with
between these
up among the vitamin A compared to reduced mannitol
markers and growth
the placebo group:
parameters or
excretion, with no
overall effect on L:M. parasitosis.
• Lactulose: 0.21 to 0.74, p=0.042
• Mannitol: 3.06 to 8.25, p=0.008
Vitamin A
Cut-point values for
lactoferrin positivity
Overall proportion of lactoferrin was supplementation
and abnormal L:M
was
not
associated
23% initially. At 1 mo follow-up, there
were not described.
with
presence
of
was no difference in prevalence
lactoferrin or
between vitamin A (33%) and

Evidence Table 2. Markers of permeability.

Reference and Study
Location and
Design and
Outcomes of
Target Population Sample Size
Diagnostic Interest
lactoferrin and specific
intestinal
immunological
cytokines as markers
of intestinal
inflammation among
nutritionally at-risk
children who received
either vitamin A or
placebo
2005
Fortaleza, Brazil RCT
Lima AA et al.
Intestinal barrier
function and weight
gain in malnourished
children taking
glutaminesupplemented enteral
formula
L:M as a marker of
intestinal permeability
and various stool tests
among children with
malnutrition or PD who
received either glycine
or glutamine
supplemented formula
or placebo

2-60 mo olds
hospitalized with
WAZ score <-2,
~70% of whom
had PD.

n=80;
n=53 received
supplemented
formula
• 27 with glycine
• 26 with
glutamine
n=27 received
nonsupplemented
formula

Biomarker

Results

Conclusion

Comments

placebo (31%) groups.

intestinal cytokine
response.

Exclusively
breastfed children
were excluded from
study participation
due to assessment
of stool lactoferrin.

Cytokine concentrations did not
significantly differ between placebo
and vitamin A groups.

Urine Tests*:
1
• Lactulose
• Mannitol
• L:M
Stool Tests**:
• Lactoferrin
• Leukocytes
• Occult blood
• Reducing
substances (RS)
* n=80 tested at
enrollment, n=65
tested at day 10.
** n=60 tested.

2

Mean L:M (SE):
L:M significantly
The relationship
• Glutamine group:
improved in the
between stool
markers and L:M
• Baseline: 0.31 (0.10) (similar in glutamine group
was not reported.
only.
all three groups)
• Day 10: 0.10 (0.02); significant
Data were not
>50% of subjects
decrease, (p=0.01)
stratified by history
• No significant decrease in L:M in had intestinal
of PD.
inflammation by
glycine and nonsupplemented
stool lactoferrin.
formula groups at day 10
Fecal fat was
Fecal leukocytes,
RS,
and
occult
blood
assessed, but
Mean lactulose (SE):
were
detected
in
results were not
• Glutamine group:
reported.
fewer
subjects
than
• Baseline: 0.97 (0.46) (similar in
lactoferrin.
all three groups)
Cut-off values for
• Day 10: NS decrease in all 3
lactoferrin positivity
groups
were not described.
Mean mannitol (SE):
Exclusively
• Glutamine group:
breastfed children
• Baseline: 3.42 (0.64) (similar in
were excluded from
all three groups)
study participation
• Day 10: NS decrease in all 3
due to assessment
groups
of stool lactoferrin.
Proportion of stool markers at
baseline among all subjects:
• Lactoferrin: 53.3%
• Leukocytes: 11.7%
• RS: 3.3%
• Occult blood: 5.0%

1
2

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
2007

Location and
Design and
Target Population Sample Size
RCT

Lima NL et al.

Parque
Universitario,
Fortaleza, Brazil

Wasting and intestinal
barrier function in
children taking alanylglutaminesupplemented enteral
formula

6 mo-8 yr olds
(mean age 3.5 yr)
from an urban
setting with HAZ,
WAZ, or WHZ
scores <-1.

n=51 received
alanyl-glutamine
treatment

Jamalpur district,
northern
Bangladesh

RCT*

n=107;

Biomarker

Results

Conclusion

Urine Tests:
1
• Lactulose
• Mannitol
• L:M

L:M median (range) at baseline:
• Treatment: 0.0385 (0.8922 [sic])
• Placebo: 0.0302 (5.5812 [sic])

Even though
lactulose excretion
improved in the
treatment group,
mannitol excretion
worsened with
overall L:M not
changing.

n=56 received
glycine placebo

L:M as a marker of
intestinal permeability
in assessing alanylglutamine supplement
to improve intestinal
barrier function in
malnourished children
compared to glycinecontaining placebo
supplement

2001
Northrop-Clewes CA
et al.

2-5 yr olds from
Anthelmintic treatment poor rural villages,
of rural Bangladeshi
sampled randomly
children: effect on host from a larger
physiology, growth,
cohort study.
and biochemical status
1

n=109;

Blood Tests
• α 1antichymotrypsin
• Albumin
• Total protein

n=54 received
bimonthly empiric
antihelminthic
Urine Test:
treatment
L:M
n=55 received

Lactulose and mannitol results were expressed as % of dose administered.
Reported results were adjusted for age and season.
3
Reported results were adjusted for age and season.
4
Geometric mean.
2

Comments

Authors state that
L:M median and
range values were
within the
Lactulose and mannitol excretion
confidence interval
both significantly decreased in the
for values of
treatment group only (p=0.05 for
healthy children in
2
both sugars) . L:M did not change
the study
significantly within or across groups
community; no
days after treatment.
Lactulose, mannitol reference was
cited.
and L:M did not
Lactulose excretion was not
change significantly
associated with WHZ, WAZ or HAZ in the placebo
Although the
3
scores in either group . Mannitol
authors defined
group.
was not associated with growth
persistent and
parameters in the control group, but
chronic diarrhea in
2
was associated with WHZ (r =their methods, they
2
0.386, p=0.027) and WAZ (r =did not report data
0.385, p=0.027) scores in the
stratified according
supplemented group. Data for L:M
to these conditions.
and growth parameter association
was not provided.
Authors provide
2
negative R values
when reporting
Pearson’s
correlation analysis
results; these likely
actually represent r
values.
4
Mean L:M at baseline:
L:M ratios were high Baseline study data
overall and
were lost, so
• Treatment: 0.22
analysis began with
demonstrated
• Placebo: 0.25
seasonal variation. samples taken at
month 2.
Seasonal variation in L:M was
Intra-individual L:M
observed, with highest values
The relationship
values did not
following the monsoon season.
change significantly between the serum
Within-subject L:M analysis showed over time, nor were markers and
they associated with intestinal

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Stools were
placebo
L:M as a marker of
assessed for
intestinal permeability, helminthiasis and
and α 1giardiasis. Growth * Randomized at
the village level.
antichymotrypsin as a was followed
marker of inflammation longitudinally.
and immune activation
to treatment among
children randomized to
bimonthly
antihelminthics or
placebo.

2009

Kathmandu, Nepal Cohort

n=86;
3-18 mo olds in
two cohorts:
n=48 in squatter
Pathways leading to 1. All children in
target age range cohort
early growth faltering:
from four
An investigation into
n=38 in lower
squatter
the importance of
middle-class
settlements
mucosal damage and
cohort
immunostimulation in Randomly
selected, agedifferent sociomatched cohort
economic groups in
from lower middleNepal
class, periurban
Panter-Brick C et al.

1

Geometric mean.

Biomarker

Results

Conclusion

Comments

Among 93 subjects
with L:M at baseline:
• 46 received
treatment
• 47 received
placebo

no significant association with
intestinal helminthiasis and no
significant improvement in treatment
or placebo groups over 1 yr. L:M
was generally not associated with
giardiasis (with the exception of one
group at one study interval).

helminthiasis or
consistently
associated with
giardiasis.

permeability was
not reported.

Among 66 subjects
with repeated L:M
testing:
• 34 received
treatment
• 32 received
placebo

Urine Test:
Lactose:Cr
Blood Test:
Hemoglobin

L:M was inversely correlated with
∆HAZ and ∆WAZ scores at some of
the follow-up intervals (r=-0.22,
p<0.02 and r=-0.21, p<0.05,
respectively, at 12 mo follow-up
visit).

Inverse correlations
were seen between
L:M and growth
parameters.

Serum markers were
within normal range.
The only significant
change in these
markers was a
Mean serum ACT, albumin and total decrease in total
protein were within normal ranges
protein in the
and were not associated with growth treatment group
parameters. ACT and albumin
without concomitant
concentrations did not significantly change in albumin;
change with treatment, whereas total this suggested a
protein concentrations did (p<0.001). decrease in
globulins (not
directly measured),
perhaps due to
decreased
inflammation.
1
Mean Lactose:Cr (CI):
Authors speculate Specific sugar
• Squatter: 0.14 (0.12, 0.16)
that Lactose:Cr
excretion was
• Middle Class: 0.08 (0.07, 0.10)
accounted for less of normalized to
• Statistically significant difference the deterioration in urinary creatinine to
control for variation
between the 2 groups among the nutritional status
6-12 mo olds (p=0.007) and 18-24 among the squatter in renal function.
mo olds (p=0.002), but not among children because of
Authors suggest
12-18 mo olds.
several factors,
• For both SES groups, Lactose:Cr including poorer
that while
Lactose:Cr might
values decreased with increasing nutritional intake,
not be as accurate
age (p<0.001).
that impact the
nutritional status of as L:M, it might be
HAZ, WAZ, WHZ, and ∆WAZ scores children with lower a more field-friendly
were strongly associated with mean socio-economic
assessment of

Evidence Table 2. Markers of permeability.

Reference and Study
Location and
Design and
Outcomes of
Target Population Sample Size
Diagnostic Interest
Lactose:creatinine
households
ratio (Lactose:Cr) as a
marker of intestinal
permeability and
hemoglobin, albumin,
α-1-acid glycoprotein,
and IgG as markers of
immunostimulation.
The latter were also
assessed for their
relationship to
nutritional status.

2000
Quadro L et al.

Goncalves Dias
Cross-sectional
favela in Fortaleza,
Brazil
n =30

Retinol and retinol1-9 yr olds with
binding protein: gut
mild malnutrition
integrity and circulating selected from a
immunoglobulins
large cohort of
children from an
L:M as a marker of
urban slum. They
small intestinal
were recruited at
permeability, and its
birth and followed
correlation with serum longitudinally.
retinol among mildly
malnourished children 19 (63%) had
some degree of
vitamin A
deficiency—all of
1

Biomarker

Results

Conclusion

Lactose:Cr (p<0.001 each) as was status.
∆HAZ score (p=0.004); ∆WHZ score
was not. The strength and
magnitude of association between
∆WAZ score and Lactose:Cr was
most pronounced among the
wealthier cohort and there was no
association between ∆HAZ score
and Lactose:Cr among the squatter
children.
Hemoglobin concentrations were
inversely related to Lactose:Cr
2
(r =0.018, p<0.001).

Urine Tests:
1
• Lactulose
• Mannitol
• L:M

Lactulose and mannitol results were expressed as % of dose administered.

Comments
mucosal damage
compared to L:M,
requiring only spot
urine collection and
no substrate
dosing. However,
L:M was not
assessed in this
study; direct
comparison of the
two tests was not
possible.

While hemoglobin
concentration was
inversely related to
Lactose:Cr, testing
for associations of
other measured
blood markers (IgG,
AGP and albumin)
with Lactose:Cr
was not reported.
80% of subjects had abnormal L:M, Children with low
The L:M normal
defined as >=0.030.
serum retinol had
cutoff was defined
lower than for most
higher L:M,
Serum retinol was:
apparently mediated other L:M studies,
• Inversely correlated with L:M
as 0.030. The
by mannitol
authors reference
(r=0.46, p=0.012)
excretion.
• Directly correlated with mannitol
several studies
regarding use of
(r=0.66, p<0.01)
Not correlated with lactulose (data
this cut point.
not reported)

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

these had mild
deficiency, except
for 2 with
moderately low
concentrations.
2004
Dhaka,
RCT
Bangladesh
n=57;
Rabbani GH et al.
5-12 mo old males
Green banana and
n=19 received
admitted to the
green banana
pectin improve small hospital of the
and rice
intestinal permeability International
and reduce fluid loss in Centre for
Bangladeshi children Diarrhoeal Disease n=17 received
Research with PD pectin and rice
with persistent
but without other
diarrhea
n=21 received
concurrent
rice alone
L:M as a marker of
illnesses.
(placebo)
intestinal permeability
among infants with PD
who are treated with
green banana, pectin,
or rice diet

1

Biomarker

Results

Urine Tests:
1
• Lactulose
• Mannitol
• L:M

Mean L:M (SD) by treatment group,
pre- and post-treatment:
• Banana: pre=0.50 (0.14),
post=0.21 (0.12), p<0.01
• Pectin: pre=0.54 (0.17), post=0.23
(0.09), p<0.01
• Placebo: pre=0.41 (0.11),
post=0.45 (0.13), p>0.6

Lactulose and mannitol results were expressed as % of dose administered.

Conclusion

L:M values were
high at baseline
among the study
population of
inpatient young
children with PD.
Mean L:M
significantly
improved with the
Lactulose and mannitol excretion did green banana or
not differ between groups at
pectin intervention
baseline.
but were still above
normal range
Lactulose excretion was not
following 7 days of
significantly reduced after
treatment. The
intervention in the placebo group.
improvements in L:M
Mean (SD):
were driven by both
• Pre-treatment: 1.45 (0.12)
mannitol and
• Post-treatment: 1.35 (0.15)
lactulose, with the
latter having an
Both treatment groups had 70-80% impact of greater
reduced lactulose excretion following magnitude.
treatment (p<0.01).
Authors cite studies
Mannitol excretion increased in all
postulating that the
groups compared to their preeffectiveness of
treatment values, but only
green banana in
significantly so in the banana and
reducing diarrheal
pectin groups (p<0.05).
fluid loss is due to its
high content of
Mean mannitol % excretion (SD),
amylase-resistant
pre- vs. post-treatment:
starch, which
• Banana: 1.82 (0.13) vs. 3.21
undergoes
bacterial
(0.16)
• Pectin: 1.91 (0.12) vs. 3.2 (0.18) fermentation into
• Placebo: 2.10 (0.11) vs. 2.33
short-chain fatty

Comments

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

2009
Ritchie BK et al.
13C-sucrose breath
test: novel use of a
noninvasive biomarker
of environmental gut
health

Location and
Design and
Target Population Sample Size

Geometric mean.

Results
(0.18)

Darwin and
Adelaide, Australia
4 mo-5 yr old
Aboriginal children
admitted to
hospital with
diarrhea.

Two control
Sucrose breath test
groups:
(SBT) as a marker of 1. Aboriginal
controls
small bowel mucosal
admitted to
damage vis a vis
sucrase activity among hospital with
an Australian
non-GI
Aboriginal population.
symptoms (50%
had pneumonia)
Also compared SBT
2. Healthy, nonwith serum
Aboriginal
lactulose:rhamnose
controls
ratio (L:R)
recruited from
community

1

Biomarker

Conclusion

Comments

acids in the colon,
stimulating colonic
The banana and pectin groups
salt and water
stopped having diarrhea more often absorption. Pectin is
compared to controls (e.g. p<0.01 by thought to work by a
day 4). Among the banana and
similar mechanism.
pectin groups, stool reductions were Authors also
associated with percent change in
suggest that short
L:M before and after treatment
chain fatty acids
2
2
(R =0.84 for pectin and R =0.86 for might affect enterobanana; p<0.05 for each).
hormones and
growth factors,
resulting in the
observed changes in
intestinal
permeability [206].
Case-control
Blood Tests:
20/32 (63%) of Aboriginal children
SBT values were
Abnormal L:R ratios
had abnormal L:R ratios.
significantly lower
were defined as
• L:R
n=43;
and L:R values were >16; no reference
(32 Aboriginal cases
1
significantly higher or derivation was
and controls tested) Mean L:R (CI):
n=18 Aboriginal • C-reactive protein • Diarrhea cases: 31.8 (24.9, 40.7) among Aboriginal
provided for this
cases with AD
•
Aboriginal
controls
without
cut-point.
children
with
(CRP)
diarrhea
than
among
diarrhea:
11.4
(8.5,
15.5),
• Mean Corpuscular
n=25 controls:
significant difference (p<0.0001) those without GI
L:R test was not
Volume (MCV)
symptoms. SBT was conducted among
• 18 Aboriginal, • Hemoglobin
SBT Mean (CI):
also significantly
the non-Aboriginal
without diarrhea
• Diarrhea cases: 1.9% (0.9, 3.0),
controls.
lower among
• 7 nonp<0.0001 compared to nonAboriginal controls
Aboriginal,
Breath Test:
13
SBT/L:R correlation
Aboriginal controls and p=0.004 than among nonhealthy
C sucrose breath
analysis was based
compared
to
Aboriginal
controls
Aboriginal
children
test (SBT)
• Aboriginal controls: 4.1% (3.0,
on data for
without diarrhea.
Aboriginal cases
5.2), p=0.032 compared to non- This is consistent
with previous reports and controls
Aboriginal controls
• Non-Aboriginal controls: 6.1%
of high prevalence of combined; stratified
clinically silent TE in analysis was not
(4.8, 7.3)
Significant differences were
reported and could
this population.
observed between all three groups.
be of interest
SBT was
considering the
SBT results were not associated with significantly
large difference in
wasting or with patient age or
inversely correlated L:R observed
breastfeeding status.
with L:R.
between these

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

groups.

SBT and L:R were inversely
correlated (r=0.67; CI: 0.42, 0.62;
p<0.0001). L:R explained 45% of the
variance in SBT; diarrhea explained
28% of variance.

2001
Rollins NC et al.

Durban, South
Africa

1, 6, and 14 wk old
infants born to
Feeding mode,
intestinal permeability, HIV-infected
mothers.
and neopterin
excretion: A
longitudinal study in
infants of HIV-infected
South African women

Cohort
n=272

Urine Tests:
1
• Lactulose
• Mannitol
• L:M
• Neopterin

2000
Rollins NC et al.
Vitamin A
1

A non-significant, positive trend in
neopterin excretion was observed
among HIV-infected infants.

Durban, South
Africa
6-60 mo old
inpatients or

RCT
n=139;
n=66 received

Urine Tests:
3
• Lactulose
• Mannitol
• L:M
• Neopterin

Lactulose and mannitol results were expressed in mg.
Geometric mean.
3
For lactulose, mannitol, and neopterin results, excretion measurement was not specified.
4
Geometric mean.
2

Associations of
MCV, CRP, and
hemoglobin with
SBT after adjusting
for potentially
confounding
variables were not
reported.

SBT was associated with increased
MCV, relative risk (CI)=3.9 (2.8, 5.0).
SBT was not associated with
hemoglobin or CRP.
2
Mean L:M (CI):
L:M was generally Assessment of
normal (compared to association
• HIV-infected subjects:
UK values) for non- between L:M and
• 1 wk: 0.12 (0.06, 0.27)
HIV-infected infants, neopterin was not
• 6 wk: 0.24 (0.15, 0.38)
but significantly
reported.
• 14 wk: 0.24 (0.14, 0.44)
increased
among
• Uninfected subjects:
HIV-infected
• 1 wk: 0.13 (0.09, 0.19)
subjects, especially
• 6 wk: 0.08 (0.06, 0.11)
after 6 weeks.
• 14 wk: 0.09 ( 0.07, 0.13)
HIV-infection by 14 wk of age was
significantly associated with
increased L:M.

L:M as a marker of gut
mucosal integrity and
urinary neopterin
excretion as a marker
of cell-mediated
immunity in infants
with and without HIV
infection

Comments

4

Mean L:M:
• Group 1:
• Day 0: ~1.8
• Day 3: ~2.4
• Group 2:

The increased L:M
in HIV-infected
infants was primarily
driven by lactulose
rather than mannitol.
Higher neopterin
excretion by HIVinfected infants was
observed but this
was not statistically
significant.
Mean L:M ratios
Urine testing could
were very high
only be conducted
(~10x) (at baseline in the laboratory on
and at day 3 in both certain days; hence
groups) compared to only a subset of

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
supplementation of
South African children
with diarrhea: optimum
timing for improving
biochemical and
clinical recovery and
subsequent vitamin A
status
L:M as a marker of
intestinal permeability
and urinary neopterin,
serum α-1 acid
glycoprotein, and Creactive protein as
markers of
inflammation among
children with severe
diarrhea

Location and
Design and
Target Population Sample Size
outpatients with
severe diarrhea.

Biomarker

vitamin A on
admission (group
1)
Blood Tests:
• C-reactive protein
n=73 received
(CRP)
vitamin A after
• α-1 acid
clinical
glycoprotein (AGP)
improvement
(group 2)
49 subjects received
urine testing:
• Group 1: n=25
Treatment
• Group 2: n=24
involved vitamin A
supplementation
either on the day Blood and urine were
of
tested on days 0 and
admission or after 3.
acute diarrheal
symptoms had
resolved.

Results

Conclusion

other studies in this
review. Study
authors suggested
There were no differences in mean (via personal
L:M between groups or within groups correspondence)
that this could have
between days 0 and 3, although
there was a significant difference in been due to the
paired analysis within individuals at severity of illness in
the sample
the two time points (data not
presented, and direction, magnitude population (children
hospitalized for
and degree of significance not
diarrhea).
reported).
• Day 0: ~1.2
• Day 3: ~0.7

Comments
subjects underwent
those tests.

Group 2 patients
had significantly
higher CRP, nonsignificantly higher
WBCs and AGP,
and lower retinol
and retinol-binding
protein
concentration
compared to group
1 at baseline.
Vitamin A
Lactulose and mannitol excretion
Authors note that
administration did
were assessed only in the paired
these parameters
not result in
analysis. Lactulose excretion
suggest that Group
significant
decreased between days 0 and 3
(magnitude of effect and degree of improvement in L:M, 2 patients might
neopterin, or AGP have been more ill
significance not reported), while
regardless of timing at baseline. For the
mannitol excretion showed no
subset of 49
of vitamin A
change.
patients undergoing
administration.
1
urine testing, the
Mean neopterin and AGP
mean L:M and
concentrations did not differ between
neopterin
groups or within groups on the
concentrations
different study days or in the paired
were lower among
analysis. When initial CRP (~2x
Group 2 than Group
higher in Group 2 compared to
1 subjects (NS).
Group 1, p<0.004) was taken into
However, baseline
account, mean CRP on day 3 did not
differences in acute
differ between the 2 groups.
phase and vitamin
However in the paired analysis, CRP
A markers at
concentrations were significantly
baseline were not
different between days 0 and 3.
reported separately
for these 49
subjects.
Data for lactulose
and mannitol
excretion were not

1

Geometric mean.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

2000
Thurnham DI et al.

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

Comments
reported separately.
Rationale for
additional analyses
of these molecules
expressed as ratios
with creatinine was
not explained.

Orissa State, India

Subjects were
recruited from 2
Innate immunity, gut sources:
integrity, and vitamin A 1. Hospital-based
in Gambian and Indian infants admitted
infants
for “diarrheal or
respiratory
L:M as a marker of
disease,” mean
intestinal integrity
age 9 mo
among children
2. Clinic-based
receiving vitamin A
infants with
supplementation
“minor
ailments”, age
not specified

Authors suggest
that their 3-day
testing period
(based on their
previous work in a
different setting
[207] might have
been too short to
identify effect as
demonstrated by
McCullough et al. at
10 days after
presentation [208].
RCT
Urine Test:
Mean L:M was ~3-fold higher among Mean L:M values,
Precise numerical
L:M
hospitalized compared to clinic
including postvalues were not
n=174;
patients at baseline. Within the
intervention values, reported, rather L:M
allocation groups, mean baseline
results were
were 2-5 times
n=94 hospitalFor hospital-based
L:M did not differ for either the
portrayed in figures
higher than those
based
hospitalized or clinic subjects.
subjects, L:M was
observed in the UK with units
assessed at baseline,
expressed in mg,
[209].
• 31 received
Among the hospital cohort, mean
making it difficult to
vitamin A at day discharge from
hospital, and 10 or 30 L:M declined significantly in the two L:M reduction was compare these
1
days after discharge. vitamin A groups compared to the
accelerated among results to those of
• 32 received
placebo group, and remained lower vitamin Aother studies.
vitamin A at
at day 30 among the treatment
supplemented
discharge (up to For clinic-based
groups, but the difference was no
subjects, L:M was
children, but end-of- Information on
day 5)
assessed at baseline, longer significant compared to the
study mean values study design, such
• 31 received
4, and 8 wk.
placebo group.
as randomization
did not differ
placebo
statistically between scheme, was
Among the clinic cohort, mean L:M allocation groups in limited.
n=80 clinicreduction was accelerated in vitamin either the clinic or
based*
A-supplemented children. However, the hospital cohorts. The article also
mean L:M did not significantly differ
reported rebetween treatment groups at any
analyzed data from
Clinic-based
time point.
a 1991 report from
subjects were

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

2009
Trehan I et al.
A randomized, doubleblind, placebocontrolled trial of
rifaximin, a
nonabsorbable
antibiotic, in the
treatment of tropical
enteropathy
L:M,
sucrose:lactulose, and
sucralose:lactulose as
markers of small
intestinal, gastric, and
colonic permeability,
respectively, among
those receiving
rifaximin or placebo

Location and
Design and
Target Population Sample Size

Biomarker

Results

randomized to
receive vitamin A
weekly for 8 wk or
placebo.

The rate of decline in L:M was most
steep among the vitamin A-treated
hospitalized patients, in whom the
mean L:M value decreased by 63%
over 30 days, followed by placebo* Number of
treated hospitalized patients, with a
subjects in each
decrease of 38% over 30 days.
treatment group
Mean L:M decreased by 57% in the
was not specified.
vitamin A-treated clinic patients,
while there was no change in L:M
among the clinic placebo group.
Limela, Malawi
RCT
Urine Tests
At enrollment:
1
• Lactulose
• Mean mannitol (SD):
All 3-5 yr olds from n=144;
• Mannitol
• Treatment: 9.57 (5.24)
the village were
• Placebo: 10.29 (6.62)
• Sucrose (SUC)
n=72 received
recruited.
• Mean lactulose (SD):
• Sucralose (SCL)
2
rifaximin for 7
• L:M
• Treatment: 0.30 (0.18)
days
• Sucrose:lactulose
• Placebo: 0.34 (0.25)
ratio (SUC:L)
• Mean SUC (SD):
n=72 received
• Sucralose:lactulose
• Treatment: 0.062 (0.04)
placebo
ratio (SCL:L)
• Placebo: 0.074 (0.058)
•
Mean
SCL (SD):
It was presumed
•
Treatment:
0.51 (0.29)
that if SBBO is
Subjects were tested
•
Placebo:
0.58
(0.53)
the etiology for
before and after
•
Mean
L:M
(SD):
enteropathy,
treatment.
• Treatment: 0.18 (0.12)
treatment with
• Placebo: 0.17 (0.09)
rifaximin would
• Mean SUC:L (SD):
result in improved
intestinal integrity.
• Treatment: 0.50 (0.34)
• Placebo: 0.64 (0.90)
• Mean SCL:L (SD):
• Treatment: 0.42 (0.32)
• Placebo: 0.39 (0.23)
• For both groups combined:
• 76% had L:M >0.10
• 34% had L:M >0.20
No significant post- intervention

1
2

Conclusion

Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.
Type of mean for sugar ratios not specified.

Comments
The Gambia [209].

There was a high
proportion with
elevated L:M which
did not change with
rifaximin treatment.

Methodological
differences in
specimen collection
and testing, in
particular for SCL
excretion, might
Baseline L:M
account for some
differences in
measurements in
this study resembled values compared to
those of another
other studies.
Malawian population
in similar
This was the first
use of SCL for siteenvironmental
specific absorption
conditions [120].
testing in a
SCL excretion in this developing country
population was
setting.
similar to that found
in healthy American
children (0.4%),
while SCL:L was
comparatively lower
(0.8) and driven by
lactulose [210].
SCL:L might be a
better marker of
colonic permeability
[211-213]. Results

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

2008

Fortaleza, Brazil

Vieira MM et al.

n=102
2 mo-9 yr olds
(mean age 41 mo)
from an
impoverished
urban community,
eligible if HAZ
score <median
for their
community.

Carotenoids, retinol,
and intestinal barrier
function in children
from northeastern
Brazil
L:M as marker of
intestinal barrier
function, fecal
lactoferrin and
leukocytes as markers
of intestinal
inflammation, and
CRP and AGP as
acute phase reactants
among children with
varying vitamin A
1

Cross-sectional

Biomarker

Urine Tests:
1
• Lactulose
• Mannitol
• L:M
(97 tested)

Results

Conclusion

differences were observed in any
fractional sugar excretion or dual
sugar test, including among children
with elevated pre-intervention L:M.

from this study
potentially indicate
that colonic
permeability was
normal.

48.5% had abnormal L:M.
L:M and excretion of each sugar
separately did not vary with retinol
concentration.
L:M was associated with levels of
common dietary carotenoids,
primarily driven by lactulose.
However, the association was not
always statistically significant, and
the direction of association varied
depending on precursor.

Few data exist on
SUC excretion.
Results in this trial
are similar to those
found in another
Malawian population
(0.06% SUC
excretion) [120]
and high compared
to healthy older
children from
developed country
settings (0.020.03%) [210, 212].
Almost half of
subjects had
increased L:M, and
~40% of subjects
had increased
lactoferrin.

While serum retinol
concentrations were
not associated with
L:M, serum
carotenoids were;
authors suggest that
these retinol
Blood Tests:
40%
of
stool
samples
were
positive
precursors might be
• C-reactive protein
for lactoferrin.
more sensitive
(CRP)
predictors of
• α-1-acid
1%
of
stool
samples
were
positive
impaired intestinal
glycoprotein (AGP)
for fecal leukocytes.
function. However,
the reported
30% of stool samples were positive direction of
Stool Tests:
• Lactoferrin
(93 tested)
• Leukocytes

Lactulose and mannitol results were expressed as % of dose administered.

Comments

L:M threshold for
abnormal values
was defined as
>0.0864 [214]. Cutoff values for
lactoferrin positivity
were not described.
Relationships
between acute
phase proteins and
measures of
intestinal
permeability or
inflammation were
not reported.
Relationships
between L:M and
lactoferrin or fecal
leukocytes as well
as those between

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest
status

2007

Location and
Design and
Target Population Sample Size

West Kiang region, Cohort
Gambia
n=72
Williams EA et al.
4-10 mo olds from
Glutamine or
a rural area
A double-blind,
followed during the placebo of
placebo-controlled,
5-month rainy
nonessential
glutaminesupplementation trial season and for 6 amino acids was
months afterward. orally
in growth-faltering
administered
Gambian infants
twice daily during
rainy season; L:M
L:M and plasma
ratio was
immunoglobulins and
measured
acute phase reactant
monthly, and
proteins (albumin, Cplasma samples
reactive protein, and
were collected 3
alpha-1times.
antichymotrypsin) in
community-based
Gambian infants
enrolled in a glutamine
trial

Biomarker

Urine Tests:
1
• Lactulose
• Mannitol
• L:M
Blood markers
• C-reactive protein
(CRP)
• Alpha-1
antichymotrypsin
(ACT)
• IgA
• IgG
• IgM
• Albumin

Results

Conclusion

Comments

for parasites but this had no impact
on L:M results, lactoferrin, or acute
phase reactants.

association varied,
making
interpretation of
these results
unclear.

retinol or
carotenoids and
lactoferrin or fecal
leukocytes were not
reported.

2

Mean L:M (CI):
• Baseline:
• Glutamine group: 0.33 (0.25,
0.43)
• Placebo group: 0.33 (0.26,
0.41)
• Post-intervention:
• Glutamine group: 0.29 (0.23,
0.35)
• Placebo group: 0.26 (0.21,
0.32)
Mean excretion of lactulose (CI):
• Baseline:
• Glutamine group: 0.21 (0.16,
0.28)
• Placebo group: 0.20 (0.15,
0.26)
• Post-intervention:
• Glutamine group: 0.17 (0.13,
0.21)
• Placebo group: 0.14 (0.11,
0.18)
Mean excretion of mannitol (CI):
• Baseline:
• Glutamine group: 2.65 (2.02,

1
2

Lactulose and mannitol results were expressed as % of dose administered.
Geometric mean.

Exclusively
breastfed children
were excluded from
study participation
due to assessment
of stool lactoferrin.
L:M values were
The relationships
elevated in this
between L:M and
population, with no growth parameters,
significant change immuno-globulins,
and acute phase
after the
proteins were not
intervention.
None of the plasma reported.
markers differed
significantly between
treatment and
placebo groups,
either at baseline or
at the end of
supplementation.
Growth outcomes
did not differ
significantly across
treatment groups.

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results
3.48)
• Placebo group: 2.50 (1.87,
3.36)
• Post-intervention:
• Glutamine group: 2.48 (1.99,
3.11)
• Placebo group: 2.14 (1.62,
2.82)
L:M values did not differ significantly
between treatment groups before or
following intervention. However, a
repeated measures ANOVA showed
that during supplementation, L:M
values were borderline elevated
among the glutamine-supplemented
group relative to the placebo group
(p=0.05), counter to expectation.
Neither ACT, CRP, albumin, nor
immunoglobulins IgA, IgG, or IgM
differed significantly between
treatment and placebo groups, either
at baseline or at the end of
supplementation.
Mean levels of IgA and IgG
increased during the study (p
<0.001), while IgM levels did not.
Concentrations of each of these
immunoglobulins did not differ
between treatment and placebo
groups.
Plasma albumin, ACT, and CRP
values showed no change over the
course of the study.
Proportions of children with elevated
CRP ranged from 30-41% at
different collection time points. The
glutamine intervention had no effect
on proportion of children with

Conclusion

Comments

Evidence Table 2. Markers of permeability.
Reference and Study
Outcomes of
Diagnostic Interest

Location and
Design and
Target Population Sample Size

Biomarker

Results

Conclusion

Comments

elevated CRP.
Treatment and placebo groups
experienced decreases in WAZ,
HAZ, and MUAC coinciding with the
rainy season; however, there was no
significant difference observed
between the groups for any of these
parameters.

2000

Durban, South
Africa

Cross-sectional Urine Test:
L:M
analysis of
baseline data
Willumsen JF et al.
prior to
HIV-infected
randomization for
Subclinical mastitis as breastfeeding
mothers and their an RCT
a risk factor for
infants followed up
mother-infant HIV
n=104 mothers
to 14 wk of age.
transmission
L:M as a marker of
infant intestinal
permeability and its
relationship with
subclinical maternal
mastitis

Women recruited
from antenatal
clinic via a vitamin
A supplementation
trial to reduce
mother-to-child
HIV transmission.
Lima, Peru

2000

Treatment and placebo groups did
not differ in morbidity indices (i.e.
percentage of time reported with a
particular illness or illness overall).
There was no significant association Subclinical mastitis
between L:M and subclinical mastitis was not associated
as measured by milk Na/K.
with magnitude of
L:M.

n=108 infants (4
pairs of twins),
(26 were HIVinfected by 3 mo
of age)

Arithmetic mean.

Urine Test:
L:M

1

Mean L:M (SE) at day 1, day 20:
• Rotavirus only: 0.67 (0.38), 0.19
Zhang Y et al.
0-36 mo olds with n=36;
(0.09)
watery diarrhea
• Cryptosporidium only: 0.76 (0.43),
n=29 cases:
Enrollment and
Lactulose-mannitol
admitted to oral
0.28 (0.14)
convalescent (at day • Bacterial infection: ranged from
intestinal permeability rehydration unit of • 15 with C.
test in children with
hospital.
parvum alone 20) L:M ratios were
0.2-0.87, 0.11-0.99
diarrhea caused by
• 7 with rotavirus assessed.
• Unknown etiology: 0.26 (0.12),
rotavirus and
alone
0.29 (0.18)
Cryptosporidium
• 7 with bacteria
(alone or with
Mean L:M ratios significantly
1

Case-control

L:M ratios were
significantly
elevated in children
with rotavirus or
Cryptosporidium
infection compared
to those with
diarrhea not caused
by rotavirus,
Cryptosporidium, or
identifiable bacteria.

Actual L:M values
were not reported
but are found in a
companion study,
also included in this
review [119].The
study group in
Willumsen, et al.
represents a
subsample of the
study population
reported in the
companion study.

Evidence Table 2. Markers of permeability.

Reference and Study
Location and
Design and
Outcomes of
Biomarker
Target Population Sample Size
Diagnostic Interest
L:M as a marker of
rotavirus or
Cryptosporidium
intestinal permeability
)
in children with
diarrhea
n=7 controls with
unknown etiology

Results

Conclusion

Comments

differed between the unknown
etiology and both the rotavirus (p<
0.01) and Cryptosporidium groups
(p<0.05) at baseline, but not at day
20.

Mean L:M did not
change significantly
among those with
diarrhea of unknown
etiology, but did
Mean L:M ratios decreased between significantly
baseline and day 20 for both the
decrease among
rotavirus (p<0.001) and
those infected with
Cryptosporidium (p<0.05) groups.
rotavirus or
Cryptosporidium,
Among the group of subjects with
reaching ratios
enteric bacterial infections, the
similar to those with
causative agents identified and
diarrhea of unknown
mean L:M ratios (baseline, day 20) etiology.
were: Campylobacter jejuni and
rotavirus infection (0.86, 0.18), C.
jejuni and
Cryptosporidium infection (0.87,
0.53), Salmonella sp. (0.2, 0.11), C.
jejuni (0.69,
0.99), and Aeromonas sp. (0.38,
0.11). The L:M ratios of this group of
seven infants were not included in
the statistical analyses.

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these studies
did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Further details on L:M studies can be found in Table 19.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.3.1 The Urinary Lactulose:Mannitol Ratio (L:M)
The urine L:M test is the permeability test that has been most extensively used to
measure gut function in children in the literature identified for this review. This noninvasive test
involves oral administration of a dose of both sugars (i.e., lactulose and mannitol), followed by a
timed urine collection. As reviewed above, lactulose is a large sugar (a disaccharide) that is
minimally absorbed from an intact small intestine. However, if permeability is altered, this
disaccharide traverses intracellular spaces of the gut, is then cleared by glomerular filtration
without renal tubular reabsorption, and becomes measurable in the urine. Mannitol is a sugar
alcohol that is absorbed (via transcellular pathways) proportional to the small bowel absorptive
capacity (i.e. surface area). Shortened microvilli diminish uptake and subsequent urinary
excretion of mannitol, which, like lactulose, is filtered and not reabsorbed.

5.3.1.1 Technical Issues with the L:M Test
Prior to delving into the results of the L:M tests, it is important to note that all of the
biomarkers examined in this review have particular and general performance considerations,
perhaps none more so than the L:M test. These considerations for the L:M test are summarized
in Table 14, which demonstrates the tremendous variability in methods, citation of methods,
ranges of purported normal values of abnormal cutoff points, and the way that results were
reported across the 25 studies that we reviewed that used L:M as a marker.
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Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2004
Campbell DI et al.
Intestinal inflammation
measured by fecal neopterin in
Gambian children with
enteropathy

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

2 mo olds from a
rural area followed
until 15 mo of age.

Not specified

1 hr after
A
loading dose

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval
5 hr

Central
Tendency
Measure for
L:M

Comparisons to
5
Other Studies

Enzymatic assay
Mean, type
per Northrop CA et not specified,
al. [215] and Lunn (CI)
PG et al. [216]

6

Normal value cut points : <0.10 based on UK norm. Campbell DI et al. cited Travis & Menzies et al. [201] but it was unclear if the citation was related to normal values
for lactulose and mannitol individually or also for L:M. Travis & Menzies did not report primary L:M data, but cited a mean (type not specified) of 0.016 (SEM 0.002), per
Juby et al. [217], as normal.
2003
Campbell DI et al.
Growth faltering in rural
Gambian infants is associated
with impaired small intestinal
barrier function

2-11 mo olds from
a rural village
followed up to 14
mo of age.

Not specified

2 hr after
A
loading dose

5 hr

Enzymatic assay
per Northrop CA et
al. [215] and Lunn
& Northrop-Clewes
[218]

Geometric
mean (CI,
range)

Gambian children
[209]

Normal value cut points: Based on UK norms, value was not specified, per Freeman JV et al. [219], Weaver [220], Lunn PG et al. [202], and Lunn [52]. Freeman JV et
al. [219] reported no data relevant to L:M. Weaver reported data for breastfed English infants and a derived median L:M from this data of ~0.2. Lunn PG et al. [202]
reported a mean (SEM) L:M for UK 3-15 mo olds of 0.12 (0.02) based on “data from [their] laboratory”, but did not portray the data or cite another reference. Text suggests
this was a geometric mean, but this was not clearly stated. Lunn [52] described L:M patterns, but not specific values.

1

Some titles are abbreviated.
A = 400 mg/kg of lactulose, 100 mg/kg of mannitol, B = not reported, C = 4 g lactulose, 1 g mannitol, D = 5 g lactulose, 1 g mannitol, E = 200 mg/kg of lactulose,
50 mg/kg of mannitol, F = 400 mg/kg of lactulose, 100 mg/kg of mannitol, G = 400 mg/kg of lactulose (maximum 4 g), 100 mg/kg of mannitol (maximum 1 g), H =
500 mg/kg of lactulose (maximum 5 g), 100 mg/kg of mannitol (maximum 1 g).
3
Where authors cited references for these parameters, they are provided.
4
Where authors cited references for these parameters, they are provided.
5
Other than studies presented within the “Normal value cut points” row.
6
Where authors cited references for normal value cut-points, they are provided along with the relevant information from those citations.
2

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2003
Campbell DI et al.
Chronic T cell-mediated
enteropathy in rural west African
children: relationship with
nutritional status and small
bowel function

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

6 mo-3 yr old
malnourished inand out-patients
from rural areas.
Compared to wellnourished UK
children with GI
complaints other
than diarrhea.

Not specified

Not reported B

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

Comparisons to
5
Other Studies

5 hr

Not clearly
indicated

Asymptomatic
Gambian children
[209]

Enzymatic assay
per Sullivan PB et
al. [221] and Lunn
PG et al. [209]

Normal value cut points: <0.10 based on UK norms, per Fagundes-Neto U et al. [17] and Beattie RM et al. [222]. We were unable to obtain the article by Fagundes-Neto
U et al. to verify. No relevant L:M data were found in Beattie RM et al.

2002
2-60 yr olds from
rural communities.
Campbell DI et al.
Age-related association of small
intestinal mucosal enteropathy
with nutritional status in rural
Gambian children

Not specified

Not reported C

5 hr

Enzymatic assay
per Northrop CA et
al. [215], and Lunn
& Northrop-Clewes
[218]

Mean, type
Adults in UK &
not specified, tropics [57] and
(SE)
previous results in
Gambian & UK
subjects [202]

Normal value cut points: <0.10 based on UK norm per Freeman JV et al. [219] and Travis & Menzies [201]. Freeman JV et al. reported no relevant data. Travis &
Menzies cited a mean (type not specified) L:M ratio of 0.016 (SEM 0.002), per Juby LD et al. [217], as normal.
2003
2-97 mo olds from
an urban
Chen P et al.
shantytown.
Association of vitamin A and
zinc status with altered intestinal
permeability
Normal value cut points: Not reported.

Not specified

Not reported D

5 hr

HPLC
per Barboza MS et
al. [214]

Mean, type
not specified
(SD)

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2007
Darboe MK et al.
Effectiveness of an early
supplementation scheme of
high-dose vitamin A versus
standard WHO protocol in
Gambian mothers and infants

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

0-12 mo olds from
a rural community.

Inclusion:
Not reported E
successfully
obtained cord
blood sample
Exclusion: birth
weight <2.2 kg,
<37 wk gestation,
congenital
anomalies or
severe
peripartum illness

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

5 hr

Geometric
mean

Enzymatic assay
per Lunn PG et al.

Comparisons to
5
Other Studies

[209]

Normal value cut points: <0.30, authors derived this from Lunn PG et al. [202] UK infants’ mean plus 2 SD. Lunn PG et al. stated a mean (type not specified) (SE) of
0.12 (0.02) based on “most recent data from this laboratory”, data not shown or cited.

2001
Filteau SM et al.
The effect of antenatal vitamin A
and (beta)-carotene
supplementation on gut integrity
of infants of HIV-infected South
African women

Infants of HIVNot specified
infected women
recruited from
antenatal clinic and
followed until 14 wk
of age.

Not reported A

5 hr

Enzymatic assay
per Lunn PG et al.
[209] and
Willumsen JF et al.
[207]

Geometric
mean (CI)

Normal value cut points: Based on norms, values not specified, per Catassi C et al. [223] and Lunn PG et al. [209]. Catassi C et al. reported data from 72 Italian infants.
Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging from 1.27 (0.73)-0.22
(0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Lunn PG et al. stated that UK infants’ norm
as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2005
Galpin L et al.
Effect of Lactobacillus GG on
intestinal integrity in Malawian
children at risk of tropical
enteropathy

Population

Exclusion/
Inclusion
Criteria

36-60 mo olds from Exclusion:
a rural community. evidence of
severe acute
malnutrition or
severe chronic
illness

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Overnight

D

3 hr

Central
Tendency
Measure for
L:M

Comparisons to
5
Other Studies

Cation-exchange
Arithmetic
column and
mean (SD)
refractometer by
modified method of
Catassi C et al.
[224] and Shulman
RJ et al. [225]

Normal value cut points: <0.10 based on developed world norms between 0.03-0.12, per Goto R et al. [205], van Elburg RM et al. [226], Campbell DI et al. [112]. Goto R
et al. reported data based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week; the L:M median ranged from 0.41-0.54. They also used 0.07 as a
cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. van Elburg RM et al. reported L:M based on 30
Dutch 0-16 yr olds. L:M was calculated in two ways: 1) absolute ratio of lactulose and mannitol in mmol/mol creatinine with L:M mean (type not specified) (SD) 0.043
(0.045) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) 0.034 (0.033). Campbell DI et al. reported mean (type not
specified) (SE) L:M of 0.353 (0.022) based on 26 Gambian 2-5 yr olds without diarrhea. They also reference UK norms but do not report specific values (see above).

2008
Goto R et al.
Impact of anti-Giardia and
anthelminthic treatment on infant
growth and intestinal
permeability in rural Bangladesh

3-15 mo olds from
a rural community
followed over 9
mos. Malnutrition
was prevalent.

Not specified

Not reported A

Usually 3
hr, but up
to 5-6 hr if
no urine
output
within 3 hr
per Akram
S et al.
[228]

Enzymatic assay
per Lunn PG et al.
[216] and Northrop
CA et al. [215].

Geometric
mean (SD)

Gambian and
Bangladeshi
subjects per Lunn
PG et al. [209] and
Rousham EK et al.
[229]

Normal value cut points: < upper CI for UK infants, value not specified, per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not
specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2008
Goto R et al.
Impact of intestinal permeability,
inflammation status and
parasitic infections on infant
growth faltering in rural
Bangladesh

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

Comparisons to
5
Other Studies

3-15 mo olds from
a rural community
followed over 9
mos. Malnutrition
was prevalent.

Not specified

1 hr before
load

A

5 hr for
first exam.
Reduced
to 3 hr
subseque
ntly if
subject
voided
within first
90
minutes
per Akram
S et al.
[228]

Geometric
mean, mean
7
log L:M (SD
reported for
logged value)

Gambian and
Bangladeshi
subjects per Lunn
PG et al. [209] and
Rousham EK et al.
[229]

Enzymatic assay
per Lunn PG et al.
[216] and Northrop
CA et al. [215]

Normal value cut points: Geometric mean 0.12 for UK infants per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD)
of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.

2002
Goto R et al.
Poor intestinal permeability in
mildly stunted Nepali children:
Associations with weaning
practices and Giardia lamblia
infection

0-5 yr olds from two Not specified
urban squatter
settlements.
Malnutrition was
prevalent.

1 hr after
A
load (with
the
exception of
breastfeedin
g)

5 hr

Enzymatic assay
per Lunn PG et al.
[216];
Northrop CA et al.
[215]; Blood et al.
[230]; Lunn &
Northrop-Clewes
[218]

Geometric
mean (range,
geometric
8
SE )

Bangladeshi
subjects per
Northrop-Clewes
CA et al. [150] and
Rousham EK et al.
[229]. Gambian
subjects per
Lunn PG et al. [202]
and Behrens RH et
al. [231].
Guatemalan
9
subjects per
Goto R et al. [205]

Normal value cut points: <0.12 based on UK geometric mean per Lunn PG et al. [202]. Lunn et al. stated that UK infants’ norm as a mean (type not specified) (SD) of
0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.

7

Authors present positive log L:M values, however, logged values would be expected to be negative for ratios between 0-1 as is the case for L:M ratios.
Authors calculated the geometric standard error using the formula: antilog (mean + standard error of logged values) - geometric mean.
9
For this study, medians were reported rather than means.
8

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2010
Lima AA et al.
Effects of vitamin A
supplementation on intestinal
barrier function, growth, total
parasitic, and specific Giardia
spp infections in Brazilian
children

Population

Exclusion/
Inclusion
Criteria

2 mo-9 yr olds from Inclusion: HAZ
an impoverished
score
urban community.
<community
median
Exclusion:
exclusively
breast-fed,
participant in
another study in
past 2 yr, or
febrile illness at
enrollment

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

Not reported F

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

Per
Barboza
MS et al.
[214]

Per Lunn PG et al.
[216] and Northrop
CA et al. [215]

Median
10
(range )

5 hr

HPLC per Barboza
MS et al. [214]

Mean, type
not specified,
(SE)

Normal value cut points: Not reported.

2005
Lima AA et al.
Intestinal barrier function and
weight gain in malnourished
children taking glutaminesupplemented enteral formula

2-60 mo olds
hospitalized with
malnutrition, ~70%
of whom had PD.

Inclusion: history 3 hr before
of PD or WAZ
load
score <-2 and
consent to 10-day
hospital stay
Exclusion:
exclusively
breast-fed,
intolerant to
cow's milk,
participant in
another study in
past 2 yr, illness
at enrollment

G

Normal value cut points: Not reported.

10

Authors used the term "range," but for some of the L:M medians, only one value was reported, apparently the maximum L:M value observed.

Comparisons to
5
Other Studies

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2007
Lima NL et al.
Wasting and intestinal barrier
function in children taking alanylglutamine-supplemented enteral
formula

Population

Exclusion/
Inclusion
Criteria

Fasting

6 mo-8 yr olds from
an urban setting
with HAZ, WAZ, or
WHZ scores <-1.

Exclusion:
3 hr before
exclusively
load
breast-fed,
participant in
another study in
the past 2 yr,
sibling enrolled in
this study,
chronic or severe
or febrile illness
at enrollment

Loading
Doses of
Lactulose
and
2
Mannitol

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

D

5 hr

Median
i
(range )

HPLC per Barboza
MS et al. [214]

Comparisons to
5
Other Studies

Normal value cut points: Within the CI for values of healthy children in the community, values were not reported and no reference was provided.
2001
Northrop-Clewes CA et al.
Anthelmintic treatment of rural
Bangladeshi children: effect on
host physiology, growth, and
biochemical status

2-5 yr olds from
poor rural villages.

Not specified

2 hr before
and after
load

C

5 hr

Enzymatic assay
per Northrop CA et
al. [215], and Lunn
&
Northrop-Clewes
[218]

Geometric
mean, mean
log L:M (SE
reported for
logged value)

Bangladeshi
subjects per
Northrop CA et al.
[232]

Normal value cut points: <~0.15 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD) of 0.12
(0.09), but did not portray the related data or cite another reference for this UK norm.
2000
Quadro L et al.
Retinol and retinol-binding
protein: gut integrity and
circulating immunoglobulins

1-9 yr olds with mild
malnutrition from an
urban slum. Vitamin
A deficiency was
prevalent.

Inclusion: no sign Overnight
of infection or
other obvious
illness

D

5 hr

HPLC
per Bao Y et al.
[233]

None
reported

Normal value cut points: <0.030 based on norms per Lima AA et al. [234], Deitch [235], Ukabam & Cooper [236],Wyatt J et al. [237], Pearson AD et al. [238], and Ford
RP et al. [227] Lima AA et al. reported mean L:M (type not specified) (SE) of 0.017 (0.002) based on data from 13 Brazilian adults without HIV infection. Deitch reported
mean L:M from 8 healthy American adult controls. Mean L:M was 1.7; SE was only presented graphically. L:M was expressed as lactulose/mannitol x 100 and the ratio
was calculated as units rather than % dose administered; type of mean was not otherwise specified. Baseline values of mannitol (from pre-test samples) were subtracted
from test samples. Ukabam & Cooper reported separate lactulose and mannitol excretion means for 25 healthy adult controls, presumably from the UK based on address
of corresponding author. They did not report data on the L:M ratio. Wyatt J et al. reported mean (type not specified) L:M (SE) of 0.018 (0.002) based on data from 30
healthy adults (presumably in Austria based on corresponding author’s address.) They defined a normal cutoff of 0.030 based on mean L:M + 2 SD. Pearson AD et al.
reported mean L:M (type not specified) (range) of 0.018 (0.005-0.028) based on data from 31 healthy 2-13 yr olds (presumably in UK based on corresponding author’s
address.) Ford RP et al. reported no data relevant to L:M.

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2004
Rabbani GH et al.
Green banana and pectin
improve small intestinal
permeability and reduce fluid
loss in Bangladeshi children with
persistent diarrhea

Population

Exclusion/
Inclusion
Criteria

Fasting

5-12 mo old males
admitted to hospital
with PD but without
other concurrent
illnesses.

Inclusion: male,
3 hr before
PD
load
Exclusion:
concurrent illness

Loading
Doses of
Lactulose
and
2
Mannitol

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

D

5 hr

Mean, type
not specified
(SD)

Enzymatic assay
per Behrens et al.
[239], and
Yamanaka [240]

Comparisons to
5
Other Studies

Normal value cut points: Based on norms, value not specified, per Lunn PG et al. [209], Barboza MS et al. [214], Behrens RH et al. [231], Roy SK et al. [241], Ford RP
et al. [227]. Lunn PG et al. stated that UK infants’ normal values are: mean (type not specified) (SD) 0.12 (0.09), but did not portray the related data or cite another
reference for this UK value. Barboza MS et al. reported mean L:M (type not specified) (SD) of 0.0394 (0.0235) based on 15 Brazilian under-5s from a low SES area
without diarrhea in the preceding 2 weeks. Behrens RH et al. reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on
60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median. Roy SK et al.
reported geometric mean L:M (CI) of 0.13 (0.1, 0.16) based on 53 asymptomatic Bangladeshi controls. Ages of controls were not described but diarrheal cases were aged
3-24 mo. Ford RP et al. reported no data relevant to L:M.

2001
1, 6, and 14 wk old Not specified
infants born to HIVRollins NC et al.
infected mothers.
Feeding mode, intestinal
permeability, and neopterin
excretion: A longitudinal study in
infants of HIV-infected South
African women

Not reported A

5 hr

Enzymatic assay
Geometric
per Willumsen JF et mean (CI)
al. [207]

Normal value cut points: Based on norms, value not specified, per Catassi C et al. [223] and Behrens RH et al. [231]. Catassi C et al. reported mean L:M based on data
from 72 Italian infants. Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging
from 1.27 (0.73)-0.22 (0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Behrens RH et al.
reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on 60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS
median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median.

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2000
Rollins NC et al.
Vitamin A supplementation of
South African children with
diarrhea: optimum timing for
improving biochemical and
clinical recovery and subsequent
vitamin A status

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

6-60 mo old in- or
out-patients with
severe diarrhea.
Intestinal
permeability tests
could be performed
only for a subset of
inpatients.

Exclusion:
children with
dysentery,
metabolic
acidosis,
circulatory
impairment,
severe
electrolyte
disturbances, or
inability to take
oral fluids

Not reported A

5 hr

Enzymatic assay
Geometric
per Willumsen JF et mean (CI)
al. [207]

Not reported B

5 hr

Not specified per
Lunn PG et al.
[209]

Comparisons to
5
Other Studies

Normal value cut points: Not reported.
2000
Thurnham DI et al.
Innate immunity, gut integrity,
and vitamin A in Gambian and
Indian infants

Inpatients with
Not specified
diarrheal or
respiratory disease,
mean age 9 mos.
And out-patients
with “minor
ailments”, age not
specified.

Mean, type
not specified
(SE)

Normal value cut points: <0.12 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD) of 0.12
(0.09), but did not portray the related data or cite another reference for this UK norm.
2009
Trehan I et al.
A randomized, double-blind,
placebo-controlled trial of
rifaximin, a nonabsorbable
antibiotic, in the treatment of
tropical enteropathy

3-5 yr olds from a
rural village.

Exclusion:
Overnight
chronic
debilitating
illness, congenital
abnormalities, or
severe acute
malnutrition

D

4 hr

HPLC per Shulman Mean, type
RJ et al. [212] and not specified
Scarpignato C et al. (SD)
[242]

Normal value cut points: <0.10 based on norms of 0.03-0.12 per Campbell DI et al. [112], Goto R et al. [205], and Galpin L et al. [120]. Campbell DI et al. reported mean
(type not specified) (SE) L:M of 0.353 (0.022) based on 26 Gambian 2-5 yr olds without diarrhea. They also reference UK norms but do not report specific values (see
above). Goto R et al. reported L:M values based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week. L:M median ranged from 0.41-0.54. They
also used 0.07 as a cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. Galpin L et al. reported
arithmetic mean (SD) L:M of 0.18 (0.16) and 0.22 (0.20) based on 2 groups of 80 and 81 healthy Malawian 3-5 yr old children, respectively.

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

Population

2008
2 mo-9 yr olds from
an impoverished
Vieira MM et al.
urban community.
Carotenoids, retinol, and
intestinal barrier function in
children from northeastern Brazil

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

Inclusion: HAZ
score
<community
median
Exclusion:
exclusively
breast-fed,
participants in
another study in
past 2 yr or
febrile illness at
enrollment

1 hr after
H
load, fasted
prior as well,
but duration
not
specified.

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval

Central
Tendency
Measure for
L:M

5 hr

Mean
(SD);
however, only
the
proportion of
normal
values was
reported
rather than
the mean

HPLC per Bao Y et
al.
[233], Lima, et al.
[234], and Barboza
MS et al. [214]

Comparisons to
5
Other Studies

Normal value cut points: <0.0864, calculated as mean + 2SD based on data from Barboza MS et al. [214]: mean L:M (type not specified) (SD) of 0.0394 (0.0235) based
on 15 Brazilian under-5s from low SES area without diarrhea in preceding 2 weeks.
2007
Williams EA et al.
A double-blind, placebocontrolled, glutaminesupplementation trial
in growth-faltering Gambian
infants

4-10 mo olds from
a rural area
followed during the
5-month rainy
season and for 6
months afterward

All age-eligible
children in the
study villages
were included

None predose
(stating
ethical
considerations);
2 hr postdose
(exception
of water
allowed)

Inclusion:
breastfeeding

Not
B
reported

F

5 hr

Not specified.
Geometric
Williams et al. cited mean, (CI)
Travis and Menzies
[201] generally
regarding L:M
assessment of
intestinal
permeability; it was
unclear which
aspects of Travis
and Menzies’
methods were
being referenced.

Normal value cut points: Not reported.
2000
Willumsen JF et al.
Subclinical mastitis as a risk
factor for mother-infant HIV
transmission

Infants of HIVinfected
breastfeeding
mothers, followed
up to 14 wk of age.

Normal value cut points: Not reported.

Not
specified

Enzymatic assay
None
per Willumsen JF et reported
al. [207]

Table 14. Comparisons of L:M test study methods and reporting frameworks.
Reference

1

2000
Zhang Y et al.
Lactulose-mannitol intestinal
permeability test in children with
diarrhea caused by rotavirus
and Cryptosporidium

Population

Exclusion/
Inclusion
Criteria

Fasting

Loading
Doses of
Lactulose
and
2
Mannitol

0-36 mo olds with
watery diarrhea
admitted to a
hospital oral
rehydration unit.

Inclusion: watery Not reported A
diarrhea and
stool positive for
rotavirus or
Cryptosporidium
Exclusion:
dysentery, history
of renal disease,
or current
antibiotic use

Urine
Laboratory
Collection Analysis Method4
Post
Loading
Dose Time
3
Interval
5 hr

Central
Tendency
Measure for
L:M

Comparisons to
5
Other Studies

Enzymatic assay
Arithmetic
and
mean (SE).
spectrophotometer. Also reported
raw data
allowing for
further
analysis by
the reader.

Normal value cut points: Not reported.
Abbreviations: AIDS=Acquired immune deficiency syndrome, CI=95% confidence interval, GI=Gastrointestinal, HAZ=Height-for-age Z (score), HFA=Height-for-age,
HIV=Human immunodeficiency virus, HPLC=High performance liquid chromatography, hr=Hour(s), L=Lactulose, L:M=lactulose:mannitol, M=Mannitol, mo=Month(s),
PD=Persistent diarrhea, SD=Standard deviation, SE=Standard error, TB=Tuberculosis, UK=United Kingdom, WAZ=Weight-for-age Z (score), WFA=Weight-for-age,
WHZ=Weight-for-height Z (score), wk=Week(s), yr=Year(s)

An important initial methodological consideration is that administration of a loading dose
is required; dosing among the studies we reviewed varied. Ideally, the dosing should be related
to body mass, or at least to body weight, in view of the large range in body size and composition
of the subjects to whom it is administered. Such dosing was reported to have been performed in
only 13 of the 25 L:M studies we reviewed. It should be noted that either or both of these
molecules can cause diarrhea via their hyperosmolar properties, and that sometimes the load
causes vomiting. These side effects, although not serious, might be more prominent among
children with certain characteristics thus skewing results. Indeed, the hyperosmolar effect is
proposed to potentially interfere with absorption by causing solvent drag (retention of the
measured solute in the gut), and has prompted consideration of a liquid meal with which to
administer these exomolecular probes of intestinal absorption and permeability [184].
Because gastric emptying could delay kinetics of absorption, a standard and perhaps
prolonged fasting interval should be employed. This presents a challenge when testing infants
who cannot tolerate fasts of greater than 3-6 hours depending on age, especially if exclusively
breastfed since breastmilk is easily and relatively quickly digested. Furthermore, even a threehour fasting interval may not be tolerated among acutely malnourished children. However,
fasting is most important for assessment of individual component measurements. Twelve of the
25 reviewed studies reported that the children were fasted prior to challenge, but the duration of
fasting differed across studies.
There are additional theoretical concerns with hyperosmolar sugar absorption tests.
First, there is evidence in humans that intestinal permeability can be altered by the
administration of such solutes [243, 244]. Second, there is a small degree of endogenous
mannitol production and excretion [243]. Third, the use of lactulose can accelerate orocecal
transit time [245]. None of these factors were mentioned by any of these studies. These
potential technical limitations have also not received much attention outside of the field of
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environmental enteric dysfunction in the last two decades. Both the individual mannitol and
lactulose component measures provide unique information as mentioned above, and thus
should be reported separately; nearly three-quarters of the studies we reviewed did so. Ideally,
the individual components should be presented as percent of dose administered, and also as an
(ideally standardized) osmolarity of the ingested probe. Of the 18 studies reporting that
components were measured separately, 11 presented results as such. Indeed, the report of
Lima et al. exemplifies the merit of reporting such metadata, as a paradoxically inverse
relationship between mannitol uptake and poor growth was identified [139].
Five-hour timed urine collections are considered standard. Timed urine collection among
infants and young children presents a challenge in the best of circumstances and it can be even
more challenging when subjects have loose stools, as is often the case among the very cohort
of children for whom assessment of intestinal permeability is desired. Urine collection times
varied across the studies in this review, and two did not report the information. Additionally,
urinary bacteria, either representing clinical bacteriuria or contamination and replication prior to
freezing, could alter sugar concentrations [246].
Laboratory detection method varied as described in Table 14. Limits of normal results
have not been determined for populations in resource-limited settings. Comparisons are made
to those derived from developed-country settings. Table 14 demonstrates the various norms,
primarily from the United Kingdom (UK), that were cited and referenced within the studies that
we reviewed. Furthermore, the results were reported in varying ways. For example, L:M values
can change with age of the subject, and in the setting of low urinary flow, as in dehydration, the
impermeability of the proximal tubule has not been adequately assessed in children.
Stratification of results based on age was often non-existent or suboptimal for determining its
contribution to high L:M values. Also, it was difficult to compare the same age groups between
studies. Perhaps the most striking deficiency was the lack of standard reporting of central

137

tendency measures, which were variably provided as medians or means. The latter were
calculated as arithmetic or geometric means; the geometric method is more appropriate for ratio
measures such as L:M. Some studies did not report central tendency measures but only the
proportion with abnormal results. Among the 25 L:M studies we reviewed, three reported no
central tendency values, two reported medians, and 20 reported means. Of the studies reporting
means, 10 reported the geometric mean, which is a mathematically preferred expression of a
mean for ratios, while two reported arithmetic means, and eight reported means without
specifying their type. Clearly, despite the relative abundance of recent L:M data, the wide
variation in study and reporting methods hamper our ability to make inter-study comparisons.

5.3.1.2 Range of L:M Values Reported
The majority of studies that we reviewed found elevated L:M values in their subjects,
consistent with reports from before the interval of publication of papers that we assessed for this
systematic review (i.e., studies published prior to 2000). These elevated L:M values were largely
compared to norms reported for Western (primarily from the UK) childhood values [201, 217,
220, 223, 226, 235, 237, 238] and less often related to presumed norms of children in
developing-country settings [112, 120, 205, 214, 231, 234, 241].
Delineation of normal values is a challenge for several reasons. Normative curves are
often established based on assessments among a small sample of children in a developed
country. Two standard deviations are frequently used as cutoff point to define normal/abnormal
levels. However, this may not always be an appropriate method for a variety of reasons. Genetic
factors might or might not influence test results. Marker response to environmental exposures
might, at least initially, reflect adaptive rather than pathologic responses.
As noted above, comparison of L:M values across the 25 studies that we reviewed was
also challenged by differences in the way the values were reported (see Table 14). Among
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studies reporting the ratio results as geometric means, the values (ratios) ranged from 0.08 to
2.4 and both extremes were published by the same author group in two different studies,
although among different populations. The lowest (i.e. least abnormal) values were reported
among HIV-negative South African infants under four months of age born to HIV-infected
mothers [160, 161], while the highest values were found in children aged six to 60 months
hospitalized with severe diarrhea, also in South Africa [161]. The fact that the highest values
were an order of magnitude higher than in other studies reviewed led us to speculate that L:M
values might have been expressed as a multiple for portrayal on the same graph with urinary
neopterin and serum retinol-binding data.
Among children in rural Bangladesh, one study found a geometric mean L:M value of
0.15 [123]. In two different rural Bangladesh intervention trials, baseline L:M values were 0.18 in
each of the anti-helminthic treatment groups and 0.16 in the placebo group in the same setting
[122], but were 0.22 and 0.25 in a different rural setting also among anti-helminthic treatment
and placebo groups, respectively [150].
In Nepal, the mean L:M value among mildly stunted children aged 0-60 months was
0.26, but did significantly differ between those infected with Giardia (0.43) vs. those without
evidence of giardiasis (0.25) [124]. A series of studies conducted in The Gambia reported L:M
geometric mean values of 0.169 [110], 0.353 [112], and 0.31 [15]. Another study demonstrated
similar results, ranging from 0.26 to 0.37 in placebo-treated children, depending on month of the
study [170]. These studies support the concept of widespread intestinal permeability issues
among children in developing settings with considerable variation between studies, generally
finding a greater degree of permeability in central African settings.
However, in contrast to the Asian and central African studies, some South African [119,
160] studies found L:M values that were similar to established norms (i.e., mean values from
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healthy children in developed settings). These apparent contradictions could reflect the
emergence of the economies in which these children reside, with concomitant improvement in
gut health. Three [119, 160, 161] of the four L:M studies from South Africa presented geometric
means (notably, each of these four studies were performed by the same investigator group).
The fourth study [171] presented a subset of data published by Filteau et al. [119]. Filteau et al.
[119] and Rollins et al. [160] assessed L:M among infants born to HIV-infected mothers and
generally found normal values that did not increase with age. Filteau et al. also noted no change
in L:M measures with increasing morbidity. However, in both studies the mean value of L:M for
the infants who became infected with HIV was increased; the Rollins et al. observational study
reported a mean of 0.24 and the Filteau et al. intervention trial reported a mean of almost 0.5
among those whose mothers had not received vitamin A supplementation.
Similarly, some South American [137, 139] studies found L:M values that were similar to
mean values for healthy children. Six L:M studies from Brazil were conducted by one team of
investigators [113, 137-139, 156, 169]. Three of the studies reported baseline L:M values but
did not classify them as normal or abnormal [113, 137, 138]. Two studies assessing similar
populations of mildly malnourished children from an impoverished urban community in Brazil
[156, 169] reported that a high proportion of their subjects had abnormal L:M values. L:M
median and range data collected a few years later in the same setting and with the same
inclusion criteria were noted by the authors to be within the confidence interval for values of
healthy children in the study community [139] (the reference for this confidence interval was not
cited).
Several studies measured the variability of L:M values between and within individuals.
Some of these identified wide ranges [122, 124], and Campbell et al. [112] found that L:M
showed significant intra-subject correlation between tests conducted 3.5 months apart. In
contrast, Northrop-Clewes et al. [150] observed that intra-individual L:M values in the placebo
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group of an anti-helminthic trial did not change significantly over 12 months. Of note, L:M values
might change with increasing age because of normal changes of physiologic maturation.
However, the studies that we reviewed rarely reported data stratified by age, thereby prohibiting
rigorous comparisons from one study to the next.
Very few studies investigated longitudinal change in a measure of central tendency of
L:M values for their study sample. Campbell et al. found a small but significant improvement in
mean L:M value between the two study time points (from 0.198 to 0.172, type of mean not
mentioned), driven by an improvement in mannitol recovery with no change in lactulose
excretion [112]. The interval between sampling was 3.5 months.
Three studies observed seasonal variation in L:M values. Two of these studies were
conducted in rural Bangladesh; the timing of peak L:M values differed slightly between them. In
one study [122], the highest values were observed during the monsoon season while in the
other [150], the peak followed the monsoon season. A study in The Gambia reported monthly
variation in geometric mean L:M values, ranging from 0.37 in July to 0.26 in October in placebotreated children [170].

5.3.1.3 Associations between L:M and Growth Outcomes
The L:M test has been used extensively to assess small intestinal function in relation to
nutritional status in children in resource-limited settings. Several studies have found inverse
relationships between L:M and growth parameters, while others have not (Table 15). Goto et al.
[123] and Campbell et al. [110] found that L:M was inversely associated with height-for-age Zscores (HAZ) and weight-for-age Z-scores (WAZ). A longitudinal study by Goto et al. [122]
found associations between change in L:M and changes in weight-for-age Z-scores (∆WAZ) and
weight-for-height Z-scores (∆WHZ),showing improvement in growth parameters with decreased
L:M values. A later study by Campbell et al. [15] found that long-term height gain was negatively
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associated with mean L:M value. Northrop-Clewes et al. [150] observed that L:M was inversely
correlated with change in height-for-age Z- (∆HAZ) and ∆WAZ scores at 12 months of follow-up.
However, several studies did not find an association between L:M and growth
parameters. Goto et al. [124] reported no association between L:M values and growth status,
although they did not specify which of the assessed growth measures (HAZ and WAZ) were
used to evaluate this. A 2003 study by Campbell et al. similarly found no association between
L:M and grade of protein energy malnutrition [111]. The same group earlier demonstrated that
L:M was inversely associated with HAZ after correcting for age, gender, and study visit, but not
with WAZ or body mass index z-scores [112]. In these studies, the association with HAZ was
mainly attributed to the greater lactulose excretion in subjects with poorer HAZ scores and was
constant across all age groups. There was no significant association between L:M calculated as
the mean of the two data collection points and change in nutritional status parameters.
Several factors complicate comparison of the relationship between L:M and growth
parameters across studies. Anthropometric indices used in these assessments varied. Markers
were sometimes associated with different anthropometric measures within the same study. In
one instance [112], a relationship was identified between L:M and HAZ score but not WAZ
score. When the relationship between L:M values and growth parameters is not reported, it is
not clear if the anthropometric indicator was either not evaluated or whether a significant
relationship was not identified (i.e., only positive results were presented). One study assessed
association with single sugar excretion only, reporting no significant associations between HAZ,
WAZ, or weight-for-height Z- (WHZ) scores and lactulose, but significant associations with both
WAZ and WHZ scores and mannitol [139]. The article did not mention HAZ score when
reporting the results of mannitol analyses, leaving unspecified whether the relationship was
assessed and found to be nonsignificant, or not assessed at all.
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Table 15. Associations between anthropometric indicators and biomarkers of EED.
Data presented are from one study unless otherwise indicated in parentheses.

Anthropometric
Z- score

L:M

HAZ

Y (3)
N (1)

∆HAZ
WAZ

Y (2)
Y (2)
N (3)

∆WAZ
WHZ

Y (2)
Y

Lactulose Mannitol Lactose:creatinine
N

Y

N

Y

Y
Y

N

Y

Y
Y

Urine Intestinal
Stool
Stool
nitric maltase
lactoferrin neopterin
oxide activity

N

Intestinal
lactase
Histopathology
activity
Y
By 2 of 3 digital
morphometric
1
measures : Y

Y
N

N

Y

By 2 of 3 digital
morphometric
measures*: Y
Endoscopy: N
Histopathology:
N (2)
Y (1)

Y
By 2 of 3 digital
morphometric
1
measures : Y

∆WHZ
Y
BMI
N
Y=yes, a statistically significant relationship was found.
N=no, a statistically significant relationship was not found.

1

The three digital morphometry measures included enterocyte height, enterocyte brush border, and enterocyte nucleus height. The two measures
that were significantly associated with anthropometric indicators differed for each type of anthropometric indicator assessed.

5.3.1.4 Associations between L:M and Other Outcomes
Four studies assessed the potential association between L:M values and Giardia
infection. Two found no association [15, 123]. A Bangladeshi antihelmintic trial [150] found that
L:M and giardiasis were not associated overall; they only identified an association among the
treatment group in their intervention trial at a single time point over the course of the 12-month
study period. In the fourth study, the geometric mean L:M among mildly stunted Nepalese
children from urban squatter settlements aged five years and under was 0.26, but statistically
significantly differed between Giardia-infected and non-infected children (0.43 vs. 0.25,
respectively) [124].
Several studies investigated the relationship between subject age and L:M values; three
found no association [113, 119, 124]. Goto et al. demonstrated a decreasing L:M trend with age
among a cohort of Bangladeshi 3-15 month olds [123]. Campbell et al. [112] compared
Gambian 2-5 year olds with older children and found a significant association between age and
L:M values as well as a small but statistically significant improvement in mean L:M over 3.5
months driven by improved mannitol excretion without change in lactulose excretion. They later
[110] reported study results among another cohort of Gambian children that showed that L:M
values showed a large and statistically significant increase between 12 weeks and one year of
age, a change driven by both increasing lactulose and decreasing mannitol excretion. Darboe et
al. [115] observed that L:M values rose by about 50% from age two months to one year, but did
not analyze the trend statistically.
Various studies examined the L:M marker in the context of other conditions. No
association was found between L:M and diarrhea history [124] or helminthiasis [150, 205].
Associations were found between L:M and infection with HIV [119, 160] and Cryptosporidium
and rotavirus [172]. Two studies reported seasonal L:M variation in rural Bangladesh, with
peaks during [122] or following [150] monsoon season.
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5.3.1.5 Use of the L:M Test as an Endpoint for Intervention Trials
Multiple studies have used the L:M marker as an endpoint to assess intestinal
permeability in randomized, controlled trials. The specific interventions varied widely, including
micronutrient supplementation, probiotics, therapeutic diets, and antibiotic and anti-helminthic
drug administration.
Four studies utilized L:M as an outcome in vitamin A supplementation intervention trials
and found no association with L:M overall [115, 119, 137, 168] although Filteau et al. did identify
a significant reduction in L:M values among HIV-infected children treated with vitamin A [119].
While Darboe et al. noted that a vitamin A-supplemented group experienced a reduction in
lactulose uptake, they also observed an accompanying decrease in mannitol absorption;
therefore the ratio of the two sugars did not change [115]. This finding demonstrates the value
of reporting the absorption of the two sugars separately, in addition to reporting the ratio. In
contrast, Chen et al. observed improved L:M values after treating a cohort with persistent
diarrhea or low WAZ with a single dose of vitamin A and a two-week course of daily zinc [113].
Lima et al. conducted two studies using L:M as an outcome to assess the beneficial
effects of formulas of different compositions used in therapeutic rehabilitation of children with
persistent diarrhea and/or malnutrition. In the study assessing glycine-supplemented formula,
L:M values improved in the treatment group [138]. However in a trial in which this group
examined alanyl-glutamine-supplemented formula, even though lactulose excretion improved,
mannitol excretion worsened and therefore L:M values did not change after the intervention
[139]. In another trial of glutamine supplementation, conducted by Williams et al. in The
Gambia, the intervention did not improve L:M values; in fact, analysis by repeated measures
analysis of variance (ANOVA) indicated that L:M values were borderline elevated in the
glutamine-supplemented group (p=0.05), contrary to what was expected [170].

145

Another dietary intervention trial examined the efficacy of green banana and pectin
among children with persistent diarrhea [157]. While post-intervention L:M values were still
elevated, both lactulose and mannitol excretion improved after treatment, with lactulose being
the primary driver of the improvements seen in the ratio of these two sugars.
Four other trials examined the degree to which L:M values improved as a result of
various interventions, with no effect observed: probiotics [120] and antibiotics (rifaximin) [13] to
target small bowel bacterial overgrowth as a potential cause of impaired intestinal integrity in
Malawi, and various anti-helminthic and anti-Giardia treatments in Bangladesh [122, 150].
Interestingly, a Brazilian vitamin A trial demonstrated reduced lactulose as well as mannitol
excretion, but an unchanged overall ratio [137], thereby highlighting the value of reporting
absorption of the sugars separately.
In many of these studies, power considerations were not addressed at all, or
incompletely addressed, and were often subordinated to study realities. Several examples
illustrate the issue. Goto et al. recruited 222 children, into two treatment groups and one
placebo group [122]. They estimated their sample size based on baseline recent Bangladeshi
infant data [247]. They calculated that to improve HAZ by 33%, a sample size of 68 was needed
(using an α of 0.05, and 80% power). For WAZ, the sample size needed was 73. So, after
allowing for attrition, they aimed to recruit approximately 100 infants in each group. The antiGiardia treatment used in this study, secnidazole, is unpalatable, so there was concern that
there might be more attrition in those receiving this treatment. Therefore the treatment groups
were increased by about 10% relative to the control group (n = 142, 141 and 127, respectively).
However, because of large loss of subjects to follow-up as well as other methodological issues,
including inaccurate dosing by many subjects and switching to analysis on actual treatment
received rather than on an "intent-to-treat" basis, the final group sizes were 75 (secnidazole &
albendazole), 59 (secnidazole only), and 88 (control). Hence, the size of the second group fell
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below sample size targets for adequate power, while the other groups were still of sufficient size
for projected HAZ and WAZ outcomes.
Northrop-Clewes et al. [150] did not report sample size calculations, indicating that their
target sample size of 120 was based on logistical reasons. They went on to state “the null effect
of deworming in this study could perhaps have stemmed from an inadequate sample size or
duration of follow-up. However, significant improvements were observed in studies with smaller
samples (e.g., n = 23, n = 55, and n = 72; 42, 10, 11) and of much shorter duration (seven and
nine weeks) [248-250]". This comparison draws attention to the potential role of publication bias
in any review of the literature.

5.3.1.6 Associations between L:M and Other Markers
Five of the 25 publications examined L:M results in relation to other potential markers of
intestinal dysfunction, including one study that found that it was not correlated with urinary
lactose or lactose:lactulose [124]. Two studies assessed L:M and markers of systemic
inflammation and found differing results [110, 123]. A fourth study found no correlation with stool
neopterin [15]. The only study that we reviewed that examined L:M in relation to intestinal tissue
reported a variety of intestinal tissue measurements by morphometry and reported positive
correlation with mucosal B-lymphocyte density, intraepithelial lymphocytes (IEL), and IELs
staining positive for perforin [111]. It is not clear if the other intestinal markers were not
correlated or merely not assessed for correlation.

5.3.2 The Lactulose:Rhamnose Ratio (L:R)
Similar to the L:M, the lactulose:rhamnose ratio (L:R) has been used as an index of gut
mucosal function. As in the L:M test, lactulose is used as the measure of barrier function, but
rhamnose replaces mannitol as the marker of absorptive capacity. L:M is performed on urine
samples and, as mentioned above, in timed collections, ranging from three to six hours. The L:R
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test had been performed on similarly timed urine specimens as well. To our knowledge, there
are no published data comparing rhamnose directly to mannitol in children with enteric
dysfunction, but in adults with inflammatory bowel disease the two sugars are absorbed
comparably [251].

5.3.2.1 The L:R Test as a Reflection of Issues in Serum or Urine Sugar
Testing in Children
Recent advances in high-performance liquid chromatography (HPLC) now permit
sensitive detection of lactulose, mannitol and rhamnose in the blood. While timed blood
specimens have been evaluated in animals and human adults [252-256], the invasiveness of
repeated phlebotomies presents practical and ethical challenges in pediatric research. However,
collection of urine over a period of time in young children, while less invasive, is not a trivial task
either. While application of urine “bag” collectors permits noninvasive capture of urine, loss of
urine because of leakage around the bag is common, as is contamination by stool, especially
among children with diarrhea. Indeed, it should be noted that the children in most need of
intestinal function testing often have diarrhea, and the ingestion of the sugar loads themselves
can lead to osmotic diarrhea.
Haase et al. compared the validity of L:R testing on one-time collections of blood to 5hour urine collections [125] in children. They found that blood L:R values were consistently
lower than urine L:R values by a geometric mean (95% confidence interval (CI)) of 1.09 (1.02,
1.16). There was substantial agreement between the two tests as measured by a kappa statistic
of concordance (95% CIs) of 0.71 (0.51, 0.92). Assuming urine L:R as a gold standard, Haase
et al. calculated sensitivity and specificity of blood L:R as 81% and 89% respectively.
As discussed above, test failure can occur for various reasons when tests rely on urine
samples, particularly timed samples. However, test failure can also occur with blood specimens
because of insufficient volumes collected to run the assay, and potentially from edema if blood

148

is obtained by finger stick [257]. In addition, the assay cannot be performed using either analyte
if children vomit, or refuse to ingest, the sugars. Haase et al. defined test “failure” as emesis of
the sugar load, urine leakage or contamination with stool, or blood collection insufficient for
analysis (<0.25 mL of plasma). While they did not delineate the reasons for failure among the
blood vs. the urine collections, they did observe a significantly higher failure rate for the urine
(37%) compared to the blood assays (10%) (p<0.0001). Interestingly, a study published in 1999
(and therefore not included in the analysis of this systematic review) by the same authors also
reported a 37% failure rate for urine L:R testing and in this earlier study they specified the
proportions by cause of failure. They noted that the failure rate for a five-hour urine collection
varied between 47% (32 of 68) in girls with acute diarrhea to 17% (14 of 82) in non-diarrheal
controls. They also noted that causes of test failure consisted of vomiting or refusal to drink the
probe sugar solution in 21 (9%) of the tests [258].
The remaining four studies that used L:R as a marker of gut permeability measured
these ratios in blood specimens. We found that rates of technical failure of testing were not
often reported in the sugar absorption/permeability studies that we reviewed. Of the four studies
using serum L:R, two discussed failure to complete testing. One study specifically reported
difficulty with venipuncture in two of 34 subjects [159]. In the other study, L:R was measured at
baseline as well as following an intervention with specific milk formulas [134]. It was not entirely
clear, but it did seem that baseline L:R testing was successfully completed on all subjects while
there was a reported “failure” of post-intervention testing among 10 of 150 children. Reasons for
test failure in the second determination were not reported. Among the five studies that used Dxylose (either urine or serum) [136, 146, 147, 152, 155] no mention was made of lack of
completion of testing among the subjects enrolled. Only seven [124, 138, 139, 150, 161, 169,
172] of the 25 urinary L:M studies included in this review specifically mentioned the number of
children who completed L:M testing compared to the number recruited into the study. It was not
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always clear why incomplete L:M testing occurred, but it appears that in five of these studies
there was a failure in testing because of improper compounding of the sugar solution, inability to
collect urine during the testing period, urine leakage or stool contamination, or refusal to ingest
the sugar solution. Similar to the study that expressly measured and reported failure rates in L:R
testing [125], Goto et al. reported in 1999 (and therefore not included in this review) that the L:M
test failure rates were 32% [205].
It should be noted that each of the five L:R studies in this review was conducted by the
same researchers in Darwin, Northern Territories, Australia (one of their studies also included
subjects from Adelaide, South Australia, Australia). It appears that some of the studies might
represent data from overlapping cohorts of children. It should also be noted that while Australia
clearly falls within the classification of a high income country, our inclusion definition of children
in “developing-country setting” included marginalized or indigenous populations in a developed
country who are plausibly exposed to the same environmental and/or infectious risks for EED as
children in developed-country settings. In fact, research among Aboriginal populations in
Australia has contributed a great deal to the EED field [58, 258].

5.3.2.2 Range of L:R Values Reported and Associations with Growth
Outcomes
Many investigators report the L:R value multiplied by 100 for ease of reporting; this
convention was followed within the articles examined for this review. The geometric mean was
the measure of central tendency consistently used in these studies, facilitating comparison of
results. However, while the L:M studies referenced various ranges of normal standards, none of
the L:R studies cited such reference standards. Furthermore, the three studies that reported the
proportion of children with abnormal L:R results used different cutoff points and did not cite
references for these demarcations of normal and abnormal values that they employed. One
study defined an abnormal L:R value as >16, with 20 of 32 children (63%) exhibiting values
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above this threshold [159], another used 7.2 as their defined cutoff point with 112 of 152
subjects (74%) above that threshold [43], and a third explained the derivation of its cutoff point
of >5.6 as two standard deviations above the arithmetic mean for non-Aboriginal children
without diarrhea [58]. No citation was given for this standard value, implying that it might have
been derived from the data collected in this study. However, the authors reported that none of
the study’s non-Aboriginal children without diarrhea had abnormal permeability values,
suggesting that perhaps the cutoff point was derived from a different study. While their study
included Aboriginal children with diarrhea, they did not report proportions of children with L:R
values >5.6 for this group.
Three studies compared serum L:R values among primarily Aboriginal cases with
diarrhea and controls without this disorder. Baseline geometric means for L:R (95% CIs) in the
two studies ranged from 3.7 (2.8, 4.9) [134] to 5.9 (4.4, 7.8) [125] to 11.4 (8.5, 15.5) [159]
among controls and 9.4 (6.7, 13.1) [125] to 12.8 (10.3, 16.0) [134] to 31.8 (24.9, 40.7) [159]
among cases.
In a randomized trial of three different milk formulas in Aboriginal children with
malnutrition and/or diarrhea, baseline geometric mean L:R values (95% CIs) were 14.9 (10.4,
21.5) in one treatment group; baseline values were similar in the other groups [134]. Although
subjects were randomized to treatment groups, the study did not include a control arm of
standard care to which change in L:R could be compared. Mean improvement in L:R (95% CIs)
was 13.0 (9.3, 16.6) with some significant differences across treatment groups. This was the
only study in this review using L:R as an outcome measure in an intervention trial.
A similar study reported that mean L:R values among Aboriginal children were
approximately double those of non-Aboriginal children, whether examining across groups of
subjects either with or without diarrhea, consistent with the authors’ suggestion that clinically
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silent enteric dysfunction is prevalent among Aboriginal children [58]. Geometric mean L:R
among the children without diarrhea was 2.5 and 4.6 among non-Aboriginal and Aboriginals,
respectively (p=0.02). Geometric mean L:R among those with diarrhea was 7.9 and 16.4 among
non-Aboriginals and Aboriginals, respectively (p=0.002).
One study examined the relationship between L:R and growth and found no association
with nutritional status or age. Associations were, however, found between high L:R and acidosis
(p=0.007), hypokalemia (p=0.035) and diarrhea severity (p=0.001) among children with diarrhea
[58].

5.3.2.3 Associations between L:R and Other Markers
Serum L:R was compared to other biomarkers for EED in three of the other four studies.
Ritchie et al. found L:R to be significantly inversely correlated with the 13C sucrose breath test
(r=0.67; CI: 0.42, 0.62; p<0.0001) [159]. Kukuruzovic et al. studied urinary nitric oxide excretion
in relation to L:R in Aboriginal and non-Aboriginal in-patients with acute diarrhea, nongastrointestinal infections, or without infections or diarrhea [43]. They found that
NO2/NO3:creatinine and L:R were correlated (r=0.37, p<0.001), after adjusting for age and race.
The association was stronger for lactulose permeability, with an effect ratio (95% CIs) of 1.47
(1.29, 1.66), than it was for rhamnose malabsorption, with an effect ratio (95% CIs) of 0.80,
(0.67, 0.97). NO2/NO3 concentrations decreased significantly less rapidly than L:R values
among children recovering from diarrhea. Another study by Kukuruzovic et al. assessed the
association between L:R and red cell indices, stool reducing substances, and lactosemia and
identified an association only with the latter, but the degree of correlation was minimal [58].

5.3.2.4 Methodological Issues with the L:R Test
Overall, there were fewer issues with consistency in reporting of L:R results across
studies, perhaps because all of the L:R studies in our review were performed by the same group
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of investigators. Four of the five studies reported a measure of central tendency for L:R and it
was consistently in the form of a geometric mean multiplied by 100. Dosing of the sugars was
the same across the studies. The timing for serum sampling was similar, with most using a
collection time of 90 minutes following administration of the dose; only one study differed
slightly, with testing occurring in a range between 90 to 120 minutes. HPLC was the test method
for the serum L:R throughout. However, in striking contrast to the L:M studies, reference
standards for L:R values were not cited. The three studies that reported proportions with
abnormal L:R values used markedly different cutoff values that were either not defined or given
insufficient explanation.
The urinary L:R test has disadvantages typical of any urinary method for dual-sugar
permeability testing; the serum method avoids these issues, and, indeed, Haase et al. found a
lower test failure rate with this method.

5.3.3 Serum and Urinary Lactose
As mentioned above, we assigned markers to categories based on their best fit,
recognizing that biomarkers could indicate derangement of more than one function. For
example, lactose is not normally absorbed across the intestine, but rather requires breakdown
to products that are absorbed, namely galactose and glucose. This digestion is catalyzed by
lactase, an intestinal brush border enzyme. While the presence of lactose in the serum or urine
would in most instances indicate a lack of lactase (as opposed to presence of lactose excessive
to lactase saturation), it also, and primarily, reflects a permeability defect, because even if
lactose is not broken down, its size should preclude traversing the mucosa unless a porosity
defect also exists.
We identified three studies that measured lactose in the blood (n=1) or urine (n=2) in the
context of putative intestinal injury. Kukuruzovic et al. tested markers of intestinal permeability,
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including serum lactose, among hospitalized Aboriginal and non-Aboriginal children with and
without diarrhea [58]. Circulating lactose was detected in 38% of Aboriginal cases and 12% of
controls (Aboriginal and non-Aboriginal combined). Lactosemia was weakly associated with an
abnormal L:R. Another study of children from two urban squatter settlements with high rates of
malnutrition primarily focused on identifying lactase deficiency via urinary lactose:lactulose,
finding that nearly half of subjects had low lactase activity [124]. Urinary lactose concentration,
as well as lactose:lactulose ratio, decreased with increasing age, but neither was associated
with the L:M. The authors noted that lactose concentrations and lactose:lactulose ratios were
significantly higher in breastfed subjects than those not breastfed, despite similar L:M values.
However, the paper did not specify the nature of the dietary lactose sources in the nonbreastfed babies. That is to say, if the bioavailability of the lactose or the quantity ingested is
low, mucosal function could appear to be inappropriately normal. The final study measured the
lactose:creatinine (L:Cr) ratio in Nepali children living either in squatter settlements or lower
middle-class periurban households [151]. Mean L:Cr was significantly higher among the
squatter compared to the lower-middle class group. For both SES groups, L:Cr values
decreased with increasing age (p<0.001). HAZ, WAZ, WHZ, and ∆WAZ scores were strongly
associated with mean L:Cr (p<0.001 for each parameter) as was ∆HAZ score (p=0.004); ∆WHZ
score was not. Interestingly, the strength and magnitude of association between ∆WAZ score
and L:Cr was most pronounced among the wealthier cohort and there was no association
between ∆HAZ score and L:Cr among the squatter children, perhaps because of poor diets
accounting for more of an effect among the squatter children.

5.3.4 Summary of Markers of Permeability
Despite logistical challenges, the L:M and L:R tests and other tests of permeability have
been utilized extensively to assess intestinal function in children in resource-limited settings.
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L:M values were often, but not always, elevated above published developed country
norms in community-based studies of asymptomatic children in resource-limited settings. The
other tests of permeability generally were not compared to a reference standard, limiting
comparison of results across studies and different settings.
The L:M test was more extensively studied than the other permeability markers and was
used more widely as an endpoint for intervention trials, including evaluation of micronutrient
supplementation, dietary interventions and probiotics, and anti-bacterial and anti-parasitic drug
treatments. L:R was used as an outcome measure for one intervention study. With new HPLC
laboratory methods that are sufficiently sensitive to detect lactulose, rhamnose and other
sugars, dual sugar tests might become more widely used.
While we identified two studies that compared serum L:R to serum lactose [58] and L:M
to urinary lactose and lactose:lactulose [124], we did not find comparisons of L:M and L:R test
results; a head-to-head comparison of the two most extensively used permeability tests would
be informative.
The relationship between L:M and age varied across studies; some observed an
association [110, 112, 115, 123], while others did not [113, 119, 124]. The single study that
investigated the relationship between L:R and age did not find an association [58]. Furthermore,
while most studies found an inverse association between L:M and anthropometric status, results
were mixed. One study investigated the relationship between L:R and growth, and did not
observe an association [58].
As with the D-xylose and endomolecular tests of absorption, lack of consistency in what
was used as a cutoff point for normal (or what was reported to have been used) in the dual
sugar permeability tests made it very difficult to compare results from one study to the next.
Across permeability tests, we found a wide spectrum of depth of reporting and insufficient
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details were often provided. The L:M studies best portrayed issues with methodology, reporting,
and poor comparability caused by wide differences in how the test was performed across
studies, differences in subject preparation and feeding mode, dosage of test sugars, and timing
of urine collection, all of which can influence test results. Further complicating comparability, the
measures of central tendency for reporting L:M varied.
While L:R tests have been conducted by evaluating the different biological sampling
media of urine or serum, the serum test was used much more widely in the last decade and
serum tests have been conducted in a much more standard manner than the urinary L:M test.
Urinary L:R has disadvantages typical of any urinary method for dual-sugar permeability testing;
the serum method avoids these, and Haase et al. [125] found fewer test failures with this
method.
We found only one example of the urinary lactose:creatinine test having been employed
in a pediatric population in a resource-limited setting [151]. The lactose in the urine is waste
from endogenous metabolism of ingested material, and the creatinine is also a waste product
naturally present in the urine. Testing endogenous metabolites eliminates the need for a loading
dose as well as a post-dose delay of multiple hours for sample collection, which are inherent
parameters of dual-sugar tests. These aspects of the L:Cr test could provide advantages
compared to dual-sugar tests in resource-limited settings. However, in comparing the tests, it
will be important to consider other parameters such as sample processing, as well as the
comparative accuracy and reproducibility of the different tests. Recent data on the use of the
L:Cr ratio to assess intestinal permeability in pediatric populations in resource-limited settings is
scarce. None of the studies from our review assessed both L:M and L:Cr ratios in the same
individuals, so it is not possible to compare the tests directly from the available data.

156

It should be noted that many elements of this chapter, especially pertaining to the L:M
test, were published in 2014 [185].

5.4 Markers of Digestion
Twelve studies [43, 53, 58, 102, 109, 124, 132, 138, 147-149, 159] utilized a variety of
markers that reflect intestinal digestive function. The particular data relevant to this review are
listed for each of these studies in Evidence Table 3. Thirteen markers were assessed across the
studies: eleven and two were markers of carbohydrate and lipid digestion, respectively. Testing
for reducing substances in the stool was used in four studies as a marker of nonspecific poor
digestion of sugars [43, 58, 132, 138]. Two other studies used biopsied intestinal tissue to
measure specific disaccharidase activity or mRNA abundances [53, 109]. Three studies tested
exhaled breath to assess maldigestion of lactose or sucrose [102, 147, 159].
One study employed urine lactose:lactulose ratio as a marker of lactase function [124].
Lastly, two studies, both by the same investigators, assessed intestinal lipid digestive capacity
by measuring total triglyceride compared to fatty acids in the stool [148, 149].
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Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest
2002
Alves GM et al.
Nutritional status
and breath hydrogen
test with lactose and
lactulose in Terena
Indian children
Lactose hydrogen
breath test (HBT) as
a marker of lactase
activity, and
lactulose HBT as a
marker of SBBO
2003
Bustos M et al.

Location and
Target Population

Design and
Sample Size

Limão Verde and
Cross-sectional
Córrego Seco, Mato
Grosso du Sul, Brazil n=264;
All children <10 yr
old were recruited
from these rural
villages.

Cochabamba,
Bolivia

3-34 mo old
Disaccharidase
Amerindians
deficiency in Bolivian hospitalized with PD
children with
and moderate or
persistent diarrhea severe malnutrition
in an urban setting.
Jejunal biopsy and
disaccharidase
activities in children
with PD and different
forms of malnutrition

<5 yr old: n=145

Biomarker

Results

Conclusion

Comments

Breath Tests:
• Lactose HBT
(251 tested)
• Lactulose HBT
(252 tested)

Lactose HBT:
• Elevated: 27.1% among all
subjects
• Borderline: 43.0% among all
subjects
• 0% of subjects <4 yr had
elevated or borderline results

The prevalence of
lactase deficiency as
measured by lactose
HBT was >25%, but
non-existent among
those <4 yr of age.

Assessment of
association
between lactulose
and lactose
absorption was not
reported.

(However results
were provided by
<4 and >4 yr old
age groups.)

Cohort
n=42 cases with
PD and
malnutrition:
• 2 with
kwashiorkor
• 20 with
marasmus
• 20 with
marasmickwashiorkor

Lactulose HBT positive:
• 11.5% of all subjects
8.6% of subjects <4 yr

Jejunal tethered
capsule biopsy:
• Histopathology
• Disaccharidase
activity:
• Lactase
• SucroseIsomaltase
• Maltase

Most subjects had mild to
moderate (score of 2-3)
histological abnormalities, with
one kwashiorkor patient having
completely flat villi.

Second biopsy showed a trend
of improved mucosa, but
difference was not significant
based on histology score,
intraepithelial lymphocyte
Histology was scored density, or degree of infiltration
of lamina propria.
on a scale of 1
(normal) to 4 (severe
Percentages with enzymatic
Children were
morphological
activity below normal at
assessed on
damage or flat
baseline, discharge:
admission and at mucosa).
• Lactase: 64%, 59%
three weeks, after
• Sucrase-isomaltase: 97%,
diarrhea had
90%
resolved and
anthropometrics
• Maltase: 45%, 52%
were improving.
All changes were statistically
significant.
Lactase recovery was
associated with admission HAZ
(p=0.05) and WAZ (p=0.03)
scores.

Prevalence of SBBO as
assessed by lactulose
HBT was ~10%.

Patients had diminished
intestinal disaccharidase
activity and substantial
pathology on biopsy at
admission and at three
weeks, despite clinical
improvements and
tolerance of lactosecontaining formula.

Spanish language
article.
Values for
subnormal
disaccharidase
activity were not
provided.
The magnitude of
lactase inverse
association with
growth parameters
was not reported.
Authors did not
report whether they
had tested for
associations
between maltase or
sucrose-isomaltase
and growth
parameters.

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

2002

Location and
Target Population

Kathmandu, Nepal

Design and
Sample Size

Cross-sectional

n=210
0-5 yr olds (mean
age 3.8 yr) from two
Poor intestinal
urban squatter
permeability in mildly settlements.
stunted Nepali
children:
37% and 33% of
Associations with
subjects were
weaning practices
stunted and
and Giardia lamblia underweight,
infection
respectively.
Goto R et al.

L:M as a marker of
intestinal
permeability, and
assessment of
association with
giardiasis,
helminthiasis,
nutritional practices,
and growth status.

1

Biomarker

Conclusion

Despite continued high
disaccharidase deficiency
prevalence at discharge, all
children tolerated the lactosecontaining formula challenge.
L:M:
• 92% had values >UK norms
3
• Mean L:M (SD, range): 0.26
(0.21, 0.04-1.71).
• Giardia-infected versus
uninfected means: 0.43 vs.
0.25, p=0.014

L:M ratios were high
overall.

Urine Tests:
1
• Lactulose
• Mannitol
2
• Lactose
(168 tested)
• L:M
(158 tested)
• Lactose:lactulose
The duration of ingestion of solid
ratio
foods (with or without concurrent
(157 tested)
breastfeeding) was not
associated with L:M in
multivariate analysis.

Lactulose and mannitol results were expressed as % of dose administered.
Lactose results were expressed in mg/L.
3
Geometric mean.
2

Results

Comments

Low lactase activity
was defined as
lactose:lactulose
Wide individual variation ratio >0.4.
was observed in L:M
Specific L:M data
ratios.
by WAZ and HAZ
L:M was associated with scores were not
reported, although
giardiasis but not
authors state that
helminthiasis.
L:M was not
associated with
Urinary lactose
“growth status.”
concentrations and
lactose:lactulose ratios
L:M was correlated with longer were significantly higher
in breastfed subjects
duration of breastfeeding
(r=0.27, p<0.019). Specifically, than in those that were
children who breastfed for >2 yr not breastfed, despite
similar intestinal
had higher L:M ratios than
permeability values.
children who breastfed for
shorter times (data not
There were some
provided).
unexpected findings: the
duration of
L:M was not associated with:
• History of diarrhea in the week breastfeeding, and not
the timing of introduction
preceding testing
of solid foods, was
• Helminthiasis
correlated with L:M, and
• Age
the correlation was
• WAZ or HAZ scores
direct, not inverse.
Lactulose excretion ranged from Authors speculate that
0.02–15.00. Mannitol excretion this could be due to
higher mean age of their
ranged from 0.5–15.00.

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

cohort compared to
47% showed low lactase activity. another study that
Lactose values and
demonstrated beneficial
lactose:lactulose ratios
effect of duration of
2
decreased with age (R =28%,
breastfeeding on
p<0.0001), but were not
reduced L:M in
associated with sex, ethnicity,
Guatemala [205].
and location nor were they
associated with L:M.
1

Mean urinary lactose
concentrations (mg/L) by feeding
mode:
• Breastfed: 172.5
• Non-breastfed: 44.5, p<0.0001
corrected for infant age
2

Mean lactose:lactulose ratio by
feeding mode:
• Breastfed: 2.76
• Non-breastfed: 0.31,
p<0.0001 corrected for infant
age
Mean L:M by feeding mode:
• Breastfed: 0.23
Non-breastfed: 0.28, nonsignificant, p-value not specified
2002
Port-au-Prince, Haiti Case-control
Stool Tests:
Proportion RS-positive:
Fecal lactoferrin was
identified most often in
• Reducing
• 33.3% cases
Kirkpatrick BD et al. <18 mo olds from a n=49;
children with diarrhea,
substances (RS) • 64.7% diarrhea controls
low SES setting
• Lactoferrin
• 46.7% healthy controls, (p=0.2) especially in those with
Cryptosporidium. While
n=17 cases with • Cytokines:
Cryptosporidiosis
recruited from the
Cryptosporidium
stimulates an
rehydration unit of
• TNF-α receptor Proportion lactoferrin-positive: some fecal cytokines
and diarrhea (5
inflammatory
GHESKIO HIV
were detected in as
• 83.3% cases
I
3
with PD)
intestinal response Center with
many as 40% of healthy
• 60.0% diarrhea controls
• IL-4
diarrhea and
in malnourished
controls and 70% of
• 28.6% healthy controls,
• IL-8
Cryptosporidium
n=32 controls
Haitian children
controls with diarrhea,
(p=0.01)
• IL-10
without
infection. Controls
they were generally
• IL-13
1

Geometric mean.
Geometric mean.
3
The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.
2

Reported results
were not stratified
by persistent vs.
acute diarrhea
status.
Cut-off values for
lactoferrin positivity
were not described.
Stools from children

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest
Stool lactoferrin,
reducing
substances,
leukocytes and
cytokines as
markers of intestinal
inflammation of
children with and
without
Cryptosporidium
infection

Location and
Target Population

Design and
Sample Size

recruited from an
outpatient clinic
without
Cryptosporidium
infection included
those with and
without diarrhea.

Cryptosporidium;
• IFN- γ
• 17 with diarrhea
(5 with PD)
Blood Test:
• 15 healthy
WBC

Biomarker

Results

Conclusion

Comments

IFN-γ was not recovered in any associated with
who were
Cryptosporidium
stools.
breastfeeding were
infection. The other stool not tested for
All other fecal cytokines were
tests did not discriminate lactoferrin.
significantly associated with
by diarrhea or
Cryptosporidium cases
Cryptosporidium status.
compared to diarrhea and
healthy controls.
Additionally, TNF-α receptor I,
IL-8, IL-13 were found in
diarrhea and healthy controls,
while IL-4 and IL-10 were not.
Fecal lactoferrin was associated
with the presence of TNF-α
receptor I (point estimate not
provided, p=0.03).

Mean WBC counts were within
normal range in all 3 groups.
2003
Darwin,
Case-control
Urine Test:
NO among Aboriginal children
Australia
Nitric Oxide (NO)*
with diarrhea was >3x higher
n=318;
than any other group and >5x
Kukuruzovic R et al.
higher than in non-Aboriginal
1-6 yr old Aboriginal
controls.
Increased nitric
and non-Aboriginal n=169 cases with Blood Tests:
oxide production in hospital inpatients. AD
• L:R
• NO was >3x and >2x higher
(154 Aboriginal) • Mean corpuscular
acute diarrhea is
among Aboriginal than nonassociated with
Subjects were
Aboriginal children in the
volume (MCV)
abnormal gut
grouped as follows: n=149 controls:
diarrhea (p<0.001) and no
permeability,
1. Children with AD • 73 with non-GI
infections groups (p<0.001),
hypokalemia and
2. Children with no
infections (49 Stool Test:
respectively, but there was
malnutrition in
diarrhea but with
Aboriginal)
no difference between them
Reducing
tropical Australian
non-GI infectious • 76 with no
in the non-GI infections
substances (RS)**
aboriginal children
conditions
group.
infections (29 (169 cases tested)
3. Children without
• NO was >3x and ~2x higher
Aboriginal)
Nitric oxide (NO) as
GI or infectious
in the diarrhea compared to
a marker of intestinal conditions
the no infections group
* NO is an unstable
permeability and
among Aboriginals
free radical and is
inflammation, and
(p<0.001) and nonconverted to nitrite
lactulose:rhamnose
Aboriginals (p<0.03),
and nitrate. Urine
ratio (L:R) as a
respectively.
nitrate (NO3)+ nitrite
marker of intestinal
•
NO
was virtually the same
(NO2) was expressed

NO2 + NO3:Cr ratio, as a
measure of endogenous
nitric oxide production,
was used as a marker of
gut permeability and
inflammation, with an
attempt to identify how
much more it reflects as
response to
inflammation from GI vs.
non-GI infections.
Among non-Aboriginal
controls, NO production
was the same among
those with diarrhea and
non-GI infections (and
higher compared to
controls). NO was
highest by far among
Aboriginal children with
diarrhea compared to

Positive stool RS
was defined as
>0.5%.
Abnormal L:R was
defined as >7.6; no
reference or
derivation was
provided for this
cut-point.
Study population
appears to be the
same as in another
Kukuruzovic, et al.
study also included
in this review which
assessed serum
lactulose:rhamnose
as a marker of
intestinal
permeability [58].

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
permeability and the
relationship between
NO and L:R, growth
parameters, mean
corpuscular volume
(as a surrogate of
iron deficiency), and
stool reducing
substances among
children with and
without diarrhea

2002
Kukuruzovic RH et
al.
Small bowel
intestinal
permeability in
1

Darwin, Australia

Design and
Sample Size

Biomarker

Conclusion

Comments

as a ratio with urine
creatinine (NO2 +
NO3:Cr) in order to
account for
differences in urine
concentration.

among the Aboriginal non-GI any other group. Authors
infections and no infections suggest that high basal
groups, as well as among
concentrations of NO
the non-Aboriginal diarrhea among Aboriginal
and non-GI infections
children due to (clinically
groups.
silent) enteropathy could
explain the
112/152 (74%) and 31/169
** Measured only
concentrations seen
among children with (18%) of children with AD had
among Aboriginal
abnormal L:R ratios and positive controls in this study.
profuse diarrhea.
stool RS, respectively.
NO appeared to
NO and L:R were measured at decrease significantly
“convalescence” on Day 5
more slowly than L:R
among those with diarrhea: the among children
mean improvement in NO was recovering from
21.7% compared with 54.6% for diarrhea.
L:R (p=0.01).
NO was found to
correlate with L:R. NO
NO and L:R were correlated
was more strongly
1
(n=193, r=0.37, p<0.001) ; the correlated with lactulose
correlation was stronger for
than rhamnose.
lactulose (effect ratio=1.47,
p<0.001) than for rhamnose
2
(effect ratio=0.80, p=0.02 ).

Case-control

Blood Tests:
• Lactose
Cases were
n=375 admissions • Lactulose 4
Aboriginal and non- for 306 children; • Rhamnose
Aboriginal children
• L:R
admitted to hospital n=285 case
• Hemoglobin
with diarrhea.
admissions for
• Mean corpuscular
Controls were
AD (264

Reported results appear to have been adjusted for age and race.
Reported results were adjusted for age and race.
3
Reported results among children with diarrhea were adjusted for age and race.
4
Lactulose and rhamnose results were expressed as % of dose administered.
5
Geometric mean.
2

Results

NO was not correlated with stool
3
RS or MCV, but was correlated
with lower WAZ score (effect
ratio=0.88, p=0.05).
27/75 (36%) of Aboriginal
controls and 0 non-Aboriginal
controls had abnormal L:R
ratios.
5

Mean L:R at baseline:
Cases:
• Aboriginal: 16.4

Mean L:R ratios of
Aboriginal children were
approximately double
those of non-Aboriginal
children both among
those with and without
diarrhea, consistent with
authors’ suggestion that

Positive stool RS
was defined as
>0.5%.
Abnormal L:R was
defined as >5.6,
derived from 2 SD
above the

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest
Australian Aboriginal
children

Location and
Target Population

Design and
Sample Size

Aboriginal and non- Aboriginal)
Aboriginal children
admitted without GI n=90 control
Serum lactulose:
admissions with
illnesses.
no diarrhea (74
rhamnose ratio
Aboriginal)
(L:R), serum lactose,
and stool reducing
substances as
markers of intestinal
permeability among
Aboriginal and nonAboriginal children
with and without
diarrhea

Biomarker
volume (MCV)
Stool Test:
Reducing
substances (RS)*

Results

Conclusion

• Non-Aboriginal: 7.9, p=0.002

clinically silent
enteropathy is prevalent
among Aboriginal
children.

compared to Aboriginal cases
Controls:
• Aboriginal: 4.6
• Non-Aboriginal: 2.5, p=0.02
compared to Aboriginal
controls
1

L:R testing was
Mean improvement in L:R (CI)
repeated on day 5 for at day 5 among those with
a subset of Aboriginal repeat testing:
subjects:
• Aboriginal cases: 14.6 (11.2,
• 174/264 admissions 18.0)
for acute diarrhea • Aboriginal controls: -0.63 (4.0, 2.7)
• 25/74 control
admissions
2
Mean lactulose recovery :
• Cases day 1: 0.085 (0.070–
0.103)
* Measured only
•
Cases day 5: 0.039 (0.033–
among children with
0.046)
profuse diarrhea
• Controls: 0.024 (0.019–0.029)
when “clinically
indicated". Number All 3 values significantly differed
tested not provided. from one another.
Mean rhamnose recovery:
• Cases day 1: 0.479 (0.424–
0.542)
• Cases day 5: 0.555 (0.498–
0.616)
• Controls: 0.585 (0.500–0.685)
These values did not
significantly differ from one
another.
Confidence intervals (CIs) in the
authors' graphical representation
of mean L:R at admission did
not overlap, and the difference in

1

Comments

arithmetic mean for
non-Aboriginal
controls in this
study. The rationale
for the choice of 2
Mean L:R significantly SD above the
arithmetic, instead
improved over 5 days
among Aboriginal cases. of the geometric,
Children with severe
mean is not clear.
Proportions of
diarrhea had higher
cases with
mean L:R.
abnormal
concentrations
Higher case L:R was
were not reported.
driven more by high
lactulose than by low
Analysis included
rhamnose.
Similarly, improvement data for 69 children
in L:R among cases was with repeat
primarily due to
admissions; this
might violate
decreased lactulose.
independence
Stool RS and serum
assumptions for
their statistical
lactose were found in
analysis methods.
approximately onequarter and one-third of
Repeat L:R testing
Aboriginal cases,
respectively. The latter was conducted on
was weakly associated controls of both
with increased lactulose. racial groups, but
among cases it was
only conducted on
Aboriginal cases.
This study appears
to report on the
same population as
in the Kukuruzovic,
et al. 2003
reference also

Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated.
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577.
2
Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

means was particularly evident
between Aboriginal and nonAboriginal subjects.
Factors associated with L:R
1
among cases were :
• Acidosis (p=0.007)
• Hypokalemia (p=0.035)
• Diarrhea severity (p=0.001)
Age and malnutrition were not
associated with L:R.
38% and 27% of Aboriginal
cases had positive serum
lactose and stool RS,
respectively. 12% of Aboriginal
and non-Aboriginal controls
combined had lactosemia.

2005
Lima AA et al.

Fortaleza, Brazil

2-60 mo olds
hospitalized with
Intestinal barrier
WAZ score <-2,
function and weight ~70% of whom had
gain in malnourished PD.
children taking
glutaminesupplemented
enteral formula
L:M as a marker of
1

RCT
n=80;
n=53 received
supplemented
formula
• 27 with glycine
• 26 with
glutamine
n=27 received

Urine Tests*:
3
• Lactulose
• Mannitol
• L:M
Stool Tests**:
• Lactoferrin
• Leukocytes
• Occult blood
• Reducing
substances (RS)

Reported results were adjusted for confounding variables, unless otherwise noted.
Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.
3
Lactulose and mannitol results were expressed as % of dose administered.
4
Type of mean not specified.
2

Presence of lactosemia was
associated with L:R, adjusted
relative risk (CI)=1.06 (1.03,
2
1.10) . Stool RS, anemia, and
MCV were not associated with
L:R.
4
Mean L:M (SE):
L:M significantly
• Glutamine group:
improved in the
glutamine group only.
• Baseline: 0.31 (0.10)
(similar in all three groups)
>50% of subjects had
• Day 10: 0.10 (0.02);
intestinal inflammation
significant decrease,
by stool lactoferrin.
(p=0.01)
• No significant decrease in L:M Fecal leukocytes, RS,
and occult blood were
in glycine and
detected in fewer
nonsupplemented formula
subjects than lactoferrin.
groups at day 10

Comments
included in this
review, which
assessed nitric
oxide excretion
[43].
Authors reiterate
the advantages of
serum over timed
urine collection for
assessment of L:R,
as discussed in
another publication
in this review [125]

The relationship
between stool
markers and L:M
was not reported.
Data were not
stratified by history
of PD.
Fecal fat was
assessed, but
results were not
reported.

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
intestinal
permeability and
various stool tests
among children with
malnutrition or PD
who received either
glycine or glutamine
supplemented
formula or placebo

Design and
Sample Size
nonsupplemented
formula

2002

Hermosillo, Sonora, Case-control
Mexico
n=13;
Moya-Camarena SY
3-6 yr olds in a
et al.
<5 yr old:
periurban setting
attending preschool n=5
Effects of
centers meeting
asymptomatic
Giardia intestinalis inclusion criteria of n=7
no GI symptoms, no asymptomatic
infection on
cases infected
antibiotics in the
carbohydrate
absorption in well- preceding 3 wk, and only with G.
intestinalis
nourished Mexican no SBBO by
lactulose HBT and
children
n=6 controls
Indican test.
without Giardia
Lactose hydrogen
breath test (HBT) as
a marker of lactose
Cases were
absorption, and
evaluated before
xylose breath test
and urinary excretion
and 3 wk after
as markers of xylose
treatment with
1

D-xylose results were expressed as % of dose administered.

Biomarker

* n=80 tested at
enrollment, n=65
tested at day 10.
** n=60 tested.

Breath Tests*:
• Lactose HBT
• D-Xylose HBT**
Urine Test:
,1
D-xylose**
* Reported as parts
per million (ppm)
post-substrate
ingestion after
subtraction of
baseline, presubstrate H2
concentrations. A
positive HBT is
considered to be a
rise of >20ppm in
breath H2 above

Results

Conclusion

Mean lactulose (SE):
• Glutamine group:
• Baseline: 0.97 (0.46)
(similar in all three groups)
• Day 10: NS decrease in all
3 groups

Cut-off values for
lactoferrin positivity
were not described.
Exclusively
breastfed children
were excluded from
study participation
due to assessment
of stool lactoferrin.

Mean mannitol (SE):
• Glutamine group:
• Baseline: 3.42 (0.64)
(similar in all three groups)
• Day 10: NS decrease in all
3 groups
Proportion of stool markers at
baseline among all subjects:
• Lactoferrin: 53.3%
• Leukocytes: 11.7%
• RS: 3.3%
Occult blood: 5.0%
Mean lactose HBT (SE):
• Cases pre-treatment: 3.6
(0.75) ppm
• Cases post-treatment: -0.85
(0.75) ppm (p<0.05 compared
to pre-treatment)
• Controls: 0.19 (0.81) ppm
(p<0.05 compared to pretreatment cases)
Mean xylose HBT (SE):
• Cases pre-treatment: 2.2
(0.69) ppm for infected group
• Cases post-treatment: -4.16
(0.69) ppm (p<0.05 compared
to pre-treatment)
• Controls: 1.13 (0.74) ppm (NS
compared to pre-treatment
cases)
Mean urinary excretion of xylose

Comments

Lactose HBT
concentrations were
normal according to
established cut-points
among all subjects.

Statistical methods
might not have
been adequate to
account for intrasubject correlation
when comparing
However, lactose HBT the same group of
was significantly higher subjects (cases)
among cases compared before and after
treatment.
to controls and there
was also a significant
decrease in lactose HBT Investigators
among cases after
wished to exclude
treatment. The clinical children with SBBO.
relevance of such mildly As such, inclusion
elevated HBT results in criteria restricted
participants to
asymptomatically
those with
infected children is
adequate
unclear.
production of H2
Results did not
following ingestion

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest
absorption in wellnourished children
with asymptomatic
giardiasis and noninfected controls

Location and
Target Population

Design and
Sample Size
tinidazole. Posttreatment stools
were verified for
absence of
parasites.

Biomarker
baseline H2
concentration.

Results

Conclusion

(SE) among cases pre-treatment demonstrate xylose
and post- treatment was 34% (3) malabsorption by either
and 46% (11), respectively (NS), urinary or breath
** Investigators did well above cut-offs indicative of measures among any
not specify the xylose malabsorption.
group. While urinary
enantiomer used,
results did not differ
however test
before and after
functionality
treatment, case xylose
characteristics lead
HBT was significantly
us to assume that it
lower after treatment;
was the dextrorotary
again the clinical
(D) enantiomer.
significance of such
results is not apparent.
2002
Kingston, Jamaica Case-series
Stool Tests:
Median total stool excretion of High concentrations of
13
13
C in phase 1 was 9% (range:
C (compared to
• Total and
13
n=24
1%-29%) and did not vary
Murphy JL et al.
5-23 mo olds
healthy UK children)
fractionated C
between TG groups.
admitted to the
[190] were observed in
following
13
Maldigestion and
Tropical Metabolism
ingestion of one Median C excretion dropped half of the subjects at
13
33%-99% in phase 2 and 86%- admission, reflecting
malabsorption of
Research Unit of the Subjects were
of three C
divided into 3
95% in phase 3 compared to
dietary lipid during University of the
impaired digestion or
labeled
groups of 8
severe childhood
West Indies with
absorption.
triglycerides (TG): phase 1 (p<0.05 each).
malnutrition
severe malnutrition. children, each
trilaurin, triolein,
group receiving a or trilinolein*
Over the study period, there
The differences in stool
13
different labeled • 13C stool assay
were significant associations
C were wide but not as
Stool recovery of
triglyceride.
between total lipid and the
extreme as in a previous
radiolabeled
following
13
amount of C labeled TGs in
study by same
products as markers
administration of
Data were
stool for some groups, but not
investigators (also
of lipid digestion and
labeled fatty acid
collected in three 13C glycocholate** for others.
examined in this review)
absorption, and bile
separate phases
using a different TG
salt deconjugation
13
as described
Median C in TG and FA was (tripalmitin) substrate
as a marker of
above in JL
similar across TG groups in all [149].
SBBO among
* To assess fat
Murphy et al.
children with severe
excretion as a % of phases. 13C FA recovery was
13
2001 [149].
C excretion did not
malnutrition
dose administered. similar and reduced by ~2/3
13
compared to Phase 1. C TG
significantly differ
Also assessed
13
proportion of C in was not detectable in Phases 2 between TG groups and
declined with improving
triglyceride (TG) and or 3. Statistical comparisons
between
phases
were
not
clinical course.
fatty acid (FA)
reported.
fractions to
Similar to their previous
distinguish excretion
13
C after radiolabeled
study, significantly more
caused impaired
13
digestion (presence glycocholate administration was C in stool was
detected in stool at quantities
recovered as FA than
of TG) vs. poor
TG, reflecting impaired
absorption (presence considered to be in excess of

Comments
of lactulose and
with minimal urinary
indoxyl sulfate
excretion. The
number of children
excluded due to
failure to meet
these criteria was
not reported.

Authors state that
the study was not
powered to
compare the
different TGs, but
they contend that
medium chain
trilaurin did not
appear to be
processed
differently than the
longer chain TGs
triolein and
trilinolein.
Authors did not
describe the
method used to
assign subjects to
different TG groups.
While it was noted
that some subjects
had positive stool
cultures, details
were not provided
on the nature of the
enteric infections.

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker
of FA).

Results

the 7% recovery of dose
administered upper limit of
** To assess bile salt normal in U.S. adults in [189]:
deconjugation in the • Phase 1: 13/24 (54%)
• Phase 2: 5/24 (20.8%)
bowel caused by
• Phase 3: 3/24 (12.5%)
SBBO; conducted
after the TG
assessment and a 3
day washout period.
2001
Kingston, Jamaica Case-series
Stool Tests:
Mean fecal fat (SD):
• Phase 1: 2.4 g/day (3.6) or
• Fecal fat*
7-23 mo olds with
n=8
Murphy JL et al.
5.9% (9.4) of dietary lipid
• Total and
13
malnutrition admitted
intake
fractionated C
Gastrointestinal
to the University of
• Phase 2: 1.7 (0.9) g/day, or
assay after
Data were
handling and
the West Indies.
3.3% (2.4) of intake
administration of
metabolic disposal of
collected in three 13C tripalmitin
• Phase 3: 0.9 (0.6) g/day, or
13
C-labelled
separate phases
1.4% (0.7) of intake
(TP)**
13
(each lasting 9
• Differences between phases
tripalmitin during
• C assay after
days):
were not statistically
rehabilitation from
administration of
1. Within 48 hours 13C glycocholate
significant.
childhood
of admission
malnutrition
(GCA)***
13
2. During early
Total excretion of C in stool
also varied widely across
Fecal fat, stool
rehabilitation
3. During late
patients (0%-44%) and did not
recovery of
Breath Tests:
13
differ between study phases.
rehabilitation
radiolabeled
• CO2 after
products, and breath
administration of
13
Correlation between fecal fat
tests as markers of
C glycocholate
13
and C (r=0.48; p<0.05) was
lipid digestion and
(GCA)***
13
observed.
absorption and bile
• CO2 after
salt deconjugation
administration of
13
Lack of lipid digestion and
as a marker of
C TP****
absorption were assessed by
SBBO among
measuring TG and FA fractions,
children with severe
13
respectively. Mean C TG
malnutrition
* In 72 hour stool
collection (measured recovery (SD) (% of
as total grams and as administered dose), number of
patients excreting TG:
% of dietary fat
• Phase 1: 0.7% (1.6), n=3
intake).
• Phase 2: 0.9% (2.8), n=1
• Phase 3: no recovery from
** To assess fat
any subjects, differences
excretion as a % of
between phases were NS
dose administered.
Also assessed

Conclusion

Comments

absorption over poor
lipid digestion/
hydrolysis. Unlike in their
previous study, there
was evidence of SBBO
as measured post13
ingestion of C
glycocholate.
Mean fecal fat was not
elevated compared to
published norms [191,
192] during any study
phase.

Statistical methods
might be
inappropriate for a
small sample.

All subjects were
There was wide variation treated with
in fecal fat at
antibiotics including
presentation, and wide metronidazole for
13
presumptive SBBO;
variations in stool C
across subjects. Authors this might have
indicate that this is the affected GCA
first such assessment in testing.
malnourished children;
previous studies on
healthy children from the
UK demonstrated
average excretion of 6%
[190].

The majority of excreted
13
C was in the form of
FA rather than TG.
Authors interpreted this
to reflect failure of lipid
absorption in the face of
adequate digestion/
hydrolysis. Each form
(FA and TG) was found
in decreasing values as
the study phases
progressed, suggesting
improved digestion and
absorption, although

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

13

proportion of C in
triglyceride (TG) and
fatty acid (FA)
fractions to
distinguish excretion
caused by impaired
digestion (presence
of TG) vs. poor
absorption (presence
of FA).

2000

Sao Paulo, Brazil

Nichols B et al.

Cases were children n=33;
(mean age 9.9 mo,
SD 8.1) hospitalized n=24 cases
with malnutrition
refractory to dietary n=9 controls
rehabilitation.

Contribution of
villous atrophy to
reduced intestinal
maltase in infants
with malnutrition

Biomarker

Controls were

Case-control

Subjects were

Results

Conclusion

13

results did not differ
significantly.

C FA fraction in stool declined
during rehabilitation.
13
Mean C FA recovery (SD):
• Phase 1: 6.0% (7.3)
• Phase 2: 4.8% (3.7)
• Phase 3: 3.3% (3.8),
differences between phases
were NS

Fecal fat was correlated
with concentrations of
13
C in stool.
There was no evidence
of SBBO or bile acid
malabsorption.

Comments

Mean FA values were ~9x (NS),
13
5x (p<0.001), and 3x (p<0.05)
CO2 excretion following
13
higher than mean TG values in administration of C TP
*** To assess bile
salt deconjugation in Phases 1, 2, and 3, respectively. was minimal, suggesting
a propensity for
the bowel caused by
Following administration of
deposition in adipose
SBBO; conducted
13
labeled TP, absorbed C label tissues rather than
after the TG
oxidation for immediate
assessment and a 3 by breath analysis was ~5%
energy needs. The
day washout period. (range 0%-21.2%) and similar
across study phases.
authors report that this
breath test has not been
**** Expressed as a
Following the administration of widely used, but that
percentage of
absorbed label (dose labeled GCA, there was either healthy UK children
13
administered - label no or minimal recovery of C in have breath excretion
13
recovered in stool) to stool and CO2 on breath (as % values from 15%-43%
[190], compared to a
assess oxidation for of dose administered) in all
mean of 5% and range
acute energy needs. phases.
0%-21% in this cohort;
the latter findings were
more similar to results
from kwashiorkor
13
patients where Clabeled oleic acid was
used as substrate [193].
Jejunal capsule
Mean villous atrophy score (SD): The malnourished
Tissue from
biopsy:
• Cases: 2.6 (0.8)
children had significantly patients requiring
• Controls: 1.2 (0.5), p=0.006) greater villous atrophy
intestinal resection
• Histopathology*
as part of their
than
the
younger
• Maltase activity
WAZ
score
was
correlated
with
biliary atresia
controls.
• Intestinal
villous
atrophy
(r=0.65,
pvalue
management
messenger RNA
not reported).
Among the subset tested provides an
(mRNA)
for mRNA messages,
opportunity to
abundances:
13/25 [sic] cases and 0/5
maltase activity as well assess presumably
• Maltase“normal” intestinal
glucoamylase controls had subnormal (defined as the mRNA

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest
Jejunal biopsy,
maltase activity, and
enzyme messenger
RNAs among
malnourished and
well-nourished
children. Assessed
association between
maltase and villous
atrophy and other
mucosal intestinal
markers indicative of
loss of enterocytes
and enterocytic
function.

Location and
Target Population

Design and
Sample Size

children (mean age
3.6 mo, SD 1.0) with
HAZ and WAZ
scores >-2 and
normal intestinal
mucosa on biopsy,
hospitalized for
Kasai procedure for
biliary atresia.

matched on
height and
weight; ages
differed within
matched sets.

Biomarker

Results

(MGA)
as <94 U/g protein) of maltase
activity; mean maltase was 34%
• Sucraseisomaltase (SI) lower among cases (p=0.11).
Maltase activity did not appear
• Villin, a
to decrease with WAZ score
structural
(further details not provided).
protein
expressed only
in enterocytes However, in sub-analyses
among those samples with an
• Sodiumadequate β-actin, a
activated
housekeeping gene message,
luminal
(n=10 cases, n=9 controls),
glucosecases’ findings expressed as a
galactose
mean percent of controls' (SD)
transporter 1
included:
(SGLT), a
• Villous length (reciprocal of
functional
atrophy score): 38.9 (41.6),
protein
p=0.004
expressed only
in enterocytes • Maltase activity: 37.1 (23.2),
p=0.001
• β-actin
• MGA mRNA: 45.1 (36.4),
p=0.016
•
Villin mRNA: 52.5 (22.6),
* Mucosal atrophy
p=0.003
was scored on a
scale of 1 (absence • SGLT mRNA: 66.6 (23.1),
p=0.057
of atrophy compared
to an organ donor) to • β-actin: 88.2 (15.8), p=0.189
4 (similar to children
Both villous length and maltase
with active CD).
activity in a subset of cases
were less than 40% of control
Histology among
values.
controls was on
surgically resected
MGA, villin, and SGLT mRNA
tissue.
abundances were correlated
with villous atrophy score
(r=0.73), (r=0.76), and (r=0.54),
respectively (p-values not
1
reported) .
MGA mRNA abundance was

1

Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin.

Conclusion

Comments

abundances for MGA,
villin and SGLT were
significantly correlated
with case status and
were correlated with
villous atrophy.

architecture.
However, unless
they mocked up ex
vivo mucosal
biopsies in these
controls, resections
will have lower
While maltase deficiency proportions of
has been reported in
villous to
submucosa tissue
malnutrition in other
studies, authors assert compared to cases’
samples derived
that these are the first
from mucosal
results that directly
support the hypothesis biopsies. While this
probably doesn’t
that reductions in
maltase activity are due affect histology, it
to villous atrophy. This might affect
enterocyte
study also nicely
functional assays
correlates mRNA
relative abundance with and mRNA
determination, as
function.
transmural tissue
will bring in more
diverse populations
of cells; only some
of them might have
transcripts of
interest. However,
the bias is likely in a
direction that would
reduce effect size.
It was unclear if
control inclusion
criteria included
absence of atrophy
or if all potential
controls lacked
atrophy.
Statistical methods

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Study Outcomes of
Diagnostic Interest

2009

Location and
Target Population

Design and
Sample Size

Biomarker

Geometric mean.

Conclusion

correlated with maltase activity
(r=0.32).

Blood Tests:
• L:R
n=43;
Ritchie et al.
(32 Aboriginal
4 mo-5 yr old
cases and controls
13C-sucrose breath Aboriginal children n=18 Aboriginal
tested)
test: novel use of a admitted to hospital cases with AD
• C-reactive protein
with diarrhea.
noninvasive
(CRP)
n=25 controls:
biomarker of
• Mean Corpuscular
Two control groups: • 18 Aboriginal,
environmental gut
Volume (MCV)
1. Aboriginal controls without diarrhea • Hemoglobin
health
admitted to
• 7 nonSucrose breath test
hospital with non- Aboriginal,
(SBT) as a marker of GI symptoms
healthy
Breath Test:
13
small bowel mucosal (50% had
C sucrose breath
1

Results

Darwin and
Adelaide, Australia

Case-control

20/32 (63%) of Aboriginal
children had abnormal L:R
ratios.
1

Mean L:R (CI):
• Diarrhea cases: 31.8 (24.9,
40.7)
• Aboriginal controls without
diarrhea: 11.4 (8.5, 15.5),
significant difference
(p<0.0001)
SBT Mean (CI):
• Diarrhea cases: 1.9% (0.9,

Comments
might not have
adequately taken
into account the
small sample size
and matching
scheme.

SBT values were
significantly lower and
L:R values were
significantly higher
among Aboriginal
children with diarrhea
than among those
without GI symptoms.
SBT was also
significantly lower
among Aboriginal
controls than among
non-Aboriginal children
without diarrhea. This is

Subsets of subjects
were investigated
for various tests.
For example, 10
cases had mRNA
analyses based on
β-actin adequacy.
Another instance of
selected testing
was the subset of
22 and 15 cases
that had WAZ score
to histology and
mRNA correlation
analyses,
respectively.
Rationale for subset
selection was not
thoroughly
described.
Abnormal L:R ratios
were defined as
>16; no reference
or derivation was
provided for this
cut-point.
L:R test was not
conducted among
the non-Aboriginal
controls.
SBT/ L:R
correlation analysis

Evidence Table 3. Markers of digestion.
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and
Location and
Design and
Study Outcomes of
Target Population
Sample Size
Diagnostic Interest
damage vis a vis
pneumonia)
sucrase activity
2. Healthy, nonamong an Australian Aboriginal controls
recruited from
Aboriginal
community
population. Also
compared SBT with
serum
lactulose:rhamnose
ratio (L:R)

Biomarker

Results

Conclusion

test (SBT)

3.0), p<0.0001 compared to
non-Aboriginal controls and
p=0.004 compared to
Aboriginal controls
• Aboriginal controls: 4.1% (3.0,
5.2), p=0.032 compared to
non-Aboriginal controls
• Non-Aboriginal controls: 6.1%
(4.8, 7.3)
Significant differences were
observed between all three
groups.

consistent with previous
reports of high
prevalence of clinically
silent TE in this
population.

SBT results were not associated
with wasting or with patient age
or breastfeeding status.
SBT and L:R were inversely
correlated (r=0.67; CI: 0.42,
0.62; p<0.0001). L:R explained
45% of the variance in SBT;
diarrhea explained 28% of
variance.

Comments

was based on data
for Aboriginal cases
and controls
combined; stratified
analysis was not
reported and could
be of interest
SBT was significantly
inversely correlated with considering the
large difference in
L:R.
L:R observed
between these
groups.
Associations of
MCV, CRP, and
hemoglobin with
SBT after adjusting
for potentially
confounding
variables were not
reported.

SBT was associated with
increased MCV, relative risk
(CI)=3.9 (2.8, 5.0). SBT was not
associated with hemoglobin or
CRP.
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.4.1 Sucrose and Lactose Breath Tests
Three studies used breath tests to detect the presence of lactose (n=2) [102, 147] or sucrose
(n=1) [159] in the intestines after administration of a loading dose activity. These disaccharides should, in
normal intestinal health, be split by the brush border enzymes lactase or sucrase to glucose and
galactose or fructose, respectively. While these breath tests also reflect intestinal capacity to absorb these
monosaccharides, we classified them as markers of digestive function first and foremost, because
enzymatic cleavage of the ingested sugars is a cardinal intestinal process required for absorption to take
place. Breath tests can measure various molecules in exhaled breath, most commonly hydrogen.
Normally, very little hydrogen is detected in breath after an overnight fast; however, hydrogen is produced
when undigested substances such as lactose are fermented by intestinal bacteria. The sucrose breath
test (SBT) assessed in this review measured exhaled CO2, a normal by-product of disaccharide
metabolism which will be found in reduced amounts if there is reduced sucrase activity. Because
genetically ordained age-associated lactose intolerance becomes common beyond infancy in many
populations irrespective of intestinal mucosal health, the possibility exists that sucrase activity might serve
as a better marker of overall intestinal function because such age-related decline in tolerances are not
known to be associated with sucrose.
CO2 exhalation in the SBT was significantly lower among Aboriginal children with diarrhea
compared to those without gastrointestinal symptoms, as well as among Aboriginal controls compared to
non-Aboriginal children without diarrhea. SBT results were not associated with age, breastfeeding status,
or wasting [159]. SBT results were significantly inversely correlated with L:R values (r=0.67), but this was
assessed among all Aboriginal subjects (cases and controls) combined. L:R values differed largely
between these groups; it would be useful to investigate the relationship between SBT and L:R stratified on
diarrhea status. SBT results were also associated with one other marker, mean corpuscular volume, but
were not associated with blood C-reactive protein, an index of systemic inflammation, or with hemoglobin,
concentrations of which can be reduced for a variety of reasons, including acute and chronic systemic
inflammation. While this study suggests that SBT is a promising diagnostic test for EED, this was the only
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publication that analyzed the SBT in children in a developing country setting or among marginalized
populations during the time period under review.
Two studies utilized hydrogen breath tests (HBT) to assess lactase function [102, 147]. Each study
also assessed either lactulose or D-xylose as substrates using the HBT. These two substrates for breath
hydrogen analyses are primarily used to identify small bowel bacterial overgrowth (SBBO) and
malabsorption, respectively, and as such they are discussed in those sections. Prevalence of abnormal
lactose absorption differed between these two studies. Lactose absorption among indigenous Brazilian
children with mild malnutrition was abnormal in more than one fourth of the subjects [102]. In wellnourished Mexican children, HBT values in cases with asymptomatic giardiasis were only mildly elevated
but remained below concentrations that have been used as criteria for lactose malabsorption [147]. Cases
had HBTs before and after anti-giardiasis treatment. The pre-treatment HBT excretion was significantly
higher compared to controls without giardiasis and to post-treatment values. The clinical relevance of
such mildly elevated HBT results in asymptomatically infected children remains unclear, however.
The discrepancy in results between the studies was unexpected, and the reason for it remains
unclear. Both studies used the same cutoff for normal values, but the proportions of children with lactase
deficiency were quite different. The differences might reflect numerous factors including differences in
age, nutritional status, and age-related lactose intolerance. Another potential contributing factor is the
exclusion of children with SBBO from the Mexican study but not from the Brazilian study, in which greater
than 10% of the subjects had SBBO by lactulose HBT. An additional complication in assessing mucosal
function, at least in children four years of age and older, is that there is a high prevalence of genetic
lactase deficiency in many of the populations at risk for enteropathy, including in Latin America, Africa and
Asia [259] and among Native Americans [260].
Neither of the HBT studies assessed the relationship of the test with growth outcomes in a
statistically interpretable manner. While the Mexican study found normal D-xylose absorption by breath
hydrogen testing in case (and control) subjects, neither this study nor the Brazilian study statistically
analyzed the association between growth and the lactose HBT.
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5.4.2 Stool Reducing Substances
Reducing substances are those that reduce copper salts in a hot solution to a chromogenic less
oxidized state. These substances include glucose, lactose, fructose, galactose, and pentose. Like breath
tests, reducing substances can indicate malabsorption, but also primarily identify maldigestion. This test
has been used for decades to differentiate diarrhea secondary to infection from that caused by
noninfectious intestinal dysfunction, particularly lactose intolerance. A condition of the test is that it must
be performed on liquid stool.
Four studies [43, 58, 132, 138] assessed the prevalence of stool reducing substances to
investigate digestive pathology. The proportion of positive tests for stool reducing substances among
subjects varied widely across studies. Only 3.3% of Brazilian children hospitalized with malnutrition or
persistent diarrhea had positive tests for stool reducing substances (definition of positive not provided)
[138]. In contrast, tests in Haitian children with and without diarrhea were positive for stool reducing
substances in one-third of those with diarrhea and cryptosporidiosis, in two-thirds of those with diarrhea
but no evidence of Cryptosporidium infection, and in nearly half of controls without diarrhea [132], though
the accuracy of this test on non-diarrheal stools is assumed to be inadequate because the non-absorbed
sugars reportedly partition to the aqueous phase [261]. Hence, finding these sugars in solid stools, while
unexpected, probably indicates of some degree of maldigestion. Again, cutoff points defining positivity
were not provided, and there was no statistical difference between groups for this parameter (p=0.2).
Two studies investigated reducing substances among Aboriginal and non-Aboriginal Australian
children with diarrhea; a positive result was defined as stool containing sugar concentrations >0.5 %. In
the first of these, one-quarter of Aboriginal diarrheal cases tested positive for stool reducing substances
[58]. In the subsequent study by the same authors almost one-fifth of children with profuse diarrhea tested
positive [43].
Only one study of reducing substances examined its association with clinical outcomes, and this
study found that the marker was associated with severity of diarrheal illness [58]. The same study found
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that among subjects with diarrhea, a positive test for reducing substances was associated with high L:R
by univariate analysis, but the association did not hold up in their multivariate model. Another study also
examined the association between reducing substances and urinary nitric oxide among Aboriginal and
non-Aboriginal children with acute diarrhea, but found none [43].

5.4.3 Intestinal Disaccharidases
Two studies assessed intestinal disaccharidase activity as a marker of digestive pathology on
jejunal specimens obtained by capsule biopsy--Bolivian children with persistent diarrhea and malnutrition
[109] and Brazilian children with refractory malnutrition [53]. Of note, the latter study utilized a unique
control group, children without severe malnutrition undergoing intestinal resection as part of the
management of their biliary atresia. Both studies assessed the proportion of children with maltase
activities that were below normal, and the Bolivian study also measured sucrase-isomaltase and lactase
activities. Both studies reported similar prevalences of abnormally low maltase activity in approximately
half of the subjects with enteric dysfunction, but only one of these studies provided a defined cut point for
abnormal (<94U/g protein) [53]. The deficiency in other disaccharidase activities was not as prevalent as
that of maltase. In addition to maltase activity, the Brazilian study also measured abundance of
messenger RNA for maltase-glucoamylase (MGA) and sucrase-isomaltase in small intestinal tissue, and
found that they were correlated with the activity of maltase at the messenger RNA abundance.
The Brazilian study found no association between WAZ score and tissue maltase activity (no other
details were provided), while the Bolivian study found that intestinal lactase concentrations were
significantly and positively associated with WAZ and less strongly associated with HAZ at admission.
Unfortunately, they did not detail the magnitude of these associations or report if they assessed maltase
and sucrase-isomaltase association with growth parameters. Because intestinal disaccharidase activity is,
by its nature, measured on intestinal tissue, it was relatively straightforward for these studies to assess
marker association with intestinal histopathology. Maltase-glucoamylase (MGA) mRNA abundances were
strongly correlated with both maltase activity and villous atrophy. The Bolivian study did not attempt to
correlate disaccharidase activity with histopathology.
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5.4.4 13C Assessment in Stool after Lipid Administration
Two studies by the same group of investigators in the same setting [148, 149] with a total sample
size of 32 severely malnourished children assessed digestion by administering radiolabeled lipids. They
then measured the amount of radiolabel excreted in the stool in the forms of triglyceride (TG) and fatty
acid (FA), with recovery of fatty acids interpreted to indicate adequate lipid breakdown but poor absorption
while recovery of triglycerides marked poor digestive function. Both studies found widely varying

13

C in

stool, although the variation was less marked in their later study; however the sample size was only eight
patients [148].
In both of these studies, the majority of excreted 13C was in the form of FA rather than TG,
reflecting a failure of lipid absorption in the face of adequate digestion. Each labeled lipid form (FA and
TG) was found in decreasing concentrations as the study progressed, suggesting improved digestion and
absorption, although concentrations did not differ significantly with time.
The two studies differed in their findings related to small bowel bacterial overgrowth; the first study
[149] found no evidence for bacterial overgrowth while the second [148] did, as measured by the recovery
of label in the stool after ingestion of 13C glycocholate.
The first of these studies [149] additionally investigated fecal fat as a marker and found that it was
associated with concentrations of 13C in stool.

5.4.5 Urinary Lactose:Lactulose Ratio
We considered serum and urinary lactose to be primarily measures of gut permeability, as
described above. As a large molecule, lactose should not enter the system unless there is a permeability
defect. It should be recognized, however, that presence of lactose in the serum or urine could be
complicated by lactase deficiency. However, lactase deficiency without a permeability defect would not be
expected to result in the presence of lactose in the blood or urine. When urinary lactose is normalized
against another marker for permeability, the lactose:lactulose ratio is primarily a marker of lactose
digestion. One study assessed this marker and found that nearly half of subjects had low lactase activity,
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defined as lactose:lactulose ratio >0.4 [124]. Urinary lactose and lactose:lactulose ratios significantly
decreased with age and were significantly elevated among breast-fed compared to non-breastfed infants,
adjusting for age, despite similar intestinal permeability values as measured by L:M. The markers were
not associated with sex, ethnicity, or location. Lactose and lactose:lactulose ratios were not associated
with L:M.

5.4.6 Summary of Markers of Digestion
A broad range of markers was used to assess digestive function in children in resource-limited
settings. Intestinal disaccharidases were affected in subjects with persistent diarrhea and/or malnutrition.
The sucrose and lactose HBTs showed varying degrees of digestive disturbance across studies with
subjects of differing health conditions. Results for maltase activities were consistent across the two
studies in which they were sought in intestinal tissues. Several different methods were used to assess
intestinal enzyme capacity, and results between methods were consistent where comparable.
Few markers of digestion were investigated in relation to biopsy or tests of intestinal permeability.
Breath tests in particular lacked comparison to other standard markers.
Varying associations were observed between markers of digestion and growth parameters. The
sucrose breath test was not associated with growth [159]. The studies of intestinal disaccharidases found
different results for different enzymes; one study found no association between maltase and wasting while
the other found an association between lactase and growth parameters [53, 109]. The relationship
between abnormal markers of digestion and growth outcomes was not reported for either hydrogen breath
tests or stool reducing substances.
The sucrose breath test results were significantly associated with the L:R; the concentration of
exhaled hydrogen was inversely associated with the L:R [159]. This test might be useful as a noninvasive
marker of enteric dysfunction, although replication of these results is needed before a judgment as to their
value can be made.
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5.5 Markers of Intestinal Inflammation and Intestinal
Immune Activation
Eighteen studies utilized a variety of markers that reflect intestinal inflammation or immune
activation among children in resource-limited settings. The data relevant to this review are listed for each
of these studies in Evidence Table 4. Eight types of markers were assessed across the studies, most of
which were examined in stool. Lactoferrin was the most commonly assessed marker among these
reports; nine studies utilized it to assess intestinal inflammation. Additionally, fecal cytokines, leukocytes,
and neopterin were measured in five [101, 131, 132, 137, 140], four [104, 138, 158, 169], and one [15]
studies, respectively. Two studies by the same group of investigators assessed fecal IgE [142, 143].
Intestinal tissue cytokines, immune and inflammatory cell markers, and duodenal aspirate
immunoglobulins were investigated in one study apiece.
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Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
2003
Fortaleza,
Brazil
Alcantara CS et al.
3-43 mo olds
Interleukin-8, tumor recruited from a
shantytown
necrosis factorcommunity who
alpha, and
were screened for
lactoferrin in
immunocompetent enteric pathogens.
hosts with
There was a high
experimental and
prevalence of
Brazilian children
malnutrition among
with acquired
the cases.
cryptosporidiosis
Fecal cytokines and
lactoferrin as
markers of intestinal
inflammation among
children with and
without
Cryptosporidium
parvum.

(Adults
experimentally
exposed to C.
parvum by
ingestion were also
studied; these data
were not included
in this review.)

Design and
Sample Size
Case-control

Biomarker

Stool tests:
• Lactoferrin
n=32;
(17 cases and 15 controls
tested)
n=17 cases with C. • IL-8
parvum:
(13 cases and 15 controls
• 4 with no
tested)
diarrhea
• TNF-α
• 10 with AD
(10 cases and 0 controls
• 3 with PD
tested)
n=15 controls with
no diarrhea or
enteric pathogens
and comparable
HAZ and WAZ
scores to cases

Results

Conclusion

Comments

Lactoferrin positive:
• 12/17 cases
• 1/4 cases without
diarrhea
• 8/10 AD cases
• 3/3 PD cases
• 3/15 controls (p=0.006
compared to cases)

The proportion of
children who tested
positive for fecal
lactoferrin was
greater in those
with
cryptosporidiosis,
especially those
symptomatic with
diarrhea, than in
uninfected controls,
although 20% of
the control group
tested positive.

Direct comparisons
between various
stool tests were
not reported.

IL-8 detectable:
• 3/13 all cases
• 0/2 cases without
diarrhea
• 3/10 AD cases
• 0/1 PD cases
• 6/16 controls (p=0.435
compared to cases)

Fecal IL-8 did not
differ between
those with and
without
TNF-α detectable:
Cryptosporidium
• 0/10 cases
infection. TNF-α
was not elevated
among children
with
Cryptosporidium
infection.
2009
Lusaka, Zambia
Case-control
Endoscopic duodenal
Biopsy findings among the
Mucosal
biopsy:
Zambian compared to the UK architecture was
12.2-19.8 mo olds n=41*;
markedly abnormal
Amadi B et al.
children:
• Histopathology
with PD and
compared to UK
•
Villous
height
reduced
• Densities in lamina propria
controls but did not
Reduced production malnutrition
n=41 cases with
• Crypt depth increased
and crypt epithelium:
admitted to the
vary between
of sulfated
PD and
• Cell proteins:
• ~50% reduction in
marasmus and
glycosaminoglycans malnutrition ward of malnutrition:
crypt:villous ratio
• Glycosaminoglycan
occurs in Zambian a teaching hospital. • 18 with
(GAG)
• Values for lamina propria cell kwashiorkor
children with
marasmus
densities were not reported presentations of
• Enterocyte heparan
malnutrition.
kwashiorkor but not
• 8 with marasmic
sulfate proteoglycan
for UK subjects
marasmus
kwashiorkor
(HSPG)
Inflammatory cell
• 15 with
• Syndecan-1
No significant differences in
Duodenal biopsy
densities were
kwashiorkor
• Inflammatory cell
crypt or villous measures or
generally higher
including
markers:
lamina propria cell densities
compared to UK
assessments of
n=19 healthy
• CD3 IEL
were observed between
children and
intestinal markers in
control children
• Ki67
nutritional groups or after
children with PD and
showed different
from UK
• Human leukocyte
nutritional rehabilitation.

Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution and were
considered
negative if there
was no reaction at
1:25.
Four subjects were
breastfed and were
tested for
lactoferrin.

27 subjects were
HIV positive;
incidence was
lower in the
kwashiorkor group.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
different forms of
malnutrition

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

patterns across the
Intestinal markers:
malnutrition
* UK subjects are
• Inflammatory markers were presentations.
presented in this
seen in higher densities
table due to
compared to the UK children. Tissue
concentrations of
comparisons of
There were significant
HSPG and GAG
interest made in
differences between the
the review.
different nutritional groups in were reduced
However we do not
especially amongst
the specific types of
include these
children with
inflammatory markers.
kwashiorkor.
subjects in the
• There was a significant
sample size for this
reduction in GAGs and HSPG Intestinal protein
review.
markers did not
in the kwashiorkor group
compared to UK children, but differ amongst the
malnutrition groups.
no significant differences
between kwashiorkor and
other presentations of
malnutrition.
• There was no difference in
epithelial syndecan-1 protein
expression between the
malnutrition groups (data not
available for UK controls).
2000
Dhaka, Bangladesh Case-control
Blood tests:
WBC total and differential,
Some immune and The number of
immunoglobulin
subtypes,
inflammatory
controls was
• IFN-γ
7-12 mo olds with n=136;
markers
were
relatively small and
Azim T et al.
cytokines,
transferrin,
and
• TNF-α
6-8 days of watery
associated
with
their nutritional
albumin
did
not
differ
between
• WBC (total and differential)
Immune response of diarrhea attending n=38 cases with
acute
and/or
status was not
cases
with
diarrhea
or
controls,
• IgA
Bangladeshi
the International
persistent
diarrhea.
reported.
PD
nor
did
stool
leukocyte
or
• IgG
children with acute Centre for Diarrheal
erythrocyte counts.
• IgM
Disease Research. n=98 controls:
The only marker
diarrhea who
• Transferrin
The percentages of neutrophils that was
subsequently have
• 85 with AD
• Albumin
significantly
that polarized in response to
persistent diarrhea Cases were those • 13 with no
• Immune function tests:
who went on to
associated with
stimulation
were
significantly
diarrhea
• Neutrophil polarization
progression to PD
Immune activation develop PD,
higher in subjects with AD or
response to chemotactic PD compared to those without was a negative
controls were those
tests, as well as
factor
who did not.
DTH response to
transferrin and
diarrhea; there was no
•
Neutrophil opsonization difference between the two
tuberculin antigen
albumin as markers
to yeast
(odds ratio=3.8, CI:
of nutritional status An additional group
diarrhea groups.
• Mononuclear cell
1.4, 9.9). This was
among children with of subjects without
proliferation,
diarrhea were
calculated from a
and without PD
Opsonization did not vary
spontaneous and in
recruited from a
logistic regression
between any groups.
response to stimuli with
nutrition follow-up
analysis that only
antigen DR-1 (HLADR)

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
unit.

Design and
Sample Size

Prevalence of
malnutrition was
high in all groups.

2007

Goncalves Dias
Cohort
favela in Fortaleza,
Brazil
Bushen OY et al.
n=42
(41 tested)
Heavy
All newborns from
an urban
cryptosporidial
infections in children shantytown were
Stools were
in northeast Brazil: recruited at birth
collected at regular
and followed for up intervals as well as
comparison of
Cryptosporidium
to 4 yr.
during episodes of
hominis and
diarrhea.
Cryptosporidium
This study included
parvum
only children testing
positive for
Fecal lactoferrin as Cryptosporidium.
a marker of
intestinal
inflammation in
children with
Cryptosporidium

Biomarker
mitogens

Results

Conclusion

Comments

Monocyte spontaneous
included children
proliferation counts were less with diarrhea.
than half among children with
no diarrhea compared to those
with AD (p<0.001) or with PD
(p=0.011); there was no
difference between the two
diarrhea groups.

Skin Test:
• Delayed-type
hypersensitivity response
(DTH) to tuberculin,
tetanus, diphtheria,
Streptococcus, Proteus,
Candida, and Trichophyton Monocyte proliferation in
response to stimulation did not
differ between the 3 groups.
Stool tests:
The proportion with DTH
• Leukocytes
responses differed among the
• Red blood cells
three groups only in response
to tuberculin (p=0.021). More
PD subjects had a negative
tuberculin response than did
subjects with AD (p=0.024).
Stool Test:
68.3% were lactoferrinLactoferrin
positive; there were no
differences in positivity
between subjects with C.
hominis and C. parvum spp.
67.9% of lactoferrin-positive
subjects had very high titers.

Lactoferrin was
correlated with
younger age and
symptomatic
infection among
those infected with
C. parvum.

Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution and were
considered
negative if there
Lactoferrin did not was no reaction at
significantly predict 1:50 and highly
growth outcomes. positive at >1:400.

Younger children were more
often lactoferrin-positive
(p=0.03). The difference was
mediated by C. parvum; 87.5% Cryptosporidium
of ≤1 year olds compared to
species-specific
40.0% of older children with C. differences were
parvum were lactoferrinobserved in
positive (p=0.04). There was no lactoferrin results.
In contrast to C.
difference among those
parvum, there was
infected with C. hominis.
no association
Lactoferrin was correlated with between lactoferrin
symptomatic infection among and symptomatic/
those with C. parvum: 78.6% of asymptomatic C.

Data were part of a
larger study;
similar data on
lactoferrin in
Giardia-infected
children was
published by A.
Kohli, et al. (also
included in this
review), using a
slightly different

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

2004

Cohort

Keneba, Gambia

1

Conclusion

hominis infection
(p=0.231). In
addition, similar
proportions of
asymptomatic
Lactoferrin was not correlated children with C.
with degree of oocyst shedding hominis had high
fecal lactoferrin
(p=0.28).
titers as had
Lactoferrin was correlated with undetectable
∆HAZ score among those with results.
C. parvum, although this
observation was not statistically
significant (r=-0.39, p=0.13).

Stool Test:
Neopterin
Urine Tests:
2
• Lactulose
• Mannitol
• L:M

Reported results were adjusted for confounding variables, unless otherwise noted.
Lactulose and mannitol results were expressed as % of dose administered.
3
Geometric mean.
2

Results
symptomatic children
compared to no asymptomatic
children had a positive test
1
(r=0.67, p=0.004 ).

2 mo olds from
n=72
rural area followed
until 15 mo of age.
Intestinal
Subjects were
inflammation
evaluated with
measured by fecal
twice-weekly
neopterin in
questionnaire to
Gambian children
determine diarrhea
with enteropathy:
morbidity, clinic
association with
growth failure,
assessments of
Giardia lamblia, and
growth, and
screening
intestinal
laboratory tests
permeability
every 2 mo.
Fecal neopterin and
L:M as markers of
intestinal
inflammation and
permeability,
respectively, and
their correlation with
growth status and
Campbell DI et al.

Biomarker

Comments

grading scale for
reporting
lactoferrin results
[133]. Rather than
exclude breastfed
children, Bushen et
al. stratified results
on breastfeeding
status and found
no difference in
positive/ negative
results, including
when examined
among younger
and older children.
Mean neopterin concentration L:M and mean fecal Study population
was negatively correlated with neopterin
might have some
concentration were overlap with that of
long-term height (r=-0.29,
Campbell et al.
p<0.009) and weight (r=-0.36, not correlated.
also included in
p<0.007) gain, but not with
Mean L:M in the
this review [110].
giardiasis.
Gambian children
3
was substantially
Mean L:M (CI): 0.31 (0.26,
higher than normal
0.34).
values in children in
the UK. These high
Mean excretion of lactulose
L:M ratios appear
(CI): 0.20 (0.18, 0.23).
to be driven by
mannitol excretion.
Mean excretion of mannitol
(CI): 3.0 (2.8, 3.2).
Mean L:M was negatively
correlated with long-term height
gain (r value not provided,
p<0.0001), but was not
correlated with presence of
Giardia.
L:M and fecal neopterin were

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Design and
Study Outcomes of
Target Population Sample Size
Diagnostic Interest
Giardia recovery in
the stool
2003
Fajara and Sibanar, Case-control
The Gambia
Campbell DI et al.
n=40 cases:
6 mo-3 yr old
• Group 1: n=4
Chronic T cellhospital- and clinic- • Group 2: n=11 (7
based cases from
mediated
with diarrhea)
enteropathy in rural rural communities. • Group 3: n=25
west African
(18 with
children: relationship Case groups based diarrhea)
with nutritional
on differences in
nutritional status: n=34 with case
status and small
bowel function
• WAZ score >-2,
tissue samples
with GI
sufficient for
complaints other cytokine
L:M as a marker of
than diarrhea
immunoreactivity
intestinal
• Grade I protein
tests:
permeability, small
energy
• Group 1: n=3
bowl biopsy with
malnutrition
• Group 2: n=8
assessment of
(PEM) (WAZ
• Group 3: n=23
intestinal immune
score -2 to -4)
markers, and
and
computerized
unresponsive to
morphometric
nutritional
analysis among rural supplements,
Gambian children
with or without
with differing
diarrhea
degrees of
• Grade II PEM
malnutrition and
(WAZ score <-4)
compared to wellwith or without
nourished UK
diarrhea
children
Controls from UK*
who were well
nourished children
with GI complaints
other than diarrhea
and with normal
endoscopy results
1
2

Biomarker

Results

Conclusion

Comments

not correlated (p=0.11).
Endoscopic
small bowel biopsy, site not
specified:
• Histopathology
• Morphometric assessment
by computer analysis*
• Intestinal tissue cytokines
and immune markers:
• CD-3
• CD-4
• CD-8
• CD-19
• CD-25
• HLA-DR
• Perforin
• γδ T-cell receptor
• Syndecan-1
• TNF-α
• IFN-γ
• TGF-β
• IL-10
Urine Tests:
1
• Lactulose
• Mannitol
• L:M
* Biopsy involved
morphometric assessment
by computer analysis of
villous height, crypt depth,
villous:crypt ratio, and
intraepithelial lymphocyte
(IEL) density (per 100
epithelial cells).

Lactulose and mannitol results were expressed as % of dose administered.
These figures are presumed to represent IEL means; however, this was not explicitly stated.

Crypt-hyperplasia and villous
atrophy were observed among
all Gambian subjects, and the
degree of histopathology did
not differ among cases with
differing nutritional status, nor
was there a correlation with
diarrhea.

All Gambian
Statistical
subjects had
methodology was
evidence of
not sufficiently
enteropathy with
detailed to
crypt-hyperplasia determine what
and villous atrophy, was compared
and mean IELs >2 (e.g. type of central
SD above UK
tendency measure
norms, independent and variance
2
of nutritional status calculations for
IEL means were ~3-fold
and diarrhea
L:M not stated).
higher in Gambian than UK
history.
children.
Duration of
Elevation of cellMedian CD3, CD4, CD8,
diarrhea not
mediated intestinal specified, but
CD19, and CD25 cell counts
were significantly higher (2-5x markers and
assumed to be
mucosal
higher) among each case
persistent.
proinflammatory
group compared to the UK
cytokines was
controls.
Mucosal
present across the lymphocyte
IEL, γδ, syndecan-1, HLA-DR, 3 Gambian groups, densities, cytokine
variably correlated immunoreactivity,
and perforin were detected
among the Gambian children in with nutritional
and L:M results
varying degrees but were not status.
were not stratified
reported for UK controls.
by history of
L:M ratios were
Syndecan, CD3, and CD8
diarrhea.
elevated in all
displayed a gradient
Gambian groups,
proportional to malnutrition
without apparent
severity.
correlation to host
nutritional status.
All Gambian groups showed
higher lamina propria cytokineimmunoreactive mononuclear
2
cell density (~200-450/mm )
2
than UK controls (30-80/mm ).
Among subjects with elevated
cytokines, similar densities

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Design and
Study Outcomes of
Target Population Sample Size
Diagnostic Interest
were also studied.

Biomarker

Results

Conclusion

Comments

Differences in
immunoglobulin
concentrations
were limited among
children with PD
infected with
Giardia compared
to children without
such conditions.

The number of
controls was small
due to constraints
in obtaining
duodenal aspirate
from children
without GI
symptoms.

were seen for both proinflammatory (IFN-γ and TNFα) and putative regulatory (IL10 and TGF-β) cytokines.
Epithelial expression of TGF-β
was also enhanced compared
to UK controls, but subjects
with poorer nutritional status
had lower densities of mucosal
TGF-β+ cells, with median
densities of 420 and 250
2
cells/mm in the grade I and
grade II PEM groups,
respectively.

* UK subjects are
presented in this
table due to
comparisons of
interest made in the
review. However
we do not include
these subjects in
the sample size for
this review.

1

L:M values :
• Group 1: 0.53 (0.4-1.3)
• Group 2: 0.47 (0.02-2.20)
• Group 3: 0.73 (0.14-2.2)
• Not assessed among the UK
controls
Nutritional status was not
associated with L:M, recoveries
of lactulose or mannitol.

2001

New Delhi, India

Kapoor S et al.

<12 yr olds
n=40;
admitted to hospital
with PD and
n=30 cases with
Giardia.
PD and Giardia

Giardiasis--clinical
and diagnostic
perspective
Immunoglobulin
concentrations in
1

Case-control

Controls had no
n=10 controls
diarrhea and were without diarrhea
hospitalized for

Duodenal secretion
aspirates:
• IgG
• IgM
• IgA
Blood Tests:
• IgG
• IgM

Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

L:M was correlated with
mucosal B lymphocyte density
(r=0.57, p<0.05), IEL (r=0.51,
p<0.02), and perforin+ IEL (r=0.64, p<0.03).
Higher mean concentrations of
IgM were found in duodenal
aspirates of cases compared to
controls (p<0.05).
Mean concentrations of
duodenal IgA and IgG did not
differ between cases and
controls.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
duodenal fluid and non-GI conditions.
serum among
children with PD and Most cases were
Giardia infection
<7 yr old, with n=19
compared to those <3 yr old. Ages of
controls were not
without diarrhea
specified.
2006
Port-au-Prince,
Haiti
Kirkpatrick BD et al.
<36 month olds
recruited from
Childhood
cryptosporidiosis is GHESKIO HIV
1
Center with
associated with a
persistent systemic Cryptosporidium
infection and
inflammatory
healthy controls.
response
Fecal cytokines and
lactoferrin as
markers of intestinal
mucosal
inflammation among
children with and
without
Cryptosporidium
infection

1

Subjects were
followed-up at 6
and 9 months after
infection resolved.

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

• IgA

Cohort
n=73;
n=42 cases with
diarrhea and
Cryptosporidium
infection
(18 with PD)

Stool Tests:
• Lactoferrin
• Cytokines:
• IFN-γ
• TNF-α
• TGF-β
• IL-4
• IL-8
• IL-10

n=31 healthy
controls without
diarrhea and
Cryptosporidiumnegative

HIV status of
subjects varied.
There was a high
prevalence of
malnutrition in the
study population.

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Proportion lactoferrin-positive
at enrollment:
• Cases: 51.2%
• Controls: 4.0%

Lactoferrin was
present among half
of subjects with
cryptosporidiosis
and uncommon
among those
Cases had higher
concentrations of TNF-α than without such
controls at enrollment (p=0.04), infection.
but no difference was observed
Fecal TNF-α was
at follow-up.
higher among
Controls had almost 2x higher cases at enrollment
but did not persist
fecal IFN-γ at enrollment
when infection
(p=0.1); the magnitude of
difference increased (to almost resolved.
3x) and was statistically
Paradoxically,
significant at the 6- and 9controls’
month follow-up (p=0.01 and
comparatively
p=0.03, respectively).
higher fecal IFN-γ
increased in both
No differences in fecal
concentrations of TGF-β, IL-8, magnitude and
degree of statistical
IL-4, or IL-10 were noted
significance at
between groups.
follow-up.

Cut-off values for
lactoferrin positivity
were not provided.
Breastfed children
(>85% of cases
and controls) were
included in testing.
Proportions at
follow-up were not
reported.
The association of
fecal cytokines and
lactoferrin with
growth
parameters, history
of PD, and HIV
status were not
reported, nor was
their association
with each other.

Various markers of
systemic
inflammation,
Of the remaining
including serum
fecal cytokines
cytokines, were
assessed, there
measured but their
were no differences relationship with
between cases and markers of
controls.
intestinal
inflammation was
not reported.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

2002

Case-control

Kirkpatrick BD et al.

Port-au-Prince,
Haiti

<18 mo olds from a
low SES setting
Cryptosporidiosis
recruited from the
stimulates an
rehydration unit of
inflammatory
intestinal response GHESKIO HIV
1
Center with
in malnourished
diarrhea and
Haitian children
Cryptosporidium
infection. Controls
Stool lactoferrin,
recruited from an
reducing
outpatient clinic
substances,
without
leukocytes and
Cryptosporidium
cytokines as
markers of intestinal infection included
those with and
inflammation of
without diarrhea.
children with and
without
Cryptosporidium
infection

n=49;
n=17 cases with
Cryptosporidium
and diarrhea (5
with PD)

Biomarker

Results

Stool Tests:
• Reducing substances (RS)
• Lactoferrin
• Cytokines:
• TNF-α receptor I
• IL-4
• IL-8
• IL-10
• IL-13
• IFN- γ

Proportion RS-positive:
• 33.3% cases
• 64.7% diarrhea controls
• 46.7% healthy controls,
(p=0.2)

n=32 controls
without
Cryptosporidium;
• 17 with diarrhea Blood Test:
(5 with PD)
• WBC
• 15 healthy

Conclusion

Comments

Fecal lactoferrin
Reported results
was identified most were not stratified
often in children
by persistent vs.
with diarrhea,
acute diarrhea
especially in those status.
with
Proportion lactoferrin-positive: Cryptosporidium. Cut-off values for
While some fecal lactoferrin positivity
• 83.3% cases
cytokines were
were not
• 60.0% diarrhea controls
detected
in
as
described.
• 28.6% healthy controls,
many as 40% of
(p=0.01)
healthy controls
Stools from
and
70%
of
controls
children who were
IFN-γ was not recovered in any
with
diarrhea,
they
breastfeeding were
stools.
were generally
not tested for
associated
with
lactoferrin.
All other fecal cytokines were
Cryptosporidium
significantly associated with
infection. The other
Cryptosporidium cases
stool tests did not
compared to diarrhea and
discriminate by
healthy controls.
diarrhea or
Additionally, TNF-α receptor I, Cryptosporidium
IL-8, and IL-13 were found in status.
diarrhea and healthy controls,
while IL-4 and IL-10 were not.
Fecal lactoferrin was
associated with the presence of
TNF-α receptor I (point
estimate not provided, p=0.03).

2008

Goncalves Dias
Cohort
favela in Fortaleza,
Brazil
Kohli A et al.
n=108 stool
samples from 47
Giardia duodenalis All newborns from children
assemblage, clinical an urban
presentation and
shantytown were
Stools were
1

Stool Test:
Lactoferrin

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Mean WBC counts were within
normal range in all 3 groups.
Proportion of positive
lactoferrin results decreased
with each new Giardia
infection, p=0.015:
st
1.1 infection: 74.0% (15.2% of
those testing positive had
high titers)

Increased
concentrations of
lactoferrin were
observed more
frequently with first
time Giardia
infections.

Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution; the
following scale was

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
markers of intestinal
inflammation in
Brazilian children

Location and
Target Population

recruited at birth
and followed for up
to 4 yr. Those with
Giardia recovered
Fecal lactoferrin as from stools were
included in this
a marker of
study.
intestinal
inflammation in
Giardia-infected
children and its
association with
persistence of
diarrhea

Design and
Sample Size

Biomarker

Results
nd

collected at regular
intervals as well as
during episodes of
diarrhea.

2.2 infection: 40.0% (5.3% of
those testing positive had
high titers)
rd
3.3 infection: 1 (20.0%) tested
positive (at a high titers)
Increasing titers of lactoferrin
were associated with longer
duration of diarrhea, p=0.017:
• Negative: 2.2 days
• Low: 9.7 days
• High: 14.6 days
Lactoferrin results did not differ
between symptomatic and
asymptomatic children at first
infection, but those with
symptoms had positive results
with recurrent infections with
greater frequency (75.0% vs. 0
in asymptomatic repeat
infections, p=0.017.)

2010

Fortaleza, Brazil

RCT

2 mo-9 yr olds
n=79;
(mean 43 mo) from
Effects of vitamin A an impoverished
n=40 received
supplementation on urban community, placebo
eligible if HAZ
intestinal barrier
(tocopherol)
score was <median
function, growth,
total parasitic, and for their community. n=39 received
specific Giardia spp
vitamin A (retinyl
Lima AA et al.

1

Urine Tests:
1
• Lactulose
• Mannitol
• L:M

Median L:M at baseline was
0.089. There was no significant
change in L:M at 4 mo followup within either treatment
group.

Stool Tests:
• Lactoferrin
• Cytokines:
• IFN-γ

No significant difference in L:M
was observed between
treatment groups.

For lactulose and mannitol results, excretion measurement was not specified.

Conclusion

Comments

Concentrations
used:
were associated
• High = positive
with longer duration at 1:400-1:3200
of diarrhea,
dilution
although these
• Low = positive at
results were not
1:25-1:200
presented
• Negative = no
separately for first
reaction at 1:25
and recurrent
infections.
Stools from
children who were
Stool lactoferrin
breastfeeding were
might be useful in not tested.
predicting duration
of diarrheal illness Data were part of a
in G. duodenalis- larger study;
infected children. similar data on
lactoferrin in
Cryptosporidiuminfected children
were published by
O.Y. Bushen, et al.
(also included in
this review);
however, Bushen
et al. used a
slightly different
grading scale for
reporting
lactoferrin results
[108].
Frequency of stool Authors did not
lactoferrin varied
report testing for
between 23%-32%. associations
between urinary
While vitamin A
markers of
supplementation
intestinal
was associated
permeability and
with reduced
concentrations of
lactulose excretion, fecal cytokines, or
it was also
between these

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
infections in
Subjects were
Brazilian children: a screened for
intestinal parasites,
prospective
randomized, double- and longitudinal
anthropometrics
blind, placebowere assessed.
controlled trial

Design and
Sample Size
palmitate)
Subjects were
treated every 4
mo.

Biomarker
• TNF-α
• IL-4
• IL-10

Results

Conclusion

Comments

Both median lactulose and
mannitol excretions decreased
at 4 mo follow-up among the
vitamin A compared to the
placebo group:
• Lactulose: 0.21 to 0.74,
p=0.042
• Mannitol: 3.06 to 8.25,
p=0.008

associated with
reduced mannitol
excretion, with no
overall effect on
L:M.

markers and
growth parameters
or parasitosis.

Cut-point values
for lactoferrin
Vitamin A
positivity and
L:M as a marker of
supplementation
abnormal L:M were
was not associated not described.
intestinal barrier
with presence of
function, and stool
Exclusively
lactoferrin and
Overall proportion of lactoferrin lactoferrin or
intestinal
cytokine
breastfed children
specific intestinal
was 23% initially. At 1 mo
response.
were excluded
immunological
follow-up, there was no
from study
cytokines as
difference in prevalence
participation due to
markers of intestinal
between vitamin A (33%) and
assessment of
inflammation among
placebo (31%) groups.
nutritionally at-risk
stool lactoferrin.
children who
Cytokine concentrations did not
received either
significantly differ between
vitamin A or placebo
placebo and vitamin A groups.
2
2005
Fortaleza, Brazil
RCT
Urine Tests*:
Mean L:M (SE):
L:M significantly
The relationship
1
improved in the
between stool
• Lactulose
• Glutamine group:
2-60 mo olds
glutamine group
markers and L:M
Lima AA et al.
n=80;
• Mannitol
• Baseline: 0.31 (0.10)
hospitalized with
only.
was not reported.
(similar in all three
• L:M
WAZ score <-2,
Intestinal barrier
n=53 received
groups)
>50% of subjects Data were not
function and weight ~70% of whom had supplemented
• Day 10: 0.10 (0.02);
gain in malnourished PD.
had intestinal
stratified by history
formula
Stool Tests**:
significant decrease,
children taking
inflammation by
of PD.
• 27 with glycine • Lactoferrin
(p=0.01)
stool lactoferrin.
glutamine• 26 with glutamine • Leukocytes
• No significant decrease in
Fecal leukocytes, Fecal fat was
supplemented
L:M in glycine and
• Occult blood
RS, and occult
assessed, but
enteral formula
n=27 received
nonsupplemented
formula
• Reducing substances (RS)
blood
were
results were not
nonsupplemented
groups at day 10
detected in fewer reported.
L:M as a marker of
formula
subjects than
intestinal
* n=80 tested at enrollment, Mean lactulose (SE):
lactoferrin.
Cut-off values for
permeability and
• Glutamine group:
n=65 tested at day 10.
lactoferrin positivity
various stool tests
• Baseline: 0.97 (0.46)
were not
among children with
(similar in all three
** n=60 tested.
described.
malnutrition or PD
groups)
who received either
• Day 10: NS decrease in
Exclusively
glycine or glutamine
all 3 groups
1
2

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
supplemented
formula or placebo

2006
Long KZ et al.
The effect of vitamin
A supplementation
on the intestinal
immune response in
Mexican children is
modified by
pathogen infections
and diarrhea
Fecal cytokines as
markers of intestinal
mucosal immune
activation in children
with and without GI
pathogens receiving
vitamin A or placebo

1

Mexico City,
Mexico
All 5-15 mo olds
within a periurban
community were
eligible to be
screened for
participation.

Design and
Sample Size

Biomarker

Results

Conclusion

Mean mannitol (SE):
• Glutamine group:
• Baseline: 3.42 (0.64)
(similar in all three
groups)
• Day 10: NS decrease in
all 3 groups

RCT

Stool Tests:
Cytokines:
• IL-4
n=505 stool
samples from 127 • IL-6
• IFN-γ
children;
n=243 stool
samples from 57
who received
vitamin A
supplementation
n=262 stool
samples from 70
who received
placebo
Participants were
followed regularly;
diarrhea history
was tracked and
stool samples were
tested.

Proportion of stool markers at
baseline among all subjects:
• Lactoferrin: 53.3%
• Leukocytes: 11.7%
• RS: 3.3%
• Occult blood: 5.0%
Positive tests for fecal
cytokines:
• IL-4: ~55%
• IFN-γ: ~50%
• IL-6: ~40%

Differences in fecal
cytokine
concentrations due
to vitamin A
supplementation
were observed only
in the subset of
There were no significant
subjects with GI
differences in proportions of
these fecal cytokines between infection or
diarrhea.
vitamin A-supplemented and
placebo subjects.
Vitamin A-supplemented
children with diarrhea had
lower median IFN-γ
concentrations (odds
1
ratio =0.51; CI: 0.26, 0.99) and
higher IL-4 concentrations
(odds ratio=2.14; CI: 0.94,
4.87) compared to children with
diarrhea in the placebo group
in a nonrandomized analysis.
IL-6 concentrations did not
differ in this analysis. There
were no differences between
the two groups among those

Comments
breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.

Pre-intervention
fecal cytokine
concentrations
were not reported.
Differences in fecal
cytokines between
all subjects with
and without GI
infections or
history of diarrhea
were not directly
reported; all
differences were
described in terms
of vitamin A
interaction.

The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

2001

Design and
Sample Size

Biomarker

Conclusion

Comments

without diarrhea.

Nested caseStool Test:
IgE
control within a
Mahmud MA et al. Newborns recruited cohort study
at birth from a rural
Sociodemographic, village and followed n=392 episodes of
environmental and for the first year of diarrhea (including
41 episodes of PD)
clinical risk factors life.
among 152
for developing
infants* )
persistent diarrhea Surveillance of
among infants in a diarrhea symptoms
rural community of identified 392
episodes of
* Stool samples
Egypt
diarrhea, 41 (11%) from each PD
of which were
episode were
Stool IgE as a
persistent.
counted as a case
marker of
for analysis and
gastrointestinal
compared to
allergy and its
randomly selected
association with
AD episodes and
persistent vs. acute
to non-diarrheal
diarrhea
samples.

Bilbeis, Egypt

2001

Bilbeis, Egypt

Mahmud MA et al.

Newborns recruited n=152
at birth from a rural followed for 29,036

1

Results

Cohort

Stool Test:
IgE

Reported results were adjusted for confounding variables, unless otherwise noted.

Differences in median
concentrations of fecal
cytokines by types of enteric
pathogens were also observed.
Fecal IgE was detected more
frequently in stools from
episodes of PD compared to
episodes of AD: odds ratio
1
(CI) =3.3 (1.0, 10.9).

Fecal IgE was
Sampling was
detected 3 times
based on episodes
more frequently
of diarrhea within a
during episodes of cohort of infants;
PD than AD and 5 individual infants
times more
could have
Fecal IgE was detected more frequently in PD
contributed more
stools than in stools than one diarrheal
frequently in stools from
episodes of PD than in stools from those without episode.
Additionally, it
from children without diarrhea: diarrhea.
appears that an
odds ratio (CI)=4.84 (1.1, 21.7).
individual could
also have been
included as a case
of PD, a control
with AD, or a nondiarrhea stool
within the same
analysis.

Overall incidence of fecal IgE: Substantial
0.39/child-year
incidence of fecal
IgE was observed
By age group:
in this setting in

Study population
appears to be the
same as in another
Mahmud, et al.
study also included
in this review
which reported the
prevalence of fecal
IgE by gender and
age within the
cohort [143].
Study population
appears to be the
same population
as in another

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
Increased fecal IgE village and followed
among infants in a for the first year of
rural community of life.
Egypt: an analysis of
associated risk
factors
Fecal IgE as a
marker of intestinal
inflammation among
children with
diarrhea
2001
Dhaka,
Bangladesh
Rabbani GH et al.
2-6 yr olds with
Increased nitrite and cholera or
nitrate
shigellosis admitted
to the hospital.
concentrations in
sera and urine of
patients with cholera Controls were
or shigellosis
recruited from the
healthy attendants
To assess and
of patients or from
compare nitric oxide children of hospital
staff.
as a marker of
intestinal
inflammation among Mean age (SD) in
children with cholera yr:
or shigellosis or
• Shigellosis
healthy controls.
cases: 3.8 (1.2)
Evaluated to assess • Cholera cases:
4.2 (1.4)
nitric oxide
• Controls: 4.7
production during
(1.8)
infection of small
bowel without
inflammatory lesion
(e.g., cholera) and
during infection
causing colon
inflammation (e.g.,
shigellosis).

Design and
Sample Size

Biomarker

infant days

•
•
•
•

Stools were
collected during
episodes of
diarrhea.

Case-control
n=63;
n=45 cases:
• 24 with cholera
• 21 with
shigellosis
n=18 healthy
controls
Samples were
collected from
cases on
admission
and upon
discharge (after 710 days of
treatment).

Results
< 3 mo: 0.28/child-yr
3-6 mo: 0.42/child-yr
6-9 mo: 0.16/child-yr
>9 mo: 0.12/child-yr

Conclusion

Comments

infants.

Mahmud, et al.
reference also
included in this
review which
assessed the
relationship
between fecal IgE
and PD [142].

IgE incidence
peaked at 3-6 mo
of age.

Relative risks (CI):
• 3-6 compared to >9 mo olds: Male gender was
associated with
3.28 (1.03, 13.60)
fecal IgE.
• Male gender: 1.82 (0.83,
4.18)
Urine Test:
Nitric Oxide (NO)*
Blood Tests:
• Nitrite (NO2)
• Nitrate (NO3)
• WBC
Stool Test:
Leukocytes
* Nitric oxide (NO) is an
unstable free radical that is
converted to nitrite and
nitrate. Urine NO2 + NO3
were expressed as a ratio
with urine creatinine in order
to account for differences in
urine concentration.

In children with shigellosis,
median serum NO was ~8x
higher at baseline than in
controls and significantly
differed from convalescent
concentrations (p<0.01).
Concentrations declined by
52% of baseline during the
recovery period but did not
return to values found in the
controls (measure of statistical
significance not reported).
In children with cholera,
median serum NO
concentrations at baseline
were ~4x higher than in control
subjects. Recovery
concentrations decreased 52%
from baseline (p<0.01);
convalescent values did not
differ from the values in
controls (p<0.4).
Median urinary NO ratios were
similar among those with
Shigella and V. cholerae
infection, both upon admission
and discharge. Initial values
were ~2x higher than upon
discharge (p<0.05 and 0.01,

NO as measured
by both serum and
urinary NO2 and
NO3 concentrations
was significantly
elevated at
presentation during
acute illness
compared to 7-10
days after
hospitalization in
both cholera and
shigellosis.

Some values
reported in table
format conflict with
the text; columns
of data appear to
be transposed.

Assessment for
NO correlation with
fecal leukocyte
counts was not
reported, nor was
the correlation
between urinary
Median serum NO NO and total blood
concentrations in WBC.
cholera patients
were ~half of those
with shigellosis
both upon
admission and
upon discharge and
concentrations
were much higher
in cases than in
controls, Such
striking differences
were not observed
for urinary NO
results.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

Biomarker

Results

Conclusion

respectively). Control median
NO was of an intermediate
concentration between cases’
admission and discharge
median concentrations; the
difference between control and
case admission values was
NS.

Serum NO
concentrations
correlated with total
blood WBC in
shigellosis cases.

Comments

Mean blood WBC counts (SD):
• Shigellosis: 19.6 (3.3)
• Cholera: 8.3 (2.8)
• Controls: 7.1 (1.8)
Mean fecal WBC/high power
field (SD):
• Shigellosis: 38 (17)
• Cholera: 5 (2)
• Controls: 3 (1)

2006

Vhembe, South
Africa

Cross-sectional

n=26 <5 yr old:
0.1-88 yr olds from • 22 hospitalCryptosporidium
semi-urban
based subjects
species: preliminary community included • 4 school-based
subjects
descriptions of the patients
hospitalized with
prevalence and
genotype distribution diarrhea or other GI
among school
complaints as well
Samie A et al.

Stool Test:
Lactoferrin

Serum NO correlated with
blood WBC count in shigellosis
2
cases at baseline (r =0.92,
p<0.01), but only to a slight
degree upon discharge
2
(r =0.26, no p-value reported)
and there was no correlation
among the cholera cases.
Serum NO correlated with stool
volume at presentation
2
(r =0.85, statistically significant
per authors, p-value not
reported).
16/22 patients and 0/4 students Lactoferrin
Among the entire
were lactoferrin positive.
prevalence was
study cohort of all
high among
ages, lactoferrin
While examination of lactoferrin children
results were similar
association with history of
hospitalized with
among
diarrhea or other GI hospitalized
diarrhea or with
Cryptosporidium infection was symptoms,
patients regardless
of Cryptosporidium
regardless of
not reported, only 3/22 and
status (influence of
16/22 hospitalized patients and Cryptosporidium
2/4 and 3/4 school children
status.
HIV infection was

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
children and hospital as students
patients in the
attending nearby
schools.
Venda region,
Limpopo Province,
South Africa

Design and
Sample Size

Biomarker

were positive for
Cryptosporidium and had a
history of diarrhea,
respectively.

Stool lactoferrin as a
marker of intestinal
inflammation among
hospitalized patients
and school children

2008

Fortaleza, Brazil

Cross-sectional

2 mo-9 yr olds
n=102
(mean age 41 mo)
Carotenoids, retinol, from an
and intestinal barrier impoverished urban
function in children community, eligible
if HAZ score
from northeastern
<median
Brazil
for their community.
L:M as marker of
intestinal barrier
function, fecal
lactoferrin and
leukocytes as
Vieira MM et al.

1

Results

Urine Tests:
1
• Lactulose
• Mannitol
• L:M
(97 tested)
Stool Tests:
• Lactoferrin
(93 tested)
• Leukocytes
lood Tests:
• C-reactive protein (CRP)

Lactulose and mannitol results were expressed as % of dose administered.

Conclusion
Lactoferrin was not
found among
school-recruited
children, most of
whom did have a
history of diarrhea.
Two of the four
school children
were
Cryptosporidiumpositive.

Comments
not reported).
Among school
children, lactoferrin
was more
frequently found to
be positive among
those infected with
Cryptosporidium;
statistical testing
was not reported.
Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution and was
considered
negative if there
was no reaction at
1:25.

Some subjects
were breastfed and
were tested for
lactoferrin.
48.5% had abnormal L:M.
Almost half of
L:M threshold for
subjects had
abnormal values
increased L:M, and was defined as
L:M and excretion of each
sugar separately did not vary ~40% of subjects >0.0864 [214]. Cuthad increased
off values for
with retinol concentration.
lactoferrin.
lactoferrin positivity
L:M was associated with levels
were not
of common dietary carotenoids, While serum retinol described.
primarily driven by lactulose.
concentrations
Relationships
However, the association was were not
associated with
between acute
not always statistically
phase proteins and
significant, and the direction of L:M, serum
association varied depending carotenoids were; measures of
authors suggest
intestinal
on precursor.
that these retinol
permeability or

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
markers of intestinal
inflammation, and
CRP and AGP as
acute phase
reactants among
children with varying
vitamin A status

Design and
Sample Size

Biomarker

Results

Conclusion

• α-1-acid glycoprotein
(AGP)

40% of stool samples were
positive for lactoferrin.

precursors might be inflammation were
more sensitive
not reported.
predictors of
Relationships
impaired intestinal between L:M and
function. However, lactoferrin or fecal
the reported
leukocytes as well
direction of
as those between
association varied, retinol or
making
carotenoids and
interpretation of
lactoferrin or fecal
these results
leukocytes were
unclear.
not reported.

1% of stool samples were
positive for fecal leukocytes.
30% of stool samples were
positive for parasites but this
had no impact on L:M results,
lactoferrin, or acute phase
reactants.

Comments

Exclusively
breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.5.1 Fecal Lactoferrin
Fecal lactoferrin reflects infiltration of intestinal mucosa by polymorphonuclear
neutrophils. The lactoferrin test might be more sensitive than assays for detection of leukocytes
in stool because the former does not rely on the detection of whole cells, or on visualizing
technology and trained observers. Its usefulness as a marker is enhanced by its relative stability
in feces at room temperature.
We reviewed nine studies that utilized stool lactoferrin as a measure of intestinal
inflammation. Populations in two of these studies appear to overlap [108, 133].

5.5.1.1 Prevalence of Fecal Lactoferrin
The proportion of lactoferrin-positive stools varied widely across publications whose
study populations also varied in terms of nutritional status and health conditions such as
diarrhea symptoms and infection with enteric parasites. The proportion of subjects whose stools
tested positive for lactoferrin ranged from 13 to 74% [132, 133].
Two studies assessed stools of children whose HAZ scores were below the median and
found that 23 to 40% were lactoferrin-positive [137, 169]. Another study found that 53% of
subjects with malnutrition or persistent diarrhea had lactoferrin in their stools [138]. Samie et al.
measured lactoferrin in 26 stools of children hospitalized with diarrhea or other gastrointestinal
complaints and in stools of four primary school children, three of whom had diarrhea at the time
of testing [162]. None of the schoolchildren and 73% of the inpatients had lactoferrin in their
stools.
Several studies measured stool lactoferrin in children with parasitic infections. The
proportion of Brazilian children infected with Giardia whose stools tested lactoferrin-positive
decreased with each subsequent infection [133]. At first infection, 74% of subjects’ stools were
lactoferrin positive, 15% of which had high lactoferrin concentrations, defined as 1:400-1:3200
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dilution in an agglutination reaction. At second infection, 40% were positive, of which 5% had
high concentrations of this marker. At third infection, 20% tested positive, all of which had a high
concentration of lactoferrin. Interestingly, lactoferrin results did not differ between symptomatic
and asymptomatic children at first colonization by these parasites, but those with symptoms
were more likely to produce stools that tested positive with recurrent infections. In a study
among children from an impoverished Brazilian community with HAZ scores less than the
median, nearly one-third of stools were positive for parasites, but parasitic infection was not
associated with presence of stool lactoferrin [169].
Four studies measured stool lactoferrin in children with Cryptosporidium infection. One
study tested stool lactoferrin in infants and children with Cryptosporidium parvum diarrhea,
controls with diarrhea of different etiology, and healthy controls [132]. Lactoferrin was detected in
60% of stools from C. parvum-infected cases, 35% of diarrhea control stools, and 13% of
healthy control stools. This difference across groups was statistically significant. Two other
studies also found that the proportion of subjects with lactoferrin-positive stools was about 50
percentage points higher among cases compared to controls [101, 131]. Bushen et al. reported
lactoferrin results only on Cryptosporidium-infected children; 68% were positive for lactoferrin
and 68% of these subjects tested positive at a high titer, defined as positive at >1:400 dilution
[108]. There were no differences in prevalence of lactoferrin-positivity between subjects with C.
hominis and C. parvum spp.

5.5.1.2 Associations between Fecal Lactoferrin and Growth or Other
Outcomes
Fecal lactoferrin did not significantly predict growth outcomes in the one study that
assessed this relationship [108]. This was also the only study to assess the marker’s relationship
to breastfeeding and age. While there was no association with breastfeeding, younger subjects’
stools were significantly more likely to be lactoferrin-positive. This difference, however, was
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mediated by C. parvum; there was no age-associated difference among those infected with C.
hominis.
Three studies found significant associations between fecal lactoferrin and
cryptosporidiosis [101, 131, 132]. A fourth study reported a high proportion of positive stools
from infected subjects but did not enroll uninfected children, so assessment of association with
presence of infection was not possible [108]. That study did, however, test the relationship of
fecal lactoferrin with oocyst shedding and found no association. A fifth study that had a small
proportion of subjects infected with Cryptosporidium species did not report examining for
association with fecal lactoferrin and infection, but based on the numerical data presented such
an association was not mathematically possible [162].
Fecal lactoferrin was used as an outcome measure in one intervention trial testing the
efficacy of vitamin A supplementation on intestinal barrier function, growth, and intestinal
parasite infections [137]. No difference was observed in fecal lactoferrin results among treatment
and placebo groups.

5.5.1.3 Association between Fecal Lactoferrin and Other Markers
Despite the number of studies that utilized fecal lactoferrin, only one study examined the
association between fecal lactoferrin and another biomarker and found that fecal lactoferrin was
significantly associated with the presence of tumor necrosis factor-α receptor I (TNF-αRI).
Although the investigators also tested for other fecal cytokines, leukocytes and reducing
substances, they did not report attempts to associate lactoferrin presence or concentration and
these other markers in these subjects [132].

5.5.1.4 Methodological Issues with the Fecal Lactoferrin Test
The stool lactoferrin assay was generally performed with commercial kits. Methods
described were similar across studies and results graded based on agglutination reaction
positivity with increasing dilution. Six studies did not clearly report their cutoff for a positive test
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[131, 132, 137, 138, 162, 169]. Two studies defined a positive threshold as a titer of >1:50 [101,
108], another as >1:25 [133]. Two studies defined high titers of positivity to be values >1:400
[108, 133].
Ingestion of breast milk might cause lactoferrin to be detected in the stool, in the absence
of intestinal inflammation. Most of the lactoferrin studies in this review did not discuss this
potential issue within the context of their research. One study that tested a wide age range of
subjects did not mention the breastfeeding status of those being tested [162]. Five of the studies
excluded breastfeeding subjects from lactoferrin testing [132, 133, 137, 138, 169]. Several
studies, however, tested fecal lactoferrin in subjects known to be breast feeding [101, 108, 131],
and one of these studies assessed the association between breastfeeding and stool lactoferrin
but found none [108].

5.5.2 Fecal Cytokines
Five studies [101, 131, 132, 137, 140] measured concentrations of stool cytokines as
indicators of intestinal inflammation; four of these studies investigated fecal cytokines in relation
to gastrointestinal infection [101, 131, 132, 140]. The most commonly measured fecal cytokines
were IFN-γ, TNF-α or TNF-αRI, and IL-4; each was assessed in four studies. IL-8 and IL-10
were each measured in three studies, while TGF-β, IL-6 and IL-13 were each measured in one.

5.5.2.1 Prevalence of Fecal Cytokines
Three of the five studies of fecal cytokines reported the proportion of subjects with
positive tests. The proportion of samples with detectable cytokines in stool varied widely by
cytokine and by study, ranging from 3% for IL-4 [132] to 55%, also for IL-4 [140]. In a study of
children with and without gastrointestinal pathogens, about half of the stool samples were
positive for IL-4, IFN-γ, and/or IL-6, respectively [140]. In contrast, in a study that measured a
panel of cytokines in the stools of children with and without diarrhea, IFN-γ was not recovered in
any stools and IL-4 was only detected in 3% of samples [132]. Only IL-13 and TNF-αRI were
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detected in a substantial proportion of these subjects’ stools; the former was detected in 32%
and the latter in 52%. IL-8 was detected in 15% and IL-10 in 12% of stools. At 4-month follow-up
in a subset of subjects, IL-8 was found in 6% and IFN-γ, IL-4, and IL-10 were not found in any
stools. Among subjects in whom TNF-αRI was detected in stool during acute infection, this
cytokine persisted at lower concentrations in stools of 50% of cases but was not detected in
stools of controls. Some subjects previously negative for fecal TNF-αRI were positive at followup. In a study of fecal IL-8 and TNF-α in children with or without C. parvum infection, IL-8 was
detectable in 31% of subjects without significant differences based on infection status [101].
TNF-α was only investigated in infected children and was detected in stools of 40%, all of whom
had acute diarrhea; however, none had high fecal concentrations of the cytokine.

5.5.2.2 Associations between Fecal Cytokines and Growth or Other
Outcomes
None of the studies of fecal cytokines reported assessment of their relationship to growth
outcomes in the children studied.
Three studies investigated the relationship between fecal cytokines and Cryptosporidium
infection. While IFN-γ was not identified in any stools in a Haitian study, fecal TNF-αRI, IL-8, IL13, IL-4 and IL-10 were significantly associated with C. parvum infection [132]. Interestingly,
some of these cytokines (TNF-αRI, IL-8, IL-13) were found in children with non-Cryptosporidium
diarrhea and in children without diarrhea while other cytokines (IL-4 & IL-10) were not. Fecal
cytokines were not associated with presence of co-pathogens in the stool. A subsequent study
by the same investigators measured concentrations of IFN-γ, TNF-α, TGF-β, IL-4, IL-8, and IL10 at multiple time points over nine months in stools of children with and without
Cryptosporidium infection [131]. In contrast to their previous study, there were no differences in
fecal concentrations of TGF-β, IL-8, IL-4 or IL-10 between those children with and without
Cryptosporidium infection. Also, in contrast to their previous study, IFN-γ was detected and
concentrations in stools of controls were almost double those of cases at enrollment, but this
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difference was not statistically significant. At six- and nine-month follow-up, however,
concentrations in stools of controls increased to almost triple that of cases and the difference
was significant. Fecal TNF-α was only assessed in the second study; those with
cryptosporidiosis had significantly higher concentrations at enrollment, but this did not persist at
follow-up, i.e., after infection had resolved. A Brazilian study only measured TNF-α among 10 C.
parvum-infected children and found no samples with elevated concentrations. IL-8 was
measured among those with and without C. parvum infection, but the proportions of those with
detectable serum concentrations did not differ between the groups [101].
Two randomized, controlled trials of vitamin A supplementation used fecal cytokines as
outcome measures [137, 140]. In one, IL-4, IL-6 and IFN-γ were measured as the primary
endpoints of the intervention in children with and without gastrointestinal pathogens [140].
Overall no significant difference was observed in stool cytokine concentrations between vitamin
A-supplemented and placebo subjects. However the relationship between fecal cytokine
concentrations and vitamin A supplementation was modified by both gastrointestinal infection
and diarrhea. Similarly in the second study, vitamin A supplementation was not associated with
an intestinal cytokine response [137].

5.5.2.3 Associations between Fecal Cytokines and Other Markers
Fecal cytokines were compared to other markers in only one of these studies, finding that
TNF-αRI was significantly associated with fecal lactoferrin [132].

5.5.3 Fecal Leukocytes
Four studies collected data on stool leukocytes. Two of these studies reported the
proportion of tests positive for the presence of leukocytes. These values ranged from 1% among
children with HAZ scores below the local median [169] to 11.7% among children hospitalized
with malnutrition or persistent diarrhea [138]. Two studies compared fecal leukocytes across
subject groups with different gastrointestinal conditions. In one study, where neither proportions
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of positive nor fecal leukocyte counts were reported, the investigators found that fecal leukocytes
did not differ between children with acute diarrhea, some of whom went on to develop persistent
diarrhea, and controls without diarrhea [104]. The second of these two studies found that mean
fecal leukocyte counts were nearly eight times higher in shigellosis cases than in cholera cases
and nearly 13 times higher in shigellosis than in healthy controls [158].

5.5.4 Fecal Neopterin
One study measured fecal neopterin as an indicator of intestinal inflammation, following
subjects from 2-15 months of age [15]. No association was observed between L:M and fecal
neopterin. Mean neopterin concentrations were negatively associated with long-term height gain,
but were not associated with Giardia recovery in stools.

5.5.5 Fecal IgE
Two studies assessed fecal IgE as a marker of intestinal inflammation; both appear to
have been conducted on the same population. The first was a community-based cohort study
that investigated incidence of fecal IgE by gender and age group [143]. The incidence of fecal
IgE was substantial, at 0.39/child-years, and peaked at 3-6 months of age. The second study
assessed the relationship between stool IgE and persistent and/or acute diarrhea [142]. Fecal
IgE was detected greater than three times more frequently among stools from episodes of
persistent diarrhea compared to stool from episodes of acute diarrhea (OR (95% CIs) =3.3 (1.0,
10.9)) and nearly five times more frequently in persistent diarrhea stools than in stools from
those without diarrhea (OR (95% CIs) =4.8 (1.07, 21.7)).

5.5.6 Inflammatory Intestinal Cell Markers
One study assessed inflammatory cell markers in intestinal tissue [103]. Densities of cell
proteins and inflammatory markers in the lamina propria and crypt epithelium in Zambian
children with persistent diarrhea and different forms of malnutrition were compared across
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groups and to those in healthy controls from the UK. Immunohistochemistry was performed on
intestinal tissue obtained by endoscopic biopsy. The intestinal cell proteins studied were
glycosaminoglycans (GAG), heparan sulfate proteoglycan (HSPG), and syndecan-1. The
inflammatory cell markers measured were CD3+ intraepithelial lymphocytes (IEL), human
leukocyte antigen DR-1 (HLA-DR), and Ki67, a crypt epithelial nuclear proliferative marker.
Inflammatory markers were observed at higher concentrations in the Zambian subjects
than in the UK controls. There were significant differences in specific types of inflammatory
markers across malnutrition groups. There was a significant reduction in intestinal GAG and
HSPG in the kwashiorkor group compared to UK children, but there were no significant
differences in these values between the children with kwashiorkor and those with other types of
malnutrition. There was no difference in epithelial syndecan-1 protein expression between the
malnutrition groups; data for this marker were not reported for the UK controls.
These markers were not compared to other types of markers of intestinal function.

5.5.7 Intestinal Tissue Cytokines and Immune Markers
While scintigraphy and counts of intraepithelial white blood cells (WBCs) and leukocyte
presence in the lamina propria provide assessments of intestinal inflammation, scintigraphy can
be used more broadly to study intestinal pathology and as such is listed in section VII on
nonspecific markers of intestinal injury. Because WBCs are sought in biopsies along with
assessments of intestinal architecture, histopathology, including assessment of WBC infiltration,
is listed in section VII as well.
Only one study assessed intestinal tissue cytokines and immune markers. Markers were
compared between rural Gambian children with differing degrees of malnutrition and UK control
subjects with normal endoscopic results [111]. They assessed cytokine immunohistochemistry of
intestinal tissue using antibodies against syndecan-1, perforin, γδ T-cell receptor, CD-3, CD-4,
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CD-8, CD-19, CD-25, HLA-DR, TNF-α, IFN-γ, TGF-β, and IL-10. Median CD3+, CD4+, CD8+,
CD19+, and CD25+ cell counts were 2-5 times higher among each case group compared to the
UK controls; these differences were statistically significant. IEL, γδ, syndecan-1, HLA-DR, and
perforin were detected among the Gambian children in varying degrees but were not reported for
UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity.
All Gambian groups had greater density of cytokine-immunoreactive mononuclear cells in the
lamina propria than UK controls. Among subjects with elevated cytokines, similar densities were
seen for both pro-inflammatory (IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β)
cytokines. Epithelial expression of TGF-β in Gambian subjects was also enhanced compared to
UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF-β+
cells. A marker of intestinal permeability, L:M was significantly associated with mucosal B
lymphocyte, IEL, and perforin-positive IEL densities.

5.5.8 Duodenal Aspirates for Immunoglobulins
One study measured immunoglobulin concentrations in duodenal fluid as a marker of
intestinal inflammation [128]. Concentrations of duodenal immunoglobulin were compared in
hospitalized children with both persistent diarrhea and Giardia infection and controls without
diarrhea or gastrointestinal infection. Significantly higher mean concentrations of IgM were found
in duodenal aspirates of cases compared to controls. Mean concentrations of duodenal IgA and
IgG did not differ between cases and controls, however.

5.5.9 Summary of Markers of Intestinal Inflammation
A variety of markers were assessed with a preponderance of studies using fecal
lactoferrin. Lactoferrin was measured among study populations with varying characteristics.
Lactoferrin results varied considerably as did results of other measures of intestinal
inflammation.
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Of note, among studies that met our review inclusion criteria, there was a complete
absence of research utilizing fecal calprotectin (a protein produced by neutrophils and
monocytes). This marker has been found in stools of patients with inflammatory bowel diseases
in developed country settings during the time period of this review [262-264], but we found no
analyses of its prevalence and potential role as a diagnostic tool in children with EED.
A threshold for normal for tests of intestinal inflammation was often not defined by
authors. Generally data on these markers were not collected longitudinally so it is not clear how
much intra-individual variation exists. Only one study statistically compared markers of intestinal
inflammation to each other, and found a relationship between TNF-αR1 and lactoferrin [132].
None of the intestinal inflammation studies compared these markers to biopsy results or to other
tests of intestinal dysfunction such as permeability or absorption.
An important consideration in evaluating these tests is the overall feasibility of performing
them, especially in resource-limited settings. For example, stool is a somewhat easier analyte to
obtain than blood (especially non-capillary assessments) and even urine among young children.
Duodenal aspirates are, of course, more invasive tests and examination of intestinal tissue can
only be performed on biopsy specimens, limiting their feasible use. Nonetheless, stool is an
imperfect analyte. Production of sample cannot be scheduled, and the mechanics of obtaining
the specimen are sometimes challenging, necessitating using adhesive bags or collection from
diapers. In addition, stool is probably more biohazardous than blood, and certainly more than
urine, and often elicits handling concerns by laboratory staff and couriers.

5.6 Markers of Systemic Inflammation and Systemic
Immune Activation
Markers of systemic immune function and inflammatory response might provide
informative indirect evidence of precursors to, or consequences of, small intestinal injury.
204

Indeed, the hypothesis that local inflammation could be reflected in systemic markers is
intriguing. There is precedent for associations between markers of organ-specific inflammation
and systemic inflammation, with the best studied being coronary artery and inflammatory bowel
diseases. The atherosclerotic lesion in coronary artery disease and the small and/or large bowel
inflammation in Crohn’s disease and ulcerative colitis are characterized by acute and chronic
inflammatory changes, and, as such, could be analogous to the lesions found in EED. By
extension, there is ample evidence of an association between systemic markers of inflammation
and acute coronary artery events, including myocardial infarction, sudden cardiac death, and
cerebrovascular accidents, and of intestinal disease activity in inflammatory bowel diseases.
Concentrations of circulating C-reactive protein (CRP) have, indeed, emerged as strong
predictors of such events in adults, and complement the use of lipid profiles, which are a more
specific biomarker of coronary artery disease [265-267]. Systemic CRP or erythrocyte
sedimentation rates are indices of inflammatory bowel disease activity [268, 269].
In the case of EED, there is justification for seeking evidence of systemic inflammation as
a biomarker, based on the precedent of coronary artery disease and inflammatory bowel
diseases. However, there are additional justifications: the pathophysiology of environmental
enteric dysfunction might result in, or be associated with, a hyperpermeable gut. Such increased
bowel permeability would expose the host to a variety of injurious substances, most particularly
microbial inflammatory drivers, and the host response could either be a surrogate for
inflammation, or reflect the process that leads to enteric dysfunction. For example, one or more
bacterial molecules could be absorbed, leading to a pro-inflammatory host response, as
manifested by elevated CRP, but such a response could be an appropriate reaction to the gut
that enables the molecules to be absorbed.
To hone in on assessments of systemic inflammation and immune function that could be
helpful as markers of enteric dysfunction, we reviewed those studies that examined the markers
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among children with presentations such as persistent diarrhea, or investigations of the markers
in relationship to markers of intestinal inflammation or dysfunction.
It should be noted that there can be considerable overlap between the primary
assignment of many of these markers of systemic inflammation and nutrient testing (e.g., serum
albumin, total protein, hemoglobin, and blood counts.) For example, while hypoalbuminemia,
hypo- or hypergammaglobulinemia, and impaired erythropoiesis are indicators of nutritional
status, they can also reflect systemic immune activation [270-273]; as such, they were assigned
to this section. For purposes of this review, if a test could be related to inflammatory activation
and measured the product of a nutrient (such as hemoglobin) and not the nutrient itself (such as
iron), then we included the test in our review.
We identified a diverse set of markers from 23 studies that we assigned to the category
of systemic inflammation but which could serve as biomarkers for intestinal inflammation.
Relevant data for each of the studies in this category can be found in Evidence Table 5. The
most commonly employed markers were CRP, albumin, hemoglobin, transferrin, and varying
total and immunoglobulin class concentrations. Additional markers included circulating cytokines
and/or chemokines, total oxidant status, circulating α-1-acid glycoprotein (AGP), serum
mannose-binding lectin, and urinary neopterin. Three studies assessed nitric oxide [43, 158] and
plasma endotoxin and IgG endotoxin-core antibody [110], which are markers that could reflect
systemic inflammation driven by intestinal processes. One study also included data on multiple
markers of cellular, as well as humoral, immunity [104].
Although we did not systematically seek studies that assessed systemic marker
association with nutritional status, among the studies that used markers of systemic
inflammation or immune activation that were included in this review, seven assessed systemic
inflammatory markers in relation to anthropometric indices [43, 110, 122, 123, 130, 150, 151].
The relationships varied widely across markers and sometimes across different growth
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parameters for the same marker. Some data associated circulating markers of systemic
inflammation and stunting; the markers with the strongest associations were albumin and α-1acid glycoprotein, each in an inverse relationship [123].
Six studies investigated association of systemic markers with persistent diarrhea [104,
106, 107, 114, 130, 166]. Those identified at significantly lower concentrations in children with
persistent diarrhea relative to children without diarrhea included: serum total protein [106, 107],
hemoglobin [106, 166], mean corpuscular volume (MCV) and mean corpuscular hemoglobin
(MCH) [166], lymphocyte counts [166], and anti-oxidant concentrations [107]. Albumin
concentrations were also lower in children with persistent diarrhea; this relationship was
statistically significant in one study [106] but not in another [166]. Sample size differences could
explain the effect discrepancy with six 6-24 month olds with persistent diarrhea in the latter [166]
compared to 96 6-36 month olds in the former [106]. While albumin concentrations are known to
increase with increasing age, the slightly older cohort in the study that found an association is
unlikely to explain the discrepancy in results.
Markers found at higher levels in children with persistent diarrhea compared to those with
no diarrhea were total oxidant status, thiobarbituric reactive substances, and DNA damage
[107]. In addition, assays of neutrophil polarization and monocyte spontaneous proliferation
showed increased responsiveness in children with acute or persistent diarrhea relative to those
without diarrhea [104]. A negative delayed-type hypersensitivity response to tuberculin antigen
was also associated with progression from acute to persistent diarrhea [104].
Only one study utilizing markers of systemic inflammation investigated both growth
outcomes and persistent diarrhea; this was in relation to serum mannose-binding lectin [130],
which was not significantly associated with either.
Five studies investigated the relationship of systemic inflammatory markers to gut
permeability. Associations were found between IgG, IgA, IgM, and IgG endotoxin core antibody
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and intestinal function as measured by the L:M ratio [110] and between hemoglobin
concentration and the lactose:creatinine ratio [151]. Additionally a correlation was observed
between urinary nitric oxide and the serum L:R ratio [43]. In contrast, anemia and mean
corpuscular volume (MCV) were not associated with serum L:R [58], and associations were not
found between the L:M ratio and other markers such as α-1-acid glycoprotein (AGP), total IgG,
albumin, or hemoglobin concentrations [123]. Furthermore, only one of these studies included
biopsy, but the authors did not report assessing the relationship between markers of systemic
inflammation and histology [146].
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Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2000

Location and
Target Population

Design and
Sample Size

Dhaka, Bangladesh Case-control

Azim T et al.

7-12 mo olds with 68 days of watery
Immune response of diarrhea attending
Bangladeshi children the International
with acute diarrhea Centre for Diarrheal
who subsequently
Disease Research.
have persistent
Cases were those
diarrhea
who went on to
develop PD, controls
Immune response
were those who did
tests, as well as
not.
transferrin and
albumin as markers
of nutritional status An additional group
among children with of subjects without
diarrhea were
and without PD
recruited from a
nutrition follow-up
unit.
Prevalence of
malnutrition was high
in all groups.

n=136;
n=38 cases with
PD
n=98 controls:
• 85 with AD
• 13 with no
diarrhea

Biomarker

Results

Conclusion

Comments

Blood tests:
WBC total and differential,
Some immune and The number of
immunoglobulin subtypes, cytokines, inflammatory
controls was
• IFN-γ
transferrin, and albumin did not differ markers were
relatively small and
• TNF-α
between
cases
with
diarrhea
or
their nutritional
associated
with
• WBC (total and
controls,
nor
did
stool
leukocyte
or
status was not
acute
and/or
differential)
erythrocyte
counts.
reported.
persistent
diarrhea.
• IgA
• IgG
The percentages of neutrophils that The only marker that
• IgM
polarized in response to stimulation was significantly
• Transferrin
were significantly higher in subjects associated with
• Albumin
with AD or PD compared to those
progression to PD
• Immune function
without diarrhea; there was no
was a negative DTH
tests:
difference between the two diarrhea response to
• Neutrophil
groups.
tuberculin antigen
polarization
(odds ratio=3.8, CI:
response to
Opsonization did not vary between 1.4, 9.9). This was
chemotactic factor any groups.
calculated from a
• Neutrophil
logistic regression
opsonization to Monocyte spontaneous proliferation analysis that only
yeast
counts were less than half among
included children
• Mononuclear cell children with no diarrhea compared with diarrhea.
proliferation,
to those with AD (p<0.001) or with
spontaneous and PD (p=0.011); there was no
in response to
difference between the two diarrhea
stimuli with
groups.
mitogens
Monocyte proliferation in response to
stimulation did not differ between the
Skin Test:
3 groups.
• Delayed-type
hypersensitivity The proportion with DTH responses
response (DTH) differed among the three groups only
to tuberculin,
in response to tuberculin (p=0.021).
tetanus,
More PD subjects had a negative
diphtheria,
tuberculin response than did
Streptococcus, subjects with AD (p=0.024).
Proteus,
Candida, and
Trichophyton
Stool tests:
• Leukocytes
• Red blood cells

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2003

Location and
Target Population

Design and
Sample Size

Kampala and Mpigi, Case-control
Uganda
n=192;
Bitarakwate E et al.
6-36 mo olds with
Serum zinc status of PD, recruited from n=96 cases with
hospital, and healthy PD
children with
persistent diarrhoea controls recruited
mainly from the local n=96 healthy
admitted to the
controls
population.
diarrhoea
management unit of
Mulago Hospital,
Uganda
Serum protein,
albumin, and
hemoglobin among
children with and
without PD
2010
Bukhari AS et al.
DNA damage and
plasma
homocysteine
concentrations are
associated with
serum metabolites
and mineral
constituents' profiles
in children with
persistent diarrhea
Serum proteins,
metabolites, and
levels of DNA
damage among
children with and
without PD

Faisalabad, Pakistan Case-control
3-6 yr olds admitted n=72;
to hospital with PD
and healthy controls. n=36 cases with
PD
n=36 healthy
controls

Biomarker

Results

Conclusion

Blood Tests:
• Albumin
• Total protein
• Hemoglobin

PD cases:
7.47.9% low serum protein
8.69.7% low serum albumin
9.Low mean hemoglobin (10.5 g/dL)

Decreased albumin,
serum total protein
and hemoglobin
concentrations were
associated with PD.

For controls, means of all three
laboratory values were within normal
range; percent of subjects with
abnormal values are not reported.

Comments

All three test results were
significantly lower in children with PD
than in controls (p< 0.01 for each
comparison).

Blood Tests:
Mean values significantly higher
Serum proteins and among PD cases than in healthy
controls:
metabolites:
10.LDL
• Albumin
11.Homocysteine
• Globulin
12.TOS
• Homocysteine
13.TBARs
• Total protein
• Total cholesterol, 14.DNA damage
HDL, LDL,
Mean values significantly lower
triglycerides
among PD cases than in healthy
• AST, ALT
controls:
• T3, T4
15.Total protein
• Total oxidant
16.T4
status (TOS), Total
17.TAS
anti-oxidant status
(TAS), and
thiobarbituric
reactive
substances
(TBARS)
• DNA damage to
lymphocytes

Multiple serum
markers were
associated with PD,
especially DNA
damage to
lymphocytes
(p=0.0001).

Control recruitment
strategy was not
well described.
TOS, TBARS and
TAS were
incompletely
defined.

The authors
speculate that zinc Some values
differed by gender
deficiency, more
commonly found in in both the case
the children with PD, and control groups:
might be responsible 18.Triglycerides
for increased
19.Total cholesterol
20.HDL
homocysteine
concentrations and 21.T3
play an important
Multiple markers
role in mediating
studied; analyses
DNA damage.
did not appear to
address potential
confounding.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2003
Campbell DI et al.

Location and
Target Population

Design and
Sample Size

Keneba, The
Gambia

Cohort

All 2-11 mo olds
Growth faltering in were recruited from
this rural village and
rural Gambian
infants is associated followed up to 14 mo
with impaired small of age.
intestinal barrier
function, leading to
endotoxemia and
systemic
inflammation
L:M as a marker of
intestinal
permeability and its
relationship with
various inflammatory
markers and
endotoxin

1

n=71

Biomarker

Results

Conclusion

Comments

Urine Tests:
1
• Lactulose
(53 tested)
• Mannitol
(52 tested)
• L:M
(52 tested)

At 8 wk of age:
2
• Mean L:M: 0.169 (CI: 0.145,
0.198; range: 0.058-0.657)
• Mean lactulose recovery: 0.202
(SD=0.159; range: 0.009-0.640)
• Mean mannitol recovery: 3.80
(SD=2.35; range: 0.52-8.58)

Mean L:M ratios
were elevated at 8
weeks of age, and
more than doubled
in the first year of
life.

Presence of malaria
parasites was
assessed by blood
smear at each
study visit; the only
parameter
associated with
malaria was CRP.
Authors did not
report investigating
relationships
between certain
serum parameters
(blood counts, CRP
concentrations) and
L:M.

Blood tests:
• Albumin
• CBC
• C-reactive
protein (CRP)
• IgA
• IgM
• IgG
• Plasma endotoxin
• IgG endotoxincore antibody

For lactulose and mannitol results, excretion measurement was not specified.
Geometric mean.
3
Geometric mean.
2

L:M more than doubled between 12
wk-1 yr of age (r=0.44, p<0.001) and
was driven by both increasing
lactulose (r=0.18, p<0.001) and
decreasing mannitol (r=-0.14,
p<0.01) excretion with age.
WAZ and HAZ scores were
negatively correlated with L:M (r=0.41, p<0.001), and primarily driven
by lactulose excretion (r=-0.39,
p<0.001).
Laboratory values were consistent
with chronic, low level
immunostimulation:
• 50% of platelet and 39% of
leukocyte counts were elevated,
especially mean lymphocyte
counts which were almost twice
expected values [198].
3
• While the mean CRP was within
the normal range, 25% of values
were above the upper limit of
normal (5 mg/L), and 17% were
>10 mg/L [198].
• Mean IgG, IgA and IgM
concentrations were near normal
at 8 wk of age, but increased
rapidly; all three were elevated
above expected values in all other

Many markers of
inflammation and
endotoxin release
were significantly
correlated with L:M
and lactulose
recovery.
Poor growth was
significantly
correlated with L:M
ratios, primarily due
to lactulose
excretion.
Authors postulate
that while general
markers of
inflammation cannot
be specifically
ascribed to a gut
source, endotoxin
and its related core
antibody are
potentially a direct
measure of intestinal
inflammation due to
gut gram negatives
as a primary source
of endotoxin release
among subjects
without sources of

Study population
might have overlap
with that of
Campbell et al.
2004 also included
in this review [15].

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

age groups [198, 199].
extra-intestinal gram
1
negative infection.
• Mean free plasma endotoxin
concentration was twice the upper
limit of normal [200] and IgG
endotoxin-core antibody
concentrations were also elevated
[198].
• However, mean albumin
concentrations (and
concentrations within SD) were
generally within normal range
[198].
L:M was correlated with
IgG and IgA (r=0.41 and 0.41,
respectively, p<0.001), and IgM
(r=0.28, p<0.02).
IgG and IgA were also correlated
with lactulose recovery (r=0.26 and
0.25, respectively, p<0.02).
IgG endotoxin core antibody
concentration was correlated with
L:M and driven by lactulose
recovery, (r=0.35, p<0.005 for both).

2002

Kampala, Uganda

Cohort

n=225
9 mo old HIVinfected children
Risk factors and
followed at Mulago
cumulative incidence hospital until 36 mo
of anaemia among of age.
human
More than 40% were
immunodeficiency
stunted and/or
virus-infected
children in Uganda underweight at
Clark TD et al.

1

Geometric mean.

Blood Test:
Hemoglobin

Endotoxin concentrations were
correlated with lactulose recovery
(r=0.36, p<0.02) only.
While chronic diarrhea was
While there was a
associated with moderate anemia in high prevalence of
a univariate analysis (odds ratio=2.5, anemia (<11 g/dL)
CI: 1.0, 6.3), it was either not
and moderate
associated with moderate anemia
anemia (<9 g/dL)
(hemoglobin <9 g/dL) in a
(92% and 35% at 9
multivariate model or not included in months,
the model
respectively) among
this cohort of HIVinfected children,
chronic diarrhea

The association
between chronic
diarrhea and other
assessed
hematologic
markers (any
degree of anemia,
mean corpuscular
volume, and mean
corpuscular
hemoglobin

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Association of
chronic diarrhea with
moderate anemia in
HIV-infected children

2008
Goto R et al.
Impact of antiGiardia and
anthelminthic
treatment on infant
growth and intestinal
permeability in rural
Bangladesh: a
randomised doubleblind controlled
study
L:M as a marker of
intestinal
permeability, IgG as
a marker of chronic
immune stimulation,
and α-1-acid
glycoprotein as an
acute phase reactant
among children
undergoing antiparasitic
presumptive
treatment vs.
placebo. Also
assessed markers’
associations with
1

Geometric mean.

Location and
Target Population

Design and
Sample Size

Biomarker

enrollment.

Dhamrai Upazila,
Bangladesh
3-15 mo olds from a
rural area were
enrolled and
followed in a 9-mo
trial.
There was a high
prevalence of
malnutrition in the
study population.

RCT
n=222*
n=75 received
anti-Giardia and
anthelminthic
treatment
n=59 received
anti-Giardia
treatment only
n=88 received
placebo
* Those who fully
participated and
for whom data
were analyzed
are included in
this review.

Urine Test:
L:M
Blood Tests:
• α-1-acid
glycoprotein
(AGP)
• IgG
• Albumin

Results

Conclusion

Comments

appears to have not concentration) was
been associated
not reported.
with anemia in the
multivariate analysis.
However, the text
did not specifically
state whether
chronic diarrhea was
tested in the
multivariate model.
1
Mean L:M (SD) at baseline was
High L:M ratios
High L:M ratios
0.18 (0.24) in treatment groups, with overall with
were defined as
no significant difference in placebo substantial seasonal greater than the
group or in testing post-intervention. and within-infant
upper CI for UK
infants.
variability.
Proportion with elevated L:M at any
study time point varied between
Interventions did not Same study
58%-74%. >57% consistently
impact L:M or serum population as
elevated L:M ratios.
immune markers.
reported by this
group in another
Seasonal variation in L:M was
study also included
There was
observed (p <0.001), with highest
in this review [123].
improvement in
mean values in the monsoon
weight with better
season.
L:M values, the
degree to which this
L:M was associated with ∆WAZ and occurred was not
∆WHZ scores at 24 weeks (p=0.001 reported.
and p<0.001, respectively, point
estimates not provided.)
Serum immune marker values were
similar in all groups and did not
change substantially with
interventions.
AGP concentrations were negatively
associated with ∆WAZ score at 24
weeks (p=0.004, point estimate not
provided), and were associated with
∆WHZ score at 12 weeks but not at
24 weeks.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
growth parameters.
2008
Dhamrai Upazila,
Bangladesh
Goto R et al.
3-15 mo olds from a
Impact of intestinal rural area were
enrolled and
permeability,
inflammation status followed in a 9-mo
trial.
and parasitic
infections on infant
There was a high
growth faltering in
prevalence of
rural Bangladesh
malnutrition in the
L:M as a marker of study population.
intestinal
permeability, IgG as
a marker of chronic
immune stimulation,
and α-1-acid
glycoprotein as an
acute phase
reactant. Also
assessed laboratory
values’ associations
with giardiasis and
growth parameters.

2007

Delhi, India

Design and
Sample Size

Longitudinal data Urine Test:
extracted from an L:M
RCT [123]
n=298

Blood Tests:
• α-1-acid
glycoprotein
(AGP)
Urine and blood
• IgG
samples were
collected every 3 • Albumin
• Hemoglobin
mo and
anthropometric
measurements
were collected
monthly.

Case-control

Children (ages
n=80;
unspecified)
Fecal occult blood admitted with severe n=50 cases with
screening in children malnutrition and age- severe
malnutrition
matched healthy
with severe
controls recruited
malnutrition
n=30 healthy
from an
Fecal occult blood immunization clinic. controls
Jain S et al.

1

Geometric mean.

Biomarker

Stool Test:
Occult blood
Blood Test:
Hemoglobin

Results
1

Mean L:M: 0.15
L:M showed a decreasing trend with
age (p=0.003), and was associated
with female gender (p=0.004), HAZ
score (p=0.039), and WAZ score
(p=0.019), but not with giardiasis or
any of the serum immune markers.

Conclusion

Comments

Mean L:M was
elevated. L:M was
not associated with
any of the tested
serum markers of
inflammation or with
giardiasis.

Helminthiasis
prevalence was
very low; testing for
association with
markers was not
performed.

Giardiasis was
IgG rose with
defined as
IgG, AGP, and albumin were
increasing age at the presence of a
Giardia-specific IgM
associated with giardiasis, but
rate expected
hemoglobin was not.
response.
(compared to UK
norms) [199] but at
Mean circulating albumin
Same study
higher
concentration was normal for age
population as
concentrations
[203]. Compared to UK age-matched across all ages.
reported by this
reference [199], rate of rise in IgG
group in another
with increasing age was similar, but
study also included
concentrations were consistently
in this review [122].
~3g/L higher.
Cut-off values
IgG was not associated with growth
representing
parameters. Albumin was associated
elevated
with HAZ score only (p=0.016). AGP
concentrations
was inversely associated with HAZ
have not been
(p=0.011) and WAZ (p=0.005)
determined for
scores
AGP. UK norms for
10 mo olds-adults
are 0.88 g/L mean
(0.21 SD) [204].
Fecal occult blood test was positive A high proportion of Among cases, half
in 30/50 (60%) cases and 0/30
severely
had a presenting
controls.
complaint of
malnourished
diarrhea (duration
children had a
Among cases positive for fecal
positive fecal occult not specified), but
occult blood, 20 (66.7%) were found blood test,
the authors did not
to have hemoglobin <8 g/dL.
report results
compared with no
stratified by
positives among
Enteric infections:
diarrhea duration.
healthy controls.
• Parasitic infections were detected

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
among severely
malnourished
children compared to
healthy controls

Design and
Sample Size

2001

New Delhi, India

Kapoor S et al.

<12 yr olds admitted n=40;
to hospital with PD
and Giardia.
n=30 cases with
PD and Giardia
Controls had no
diarrhea and were n=10 controls
hospitalized for non- without diarrhea
GI conditions.

Giardiasis--clinical
and diagnostic
perspective
Immunoglobulin
concentrations in
duodenal fluid and
serum among
children with PD and
Giardia infection
compared to those
without diarrhea
2006

Case-control

Most cases were <7
yr old, with n=19 <3
yr old. Ages of
controls were not
specified.
Port-au-Prince, Haiti Case-control

Kirkpatrick BD et al. <36 mo old inner-city n=99;
residents recruited
Serum mannosefrom the rehydration n=49 cases with
Cryptosporidium
binding lectin
unit at the State

Biomarker

Duodenal secretion
aspirates:
• IgG
• IgM
• IgA
Blood Tests:
• IgG
• IgM
• IgA

Blood Test:
Mannose-binding
lectin (MBL)

Results

Conclusion

Comments

in 14/50 (28%) of cases, 12
Malnourished
Authors did not
(85.7%) of whom tested positive for children with
provide differences
fecal occult blood.
in proportions of
identifiable
occult blood among
• Bacterial infections were detected pathogens more
often tested positive those with and
in 18/50 (36%) of cases, 13
without specific
(72.2%) of whom tested positive for for fecal occult
enteric pathogens.
blood, although
fecal occult blood.
• Of the remaining 18 for whom an approximately 25%
of those without an Statistical analysis
enteric pathogen was not
identified, 5 (27.8%) tested positive identifiable pathogen was not provided;
also tested positive. data were reported
for fecal blood.
as proportions only.
Presence
of
fecal
Among the 30 cases with fecal
occult blood, 16 were breastfed, 11 blood did not appear Matching scheme
was not defined.
were fed cow’s milk, and 3 were fed to vary by feeding
mode (e.g. breast
formula.
milk, cow’s milk, or
formula), although
data presented were
limited.
Higher mean concentrations of IgM Differences in
The number of
were found in duodenal aspirates of immunoglobulin
controls was small
cases compared to controls
concentrations were due to constraints
(p<0.05).
in obtaining
limited among
duodenal aspirate
children with PD
infected with Giardia from children
Mean concentrations of duodenal
IgA and IgG did not differ between compared to
without GI
cases and controls.
symptoms.
children without
such conditions.

Serum MBL concentrations were
lower in cases than in healthy
controls (p=0.002) and diarrhea
controls (p=0.045).
Percentage MBL-deficient:

While
MBL deficiency was
cryptosporidiosis
defined as
was associated with concentrations <70
ng/mL.
MBL deficiency,
MBL concentrations
were not significantly

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
deficiency is
associated with
cryptosporidiosis in
young Haitian
children

Mannose-binding
lectin as a marker of
innate immune
activation among
children with and
without
Cryptosporidium
infection

2002

Location and
Target Population

Design and
Sample Size

University Hospital
or from GHESKIO
1
HIV Center .

infection
(22 with PD)

All subjects were
HIV-negative.

Biomarker

n=9 diarrhea
controls negative
for
Cryptosporidium
n=41 healthy
controls without
diarrhea and
Cryptosporidiumnegative

Stool Tests:
• Reducing
Kirkpatrick BD et al. <18 mo olds from a n=49;
substances (RS)
low SES setting
• Lactoferrin
n=17 cases with • Cytokines:
Cryptosporidiosis
recruited from the
Cryptosporidium
stimulates an
rehydration unit of
• TNF-α receptor
and diarrhea (5
inflammatory
GHESKIO HIV
I
3
with PD)
intestinal response Center with
• IL-4
diarrhea and
in malnourished
• IL-8
Cryptosporidium
n=32 controls
Haitian children
• IL-10
without
infection. Controls
• IL-13
Cryptosporidium;
recruited from an
Stool lactoferrin,
• IFN-γ
• 17 with
outpatient clinic
reducing
diarrhea (5 with
without
substances,
Cryptosporidium
PD)
leukocytes and
Blood Test:
• 15 healthy
infection included
cytokines as
• WBC
markers of intestinal those with and
without diarrhea.
inflammation of
children with and
without
1

Port-au-Prince, Haiti Case-control

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.
Reported results were adjusted for confounding variables, unless otherwise noted.
3
The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.
2

Results

Conclusion

• 36.7% cases
• 9.8% healthy controls
• 0 diarrhea controls

associated with
mean duration of
diarrhea or history of
PD.

Comments

Cryptosporidiosis was associated
with MBL deficiency (odds
2
ratio=22.4; CI: 3.1, 160.8 ).
Among cases, the proportion of
those with PD was nearly double
among those with MBL deficiency
compared to those without MBL
deficiency, but these results were
not significant (p=0.13). MBL
deficiency was not associated with
duration of diarrhea (p=0.37) among
those with cryptosporidiosis nor with
anthropometric status among either
cases or controls.
Proportion RS-positive:
• 33.3% cases
• 64.7% diarrhea controls
• 46.7% healthy controls, (p=0.2)

Fecal lactoferrin was Reported results
identified most often were not stratified
by persistent vs.
in children with
diarrhea, especially acute diarrhea
status.
in those with
Cryptosporidium.
Proportion lactoferrin-positive:
Cut-off values for
While some fecal
• 83.3% cases
lactoferrin positivity
cytokines
were
• 60.0% diarrhea controls
were not described.
detected
in
as
many
• 28.6% healthy controls, (p=0.01)
as
40%
of
healthy
IFN-γ was not recovered in any
controls and 70% of Stools from children
stools.
who were
controls with
diarrhea, they were breastfeeding were
All other fecal cytokines were
generally associated not tested for
significantly associated with
lactoferrin.
Cryptosporidium cases compared to with
Cryptosporidium
diarrhea and healthy controls.
infection. The other
Additionally, TNF-α receptor I, IL-8, stool tests did not
discriminate by
IL-13 were found in diarrhea and
healthy controls, while IL-4 and IL-10 diarrhea or

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
Cryptosporidium
infection

2003
Kukuruzovic R et al.
Increased nitric
oxide production in
acute diarrhea is
associated with
abnormal gut
permeability,
hypokalemia and
malnutrition in
tropical Australian
aboriginal children

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

were not.

Cryptosporidium
status.

Fecal lactoferrin was associated with
the presence of TNF-α receptor I
(point estimate not provided,
p=0.03).

Darwin,
Australia
1-6 yr old Aboriginal
and non-Aboriginal
hospital inpatients.

Subjects were
grouped as follows:
• Children with AD
• Children with no
diarrhea but with
non-GI infectious
conditions
• Children without GI
Nitric oxide (NO) as
or infectious
a marker of intestinal conditions
permeability and
inflammation, and
lactulose:rhamnose
ratio (L:R) as a
marker of intestinal
permeability and the
relationship between
NO and L:R, growth
parameters, mean
corpuscular volume
(as a surrogate of
iron deficiency), and
stool reducing
substances among
children with and
without diarrhea

Mean WBC counts were within
normal range in all 3 groups.
Case-control
Urine Test:
NO among Aboriginal children with
Nitric Oxide (NO)* diarrhea was >3x higher than any
n=318;
other group and >5x higher than in
non-Aboriginal controls.
n=169 cases with Blood Tests:
• NO was >3x and >2x higher
AD
• L:R
among Aboriginal than non(154 Aboriginal) • Mean
Aboriginal children in the
corpuscular
diarrhea (p<0.001) and no
volume (MCV)
n=149 controls:
infections groups (p<0.001),
respectively, but there was no
• 73 with non-GI
infections (49
difference between them in the
Stool Test:
Aboriginal)
non-GI infections group.
Reducing substances • NO was >3x and ~2x higher in
76 with no
(RS)**
infections (29
the diarrhea compared to the no
(169 cases tested)
Aboriginal)
infections group among
Aboriginals (p<0.001) and nonAboriginals (p<0.03),
respectively.
* NO is an unstable
• NO was virtually the same
free radical and is
among the Aboriginal non-GI
converted to nitrite
infections and no infections
and nitrate. Urine
groups, as well as among the
nitrate (NO3)+ nitrite
non-Aboriginal diarrhea and
(NO2) was expressed
non-GI infections groups.
as a ratio with urine
creatinine (NO2 +
NO3:Cr) in order to 112/152 (74%) and 31/169 (18%) of
children with AD had abnormal L:R
account for
differences in urine ratios and positive stool RS,
respectively.
concentration.
NO and L:R were measured at
** Measured only
among children with “convalescence” on Day 5 among
those with diarrhea: the mean
profuse diarrhea.
improvement in NO was 21.7%

Comments

NO2 + NO3:Cr ratio, Positive stool RS
as a measure of
was defined as
>0.5%.
endogenous nitric
oxide production,
Abnormal L:R was
was used as a
defined as >7.6; no
marker of gut
reference or
permeability and
inflammation, with derivation was
an attempt to identify provided for this
how much more it
cut-point.
reflects as response
to inflammation from Study population
appears to be the
GI vs. non-GI
same as in another
infections.
Kukuruzovic, et al.
Among nonstudy also included
Aboriginal controls, in this review which
NO production was assessed serum
lactulose:rhamnose
the same among
those with diarrhea as a marker of
intestinal
and non-GI
permeability [58].
infections (and
higher compared to
controls). NO was
highest by far
among Aboriginal
children with
diarrhea compared
to any other group.
Authors suggest that
high basal
concentrations of
NO among
Aboriginal children

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

2002

Darwin, Australia

Kukuruzovic RH et
al.

Biomarker

Conclusion

due to (clinically
silent) enteropathy
could explain the
NO and L:R were correlated (n=193, concentrations seen
1
r=0.37, p<0.001) ; the correlation
among Aboriginal
was stronger for lactulose (effect
controls in this
ratio=1.47, p<0.001) than for
study.
rhamnose (effect ratio=0.80,
2
p=0.02 ).
NO appeared to
decrease
NO was not correlated with stool
significantly more
3
RS or MCV, but was correlated with slowly than L:R
lower WAZ score (effect ratio=0.88, among children
p=0.05).
recovering from
diarrhea.
NO was found to
correlate with L:R.
NO was more
strongly correlated
with lactulose than
rhamnose.
Case-control
Blood Tests:
27/75 (36%) of Aboriginal controls
Mean L:R ratios of
and 0 non-Aboriginal controls had
Aboriginal children
• Lactose
abnormal L:R ratios.
were approximately
n=375 admissions • Lactulose 4
double those of nonfor 306 children; • Rhamnose
5
Mean L:R at baseline:
Aboriginal children
• L:R
Cases:
both among those
n=285 case
• Hemoglobin
with and without
admissions for
• Mean corpuscular • Aboriginal: 16.4
diarrhea, consistent
AD (264
• Non-Aboriginal: 7.9, p=0.002
volume (MCV)
with authors’
Aboriginal)
compared to Aboriginal cases
suggestion that
Controls:
clinically silent
n=90 control
1.Aboriginal:
4.6
Stool Test:
enteropathy is
admissions with Reducing substances 2.Non-Aboriginal: 2.5, p=0.02
no diarrhea (74 (RS)*
compared to Aboriginal controls prevalent among
Aboriginal children.
Aboriginal)
1
Mean improvement in L:R (CI) at
Mean L:R
day 5 among those with repeat
L:R testing was
significantly
testing:

Reported results appear to have been adjusted for age and race.
Reported results were adjusted for age and race.
3
Reported results among children with diarrhea were adjusted for age and race.
4
Lactulose and rhamnose results were expressed as % of dose administered.
5
Geometric mean.
2

Results

Comments

compared with 54.6% for L:R
(p=0.01).

Cases were
Aboriginal and nonAboriginal children
Small bowel
admitted to hospital
intestinal
with diarrhea.
permeability in
Controls were
Australian Aboriginal Aboriginal and nonchildren
Aboriginal children
admitted without GI
Serum lactulose:
illnesses.
rhamnose ratio
(L:R), serum lactose,
and stool reducing
substances as
markers of intestinal
1

Design and
Sample Size

Positive stool RS
was defined as
>0.5%.
Abnormal L:R was
defined as >5.6,
derived from 2 SD
above the
arithmetic mean for
non-Aboriginal
controls in this
study. The rationale
for the choice of 2
SD above the
arithmetic, instead
of the geometric,
mean is not clear.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
permeability among
Aboriginal and nonAboriginal children
with and without
diarrhea

Design and
Sample Size

Biomarker

Results

repeated on day 5 for • Aboriginal cases: 14.6 (11.2,
a subset of Aboriginal
18.0)
subjects:
• Aboriginal controls: -0.63 (-4.0,
• 174/264 admissions
2.7)
for acute diarrhea
2
Mean lactulose recovery :
• 25/74 control
admissions
• Cases day 1: 0.085 (0.070–
0.103)
• Cases day 5: 0.039 (0.033–
* Measured only
0.046)
among children with
• Controls: 0.024 (0.019–0.029)
profuse diarrhea
All 3 values significantly differed
when “clinically
from one another.
indicated." Number
tested not provided. Mean rhamnose recovery:
• Cases day 1: 0.479 (0.424–0.542)
• Cases day 5: 0.555 (0.498–0.616)
• Controls: 0.585 (0.500–0.685)
These values did not significantly
differ from one another.

Conclusion

Comments

improved over 5
days among
Aboriginal cases.
Children with severe
diarrhea had higher
mean L:R.

Proportions of
cases with
abnormal
concentrations
were not reported.

Analysis included
Higher case L:R was data for 69 children
driven more by high with repeat
lactulose than by low admissions; this
rhamnose.
might violate
Similarly,
independence
improvement in L:R assumptions for
among cases was their statistical
analysis methods.
primarily due to
decreased lactulose.
Repeat L:R testing
Stool RS and serum was conducted on
lactose were found controls of both
racial groups, but
in approximately
among cases it was
one-quarter and
only conducted on
one-third of
Confidence intervals (CIs) in the
Aboriginal cases.
Aboriginal cases,
authors' graphical representation of
respectively. The
mean L:R at admission did not
This study appears
latter was weakly
overlap, and the difference in means
to report on the
associated with
was particularly evident between
increased lactulose. same population as
Aboriginal and non-Aboriginal
in the Kukuruzovic,
subjects.
et al. 2003
reference also
Factors associated with L:R among
included in this
3
cases were :
review, which
• Acidosis (p=0.007)
assessed nitric
• Hypokalemia (p=0.035)
oxide excretion
• Diarrhea severity (p=0.001)
[43].
Age and malnutrition were not
associated with L:R.

1

Authors reiterate
the advantages of
serum over timed

Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated.
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health. 2002. 38(6):571-577.
2
Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.
3
Reported results were adjusted for confounding variables, unless otherwise noted.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

2001

Location and
Target Population

Design and
Sample Size

Results
38% and 27% of Aboriginal cases
had positive serum lactose and stool
RS, respectively. 12% of Aboriginal
and non-Aboriginal controls
combined had lactosemia.

New Delhi,
India

Case-series

n=94;
(38 with repeat
0-15 yr old
biopsies)
Tropical sprue in
gastroenterology
north Indian children clinic patients with
<5 yr old: n=44
PD.
D-xylose and
duodenal biopsy as Those with abnormal
morphology on
markers of TS
biopsy, abnormal Dxylose test, and
clinical response to
antibiotics were
diagnosed as having
TS.
Mittal SK et al.

Biomarker

Those with abnormal
morphology and
response to glutenfree diet were
diagnosed with CD.
We include data on
these subjects for
comparative
reasons.

Comments
urine collection for
assessment of L:R,
as discussed in
another publication
in this review [125].

Presence of lactosemia was
associated with L:R, adjusted
1
relative risk (CI)=1.06 (1.03, 1.10) .
Stool RS, anemia, and MCV were
not associated with L:R.
Duodenal biopsy,
36 (38.3%) were diagnosed with TS More than half of the Biopsy results were
method not specified: including 14/44 (31.8%) who were
GI clinic patients
not provided for
Histopathology
under 5 years of age.
with PD had some patients without TS
or CD.
degree of villous
18 (19.1%) were diagnosed with CD. atrophy.
Blood Tests:
It was unclear if
• Hemoglobin
Degree of villous atrophy among TS More than one-third there were patients
• D-xylose*
vs. CD patients:
and almost one-fifth with abnormal Dxylose and
of subjects were
• Mild in 8/36 (22.2%) vs. 0
histology who did
diagnosed
with
TS
• Moderate in 23/36 (63.9%) vs. 4/18
* Not specified
not respond to
and
CD,
(22.2%)
whether from urine or • Severe in 5/36 (13.9%) vs. 14/18 respectively.
antibiotic therapy
serum, and units of
and therefore were
(77.8%)
measurement not
By study diagnostic not diagnosed with
TS.
provided.
definition, all TS
Mean hemoglobin concentration
(range) among TS patients was 8.3 patients improved
Cut-off points used
g/dL (5.5-11) and did not differ from with treatment.
Among
those
who
to define abnormal
values of those with CD.
had repeat biopsies, D-xylose tests were
not provided.
almost threeAmong the 22 TS patients, repeat
quarters showed
biopsies showed:
normalization of
• 16 with normalization
histology, while 23%
• 5 with improvement
• 1 worsened despite marked clinical had partial
improvement and 1
improvement
patient had
The D-xylose test was abnormal in worsened pathology.
all TS patients by diagnostic
definition.

1

Conclusion

Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2001

Location and
Target Population

Design and
Sample Size

Jamalpur district,
RCT*
northern Bangladesh
Northrop-Clewes CA
n=109;
et al.
2-5 yr olds from poor
rural villages,
n=54 received
Anthelmintic
sampled randomly bimonthly empiric
treatment of rural
from a larger cohort antihelminthic
treatment
Bangladeshi
study.
children: effect on
n=55 received
Stools were
host physiology,
placebo
assessed for
growth, and
biochemical status helminthiasis and
giardiasis. Growth
* Randomized at
L:M as a marker of was followed
the village level.
longitudinally.
intestinal
permeability, and α
1-antichymotrypsin
as a marker of
inflammation and
immune activation to
treatment among
children randomized
to bimonthly
antihelminthics or
placebo.

2009

Kathmandu, Nepal

Cohort

Panter-Brick C et al. 3-18 mo olds in two n=86;
1
2

Geometric mean.
Geometric mean.

Biomarker

Results

Blood Tests:
• α 1antichymotrypsin
(ACT)
• Albumin
• Total protein

Mean L:M at baseline:
• Treatment: 0.22
• Placebo: 0.25

1

Seasonal variation in L:M was
observed, with highest values
following the monsoon season.

Conclusion

Comments

L:M ratios were high
overall and
demonstrated
seasonal variation.

Baseline study data
were lost, so
analysis began with
samples taken at
month 2.

Intra-individual L:M
The relationship
values did not
change significantly between the serum
Within-subject L:M analysis showed over time, nor were markers and
Urine Test:
they associated with intestinal
no significant association with
L:M
permeability was
helminthiasis or
intestinal helminthiasis and no
not reported.
consistently
significant improvement in treatment
associated
with
Among 93 subjects or placebo groups over 1 yr. L:M
giardiasis.
with L:M at baseline: was generally not associated with
giardiasis
(with
the
exception
of
one
• 46 received
Inverse correlations
group at one study interval).
treatment
were seen between
• 47 received
L:M and growth
L:M was inversely correlated with
placebo
∆HAZ and ∆WAZ scores at some of parameters.
Among 66 subjects the follow-up intervals (r=-0.22,
Serum markers were
p<0.02 and r=-0.21, p<0.05,
with repeated L:M
within normal range.
respectively,
at
12
mo
follow-up
testing:
The only significant
visit).
• 34 received
change in these
treatment
markers was a
Mean
serum
ACT,
albumin
and
total
• 32 received
decrease in total
protein
were
within
normal
ranges
placebo
and were not associated with growth protein in the
treatment group
parameters. ACT and albumin
concentrations did not significantly without concomitant
change with treatment, whereas total change in albumin;
protein concentrations did (p<0.001). this suggested a
decrease in
globulins (not
directly measured),
perhaps due to
decreased
inflammation.
2
Urine Test:
Mean Lactose:Cr (CI):
Authors speculate Specific sugar
Lactose:Cr
• Squatter: 0.14 (0.12, 0.16)
that Lactose:Cr
excretion was
• Middle Class: 0.08 (0.07, 0.10)
accounted for less of normalized to

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

cohorts:
Pathways leading to • All children in
n=48 in squatter
early growth
target age range cohort
faltering: An
from four squatter
n=38 in lower
investigation into the settlements
• Randomly
middle-class
importance of
cohort
selected, agemucosal damage
matched cohort
and
from lower middleimmunostimulation
class, periurban
in different sociohouseholds
economic groups in
Nepal

Biomarker
Blood Test:
Hemoglobin

Lactose:creatinine
ratio (Lactose:Cr) as
a marker of intestinal
permeability and
hemoglobin,
albumin, α-1-acid
glycoprotein, and
IgG as markers of
immunostimulation.
The latter were also
assessed for their
relationship to
nutritional status.

2001

• Statistically significant difference

Dhaka,
Bangladesh

Case-control

Urine Test:
Nitric Oxide (NO)*
Blood Tests:
• Nitrite (NO2)
• Nitrate (NO3)
• WBC

Conclusion

the deterioration in
nutritional status
among the squatter
children because of
several factors,
including poorer
nutritional intake,
that impact the
nutritional status of
HAZ, WAZ, WHZ, and ∆WAZ scores children with lower
were strongly associated with mean socio-economic
Lactose:Cr (p<0.001 each) as was status.
∆HAZ score (p=0.004); ∆WHZ score
was not. The strength and
magnitude of association between
∆WAZ score and Lactose:Cr was
most pronounced among the
wealthier cohort and there was no
association between ∆HAZ score
and Lactose:Cr among the squatter
children.
between the 2 groups among the
6-12 mo olds (p=0.007) and 18-24
mo olds (p=0.002), but not among
12-18 mo olds.
• For both SES groups, Lactose:Cr
values decreased with increasing
age (p<0.001).

Hemoglobin concentrations were
inversely related to Lactose:Cr
2
(r =0.018, p<0.001).

n=63;
2-6 yr olds with
Increased nitrite and cholera or shigellosis n=45 cases:
admitted to the
nitrate
• 24 with cholera
hospital.
concentrations in
• 21 with
sera and urine of
shigellosis
patients with cholera Controls were
Rabbani GH et al.

Results

Comments
urinary creatinine to
control for variation
in renal function.
Authors suggest
that while
Lactose:Cr might
not be as accurate
as L:M, it might be
a more field-friendly
assessment of
mucosal damage
compared to L:M,
requiring only spot
urine collection and
no substrate
dosing. However,
L:M was not
assessed in this
study; direct
comparison of the
two tests was not
possible.

While hemoglobin
concentration was
inversely related to
Lactose:Cr, testing
for associations of
other measured
blood markers (IgG,
AGP and albumin)
with Lactose:Cr
was not reported.
In children with shigellosis, median NO as measured by Some values
serum NO was ~8x higher at
both serum and
reported in table
baseline than in controls and
urinary NO2 and NO3 format conflict with
significantly differed from
concentrations was the text; columns of
convalescent concentrations
significantly elevated data appear to be
(p<0.01). Concentrations declined by at presentation
transposed.
52% of baseline during the recovery during acute illness
period but did not return to values
Assessment for NO
compared to 7-10
found in the controls (measure of
days after
correlation with

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
or shigellosis

To assess and
compare nitric oxide
as a marker of
intestinal
inflammation among
children with cholera
or shigellosis or
healthy controls.
Evaluated to assess
nitric oxide
production during
infection of small
bowel without
inflammatory lesion
(e.g., cholera) and
during infection
causing colon
inflammation (e.g.,
shigellosis).

Location and
Target Population

Design and
Sample Size

recruited from the
n=18 healthy
healthy attendants of controls
patients or from
children of hospital
Samples were
staff.
collected from
Mean age (SD) in yr: cases on
• Shigellosis cases: admission
and upon
3.8 (1.2)
• Cholera cases: 4.2 discharge (after
7-10 days of
(1.4)
• Controls: 4.7 (1.8) treatment).

Biomarker

Results

Conclusion

statistical significance not reported). hospitalization in
both cholera and
shigellosis.
In children with cholera, median
serum NO concentrations at
Median serum NO
baseline were ~4x higher than in
concentrations in
* Nitric oxide (NO) is control subjects. Recovery
an unstable free
concentrations decreased 52% from cholera patients
were ~half of those
radical that is
baseline (p<0.01); convalescent
converted to nitrite
values did not differ from the values with shigellosis both
upon admission and
and nitrate. Urine
in controls (p<0.4).
upon discharge and
NO2 + NO3 were
expressed as a ratio Median urinary NO ratios were
concentrations were
with urine creatinine similar among those with Shigella
much higher in
in order to account
and V. cholerae infection, both upon cases than in
for differences in
controls, Such
admission and discharge. Initial
urine concentration. values were ~2x higher than upon
striking differences
were not observed
discharge (p<0.05 and 0.01,
for urinary NO
respectively). Control median NO
was of an intermediate concentration results.
between cases’ admission and
Serum NO
discharge median concentrations;
the difference between control and concentrations
correlated with total
case admission values was NS.
blood WBC in
shigellosis cases.
Mean blood WBC counts (SD):
• Shigellosis: 19.6 (3.3)
• Cholera: 8.3 (2.8)
• Controls: 7.1 (1.8)
Stool Test:
Leukocytes

Mean fecal WBC/high power field
(SD):
• Shigellosis: 38 (17)
• Cholera: 5 (2)
• Controls: 3 (1)
Serum NO correlated with blood
WBC count in shigellosis cases at
2
baseline (r =0.92, p<0.01), but only
to a slight degree upon discharge
2
(r =0.26, no p-value reported) and
there was no correlation among the
cholera cases. Serum NO correlated
with stool volume at presentation

Comments
fecal leukocyte
counts was not
reported, nor was
the correlation
between urinary NO
and total blood
WBC.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2009

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Darwin and
Adelaide, Australia

Case-control

SBT results were not associated with
wasting or with patient age or
breastfeeding status.
SBT and L:R were inversely
correlated (r=0.67; CI: 0.42, 0.62;
p<0.0001). L:R explained 45% of the
variance in SBT; diarrhea explained
28% of variance.
SBT was associated with increased
MCV, relative risk (CI)=3.9 (2.8, 5.0).
Geometric mean.

Comments

2

(r =0.85, statistically significant per
authors, p-value not reported).
20/32 (63%) of Aboriginal children
had abnormal L:R ratios.

Blood Tests:
• L:R
n=43;
Ritchie BK et al.
(32 Aboriginal
1
4 mo-5 yr old
cases and controls Mean L:R (CI):
13C-sucrose breath Aboriginal children n=18 Aboriginal
• Diarrhea cases: 31.8 (24.9,
tested)
test: novel use of a admitted to hospital cases with AD
40.7)
• C-reactive protein
with diarrhea.
noninvasive
(CRP)
• Aboriginal controls without
n=25 controls:
biomarker of
diarrhea: 11.4 (8.5, 15.5),
• Mean Corpuscular
Two control groups: • 18 Aboriginal,
environmental gut
Volume (MCV)
• significant difference
health
• Aboriginal controls without diarrhea • Hemoglobin
(p<0.0001)
admitted to
• 7 nonSucrose breath test
hospital with non- Aboriginal,
SBT Mean (CI):
(SBT) as a marker of GI symptoms
healthy
Breath Test:
• Diarrhea cases: 1.9% (0.9,
13
small bowel mucosal (50% had
C sucrose breath
3.0), p<0.0001 compared to
damage vis a vis
pneumonia)
test (SBT)
non-Aboriginal controls and
sucrase activity
Healthy, nonp=0.004 compared to
among an Australian Aboriginal controls
Aboriginal controls
Aboriginal
recruited from
• Aboriginal controls: 4.1%
population. Also
community
(3.0, 5.2), p=0.032
compared SBT with
compared to non-Aboriginal
serum
controls
lactulose:rhamnose
• Non-Aboriginal controls:
ratio (L:R)
6.1% (4.8, 7.3)
• Significant differences were
observed between all three
groups.

1

Conclusion

SBT values were
Abnormal L:R ratios
significantly lower
were defined as
and L:R values were >16; no reference
significantly higher or derivation was
provided for this
among Aboriginal
cut-point.
children with
diarrhea than among
those without GI
L:R test was not
symptoms. SBT was conducted among
also significantly
the non-Aboriginal
controls.
lower among
Aboriginal controls
SBT/L:R correlation
than among nonAboriginal children analysis was based
on data for
without diarrhea.
Aboriginal cases
This is consistent
with previous reports and controls
of high prevalence of combined; stratified
clinically silent TE in analysis was not
reported and could
this population.
be of interest
considering the
SBT was
large difference in
significantly
inversely correlated L:R observed
between these
with L:R.
groups.
Associations of
MCV, CRP, and
hemoglobin with
SBT after adjusting
for potentially
confounding
variables were not
reported.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

2001

Durban, South Africa Cohort

Rollins NC et al.

1, 6, and 14 wk old n=272
infants born to HIVinfected mothers.

Feeding mode,
intestinal
permeability, and
neopterin excretion:
A longitudinal study
in infants of HIVinfected South
African women

Design and
Sample Size

Biomarker

Urine Tests:
1
• Lactulose
• Mannitol
• L:M
• Neopterin

L:M as a marker of
gut mucosal integrity
and urinary
neopterin excretion
as a marker of cellmediated immunity
in infants with and
without HIV infection

Results
SBT was not associated with
hemoglobin or CRP.
2
Mean L:M (CI):
• HIV-infected subjects:
• 1 wk: 0.12 (0.06, 0.27)
• 6 wk: 0.24 (0.15, 0.38)
• 14 wk: 0.24 (0.14, 0.44)
• Uninfected subjects:
• 1 wk: 0.13 (0.09, 0.19)
• 6 wk: 0.08 (0.06, 0.11)
• 14 wk: 0.09 ( 0.07, 0.13)
HIV-infection by 14 wk of age was
significantly associated with
increased L:M.
A non-significant, positive trend in
neopterin excretion was observed
among HIV-infected infants.

Conclusion

Comments

L:M was generally Assessment of
normal (compared to association
UK values) for non- between L:M and
HIV-infected infants, neopterin was not
reported.
but significantly
increased among
HIV-infected
subjects, especially
after 6 weeks.
The increased L:M
in HIV-infected
infants was primarily
driven by lactulose
rather than mannitol.

Higher neopterin
excretion by HIVinfected infants was
observed but this
was not statistically
significant.
4
2000
Durban, South Africa RCT
Urine Tests:
Mean L:M:
Mean L:M ratios
Urine testing could
3
were very high
only be conducted
• Group 1:
• Lactulose
n=139;
Rollins NC et al.
6-60 mo old
(~10x) (at baseline in the laboratory on
• Day 0: ~1.8
• Mannitol
inpatients or
and at day 3 in both certain days; hence
• Day 3: ~2.4
• L:M
n=66 received
groups) compared to only a subset of
Vitamin A
outpatients with
• Group 2:
• Neopterin
vitamin A on
other studies in this subjects underwent
supplementation of severe diarrhea.
• Day 0: ~1.2
admission (group
those tests.
review. Study
South African
• Day 3: ~0.7
1)
authors
suggested
children with
Blood Tests:
Group 2 patients
diarrhea: optimum
• C-reactive protein There were no differences in mean (via personal
n=73 received
had significantly
correspondence)
timing for improving
(CRP)
L:M between groups or within groups
vitamin A after
higher CRP, nonthat
this
could
have
biochemical and
between days 0 and 3, although
• α-1 acid
clinical
significantly higher
been
due
to
the
clinical recovery and
there was a significant difference in
glycoprotein
improvement
WBCs and AGP,
severity
of
illness
in
subsequent vitamin
paired
analysis
within
individuals
at
(AGP)
(group 2)
and lower retinol
the
sample
A status
the two time points (data not
1

Lactulose and mannitol results were expressed in mg.
Geometric mean.
3
For lactulose, mannitol, and neopterin results, excretion measurement was not specified.
4
Geometric mean.
2

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

L:M as a marker of
intestinal
permeability and
urinary neopterin,
serum α-1 acid
glycoprotein, and Creactive protein as
markers of
inflammation among
children with severe
diarrhea

Location and
Target Population

Design and
Sample Size

Biomarker

49 subjects received
urine testing:
Treatment
• Group 1: n=25
involved vitamin A • Group 2: n=24
supplementation
either on the day
of admission or Blood and urine were
after acute
tested on days 0 and
diarrheal
3.
symptoms had
resolved.

Results

Conclusion

Comments

presented, and direction, magnitude population (children and retinol-binding
and degree of significance not
hospitalized for
protein
reported).
concentration
diarrhea).
compared to group
Lactulose and mannitol excretion
1 at baseline.
Vitamin A
were assessed only in the paired
Authors note that
administration did
analysis. Lactulose excretion
these parameters
not result in
decreased between days 0 and 3
suggest that Group
significant
(magnitude of effect and degree of improvement in L:M, 2 patients might
significance not reported), while
neopterin, or AGP have been more ill
mannitol excretion showed no
regardless of timing at baseline. For the
change.
subset of 49
of vitamin A
patients undergoing
administration.
1
Mean neopterin and AGP
urine testing, the
2
concentrations did not differ between
mean L:M and
groups or within groups on the
neopterin
different study days or in the paired
concentrations
analysis. When initial CRP (~2x
were lower among
higher in Group 2 compared to
Group 2 than Group
Group 1, p<0.004) was taken into
1 subjects (NS).
account, mean CRP on day 3 did not
However, baseline
differ between the 2 groups.
differences in acute
However in the paired analysis, CRP
phase and vitamin
concentrations were significantly
A markers at
different between days 0 and 3.
baseline were not
reported separately
for these 49
subjects.
Data for lactulose
and mannitol
excretion were not
reported separately.
Rationale for
additional analyses
of these molecules
expressed as ratios
with creatinine was
not explained.

1
2

Geometric mean.
Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

2003

Cairo, Egypt

Soliman SM et al.

6-24 mo olds with
diarrhea were
Role of micronutrient recruited from Almixture in acute and Sahel teaching
persistent diarrhea in hospital malnutrition
infants and its
clinic.
impact on nutritional
status
5/6 PD cases and
10/14 AD cases had
Blood cell and
some degree of
albumin markers
malnutrition.
among infants with
acute, persistent or Infants with PD had
no diarrhea, and
significantly lower
effects on these
vitamin A and zinc
markers after 10
stores compared to
days of
controls. Those with
supplementation
AD had significantly
with micronutrient
lower vitamin A
mixture (containing stores.
vitamin A, zinc and
other micronutrients)
among subjects with
and without diarrhea

Design and
Sample Size

Case-control
n=30;
n=20 cases:
• 6 with PD
• 14 with AD
n=10 healthy
controls*
* Controls were
age- and sexmatched to
cases.

Biomarker

Results

Conclusion

Comments

Authors suggest
that their 3-day
testing period
(based on their
previous work in a
different setting
[207] might have
been too short to
identify effect as
demonstrated by
McCullough et al. at
10 days after
presentation [208].
Blood Tests:
Mean baseline hemoglobin was
Albumin and many Information on
• Complete blood
significantly lower in infants with AD hematologic markers control recruitment
count and
and PD (p<0.05 for each group) than were low at baseline and
differential
in controls
among infants with anthropometrics
• Red cell measures:
diarrhea, especially were not specified.
Mean MCV and MCH were lower in in those with PD,
• Mean
those with AD (p<0.025 and p<0.01, compared to those Sample size was
corpuscular
small when
without diarrhea;
volume (MCV) respectively) and PD (p<0.01 for
both
markers)
compared
to
controls.
stratified by
some
of
these
• Mean
case/control
differences were
corpuscular
Mean lymphocyte counts among PD statistically
groups, especially
hemoglobin
cases were low compared to those significant.
for PD cases (n=6).
(MCH)
of controls (p<0.01).
Controls were
Parameters
• Mean
generally normalized reported to have
corpuscular
Other markers did not vary
after micronutrient been matched to
hemoglobin
significantly
at
baseline.
However,
cases, yet there
supplementation.
concentration
among
infants
with
PD,
mean
were half the
(MCHC)
albumin
was
abnormally
low,
number of controls
• Transferrin
although
it
was
not
significantly
than cases and
saturation
different compared to controls or
statistical testing
• Albumin
those with AD.
(student’s t-test)
Mean albumin (g/dL) (SE):
was not
commensurate with
• PD: 2.9 (0.27)
matched case• AD: 3.29 (0.25)
control
• Controls: 3.37 (0.21)
methodology.
Following micronutrient
supplementation, mean hemoglobin,
MCV, lymphocyte counts and
albumin increased in both diarrhea

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

2008

Fortaleza, Brazil

Design and
Sample Size

Cross-sectional

2 mo-9 yr olds
n=102
(mean age 41 mo)
Carotenoids, retinol, from an
and intestinal barrier impoverished urban
function in children community, eligible if
HAZ score <median
from northeastern
for their community.
Brazil
Vieira MM et al.

L:M as marker of
intestinal barrier
function, fecal
lactoferrin and
leukocytes as
markers of intestinal
inflammation, and
CRP and AGP as
acute phase
reactants among
children with varying
vitamin A status

Biomarker

Results

Conclusion

groups to concentrations on par with
control baseline concentrations
(albeit increases were NS except
within the PD group). MCH improved
to concentrations on par with the
control group only among the infants
with AD.
Urine Tests:
48.5% had abnormal L:M.
Almost half of
1
• Lactulose
subjects had
• Mannitol
L:M and excretion of each sugar
increased L:M, and
• L:M
separately did not vary with retinol ~40% of subjects
concentration.
(97 tested)
had increased
lactoferrin.
L:M was associated with levels of
Stool Tests:
common dietary carotenoids,
While serum retinol
primarily driven by lactulose.
concentrations were
• Lactoferrin
However, the association was not
not associated with
(93 tested)
always statistically significant, and L:M, serum
• Leukocytes
the direction of association varied
carotenoids were;
depending on precursor.
authors suggest that
these retinol
Blood Tests:
40%
of
stool
samples
were
positive
precursors might be
• C-reactive protein
for
lactoferrin.
more sensitive
(CRP)
predictors of
• α-1-acid
1% of stool samples were positive
impaired intestinal
glycoprotein
for fecal leukocytes.
function. However,
(AGP)
the reported
30% of stool samples were positive direction of
for parasites but this had no impact association varied,
on L:M results, lactoferrin, or acute making
phase reactants.
interpretation of
these results
unclear.

Comments

L:M threshold for
abnormal values
was defined as
>0.0864 [214]. Cutoff values for
lactoferrin positivity
were not described.
Relationships
between acute
phase proteins and
measures of
intestinal
permeability or
inflammation were
not reported.
Relationships
between L:M and
lactoferrin or fecal
leukocytes as well
as those between
retinol or
carotenoids and
lactoferrin or fecal
leukocytes were not
reported.
Exclusively
breastfed children
were excluded from
study participation
due to assessment
of stool lactoferrin.

1

Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest
2007

Location and
Target Population

Design and
Sample Size

West Kiang region,
Gambia

Cohort

Biomarker
Urine Tests:
1
• Lactulose
• Mannitol
• L:M

Results
2

Mean L:M (CI):
• Baseline:
n=72
Williams EA et al.
• Glutamine group: 0.33 (0.25,
4-10 mo olds from a
0.43)
A double-blind,
rural area followed Glutamine or
• Placebo group: 0.33 (0.26,
placebo-controlled, during the 5-month placebo of
Blood markers
0.41)
glutaminerainy season and for nonessential
• C-reactive protein • Post-intervention:
supplementation trial 6 months afterward. amino acids was
(CRP)
• Glutamine group: 0.29 (0.23,
in growth-faltering
orally
0.35)
• Alpha-1 antiadministered
Gambian infants
chymotrypsin
• Placebo group: 0.26 (0.21,
twice daily during
(ACT)
0.32)
rainy season; L:M • IgA
L:M and plasma
ratio was
immunoglobulins
Mean excretion of lactulose (CI):
• IgG
measured
and acute phase
• Baseline:
• IgM
monthly, and
reactant proteins
• Glutamine group: 0.21 (0.16,
• Albumin
plasma samples
(albumin, C-reactive
0.28)
were collected 3
protein, and alpha-1• Placebo group: 0.20 (0.15,
times.
antichymotrypsin) in
0.26)
community-based
•
Post-intervention:
Gambian infants
• Glutamine group: 0.17 (0.13,
enrolled in a
0.21)
glutamine trial
• Placebo group: 0.14 (0.11,
0.18)
Mean excretion of mannitol (CI):
• Baseline:
• Glutamine group: 2.65 (2.02,
3.48)
• Placebo group: 2.50 (1.87,
3.36)
• Post-intervention:
• Glutamine group: 2.48 (1.99,
3.11)
• Placebo group: 2.14 (1.62,
2.82)
L:M values did not differ significantly
between treatment groups before or
following intervention. However, a
1
2

Lactulose and mannitol results were expressed as % of dose administered.
Geometric mean.

Conclusion

Comments

L:M values were
elevated in this
population, with no
significant change
after the
intervention.

The relationships
between L:M and
growth parameters,
immuno-globulins,
and acute phase
proteins were not
reported.

None of the plasma
markers differed
significantly
between treatment
and placebo groups,
either at baseline or
at the end of
supplementation.
Growth outcomes
did not differ
significantly across
treatment groups.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
repeated measures ANOVA showed
that during supplementation, L:M
values were borderline elevated
among the glutamine-supplemented
group relative to the placebo group
(p=0.05), counter to expectation.
Neither ACT, CRP, albumin, nor
immunoglobulins IgA, IgG, or IgM
differed significantly between
treatment and placebo groups, either
at baseline or at the end of
supplementation.
Mean levels of IgA and IgG
increased during the study
(p<0.001), while IgM levels did not.
Concentrations of each of these
immunoglobulins did not differ
between treatment and placebo
groups.
Plasma albumin, ACT,
and CRP values showed no change
over the course of the study.
Proportions of children with elevated
CRP ranged from 30-41% at
different collection time points. The
glutamine intervention had no effect
on proportion of children with
elevated CRP.
Treatment and placebo groups
experienced decreases in WAZ,
HAZ, and MUAC coinciding with the
rainy season; however, there was no
significant difference observed
between the groups for any of these
parameters.
Treatment and placebo groups did
not differ in morbidity indices (i.e.

Conclusion

Comments

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

percentage of time reported with a
particular illness or illness overall).
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.7 Markers of Microbial Drivers
Markers of microbial environments, such small bowel bacterial overgrowth (SBBO), were
reviewed, while markers for specific enteric organisms were beyond the scope of this review. The
data from each of the studies relevant to this review are listed in Evidence Table 6.
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Evidence Table 6. Markers of microbial drivers.
Biomarkers in bold are primarily markers of microbial drivers.
Reference and
Study Outcomes of
Diagnostic Interest
2002
Alves GM et al.
Nutritional status
and breath hydrogen
test with lactose and
lactulose in Terena
Indian children

Location and
Target Population

Limão Verde and
Cross-sectional
Córrego Seco, Mato
Grosso du Sul, Brazil n=264;
All children <10 yr
old were recruited
from these rural
villages.

Lactose hydrogen
breath test (HBT) as
a marker of lactase
activity, and
lactulose HBT as a
marker of SBBO
2000
Sao Paulo, Brazil
Fagundes-Neto U et 2-10 mo olds with
al.
PD and protein
calorie malnutrition
Studies of the small consecutively
bowel surface by
admitted to Sao
scanning electron
Paulo Hospital.
microscopy in infants
with persistent
diarrhea
Scanning electron
microscope (SEM)
and light microscope
(LM) analyses of
small intestinal
biopsy among
infants with PD with
and without SBBO

Design and
Sample Size

<5 yr old: n=145

Biomarker

Results

Conclusion

Breath Tests:
• Lactose HBT
(251 tested)
• Lactulose HBT
(252 tested)

Lactose HBT:
• Elevated: 27.1% among all
subjects
• Borderline: 43.0% among all
subjects
• 0% of subjects <4 yr had elevated
or borderline results

The prevalence of Assessment of
lactase deficiency as association
measured by lactose between lactulose
HBT was >25%, but and lactose
non-existent among absorption was not
those <4 yr of age. reported.

(However results
were provided by
<4 and >4 yr old
age groups.)

Case-series
n=16

Jejunal secretions
aspirate:
Bacterial
concentrations

Lactulose HBT positive:
• 11.5% of all subjects
• 8.6% of subjects <4 yr

Prevalence of SBBO
as assessed by
lactulose HBT was
~10%.

68.7% had bacterial overgrowth
4
(concentration >10 colonies/mL): 3
had enteropathogenic E. coli while
the rest had colonic microflora.

Histological
abnormalities were
noted in all subjects
by LM and SEM.

All small intestine specimens had
Jejunal tethered
morphological abnormalities on LM:
capsule biopsy:
• 43.7% moderate villous atrophy
Histopathology by LM • 56.3% subtotal villous atrophy
and SEM
SEM revealed abnormalities of
varying intensity:
Rectal tethered
• Among the 11 with SBBO, villous
capsule biopsy:
atrophy ranged from Grade II
Histopathology
(n=4), Grade III (n=2), to Grade IV
(n=3).
• For the 5 subjects without SBBO,
villous atrophy ranged from Grade
I (n=1) to Grade 2 (n=4).
• A mucous-fibrinoid pseudomembrane over enterocytes was
noted in 7 of the 11 with SBBO
and none of the others.
• Other abnormalities noted on

SEM included:

• Mucus and debris covered large

Comments

Inconsistent
reporting of
proportions of
histopathologic
findings among all
Degree of villous
subjects and by
SBBO status;
atrophy noted on
SEM seemed to be assessment of
potential
correlated with
SBBO (no statistical relationship with
tests were reported). SBBO between
different histologic
Authors speculate findings was not
possible.
that the mucousfibrinoid pseudomembrane partially
covering enterocytes
is consistent with a
malabsorptive
process, with the
findings of fat
droplets on
enterocytes
surfaces, and with
the state of
malnutrition of the
subjects.

Evidence Table 6. Markers of microbial drivers.
Biomarkers in bold are primarily markers of microbial drivers.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

areas of the villous surface

• Derangement of the enterocytes

(in some cases cell borders were
not clearly defined)
• Reduced height and number (or
absence in some places) of
microvilli
• Lymphocytes and fat droplets
were observed over the surface of
1
enterocytes (18%)
10 subjects had colitis on rectal
biopsy; this was not associated with
SBBO or degree of small intestinal
pathology on SEM.
13
2002
Kingston, Jamaica Case-series
Stool Tests:
Median total stool excretion of C in
phase 1 was 9% (range: 1%-29%)
• Total and
13
n=24
and did not vary between TG
Murphy JL et al.
5-23 mo olds
fractionated C
admitted to the
following ingestion groups.
13
13
Maldigestion and
Tropical Metabolism
of one of three C Median C excretion dropped 33%malabsorption of
Research Unit of the Subjects were
labeled triglycerides 99% in phase 2 and 86%-95% in
divided into 3
phase 3 compared to phase 1
dietary lipid during University of the
(TG): trilaurin,
groups of 8
(p<0.05 each).
severe childhood
West Indies with
triolein, or
malnutrition
severe malnutrition. children, each
trilinolein*
group receiving a • 13C stool assay
Over the study period, there were
different labeled
significant associations between
Stool recovery of
following
13
triglyceride.
radiolabeled
administration of total lipid and the amount of C
products as markers
labeled fatty acid labeled TGs in stool for some
13
Data were
of lipid digestion and
C glycocholate** groups, but not for others.
collected in three
absorption, and bile
13
separate phases
Median C in TG and FA was
salt deconjugation
as described
similar across TG groups in all
as a marker of
* To assess fat
above in JL
SBBO among
excretion as a % of phases. 13C FA recovery was
Murphy et al.
children with severe
dose administered. similar and reduced by ~2/3
13
2001 [149].
compared to Phase 1. C TG was
malnutrition
Also assessed
13
proportion of C in not detectable in Phases 2 or 3.
triglyceride (TG) and Statistical comparisons between
phases were not reported.
fatty acid (FA)
fractions to
13
distinguish excretion C after radiolabeled glycocholate
1 These SEM results were not presented separately for those with and without SBBO.

High concentrations Authors state that
13
of C (compared to the study was not
healthy UK children) powered to
[190] were observed compare the
in half of the
different TGs, but
they contend that
subjects at
admission, reflecting medium chain
impaired digestion or trilaurin did not
absorption.
appear to be
processed
differently than the
The differences in
13
stool C were wide longer chain TGs
but not as extreme triolein and
trilinolein.
as in a previous
study by same
investigators (also Authors did not
describe the
examined in this
method used to
review) using a
assign subjects to
different TG
different TG groups.
(tripalmitin)
substrate [149].
While it was noted
13
C excretion did not that some subjects
had positive stool
significantly differ
between TG groups cultures, details

Evidence Table 6. Markers of microbial drivers.
Biomarkers in bold are primarily markers of microbial drivers.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker
caused impaired
digestion (presence
of TG) vs. poor
absorption (presence
of FA).

Results

administration was detected in stool
at quantities considered to be in
excess of the 7% recovery of dose
administered upper limit of normal in
U.S. adults in [189]:
• Phase 1: 13/24 (54%)
** To assess bile salt • Phase 2: 5/24 (20.8%)
deconjugation in the • Phase 3: 3/24 (12.5%)
bowel caused by
SBBO; conducted
after the TG
assessment and a 3
day washout period.

Conclusion

Comments

and declined with
improving clinical
course.

were not provided
on the nature of the
enteric infections.

Similar to their
previous study,
significantly more
13
C in stool was
recovered as FA
than TG, reflecting
impaired absorption
over poor lipid
digestion/ hydrolysis.
Unlike in their
previous study, there
was evidence of
SBBO as measured
13
post-ingestion of C
glycocholate.
2001
Kingston, Jamaica Case-series
Stool Tests:
Mean fecal fat (SD):
Mean fecal fat was Statistical methods
might be
• Fecal fat*
• Phase 1: 2.4 g/day (3.6) or 5.9% not elevated
7-23 mo olds with
n=8
inappropriate for a
Murphy JL et al.
compared
to
(9.4)
of
dietary
lipid
intake
• Total and
13
small sample.
malnutrition admitted
fractionated C
• Phase 2: 1.7 (0.9) g/day, or 3.3% published norms
Gastrointestinal
to the University of
[191, 192] during
assay after
(2.4) of intake
Data were
All subjects were
handling and
the West Indies.
administration of
• Phase 3: 0.9 (0.6) g/day, or 1.4% any study phase.
metabolic disposal of
collected in three 13C tripalmitin
treated with
(0.7)
of
intake
13
C-labelled
separate phases
antibiotics including
(TP)**
• Differences between phases were There was wide
13
(each lasting 9
tripalmitin during
variation in fecal fat metronidazole for
• C assay after
not statistically significant.
days):
rehabilitation from
at presentation, and presumptive SBBO;
administration of
• Within 48 hours 13C glycocholate Total excretion of 13C in stool also
this might have
childhood
wide variations in
13
of admission
C
across
affected GCA
malnutrition
stool
(GCA)***
varied widely across patients (0%• During early
testing.
subjects.
Authors
44%) and did not differ between
Fecal fat, stool
rehabilitation
indicate that this is
Breath Tests:
study phases.
13
• During late
recovery of
the first such
• CO2 after
rehabilitation
radiolabeled
administration of Correlation between fecal fat and 13C assessment in
13
products, and breath
malnourished
C glycocholate (r=0.48; p<0.05) was observed.
tests as markers of
children; previous
(GCA)***
13
lipid digestion and
studies on healthy
Lack of lipid digestion and
• CO2 after
children
from the UK
absorption and bile
absorption were assessed by
administration of
13
demonstrated
salt deconjugation
measuring TG and FA fractions,
C TP****
13
as a marker of
respectively. Mean C TG recovery average excretion of
6% [190].
SBBO among
(SD) (% of administered dose),
children with severe
number of patients excreting TG:
* In 72 hour stool

Evidence Table 6. Markers of microbial drivers.
Biomarkers in bold are primarily markers of microbial drivers.
Reference and
Study Outcomes of
Diagnostic Interest
malnutrition

Location and
Target Population

Design and
Sample Size

Biomarker

Results

collection (measured •
as total grams and as •
% of dietary fat
•
intake).

Conclusion

The majority of
13
excreted C was in
the form of FA rather
than TG. Authors
interpreted this to
** To assess fat
reflect failure of lipid
excretion as a % of 13C FA fraction in stool declined
absorption in the
dose administered. during rehabilitation.
face of adequate
13
Also assessed
digestion/hydrolysis.
Mean
C
FA
recovery
(SD):
13
proportion of C in • Phase 1: 6.0% (7.3)
Each form (FA and
triglyceride (TG) and • Phase 2: 4.8% (3.7)
TG) was found in
fatty acid (FA)
decreasing values
• Phase 3: 3.3% (3.8),
fractions to
differences between phases were as the study phases
distinguish excretion
progressed,
NS
suggesting improved
caused by impaired
digestion (presence Mean FA values were ~9x (NS), 5x digestion and
absorption, although
of TG) vs. poor
(p<0.001), and 3x (p<0.05) higher
absorption (presence than mean TG values in Phases 1, results did not differ
significantly.
of FA).
2, and 3, respectively.
*** To assess bile
salt deconjugation in
the bowel caused by
SBBO; conducted
after the TG
assessment and a 3
day washout period.

Phase 1: 0.7% (1.6), n=3
Phase 2: 0.9% (2.8), n=1
Phase 3: no recovery from any
subjects, differences between
phases were NS

Following administration of labeled Fecal fat was
13
correlated with
TP, absorbed C label by breath
of
analysis was ~5% (range 0%-21.2%) concentrations
13
C
in
stool.
and similar across study phases.
There was no
evidence of SBBO
Following the administration of
labeled GCA, there was either no or or bile acid
13
minimal recovery of C in stool and malabsorption.

**** Expressed as a 13CO on breath (as % of dose
2
percentage of
administered) in all phases.
absorbed label (dose
administered - label
recovered in stool) to
assess oxidation for
acute energy needs.

13

CO2 excretion
following
13
administration of C
TP was minimal,
suggesting a
propensity for
deposition in
adipose tissues
rather than oxidation
for immediate
energy needs. The
authors report that
this breath test has
not been widely

Comments

Evidence Table 6. Markers of microbial drivers.
Biomarkers in bold are primarily markers of microbial drivers.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

used, but that
healthy UK children
have breath
excretion values
from 15%-43%
[190], compared to a
mean of 5% and
range 0%-21% in
this cohort; the latter
findings were more
similar to results
from kwashiorkor
13
patients where Clabeled oleic acid
was used as
substrate [193].
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.7.1 Lactulose Hydrogen Breath Test (HBT)
Alves et al. utilized the lactose hydrogen breath test (HBT) to measure of lactose absorption
and the lactulose HBT as a measure of SBBO in a community-based study of indigenous children in
Brazil [102]. Prevalence of SBBO in the study subjects was 12% among subjects below four years of
age, and overall 9% had SBBO. The authors did not report on the relationship between lactulose and
lactose absorption.
In a study of intestinal function among well-nourished children with asymptomatic giardiasis
and healthy controls in Mexico, Moya-Camarena et al. utilized the lactulose HBT and the indican test
to exclude subjects with SBBO. No further data were reported on results of the lactulose HBT;
therefore we did not include this study in this section of our review [147].

5.7.2 13CO2 in Breath or Stool after Administration of
13
C Glycocholate as Marker for SBBO
Murphy et al. [149] assessed gastrointestinal function by stool tests with [149] or without [148]
breath tests in children hospitalized for rehabilitation of malnutrition. The 13CO2 breath test was
performed after administering 13C glycocholate (GCA) to assess bile salt deconjugation in the bowel
caused by SBBO. The test was conducted after a similar assessment with triglyceride and a
subsequent 3-day washout period. Results were expressed as percent of administered dose. In their
initial study, following the administration of labeled GCA, there was no or minimal recovery of 13C in
stool and 13CO2 on breath in all study phases. The authors interpreted these results to indicate that
the GCA was not malabsorbed and that the subjects did not show evidence of bile salt
deconjugation. In the subsequent larger study, however, 13C from labeled GCA was recovered in the
stool in more than one-third of the children, indicating the presence of SBBO [148].
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5.7.3 Intestinal Aspirates for Bacterial Concentrations
Fagundes-Neto et al. analyzed jejunal aspirates and small intestinal biopsies of hospitalized
infants with persistent diarrhea and malnutrition by scanning electron microscopy (SEM) and light
microscopy [118]. Based on bacterial concentration in jejunal aspirates, more than two-thirds of
subjects had bacterial overgrowth (concentration >104 colonies/mL), and three were infected with
enteropathogenic E. coli while the rest had colonic microflora in their small bowel. Histological
abnormalities were noted in all subjects by light microscopy and SEM. The degree of villous atrophy
noted on SEM seemed to correlate with SBBO, but statistical testing was not provided.
Fagundes-Neto et al. also reported a mucous-fibrinoid pseudo-membrane that partially
covered enterocytes [118]. They speculated that it could indicate a malabsorptive process, based on
the findings of fat droplets on enterocyte surfaces and the malnourished condition of the subjects.
Reporting of proportions of histopathologic findings among all subjects and by SBBO status,
as well as statistical assessment of potential correlation with SBBO between different histologic
findings, would have benefitted the analysis.

5.8 Markers of Nonspecific Intestinal Injury
The matter of small bowel biopsies and EED is complex. From initial investigations nearly five
decades ago, the histopathologic appearance of the small bowel defined the entity. Sentinel papers
from Southeast Asia and elsewhere formed the basis of our understanding of the entity on which we
have focused in this review [274, 275]. Also, there is an extensive tradition of pathological
assessments of the bowel and other organs in a variety of syndromes and diseases, and histological
assessment is often considered the gold standard to which biomarkers are compared. Histology
certainly can inform the nature of lesions. In the digestive system, microscopic evaluation of tissue
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can often help differentiate infectious from noninfectious inflammations, assess the degree of allergic
reaction if present, suggest the principal effector cells, and identify malignant potential (rare in these
subjects). Specific diagnoses can also be made by histologic evaluation of the small bowel; wellknown examples are celiac disease and Crohn’s disease.
In view of the potential value of relating biopsies to biomarkers, we sought to find any relation
between this putatively definitive test (small bowel biopsy) and any laboratory test or abnormality.
The data relevant to this review are listed for each of these 18 biopsy studies in Evidence Table 7.
We also include other markers of non-specific intestinal injury in Evidence Table 7, including three
studies utilizing fecal occult blood or red blood cells and one employing Tc-99m dextran scintigraphy.
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Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
2009
Lusaka, Zambia

Design and
Sample Size
Case-control

Biomarker

Results

Conclusion

Comments

Endoscopic duodenal
Biopsy findings among the
Mucosal
27 subjects were
biopsy:
Zambian compared to the UK
architecture was
HIV positive;
children:
Amadi B et al.
12.2-19.8 mo olds n=41*;
markedly abnormal incidence was
• Histopathology
with PD and
compared to UK
lower in the
• Villous height reduced
• Densities in lamina
n=41 cases with
Reduced production malnutrition
controls
but
did
not
kwashiorkor group.
propria and crypt
• Crypt depth increased
PD and
of sulfated
admitted to the
vary
between
epithelium:
• ~50% reduction in crypt:villous
glycosaminoglycans malnutrition ward of malnutrition:
marasmus and
ratio
• Cell proteins:
occurs in Zambian a teaching hospital. • 18 with
• Glycosaminoglyca • Values for lamina propria cell kwashiorkor
children with
marasmus
n (GAG)
densities were not reported for presentations of
kwashiorkor but not
malnutrition.
• 8 with marasmic
• Enterocyte heparan UK subjects
marasmus
kwashiorkor
sulfate
• 15 with
No significant differences in crypt Inflammatory cell
proteoglycan
Duodenal biopsy
densities were
kwashiorkor
or villous measures or lamina
(HSPG)
including
generally higher
propria cell densities were
• Syndecan-1
assessments of
compared to UK
n=19 healthy
observed between nutritional
• Inflammatory cell
intestinal markers in
children and
control children
groups
or
after
nutritional
markers:
children with PD and
showed different
from UK
rehabilitation.
• CD3 IEL
different forms of
patterns across the
• Ki67
malnutrition
malnutrition
Intestinal
markers:
• Human leukocyte
presentations.
* UK subjects are
antigen DR-1 (HLA- • Inflammatory markers were
presented in this
seen in higher densities
DR)
table due to
compared to the UK children. Tissue
concentrations of
comparisons of
There were significant
HSPG and GAG
interest made in
differences between the
were reduced
the review.
different nutritional groups in
especially amongst
However we do not
the specific types of
children with
include these
inflammatory markers.
kwashiorkor.
subjects in the
• There was a significant
sample size for this
reduction in GAGs and HSPG Intestinal protein
markers did not
review.
in the kwashiorkor group
compared to UK children, but differ amongst the
malnutrition groups.
no significant differences
between kwashiorkor and other
presentations of malnutrition.
• There was no difference in
epithelial syndecan-1 protein
expression between the
malnutrition groups (data not
available for UK controls).
2000
Dhaka, Bangladesh Case-control
Blood tests:
WBC total and differential,
Some immune and The number of
immunoglobulin subtypes,
inflammatory
controls was
• IFN-γ
cytokines, transferrin, and
relatively small and
Azim T et al.
7-12 mo olds with 6- n=136;
markers were
• TNF-α
albumin did not differ between
their nutritional
8 days of watery
associated with
• WBC (total and

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
Immune response of diarrhea attending
Bangladeshi children the International
with acute diarrhea Centre for Diarrheal
who subsequently Disease Research.
have persistent
Cases were those
diarrhea
who went on to
Immune activation develop PD,
tests, as well as
controls were those
transferrin and
who did not.
albumin as markers
of nutritional status An additional group
among children with of subjects without
and without PD
diarrhea were
recruited from a
nutrition follow-up
unit.

Design and
Sample Size
n=38 cases with
PD
n=98 controls:
• 85 with AD
• 13 with no
diarrhea

Prevalence of
malnutrition was
high in all groups.

Biomarker

Delhi, India

1-18 yr olds with a
presentation
Celiac disease with consistent with CD
mild to moderate
(combination of
histological changes chronic diarrhea,
Bhatnagar S et al.

Case-series
n=107

Conclusion

Comments

differential)
cases with diarrhea or controls, acute and/or
status was not
nor did stool leukocyte or
persistent diarrhea. reported.
• IgA
erythrocyte counts.
• IgG
The only marker
• IgM
The
percentages
of
neutrophils
that was
• Transferrin
that
polarized
in
response
to
significantly
• Albumin
stimulation
were
significantly
associated with
• Immune function tests:
higher
in
subjects
with
AD
or
PD
progression to PD
• Neutrophil polarization
compared
to
those
without
was a negative
response to
diarrhea;
there
was
no
difference
DTH response to
chemotactic factor
between
the
two
diarrhea
tuberculin antigen
• Neutrophil opsonization
groups.
(odds ratio=3.8, CI:
to yeast
1.4, 9.9). This was
• Mononuclear cell
Opsonization did not vary
calculated from a
proliferation,
between any groups.
logistic regression
spontaneous and in
analysis that only
response to stimuli with
Monocyte spontaneous
included children
mitogens
proliferation counts were less
with diarrhea.
than half among children with no
diarrhea compared to those with
Skin Test:
AD (p<0.001) or with PD
• Delayed-type
(p=0.011); there was no
hypersensitivity
difference between the two
response (DTH) to
diarrhea groups.
tuberculin, tetanus,
diphtheria,
Monocyte proliferation in
Streptococcus, Proteus,
response to stimulation did not
Candida, and
differ between the 3 groups.
Trichophyton
Stool tests:
• Leukocytes
• Red blood cells

2005

Results

Endoscopic duodenal
biopsy:
Histopathology

The proportion with DTH
responses differed among the
three groups only in response to
tuberculin (p=0.021). More PD
subjects had a negative
tuberculin response than did
subjects with AD (p=0.024).
70 had normal histology (defined
as crypt:villous ratio 1:2-3,
absence of lymphoid lamina
propria infiltration, and minimal
intraepithelial lymphocytes (IEL).

More than one
quarter of children
with chronic
diarrhea had
normal small
intestinal mucosa;
37 had mild changes (defined as at follow-up their

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Study Outcomes of
Diagnostic Interest
is a common cause
of chronic diarrhea
in Indian children

Location and
Target Population

Design and
Sample Size

abdominal
distension, and
growth failure),
recruited from a
Duodenal biopsy
pediatric
among children with gastroenterology
chronic diarrhea
clinic.
Subjects negative
for CD-specific
antibodies were of
interest for this
review.
2003

Cochabamba,
Bolivia

Results

Conclusion

mild blunting of villi with
crypt:villous ratio of 1:1*). A
specific etiology was identified in
only n=5:
• 2 with giardiasis
• 1 with lymphangiectasia
• 2 with chronic pancreatitis

growth had
improved and their
diarrhea had
resolved.

Only children with CD had
moderate or severe histologic
changes.

Cohort

n=42 cases with
3-34 mo old
PD and
Disaccharidase
malnutrition:
Amerindians
deficiency in Bolivian hospitalized with PD • 2 with
children with
and moderate or
kwashiorkor
persistent diarrhea severe malnutrition • 20 with
in an urban setting.
marasmus
Jejunal biopsy and
• 20 with
disaccharidase
marasmicactivities in children
kwashiorkor
with PD and different
forms of malnutrition
Children were
assessed on
admission and at
three weeks, after
diarrhea had
resolved and
anthropometrics
were improving.
Bustos M et al.

Biomarker

* Along with increased IEL and
lymphocytic lamina propria
infiltration.
Jejunal tethered capsule Most subjects had mild to
biopsy:
moderate (score of 2-3)
histological abnormalities, with
• Histopathology
• Disaccharidase activity: one kwashiorkor patient having
completely flat villi.
• Lactase
• Sucrose-Isomaltase
Second biopsy showed a trend
• Maltase
of improved mucosa, but
difference was not significant
Histology was scored on a based on histology score,
intraepithelial lymphocyte
scale of 1 (normal) to 4
density, or degree of infiltration
(severe morphological
damage or flat mucosa). of lamina propria.

Comments

No definitive
diagnosis was
reached for 86% of
subjects with
abnormal histology
(albeit most had
mild findings).

Patients had
Spanish language
diminished
article.
intestinal
Values for
disaccharidase
subnormal
activity and
disaccharidase
substantial
activity were not
pathology on
biopsy at admission provided.
and at three weeks,
despite clinical
The magnitude of
improvements and lactase inverse
tolerance of
association with
lactose-containing growth parameters
formula.
was not reported.
Percentages with enzymatic
Authors did not
activity below normal at baseline,
report whether they
discharge:
had tested for
associations
• Lactase: 64%, 59%
between maltase
• Sucrase-isomaltase: 97%, 90%
or sucrose• Maltase: 45%, 52%
isomaltase and
All changes were statistically
growth parameters.
significant.
Lactase recovery was
associated with admission HAZ
(p=0.05) and WAZ (p=0.03)
scores.
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Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

Biomarker

2003

Fajara and Sibanar, Case-control
Endoscopic
The Gambia
small bowel biopsy, site
n=40 cases:
not specified:
Campbell DI et al.
6 mo-3 yr old
• Histopathology
• Group 1: n=4
Chronic T cellhospital- and clinic- • Group 2: n=11 (7 • Morphometric
mediated
based cases from
assessment by
with diarrhea)
enteropathy in rural rural communities. • Group 3: n=25
computer analysis*
west African
(18 with diarrhea) • Intestinal tissue
children: relationship Case groups based
cytokines and immune
with nutritional
on differences in
n=34 with case
markers:
status and small
nutritional status:
tissue samples
• CD-3
bowel function
1. WAZ score >-2,
sufficient for
• CD-4
with GI complaints
cytokine
• CD-8
other than diarrhea
immunoreactivity
• CD-19
L:M as a marker of 2. Grade I protein
tests:
• CD-25
intestinal
energy malnutrition • Group 1: n=3
• HLA-DR
permeability, small (PEM) (WAZ score - • Group 2: n=8
• Perforin
bowl biopsy with
2 to -4) and
• Group 3: n=23
• γδ T-cell receptor
assessment of
unresponsive to
•
Syndecan-1
intestinal immune
nutritional
•
TNF-α
markers, and
supplementation,
•
IFN-γ
computerized
with or without
• TGF-β
morphometric
diarrhea
• IL-10
analysis among rural 3. Grade II PEM
Gambian children
(WAZ score <-4)
with differing
with or without
Urine Tests:
degrees of
diarrhea
1
• Lactulose
malnutrition and
• Mannitol
Controls from UK*
compared to well• L:M
who were well
nourished UK
nourished children
children
with GI complaints
* Biopsy involved
other than diarrhea
morphometric assessment
and with normal
by computer analysis of
endoscopy results
1
2

Lactulose and mannitol results were expressed as % of dose administered.
These figures are presumed to represent IEL means, however, this was not explicitly stated.

Results
Despite continued high
disaccharidase deficiency
prevalence at discharge, all
children tolerated the lactosecontaining formula challenge.
Crypt-hyperplasia and villous
atrophy were observed among
all Gambian subjects, and the
degree of histopathology did not
differ among cases with differing
nutritional status, nor was there
a correlation with diarrhea.
2

IEL means were ~3-fold higher
in Gambian than UK children.
Median CD3, CD4, CD8, CD19,
and CD25 cell counts were
significantly higher (2-5x higher)
among each case group
compared to the UK controls.
IEL, γδ, syndecan-1, HLA-DR,
and perforin were detected
among the Gambian children in
varying degrees but were not
reported for UK controls.
Syndecan, CD3, and CD8
displayed a gradient proportional
to malnutrition severity.
All Gambian groups showed
higher lamina propria cytokineimmunoreactive mononuclear
2
cell density (~200-450/mm ) than
2
UK controls (30-80/mm ).
Among subjects with elevated
cytokines, similar densities were
seen for both pro-inflammatory

Conclusion

Comments

All Gambian
Statistical
subjects had
methodology was
evidence of
not sufficiently
enteropathy with
detailed to
crypt-hyperplasia determine what
and villous atrophy, was compared
and mean IELs >2 (e.g. type of central
tendency measure
SD above UK
norms, independent and variance
of nutritional status. calculations for L:M
not stated)
Elevation of cellmediated intestinal Duration of
diarrhea not
markers and
specified, but
mucosal
assumed to be
proinflammatory
persistent.
cytokines was
present across the
3 Gambian groups, Mucosal
variably correlated lymphocyte
densities, cytokine
with nutritional
immunoreactivity,
status.
and L:M results not
stratified by history
L:M ratios were
of diarrhea.
elevated in all
Gambian groups,
without apparent
correlation to host
nutritional status.

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
were also studied.

Design and
Sample Size

* UK subjects are
presented in this
table due to
comparisons of
interest made in the
review. However we
do not include these
subjects in the
sample size for this
review.

Biomarker

Results

Conclusion

villous height, crypt depth,
villous:crypt ratio, and
intraepithelial lymphocyte
(IEL) density (per 100
epithelial cells).

(IFN-γ and TNF-α) and putative
regulatory (IL-10 and TGF-β)
cytokines. Epithelial expression
of TGF-β was also enhanced
compared to UK controls, but
subjects with poorer nutritional
status had lower densities of
mucosal TGF-β+ cells, with
median densities of 420 and 250
2
cells/mm in the grade I and
grade II PEM groups,
respectively.

Comments

1

L:M values :
• Group 1: 0.53 (0.4-1.3)
• Group 2: 0.47 (0.02-2.20)
• Group 3: 0.73 (0.14-2.2)
• Not assessed among the UK
controls
Nutritional status was not
associated with L:M, recoveries
of lactulose or mannitol.

2006
El Mouzan MI et al.

Riyadh, Saudi
Arabia

Retrospective
case-series

n=241 cases:
1.5 mo-18 yr olds
referred to hospital • 102 with PD
for endoscopy with • 116 with
duodenal biopsy.
unexplained
short stature
78% of subjects
Duodenal biopsy
• 11 with refractory
among children with were <12 yr old;
rickets
suspected intestinal results not
• 12 with other
presented by age.
disease
conditions
Endoscopic
duodenal biopsy in
children

1

Endoscopic duodenal
biopsy:
• Gross endoscopic
visualization
• Histopathology

Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

L:M was correlated with mucosal
B lymphocyte density (r=0.57,
p<0.05), IEL (r=0.51, p<0.02),
and perforin+ IEL (r=-0.64,
p<0.03).
14% had abnormalities on
endoscopic visualization:
• 1% had esophagitis
• 6% had gastritis, 7 (47%) of
which were H. pylori positive
• 7% had duodenitis
Biopsy results:
• PD:
• 26% normal
• 29% chronic non-specific
duodenitis

Villous atrophy was Specific results for
identified not only the 2 patients with
among 40% of
protein losing
children with PD, enteropathy were
but also among
not reported.
22%, 9%, and 17%
of those with short For 27% of cases,
stature, rickets, and the only
other conditions,
histopathology
finding was chronic
respectively.
non-specific
Authors argue that duodenitis; the

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

Biomarker

(including 2 with
protein losing
enteropathy)

Results
• 40% villous atrophy
• 5% other*

• Short stature:
• 56% normal
• 22% chronic non-specific
duodenitis
• 22% villous atrophy
• Rickets:
• 55% normal
• 36% chronic non-specific
duodenitis
• 9% villous atrophy
• Other:
• 25% normal
• 50% chronic non-specific
duodenitis
• 17% villous atrophy
• 8% other*

2000

Sao Paulo, Brazil

Case-series

Fagundes-Neto U et 2-10 mo olds with n=16
al.
PD and protein
calorie malnutrition
Studies of the small consecutively
bowel surface by
admitted to Sao
scanning electron
Paulo Hospital.
microscopy in
infants with
persistent diarrhea
Scanning electron
microscope (SEM)
and light microscope
(LM) analyses of

Jejunal secretions
aspirate:
Bacterial concentrations
Jejunal tethered capsule
biopsy:
Histopathology by LM
and SEM
Rectal tethered capsule
biopsy:
Histopathology

* 3 lymphangiectasia, 2 Giardia,
1 Mycobacterium avium
intracellulare. Findings were
reported according to presenting
symptoms.
68.7% had bacterial overgrowth
4
(concentration >10
colonies/mL): 3 had
enteropathogenic E. coli while
the rest had colonic microflora.

Conclusion

Comments

endoscopic biopsy diagnostic,
is superior to “blind” prognostic, and
capsule biopsy in therapeutic utility of
developing country identification is
settings and allows unclear.
for visualization of
the intestine.
Endoscopic
visualization results
were not reported
by condition nor in
relation to
histopathology
results; it is difficult
to assess the value
added compared to
biopsy alone.

Histological
Inconsistent
abnormalities were reporting of
noted in all subjects proportions of
by LM and SEM.
histopathologic
findings among all
Degree of villous
subjects and by
All small intestine specimens
atrophy noted on SBBO status;
had morphological abnormalities SEM seemed to be assessment of
on LM:
correlated with
potential
SBBO (no
relationship with
• 43.7% moderate villous
statistical tests
SBBO between
atrophy
different histologic
• 56.3% subtotal villous atrophy were reported).
findings was not
Authors
speculate
possible.
SEM revealed abnormalities of
that
the
mucousvarying intensity:
fibrinoid pseudo• Among the 11 with SBBO,

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
small intestinal
biopsy among
infants with PD with
and without SBBO

Design and
Sample Size

Biomarker

Results

Conclusion

villous atrophy ranged from
Grade II (n=4), Grade III (n=2),
to Grade IV (n=3).
• For the 5 subjects without
SBBO, villous atrophy ranged
from Grade I (n=1) to Grade 2
(n=4).
• A mucous-fibrinoid pseudomembrane over enterocytes
was noted in 7 of the 11 with
SBBO and none of the others.

membrane partially
covering
enterocytes is
consistent with a
malabsorptive
process, with the
findings of fat
droplets on
enterocytes
surfaces, and with
the state of
malnutrition of the
subjects.

Other abnormalities noted on
SEM included:
• Mucus and debris covered
large areas of the villous
surface
• Derangement of the
enterocytes (in some cases cell
borders were not clearly
defined)
• Reduced height and number
(or absence in some places) of
microvilli
• Lymphocytes and fat droplets
were observed over the
1
surface of enterocytes (18%)

2001

Brasilia, Brazil

Cross-sectional

6 mo-13 yr olds with n=31
acute, persistent or
chronic diarrhea,
Antiendomysial
and/or malnutrition
antibody test
reliability in children being seen at the
pediatric
with frequent
Gandolfi L et al.

1

Jejunal capsule biopsy:
Histopathology

These SEM results were not presented separately for those with and without SBBO.

10 subjects had colitis on rectal
biopsy; this was not associated
with SBBO or degree of small
intestinal pathology on SEM.
30/31 (96.8%) had abnormal
histopathology:
• Suggesting non-specific
inflammatory abnormalities in
27 (87.1%) subjects.
• Demonstrating grade 3
mucosal abnormalities in all
malnourished 1 yr olds

Comments

The vast majority of Biopsies of interest
children with
were not provided
clinically severe
in subject-specific
diarrhea and/or
detail (e.g.
malnutrition had
characteristics of
the 27 children with
some degree of
non-specific
abnormality on
inflammation were
jejunal biopsy.

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Study Outcomes of
Diagnostic Interest
diarrhea and
malnutrition: is it
celiac disease

Location and
Target Population

Design and
Sample Size

gastroenterology
service of a
university hospital
and determined to
Jejunal biopsy
have disease
among children with severity warranting
PD and/or
biopsy.
malnutrition
Subjects negative
for CD-specific
antibodies were of
interest for this
review.
2000
Islamabad, Pakistan Case-series
2 mo-12 yr olds
n=41;
• 28 with PD
referred from
An audit of pediatric various hospitals to • 9 with FTT
• 4 with short
KRL Hospital
upper
stature
Islamabad for
gastrointestinal
abdominal pain, PD,
endoscopies
short stature, FTT,
GI bleeding, or
Duodenal biopsy
among children with anemia. The
subjects of interest
PD or growth
for this review were
problems
those with PD or
growth problems.
Hafeez A et al.

2007

Delhi, India

Case-control

Jain S et al.

Children (ages

n=80;

Biomarker

Results

Conclusion

negative for enteric parasites.

Endoscopic duodenal
Biopsy:
• Gross endoscopic
visualization
• Histopathology

Stool Test:
Occult blood

Positive histopathologic findings
were identified in:
• 21/28 with PD
• 7/9 with FTT
• 3/4 with short stature

Comments
not detailed (e.g.
presence of
parasites, degree
of malnutrition
and/or diarrhea).

75% of the PD and
77% and the short
stature/FTT
patients had
abnormalities by
endoscopy.

There was possible
bias in the manner
of selection for
endoscopy. 14
biopsies were
unable to be
analyzed (from 100
More abnormalities were found
endoscopies).
Authors
assert
the
via histology than visualization,
importance
of
and findings did not necessarily
Authors did not
biopsies among
correlate.
report the
children with
endoscopic
indications for
endoscopy, due to appearance of the
lack of correlation mucosa.
between them and
Histology findings
increased
were reported by
identification of
specimen (with
abnormalities by
multiple specimens
biopsy.
from some
patients), not by
condition or by
patient, so specific
results could not be
interpreted in
regards to this
review.
Fecal occult blood test was
A high proportion of Among cases, half
positive in 30/50 (60%) cases
severely
had a presenting
and 0/30 controls.
malnourished
complaint of

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
unspecified)
Fecal occult blood admitted with
screening in children severe malnutrition
with severe
and age-matched
malnutrition
healthy controls
recruited from an
Fecal occult blood immunization clinic.
among severely
malnourished
children compared
to healthy controls

Design and
Sample Size

Biomarker

n=50 cases with
Blood Test:
severe malnutrition Hemoglobin
n=30 healthy
controls

Results

Conclusion

Comments

Among cases positive for fecal
occult blood, 20 (66.7%) were
found to have hemoglobin <8
g/dL.

children had a
positive fecal occult
blood test,
compared with no
positives among
healthy controls.

diarrhea (duration
not specified), but
the authors did not
report results
stratified by
diarrhea duration.

Malnourished
children with
identifiable
pathogens more
often tested
positive for fecal
occult blood,
although
approximately 25%
of those without an
identifiable
pathogen also
tested positive.

Authors did not
provide differences
in proportions of
occult blood among
those with and
without specific
enteric pathogens.

Enteric infections:
• Parasitic infections were
detected in 14/50 (28%) of
cases, 12 (85.7%) of whom
tested positive for fecal occult
blood.
• Bacterial infections were
detected in 18/50 (36%) of
cases, 13 (72.2%) of whom
tested positive for fecal occult
blood.
• Of the remaining 18 for whom
an enteric pathogen was not
identified, 5 (27.8%) tested
positive for fecal blood.

Presence of fecal
blood did not
appear to vary by
feeding mode (e.g.
breast milk, cow’s
milk, or formula),
although data
presented were
limited.
Abnormal Tc-99m dextran
Scintigraphy might
uptake was positive in one child be a useful,
found to have subtotal villous
noninvasive
atrophy on biopsy and another method for
thought to have abdominal
detecting intestinal
tuberculosis.
pathology.
Among the 30 cases with fecal
occult blood, 16 were breastfed,
11 were fed cow’s milk, and 3
were fed formula.

2002

New Delhi, India

Case-series

2-12 yr olds
n=3 <5 yr old
selected from
Detecting protein
hospitalized patients
losing enteropathy with symptoms
by Tc-99m dextran suspicious for
scintigraphy: A novel protein-losing
experience
enteropathy
(hypoalbuminemia
Tc-99m dextran
and edema).
scintigraphy as a
marker of proteinKapoor, S et al.

Tc-99m dextran
scintigraphy

The child with the negative scan
had marasmus and partial villous
atrophy on biopsy.

Statistical analysis
was not provided;
data were reported
as proportions
only.
Matching scheme
was not defined.

This pilot study had
a small sample
size of 8 children,
and only 3 were
younger than 5
years.

Evidence Table 7. Markers of non-specific intestinal injury.
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Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
losing enteropathy
or intestinal
inflammation
2004
Sfax, Tunisia
Laadhar A et al.
Determination of
antitransglutaminase
antibodies in the
diagnosis of celiac
disease in children:
results of a five year
prospective study

Children admitted
for endoscopic
biopsy for
symptoms of CD
(not specified).

Design and
Sample Size

Case-control
n=99

Biomarker

Results

Conclusion

Comments

Endoscopic duodenal
biopsy:
Histopathology

Of 99 subjects not meeting
diagnostic criteria for CD,
endoscopic biopsies revealed:
• 76 had normal morphology of
the intestinal mucosa
• 7 had elevated densities of
intraepithelial lymphocytes
• 10 had partial villous atrophy
(Marsh stage 2)
• 6 had various other conditions
such as giardiasis or gastritis

Among 169
children with
symptoms of CD,
41% had subtotal
or total villous
atrophy, 10% had
partial villous
atrophy or
inflammatory
findings, and 45%
had normal
biopsies.

Article in French.

Subjects of interest
for this review were
those who tested
negative for CDspecific serology
and who did not
Duodenal biopsy
among patients with meet the study
diagnostic criteria
suspected CD
for CD--subtotal or
total villous atrophy
consistent with
Marsh stages 3 or 4.
Controls were aged
3 mo-17 yr (mean
4.5 yr).

2006
Leite CA et al.

Sao Paulo, Brazil

5 mo-12 yr old
(median 24 mo)
Functional,
HIV-infected
microbiological and subjects recruited
morphological
from a hospital and
intestinal findings
clinic.
among human
immunodeficiency All subjects had
virus infected
some degree of
children
protein-energy
malnutrition.

Cohort
n=11;

Blood Test:
D-xylose
(9 tested)

n=5 patients with
current or recent Biopsy of small intestine
episode of diarrhea by tethered capsule or
endoscopy:
n=6 patients with Histopathology
no diarrhea in the (10 tested)
30 days preceding
enrollment
Rectal biopsy:

Prevalence of CD
antibodies did not
clearly align with
case/control
designation.
Because of the
way the results
were reported, we
could not extract
data on those who
tested negative for
CD-specific
serology and who
had Marsh stages
3 or 4
histopathology.

Methods section
described obtaining
duodenal biopsies,
while results and
conclusion sections
specify that jejunal
specimens were
obtained.
100% had low D-xylose
There was a high Portuguese
absorption:
prevalence (100%) language article.
of abnormal D• Mean: 15.6 mg/dL
D-xylose <25
xylose results
• SD: 5
among HIV-infected mg/dL was defined
• Range: 8.9-24.4
children, regardless as indicative of
• Median: 14.2
of diarrhea status. malabsorption.
This value is higher
Small intestinal biopsy:
than what some
All
patients
also
• 100% had some degree of
references have
had
cellular
villous atrophy based on a I-IV
noted as a cutinfiltration
of
the
grading system:
point [186].
lamina
propria
and
• Grade I: 3
varying
degrees
of
• Grade I/II: 2

Evidence Table 7. Markers of non-specific intestinal injury.
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Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
Small intestinal and
rectal biopsy to
assess morphology
and D-xylose as a
marker of
malabsorption
among HIV-infected
children

2005
Lima AA et al.

Fortaleza, Brazil

2-60 mo olds
hospitalized with
Intestinal barrier
WAZ score <-2,
function and weight ~70% of whom had
gain in malnourished PD.
children taking
glutaminesupplemented
enteral formula
L:M as a marker of
intestinal
permeability and
various stool tests
among children with
malnutrition or PD
who received either
glycine or glutamine
1
2

Design and
Sample Size

RCT
n=80;

Biomarker

Results

Conclusion

Histopathology
(6 tested)

Grade II: 1
Grade II/III: 1
Grade III/IV: 1
2 samples were too
superficial to assess
• Intraepithelial lymphocytes
were increased in half of the
biopsies.
• Lymphocytic and
polymorphonuclear (PMN)
infiltration of the lamina
propria were present in 10/10
and 7/10 biopsies,
respectively.

villous atrophy.

Urine Tests*:
1
• Lactulose
• Mannitol
• L:M

n=53 received
supplemented
formula
Stool Tests**:
• 27 with glycine • Lactoferrin
• 26 with glutamine • Leukocytes
• Occult blood
n=27 received
• Reducing substances
nonsupplemented
(RS)
formula

•
•
•
•

Rectal biopsy:
• 100% had normal architecture
• Lymphocytic and PMN
infiltration were present in 6/6
and 4/6, respectively.
2
Mean L:M (SE):
• Glutamine group:
• Baseline: 0.31 (0.10)
(similar in all three groups)
• Day 10: 0.10 (0.02);
significant decrease,
(p=0.01)
• No significant decrease in L:M
in glycine and
nonsupplemented formula
groups at day 10

Mean lactulose (SE):
• Glutamine group:
• Baseline: 0.97 (0.46)
* n=80 tested at
(similar in all three groups)
enrollment, n=65 tested at
• Day 10: NS decrease in all
day 10.
3 groups
** n=60 tested.

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.

Comments

Investigators used
a well-articulated
There was no
system of grading
correlation between villous atrophy.
D-xylose and
degree of villous
Results were not
atrophy on biopsy. presented by
diarrhea status,
perhaps due to
small sample size.

L:M significantly
improved in the
glutamine group
only.

The relationship
between stool
markers and L:M
was not reported.

>50% of subjects
had intestinal
inflammation by
stool lactoferrin.
Fecal leukocytes,
RS, and occult
blood were
detected in fewer
subjects than
lactoferrin.

Data were not
stratified by history
of PD.
Fecal fat was
assessed, but
results were not
reported.
Cut-off values for
lactoferrin positivity
were not
described.
Exclusively

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
supplemented
formula or placebo

Design and
Sample Size

Results

Conclusion

Mean mannitol (SE):
• Glutamine group:
• Baseline: 3.42 (0.64)
(similar in all three groups)
• Day 10: NS decrease in all
3 groups

2001

Varanasi, India

Mishra OP et al.

1-5 yr olds with PD n=30 with
selected randomly endoscopy
from an outpatient performed
population in a
urban setting.

Endoscopic and
histopathological
evaluation of
preschool children
with chronic diarrhea A high proportion of
the children had
Duodenal biopsy
varying degrees of
among patients with protein energy
chronic diarrhea
malnutrition.

Biomarker

Case-series

Endoscopic duodenal
biopsy:
• Gross endoscopic
visualization
• Histopathology

breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.

Proportion of stool markers at
baseline among all subjects:
• Lactoferrin: 53.3%
• Leukocytes: 11.7%
• RS: 3.3%
• Occult blood: 5.0%
7 (23.3%) had grossly abnormal
endoscopic findings:
• 5 (16.7%) with chronic
duodenitis
• 1 with duodenitis with multiple
erosions
• 1 with duodenitis with
hemorrhagic gastritis

Grossly abnormal
endoscopic
appearance was
found in onequarter of children
with chronic
diarrhea assessed
by endoscopy.
Three-quarters had
abnormal histology.
22 (73.3%) had abnormal
More than half had
histopathology:
1. 17 (56.7%) with villous atrophy villous atrophy with
mononuclear cell
with mononuclear cell
infiltration; these
infiltration
• 1 (3.3%) with villous atrophy patients had >1
month longer
and eosinophilic infiltration
• 2 (6.7%) with villous atrophy duration of diarrhea
than those with
and mononuclear and
either normal
eosinophilic infiltration
histology or
• 2 (6.7%) with only
mononuclear cell
mononuclear cell infiltration
infiltration without
Mean duration of diarrhea (SD) villous atrophy.
was not associated with gross
endoscopic findings but did vary
by histopathology:
• Normal histopathology: 9.0 wk
(6.0), n=8
• Mononuclear cell infiltration:
9.0 wk (6.0), n=2

Comments

Age,
enteropathogen
recovery, and
degree of
malnutrition were
not associated with

Authors do not
report assessing
relationship
between gross
endoscopic
findings and
histopathology.
Number of patients
with villous atrophy
and both
mononuclear and
eosinophilic
infiltration was very
small (n=2), yet
authors report a
significant
difference in their
duration of diarrhea
relative to those
with normal
histopathology.

Evidence Table 7. Markers of non-specific intestinal injury.
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Study Outcomes of
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Diagnostic Interest

2001

New Delhi,
India

Design and
Sample Size

Those with
abnormal
morphology and
response to gluten-

Results

Conclusion

Comments

gross endoscopic
• Villous atrophy with
mononuclear cell infiltration: or histopathological
findings.
14.9 wk (5.3), n=17, p<0.02
compared to normal
histopathology
• Villous atrophy with
mononuclear and eosinophilic
infiltration: 21.5 wk (2.1), n=2,
p<0.02 compared to normal
histopathology
• Villous atrophy with
eosinophilic infiltration: 6.0 wk,
n=1

Case-series

n=94;
(38 with repeat
0-15 yr old
Tropical sprue in
biopsies)
gastroenterology
north Indian children clinic patients with
<5 yr old: n=44
PD.
D-xylose and
duodenal biopsy as Those with
markers of TS
abnormal
morphology on
biopsy, abnormal Dxylose test, and
clinical response to
antibiotics were
diagnosed as
having TS.
Mittal SK et al.

Biomarker

No consistent pattern was
observed between gross
endoscopic findings or
histopathological lesions and
age, WFA, or type of
enteropathogen recovered in
stools.
Duodenal biopsy, method 36 (38.3%) were diagnosed with More than half of Biopsy results were
not specified:
TS including 14/44 (31.8%) who the GI clinic
not provided for
Histopathology
were under 5 years of age.
patients without TS
patients with PD
had some degree or CD.
18 (19.1%) were diagnosed with of villous atrophy.
Blood Tests:
CD.
It was unclear if
• Hemoglobin
More than one-third there were patients
• D-xylose*
Degree of villous atrophy among and almost one-fifth with abnormal DTS vs. CD patients:
of subjects were
xylose and
diagnosed with TS histology who did
• Mild in 8/36 (22.2%) vs. 0
* Not specified whether
not respond to
• Moderate in 23/36 (63.9%) vs. and CD,
respectively.
from urine or serum, and
antibiotic therapy
4/18 (22.2%)
units of measurement not • Severe in 5/36 (13.9%) vs.
and therefore were
By
study
diagnostic
provided.
not diagnosed with
14/18 (77.8%)
definition, all TS
TS.
Mean hemoglobin concentration patients improved
Cut-off points used
(range) among TS patients was with treatment.
Among those who to define abnormal
8.3 g/dL (5.5-11) and did not
D-xylose tests
differ from values of those with had repeat
were not provided.
biopsies,
almost
CD.
three-quarters
showed
Among the 22 TS patients,

Evidence Table 7. Markers of non-specific intestinal injury.
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Reference and
Location and
Design and
Study Outcomes of
Target Population Sample Size
Diagnostic Interest
free diet were
diagnosed with CD.
We include data on
these subjects for
comparative
reasons.

Biomarker

Results
repeat biopsies showed:
• 16 with normalization
• 5 with improvement
• 1 worsened despite marked
clinical improvement

Conclusion

Comments

normalization of
histology, while
23% had partial
improvement and 1
patient had
worsened
The D-xylose test was abnormal pathology.
in all TS patients by diagnostic
definition.
2000
Sao Paulo, Brazil
Case-control
Jejunal capsule biopsy:
Mean villous atrophy score (SD): The malnourished Tissue from
• Histopathology*
children had
patients requiring
• Cases: 2.6 (0.8)
Cases were children n=33;
• Maltase activity
Nichols B et al.
• Controls: 1.2 (0.5), p=0.006) significantly greater intestinal resection
(mean age 9.9 mo,
• Intestinal messenger
villous atrophy than as part of their
SD 8.1) hospitalized n=24 cases
RNA (mRNA)
Contribution of
biliary atresia
WAZ score was correlated with the younger
with malnutrition
abundances:
villous atrophy to
management
villous atrophy (r=0.65, p- value controls.
refractory to dietary n=9 controls
reduced intestinal
provides an
• Maltasenot reported).
Among the subset opportunity to
rehabilitation.
maltase in infants
glucoamylase (MGA)
assess presumably
tested for mRNA
with malnutrition
• Sucrase-isomaltase 13/25 [sic] cases and 0/5
Controls were
Subjects were
controls had subnormal (defined messages, maltase “normal” intestinal
(SI)
Jejunal biopsy,
children (mean age matched on height
as <94 U/g protein) of maltase activity as well as architecture.
• Villin, a structural
However, unless
maltase activity, and 3.6 mo, SD 1.0) with and weight; ages
activity; mean maltase was 34% the mRNA
protein expressed
they mocked up ex
differed within
enzyme messenger HAZ and WAZ
abundances for
only in enterocytes lower among cases (p=0.11).
vivo mucosal
matched sets.
scores >-2 and
RNAs among
Maltase activity did not appear to MGA, villin and
• Sodium-activated
biopsies in these
malnourished and normal intestinal
SGLT were
decrease with WAZ score
luminal glucosecontrols, resections
mucosa on biopsy,
well-nourished
significantly
(further details not provided).
galactose
will have lower
children. Assessed hospitalized for
correlated
with
transporter 1
proportions of
association between Kasai procedure for
case
status
and
However,
in
sub-analyses
(SGLT), a functional
villous to
maltase and villous biliary atresia.
were
correlated
among
those
samples
with
an
protein expressed
atrophy and other
with villous atrophy. submucosa tissue
only in enterocytes adequate β-actin, a
compared to cases’
mucosal intestinal
housekeeping gene message,
• β-actin
markers indicative of
While maltase
samples derived
(n=10 cases, n=9 controls),
loss of enterocytes
cases’ findings expressed as a deficiency has been from mucosal
and enterocytic
biopsies. While this
mean percent of controls' (SD) reported in
* Mucosal atrophy was
malnutrition
in
other
function.
probably doesn’t
included:
scored on a scale of 1
studies,
authors
affect histology, it
• Villous length (reciprocal of
(absence of atrophy
assert
that
these
might affect
atrophy
score):
38.9
(41.6),
compared to an organ
are
the
first
results
enterocyte
p=0.004
donor) to 4 (similar to
that
directly
support
functional assays
•
Maltase
activity:
37.1
(23.2),
children with active CD).
the hypothesis that and mRNA
p=0.001
reductions in
determination, as
Histology among controls • MGA mRNA: 45.1 (36.4),
maltase
activity
are
transmural tissue
was on surgically resected p=0.016
due
to
villous
will bring in more
tissue.
• Villin mRNA: 52.5 (22.6),
diverse populations
atrophy.
This
study
p=0.003
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Diagnostic Interest

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

• SGLT mRNA: 66.6 (23.1),
p=0.057
• β-actin: 88.2 (15.8), p=0.189

also nicely
correlates mRNA
relative abundance
with function.

of cells; only some
of them might have
transcripts of
interest. However,
the bias is likely in
a direction that
would reduce effect
size.

Both villous length and maltase
activity in a subset of cases were
less than 40% of control values.
MGA, villin, and SGLT mRNA
abundances were correlated with
villous atrophy score (r=0.73),
(r=0.76), and (r=0.54),
respectively (p-values not
1
reported) .
MGA mRNA abundance was
correlated with maltase activity
(r=0.32).

It was unclear if
control inclusion
criteria included
absence of atrophy
or if all potential
controls lacked
atrophy.
Statistical methods
might not have
adequately taken
into account the
small sample size
and matching
scheme.
Subsets of subjects
were investigated
for various tests.
For example, 10
cases had mRNA
analyses based on
β-actin adequacy.
Another instance of
selected testing
was the subset of
22 and 15 cases
that had WAZ
score to histology
and mRNA
correlation
analyses,

1

Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin.
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Study Outcomes of
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Diagnostic Interest

2003

Design and
Sample Size

Porto Alegre, Brazil Cross-sectional,
retrospective
Pires AL et al.
6 mo-5 yr old
inpatients from an n=65
Digital morphometric urban setting who
and stereologic
underwent biopsy
analysis of small
as part of a work-up
intestinal mucosa in for PD.
well-nourished and
malnourished
There was a high
children with
proportion of
persistent diarrhea children with
malnutrition in this
Computerized
study population.
morphometric and
stereologic
assessments in
proximal small
intestine biopsy in
subjects with PD

2008
Poddar U et al.

Chandigarh, India

<14 yr (mean age
6.9 yr) presenting
Is tissue
with symptoms
transglutaminase
consistent with CD
autoantibody the
(PD, FTT, and/or
best for diagnosing pallor)
celiac disease in
children of
Subjects negative
developing countries for CD were of
interest for this

Biomarker

Results

Conclusion

Small intestinal biopsies, Computerized mucosal
Enterocyte
site and method not
measures were similar to those measures show
specified*:
by micrometer and were not
some correlation
• Mucosal morphometric associated with nutritional status. with WAZ and WHZ
scores, but not with
assessment by computer
Digitally assessed enterocyte
HAZ score.
analysis (62 tested):
height, enterocyte brush border, However, surface
• Villous height
and enterocyte nucleus height
area and
• Crypt depth
correlations:
villous:crypt ratios
• Villous:crypt ratio
were not correlated
•
WAZ
score:
r=0.25
(p=0.038),
• Mucosal thickness
with any growth
r=0.26
(p=0.03),
and
r=0.24,
• Digital assessment (500x
parameter.
(p=0.05),
respectively
magnification) (65
•
WHZ
score:
r=0.29
(p=0.02),
tested):
r=0.27 (p=0.03), and r=0.16
• Enterocyte height
• Enterocyte nucleus (p=0.19), respectively
• HAZ score: r=0.16 (0.18),
height
r=0.23 (p=0.06), r=0.23 (0.06)
• Brush border
height
• Stereological analysis There was no correlation
between mucosal surface area
to assess mucosal
surface area (62 tested) and growth parameters.

* From stored specimens
previously assessed by
micrometer.
Case-control
Endoscopic duodenal
Duodenal biopsy of those with
biopsy:
giardiasis showed nonspecific
Histopathology
n=28 controls;
chronic inflammation of lamina
propria; there was no evidence
• 22 with giardiasis
of villous atrophy.
• 1 with TS
• 5 with SBBO

Duodenal biopsy
demonstrated
histological
changes
accompanying
Giardia infection.

Comments
respectively.
Rationale for
subset selection
was not thoroughly
described.

Authors did not
report the biopsy
findings in the TS
or SBBO patients.
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Study Outcomes of
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Diagnostic Interest
Duodenal biopsies in review.
controls with
giardiasis, TS, and
SBBO
2002
Chandigarh, India
Poddar U et al.
Celiac disease in
India: Are they true
cases of celiac
disease
Duodenal biopsy, Dxylose, and fecal fat
in children with
symptoms of CD but
normal mucosal
biopsy results

Design and
Sample Size

Case-control

n=47
18 mo-14 yr olds
with PD, FTT, or
pallor from a
hospital pediatric
gastroenterology
unit.
Subjects with
normal crypt:villous
ratio on biopsy were
of interest for this
review.

Biomarker

Results

Conclusion

Comments

Endoscopic duodenal
biopsy:
Histopathology

38% had chronic inflammatory
cell infiltrates in the lamina
propria.

Among controls
with normal
mucosal
architecture by
biopsy, more than
one-third had PD.

Relationships
between fecal fat,
D-xylose and
biopsy results were
not reported.

Stool Tests:
• Fecal fat*
• D-xylose**

* In 72-hour stool
collection.

55% had abnormal D-xylose
concentrations.

20% had abnormal fecal fat test. D-xylose and fecal
fat might not
No results beyond proportion
correlate well with
positive were reported for any of duodenal biopsy
the above markers.
results.

While 38% of
controls had PD,
results for the
markers studied
were not stratified
by PD for this
group.
Seven children with
biopsies consistent
with CD did not
respond to glutenfree diet and were
excluded from the
study.

** Not specified whether
from urine or serum, and
units of measurement not
provided.

Cut-off points used
to define abnormal
D-xylose tests
were not provided.
2008

Aligarh, India

Cross-sectional

1-12 yr olds (mean n=19
age 51.2 mo) from
Prevalence of iron an urban setting
deficiency anemia in with PD recruited
chronic diarrhoea
from pediatric
and celiac disease - outpatient and
A western UP
inpatient units.
experience
Those with negative
Duodenal biopsy in CD work-up were
Sherwani K et al.

Duodenal biopsy, method Six patients had partial villous
not specified:
atrophy and non-specific
Histopathology
duodenitis by biopsy.

Biopsy identified
abnormal
histopathology in
approximately 1/3
of patients who did
not have CD, but
did not identify PD
etiology in the
remainder who did
not have CD.

The 6 children with
partial villous
atrophy were
thought to have
SBBO as they
recovered after
treatment with
broad spectrum
antibiotics.

Evidence Table 7. Markers of non-specific intestinal injury.
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and
Location and
Design and
Study Outcomes of
Target Population Sample Size
Diagnostic Interest
patients with PD
subjects of interest
for this review.
2003
Santiago, Chile
Cross-sectional
0-12 yr old (median n=11
9 mo) HIV-infected
Gastrointestinal
children treated in
diseases in children hospital. A high
infected with the
proportion had PD.
human
immunodeficiency
virus
Tassara O et al.

Endoscopy and
biopsy among HIVinfected children

Biomarker

Results

Endoscopic
upper GI biopsy including
esophagus, stomach,
and/or duodenum:
• Gross endoscopic
visualization
• Histopathology

Macroscopic inflammatory
changes were observed on
endoscopy in the esophagus,
stomach or duodenum in 2
subjects.

Conclusion

Biopsy results
might show
inflammatory
damage in cases
with no
macroscopic
Biopsies of esophagus, stomach damage visible.
or duodenum showed
inflammatory changes of varying
degree in all 11 subjects.

Comments

Spanish language
article.
Inflammatory
changes identified
in the digestive
system were not
specified by site
(i.e. esophagus,
stomach or
duodenum).

Results were not
stratified by
presenting
symptoms,
including PD.
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects.
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

Our findings indicate a profound lack of enteric histologic data on pediatric populations in
resource-limited settings. Specifically, only 18 of the 77 studies that we reviewed contained any
biopsy materials, and only three of these 18 publications also included any non-intestinal tissue
candidate biomarkers [111, 136, 155]. Furthermore, only two [111, 136] of these three studies
attempted to statistically relate the less invasive, non-intestinal markers to histologic findings;
the only significant association reported was between L:M and intestinal tissue inflammation on
histopathology. Moreover, only 718 subjects aged 0-18 years were represented among the 18
biopsy studies. Ages were mixed in many studies, such that it was impossible to discern which
subjects were in the age range of maximal interest in this review (i.e., under five years of age),
and indications for the biopsies were quite diffuse (e.g., diarrhea, poorly specified abdominal
symptoms). Therefore, the subject population and data availability were suboptimal for the
purposes of this review. In addition, none of the studies that included biopsies related the
findings to the outcome of most considerable interest, i.e., stunting.
Prospectively collected small bowel biopsies may provide useful data, guide biomarker
development and validation, and reveal information about the cause(s) and pathophysiology of
EED. Appropriate conditions are necessary for biopsy studies to be illuminating. For example,
the context in which subjects and controls are selected is vital. Regarding cases, a rigorous
clinical case definition must be established that defines growth faltering and minimal extent of
intestinal functional abnormalities. Exclusion criteria should also be established for disorders
that might mimic EED, such as celiac disease or inflammatory bowel disease. The pathology
associated with these disorders, however, could inform biomarker association with intestinal
dysfunction not specific to, but nevertheless relevant to and sensitive for EED. Such markers
could be part of a set of markers used to diagnose EED. However, the usefulness of a biopsy to
guide biomarker development and validation depends on several factors. Ideally, the lesion
should be from treatment-naïve hosts; this does bring up an ethical dilemma, however. For
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example, placement of a patient on gluten free diet, even briefly, or treating a patient with
possible inflammatory bowel disease, prior to biopsies can obscure findings and render the
histopathologic evaluation less valuable. Second, biopsies obtained under protocol must take
into account the distribution of the lesion, so as to confirm the negative predictive value of any
set of biopsies. Two disorders provide some guidance in this realm. For celiac disease, the
lesion is surprisingly non-uniform [276-279], and multiple biopsies must be sought to avoid beta
error. A similar situation applies to gastric biopsies for Helicobacter pylori detection [280-286]. A
comparison group is also necessary, and to date, most “normal” or “control” tissues were from
children in developed country settings. Hence, the abnormalities noted in children’s biopsies
cannot be attributed to the disease process (enteropathy), or its consequences (stunting, most
particularly), rather than to residence in an area in which such disorders are common. In other
words, biopsy association with disease is, based on the available literature, no more strong than
EED association with geography.
A case could be made that biopsies are part of a routine evaluation of a child with failure
to thrive, and a recent publication from North America suggests that this diagnostic modality is
commonly employed in the evaluation of stunting disorders [287]. However, the precise
diagnostic yield of a biopsy is not stated in this publication, nor are the data weighted by the
symptoms or the age of the children. At this time, it remains uncertain how generalizable the
utility of these recommendations is in settings where EED is common.
The safety of a biopsy also needs to be considered in pondering the value of tissue
assessment, or of biomarker discovery or validation. If a biopsy is obtained as part of an
evaluation of poor growth, then the small risk of the biopsy usually is less than the potential
benefit. However, this calculus assumes that substantial pre-procedure and post-procedure care
is available to mitigate the likelihood of complications. The use of anesthesia in inpatient or
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outpatient settings is safe, but should conform to the highest grade of safety [288]. An additional
concern is that endoscopy of the duodenum carries a risk of causing intramural hematomas,
estimated at 0.08% of upper endoscopic procedures in the United States [289, 290]. This
complication results in small bowel obstruction, severe pain, and Ampulla of Vater obstruction
and requires management involving prolonged hospitalization and total parenteral nutrition
and/or or naso-enteral feeds. Coagulopathies such as von Willebrand Disease, other platelet
disorders, and vitamin K deficiency (the risk of which is increased in chronic diarrhea and
malabsorption) [291, 292] are thought to contribute to approximately half of endoscopy-related
duodenal hematomas [289, 290, 293-307]. Among von Willebrand Disease variants, only severe
(type 3) disease can be readily identified by available screening tests (prothrombin time)
although such assessments can be used to pre-endoscopically identify treatment-responsive
vitamin D deficiency.
If biopsies are obtained as part of a research protocol to identify markers that predict
clinically consequential EED (and even if biopsies are only used for clinical care), it is necessary
to assemble a panel of individuals whose tissues are evaluated in parallel, but who do not have
the most consequential of the complications of putative enteropathy, namely, stunting
(assuming this remains the outcome of greatest concern). It would not be possible to recruit
healthy control children for biopsies, because the procedure would offer limited benefit—
especially in relation to potential harm. However, some surrogate controls might arise as
adventitiously obtained tissue becomes available either during operations or other endoscopic
procedures, and the use of small bowel obtained at time of portoenterostomy is a particularly
inspired choice [53].
Caveats must be attached to any histologic assessment of the guts in children being
evaluated for enteropathy as part of a care plan. It is very unlikely that intestinal biopsies would
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be used as a diagnostic procedure at the beginning of an evaluation for malnutrition or poor
growth. More likely, it would be a procedure of last resort, after less invasive evaluation failed to
establish an etiology, and after attempts at nutritional and intestinal rehabilitation are undertaken
and prove unsuccessful. However, as noted above, the empiric treatment of consequential
intestinal dysfunction might change the pathology, and thereby diminish the diagnostic value of
the procedure. Also, if biopsies are obtained, and subjected to analysis, it is critical that the
materials be handled in a systematic manner, and processed per protocol, so as to maximize
the data that they generate.
In summary, there is no evidence to date that biopsies have been used to define the
entity of childhood EED, because inadequate controls have been studied (children without
evidence of functional impairment of gut function living in the same environment). There is no
evidence that the biopsies relate to the outcome of greatest concern, namely, stunting. The data
obtained from biopsies could be falsely normal, because of attempts at intestinal rehabilitation
that will presumably precede the endoscopy. This negative assessment does not mean that
biopsies are without worth, only that their value as providing case-defining information, or
guiding biomarker discovery or validation, has yet to be made. However, if biopsies are
obtained, it is critical that they be performed in a rigorous, disciplined and ethical manner, and
that the data to be obtained are maximized.

5.9 Markers of Extra-Small Intestinal Function
We included markers of non-small intestinal organ function as these might provide
important indirect assessments of precursors to or resultants of small intestinal injury. We
reviewed those markers that were examined among children with presentations potentially
consistent with enteropathy, such as persistent diarrhea, or were examined in relationship to
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markers of intestinal inflammation or dysfunction. The data relevant to this review are listed for
each of these studies in Evidence Table 8.
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Evidence Table 8. Markers of extra-small intestinal function.
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and
Location and
Design and
Study Outcomes of
Target Population
Sample Size
Diagnostic Interest
2010
Faisalabad, Pakistan Case-control

Biomarker

Results

Blood Tests:
Mean values significantly higher
Serum proteins and
among PD cases than in healthy
3-6 yr olds admitted n=72;
Bukhari AS et al.
metabolites:
controls:
to hospital with PD
• LDL
• Albumin
and healthy controls. n=36 cases with • Globulin
DNA damage and
• Homocysteine
PD
plasma
• Homocysteine
• TOS
homocysteine
• TBARs
• Total protein
n=36 healthy
concentrations are
• Total cholesterol, • DNA damage
controls
associated with
HDL, LDL,
serum metabolites
triglycerides
Mean values significantly lower
and mineral
among PD cases than in healthy
• AST, ALT
constituents' profiles
controls:
• T3, T4
in children with
• Total oxidant status • Total protein
persistent diarrhea
• T4
(TOS), Total antioxidant status (TAS), • TAS
Serum proteins,
and thiobarbituric
metabolites, and
reactive substances
levels of DNA
(TBARS)
damage among
DNA damage to
children with and
lymphocytes
without PD
2000

Sao Paulo, Brazil

Fagundes-Neto U et 2-10 mo olds with
PD and protein
al.
calorie malnutrition
Studies of the small consecutively
admitted to Sao
bowel surface by
Paulo Hospital.
scanning electron
microscopy in infants
with persistent
diarrhea
Scanning electron
microscope (SEM)
and light microscope
(LM) analyses of
small intestinal
biopsy among
infants with PD with
and without SBBO

Case-series
n=16

Jejunal secretions
aspirate:
Bacterial
concentrations

68.7% had bacterial overgrowth
4
(concentration >10 colonies/mL): 3
had enteropathogenic E. coli while
the rest had colonic microflora.

All small intestine specimens had
Jejunal tethered
morphological abnormalities on LM:
capsule biopsy:
• 43.7% moderate villous atrophy
Histopathology by LM • 56.3% subtotal villous atrophy
and SEM
SEM revealed abnormalities of
varying intensity:
Rectal tethered
• Among the 11 with SBBO, villous
capsule biopsy:
atrophy ranged from Grade II
Histopathology
(n=4), Grade III (n=2), to Grade IV
(n=3).
• For the 5 subjects without SBBO,
villous atrophy ranged from Grade
I (n=1) to Grade 2 (n=4).
• A mucous-fibrinoid pseudo-

Conclusion

Comments

Multiple serum
markers were
associated with PD,
especially DNA
damage to
lymphocytes
(p=0.0001).

Control recruitment
strategy was not
well described.
TOS, TBARS and
TAS were
incompletely
defined.

The authors
speculate that zinc Some values
deficiency, more
differed by gender
commonly found in in both the case
the children with PD, and control groups:
might be
• Triglycerides
responsible for
• Total cholesterol
increased
• HDL
homocysteine
• T3
concentrations and
play an important
Multiple markers
role in mediating
studied; analyses
DNA damage.
did not appear to
address potential
confounding.
Histological
Inconsistent
abnormalities were reporting of
noted in all subjects proportions of
by LM and SEM.
histopathologic
findings among all
Degree of villous
subjects and by
atrophy noted on
SBBO status;
SEM seemed to be assessment of
correlated with
potential
SBBO (no statistical relationship with
tests were reported). SBBO between
different histologic
Authors speculate findings was not
that the mucouspossible.
fibrinoid pseudomembrane partially
covering
enterocytes is
consistent with a
malabsorptive

Evidence Table 8. Markers of extra-small intestinal function.
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

Biomarker

Results
membrane over enterocytes was
noted in 7 of the 11 with SBBO
and none of the others.
Other abnormalities noted on SEM
included:
• Mucus and debris covered large
areas of the villous surface
• Derangement of the enterocytes
(in some cases cell borders were
not clearly defined)
• Reduced height and number (or
absence in some places) of
microvilli
• Lymphocytes and fat droplets
were observed over the surface of
1
enterocytes (18%)

2005
Galpin L et al.
Effect of
Lactobacillus GG on
intestinal integrity in
Malawian children at
risk of tropical
enteropathy
L:M and sucrose:
lactulose ratio
(SUC:L) as markers
of intestinal and
gastric permeability,
respectively, in
1

Mwenye, Malawi

RCT

Urine Tests:
2
• Lactulose
36-60 mo olds
n=164;
• Mannitol
recruited from a rural
• Sucrose (SUC)
community,
n=81 received
• L:M
excluding children Lactobacillus GG • SUC:L
with severe acute
(80 completed the
malnutrition or
study)
severe chronic
illnesses.
n=83 received
placebo
Subjects were
(81 completed the
considered at risk for study)
EED due to
residence in a
location with high
Subjects received
prevalence of EED. 30-days of

These SEM results were not presented separately for those with and without SBBO.
Lactulose, mannitol, and sucrose results were expressed as % of dose administered.
3
Arithmetic mean.
2

10 subjects had colitis on rectal
biopsy; this was not associated with
SBBO or degree of small intestinal
pathology on SEM.
At enrollment:
• 73% had L:M >0.10
• 40% had L:M >0.20
3
• Mean L:M (SD):
• Treatment: 0.18 (0.16)
• Placebo: 0.22 (0.20)
• Mean lactulose (SD) in treatment
group: 0.25 (0.17)
• Mean mannitol (SD) in treatment
group: 8.0 (4.5)
• Mean SUC:L (SD):
• Treatment: 0.58 (0.64)
• Placebo: 0.60 (0.64)
Mean excretion of sucrose (SD)
increased from 0.057 (0.042) to
0.078 (0.058) in the treatment group

Conclusion

Comments

process, with the
findings of fat
droplets on
enterocytes
surfaces, and with
the state of
malnutrition of the
subjects.

A high baseline
prevalence of
abnormal L:M was
observed, with no
change after
intervention.
High mannitol
excretion (relative to
UK norms) drove
the abnormal L:M.
There was little
effect on SUC:L with
intervention;
sucrose excretion
increased in both

Difficult to interpret
sucrose tests
because there are
limited data on
laboratory values
for these tests in
young children.

Evidence Table 8. Markers of extra-small intestinal function.
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
asymptomatic
Presumed that if
children presumed at SBBO is etiology for
risk of EED
EED, treatment with
Lactobacillus will
result in improved
gut integrity.
2006
Sao Paulo, Brazil

Design and
Sample Size

Lactobacillus GG
or placebo. Only
the 161 subjects
who completed
the study had
repeat testing.
Cohort
Blood Test:
D-xylose
n=11;
(9 tested)

5 mo-12 yr old
(median 24 mo) HIVinfected subjects
Functional,
n=5 patients with
microbiological and recruited from a
current or recent
hospital and clinic. episode of
morphological
intestinal findings
diarrhea
All subjects had
among human
immunodeficiency some degree of
n=6 patients with
protein-energy
virus infected
no diarrhea in the
malnutrition.
children
30 days
preceding
Small intestinal and
enrollment
rectal biopsy to
assess morphology
and D-xylose as a
marker of
malabsorption
among HIV-infected
children
Leite CA et al.

2003

Santiago, Chile

Cross-sectional

0-12 yr old (median n=11
9 mo) HIV-infected
Gastrointestinal
children treated in
diseases in children hospital. A high
infected with the
proportion had PD.
Tassara O et al.

Biomarker

Results

Conclusion

Comments

(p=0.01), but similar results were
treatment and
observed in the placebo group.
control groups.
Otherwise there were no changes in
lactulose, mannitol, L:M, or SUC:L
after treatment or placebo.
100% had low D-xylose absorption:
• Mean: 15.6 mg/dL
• SD: 5
• Range: 8.9-24.4
• Median: 14.2

There was a high
prevalence (100%)
of abnormal Dxylose results
among HIV-infected
children, regardless
of diarrhea status.

Portuguese
language article.

Biopsy results might
show inflammatory
damage in cases
with no macroscopic
damage visible.

Spanish language
article.

D-xylose <25
mg/dL was defined
Biopsy of small
as indicative of
intestine by tethered Small intestinal biopsy:
malabsorption. This
capsule or endoscopy: • 100% had some degree of villous
value is higher than
Histopathology
atrophy based on a I-IV grading All patients also had what some
cellular infiltration of references have
(10 tested)
system:
the lamina propria noted as a cut-point
• Grade I: 3
and varying degrees [186].
• Grade I/II: 2
Rectal biopsy:
of villous atrophy.
• Grade II: 1
Histopathology
Investigators used
• Grade II/III: 1
There
was
no
(6 tested)
a well-articulated
• Grade III/IV: 1
correlation
between
system
of grading
• 2 samples were too superficial
D-xylose
and
villous
atrophy.
to assess
• Intraepithelial lymphocytes were degree of villous
increased in half of the biopsies. atrophy on biopsy. Results were not
presented by
• Lymphocytic and
diarrhea status,
polymorphonuclear (PMN)
perhaps due to
infiltration of the lamina propria
small sample size.
were present in 10/10 and 7/10
biopsies, respectively.
Rectal biopsy:
• 100% had normal architecture
Lymphocytic and PMN infiltration
were present in 6/6 and 4/6,
respectively.
Endoscopic
Macroscopic inflammatory changes
upper GI biopsy
were observed on endoscopy in the
including esophagus, esophagus, stomach or duodenum
stomach, and/or
in 2 subjects.
duodenum:
• Gross endoscopic Biopsies of esophagus, stomach or
visualization
duodenum showed inflammatory

Inflammatory
changes identified
in the digestive
system were not

Evidence Table 8. Markers of extra-small intestinal function.
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest
human
immunodeficiency
virus
Endoscopy and
biopsy among HIVinfected children

2009

Limela, Malawi

Trehan I et al.

All 3-5 yr olds from
the village were
recruited.

A randomized,
double-blind,
placebo-controlled
trial of rifaximin, a
nonabsorbable
antibiotic, in the
treatment of tropical
enteropathy
L:M,
sucrose:lactulose,
and
sucralose:lactulose
as markers of small
intestinal, gastric,
and colonic
permeability,
respectively, among
those receiving
rifaximin or placebo

1

Design and
Sample Size

Biomarker

Results

• Histopathology

changes of varying degree in all 11
subjects.

Conclusion

Comments
specified by site
(i.e. esophagus,
stomach or
duodenum).

Results were not
stratified by
presenting
symptoms,
including PD.
RCT
Urine Tests
At enrollment:
There was a high
Methodological
1
proportion with
differences in
• Lactulose
• Mean mannitol (SD):
elevated
L:M
which
specimen collection
n=144;
• Mannitol
• Treatment: 9.57 (5.24)
did
not
change
with
and testing, in
• Sucrose (SUC)
• Placebo: 10.29 (6.62)
rifaximin
treatment.
particular for SCL
n=72 received
• Sucralose (SCL)
• Mean lactulose (SD):
excretion, might
rifaximin for 7
• L:M
• Treatment: 0.30 (0.18)
Baseline
L:M
account for some
days
• Sucrose:lactulose
• Placebo: 0.34 (0.25)
measurements
in
differences in
ratio (SUC:L)
• Mean SUC (SD):
this
study
resembled
values compared to
n=72 received
• Sucralose:lactulose
• Treatment: 0.062 (0.04)
those
of
another
other studies.
placebo
ratio (SCL:L)
• Placebo: 0.074 (0.058)
Malawian population
• Mean SCL (SD):
It was presumed
in similar
This was the first
• Treatment: 0.51 (0.29)
environmental
that if SBBO is
use of SCL for siteSubjects were tested
• Placebo: 0.58 (0.53)
conditions
[120].
the etiology for
specific absorption
before and after
• Mean L:M (SD):
enteropathy,
testing in a
treatment.
• Treatment: 0.18 (0.12)
SCL excretion in this developing country
treatment with
• Placebo: 0.17 (0.09)
population was
rifaximin would
setting.
• Mean SUC:L (SD):
result in improved
similar to that found
intestinal integrity.
in healthy American
• Treatment: 0.50 (0.34)
children (0.4%),
• Placebo: 0.64 (0.90)
while SCL:L was
• Mean SCL:L (SD):
comparatively lower
• Treatment: 0.42 (0.32)
(0.8) and driven by
• Placebo: 0.39 (0.23)
lactulose [210].
• For both groups combined:
SCL:L might be a
• 76% had L:M >0.10
better marker of
• 34% had L:M >0.20
colonic permeability
[211-213]. Results
No significant post- intervention
from this study
differences were observed in any
potentially indicate
fractional sugar excretion or dual
sugar test, including among children that colonic

Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.

Evidence Table 8. Markers of extra-small intestinal function.
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and
Location and
Study Outcomes of
Target Population
Diagnostic Interest

Design and
Sample Size

Biomarker

Results

Conclusion

with elevated pre-intervention L:M.

permeability was
normal.

Comments

Few data exist on
SUC excretion.
Results in this trial
are similar to those
found in another
Malawian population
(0.06% SUC
excretion) [120] and
high compared to
healthy older
children from
developed country
settings (0.020.03%) [210, 212].

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these
studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

One study assessed markers of liver and thyroid function among hospitalized persistent
diarrhea cases and healthy controls [107]. These authors found that thyroid hormones were
significantly lower in children with diarrhea than in controls. Liver tests showed associations in
conflicting directions.
The remaining five studies examined tests related to segments of the gastrointestinal
tract outside of the small bowel [13, 118, 120, 136, 167]. Three of these performed endoscopy
and/or biopsy on the esophagus, stomach, and/or rectum [118, 136, 167]. In a study of 11 HIVinfected malnourished children rectal biopsy tissue uniformly demonstrated normal architecture,
but increased lymphocytic and neutrophilic infiltration. Duodenal biopsies were also infiltrated
with these cells but all subjects had additionally some degree of abnormal architecture [136].
Another case series found macroscopic inflammatory changes in 18% of endoscopies and
100% of biopsies of the upper gastrointestinal tract in eight children with HIV infection, many of
whom had persistent diarrhea [167]. However, the investigators did not report whether these
findings were identified in the esophagus, stomach and/or duodenum. A third study in this
category found that nearly two-thirds of subjects had evidence of colitis based on rectal biopsy;
this was not associated with small bowel bacterial overgrowth or degree of small intestinal
pathology observed by scanning electron microscope [118].
Tests of small intestinal permeability have been described in a previous section (5.3),
but certain dual-sugar permeability tests are more specific for evaluating colonic or gastric
function. These markers include urinary sucrose, urinary sucralose, the urinary
sucrose:lactulose ratio (SUC:L), and the urinary sucralose:lactulose ratio (SCL:L). Sucrose
excretion and sucrose:lactulose (SUC:L) were components of a panel of urinary excretion tests
that comprised the clinical endpoints as measures of gastric permeability for two communitybased intervention studies, one of which additionally tested sucralose excretion and
sucralose:lactulose (SCL:L) as measures of colonic permeability. The first of these studies was
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a randomized, controlled trial of Lactobacillus GG [120]. The mean excretion of sucrose
increased in the treatment group following treatment, but similar results were observed in the
placebo group. Following the intervention, there was no change in the mean SUC:L in either
group. The second of these studies was a randomized, controlled trial that assessed L:M,
SUC:L, and SCL:L responses to treatment with rifaximin, a nonabsorbable antibiotic. The
investigators hypothesized that if small bowel bacterial overgrowth played an etiologic role in
enteropathy, treatment with the antibiotic would result in improvements in measurements of
permeability [13]. Sucralose excretion in this population was similar to that found in healthy
American children while SCL:L was comparatively lower and driven by lactulose [210]. These
results were similar to those found in another Malawian population [120] in where excretion
values were 2-3 fold greater than those excreted by healthy older children from developed
countries [210, 212]. No significant post-intervention differences were observed for any of these
markers. The authors asserted that this was the first use of sucralose for site-specific absorption
testing in a developing country setting. Few data exist on sucrose excretion, but overall values
for sucrose excretion were similar across the two studies.

5.10 Relationships between Markers of EED,
Including Histopathology
Biomarkers provide, by definition, “read-outs” or values that are related to one or more
host processes. Here we review inter-marker relationships, independent of host outcomes
(which are reviewed below).
Only four studies included assessments of “noninvasive” biomarkers (i.e., those not
requiring the introduction of an endoscope or tube into the small bowel (e.g., for visualization, to
obtain duodenal fluid or biopsy tissue) as well as intestinal histopathology [111, 136, 155]; only
two of these studies compared histopathology to less invasive markers. Leite et al. assessed
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the relationship of D-xylose and the degree of villous blunting and found no association [136].
Campbell et al. found that L:M was associated with various findings on scanning electronic
microscopy (SEM) and was correlated with mucosal B lymphocyte density, intraepithelial
lymphocyte (IEL) density, and the presence of perforin-positive IELs [111].
An additional three studies compared endoscopic visualization or markers in intestinal
tissue obtained by biopsy to standard light microscopic histopathology [53, 118, 126]. Neither
endoscopic [126] nor SEM [118] findings were associated with histopathology on light
microscopy. However, intestinal maltase activity, as well as intestinal mRNA abundances for
maltase-glucoamylase and the enterocyte-specific proteins villin and sodium-activated luminal
glucose-galactose transporter 1, were correlated with villous atrophy [53].
Twelve studies [15, 43, 58, 110, 123-125, 132, 149, 151, 158, 159] compared 15
different non-intestinal tissue markers to each other. Four of these studies assessed serum L:R
to other markers and found relationships with sucrose breath values [159], serum lactose [58],
urinary nitrites [43], and urinary L:R [125], but did not demonstrate associations with stool
reducing substances [58] or serum red blood cell markers [58]. Three other studies assessed
urinary L:M to other markers and found no associations with fecal neopterin [15], urinary lactose
or lactose:lactulose [124], or a variety of systemic immune/inflammatory markers including AGP,
total IgG, albumin, and hemoglobin [123]. However, one additional study did find that L:M was
associated with not only total serum IgM and IgA levels, but also IgG [110]. This study also
found a correlation between L:M values and IgG endotoxin core antibody concentrations, and
additionally found urinary lactulose excretion to correlate with circulating IgG endotoxin core
antibody and endotoxin concentrations. Other studies found that urinary lactose:creatinine was
inversely related to hemoglobin [151] and that fecal lactoferrin was related to TNF-α receptor I
[132]. Others found no relationship between urinary nitrite and stool reducing substances [43] or
between sucrose breath test and hemoglobin or C-reactive protein [159].
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5.11 Relationships between EED Biomarkers and
Growth or Other Outcomes of Interest
We sought to find biomarkers of processes relevant to consequential outcomes in the
host. In the context of EED, the outcome of greatest proximate interest is growth failure,
specifically linear growth failure, but other potential injuries (e.g., persistent diarrhea) and distal
consequences (e.g., delayed cognitive development) were also considered.
Eight studies attempted to associate various markers with persistent diarrhea, six of
which found such an association. In five of the six studies, these were systemic markers such
as serum proteins or indices of serum white or red blood cells [106, 107, 142, 166, 308]. A sixth
study found that concentrations of immunoglobulin in duodenal aspirates were associated with
persistent diarrhea among children infected with Giardia [128]. A study of mannose-binding
lectin (MBL) found that while a deficiency of the marker was associated with cryptosporidiosis,
MBL concentrations were not significantly associated with either duration of diarrhea or
persistent diarrhea [130]. While the eighth study did assess for hemoglobin association with
persistent diarrhea, it was not clear from the reporting of their multivariate results if there was an
association [114].
Fourteen studies [101, 103, 111, 113, 117, 121, 126, 131-133, 138, 154, 155, 167]
included subjects with and without persistent diarrhea but did not statistically assess
relationships between markers and this outcome, although five of these studies [101, 103, 117,
126, 155] did present data stratified by the outcome of persistent diarrhea.
While acute diarrhea is not a cardinal EED symptom, we included it as an outcome of
interest when looking at studies that sought its association with biomarkers of enteric
dysfunction. Our rationale was that intestinal damage or pathophysiology resulting from acute
enteric processes might still provide meaningful insights into the utility of various markers in
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representing pathologic gut processes. Eight studies [43, 58, 116, 124, 125, 159, 166, 308]
investigated the relationship between markers and acute diarrhea. It should be noted that some
of these studies included children with persistent diarrhea, but did not stratify results according
to acute or persistent presentations; we include all of these studies under the heading “acute
diarrhea”. Most of these studies found associations between acute diarrhea and the markers
investigated. One of these studies [125] found a relationship between acute diarrhea and both
urinary and serum L:R while another [58], a study limited to serum L:R testing, found
associations between diarrhea and serum L:R and lactulose. However, Goto et al. [124] did not
find an association between the L:M ratio and acute diarrhea.
Studies also found associations between acute diarrhea and other tests specific for
intestinal function, such as the sucrose breath test [159], and fecal fat [116]. Association was
also observed for two markers of innate immunity, neutrophil polarization in response to a
chemotactic factor and monocyte spontaneous proliferation assays [104], as well as nitric oxide
production [43]. While one study found associations between acute diarrhea and various red
blood cell parameters [166], another [104] found a lack of association between acute diarrhea
and other systemic markers such as white blood cells, transferrin, serum albumin, cytokines,
and immunoglobulin subtypes.
Sixteen [15, 101, 108, 121, 130-134, 136, 140, 152, 158, 162, 168, 172] studies had
subjects with and without acute diarrhea but did not statistically analyze the relationship
between markers and acute diarrhea, although three [101, 152, 162] presented data stratified by
acute diarrhea status. In two studies [101, 162], a high proportion of those with acute diarrhea
were lactoferrin positive. One of these studies [101] also found that a low proportion of cases
with acute diarrhea were positive for stool IL-8, but all of the individuals positive for stool IL-8
had acute diarrhea. The study [152] utilizing the D-xylose test found that of the eight children
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with abnormal results, one had diarrhea and of 19 children with diarrhea, only one had an
abnormal result for D-xylose.
Thirteen studies included children with symptomatic or clinically silent giardiasis [15,
105, 116, 117, 122-124, 128, 133, 137, 147, 150, 154]; diagnostic methods to identify Giardia
varied between microscopy and antigen testing. Seven of these studies investigated the
relationship between markers and giardiasis [15, 116, 123, 124, 128, 147, 150] and five found
an association between at least one marker and the infection [116, 123, 124, 128, 147],
although the studies commonly reported associations between one biomarker and not others.
Some studies found serum total IgG and AGP [123], and lactose hydrogen breath test results
[147] were significantly higher in asymptomatic, Giardia-infected children than in uninfected
controls. Significantly higher mean concentrations of total IgM were found in duodenal aspirates
of Giardia cases with persistent diarrhea compared to controls without diarrhea [128]. In a study
that included subjects with and without diarrhea, giardiasis was associated with the presence of
fecal fat, and this association held across four testing methods [116]. In contrast, a study of a
fecal marker of inflammation, neopterin, did not find an association with Giardia infection [15].
The relationship between Giardia infection and a urinary marker of intestinal permeability
differed across studies. While Goto et al. found an association between giardiasis and mean
urinary L:M value in one study [124], they did not find this association in a subsequently
published study [123]. Campbell et al. did not find an association between Giardia infection and
urinary L:M [15], and another report found that urinary L:M was not consistently associated with
giardiasis [150]. The relationship between circulating markers and Giardia infection varied by
marker; specifically, an association was observed between infection and serum albumin but not
hemoglobin concentrations [123]. Six studies [105, 117, 122, 133, 137, 154] that included both
infected and uninfected subjects did not statistically investigate the relationship between Giardia
infection and these markers, although two [105, 117] of these studies did present data stratified
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by infection status and a third [154] provided a general description of the histopathology in
infected subjects. These three studies investigated cases with intestinal symptoms consistent
with celiac disease and referred for duodenal biopsy. Among the children that were not
diagnosed as having celiac disease, the studies reported widely varying percentages of subjects
with Giardia infection: 0.8% [117], 5.4% [105], and 78.6% [154].
Eight studies presented data on children with asymptomatic and/or symptomatic
cryptosporidiosis. Five of these [101, 130-132, 172] tested the association of Cryptosporidium
infection with various markers, three of which were conducted in Haiti by the same group [130132]. Fecal lactoferrin [101, 132] serum mannose-binding lectin deficiency [130], and mean
urinary L:M [172] were associated with cryptosporidiosis. A sixth study tested longitudinally
collected stools of Brazilian children for Cryptosporidium and presented the results for the
children with infection, finding that stool lactoferrin was strongly associated with symptomatic
infection in children with C. parvum but not C. hominis [108].
In the three cryptosporidiosis studies that included testing for various fecal cytokines,
results were mixed. For example, two studies found no association between infection and IL-8
[101, 131], IL-4 [131], or IL-10 [131], while associations were identified with each of these
cytokines, as well as with IL-13, in one of the studies from Haiti [132]. One of the studies from
Haiti found an association between fecal IFN-γ and control status rather than among those with
Cryptosporidium infection [131], while the other did not detect IFN-γ in the stools of any subjects
[132].
In two additional studies of subjects with and without Cryptosporidium infection,
abnormal D-xylose results were found more often among infected children [152], while fecal
lactoferrin did not appear to be related to infection status based on the numbers reported in the
study, although statistical testing of the relationship was not described [162].
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Sixteen studies assessed the association of markers of intestinal function with nutritional
status outcomes [15, 43, 53, 108-112, 122-124, 139, 145, 150, 151, 153]. The anthropometric
assessments used in these investigations varied, and the results for given measures were
mixed. We describe the results of the eight studies that measured the relationship between L:M
and anthropometrics above (see Table 15) [15, 110-112, 122-124, 150].
Urinary lactose:creatinine [151], stool neopterin [15], and intestinal lactase activity [109]
were associated with all anthropometric indices investigated while stool lactoferrin [108] and
intestinal maltase activity were not [53]. Results for urinary nitric oxide and WAZ correlation
were of borderline statistical significance (effect ratio 0.88, p=0.05) [43].
Four studies examined the association between histopathology and growth parameters
[53, 111, 145, 153]; two studies identified no relationship between weight-for-age measures
[111, 145], while one reported that WAZ score was correlated with degree of villous atrophy
[53]. Examination of tissue by digital morphometry in another study produced ambiguous results
[153]. One of these studies also examined the relationship of weight-for-age with endoscopic
visualization of the intestine and found no association [145]. Campbell et al. found varying
results when assessing the relationship of different intestinal tissue cytokines and immune
markers with WAZ score [111].
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Chapter 6. Conclusions and Future
Implications
6.1 Summary of Findings
The 77 references from the years 2000 to 2010 provide a robust body of knowledge on
biomarkers and diagnostic tests that could be useful in the quest to identify EED pathology,
especially actionable EED, the entity most in need of identification to mitigate its long-term and
life-threatening consequences.
Markers of permeability were the most frequently utilized biomarkers in the studies that
we reviewed and the urinary L:M test was the most common of those measures. Lactoferrin, as
well as other stool markers of intestinal inflammation, were also frequently assessed. Marker
results varied greatly in terms of indicating the presence of intestinal dysfunction and degree of
dysfunction when positive. This is not unexpected given the diverse populations that were
studied, including different settings and subject presentations (e.g., asymptomatic children as
well as those with various symptoms). In 20 of the 25 studies using the L:M test, the
permeability ratio was noted to be elevated. As mentioned in the L:M section in Chapter 5,
interpretation and comparison across studies in this review were hampered by variations in the
way data were reported.

6.2 Future Biomarker and Diagnostics Research
This analysis was a comprehensive attempt to identify the most promising biomarkers or
diagnostic tests on which to base future efforts and analyses of EED. Our review found many
different biomarkers, across a wide range of diagnostic categories that have been deployed to
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assess enteric function in children in resource-poor settings. However, regrettably, the extant
literature does not permit us to recommend a specific technology or biomarker that can be used
as a standard for the diagnosis of EED. There are many reasons for this difficulty:
1. The “tests” and the studies in which they were used were not developed with a
biomarker concept in mind. The assays were performed chiefly to corroborate
processes and were related to various host characteristics, but the relation to gut
dysfunction was inferred without validation. While the preponderance of tests
reported plausibly relate to gut dysfunction, their association with this particular
pathophysiology was not proven.
2. The disorder of interest is poorly defined. It is clear that there is considerable and
convergent evidence of abnormal digestive systems in the population of interest
(children in low-income settings), and that there is an outcome (i.e., stunting) that is
conceivably related to dysfunction of the gut, but the link has not been made
conclusively.
3. Histopathological evidence of gut inflammation, which has been considered to prove
the presence of EED, is an elusive gold standard (see discussion below on small
bowel biopsies). Only two studies related histopathology to specific extra-intestinal
markers. The L:M was found to correlate with intestinal inflammatory cell infiltration
[111], while D-xylose was not associated with degree of villous atrophy [136].
Moreover, there is no evidence that histopathology is related to the ultimate outcome
of interest, namely stunting, or other consequential host injury such as vaccine failure
or increased susceptibility to infections.
4. The data presented in the publications that we analyzed often did not reflect highgrade subject reporting. For example, we often encountered data reported only in
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terms of p-values and lacking reporting of effect sizes. In the field of randomized
controlled trials, adherence to Consolidated Standards of Reporting Trials
(CONSORT) Statement guidelines [309, 310] has improved the quality of clinical
trials [311-313]. The effect of the non-systematic reporting of data in the biomarker
field is that populations are not well described, methodology is not always
discernible, and statistical tests are not completely described. The data that result
might either obscure, or overstate, the value of the tests being assessed. We
applaud efforts to standardize the quality of reporting of tests and biomarkers [314].
5. More data were certainly available than were reported. For example, there is value to
the separate and simultaneous reporting of the lactulose and mannitol clearances,
but such values were often not provided. Some studies reported a biomarker as
significantly associated with an outcome of interest or correlated with another
marker. However, often they did not mention whether other outcomes or biomarkers
examined in the study were related to the biomarker of interest, leaving the reader
unsure of whether these relationships were assessed at all or if only select (e.g.,
positive) findings were reported. Correlation analyses between the tests employed in
the study were rarely reported. The publications that we reviewed did not report
utilization of supplementary data deposition resources (e.g., supplementary or weblinked tables). However, such on-line registries for meta-data have only recently
been made widely available by journals, better enabling capacity for all data to be
fully utilized to answer questions that may not have been primary to the published
study.
6. The biomarker studies that we analyzed, in the main, were often research projectdriven. They were rarely scrutinized in the context of modern test-development
standards. Many potential aspects critical to the clinical usefulness of a test, and to
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the interpretation of the reported data, were not addressed. These include matters
pertaining to the following: specimen transport, physical condition of the specimen
(e.g., water content of stool), specimen processing prior to assay performance,
temperature sensitivity, dynamic range of the test result, inhibitors (or molecules that
could cause false positives) in the analyte, durability of the assays, inter-laboratory
variability, biologic perturbations in specimens that often contain bacteria (stool and
possibly urine), and assessments of the distribution of values in normal groups. An
additional concern is that the target biomarker is presumed to be stable in the body
fluid assayed, but this is rarely documented. We would encourage the broader use of
spiking experiments, whereby the target molecule is added to the specimen of
interest, and, ideally, recovered quantitatively. These study design, subject
characterization, laboratory and analyte specification, and analysis and reporting
considerations should be well addressed in future biomarker development work.
The multitude of test methods and procedures utilized, the disparate nature of the
studies, and the limited testing for correlation with outcomes of interest (e.g., clinical signs of
EED, histopathology or other markers of EED, or clinical outcomes of EED, such as stunting,)
restrict our ability to declare any markers as clear lead candidates that warrant major or
exclusive investment in the next phase of EED biomarker research.
It is important to note that our analysis was focused only on literature produced during
the last eleven years. We acknowledge that it is possible that additional information could be
extracted from studies published during prior years. In fact, we identified more references that
were potentially relevant to our review question from the period 1990-1999 than for the period
2000-2010. However, a review of 10 randomly selected articles published between 1990-1999
and relevant to our review question (Appendix 3) did not add significant information compared to
the 77 more recent publications included in the systematic review. Also, the aforementioned
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structural issues in the reporting of the data in the studies from the 11-year period used in this
systematic review (e.g., small sample sizes, study design and reporting issues) were also
evident in the earlier studies. Moreover, even though EED research was more prevalent in the
1970s and 1980s, secular trends in nutritional, socioeconomic, and disease conditions, as well
as laboratory, epidemiologic, and biostatistical method improvements as well as potential shifts
in etiologies raise concerns about data comparability across large intervals of time.
It is quite likely that combinations of complementary markers might be required for
different purposes. For instance, specific growth measures are used for population screening
(e.g., height-for-age Z-scores to identify prevalence of stunting within given populations), and
differ from those used for individual clinical management (i.e., growth monitoring). Another
paradigm might be to use a highly sensitive screen for enteropathy, followed by more specific
reflexive testing. An example in clinical medicine would be HIV screening followed by protein
immunoblot (Western blot) assay for specific antigenic reactivity. The situation might, however,
be more complicated for EED, as there is unlikely to be a unifactorial process or driver. Ideally,
forthcoming research will identify a marker or markers that can serve related but differing
functions. The marker or set of markers might also vary according to the function desired. For
EED, we foresee multiple potential points of testing. First, in an individual, a biomarker could be
used to detect early pathologic or functional changes, at an actionable stage before stunting and
its consequences ensue. Second, a biomarker could be used to monitor clinical
progression/recovery to determine intervention effectiveness. Third, a biomarker could be used
to measure population prevalence to determine those populations where focused attention
could mitigate morbidity and mortality from enteropathy and stunting.
It is possible that a marker of end-pathway processes common to non-EED forms of
enteropathy will have more utility than EED-specific biomarkers. However, we wish to note that
the “re-purposing” of biomarkers of other enteropathies will not result in an EED-specific marker.
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This issue would be most relevant if there is geographic overlap between EED and other
enteropathies of childhood, most notably celiac disease, as might be the case in South Asia as
evidenced by recent studies from India [315].
Different approaches probably need to be tested or developed in parallel to find the
optimal biomarkers for enteropathy, and in particular, to identify the optimal biomarkers to detect
enteropathy that results in adverse consequences for the host (mostly likely stunting). Such
strategies could consist of broad screening and biomarker discovery, using agnostic
methodologies (e.g., proteomics, genomics, and metabolomics). It is important to note that
biomarker discovery requires disciplined approaches, strong statistical support to identify
attributable risk to a specific biomarker and to avoid false discoveries, as well as validation
cohorts. Underlying any such discovery and validation is the obligation to be absolutely certain
that the core data and specimens are of the highest quality. To date, cohorts have been small,
specimens not uniformly collected and handled, and outcomes have been nebulous. These
problems need to be remedied before applying novel analytics to the problem of enteropathy.
However, the MAL-ED [316] and other cohorts might provide sufficient rigor and resources to
begin to answer these questions.
If a perfect, or even an adequate single biomarker, cannot be found, an alternative might
be the development of an “enteropathy index” which integrates a constellation of clinical
symptoms and signs and/or set of markers. Variations of the “enteropathy index” might need to
accommodate the processes of screening, diagnosing dysfunction in individual cases, and
monitoring this condition and its consequences. For example, we divided the markers into eight
categories, representing different enteric functions or expressions. An “enteropathy index” might
be represented by “stacking” one marker from each of three or more categories such as
lactoferrin (intestinal inflammation) + L:M (primarily permeability but mannitol excretion provides
a measure of absorptive function) + lactose hydrogen breath test (digestion). We wish to note
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that a recent publication by Kosek, et al. [317] provides data in support of this concept,
proposing the use of three stool markers (neopterin, myeloperoxidase, and alpha-1-antitrypsin)
reflective of inflammatory and permeability processes.
In considering data to be obtained from biopsy specimens, it will be important to balance
information to be gleaned against the small risk related to the procedure. Based on current state
of knowledge, it is not known when enteric functional deficits related to environmental
enteropathy occur in temporal relation to histopathologic changes. When EED research does
incorporate obtaining biopsies, such issues should be considered. Given the challenges in
obtaining pediatric biopsies, any future EED biopsy research should include ascertainment of
the relationship between histopathology and growth, in addition to utilization of histopathology
as a “gold standard” by which less invasive biomarker performance is gauged.
Whichever of these biomarker discovery and validation strategies is employed, we urge
rigorous adherence to standards for the design and reporting of biomarker studies. The
“STAndards for the Reporting of Diagnostic accuracy studies” or “STARD” initiative provides an
excellent framework and checklist for diagnostic accuracy studies, allowing readers to assess
for potential bias in a study (internal validity) and to evaluate generalizability (external validity).
The STARD initiative is akin to the CONSORT statement for randomized controlled trials [318]
and provides an excellent structure for consideration for development of biomarker discovery
study design and reporting guidelines [319].
In reviewing these studies, it appears that many tests were compromised by choice of
analyte, and independent of processes, it is important, looking forward, to consider the body
substance analyzed, and the benefits and drawbacks of each. These are summarized in Table
16.
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Table 16. Analyte attributes.
Comments on attributes of analyte, relevant to current and future biomarker assessments.
Attribute
1

Invasiveness
Steady state
2
assessment
Requires
processing before
freezing or long3
term storage
4
Schedulable
Consent issues

5

Components of
analyte that can be
studied
Technology to
6
obtain
7

Biohazardous
8
Offensive
Ability to collect
and bring from
9
home
10
Provenance

Blood

Urine

Stool

Breath

Biopsies

Saliva

High

Low

Low

Med

High

Med

Yes

Sometimes

Sometimes

Yes

Yes

Yes

Yes

No

No

No

Yes

No

Yes

No

No

Yes

Yes

Medium

Low

Low

Low

Yes
High

Mostly urine

Stool,
microbes

Plasma,
serum, white
cells, red cells,
host nucleic
acids

Gas

Low

Bulk
tissues,
cells,
microbes

Saliva,
microbes

Low

Low

Low

Med

High

Med (if
special
swabs
employed)

High
Med

Low
Low

Low
High

Med
Med

High
Med

Low
Med

No

Yes

Yes

No

No

Yes

Good

Fair

Fair

Good

Good

Fair

1

Invasiveness is defined as "low" if analyte is produced spontaneously by subject, "medium" if a special apparatus or
collection device is needed to obtain the specimen and "high" if mucosa or integument is breached to obtain.
2
Steady state is assessed (“yes”) if the substance studied is likely to remain stable on an hour-to-hour basis, and not
assessed (“no”) if substance studied is capable of changing profoundly in a short interval.
3
Processing (e.g., physical separation by centrifugation of components) is generally performed before long-term
storage.
4
Schedulable samplings are those that can be arranged and obtained in advance, i.e., are not generally produced on
command by children.
5
Consent issues are "low" if the substance is spontaneously produced without any physical risk to the subject,
"medium" if obtaining the substance has a degree of physical discomfort or anxiety risk such as a hematoma or pain
from a phlebotomy, and "high" if there is any possibility of injury that could result in hospitalization.
6
"Low" technology describes minimally expensive materials that are easily obtainable, such as needles and syringes;
"medium" cost pertains to special-order items, such as breath hydrogen bags; and "high" cost pertains to materials
obtained in an inpatient setting using sophisticated technology, such as endoscopic and biopsy equipment.
7
Materials are considered to have "low" biohazard risk if the likelihood of contracting a life-threatening infection are nil
if the substance is placed on an open cut or inhaled; "medium" if a serious but rarely life threatening infection would
result if the substance is placed on an open cut or inhaled (breath is placed in this category because of the possibility
of tuberculosis or other infections spread via respiratory droplets); and "high" if a life-threatening infection, most
notably HIV, would result if the substance is placed on an open cut or inhaled.
8
Offensiveness relates to a general reaction to a worker’s skin coming in contact with the substance accidentally.
9
Materials can be brought from home for analysis, with a modest amount of instruction and materials.
10
Provenance relates to low, medium, or high risk of accidental or intentional substitution by a research subject or
patient or family.
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As can be seen, each body substance has strengths and drawbacks in research studies
and clinical practice, and much of the literature chose specimens to analyze based either on
precedent or lack of suitable alternatives. In reviewing the tests, blood has many commendable
attributes, but the requirement to breach the skin to obtain the specimen adds an extreme, and
often limiting, constraint to sampling. We wish to propose for consideration the use of
transcutaneous technology to evaluate blood components. These devices are quite successful
in measuring blood gases (oxygen and carbon dioxide), bilirubin, and glucose, and their
methodology might be adaptable to either endogenous targets (e.g., iron) or challenge
substances (D-xylose), and therefore have a high likelihood of playing a useful role in detecting
and monitoring enteropathy.
In all assessments, it is important to recognize that normal or reference values are highly
abstract concepts. Often, normal values were obtained from studying cohorts of children in
developed countries, and there are rarely opportunities to establish normal values based on
putatively normal subjects in the same environment, and of the same genetic makeup, as the
subjects studied for enteropathy. Unless and until methodology and sampling of subjects are
used to establish such norms, it will be difficult to calibrate the magnitude of abnormality. This
problem is compounded by definitional issues in pathology. While we believe that intestinal
inflammation is quite likely undesirable, we cannot state with certainty that an inflamed mucosa
is wholly deleterious for children in resource-poor settings. Specifically, it is possible that low-tomoderate-grade inflammation of the gut is a homeostatic mechanism in environments in which
enteric pathogens are ubiquitous.
The obstacles we encountered in this review suggest opportunities to adhere to
publication standards in future reports of biomarker research related to EED. We were largely
hindered by inadequate definitions and reporting incompleteness. The STARD guidelines are a
very good basis for subsequent reports, but might need to be adapted in consideration of the
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biomarker field. Specifically, processes that are interrogated by the biomarker should be clearly
described, if known, and if not known, then that should be stated. Rigorous statistics should be
applied for two overriding reasons: first, it is critical that point estimates (including percent
attribution where study design allows for calculation) and confidence intervals should be
reported in addition to the less informative p-values; second, in the assessment of multiple
biomarkers identified in agnostic discovery projects, it is important to incorporate statistically
valid safeguards against false discovery via multiple comparisons.
We also believed that the authors of the texts we reviewed generally obtained more data
than they reported, probably because of page limitations or focus of the paper. Very few of the
publications reported data that were obtained exclusively in the context of biomarker
development or evaluation; many of the reports produced biomarker data in the context of other
studies. Also, there was sparse use of online repositories for storage of meta-data. As such,
considerable opportunities to review relevant data for biomarkers might have been lost.
Certainly, there are increasing capacities to archive ancillary data for interrogation by other
investigators. We are encouraged by this trend and believe that complete data deposition
should be considered a “best practice” of future enteropathy-biomarker projects. Furthermore,
systematic deposition is best facilitated, for ease of input as well as extraction of data, by
placement in the public domain.
In addition to more rigorous and transparent provision of study design and major
findings, it is apparent that future research in the field will be handicapped by current journal
publication constraints. Specifically, biomarker studies in human populations are likely to
generate volumes of data that are well in excess of the word and table limits of standard journal
articles. This is especially regrettable, because the cost of accruing human cohorts is
increasing, and therefore there is an obligation to make the most of the data that are produced
henceforth. We propose that a biomarker data repository be established, and used to advance
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research in this field, and to be accessible for future data queries. We do acknowledge,
however, that the establishment, preservation, and curation of data require resources that are
often not provided to the projects in which the data are generated. Nonetheless, a standardized,
disciplined, and logical deposition and maintenance of data while studies are performed will
reduce the expense of archiving the material after the study. Such investments will enhance and
expedite biomarker research and application for reducing the burden of stunting.

287

APPENDICES
Appendix 1. Search terms for EED articles of interest.
Search terms for EED alone are in gray, malnutrition outcomes are in pink. A combined
strategy, denoted in yellow was utilized for searches in the smaller WHO databases.

PubMed TE/ED
completed April 1, 2010 (24156 Citations)
Step 1 (24875 Citations)
("Viruses" [Mesh] OR "Bacteria" [Mesh] OR "Parasites" [Mesh]) AND "Intestinal Diseases"
[Mesh]
Step 2 (2789652 Citations)
("malnutrition" OR "undernutrition" OR "micronutrient" OR "nutritional deficiency" OR "Nutrition
Disorders" [Mesh] OR "child development" [Mesh ] OR environmental OR recurrent OR
recurring OR persistent OR chronic OR "Communicable Disease Control" [Mesh] OR
handwashing OR "hand washing" OR toilet* OR sanitation OR hygiene OR drinking)
Step 3 (478234 Citations)
(enteropathy OR enteropathies OR diarrhea OR diarrhoea OR diarrhoeal OR diarrheal OR
"Malabsorption Syndromes" [Mesh])
Step 2 AND 3 combined (93491 Citations)
Step 4 (759 Citations)
("Diarrhea" [Mesh] AND "chronic disease" [Mesh]) 1, 378
Step 5
("environmental enteropathies" OR "environmental enteropathy" OR "tropical enteropathy" OR
"tropical enteropathies" OR "sprue, tropical " [MeSH] OR "tropical sprue" OR " Idiopathic
Tropical Malabsorption Syndromes" OR " Idiopathic Tropical Malabsorption Syndrome")
Step 6 (37074 Citations)
"Intestinal Absorption" [Mesh]
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Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 (148353 Citations )
Step 7 (1826934 Citations )
"Child" [Mesh] OR "Maternal-Child Health Centers" [Mesh] OR "Child Nutrition Sciences" [Mesh]
OR "Child Health Services" [Mesh] OR "Child Nutritional Physiological Phenomena" [Mesh] OR
"Child Nutrition Disorders" [Mesh] OR "Child Mortality" [Mesh] OR "Child Welfare" [Mesh] OR
"Child Care" [Mesh] OR "Child Reactive Disorders" [Mesh] OR "Child Guidance" [Mesh] OR
"Child Reactive Disorders" [Mesh] OR "Child Behavior Disorders" [Mesh] OR "Child, Orphaned"
[Mesh] OR "Child, Institutionalized" [Mesh] OR "Child, Hospitalized" [Mesh] OR "Child
Development" [Mesh] OR "Child Behavior" [Mesh] OR "Developmental Disabilities" [Mesh] OR
"Mental Disorders Diagnosed in Childhood" [Mesh] OR "Disabled Children" [Mesh] OR
"children" [TIAB] OR "newborn*" [TIAB] OR "childhood" [TIAB] OR "baby" [TIAB] OR "babies"
[TIAB] OR "toddler" [TIAB] OR "toddlers" [TIAB] OR "infants" [TIAB] OR "infant" [TIAB] OR
"infantile" [TIAB] OR "young patient" [TIAB] OR "young patients" [TIAB] OR "Pediatric Nursing"
[Mesh] OR "Pediatric Assistants" [Mesh] OR "Hospitals, Pediatric" [Mesh] OR "Intensive Care
Units, Pediatric" [Mesh] OR "Pediatrics" [Mesh] OR "Pediatricians" [TIAB] OR "paediatricians"
[TIAB] OR "Pediatrician" [TIAB] OR "paediatrician" [TIAB] OR "Pediatrics" [TIAB] OR
"paediatrics" [TIAB] OR "Pediatric" [TIAB] OR "paediatric" [TIAB]
Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 AND Step7 (24156 Citations)

EMBASE TE/ED
completed April 1, 2010 (20052 Citations)
Step 1 (39771 Citations)
'gastroenteritis'/exp OR 'gastroenteritis' OR 'protein losing gastroenteropathy'/exp OR 'protein
losing gastroenteropathy' OR 'celiac disease'/exp OR 'celiac disease' OR 'tropical sprue'/exp
OR 'tropical sprue' OR 'infantile gastroenteritis'/exp OR 'infantile gastroenteritis' OR 'acute
gastroenteritis'/exp OR 'acute gastroenteritis' OR 'viral gastroenteritis'/exp OR 'viral
gastroenteritis' OR 'persistent diarrhea' OR 'persistent diarrhoea' OR 'recurrent diarrhea' OR
'recurrent diarrhoea'
Step 2 (4062 Citations)
'intestine mucosa permeability'/exp OR 'small intestine absorption'/exp
Step 3 (745 Citations)
'environmental enteropathies' OR 'environmental enteropathy' OR 'tropical enteropathy' OR
'tropical enteropathies' OR 'tropical sprue'/exp OR 'tropical sprue' OR 'idiopathic tropical
malabsorption syndromes' OR 'idiopathic tropical malabsorption syndrome'
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OR
Step 4 (3611 citations)
('chronic disease'/exp AND 'diarrhea'/exp) OR 'chronic diarrhea'/exp
Step 5 (3156573 Citations)
'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR
newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR
'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant*
OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age'
OR pediatr* OR paediatr* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child
health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality'
OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric
hospital' OR child*
(Step 1 OR Step 2 OR Step 3 OR Step 4) AND Step 5 (20052 Citations)

Global Health TE/ED
completed June 1, 2010 (7825 citations)
Step 1 (232244 Citations)
(child or children or newborn$ or childhood or baby or babies or toddler or toddlers or infants or
infant or infantile or "young patients" or "young patient" or pediatrics or pediatric or paediatric or
paediatrics or girls or sons or daughters or "child welfare" or "rearing practices" or unicef or
paediatr$ or "child development" or "child nutrition" or "child health" or kid or kids or
pediatricians or paediatricians).af.
Step 2 (4555 Citations)
(enteropathy or scouring).id. OR ("chronic infections" and diarrhoea).de. OR (diarrhea and
"nutritional status").id. OR ("tropical sprue$" or "tropical enteropath$" or "environmental
enteropath$" or "persistent diarrhea$" or "Persistent diarrhoea$" or "chronic diarrhoea$"
or "chronic diarrhea$" or "intestinal inflamm*" or "intestinal permeability").af.
Step 3 (620850 Citations)
(undernutrition or "tropical countries" or "tropical zones" or "parasitic infections").id. or (tropics or
"bacterial diseases").de. or (vv600 or vv210 or hh600 or ll822 or vv130).cc.
Step 4 (28447 Citations)
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"("intestinal mucosa" or "small intestine" or "gastroenteritis" or intestines or "intestinal diseases"
or "intestinal absorption").de. or (Intestines or "gastrointestinal tract").id.
Step 1 AND (Step 2 OR (Step 3 AND Step 4)) (10242 Citations)
Step 5 (*Journals indexed by PubMed and Embase removed) (2417 Citations)
"Journal of Pediatric Gastroenterology and Nutrition" [Journals] OR Journal of Clinical
Microbiology" [Journals] OR"Archives of Disease in Childhood" [Journals] OR"Pediatric
Infectious Disease Journal" [Journals] OR"Journal of Infectious Diseases" [Journals]
OR"Journal of Pediatrics" [Journals] OR
"Clinical Infectious Diseases" [Journals] OR"Infection and Immunity" [Journals] OR
"Journal of Medical Virology" [Journals] OR"Transactions of the Royal Society of Tropical
Medicine and Hygiene" [Journals] OR"Journal of Nutrition" [Journals] OR "East African Medical
Journal" [Journals]
"BMC Infectious Diseases" [Journals] OR"American Journal of Tropical Medicine and Hygiene"
[Journals] OR"Pediatric Research" [Journals] OR"Archives de Pediatrie" [Journals] OR
"Journal of Paediatrics and Child Health" [Journals] OR"Asian Pacific Journal of Allergy and
Immunology" [Journals] OR"Journal of Tropical Pediatrics" [Journals]
Step 1 AND (Step 2 OR (Step 3 AND Step 4) NOT Step 5 (7825 Citations)

PubMed Malnutrition
completed April 19, 2010 (23238 Citations)
Step 1 (2540333 Citations)
"developing country" [tiab] OR "developing countries" [tiab] OR "developing nation" [tiab] OR
"developing nations" [tiab] OR "developing population" [tiab] OR "developing populations" [tiab]
OR "developing world" [tiab] OR "less developed country" [tiab] OR "less developed countries"
[tiab] OR "less developed nation" [tiab] OR "less developed nations" [tiab] OR "less developed
population" [tiab] OR "less developed populations" [tiab] OR "less developed world" [tiab] OR
"lesser developed country" [tiab] OR "lesser developed countries" [tiab] OR "lesser developed
nation" [tiab] OR "lesser developed nations" [tiab] OR "lesser developed population" [tiab] OR
"lesser developed populations" [tiab] OR "lesser developed world" [tiab] OR "under developed
country" [tiab] OR "under developed countries" [tiab] OR "under developed nation" [tiab] OR
"under developed nations" [tiab] OR "under developed population" [tiab] OR "under developed
populations" [tiab] OR "under developed world" [tiab] OR "underdeveloped country" [tiab] OR
"underdeveloped countries" [tiab] OR "underdeveloped nation" [tiab] OR "underdeveloped
nations" [tiab] OR "underdeveloped population" [tiab] OR "underdeveloped populations" [tiab]
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OR "underdeveloped world" [tiab] OR "middle income country" [tiab] OR "middle income
countries" [tiab] OR "middle income nation" [tiab] OR "middle income nations" [tiab] OR "middle
income population" [tiab] OR "middle income populations" [tiab] OR "low income country" [tiab]
OR "low income countries" [tiab] OR "low income nation" [tiab] OR "low income nations" [tiab]
OR "low income population" [tiab] OR "low income populations" [tiab] OR "lower income
country" [tiab] OR "lower income countries" [tiab] OR "lower income nation" [tiab] OR "lower
income nations" [tiab] OR "lower income population" [tiab] OR "lower income populations" [tiab]
OR "underserved country" [tiab] OR "underserved countries" [tiab] OR "underserved nation"
[tiab] OR "underserved nations" [tiab] OR "underserved population" [tiab] OR "underserved
populations" [tiab] OR "underserved world" [tiab] OR "under served country" [tiab] OR "under
served countries" [tiab] OR "under served nation" [tiab] OR "under served nations" [tiab] OR
"under served population" [tiab] OR "under served populations" [tiab] OR "under served world"
[tiab] OR "deprived country" [tiab] OR "deprived countries" [tiab] OR "deprived nation" [tiab] OR
"deprived nations" [tiab] OR "deprived population" [tiab] OR "deprived populations" [tiab] OR
"deprived world" [tiab] OR "poor country" [tiab] OR "poor countries" [tiab] OR "poor nation" [tiab]
OR "poor nations" [tiab] OR "poor population" [tiab] OR "poor populations" [tiab] OR "poor
world" [tiab] OR "poorer country" [tiab] OR "poorer countries" [tiab] OR "poorer nation" [tiab] OR
"poorer nations" [tiab] OR "poorer population" [tiab] OR "poorer populations" [tiab] OR "poorer
world" [tiab] OR "developing economy" [tiab] OR "developing economies" [tiab] OR "less
developed economy" [tiab] OR "less developed economies" [tiab] OR "lesser developed
economy" [tiab] OR "lesser developed economies" [tiab] OR "under developed economy" [tiab]
OR "under developed economies" [tiab] OR "underdeveloped economy" [tiab] OR
"underdeveloped economies" [tiab] OR "middle income economy" [tiab] OR "middle income
economies" [tiab] OR "low income economy" [tiab] OR "low income economies" [tiab] OR "lower
income economy" [tiab] OR "lower income economies" [tiab] OR "low gdp" [tiab] OR "low gnp"
[tiab] OR "low gross domestic" [tiab] OR "low gross national" [tiab] OR "lower gdp" [tiab] OR
"lower gnp" [tiab] OR "lower gross domestic" [tiab] OR "lower gross national" [tiab] OR lmic [tiab]
OR lmics [tiab] OR "third world" [tiab] OR "lami country" [tiab] OR "lami countries" [tiab] OR
"transitional country" [tiab] OR "transitional countries" [tiab] OR "developing country" [ot] OR
"developing countries" [ot] OR "developing nation" [ot] OR "developing nations" [ot] OR
"developing population" [ot] OR "developing populations" [ot] OR "developing world" [ot] OR
"less developed country" [ot] OR "less developed countries" [ot] OR "less developed nation" [ot]
OR "less developed nations" [ot] OR "less developed population" [ot] OR "less developed
populations" [ot] OR "less developed world" [ot] OR "lesser developed country" [ot] OR "lesser
developed countries" [ot] OR "lesser developed nation" [ot] OR "lesser developed nations" [ot]
OR "lesser developed population" [ot] OR "lesser developed populations" [ot] OR "lesser
developed world" [ot] OR "under developed country" [ot] OR "under developed countries" [ot]
OR "under developed nation" [ot] OR "under developed nations" [ot] OR "under developed
population" [ot] OR "under developed populations" [ot] OR "under developed world" [ot] OR
"underdeveloped country" [ot] OR "underdeveloped countries" [ot] OR "underdeveloped nation"
[ot] OR "underdeveloped nations" [ot] OR "underdeveloped population" [ot] OR
"underdeveloped populations" [ot] OR "underdeveloped world" [ot] OR "middle income country"
[ot] OR "middle income countries" [ot] OR "middle income nation" [ot] OR "middle income
nations" [ot] OR "middle income population" [ot] OR "middle income populations" [ot] OR "low
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income country" [ot] OR "low income countries" [ot] OR "low income nation" [ot] OR "low income
nations" [ot] OR "low income population" [ot] OR "low income populations" [ot] OR "lower
income country" [ot] OR "lower income countries" [ot] OR "lower income nation" [ot] OR "lower
income nations" [ot] OR "lower income population" [ot] OR "lower income populations" [ot] OR
"underserved country" [ot] OR "underserved countries" [ot] OR "underserved nation" [ot] OR
"underserved nations" [ot] OR "underserved population" [ot] OR "underserved populations" [ot]
OR "underserved world" [ot] OR "under served country" [ot] OR "under served countries" [ot]
OR "under served nation" [ot] OR "under served nations" [ot] OR "under served population" [ot]
OR "under served populations" [ot] OR "under served world" [ot] OR "deprived country" [ot] OR
"deprived countries" [ot] OR "deprived nation" [ot] OR "deprived nations" [ot] OR "deprived
population" [ot] OR "deprived populations" [ot] OR "deprived world" [ot] OR "poor country" [ot]
OR "poor countries" [ot] OR "poor nation" [ot] OR "poor nations" [ot] OR "poor population" [ot]
OR "poor populations" [ot] OR "poor world" [ot] OR "poorer country" [ot] OR "poorer countries"
[ot] OR "poorer nation" [ot] OR "poorer nations" [ot] OR "poorer population" [ot] OR "poorer
populations" [ot] OR "poorer world" [ot] OR "developing economy" [ot] OR "developing
economies" [ot] OR "less developed economy" [ot] OR "less developed economies" [ot] OR
"lesser developed economy" [ot] OR "lesser developed economies" [ot] OR "under developed
economy" [ot] OR "under developed economies" [ot] OR "underdeveloped economy" [ot] OR
"underdeveloped economies" [ot] OR "middle income economy" [ot] OR "middle income
economies" [ot] OR "low income economy" [ot] OR "low income economies" [ot] OR "lower
income economy" [ot] OR "lower income economies" [ot] OR "low gdp" [ot] OR "low gnp" [ot]
OR "low gross domestic" [ot] OR "low gross national" [ot] OR "lower gdp" [ot] OR "lower gnp"
[ot] OR "lower gross domestic" [ot] OR "lower gross national" [ot] OR lmic [ot] OR lmics [ot] OR
"third world" [ot] OR "lami country" [ot] OR "lami countries" [ot] OR "transitional country" [ot] OR
"transitional countries" [ot] OR Africa [pl] OR Asia [pl] OR Caribbean [pl] OR West Indies [pl] OR
South America [pl] OR Latin America [pl] OR Central America [pl] OR Afghanistan [pl] OR
Albania [pl] OR Algeria [pl] OR Angola [pl] OR Antigua [pl] OR Barbuda [pl] OR Argentina [pl]
OR Armenia [pl] OR Armenian [pl] OR Aruba [pl] OR Azerbaijan [pl] OR Bahrain [pl] OR
Bangladesh [pl] OR Barbados [pl] OR Benin [pl] OR Byelarus [pl] OR Byelorussian [pl] OR
Belarus [pl] OR Belorussian [pl] OR Belorussia [pl] OR Belize [pl] OR Bhutan [pl] OR Bolivia [pl]
OR Bosnia [pl] OR Herzegovina [pl] OR Hercegovina [pl] OR Botswana [pl] OR Brazil [pl] OR
Bulgaria [pl] OR Burkina Faso [pl] OR Burkina Fasso [pl] OR Upper Volta [pl] OR Burundi [pl]
OR Urundi [pl] OR Cambodia [pl] OR Khmer Republic [pl] OR Kampuchea [pl] OR Cameroon
[pl] OR Cameroons [pl] OR Cameron [pl] OR Camerons [pl] OR Cape Verde [pl] OR Central
African Republic [pl] OR Chad [pl] OR Chile [pl] OR China [pl] OR Colombia [pl] OR Comoros
[pl] OR Comoro Islands [pl] OR Comores [pl] OR Mayotte [pl] OR Congo [pl] OR Zaire [pl] OR
Costa Rica [pl] OR Cote d'Ivoire [pl] OR Ivory Coast [pl] OR Croatia [pl] OR Cuba [pl] OR
Cyprus [pl] OR Czechoslovakia [pl] OR Czech Republic [pl] OR Slovakia [pl] OR Slovak
Republic [pl] OR Djibouti [pl] OR French Somaliland [pl] OR Dominica [pl] OR Dominican
Republic [pl] OR East Timor [pl] OR East Timur [pl] OR Timor Leste [pl] OR Ecuador [pl] OR
Egypt [pl] OR United Arab Republic [pl] OR El Salvador [pl] OR Eritrea [pl] OR Estonia [pl] OR
Ethiopia [pl] OR Fiji [pl] OR Gabon [pl] OR Gabonese Republic [pl] OR Gambia [pl] OR Gaza [pl]
OR Georgia Republic [pl] OR Georgian Republic [pl] OR Ghana [pl] OR Gold Coast [pl] OR
Greece [pl] OR Grenada [pl] OR Guatemala [pl] OR Guinea [pl] OR Guam [pl] OR Guiana [pl]
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OR Guyana [pl] OR Haiti [pl] OR Honduras [pl] OR Hungary [pl] OR India [pl] OR Maldives [pl]
OR Indonesia [pl] OR Iran [pl] OR Iraq [pl] OR Isle of Man [pl] OR Jamaica [pl] OR Jordan [pl]
OR Kazakhstan [pl] OR Kazakh [pl] OR Kenya [pl] OR Kiribati [pl] OR Korea [pl] OR Kosovo [pl]
OR Kyrgyzstan [pl] OR Kirghizia [pl] OR Kyrgyz Republic [pl] OR Kirghiz [pl] OR Kirgizstan [pl]
OR "Lao PDR" [pl] OR Laos [pl] OR Latvia [pl] OR Lebanon [pl] OR Lesotho [pl] OR Basutoland
[pl] OR Liberia [pl] OR Libya [pl] OR Lithuania [pl] OR Macedonia [pl] OR Madagascar [pl] OR
Malagasy Republic [pl] OR Malaysia [pl] OR Malaya [pl] OR Malay [pl] OR Sabah [pl] OR
Sarawak [pl] OR Malawi [pl] OR Nyasaland [pl] OR Mali [pl] OR Malta [pl] OR Marshall Islands
[pl] OR Mauritania [pl] OR Mauritius [pl] OR Agalega Islands [pl] OR Mexico [pl] OR Micronesia
[pl] OR Middle East [pl] OR Moldova [pl] OR Moldovia [pl] OR Moldovian [pl] OR Mongolia [pl]
OR Montenegro [pl] OR Morocco [pl] OR Ifni [pl] OR Mozambique [pl] OR Myanmar [pl] OR
Myanma [pl] OR Burma [pl] OR Namibia [pl] OR Nepal [pl] OR Netherlands Antilles [pl] OR New
Caledonia [pl] OR Nicaragua [pl] OR Niger [pl] OR Nigeria [pl] OR Northern Mariana Islands [pl]
OR Oman [pl] OR Muscat [pl] OR Pakistan [pl] OR Palau [pl] OR Palestine [pl] OR Panama [pl]
OR Paraguay [pl] OR Peru [pl] OR Philippines [pl] OR Philipines [pl] OR Phillipines [pl] OR
Phillippines [pl] OR Poland [pl] OR Portugal [pl] OR Puerto Rico [pl] OR Romania [pl] OR
Rumania [pl] OR Roumania [pl] OR Russia [pl] OR Russian [pl] OR Rwanda [pl] OR Ruanda [pl]
OR Saint Kitts [pl] OR St Kitts [pl] OR Nevis [pl] OR Saint Lucia [pl] OR St Lucia [pl] OR Saint
Vincent [pl] OR St Vincent [pl] OR Grenadines [pl] OR Samoa [pl] OR Samoan Islands [pl] OR
Navigator Island [pl] OR Navigator Islands [pl] OR Sao Tome [pl] OR Saudi Arabia [pl] OR
Senegal [pl] OR Serbia [pl] OR Montenegro [pl] OR Seychelles [pl] OR Sierra Leone [pl] OR
Slovenia [pl] OR Sri Lanka [pl] OR Ceylon [pl] OR Solomon Islands [pl] OR Somalia [pl] OR
Sudan [pl] OR Suriname [pl] OR Surinam [pl] OR Swaziland [pl] OR Syria [pl] OR Tajikistan [pl]
OR Tadzhikistan [pl] OR Tadjikistan [pl] OR Tadzhik [pl] OR Tanzania [pl] OR Thailand [pl] OR
Togo [pl] OR Togolese Republic [pl] OR Tonga [pl] OR Trinidad [pl] OR Tobago [pl] OR Tunisia
[pl] OR Turkey [pl] OR Turkmenistan [pl] OR Turkmen [pl] OR Uganda [pl] OR Ukraine [pl] OR
Uruguay [pl] OR USSR [pl] OR Soviet Union [pl] OR Union of Soviet Socialist Republics [pl] OR
Uzbekistan [pl] OR Uzbek OR Vanuatu [pl] OR New Hebrides [pl] OR Venezuela [pl] OR
Vietnam [pl] OR Viet Nam [pl] OR West Bank [pl] OR Yemen [pl] OR Yugoslavia [pl] OR Zambia
[pl] OR Zimbabwe [pl] OR Rhodesia [pl] OR Africa [tiab] OR Asia [tiab] OR Caribbean [tiab] OR
West Indies [tiab] OR South America [tiab] OR Latin America [tiab] OR Central America [tiab]
OR Afghanistan [tiab] OR Albania [tiab] OR Algeria [tiab] OR Angola [tiab] OR Antigua [tiab] OR
Barbuda [tiab] OR Argentina [tiab] OR Armenia [tiab] OR Armenian [tiab] OR Aruba [tiab] OR
Azerbaijan [tiab] OR Bahrain [tiab] OR Bangladesh [tiab] OR Barbados [tiab] OR Benin [tiab] OR
Byelarus [tiab] OR Byelorussian [tiab] OR Belarus [tiab] OR Belorussian [tiab] OR Belorussia
[tiab] OR Belize [tiab] OR Bhutan [tiab] OR Bolivia [tiab] OR Bosnia [tiab] OR Herzegovina [tiab]
OR Hercegovina [tiab] OR Botswana [tiab] OR Brazil [tiab] OR Bulgaria [tiab] OR Burkina Faso
[tiab] OR Burkina Fasso [tiab] OR Upper Volta [tiab] OR Burundi [tiab] OR Urundi [tiab] OR
Cambodia [tiab] OR Khmer Republic [tiab] OR Kampuchea [tiab] OR Cameroon [tiab] OR
Cameroons [tiab] OR Cameron [tiab] OR Camerons [tiab] OR Cape Verde [tiab] OR Central
African Republic [tiab] OR Chad [tiab] OR Chile [tiab] OR China [tiab] OR Colombia [tiab] OR
Comoros [tiab] OR Comoro Islands [tiab] OR Comores [tiab] OR Mayotte [tiab] OR Congo [tiab]
OR Zaire [tiab] OR Costa Rica [tiab] OR Cote d'Ivoire [tiab] OR Ivory Coast [tiab] OR Croatia
[tiab] OR Cuba [tiab] OR Cyprus [tiab] OR Czechoslovakia [tiab] OR Czech Republic [tiab] OR
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Slovakia [tiab] OR Slovak Republic [tiab] OR Djibouti [tiab] OR French Somaliland [tiab] OR
Dominica [tiab] OR Dominican Republic [tiab] OR East Timor [tiab] OR East Timur [tiab] OR
Timor Leste [tiab] OR Ecuador [tiab] OR Egypt [tiab] OR United Arab Republic [tiab] OR El
Salvador [tiab] OR Eritrea [tiab] OR Estonia [tiab] OR Ethiopia [tiab] OR Fiji [tiab] OR Gabon
[tiab] OR Gabonese Republic [tiab] OR Gambia [tiab] OR Gaza [tiab] OR Georgia Republic
[tiab] OR Georgian Republic [tiab] OR Ghana [tiab] OR Gold Coast [tiab] OR Greece [tiab] OR
Grenada [tiab] OR Guatemala [tiab] OR Guinea [tiab] OR Guam [tiab] OR Guiana [tiab] OR
Guyana [tiab] OR Haiti [tiab] OR Honduras [tiab] OR Hungary [tiab] OR India [tiab] OR Maldives
[tiab] OR Indonesia [tiab] OR Iran [tiab] OR Iraq [tiab] OR Isle of Man [tiab] OR Jamaica [tiab]
OR Jordan [tiab] OR Kazakhstan [tiab] OR Kazakh [tiab] OR Kenya [tiab] OR Kiribati [tiab] OR
Korea [tiab] OR Kosovo [tiab] OR Kyrgyzstan [tiab] OR Kirghizia [tiab] OR Kyrgyz Republic [tiab]
OR Kirghiz [tiab] OR Kirgizstan [tiab] OR "Lao PDR" [tiab] OR Laos [tiab] OR Latvia [tiab] OR
Lebanon [tiab] OR Lesotho [tiab] OR Basutoland [tiab] OR Liberia [tiab] OR Libya [tiab] OR
Lithuania [tiab] OR Macedonia [tiab] OR Madagascar [tiab] OR Malagasy Republic [tiab] OR
Malaysia [tiab] OR Malaya [tiab] OR Malay [tiab] OR Sabah [tiab] OR Sarawak [tiab] OR Malawi
[tiab] OR Nyasaland [tiab] OR Mali [tiab] OR Malta [tiab] OR Marshall Islands [tiab] OR
Mauritania [tiab] OR Mauritius [tiab] OR Agalega Islands [tiab] OR Mexico [tiab] OR Micronesia
[tiab] OR Middle East [tiab] OR Moldova [tiab] OR Moldovia [tiab] OR Moldovian [tiab] OR
Mongolia [tiab] OR Montenegro [tiab] OR Morocco [tiab] OR Ifni [tiab] OR Mozambique [tiab] OR
Myanmar [tiab] OR Myanma [tiab] OR Burma [tiab] OR Namibia [tiab] OR Nepal [tiab] OR
Netherlands Antilles [tiab] OR New Caledonia [tiab] OR Nicaragua [tiab] OR Niger [tiab] OR
Nigeria [tiab] OR Northern Mariana Islands [tiab] OR Oman [tiab] OR Muscat [tiab] OR Pakistan
[tiab] OR Palau [tiab] OR Palestine [tiab] OR Panama [tiab] OR Paraguay [tiab] OR Peru [tiab]
OR Philippines [tiab] OR Philipines [tiab] OR Phillipines [tiab] OR Phillippines [tiab] OR Poland
[tiab] OR Portugal [tiab] OR Puerto Rico [tiab] OR Romania [tiab] OR Rumania [tiab] OR
Roumania [tiab] OR Russia [tiab] OR Russian [tiab] OR Rwanda [tiab] OR Ruanda [tiab] OR
Saint Kitts [tiab] OR St Kitts [tiab] OR Nevis [tiab] OR Saint Lucia [tiab] OR St Lucia [tiab] OR
Saint Vincent [tiab] OR St Vincent [tiab] OR Grenadines [tiab] OR Samoa [tiab] OR Samoan
Islands [tiab] OR Navigator Island [tiab] OR Navigator Islands [tiab] OR Sao Tome [tiab] OR
Saudi Arabia [tiab] OR Senegal [tiab] OR Serbia [tiab] OR Montenegro [tiab] OR Seychelles
[tiab] OR Sierra Leone [tiab] OR Slovenia [tiab] OR Sri Lanka [tiab] OR Ceylon [tiab] OR
Solomon Islands [tiab] OR Somalia [tiab] OR Sudan [tiab] OR Suriname [tiab] OR Surinam [tiab]
OR Swaziland [tiab] OR Syria [tiab] OR Tajikistan [tiab] OR Tadzhikistan [tiab] OR Tadjikistan
[tiab] OR Tadzhik [tiab] OR Tanzania [tiab] OR Thailand [tiab] OR Togo [tiab] OR Togolese
Republic [tiab] OR Tonga [tiab] OR Trinidad [tiab] OR Tobago [tiab] OR Tunisia [tiab] OR Turkey
[tiab] OR Turkmenistan [tiab] OR Turkmen [tiab] OR Uganda [tiab] OR Ukraine [tiab] OR
Uruguay [tiab] OR USSR [tiab] OR Soviet Union [tiab] OR Union of Soviet Socialist Republics
[tiab] OR Uzbekistan [tiab] OR Uzbek OR Vanuatu [tiab] OR New Hebrides [tiab] OR Venezuela
[tiab] OR Vietnam [tiab] OR Viet Nam [tiab] OR West Bank [tiab] OR Yemen [tiab] OR
Yugoslavia [tiab] OR Zambia [tiab] OR Zimbabwe [tiab] OR Rhodesia [tiab] OR Africa [ot] OR
Asia [ot] OR Caribbean [ot] OR West Indies [ot] OR South America [ot] OR Latin America [ot]
OR Central America [ot] OR Afghanistan [ot] OR Albania [ot] OR Algeria [ot] OR Angola [ot] OR
Antigua [ot] OR Barbuda [ot] OR Argentina [ot] OR Armenia [ot] OR Armenian [ot] OR Aruba [ot]
OR Azerbaijan [ot] OR Bahrain [ot] OR Bangladesh [ot] OR Barbados [ot] OR Benin [ot] OR
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Byelarus [ot] OR Byelorussian [ot] OR Belarus [ot] OR Belorussian [ot] OR Belorussia [ot] OR
Belize [ot] OR Bhutan [ot] OR Bolivia [ot] OR Bosnia [ot] OR Herzegovina [ot] OR Hercegovina
[ot] OR Botswana [ot] OR Brazil [ot] OR Bulgaria [ot] OR Burkina Faso [ot] OR Burkina Fasso
[ot] OR Upper Volta [ot] OR Burundi [ot] OR Urundi [ot] OR Cambodia [ot] OR Khmer Republic
[ot] OR Kampuchea [ot] OR Cameroon [ot] OR Cameroons [ot] OR Cameron [ot] OR Camerons
[ot] OR Cape Verde [ot] OR Central African Republic [ot] OR Chad [ot] OR Chile [ot] OR China
[ot] OR Colombia [ot] OR Comoros [ot] OR Comoro Islands [ot] OR Comores [ot] OR Mayotte
[ot] OR Congo [ot] OR Zaire [ot] OR Costa Rica [ot] OR Cote d'Ivoire [ot] OR Ivory Coast [ot] OR
Croatia [ot] OR Cuba [ot] OR Cyprus [ot] OR Czechoslovakia [ot] OR Czech Republic [ot] OR
Slovakia [ot] OR Slovak Republic [ot] OR Djibouti [ot] OR French Somaliland [ot] OR Dominica
[ot] OR Dominican Republic [ot] OR East Timor [ot] OR East Timur [ot] OR Timor Leste [ot] OR
Ecuador [ot] OR Egypt [ot] OR United Arab Republic [ot] OR El Salvador [ot] OR Eritrea [ot] OR
Estonia [ot] OR Ethiopia [ot] OR Fiji [ot] OR Gabon [ot] OR Gabonese Republic [ot] OR Gambia
[ot] OR Gaza [ot] OR "Georgia Republic" [ot] OR "Georgian Republic" [ot] OR Ghana [ot] OR
Gold Coast [ot] OR Greece [ot] OR Grenada [ot] OR Guatemala [ot] OR Guinea [ot] OR Guam
[ot] OR Guiana [ot] OR Guyana [ot] OR Haiti [ot] OR Honduras [ot] OR Hungary [ot] OR India
[ot] OR Maldives [ot] OR Indonesia [ot] OR Iran [ot] OR Iraq [ot] OR Isle of Man [ot] OR Jamaica
[ot] OR Jordan [ot] OR Kazakhstan [ot] OR Kazakh [ot] OR Kenya [ot] OR Kiribati [ot] OR Korea
[ot] OR Kosovo [ot] OR Kyrgyzstan [ot] OR Kirghizia [ot] OR Kyrgyz Republic [ot] OR Kirghiz [ot]
OR Kirgizstan [ot] OR "Lao PDR" [ot] OR Laos [ot] OR Latvia [ot] OR Lebanon [ot] OR Lesotho
[ot] OR Basutoland [ot] OR Liberia [ot] OR Libya [ot] OR Lithuania [ot] OR Macedonia [ot] OR
Madagascar [ot] OR Malagasy Republic [ot] OR Malaysia [ot] OR Malaya [ot] OR Malay [ot] OR
Sabah [ot] OR Sarawak [ot] OR Malawi [ot] OR Nyasaland [ot] OR Mali [ot] OR Malta [ot] OR
Marshall Islands [ot] OR Mauritania [ot] OR Mauritius [ot] OR Agalega Islands [ot] OR Mexico
[ot] OR Micronesia [ot] OR Middle East [ot] OR Moldova [ot] OR Moldovia [ot] OR Moldovian [ot]
OR Mongolia [ot] OR Montenegro [ot] OR Morocco [ot] OR Ifni [ot] OR Mozambique [ot] OR
Myanmar [ot] OR Myanma [ot] OR Burma [ot] OR Namibia [ot] OR Nepal [ot] OR Netherlands
Antilles [ot] OR New Caledonia [ot] OR Nicaragua [ot] OR Niger [ot] OR Nigeria [ot] OR
Northern Mariana Islands [ot] OR Oman [ot] OR Muscat [ot] OR Pakistan [ot] OR Palau [ot] OR
Palestine [ot] OR Panama [ot] OR Paraguay [ot] OR Peru [ot] OR Philippines [ot] OR Philipines
[ot] OR Phillipines [ot] OR Phillippines [ot] OR Poland [ot] OR Portugal [ot] OR Puerto Rico [ot]
OR Romania [ot] OR Rumania [ot] OR Roumania [ot] OR Russia [ot] OR Russian [ot] OR
Rwanda [ot] OR Ruanda [ot] OR Saint Kitts [ot] OR St Kitts [ot] OR Nevis [ot] OR Saint Lucia
[ot] OR St Lucia [ot] OR Saint Vincent [ot] OR St Vincent [ot] OR Grenadines [ot] OR Samoa [ot]
OR Samoan Islands [ot] OR Navigator Island [ot] OR Navigator Islands [ot] OR Sao Tome [ot]
OR Saudi Arabia [ot] OR Senegal [ot] OR Serbia [ot] OR Montenegro [ot] OR Seychelles [ot]
OR Sierra Leone [ot] OR Slovenia [ot] OR Sri Lanka [ot] OR Ceylon [ot] OR Solomon Islands
[ot] OR Somalia [ot] OR Sudan [ot] OR Suriname [ot] OR Surinam [ot] OR Swaziland [ot] OR
Syria [ot] OR Tajikistan [ot] OR Tadzhikistan [ot] OR Tadjikistan [ot] OR Tadzhik [ot] OR
Tanzania [ot] OR Thailand [ot] OR Togo [ot] OR Togolese Republic [ot] OR Tonga [ot] OR
Trinidad [ot] OR Tobago [ot] OR Tunisia [ot] OR Turkey [ot] OR Turkmenistan [ot] OR Turkmen
[ot] OR Uganda [ot] OR Ukraine [ot] OR Uruguay [ot] OR USSR [ot] OR Soviet Union [ot] OR
Union of Soviet Socialist Republics [ot] OR Uzbekistan [ot] OR Uzbek OR Vanuatu [ot] OR New
Hebrides [ot] OR Venezuela [ot] OR Vietnam [ot] OR Viet Nam [ot] OR West Bank [ot] OR
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Yemen [ot] OR Yugoslavia [ot] OR Zambia [ot] OR Zimbabwe [ot] OR Rhodesia [ot] OR
Developing Countries [Mesh:noexp] OR Africa [Mesh:noexp] OR Africa, Northern [Mesh:noexp]
OR Africa South of the Sahara [Mesh:noexp] OR Africa, Central [Mesh:noexp] OR Africa,
Eastern [Mesh:noexp] OR Africa, Southern [Mesh:noexp] OR Africa, Western [Mesh:noexp] OR
Asia [Mesh:noexp] OR Asia, Central [Mesh:noexp] OR Asia, Southeastern [Mesh:noexp] OR
Asia, Western [Mesh:noexp] OR Caribbean Region [Mesh:noexp] OR West Indies [Mesh:noexp]
OR South America [Mesh:noexp] OR Latin America [Mesh:noexp] OR Central America
[Mesh:noexp] OR Afghanistan [Mesh:noexp] OR Albania [Mesh:noexp] OR Algeria
[Mesh:noexp] OR American Samoa [Mesh:noexp] OR Angola [Mesh:noexp] OR "Antigua and
Barbuda" [Mesh:noexp] OR Argentina [Mesh:noexp] OR Armenia [Mesh:noexp] OR Azerbaijan
[Mesh:noexp] OR Bahrain [Mesh:noexp] OR Bangladesh [Mesh:noexp] OR Barbados
[Mesh:noexp] OR Benin [Mesh:noexp] OR Byelarus [Mesh:noexp] OR Belize [Mesh:noexp] OR
Bhutan [Mesh:noexp] OR Bolivia [Mesh:noexp] OR Bosnia-Herzegovina [Mesh:noexp] OR
Botswana [Mesh:noexp] OR Brazil [Mesh:noexp] OR Bulgaria [Mesh:noexp] OR Burkina Faso
[Mesh:noexp] OR Burundi [Mesh:noexp] OR Cambodia [Mesh:noexp] OR Cameroon
[Mesh:noexp] OR Cape Verde [Mesh:noexp] OR Central African Republic [Mesh:noexp] OR
Chad [Mesh:noexp] OR Chile [Mesh:noexp] OR China [Mesh:noexp] OR Colombia
[Mesh:noexp] OR Comoros [Mesh:noexp] OR Congo [Mesh:noexp] OR Costa Rica
[Mesh:noexp] OR Cote d'Ivoire [Mesh:noexp] OR Croatia [Mesh:noexp] OR Cuba [Mesh:noexp]
OR Cyprus [Mesh:noexp] OR Czechoslovakia [Mesh:noexp] OR Czech Republic [Mesh:noexp]
OR Slovakia [Mesh:noexp] OR Djibouti [Mesh:noexp] OR "Democratic Republic of the Congo"
[Mesh:noexp] OR Dominica [Mesh:noexp] OR Dominican Republic [Mesh:noexp] OR East
Timor [Mesh:noexp] OR Ecuador [Mesh:noexp] OR Egypt [Mesh:noexp] OR El Salvador
[Mesh:noexp] OR Eritrea [Mesh:noexp] OR Estonia [Mesh:noexp] OR Ethiopia [Mesh:noexp]
OR Fiji [Mesh:noexp] OR Gabon [Mesh:noexp] OR Gambia [Mesh:noexp] OR "Georgia
(Republic)" [Mesh:noexp] OR Ghana [Mesh:noexp] OR Greece [Mesh:noexp] OR Grenada
[Mesh:noexp] OR Guatemala [Mesh:noexp] OR Guinea [Mesh:noexp] OR Guinea-Bissau
[Mesh:noexp] OR Guam [Mesh:noexp] OR Guyana [Mesh:noexp] OR Haiti [Mesh:noexp] OR
Honduras [Mesh:noexp] OR Hungary [Mesh:noexp] OR India [Mesh:noexp] OR Indonesia
[Mesh:noexp] OR Iran [Mesh:noexp] OR Iraq [Mesh:noexp] OR Jamaica [Mesh:noexp] OR
Jordan [Mesh:noexp] OR Kazakhstan [Mesh:noexp] OR Kenya [Mesh:noexp] OR Korea
[Mesh:noexp] OR Kosovo [Mesh:noexp] OR Kyrgyzstan [Mesh:noexp] OR Laos [Mesh:noexp]
OR Latvia [Mesh:noexp] OR Lebanon [Mesh:noexp] OR Lesotho [Mesh:noexp] OR Liberia
[Mesh:noexp] OR Libya [Mesh:noexp] OR Lithuania [Mesh:noexp] OR Macedonia [Mesh:noexp]
OR Madagascar [Mesh:noexp] OR Malaysia [Mesh:noexp] OR Malawi [Mesh:noexp] OR Mali
[Mesh:noexp] OR Malta [Mesh:noexp] OR Mauritania [Mesh:noexp] OR Mauritius [Mesh:noexp]
OR Mexico [Mesh:noexp] OR Micronesia [Mesh:noexp] OR Middle East [Mesh:noexp] OR
Moldova [Mesh:noexp] OR Mongolia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Morocco
[Mesh:noexp] OR Mozambique [Mesh:noexp] OR Myanmar [Mesh:noexp] OR Namibia
[Mesh:noexp] OR Nepal [Mesh:noexp] OR Netherlands Antilles [Mesh:noexp] OR New
Caledonia [Mesh:noexp] OR Nicaragua [Mesh:noexp] OR Niger [Mesh:noexp] OR Nigeria
[Mesh:noexp] OR Oman [Mesh:noexp] OR Pakistan [Mesh:noexp] OR Palau [Mesh:noexp] OR
Panama [Mesh:noexp] OR Papua New Guinea [Mesh:noexp] OR Paraguay [Mesh:noexp] OR
Peru [Mesh:noexp] OR Philippines [Mesh:noexp] OR Poland [Mesh:noexp] OR Portugal

297

[Mesh:noexp] OR Puerto Rico [Mesh:noexp] OR Romania [Mesh:noexp] OR Russia
[Mesh:noexp] OR "Russia (Pre-1917)" [Mesh:noexp] OR Rwanda [Mesh:noexp] OR "Saint Kitts
and Nevis" [Mesh:noexp] OR Saint Lucia [Mesh:noexp] OR "Saint Vincent and the Grenadines"
[Mesh:noexp] OR Samoa [Mesh:noexp] OR Saudi Arabia [Mesh:noexp] OR Senegal
[Mesh:noexp] OR Serbia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Seychelles
[Mesh:noexp] OR Sierra Leone [Mesh:noexp] OR Slovenia [Mesh:noexp] OR Sri Lanka
[Mesh:noexp] OR Somalia [Mesh:noexp] OR South Africa [Mesh:noexp] OR Sudan
[Mesh:noexp] OR Suriname [Mesh:noexp] OR Swaziland [Mesh:noexp] OR Syria [Mesh:noexp]
OR Tajikistan [Mesh:noexp] OR Tanzania [Mesh:noexp] OR Thailand [Mesh:noexp] OR Togo
[Mesh:noexp] OR Tonga [Mesh:noexp] OR "Trinidad and Tobago" [Mesh:noexp] OR Tunisia
[Mesh:noexp] OR Turkey [Mesh:noexp] OR Turkmenistan [Mesh:noexp] OR Uganda
[Mesh:noexp] OR Ukraine [Mesh:noexp] OR Uruguay [Mesh:noexp] OR USSR [Mesh:noexp]
OR Uzbekistan [Mesh:noexp] OR Vanuatu [Mesh:noexp] OR Venezuela [Mesh:noexp] OR
Vietnam [Mesh:noexp] OR Yemen [Mesh:noexp] OR Yugoslavia [Mesh:noexp] OR Zambia
[Mesh:noexp] OR Zimbabwe [Mesh:noexp] OR "tropical climate" OR "tropical climate" [MeSH]
OR "Vulnerable Populations" [Mesh] OR "American Native Continental Ancestry Group" [Mesh]
OR "Oceanic Ancestry Group" [Mesh] OR "aboriginals" [all fields] OR "aboriginals" [all fields] OR
"native americans" [all fields] OR "native american" [all fields] OR "first nations" [all fields] OR
inuit [all fields] OR eskimo [all fields] OR eskimos [all fields] OR maori [all fields] OR "Health
Services, Indigenous" [MeSH]
Step 2 (53847 Citations)
"Growth Disorders" [Mesh:NoExp] OR "Body Weight Changes" [Mesh] OR "Child Nutrition
Disorders" [Mesh] OR "Infant Nutrition Disorders" [Mesh]
Step 1 AND Step 2 (7592 Citations)
Step 3 (73672 Citations)
"Failure to Thrive" [Mesh] OR "Body Height" [Mesh]OR "Thinness" [Mesh] OR "Starvation"
[Mesh] OR "Protein Deficiency" [Mesh] OR "Malnutrition" [Mesh] OR "Malnutrition"
[Mesh] or "stunting" [all fields] OR "stunted" [all fields] OR "wasted" [TIAB] OR "wasting"
[TIAB] OR "height for age" [all fields] OR "weight for age" [all fields] OR "weight for
height" [all fields] OR "growth faltering" [all fields] OR "underweight" [all fields] OR "under
weight" [all fields] OR "short stature" [all fields]
(Step 1 AND Step 2) OR Step 3 (79085 Citations)
Step 4 (1848948 Citations)
'Child' [Mesh] OR 'Maternal-Child Health Centers' [Mesh] OR 'Child Nutrition Sciences' [Mesh]
OR 'Child Health Services' [Mesh] OR 'Child Nutritional Physiological Phenomena' [Mesh] OR
'Child Nutrition Disorders' [Mesh] OR 'Child Mortality' [Mesh] OR 'Child Welfare' [Mesh] OR
'Child Care' [Mesh] OR 'Child Reactive Disorders' [Mesh] OR 'Child Guidance' [Mesh] OR 'Child
Reactive Disorders' [Mesh] OR 'Child Behavior Disorders' [Mesh] OR 'Child, Orphaned' [Mesh]
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OR 'Child, Institutionalized' [Mesh] OR 'Child, Hospitalized' [Mesh] OR 'Child Development'
[Mesh] OR 'Child Behavior' [Mesh] OR 'Developmental Disabilities' [Mesh] OR 'Mental Disorders
Diagnosed in Childhood' [Mesh] OR 'Disabled Children' [Mesh] OR 'children' [TIAB] OR
'newborn*' [TIAB] OR 'childhood' [TIAB] OR 'baby' [TIAB] OR 'babies' [TIAB] OR 'toddler' [TIAB]
OR 'toddlers' [TIAB] OR 'infants' [TIAB] OR 'infant' [TIAB] OR 'infantile' [TIAB] OR 'young patient'
[TIAB] OR 'young patients' [TIAB] OR 'Pediatric Nursing' [Mesh] OR 'Pediatric Assistants'
[Mesh] OR 'Hospitals, Pediatric' [Mesh] OR 'Intensive Care Units, Pediatric' [Mesh] OR
'Pediatrics' [Mesh] OR 'Pediatricians' [TIAB] OR 'paediatricians' [TIAB] OR 'Pediatrician' [TIAB]
OR 'paediatrician' [TIAB] OR 'Pediatrics' [TIAB] OR 'paediatrics' [TIAB] OR 'Pediatric' [TIAB] OR
'paediatric' [TIAB]
Step 4 AND ((Step 1 AND Step 2) OR Step 3(34445 Citations))
Step 5 (2329420 Citations)
"Congenital Abnormalities" [Mesh] OR "Genetic Diseases, Inborn" [Mesh] OR "Endocrine
System Diseases" [Mesh]OR "Hormones, Hormone Substitutes, and Hormone Antagonists"
[Mesh] OR "Kidney Diseases" [Mesh]
(Step 4 AND ((Step 1 AND Step 2) OR Step 3)) NOT Step 5

23238 Citations

EMBASE Malnutrition
completed April 19, 2010 (17,634 Citations)
Step 1 (3,164,283 citations)
'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR
newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR
'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant*
OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age'
OR pediatr* OR paediatr* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child
health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality'
OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric
hospital' OR child*
Step 2 (4,437,122 Citations)
Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or
Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or
Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or
Herzegovina or Hercegovina or Botswana or Brazil or Bulgaria or 'Burkina Faso' or 'Burkina
Fasso' or 'Upper Volta' or Burundi or Urundi or Cambodia or 'Khmer Republic' or Kampuchea or
Cameroon or Cameroons or Cameron or Camerons or 'Cape Verde' or 'Central African
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Republic' or Chad or Chile or China or Colombia or Comoros or 'Comoro Islands' or Comores or
Mayotte or Congo or Zaire or 'Costa Rica' or 'Cote d Ivoire' or 'Ivory Coast' or Croatia or Cuba or
Cyprus or Czechoslovakia or 'Czech Republic' or Slovakia or 'Slovak Republic' or Djibouti or
'French Somaliland' or Dominica or 'Dominican Republic' or 'East Timor' or 'East Timur' or
'Timor Leste' or Ecuador or Egypt or 'United Arab Republic' or 'El Salvador' or Eritrea or Estonia
or Ethiopia or Fiji or Gabon or 'Gabonese Republic' or Gambia or Gaza or 'Georgia Republic' or
'Georgian Republic' or Ghana or 'Gold Coast' or Greece or Grenada or Guatemala or Guinea or
Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia
or Iran or Iraq or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or
Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or 'Lao PDR' or Laos or
Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or
Madagascar or Malagasy or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or
Nyasaland or Mali or Malta or 'Marshall Islands' or Mauritania or Mauritius or 'Agalega Islands'
or Mexico or Micronesia or 'Middle East' or Moldova or Moldovia or Moldovian or Mongolia or
Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or
Nepal or 'Netherlands Antilles' or 'New Caledonia' or Nicaragua or Niger or Nigeria or 'Mariana
Islands' or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru
or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or 'Puerto Rico' or
Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or 'Saint Kitts'
or 'St Kitts' or Nevis or 'Saint Lucia' or 'St Lucia' or 'Saint Vincent' or 'St Vincent' or Grenadines
or Samoa or 'Samoan Islands' or 'Navigator Island' or 'Navigator Islands' or 'Sao Tome' or
'Saudi Arabia' or Senegal or Serbia or Montenegro or Seychelles or 'Sierra Leone' or Slovenia
or 'Sri Lanka' or Ceylon or 'Solomon Islands' or Somalia or Sudan or Suriname or Surinam or
Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or
Thailand or Togo or Togolese or Tonga or Trinidad or Tobago or Tunisia or Turkey or
Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or 'Soviet Union' or 'Union
of Soviet Socialist Republics' or Uzbekistan or Uzbek or Vanuatu or 'New Hebrides' or
Venezuela or Vietnam or 'Viet Nam' or 'West Bank' or Yemen or Yugoslavia or Zambia or
Zimbabwe or Rhodesia OR ((developing or 'less developed' or 'under developed' or
underdeveloped or 'middle income' or 'low income' or 'lower income' or underserved or 'under
served' or deprived or poor*) and (countr* or nation* or population* or world)) OR ((developing
or 'less developed' or 'lesser developed' or 'under developed' or underdeveloped or middle
income or 'lower income' or 'lower income') AND (economy or economies)) OR (low* NEAR
(gdp or gnp or gross domestic or gross national )) OR ( low NEAR/3 middle ) OR (lmic OR lmics
OR third AND world OR 'lami countries' OR 'lami country') OR ( transitional AND countr*) OR
'tropic climate'/exp OR 'aborigine'/exp OR 'American Indian'/exp OR 'Eskimo'/exp OR
'Maori'/exp OR 'indigenous people'/exp
Step 3 (141,231 Citations)
'thinness' OR 'stunted' OR 'stunting' OR 'growth faltering' OR 'wasted' OR 'height for age' OR
'weight for age' OR 'weight for height' OR 'underweight' OR 'under weight' OR 'growth failure'
OR 'protein deficiency'/exp OR 'starvation'/exp OR 'underweight'/exp OR 'lean body weight'/exp
OR 'weight change'/exp OR 'growth curve'/exp OR 'growth inhibition'/exp OR 'growth rate'/exp
OR 'postnatal growth'/exp OR 'failure to thrive'/exp OR 'wasting syndrome'/exp OR
'malnutrition'/de or 'developmental, age and growth parameters'/de OR 'growth disorder'/de OR
'body height'/exp OR 'body height'/exp
Step 1 AND Step 2 AND Step 3 (24,575 Citations)
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Step 4
'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'endocrine disease'/exp OR
'hormones and agents acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR
'neoplasm'/exp
(Step 1 AND Step 2 AND Step 3) NOT Step 4 (16,833 Citations)
Step 5 (13,130 Citations)
'growth retardation'/exp
Step 1 and Step 2 and Step 5 (2,321 Citations)
Step 6 (5,6000,005)
'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'hormones and agents
acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR 'neoplasm'/exp
(Step 1 and Step 2 and Step 3) NOT Step 6 (801 Citations)
((Step 1 AND Step 2 AND Step 3) NOT Step 4) OR ((Step 1 and Step 2 and Step 5) NOT Step
6) (17,634 Citations)

WHO LILACS Database (TE/ED and Malnutrition)
completed June 17, 2010 (1617 Citations)
("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR
"weight for height" OR "weight for age" OR malnutrition) and ( Child OR Children OR newborn
OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile
OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR
paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric )

WHO SE Asia Database (IMSEAR) (TE/ED and Malnutrition)
completed June 17, 2010 (1335 Citations)
(("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR
"weight for height" OR "weight for age" OR malnutrition) AND (Child OR Children OR newborn
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OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile
OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR
paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric))

WHO Western Pacific Region Index Medicus (WPRIM) (TE/ED and Malnutrition)
completed June 17, 2010 (685 Citations)
"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR
"weight for height" OR "weight for age" OR malnutrition

WHO EMRO (IMEMR) (TE/ED and Malnutrition)
completed June 17, 2010 (459 Citations)
Child OR Children OR newborn OR childhood OR baby OR babies OR toddler OR toddlers OR
infants OR infant OR infantile OR young patient OR young patients OR Pediatricians OR
paediatricians OR Pediatrician OR paediatrician OR Pediatrics OR paediatrics OR Pediatric OR
paediatric [KeyWords] and "tropical sprue" OR "tropical enteropathy" OR "environmental
enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or
"chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR
underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition
[KeyWords]

WHO African Index Medicus (TE/ED and Malnutrition)
completed June 17, 2010 (70 Citations)
"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR
"weight for height" OR "weight for age" OR malnutrition
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Appendix 2. References used to test systematic search.
These papers were used to confirm inclusiveness in search criteria, and to confirm that filters do
not inadvertently exclude relevant work.
Reference

Setting and why selected

Brown KH, Khatun M, Ahmed G. Relationship of the xylose
absorption status of children in Bangladesh to their
absorption of macronutrients from local diets. Am J Clin Nut.
1981;34(8):1540-7.

Setting: Bangladesh
Reason for selection: Biomarker and
physiologic test studied

Fagundes-Neto U, Viaro T, Wehba J, Patrício FR, Machado
NL. Tropical enteropathy (environmental enteropathy) in
early childhood: a syndrome caused by contaminated
environment. J Trop Pediatr. 1984;30(4):204-9.

Setting: Brazil
Reason for selection: Biomarkers,
pathophysiologic correlates

Solomons NW, Mazariegos M, Brown KH, Klasing K. The
underprivileged, developing country child: environmental
contamination and growth failure revisited. Nutr Rev
1993;51(11):327-32.

Setting: Review
Reason for selection: Addresses
pathophysiology and epidemiology

Fagundes-Neto U, Martins MC, Lima FL, Patricio FR, Toledo
MR. Asymptomatic environmental enteropathy among slumdwelling infants. J Am Coll Nutr 1994;13(1):51-6.

Setting: Brazil
Reason for selection: Pathophysiology

Bhutta ZA, Hendricks KM. Nutritional management of
persistent diarrhea in childhood: a perspective from the
developing world. J Pediatr Gastroenterol Nutr
1996;22(1):17-37.

Setting: Review
Reason for selection: Therapy and
epidemiology

Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram
SG, Murphy B, Jenkins AP, et al. Geography of intestinal
1
permeability and absorption. Gut 1999;44(4):483-9 .

Setting: Qatar
Reason for selection: Pathophysiology

Campbell DI, Elia M, Lunn PG. Growth faltering in rural
Gambian infants is associated with impaired small intestinal
barrier function, leading to endotoxemia and systemic
inflammation. J Nutr. 2003;133(5):1332-8.

Setting: Gambia
Reason for selection: Biomarkers related to
stunting

Kukuruzovic R, Brewster DR, Gray E, Anstey NM. Increased
nitric oxide production in acute diarrhoea is associated with
abnormal gut permeability, hypokalaemia and malnutrition in
tropical Australian aboriginal children. Trans R Soc Trop Med
Hyg. 2003;97(1):115-20.

Setting: Australian Aboriginal children
Reason for selection: Relates a relevant
biomarker (NO production) to
lactulose/rhamnose test of intestinal
permeability

Solomons NW. Environmental contamination and chronic
inflammation influence human growth potential. J Nutr
2
2003;133(5):1237 .

Setting: Commentary
Reason for selection: Risk factors

1

The reference was not captured in the umbrella search of multiple databases with both TE/ED and stunting search
terms (i.e., PubMed + EMBASE + GH—TE/ED + stunting).
2
The reference was captured in the PubMed stunting search but lost when the child filter was added.
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Reference

Setting and why selected

Campbell DI, McPhail G, Lunn PG, Elia M, Jeffries DJ.
Intestinal inflammation measured by fecal neopterin in
Gambian children with enteropathy: association with growth
failure, Giardia lamblia, and intestinal permeability. J Pediatr
Gastroenterol Nutr. 2004;39(2):153-7.

Setting: Gambia
Reason for selection: Marker of gut
inflammation in children and inflammation is
related to another biomarker
(lactulose:mannitol ratio) and growth of
children in study

Salazar-Lindo E, Allen S, Brewster DR, Elliott EJ, Fasano A,
Phillips AD, et al. Intestinal infections and environmental
enteropathy: Working Group report of the second World
Congress of Pediatric Gastroenterology, Hepatology, and
Nutrition. J Pediatr Gastroenterol Nutr 2004;39 Suppl
2:S662-9.

Setting: Review
Reason for selection: Broadly inclusive of
topics of interest

Lima AA, Brito LF, Ribeiro HB, Martins MC, Lustosa AP,
Rocha EM, et al. Intestinal barrier function and weight gain in
malnourished children taking glutamine supplemented
enteral formula. J Pediatr Gastroenterol Nutr 2005;40(1):2835.

Setting: Brazil
Reason for selection: Pathophysiology and
treatment

Bhutta ZA. Effect of infections and environmental factors on
growth and nutritional status in developing countries. J
3
Pediatr Gastroenterol Nutr 2006;43 Suppl 3:S13-21 .

Setting: Review
Reason for selection: Epidemiology and
causative factors

Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablah R, Phua KB,
et al. Recent advances and evidence gaps in persistent
diarrhea. J Pediatr Gastroenterol Nutr 2008;47(2):260-5.

Setting: Review
Reason for selection: Broadly inclusive data

Botero-Garcés JH, García-Montoya GM, Grisales-Patiño D,
Aguirre-Acevedo DC, Alvarez-Uribe MC. Giardia intestinalis
and nutritional status in children participating in the
complementary nutrition program, Antioquia, Colombia, May
to October 2006.Rev Inst Med Trop Sao Paulo.
2009;51(5):155-62.

Setting: Colombia
Reason for selection: Studies relation
between a specific agent and nutritional
status

Goto R, Mascie-Taylor CG, Lunn PG. Impact of intestinal
permeability, inflammation status and parasitic infections on
infant growth faltering in rural Bangladesh 2009:Br J Nutr.
2009;101(10):1509-16.

Setting: Rural Bangladesh
Reason for selection: Biomarkers
associated with stunting

Humphrey JH. Child undernutrition, tropical enteropathy,
toilets, and handwashing. Lancet 2009;374(9694):1032-5.

Setting: Review
Reason for selection: Environmental factors

Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y,
Hawkes JS, et al. 13C-sucrose breath test: novel use of a
noninvasive biomarker of environmental gut health.
Pediatrics. 2009;124(2):620-6.

Setting: Australian Aboriginal children
Reason for selection: Novel biomarker
(exhaled isotope) to test intestinal
permeability

3

The reference was captured in the search with only the stunting term.
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Appendix 3. Summary of sampled references published between 1990-1999.
Method: An index of records determined to be relevant to this systematic review was sorted by
year. From this ordering, every 10th article was sampled.
1. Khoshoo V, Bhan MK, Jain R, Jayashree S, Bhandari N, Sazawal S, et al. Intestinal glucoamylase and
other disaccharidases in children with protracted diarrhoea. Indian J Med Res. 1990;92:1-4.
Sample size: 42 (all < 5 years of age)
Subjects: Persistent or chronic diarrhea and malnutrition
Markers: Jejunal biopsy, brush border disaccharidase activity, and correlation of latter with degree of
mucosal injury
Relevance to 2000-2010 set: Disaccharidase activity was investigated in one study from the previous
decade; this study adds assessment of its relationship with histology.
2. Saavedra JM, Brown KH. Nonabsorbable marker and single, random stool samples used for
measuring intestinal absorption of macronutrients in infants and children. Am J Clin Nutr. 1991;53(3):79094.
Sample size: 21 (all < 5 years of age)
Subjects: Malnourished
Markers: Fecal excretion of polyethylene glycol as a marker of intestinal absorption and in comparison to
standard balance test
Relevance to 2000-2010 set: These tests of absorption were not included in the previous decade article
set.
3. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN, Neale G. Persistent diarrhea and
malnutrition--the impact of treatment on small bowel structure and permeability. J Pediatr Gastroenterol
Nutr. 1992;14(2):208-15.
Sample size: 20 (all < 5 years of age)
Subjects: Persistent or chronic diarrhea, most also malnourished
Markers: Lactulose and mannitol fractional excretion, L:M, and jejunal biopsy; compared L:M with biopsy
results
Relevance to 2000-2010 set: The L:M test was reported in 25 studies in later decade, but none compared
it to histology.
4. Baqui AH, Sack RB, Black RE, Chowdhury HR, Yunus M, Siddique AK. Cell-mediated immune
deficiency and malnutrition are independent risk factors for persistent diarrhea in Bangladeshi children.
Am J Clin Nutr. 1993;58(4):543-48.
Sample size: 705 (all < 5 years of age)
Subjects: Persistent diarrhea, malnutrition, or asymptomatic
Markers: Cell-mediated immune response with multiple-antigen skin test
Relevance to 2000-2010 set: A similar study was published in the 2000-2010 publication set.
5. Roy SK, Akramuzzaman SM, Haider R, Khatun M, Akbar MS, Eeckels R. Persistent diarrhoea: efficacy
of a rice-based diet and role of nutritional status in recovery and nutrient absorption. Br J Nutr.
1994;71(1):123-34.
Sample size: 51 (all < 5 years of age)
Subjects: Persistent diarrhea (many also malnourished) and controls with previous history of acute
diarrhea
Markers: Comparison of nutrient absorption in cases and controls determined by 72-hour balance study
and recovery of cases following rice-based diet therapy
Relevance to 2000-2010 set: The 72 hour balance study was not reported in studies reviewed from the
later decade.
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6. Kallas MR, Patricio FR, Fagundes-Neto U. [Morphometrics of the small intestine in children with
diarrhea due to classical enteropathogenic Escherichia coli and to environmental asymptomatic
enteropathy]. Rev Assoc Med Bras. 1995;41(3):162-166. Portuguese.
Sample size: 46 (likely most or all subjects < 5 years of age; mean age was under 7 months)
Subjects: Acute or persistent diarrhea with stool culture positive for EPEC (cases) or asymptomatic
children negative for EPEC (controls)
Markers: Small intestine biopsy and morphometry
Relevance to 2000-2010 set: Histology was examined in 18 studies in the 2000-2010 set with one study
also using morphometric assessment.
7. Cooper ES, Ramdath DD, Whyte-Alleng C, Howell S, Serjeant BE. Plasma proteins in children with
trichuris dysentery syndrome. J Clin Pathol. 1997;50(3):236-240.
Sample size: 89 (many older than 5 years of age)
Subjects: Chronic diarrhea with and without Trichuris dysentery syndrome and healthy controls
Markers: Blood markers: alpha-1-antitrypsin, ceruloplasmin, albumin, globulin, fibrinogen, fibronectin,
ferritin, transferrin, plasma viscosity, hemoglobin, leukocytes, and CRP
Relevance to 2000-2010 set: Primarily assessed markers of systemic inflammation that were reviewed in
assessments of articles from the previous decade. The remaining markers are primarily assessments of
hepatic function and were not assessed in the 2000-2010 set.
8. Brooks SE, Reid WA. Scanning electron microscopy of the jejunum in children with protein-energy
malnutrition. West Indian Med J. 1997;46(1):15-21.
Sample size: 7 (all < 5 years of age)
Subjects: Fatal severe kwashiorkor or marasmic kwashiorkor
Markers: Scanning electron microscopy (SEM) and light microscopy on jejunal biopsy sections taken by
autopsy and fixed within 75 minutes after death
Relevance to 2000-2010 set: In the later decade publications, SEM and light microscopy were used in
one study to investigate jejunal morphology in 16 infants with persistent diarrhea, many of whom also had
small bowel bacterial overgrowth (as measured by jejunal secretion) and/or exhibited some degree of
malnutrition.
9. Abbas KA, Bilal R, Sajjad MI, Latif Z, Mirza NH. Fat absorption in persistent diarrhoea using 13Clabelled trioctanoin breath test. J Trop Pediatr. 1999;45(2):87-94.
Sample size: 10 (all < 5 years of age)
Subjects: Persistent diarrhea (some with malnutrition) and asymptomatic controls
13
Markers: Fat absorption by breath test after C-labelled trioctanoin administration
Relevance to 2000-2010 set: 2 studies in the 1990-1999 publication set assessed fat absorption although
not by breath test with this specific medium chain fatty acid.
10. Taniguchi K, Rikimaru T, Yartey JE, Akpedonu P, Armar-Klemesu MA, Nkrumah FK, et al.
Immunological background in children with persistent diarrhea in Ghana. Pediatr Int. 1999;41(2):162-167.
Sample size: 85 (all < 5 years of age)
Subjects: Persistent or acute diarrhea
Markers: A variety of serum markers of systemic inflammation and immune response were compared
between persistent and acute diarrhea cases, including: albumin, pre-albumin, total protein, transferrin,
IgA & IgG subclass fractions, natural killer cells, lymphocyte immunophenotypes, and T-cell activation.
Relevance to 2000-2010 set: Many of these systemic markers were examined in the 2000-2010 set,
although some were not.
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Appendix 4. Sample REDCap template.
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Appendix 5. Highly considered but excluded references.
Reference

Country

Reason for exclusion

Altuntas B, Filik B, Ensari A, Zorlu
P, Teziç T. Can zinc deficiency be
used as a marker for the diagnosis
of celiac disease in Turkish
children with short stature? Pediatr
Int. 2000;42(6):682-684.

Turkey

Biopsy data were the same as previously reported
in a 1998 publication 1 that was included in this
review. This 2000 publication adds no new data of
relevance to this review.

Bahia M, Rabello A, Brasileiro
Filho G, Penna FJ. Serum
antigliadin antibody levels as a
screening criterion before jejunal
biopsy indication for celiac disease
in a developing country. Braz J
Med Biol Res. 2001;34(11):14151420.

Brazil

The only outcomes of interest to this review that
were reported on for subjects of interest (controls
that did not have celiac disease) were that their
jejunal biopsy results were “normal,” and no other
data or specific information was reported that
pertained to this review.

Bay A, Oner AF, Celebi V, Uner A.
Evaluation of vitamin K deficiency
in children with acute and
intractable diarrhea. Adv Ther.
2006;23(3):469-474.

Turkey

Outcomes were primarily related to micronutrient
(vitamin K) deficiency or malabsorption.

Cooke ML, Goddard EA, Brown
RA. Endoscopy findings in HIVinfected children from subSaharan Africa. J Trop Pediatr.
2009;55(4):238-243.

South
Africa

Most subjects had upper gastrointestinal
conditions that were not of interest to this review.
Only 3 subjects had diarrhea, and it was unlikely
that they were all under 5 yr.

Kelly P, Musuku J, Kafwembe E,
Libby G, Zulu I, Murphy J, et al.
Impaired bioavailability of vitamin
A in adults and children with
persistent diarrhoea in Zambia.
Aliment Pharmacol Ther.
2001;15(7):973-979.

Zambia

Change in serum retinol status was assessed
following administration of oral vitamin A to adult
cases (males hospitalized with persistent diarrhea
(PD)) (n=15), controls (males hospitalized with
conditions other than PD) (n=24) and cases under
2 yr hospitalized with PD and malnutrition (n=11).
While the children with PD did have similar
degrees of change in serum retinol after vitamin A
administration compared to the adult controls, the
study did not include childhood controls. Without
childhood controls and with limited sample size of
children, interpretation and generalization of
findings to childhood enteric function is limited.

Kukuruzovic R, Robins-Browne
RM, Anstey NM, Brewster DR.
Enteric pathogens, intestinal
permeability and nitric oxide

Australia

Data on outcomes of interest to this review were
not reported.

1

Altuntas B, Kansu A, Ensari A, Girgin N. Celiac disease in Turkish short-statured children and the value
of antigliadin antibody in diagnosis. Acta Paediatr Jpn. 1998;40(5):457-460.
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Reference

Country

Reason for exclusion

production in acute gastroenteritis.
Pediatr Infect Dis J.
2002;21(8):730-739.
Kumar R, Marwaha N, Marwaha
RK, Garewal G. Vitamin K
deficiency in diarrhoea. Indian J
Pediatr. 2001;68(3):235-238.

India

Outcomes were primarily related to micronutrient
(vitamin K) deficiency or malnutrition.

Manary MJ, Hotz C, Krebs NF,
Gibson RS, Westcott JE, Arnold T,
et al. Dietary phytate reduction
improves zinc absorption in
Malawian children recovering from
tuberculosis but not in well
children. J Nutr.
2000;130(12):2959-2964.

Malawi

Subjects ranged in age from 3-13 yr, but based on
the group means and standard deviations for age,
there were likely to be few subjects under age 5
years.

Thacher TD, Obadofin MO,
O'Brien KO, Abrams SA. The
effect of vitamin D2 and vitamin D3
on intestinal calcium absorption in
Nigerian children with rickets. J
Clin Endocrinol Metab.
2009;94(9):3314-3321.

Nigeria

Study assessed differences in calcium uptake with
varying vitamin D preparations and was not an
assessment of intestinal function.

Ukarapol N, Lertprasertsuk N,
Fuchs GJ, Wongsawasdi L,
Sirisanthana V. Impact of
gastrointestinal endoscopy on HIVinfected children. Dig Endosc.
2004;16(1):26-29.

Thailand

Study described 13 colonoscopy or
sigmoidoscopy and 10 gastroduodenoscopy
sessions for 14 patients resulting in 7 possible
assessments of the small intestine. However
results were aggregated across gastrointestinal
anatomical sites, and it was difficult to extract
results of interest to this review.

Walkowiak J, Herzig KH. Fecal
elastase-1 is decreased in villous
atrophy regardless of the
underlying disease. Eur J Clin
Invest. 2001;31(5):425-430.

Poland

The age range of all subjects (n=54) was 2-16 yr
with a mean of 7.0 yr, SE=0.5. The sample size of
children of any age with presentations of interest
to this review was n=18. The high mean age of
subjects coupled with small sample size suggest
that few children with presentations meeting
inclusion criteria were likely under 5 yr. In addition,
it was unclear if the study setting met developing
country setting inclusion criteria.

Yachha SK, Aggarwal R, Srinivas
S, Srivastava A, Somani SK, Itha
S. Antibody testing in Indian
children with celiac disease. Indian
J Gastroenterol. 2006;25(3):132135.

India

While some subjects in this study were under 5 yr
of age, the subjects of interest to this review (i.e.,
the children without celiac disease who had small
intestinal biopsies) were all aged >5 yr.
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Appendix 6. Review articles with information of relevance to the systematic review.
Bhatnagar S. Laboratory diagnosis of persistent and chronic diarrhea. IJPP. 2003;5(2):125-132.
Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablah R, Phua KB, et al. Recent advances and evidence
gaps in persistent diarrhea. J Pediatr Gastroenterol and Nutr. 2008;47(2):260-265.
Bhutta ZA. Effect of infections and environmental factors on growth and nutritional status in
developing countries. J Pediatr Gastroenterol Nutr. 2006 Dec;43: Suppl 3:S13-21.
Bickler SW. Tropical enteropathy protects against Western diseases in environments of poor
sanitation. Med Hypotheses. 2006;67(1):146-150.
Brewster DR. Critical appraisal of the management of severe malnutrition: 3. Complications. J
Paediatr Child Health. 2006;42(10):583-593.
Brewster DR, Manary MJ, Menzies IS, O'Loughlin EV, Henry RL. Intestinal permeability in
kwashiorkor. Arch Dis Child. 1997; Mar;76(3):236-41.
Butler RN. Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy
of biologics including prebiotics and probiotics. Curr Pharm Des. 2008;14(14):1341-50.
Davidson G, Kritas S, Butler R. Stressed mucosa. Nestle Nutr Workshop Ser Pediatr Program.
2007;59:133-142; discussion 143-146.
Gibbons T, Fuchs GJ. Chronic enteropathy: clinical aspects. Nestle Nutr Workshop Ser Pediatr
Program. 2007;59:89-101; discussion 102-104.
Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA. Malnutrition as an enteric infectious disease
with long-term effects on child development. Nutr Rev. 2008;66(9):487-505.
Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet.
2009;374(9694):1032-35.
Mehta S. Celiac disease in India. Indian J Gastroenterol. 2008;27(1):43.
Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea,
and their impact on function and development. J Clin Invest. 2008;118(4):1277-90.
Prentice AM, Darboe MK, Growth and host-pathogen interactions. Nestle Nutr Workshop Ser Pediatr
Program. 2007;61:197-210.
Ramakrishna BS, Venkataraman S, Mukhopadhya A. Tropical malabsorption. Postgrad Med J. 2006;
82(974):779-787.
Solon JA, Morgan G, Prentice A. Mucosal immunity in severely malnourished Gambian children. J
Pediatr. 2006; 149(5) Suppl:S100-S106.
Sondheimer JM. Glutamine for childhood malnutrition: Probably not needed. J Pediatr Gastroenterol
and Nutr. 2005;40(1):24-25.
Sullivan PB. Studies of the small intestine in persistent diarrhea and malnutrition: the Gambian
experience. J Pediatr Gastroenterol Nutr. 2002;34 Suppl 1:S11-13.
Taren DL. Diarrhea and other gastrointestinal diseases. In: Gershwin ME, Nestel P, Keen CL, editors.
Handbook of Nutrition and Immunity. Humana Press; 2004;287-302.
Velasco-Benitez CA. Digestive, hepatic, and nutritional manifestations in Latin American children with
HIV/AIDS. J Pediatr Gastroenterol Nutr. 2008;47 Suppl 1:S24-26.
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Appendix 7. Evidence table of all studies included in the review.

Reference and Study
Outcomes of
Diagnostic Interest
2003
Alcantara CS et al.

Interleukin-8, tumor
necrosis factor-alpha,
and lactoferrin in
immunocompetent
hosts with
experimental and
Brazilian children with
acquired
cryptosporidiosis
Fecal cytokines and
lactoferrin as markers
of intestinal
inflammation among
children with and
without
Cryptosporidium
parvum.

2002
Alves GM et al.
Nutritional status and
breath hydrogen test
with lactose and
lactulose in Terena
Indian children
Lactose hydrogen
breath test (HBT) as a
marker of lactase
activity, and lactulose
HBT as a marker of

Location and
Target Population

Design and
Sample Size

Fortaleza,
Brazil

Case-control

3-43 mo olds
recruited from a
shantytown
community who
were screened for
enteric pathogens.
There was a high
prevalence of
malnutrition
among the cases.
(Adults
experimentally
exposed to C.
parvum by
ingestion were
also studied;
these data were
not included in
this review.)

Limão Verde and
Córrego Seco,
Mato Grosso du
Sul, Brazil
All children <10 yr
old were recruited
from these rural
villages.

n=32;
n=17 cases
with C. parvum:
• 4 with no
diarrhea
• 10 with AD
• 3 with PD

Biomarker

Results

Conclusion

Comments

Stool tests:
• Lactoferrin
(17 cases and 15
controls tested)
• IL-8
(13 cases and 15
controls tested)
• TNF-α
(10 cases and 0
controls tested)

Lactoferrin positive:
• 12/17 cases
• 1/4 cases without
diarrhea
• 8/10 AD cases
• 3/3 PD cases
• 3/15 controls (p=0.006
compared to cases)

The proportion of
children who tested
positive for fecal
lactoferrin was
greater in those
with
cryptosporidiosis,
especially those
symptomatic with
diarrhea, than in
uninfected controls,
although 20% of
the control group
tested positive.

Direct
comparisons
between various
stool tests were
not reported.

n=15 controls
with no
diarrhea or
enteric
pathogens and
comparable
HAZ and WAZ
scores to cases

Cross-sectional
n=264;
<5 yr old:
n=145
(However
results were
provided by
<4 and >4 yr
old age
groups.)

IL-8 detectable:
• 3/13 all cases
• 0/2 cases without
diarrhea
• 3/10 AD cases
• 0/1 PD cases
• 6/16 controls (p=0.435
compared to cases)
TNF-α detectable:
• 0/10 cases

Breath Tests:
• Lactose HBT
(251 tested)
• Lactulose HBT
(252 tested)

Lactose HBT:
• Elevated: 27.1% among all
subjects
• Borderline: 43.0% among
all subjects
• 0% of subjects <4 yr had
elevated or borderline
results
Lactulose HBT positive:
• 11.5% of all subjects
• 8.6% of subjects <4 yr

Fecal IL-8 did not
differ between
those with and
without
Cryptosporidium
infection. TNF-α
was not elevated
among children
with
Cryptosporidium
infection.
The prevalence of
lactase deficiency
as measured by
lactose HBT was
>25%, but nonexistent among
those <4 yr of age.
Prevalence of
SBBO as assessed
by lactulose HBT
was ~10%.

Lactoferrin
results were
graded based
on agglutination
reaction
positivity with
increasing
dilution and
were considered
negative if there
was no reaction
at 1:25.
Four subjects
were breastfed
and were tested
for lactoferrin.

Assessment of
association
between
lactulose and
lactose
absorption was
not reported.
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Reference and Study
Outcomes of
Diagnostic Interest
SBBO

Location and
Target Population

Design and
Sample Size

2009

Lusaka, Zambia

Case-control

Amadi B et al.

12.2-19.8 mo olds
with PD and
malnutrition
admitted to the
malnutrition ward
of a teaching
hospital.

n=41*;

Reduced production of
sulfated
glycosaminoglycans
occurs in Zambian
children with
kwashiorkor but not
marasmus
Duodenal biopsy
including assessments
of intestinal markers in
children with PD and
different forms of
malnutrition

n=41 cases
with PD and
malnutrition:
• 18 with
marasmus
• 8 with
marasmic
kwashiorkor
• 15 with
kwashiorkor
n=19 healthy
control children
from UK
* UK subjects
are presented
in this table
due to
comparisons of
interest made
in the review.
However we do
not include
these subjects
in the sample
size for this
review.

Biomarker

Results

Conclusion

Comments

Endoscopic duodenal
biopsy:
• Histopathology
• Densities in lamina
propria and crypt
epithelium:
• Cell proteins:
• Glycosaminoglyc
an (GAG)
• Enterocyte
heparan sulfate
proteoglycan
(HSPG)
• Syndecan-1
• Inflammatory cell
markers:
• CD3 IEL
• Ki67
• Human leukocyte
antigen DR-1
(HLA-DR)

Biopsy findings among the
Zambian compared to the UK
children:
• Villous height reduced
• Crypt depth increased
• ~50% reduction in
crypt:villous ratio
• Values for lamina propria
cell densities were not
reported for UK subjects

Mucosal
architecture was
markedly abnormal
compared to UK
controls but did not
vary between
marasmus and
kwashiorkor
presentations of
malnutrition.

27 subjects
were HIV
positive;
incidence was
lower in the
kwashiorkor
group.

No significant differences in
crypt or villous measures or
lamina propria cell densities
were observed between
nutritional groups or after
nutritional rehabilitation.

Inflammatory cell
densities were
generally higher
compared to UK
children and
showed different
patterns across the
malnutrition
presentations.

Intestinal markers:
• Inflammatory markers were
seen in higher densities
compared to the UK
children. There were
significant differences
between the different
nutritional groups in the
specific types of
inflammatory markers.
• There was a significant
reduction in GAGs and
HSPG in the kwashiorkor
group compared to UK
children, but no significant
differences between
kwashiorkor and other
presentations of
malnutrition.
• There was no difference in

Tissue
concentrations of
HSPG and GAG
were reduced
especially amongst
children with
kwashiorkor.
Intestinal protein
markers did not
differ amongst the
malnutrition
groups.
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Some immune and
inflammatory
markers were
associated with
acute and/or
persistent diarrhea.

The number of
controls was
relatively small
and their
nutritional status
was not
reported.

epithelial syndecan-1
protein expression between
the malnutrition groups
(data not available for UK
controls).
2000
Azim T et al.
Immune response of
Bangladeshi children
with acute diarrhea
who subsequently
have persistent
diarrhea
Immune activation
tests, as well as
transferrin and
albumin as markers of
nutritional status
among children with
and without PD

Dhaka,
Bangladesh
7-12 mo olds with
6-8 days of watery
diarrhea attending
the International
Centre for
Diarrheal Disease
Research.
Cases were those
who went on to
develop PD,
controls were
those who did not.
An additional
group of subjects
without diarrhea
were recruited
from a nutrition
follow-up unit.
Prevalence of
malnutrition was
high in all groups.

Case-control
n=136;
n=38 cases
with PD
n=98 controls:
• 85 with AD
• 13 with no
diarrhea

Blood tests:
• IFN-γ
• TNF-α
• WBC (total and
differential)
• IgA
• IgG
• IgM
• Transferrin
• Albumin
• Immune function
tests:
• Neutrophil
polarization
response to
chemotactic factor
• Neutrophil
opsonization to
yeast
• Mononuclear cell
proliferation,
spontaneous and in
response to stimuli
with mitogens
Skin Test:
• Delayed-type
hypersensitivity
response (DTH) to
tuberculin, tetanus,
diphtheria,
Streptococcus,
Proteus, Candida,
and Trichophyton

WBC total and differential,
immunoglobulin subtypes,
cytokines, transferrin, and
albumin did not differ
between cases with diarrhea
or controls, nor did stool
leukocyte or erythrocyte
counts.
The percentages of
neutrophils that polarized in
response to stimulation were
significantly higher in subjects
with AD or PD compared to
those without diarrhea; there
was no difference between
the two diarrhea groups.
Opsonization did not vary
between any groups.
Monocyte spontaneous
proliferation counts were less
than half among children with
no diarrhea compared to
those with AD (p<0.001) or
with PD (p=0.011); there was
no difference between the
two diarrhea groups.
Monocyte proliferation in
response to stimulation did
not differ between the 3
groups.
The proportion with DTH

The only marker
that was
significantly
associated with
progression to PD
was a negative
DTH response to
tuberculin antigen
(odds ratio=3.8, CI:
1.4, 9.9). This was
calculated from a
logistic regression
analysis that only
included children
with diarrhea.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Stool tests:
• Leukocytes
• Red blood cells
2005

Delhi, India

Case-series

Bhatnagar S et al.

1-18 yr olds with a
presentation
consistent with
CD (combination
of chronic
diarrhea,
abdominal
distension, and
growth failure),
recruited from a
pediatric
gastroenterology
clinic.

n=107

Celiac disease with
mild to moderate
histological changes is
a common cause of
chronic diarrhea in
Indian children
Duodenal biopsy
among children with
chronic diarrhea

Endoscopic duodenal
biopsy:
Histopathology

Bitarakwate E et al.
Serum zinc status of
children with
persistent diarrhea
admitted to the
diarrhea management
unit of Mulago
Hospital, Uganda

Kampala and
Mpigi, Uganda
6-36 mo olds with
PD, recruited from
hospital, and
healthy controls
recruited mainly
from the local
population.

Conclusion

responses differed among the
three groups only in response
to tuberculin (p=0.021). More
PD subjects had a negative
tuberculin response than did
subjects with AD (p=0.024).
70 had normal histology
(defined as crypt:villous ratio
1:2-3, absence of lymphoid
lamina propria infiltration, and
minimal intraepithelial
lymphocytes (IEL).
37 had mild changes (defined
as mild blunting of villi with
crypt:villous ratio of 1:1*). A
specific etiology was
identified in only n=5:
• 2 with giardiasis
• 1 with lymphangiectasia
• 2 with chronic pancreatitis

Subjects negative
for CD-specific
antibodies were of
interest for this
review.

2003

Results

Only children with CD had
moderate or severe histologic
changes.

More than one
quarter of children
with chronic
diarrhea had
normal small
intestinal mucosa;
at follow-up their
growth had
improved and their
diarrhea had
resolved.
No definitive
diagnosis was
reached for 86% of
subjects with
abnormal histology
(albeit most had
mild findings).

* Along with increased IEL
and lymphocytic lamina
propria infiltration.
Case-control
n=192;
n=96 cases
with PD
n=96 healthy
controls

Blood Tests:
• Albumin
• Total protein
• Hemoglobin

PD cases:
• 47.9% low serum protein
• 69.7% low serum albumin
• Low mean hemoglobin
(10.5 g/dL)
For controls, means of all
three laboratory values were
within normal range; percent
of subjects with abnormal
values are not reported.

Decreased
albumin, serum
total protein and
hemoglobin
concentrations
were associated
with PD.

Comments
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Reference and Study
Outcomes of
Diagnostic Interest
Serum protein,
albumin, and
hemoglobin among
children with and
without PD
2010
Bukhari AS et al.

DNA damage and
plasma homocysteine
concentrations are
associated with serum
metabolites and
mineral constituents'
profiles in children with
persistent diarrhea

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Multiple serum
markers were
associated with
PD, especially DNA
damage to
lymphocytes
(p=0.0001).

Control
recruitment
strategy was not
well described.

All three test results were
significantly lower in children
with PD than in controls (p<
0.01 for each comparison).
Faisalabad,
Pakistan
3-6 yr olds
admitted to
hospital with PD
and healthy
controls.

Case-control
n=72;
n=36 cases
with PD
n=36 healthy
controls

Serum proteins,
metabolites, and
levels of DNA damage
among children with
and without PD

Blood Tests:
Serum proteins and
metabolites:
• Albumin
• Globulin
• Homocysteine
• Total protein
• Total cholesterol,
HDL, LDL,
triglycerides
• AST, ALT
• T3, T4
• Total oxidant status
(TOS), Total antioxidant status (TAS),
and thiobarbituric
reactive substances
(TBARS)
• DNA damage to
lymphocytes

Mean values significantly
higher among PD cases than
in healthy controls:
• LDL
• Homocysteine
• TOS
• TBARs
• DNA damage
Mean values significantly
lower among PD cases than
in healthy controls:
• Total protein
• T4
• TAS

The authors
speculate that zinc
deficiency, more
commonly found in
the children with
PD, might be
responsible for
increased
homocysteine
concentrations and
play an important
role in mediating
DNA damage.

TOS, TBARS
and TAS were
incompletely
defined.
Some values
differed by
gender in both
the case and
control groups:
• Triglycerides
• Total
cholesterol
• HDL
• T3
Multiple markers
studied;
analyses did not
appear to
address
potential
confounding.

2007
Bushen OY et al.

Goncalves Dias
favela in
Fortaleza, Brazil

Heavy cryptosporidial
infections in children in
northeast Brazil:
comparison of

All newborns from
an urban
shantytown were
recruited at birth

Cohort
n=42
(41 tested)
Stools were
collected at

Stool Test:
Lactoferrin

68.3% were lactoferrinpositive; there were no
differences in positivity
between subjects with C.
hominis and C. parvum spp.
67.9% of lactoferrin-positive
subjects had very high titers.

Lactoferrin was
correlated with
younger age and
symptomatic
infection among
those infected with
C. parvum.

Lactoferrin
results were
graded based
on agglutination
reaction
positivity with
increasing
dilution and
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Reference and Study
Outcomes of
Diagnostic Interest
Cryptosporidium
hominis and
Cryptosporidium
parvum
Fecal lactoferrin as a
marker of intestinal
inflammation in
children with
Cryptosporidium

Location and
Target Population

Design and
Sample Size

and followed for
up to 4 yr.

regular
intervals as
well as during
episodes of
diarrhea.

This study
included only
children testing
positive for
Cryptosporidium.

Biomarker

Results
Younger children were more
often lactoferrin-positive
(p=0.03). The difference was
mediated by C. parvum;
87.5% of ≤1 year olds
compared to 40.0% of older
children with C. parvum were
lactoferrin-positive (p=0.04).
There was no difference
among those infected with C.
hominis.
Lactoferrin was correlated
with symptomatic infection
among those with C. parvum:
78.6% of symptomatic
children compared to no
asymptomatic children had a
positive test (r=0.67,
1
p=0.004 ).
Lactoferrin was not correlated
with degree of oocyst
shedding (p=0.28).
Lactoferrin was correlated
with ∆HAZ score among
those with C. parvum,
although this observation was
not statistically significant (r=0.39, p=0.13).

1

Reported results were adjusted for confounding variables, unless otherwise noted.

Conclusion

Comments

Lactoferrin did not
significantly predict
growth outcomes.

were considered
negative if there
was no reaction
at 1:50 and
highly positive at
>1:400.

Cryptosporidium
species-specific
differences were
observed in
lactoferrin results.
In contrast to C.
parvum, there was
no association
between lactoferrin
and symptomatic /
asymptomatic C.
hominis infection
(p=0.231). In
addition, similar
proportions of
asymptomatic
children with C.
hominis had high
fecal lactoferrin
titers as had
undetectable
results.

Data were part
of a larger
study; similar
data on
lactoferrin in
Giardia-infected
children was
published by A.
Kohli, et al. (also
included in this
review), using a
slightly different
grading scale for
reporting
lactoferrin
results [133].
Rather than
exclude
breastfed
children,
Bushen et al.
stratified results
on
breastfeeding
status and found
no difference in
positive/
negative results,
including when
examined
among younger
and older
children.
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Reference and Study
Outcomes of
Diagnostic Interest
2003
Bustos M et al.
Disaccharidase
deficiency in Bolivian
children with
persistent diarrhea
Jejunal biopsy and
disaccharidase
activities in children
with PD and different
forms of malnutrition

Location and
Target Population

Design and
Sample Size

Cochabamba,
Bolivia

Cohort

3-34 mo old
Amerindians
hospitalized with
PD and moderate
or severe
malnutrition in an
urban setting.

n=42 cases
with PD and
malnutrition:
• 2 with
kwashiorkor
• 20 with
marasmus
• 20 with
marasmickwashiorkor
Children were
assessed on
admission and
at three weeks,
after diarrhea
had resolved
and
anthropometric
s were
improving.

Biomarker

Results

Conclusion

Comments

Jejunal tethered
capsule biopsy:
• Histopathology
• Disaccharidase
activity:
• Lactase
• SucroseIsomaltase
• Maltase

Most subjects had mild to
moderate (score of 2-3)
histological abnormalities,
with one kwashiorkor patient
having completely flat villi.

Patients had
diminished
intestinal
disaccharidase
activity and
substantial
pathology on
biopsy at
admission and at
three weeks,
despite clinical
improvements and
tolerance of
lactose-containing
formula.

Spanish
language article.

L:M and mean
fecal neopterin
concentration were
not correlated.

Study
population might
have some
overlap with that

Histology was scored
on a scale of 1 (normal)
to 4 (severe
morphological damage
or flat mucosa).

Second biopsy showed a
trend of improved mucosa,
but difference was not
significant based on histology
score, intraepithelial
lymphocyte density, or
degree of infiltration of lamina
propria.
Percentages with enzymatic
activity below normal at
baseline, discharge:
• Lactase: 64%, 59%
• Sucrase-isomaltase: 97%,
90%
• Maltase: 45%, 52%
All changes were statistically
significant.
Lactase recovery was
associated with admission
HAZ (p=0.05) and WAZ
(p=0.03) scores.

Values for
subnormal
disaccharidase
activity were not
provided.
The magnitude
of lactase
inverse
association with
growth
parameters was
not reported.
Authors did not
report whether
they had tested
for associations
between
maltase or
sucroseisomaltase and
growth
parameters.

Despite continued high
disaccharidase deficiency
prevalence at discharge, all
children tolerated the lactosecontaining formula challenge.
2004

Keneba, Gambia

Cohort

Campbell DI et al.

2 mo olds from
rural area followed

n=72

Stool Test:
Neopterin

Mean neopterin concentration
was negatively correlated
with long-term height (r=0.29, p<0.009) and weight
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Reference and Study
Outcomes of
Diagnostic Interest
Intestinal inflammation
measured by fecal
neopterin in Gambian
children with
enteropathy:
association with
growth failure, Giardia
lamblia, and intestinal
permeability

Location and
Target Population
until 15 mo of age.

Fecal neopterin and
L:M as markers of
intestinal inflammation
and permeability,
respectively, and their
correlation with growth
status and Giardia
recovery in the stool

Design and
Sample Size
Subjects were
evaluated with
twice-weekly
questionnaire
to determine
diarrhea
morbidity, clinic
assessments of
growth, and
screening
laboratory tests
every 2 mo.

Biomarker

Results

Urine Tests:
2
• Lactulose
• Mannitol
• L:M

(r=-0.36, p<0.007) gain, but
not with giardiasis.
3

Mean L:M (CI): 0.31 (0.26,
0.34).
Mean excretion of lactulose
(CI): 0.20 (0.18, 0.23).
Mean excretion of mannitol
(CI): 3.0 (2.8, 3.2).

Conclusion
Mean L:M in the
Gambian children
was substantially
higher than normal
values in children
in the UK. These
high L:M ratios
appear to be driven
by mannitol
excretion.

Comments
of Campbell et
al. also included
in this review
[110].

Mean L:M was negatively
correlated with long-term
height gain (r value not
provided, p<0.0001), but was
not correlated with presence
of Giardia.
L:M and fecal neopterin were
not correlated (p=0.11).

2003
Campbell DI et al.
Growth faltering in
rural Gambian infants
is associated with
impaired small
intestinal barrier
function, leading to
endotoxemia and
systemic inflammation
L:M as a marker of
intestinal permeability
2

Keneba, The
Gambia
All 2-11 mo olds
were recruited
from this rural
village and
followed up to 14
mo of age.

Cohort
n=71

Urine Tests:
4
• Lactulose
(53 tested)
• Mannitol
(52 tested)
• L:M
(52 tested)
Blood tests:
• Albumin
• CBC
• C-reactive
protein (CRP)
• IgA

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.
4
For lactulose and mannitol results, excretion measurement was not specified.
5
Geometric mean.
3

At 8 wk of age:
5
• Mean L:M: 0.169 (CI:
0.145, 0.198; range: 0.0580.657)
• Mean lactulose recovery:
0.202 (SD=0.159; range:
0.009-0.640)
• Mean mannitol recovery:
3.80 (SD=2.35; range:
0.52-8.58)
L:M more than doubled
between 12 wk-1 yr of age
(r=0.44, p<0.001) and was
driven by both increasing

Mean L:M ratios
were elevated at 8
weeks of age, and
more than doubled
in the first year of
life.
Many markers of
inflammation and
endotoxin release
were significantly
correlated with L:M
and lactulose
recovery.

Presence of
malaria
parasites was
assessed by
blood smear at
each study visit;
the only
parameter
associated with
malaria was
CRP.
Authors did not
report
investigating
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Reference and Study
Outcomes of
Diagnostic Interest
and its relationship
with various
inflammatory markers
and endotoxin

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

• IgM
• IgG
• Plasma endotoxin
• IgG endotoxin-core
antibody

lactulose (r=0.18, p<0.001)
and decreasing mannitol (r=0.14, p<0.01) excretion with
age.

Poor growth was
significantly
correlated with L:M
ratios, primarily due
to lactulose
excretion.

relationships
between certain
serum
parameters
(blood counts,
CRP
concentrations)
and L:M.

WAZ and HAZ scores were
negatively correlated with L:M
(r=-0.41, p<0.001), and
primarily driven by lactulose
excretion (r=-0.39, p<0.001).
Laboratory values were
consistent with chronic, low
level immunostimulation:
• 50% of platelet and 39% of
leukocyte counts were
elevated, especially mean
lymphocyte counts which
were almost twice
expected values [198].
6
• While the mean CRP was
within the normal range,
25% of values were above
the upper limit of normal (5
mg/L), and 17% were >10
mg/L [198].
• Mean IgG, IgA and IgM
concentrations were near
normal at 8 wk of age, but
increased rapidly; all three
were elevated above
expected values in all other
age groups [198, 199].
7
• Mean free plasma
endotoxin concentration
was twice the upper limit of
normal [200] and IgG
endotoxin-core antibody
concentrations were also

6
7

Geometric mean.
Geometric mean.

Authors postulate
that while general
markers of
inflammation
cannot
be specifically
ascribed to a gut
source, endotoxin
and its related core
antibody are
potentially a direct
measure of
intestinal
inflammation due to
gut gram negatives
as a primary
source of endotoxin
release among
subjects without
sources of extraintestinal gram
negative infection.

Study
population might
have overlap
with that of
Campbell et al.
2004 also
included in this
review [15].
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

All Gambian
subjects had
evidence of
enteropathy with
crypt-hyperplasia
and villous atrophy,
and mean IELs >2
SD above UK
norms,

Statistical
methodology
was not
sufficiently
detailed to
determine what
was compared
(e.g. type of
central tendency

elevated [198].

• However, mean albumin

concentrations (and
concentrations within SD)
were generally within
normal range [198].

L:M was correlated with
IgG and IgA (r=0.41 and
0.41, respectively, p<0.001),
and IgM (r=0.28, p<0.02).
IgG and IgA were also
correlated with lactulose
recovery (r=0.26 and 0.25,
respectively, p<0.02).
IgG endotoxin core antibody
concentration was correlated
with L:M and driven by
lactulose recovery, (r=0.35,
p<0.005 for both).
Endotoxin concentrations
were correlated with lactulose
recovery (r=0.36, p<0.02)
only.
2003
Campbell DI et al.

Fajara and
Sibanar, The
Gambia

Chronic T cellmediated enteropathy
in rural west African
children: relationship
with nutritional status

6 mo-3 yr old
hospital- and
clinic-based cases
from rural
communities.

Case-control
n=40 cases:
• Group 1: n=4
• Group 2:
n=11 (7 with
diarrhea)
• Group 3:
n=25 (18

Endoscopic
small bowel biopsy, site
not specified:
• Histopathology
• Morphometric
assessment by
computer analysis*
• Intestinal tissue
cytokines and

Crypt-hyperplasia and villous
atrophy were observed
among all Gambian subjects,
and the degree of
histopathology did not differ
among cases with differing
nutritional status, nor was
there a correlation with
diarrhea.
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Reference and Study
Outcomes of
Diagnostic Interest
and small bowel
function

L:M as a marker of
intestinal permeability,
small bowl biopsy with
assessment of
intestinal immune
markers, and
computerized
morphometric analysis
among rural Gambian
children with differing
degrees of
malnutrition and
compared to wellnourished UK children

Location and
Target Population
Case groups
based on
differences in
nutritional status:
1. WAZ score >-2,
with GI
complaints
other than
diarrhea
2. Grade I protein
energy
malnutrition
(PEM) (WAZ
score -2 to -4)
and
unresponsive to
nutritional
supplements,
with or without
diarrhea
3. Grade II PEM
(WAZ score <4) with or
without diarrhea
Controls from UK*
who were well
nourished children
with GI complaints
other than
diarrhea and with
normal endoscopy
results were also
studied.

Design and
Sample Size
with
diarrhea)
n=34 with
case tissue
samples
sufficient for
cytokine
immunoreact
ivity tests:
• Group 1:
n=3
• Group 2:
n=8
• Group 3:
n=23

Biomarker
immune markers:
• CD-3
• CD-4
• CD-8
• CD-19
• CD-25
• HLA-DR
• Perforin
• γδ T-cell receptor
• Syndecan-1
• TNF-α
• IFN-γ
• TGF-β
• IL-10
Urine Tests:
8
• Lactulose
• Mannitol
• L:M
* Biopsy involved
morphometric
assessment by
computer analysis of
villous height, crypt
depth, villous:crypt
ratio, and intraepithelial
lymphocyte (IEL)
density (per 100
epithelial cells).

* UK subjects are
presented in this
8
9

Lactulose and mannitol results were expressed as % of dose administered.
These figures are presumed to represent IEL means; however, this was not explicitly stated.

Results
9

IEL means were ~3-fold
higher in Gambian than UK
children.
Median CD3, CD4, CD8,
CD19, and CD25 cell counts
were significantly higher (2-5x
higher) among each case
group compared to the UK
controls.
IEL, γδ, syndecan-1, HLADR, and perforin were
detected among the Gambian
children in varying degrees
but were not reported for UK
controls. Syndecan, CD3,
and CD8 displayed a gradient
proportional to malnutrition
severity.
All Gambian groups showed
higher lamina propria
cytokine-immunoreactive
mononuclear cell density
2
(~200-450/mm ) than UK
2
controls (30-80/mm ).
Among subjects with elevated
cytokines, similar densities
were seen for both proinflammatory (IFN-γ and
TNF-α) and putative
regulatory (IL-10 and TGF-β)
cytokines. Epithelial
expression of TGF-β was
also enhanced compared to
UK controls, but subjects with

Conclusion

Comments

independent of
nutritional status
and diarrhea
history.

measure and
variance
calculations for
L:M not stated).

Elevation of cellmediated intestinal
markers and
mucosal
proinflammatory
cytokines was
present across the
3 Gambian groups,
variably correlated
with nutritional
status.

Duration of
diarrhea not
specified, but
assumed to be
persistent.

L:M ratios were
elevated in all
Gambian groups,
without apparent
correlation to host
nutritional status.

Mucosal
lymphocyte
densities,
cytokine
immunoreactivit
y, and L:M
results were not
stratified by
history of
diarrhea.
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

table due to
comparisons of
interest made in
the review.
However we do
not include these
subjects in the
sample size for
this review.

Results

Conclusion

Comments

Mean L:M in
asymptomatic 2 to
5 yr olds was high
and decreased
significantly with
increasing age, but
never fell within
expected range of
values.

Subjects were
free from
diarrhea
symptoms for at
least one week
prior to urinary
assessments.

poorer nutritional status had
lower densities of mucosal
TGF-β+ cells, with median
densities of 420 and 250
2
cells/mm in the grade I and
grade II PEM groups,
respectively.
10

L:M values :
• Group 1: 0.53 (0.4-1.3)
• Group 2: 0.47 (0.02-2.20)
• Group 3: 0.73 (0.14-2.2)
• Not assessed among the
UK controls
Nutritional status was not
associated with L:M,
recoveries of lactulose or
mannitol.
L:M was correlated with
mucosal B lymphocyte
density (r=0.57, p<0.05), IEL
(r=0.51, p<0.02), and
perforin+ IEL (r=-0.64,
p<0.03).

2002
Campbell DI et al.
Age-related
association of small
intestinal mucosal
enteropathy with
nutritional status in
10

Keneba, The
Gambia and
surrounding
villages
2-60 yr olds
randomly selected
from rural
communities.

Cohort
n=162;
<5 yr old:
n=26
(23 were reassessed)

Urine Tests:
11
• Lactulose
• Mannitol
• L:M

Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.
Lactulose and mannitol results were expressed as % of dose administered.
12
Type of mean not specified.
11

12

Mean L:M (SE) in 2-5 yr old
group: 0.353 (0.022).
Mean lactulose and mannitol
% recovery was ~0.45 and
~0.65, respectively.
L:M was highest in 2-5 yr age
group and decreased with

The authors
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Reference and Study
Outcomes of
Diagnostic Interest
rural Gambian children

Location and
Target Population

Design and
Sample Size

L:M and urinary
lactulose and mannitol
recovery as a marker
of intestinal
permeability and its
association with
nutritional status at
varying ages. Also
assessed correlation
of change in L:M with
nutritional status at 3.5
mo re-visit.

Biomarker

Results
increasing age (up to age 20)
(p<0.001), but never fell
within referenced UK normal
ranges [201].
Most of the improvement in
L:M was driven by a
reduction in lactulose
excretion (p<0.001), which
fell within expected UK
ranges by age 10 yr.
In contrast, although mannitol
excretion slightly decreased
with age, this trend did not
reach statistical significance.
In fact, excretion proportions
were at all times ½ - ⅓ of
expected UK values [201].
L:M was inversely correlated
13
with HAZ score (r=-0.31,
p<0.001), but not with WAZ
or body mass index (BMI) Z
scores. The correlation with
HAZ score was mainly due to
the higher lactulose excretion
in subjects with poorer HAZ
scores (r=-0.22, p=0.001) and
held across all age groups.
There was a small
improvement in mean L:M
(SE) between the two study
time points from 0.198
(0.018) to 0.172 (0.010)
(p=0.026 for change in L:M),
driven by an improvement in
mannitol recovery with no
change in lactulose excretion.

13

Reported results were adjusted for age, sex, and visit.

Conclusion
Among all age
groups, L:M
showed significant
intra-subject
correlation between
tests conducted 3.5
months apart.
Among all age
groups, L:M was
significantly
inversely correlated
with HAZ score,
primarily driven by
lactulose excretion.

Comments
sought
correlation
between the
mean L:M of the
two visits and
∆BMIZ, ∆HAZ
and ∆WAZ
scores, but
statistical
calculations
were not
provided.
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Supplementation of
vitamin A and zinc
resulted in
significant
improvements in
L:M among the
cohort of children
with a history of PD
or low WAZ score
who received post-

Longitudinal
data were not
reported
stratifying on
underlying
condition (i.e.
PD history vs.
WAZ score).

Indices of intestinal
permeability within subjects
showed a high degree of
correlation between the two
visits:
• Lactulose: r=0.55, p<0.001
• Mannitol: r=0.24, p<0.05
• L:M: r=0.66, p<0.001
Change in measures
between visits (analysis not
stratified by age):
• Mean L:M (SD):
• Visit 1: -1.62 (0.66)
• Visit 2: -1.76 (0.55),
(p=0.026)
• Mean mannitol recovery
(SD):
• Visit 1: 5.25 (2.69)
• Visit 2: 6.28 (3.03),
(p=0.006)
• Mean lactulose recovery
(SD):
• Visit 1: 0.28 (0.20)
• Visit 2: 0.29 (0.18),
NS (p-value not
specified)
2003
Chen P et al.
Association of vitamin
A and zinc status with
altered intestinal
permeability: analyses
of cohort data from
northeastern Brazil
14
15

Goncalves Dias
favela in
Fortaleza, Brazil
2-97 mo olds
recruited from an
urban shantytown.

Cohort
n=75 with presupplement
L:M and retinol
concentrations
measured:
• 51 with presupplement
circulating

Urine Tests:
14
• Lactulose
• Mannitol
• L:M

For lactulose and mannitol results, excretion measurement was not specified.
Type of mean not specified.

Baseline mean (SD):
15
• L:M : 0.29 (0.16)
• Lactulose: 0.54 (0.29)
• Mannitol: 2.07 (0.88)
L:M was not correlated with
age. L:M was inversely
correlated with retinol (r=0.55, p<0.0005), including
after adjustment for zinc

Follow-up data
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

zinc
concentration
s measured
• 20 with postintervention*
longitudinal
follow-up of
subset with
history of PD
or low WAZ
score

L:M as a marker of
intestinal permeability
pre- and post-vitamin
A and zinc
supplementation
among children with
history of PD or low
WAZ score

Kampala, Uganda

Cohort

Clark TD et al.

9 mo old HIVinfected children
followed at
Mulago hospital
until 36 mo of age.

n=225

Risk factors and
cumulative incidence
of anemia among
human
immunodeficiency
virus-infected children
in Uganda
Association of chronic
diarrhea with
moderate anemia in
HIV-infected children

More than 40%
were stunted
and/or
underweight at
enrollment.

Conclusion

Comments

concentration and
stratification on retinol
concentrations.

supplementation
assessment. Less
than one-third of
the subjects had
post-intervention
L:M assessments.

on L:M were not
provided for the
children with
normal WAZ
score or no
history of PD.

Retinol was correlated with
mannitol (r=0.28, p=0.017)
and lactulose (r=-0.22,
p<0.063) excretion.

Unclear how
long after
supplementation
the L:M testing
was done.

Lactulose, mannitol and their
combined ratio were not
correlated with zinc
concentrations.

* These
subjects
received a
single oral
dose of vitamin
A and a 2-wk
course of daily
zinc
supplements.

2002

Results

Postsupplementation
L:M results in
the text of the
publication
differed
somewhat from
what was
reported in the
publication
table.

L:M improved after
supplementation for the
cohort of 20 children followed
longitudinally with PD or low
WAZ score:
L:M mean (SD):
• Pre-treatment: 0.28 (0.12)
• Post-treatment: 0.19 (0.07)
However, lactulose and
mannitol excretion did not
change significantly.
Blood Test:
Hemoglobin

While chronic diarrhea was
associated with moderate
anemia in a univariate
analysis (odds ratio=2.5, CI:
1.0, 6.3), it was either not
associated with moderate
anemia (hemoglobin <9 g/dL)
in a multivariate model or not
included in the model

While there was a
high prevalence of
anemia (<11 g/dL)
and moderate
anemia (<9 g/dL)
(92% and 35% at 9
months,
respectively)
among this cohort
of HIV-infected
children, chronic
diarrhea appears to
have not been
associated with
anemia in the
multivariate

The association
between chronic
diarrhea and
other assessed
hematologic
markers (any
degree of
anemia, mean
corpuscular
volume, and
mean
corpuscular
hemoglobin
concentration)
was not
reported.
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

analysis. However,
the text did not
specifically state
whether chronic
diarrhea was tested
in the multivariate
model.
2007
Darboe MK et al.
Effectiveness of an
early supplementation
scheme of high-dose
vitamin A versus
standard WHO
protocol in Gambian
mothers and infants: a
randomised controlled
trial

Keneba, The
Gambia
Subjects recruited
at birth from rural
community. Age
range during
study was 0-12
mo.

RCT
n=197

Urine Test:
L:M

n=99 received
high dose
vitamin A
protocol
n=98 received
standard dose
vitamin A
protocol

Dini E et al.
Sudan III and
steatocrit in the
detection of fecal fat in
malnourished children
Fecal fat by four
different testing
methods as a marker
16

Geometric mean.

Caracas,
Venezuela
6 mo-9 yr olds
with recruited from
an outpatient
nutrition center
and wellnourished
controls.

Case-control
n=129;
n=99 cases:
• 30 with
subclinical
malnutrition
• 34 with mild
malnutrition
• 30 with
moderate

L:M values rose by
~50% from age 2
mo to 1 yr and
were not affected
by dosing of
vitamin A.

The L:M normal
cutoff was
defined higher
than for most
other L:M
studies, as 0.30.
This was
derived from the
mean plus 2 SD
from a study of
UK infants [202]

Proportions testing positive
for fecal fat ranged from 33%41% overall, depending on
test method used.

A majority of
children studied
tested negative for
fecal fat.

Spanish
language article.

The proportion testing
positive varied by nutritional
status across testing
methods:
• 80%-100% of severely
malnourished subjects had
a positive test

The highest
percent testing
positive was in
those with severe
malnutrition,
followed by those
with subclinical-

Mean L:M differed between
the two groups only at 7 mo
(0.276 in high-dose vitamin A
group, p=0.014), although
there was no difference in
percentages with L:M >0.30.

L:M as a marker of
intestinal epithelial
integrity among infants
receiving high-dose
vitamin A or standard
vitamin A protocol
2002

16

Mean L:M and proportion
with values >0.30 among
those receiving standard
doses of vitamin A, by age:
• 2 mo: 0.195, 12%
• 5 mo: 0.197, 13%
• 7 mo: 0.212, 22%
• 9 mo: 0.286, 30%
• 12 mo: 0.322, 34%

Stool Test:
Fecal fat, by method:
• Sudan III classic
• Sudan III
modified
• Steatocrit classic
• Steatocrit acid
Each subject
underwent testing for

Control
recruitment
strategy was not
well described.
Proportions
positive for fecal
fat by history of
diarrhea (current
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Reference and Study
Outcomes of
Diagnostic Interest
of malabsorption
among children with
varying nutritional
status and wellnourished controls

Location and
Target Population

Design and
Sample Size
malnutrition
• 5 with severe
malnutrition
n=30 controls

Biomarker

Results

Conclusion

Comments

all four methods.

• Similar proportions of
subjects with subclinical,
mild or moderate
malnutrition tested positive,
ranging from 30%-47%
• 13%-27% of controls tested
positive
These differences appeared
to be significant, but
statistical comparison results
were not entirely clear.

moderate
malnutrition.
Controls had the
lowest percent
testing positive.

or previous)
were not
provided.
Authors
reported percent
agreement
between tests
but did not
report results of
statistical testing
of these
estimates.

Fecal fat did not vary based
on quantity of fat intake.
By all four methods, a high
percentage of children with
parasites tested positive
(~60%) compared to children
without parasites (25%).
Associations were observed
between infection with
Giardia lamblia or
Blastocystis hominis and
fecal fat (p<0.05); this held
true across diagnostic
methods.
The presence of diarrhea at
time of testing was positively
associated with fecal fat by all
test methods (p<0.02 for all
except steatocrit classic,
p=0.06).
The relationship between
fecal fat and history of
diarrhea in the year prior to
testing varied by test method:
• Sudan III classic: p=0.134

Subjects with
enteric parasites or
those experiencing
diarrhea at time of
testing excreted fat
significantly more
often than
uninfected children
without diarrhea,
although the
magnitude of
difference was not
reported.
There was some
variation between
the different testing
methods, for
example their
relationship with a
history of diarrhea
in the year prior to
testing.

Test results
varied by
subject
characteristics;
however,
assessments
adjusting for
potential
confounding
were not
reported.
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Diagnostic Interest

Location and
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Design and
Sample Size
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Results

Conclusion

Comments

Villous atrophy was
identified not only
among 40% of
children with PD,
but also among
22%, 9%, and 17%
of those with short
stature, rickets, and
other conditions,
respectively.

Specific results
for the 2
patients with
protein losing
enteropathy
were not
reported.

• Sudan III modified: p<0.001
• Steatocrit classic: p=0.14
• Steatocrit acid: p=0.015
Agreement between all four
methods was 72%.
Agreement between at least
three was 91.5%.
2006
El Mouzan MI et al.
Endoscopic duodenal
biopsy in children
Duodenal biopsy
among children with
suspected intestinal
disease

Riyadh, Saudi
Arabia

Retrospective
case-series

1.5 mo-18 yr olds
referred to
hospital for
endoscopy with
duodenal biopsy.

n=241 cases:
• 102 with PD
• 116 with
unexplained
short stature
• 11 with
refractory
rickets
• 12 with other
conditions
(including 2
with protein
losing
enteropathy)

78% of subjects
were <12 yr old;
results not
presented by age.

Endoscopic duodenal
biopsy:
• Gross endoscopic
visualization
• Histopathology

14% had abnormalities on
endoscopic visualization:
• 1% had esophagitis
• 6% had gastritis, 7 (47%) of
which were H. pylori
positive
• 7% had duodenitis
Biopsy results:
• PD:
• 26% normal
• 29% chronic nonspecific duodenitis
• 40% villous atrophy
• 5% other*
• Short stature:
• 56% normal
• 22% chronic nonspecific duodenitis
• 22% villous atrophy
• Rickets:
• 55% normal
• 36% chronic nonspecific duodenitis
• 9% villous atrophy
• Other:
• 25% normal
• 50% chronic nonspecific duodenitis

Authors argue that
endoscopic biopsy
is superior to
“blind” capsule
biopsy in
developing country
settings and allows
for visualization of
the intestine.
Endoscopic
visualization results
were not reported
by condition nor in
relation to
histopathology
results; it is difficult
to assess the value
added compared to
biopsy alone.

For 27% of
cases, the only
histopathology
finding was
chronic nonspecific
duodenitis; the
diagnostic,
prognostic, and
therapeutic
utility of
identification is
unclear.
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Design and
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Biomarker

Results

Conclusion

Comments

Histological
abnormalities were
noted in all
subjects by LM and
SEM.

Inconsistent
reporting of
proportions of
histopathologic
findings among
all subjects and
by SBBO status;
assessment of
potential
relationship with
SBBO between
different
histologic
findings was not
possible.

• 17% villous atrophy
• 8% other*
* 3 lymphangiectasia, 2
Giardia, 1 Mycobacterium
avium intracellulare. Findings
were reported according to
presenting symptoms.
2000

Sao Paulo, Brazil

Case-series

Fagundes-Neto U et
al.

2-10 mo olds with
PD and protein
calorie
malnutrition
consecutively
admitted to Sao
Paulo Hospital.

n=16

Studies of the small
bowel surface by
scanning electron
microscopy in infants
with persistent
diarrhea
Scanning electron
microscope (SEM)
and light microscope
(LM) analyses of small
intestinal biopsy
among infants with PD
with and without
SBBO

Jejunal secretions
aspirate:
Bacterial
concentrations
Jejunal tethered
capsule biopsy:
Histopathology by LM
and SEM
Rectal tethered capsule
biopsy:
Histopathology

68.7% had bacterial
overgrowth (concentration
4
>10 colonies/mL): 3 had
enteropathogenic E. coli
while the rest had colonic
microflora.
All small intestine specimens
had morphological
abnormalities on LM:
• 43.7% moderate villous
atrophy
• 56.3% subtotal villous
atrophy
SEM revealed abnormalities
of varying intensity:
• Among the 11 with SBBO,
villous atrophy ranged from
Grade II (n=4), Grade III
(n=2), to Grade IV (n=3).
• For the 5 subjects without
SBBO, villous atrophy
ranged from Grade I (n=1)
to Grade 2 (n=4).
• A mucous-fibrinoid pseudomembrane over enterocytes
was noted in 7 of the 11
with SBBO and none of the
others.
Other abnormalities noted on
SEM included:

Degree of villous
atrophy noted on
SEM seemed to be
correlated with
SBBO (no
statistical tests
were reported).
Authors speculate
that the mucousfibrinoid pseudomembrane partially
covering
enterocytes is
consistent with a
malabsorptive
process, with the
findings of fat
droplets on
enterocytes
surfaces, and with
the state of
malnutrition of the
subjects.
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Mean L:M overall
was within normal
range. However,
mean L:M for
placebo-treated,
HIV-infected infants
by 14 weeks was
significantly
elevated to almost
0.5.

Specific sugar
excretion was
normalized to
urinary
creatinine to
control for
variation in renal
function.

• Mucus and debris covered
large areas of the villous
surface
• Derangement of the
enterocytes (in some cases
cell borders were not clearly
defined)
• Reduced height and
number (or absence in
some places) of microvilli
• Lymphocytes and fat
droplets were observed
over the surface of
17
enterocytes (18%)
10 subjects had colitis on
rectal biopsy; this was not
associated with SBBO or
degree of small intestinal
pathology on SEM.
2001
Filteau SM et al.
The effect of antenatal
vitamin A and (beta)carotene
supplementation on
gut integrity of infants
of HIV-infected South
African women
L:M as a marker of
intestinal permeability
among infants of HIVinfected mothers
17

Durban,
South Africa
Pregnant, HIVinfected women
between 28-32 wk
gestation recruited
from antenatal
clinic. Infants were
followed until 14
wk of age.

RCT
n=238
n=119 received
vitamin A
supplements
(26 with HIV
infection)
n=119 received
placebo
(29 with HIV
infection)

Urine Tests:
18
• Lactulose
• Mannitol
• L:M
Subjects tested:
• 1 wk:
• Treatment: n=104
• Placebo: n=104
• 6 wk:
• Treatment: n=100
• Placebo: n=105
• 14 wk:
• Treatment: n=99

These SEM results were not presented separately for those with and without SBBO.
For lactulose and mannitol results, excretion measurement was not specified.
19
Geometric mean.
20
Reported results were adjusted for confounding variables, unless otherwise noted.
18

19

Mean L:M (CI) at 1 wk
among infants without reports
of illness was 0.12 (0.08,
0.17). L:M did not change
with increasing age and did
not significantly increase with
reported morbidity.
While a history of ever having
been breastfed was an
important contributor to L:M
2
at 1 wk (ΔR =0.22, p=0.008),
a significant effect was not
20
seen at 6 and 14 weeks .
Current feeding status had a
modest effect on L:M only at

While HIV infection
did not affect
mannitol excretion,
it was associated
with increased
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Reference and Study
Outcomes of
Diagnostic Interest
enrolled in a vitamin A
trial

Location and
Target Population

Design and
Sample Size
Treatment
involved
maternal
vitamin A
supplements
during
pregnancy and
at delivery.

Biomarker

Results

• Placebo: n=95

Conclusion
2

14 wk (ΔR =0.06, p=0.04).
Birth weight contributed
significantly at 1 wk
2
(ΔR =0.07, p=0.02), but
current weight did not
contribute significantly to L:M
at any time point.
HIV infection status by 14 wk
was the major factor
contributing to L:M at 6 wk
2
(ΔR =0.22, p=0.008) and 14
2
wk (ΔR =0.21, p=0.01).
Maternal HIV viral load during
pregnancy was not
consistently significantly
correlated with infant L:M.
Maternal lymphocyte counts
and plasma retinol
concentrations were not
associated with infant L:M.
While maternal vitamin A
supplementation had no
effect on L:M of uninfected
infants, it appeared to prevent
the increase in L:M of HIV21
infected infants :
22
Mean L:M (CI):
• Uninfected:
• Vitamin A group: 0.11
(0.08, 0.15)
• Placebo group: 0.09
(0.06, 0.12)
• HIV-infected:

21
22

Reported results were adjusted for confounding variables included an interaction with HIV infection.
Geometric mean.

lactulose excretion.

Comments
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

A high baseline
prevalence of
abnormal L:M was
observed, with no
change after
intervention.

Difficult to
interpret
sucrose tests
because there
are limited data
on laboratory
values for these
tests in young
children.

• Vitamin A group: 0.17
(0.13, 0.23)
• Placebo group: 0.50
(0.37, 0.68)
Mannitol was not affected by
vitamin A. HIV infection was
not consistently significantly
associated with mannitol
across age groups.
Lactulose also did not
consistently differ between
treatment groups or by HIVstatus, although vitamin A
prevention of increase in
lactulose among HIV-infected
infants neared significance at
23
14 wk (p=0.058) .
2005

Mwenye, Malawi

RCT

Galpin L et al.

36-60 mo olds
recruited from a
rural community,
excluding children
with severe acute
malnutrition or
severe chronic
illnesses.

n=164;

Effect of Lactobacillus
GG on intestinal
integrity in Malawian
children at risk of
tropical enteropathy
L:M and sucrose:
lactulose ratio (SUC:L)
as markers of
intestinal and gastric
permeability,
respectively, in
asymptomatic children
presumed at risk of
23

Subjects were
considered at risk
for EED due to
residence in a
location with high
prevalence of
EED.

n=81 received
Lactobacillus
GG
(80 completed
the study)

Urine Tests:
24
• Lactulose
• Mannitol
• Sucrose (SUC)
• L:M
• SUC:L

n=83 received
placebo
(81 completed
the study)
Subjects
received 30-

P-values are from reported results that were adjusted for confounding variables.
Lactulose, mannitol, and sucrose results were expressed as % of dose administered.
25
Arithmetic mean.
24

At enrollment:
• 73% had L:M >0.10
• 40% had L:M >0.20
25
• Mean L:M (SD):
• Treatment: 0.18 (0.16)
• Placebo: 0.22 (0.20)
• Mean lactulose (SD) in
treatment group: 0.25 (0.17)
• Mean mannitol (SD) in
treatment group: 8.0 (4.5)
• Mean SUC:L (SD):
• Treatment: 0.58 (0.64)
• Placebo: 0.60 (0.64)
Mean excretion of sucrose
(SD) increased from 0.057
(0.042) to 0.078 (0.058) in the
treatment group (p=0.01), but

High mannitol
excretion (relative
to UK norms) drove
the abnormal L:M.
There was little
effect on SUC:L
with intervention;
sucrose excretion
increased in both
treatment and
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Reference and Study
Outcomes of
Diagnostic Interest
EED

Location and
Target Population

Design and
Sample Size

Presumed that if
SBBO is etiology
for EED,
treatment with
Lactobacillus will
result in improved
gut integrity.

days of
Lactobacillus
GG or placebo.
Only the 161
subjects who
completed the
study had
repeat testing.

2001

Brasilia, Brazil

Cross-sectional

Gandolfi L et al.

6 mo-13 yr olds
with acute,
persistent or
chronic diarrhea,
and/or
malnutrition being
seen at the
pediatric
gastroenterology
service of a
university hospital
and determined to
have disease
severity
warranting biopsy.

n=31

Antiendomysial
antibody test reliability
in children with
frequent diarrhea and
malnutrition: is it celiac
disease
Jejunal biopsy among
children with PD
and/or malnutrition

Biomarker

Jejunal capsule biopsy:
Histopathology

Results

Conclusion

similar results were observed
in the placebo group.
Otherwise there were no
changes in lactulose,
mannitol, L:M, or SUC:L after
treatment or placebo.

control groups.

30/31 (96.8%) had abnormal
histopathology:

The vast majority of
children with
clinically severe
diarrhea and/or
malnutrition had
some degree of
abnormality on
jejunal biopsy.

Biopsies of
interest were not
provided in
subject-specific
detail (e.g.
characteristics
of the 27
children with
non-specific
inflammation
were not
detailed (e.g.
presence of
parasites,
degree of
malnutrition
and/or diarrhea).

High L:M ratios
overall with
substantial
seasonal and
within-infant
variability.

High L:M ratios
were defined as
greater than the
upper CI for UK
infants.

• Suggesting non-specific
inflammatory abnormalities
in 27 (87.1%) subjects.
• Demonstrating grade 3
mucosal abnormalities in all
malnourished 1 yr olds
negative for enteric
parasites.

Comments

Subjects negative
for CD-specific
antibodies were of
interest for this
review.
2008
R. Goto, et al.
Impact of anti-Giardia
and anthelminthic
treatment on infant
26

Geometric mean.

Dhamrai Upazila,
Bangladesh
3-15 mo olds from
a rural area were
enrolled and
followed in a 9-mo

RCT
n=222*
n=75 received
anti-Giardia
and

Urine Test:
L:M
Blood Tests:
• α-1-acid glycoprotein
(AGP)

26

Mean L:M (SD) at baseline
was 0.18 (0.24) in treatment
groups, with no significant
difference in placebo group or
in testing post-intervention.
Proportion with elevated L:M

Same study
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Reference and Study
Outcomes of
Diagnostic Interest
growth and intestinal
permeability in rural
Bangladesh: a
randomised doubleblind controlled study

L:M as a marker of
intestinal permeability,
IgG as a marker of
chronic immune
stimulation, and α-1acid glycoprotein as
an acute phase
reactant among
children undergoing
anti-parasitic
presumptive treatment
vs. placebo. Also
assessed markers’
associations with
growth parameters.

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

trial.

anthelminthic
treatment

• IgG
• Albumin

at any study time point varied
between 58%-74%. >57%
consistently elevated L:M
ratios.

Interventions did
not impact L:M or
serum immune
markers.

Seasonal variation in L:M
was observed (p <0.001),
with highest mean values in
the monsoon season.

There was
improvement in
weight with better
L:M values, the
degree to which
this occurred was
not reported.

population as
reported by this
group in another
study also
included in this
review [123].

There was a high
prevalence of
malnutrition in the
study population.

n=59 received
anti-Giardia
treatment only
n=88 received
placebo

L:M was associated with
∆WAZ and ∆WHZ scores at
24 weeks (p=0.001 and
p<0.001, respectively, point
estimates not provided.)

* Those who
fully
participated
and for whom
data were
analyzed are
included in this
review.

Serum immune marker
values were similar in all
groups and did not change
substantially with
interventions.
AGP concentrations were
negatively associated with
∆WAZ score at 24 weeks
(p=0.004, point estimate not
provided), and were
associated with ∆WHZ score
at 12 weeks but not at 24
weeks.

2008
Goto R et al.
Impact of intestinal
permeability,
inflammation status
and parasitic
infections on infant
27

Geometric mean.

Dhamrai Upazila,
Bangladesh
3-15 mo olds from
a rural area were
enrolled and
followed in a 9-mo
trial.

Longitudinal
data extracted
from an RCT
[122]
n=298
Urine and

Urine Test:
L:M
Blood Tests:
• α-1-acid glycoprotein
(AGP)
• IgG
• Albumin

Mean

27

L:M: 0.15

L:M showed a decreasing
trend with age (p=0.003), and
was associated with female
gender (p=0.004), HAZ score
(p=0.039), and WAZ score
(p=0.019), but not with
giardiasis or any of the serum

Mean L:M was
elevated. L:M was
not associated with
any of the tested
serum markers of
inflammation or
with giardiasis.

Helminthiasis
prevalence was
very low; testing
for association
with markers
was not
performed.

IgG rose with

Giardiasis was

Appendix 7. Evidence table of all studies included in the review.

Reference and Study
Outcomes of
Diagnostic Interest
growth faltering in
rural Bangladesh

L:M as a marker of
intestinal permeability,
IgG as a marker of
chronic immune
stimulation, and α-1acid glycoprotein as
an acute phase
reactant. Also
assessed laboratory
values’ associations
with giardiasis and
growth parameters.

2002
Goto R et al.
Poor intestinal
permeability in mildly
stunted Nepali
children: Associations
with weaning practices
and Giardia lamblia
infection
L:M as a marker of
28

Location and
Target Population

Design and
Sample Size

There was a high
prevalence of
malnutrition in the
study population.

blood samples
were collected
every 3 mo and
anthropometric
measurements
were collected
monthly.

Biomarker

Results

Conclusion

Comments

• Hemoglobin

immune markers.

increasing age at
the rate expected
(compared to UK
norms) [199] but at
higher
concentrations
across all ages.

defined as
presence of a
Giardia-specific
IgM response.

IgG, AGP, and albumin were
associated with giardiasis,
but hemoglobin was not.
Mean circulating albumin
concentration was normal for
age [203]. Compared to UK
age-matched reference [199],
rate of rise in IgG with
increasing age was similar,
but concentrations were
consistently ~3g/L higher.

0-5 yr olds (mean
age 3.8 yr) from
two urban
squatter
settlements.
37% and 33% of
subjects were
stunted and
underweight,

Cross-sectional
n=210

Urine Tests:
28
• Lactulose
• Mannitol
29
• Lactose
(168 tested)
• L:M
(158 tested)
• Lactose:lactulose
ratio
(157 tested)

Lactulose and mannitol results were expressed as % of dose administered.
Lactose results were expressed in mg/L.
30
Geometric mean.
29

Cut-off values
representing
elevated
concentrations
have not been
determined for
AGP. UK norms
for 10 mo oldsadults are 0.88
g/L mean (0.21
SD) [204].

IgG was not associated with
growth parameters. Albumin
was associated with HAZ
score only (p=0.016). AGP
was inversely associated with
HAZ (p=0.011) and WAZ
(p=0.005) scores.

Kathmandu,
Nepal

Same study
population as
reported by this
group in another
study also
included in this
review [122].

L:M:
• 92% had values >UK norms
30
• Mean L:M (SD, range):
0.26 (0.21, 0.04-1.71).
• Giardia-infected versus
uninfected means: 0.43 vs.
0.25, p=0.014

L:M ratios were
high overall.

The duration of ingestion of
solid foods (with or without
concurrent breastfeeding)
was not associated with L:M
in multivariate analysis.

L:M was
associated with
giardiasis but not
helminthiasis.

Wide individual
variation was
observed in L:M
ratios.

Low lactase
activity was
defined as
lactose:lactulose
ratio >0.4.
Specific L:M
data by WAZ
and HAZ scores
were not
reported,
although
authors state
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Reference and Study
Outcomes of
Diagnostic Interest
intestinal permeability,
and assessment of
association with
giardiasis,
helminthiasis,
nutritional practices,
and growth status.

Location and
Target Population
respectively.

Design and
Sample Size

Biomarker

Results
L:M was correlated with
longer duration of
breastfeeding (r=0.27,
p<0.019). Specifically,
children who breastfed for >2
yr had higher L:M ratios than
children who breastfed for
shorter times (data not
provided).
L:M was not associated with:
• History of diarrhea in the
week preceding testing
• Helminthiasis
• Age
• WAZ or HAZ scores
Lactulose excretion ranged
from 0.02–15.00. Mannitol
excretion ranged from 0.5–
15.00.
47% showed low lactase
activity. Lactose values and
lactose:lactulose ratios
2
decreased with age (R =28%,
p<0.0001), but were not
associated with sex, ethnicity,
and location nor were they
associated with L:M.
31

Mean urinary lactose
concentrations (mg/L) by
feeding mode:
• Breastfed: 172.5
• Non-breastfed: 44.5,
p<0.0001 corrected for
infant age
31

Geometric mean.

Conclusion

Comments

Urinary lactose
concentrations and
lactose:lactulose
ratios were
significantly higher
in breastfed
subjects than in
those that were not
breastfed, despite
similar intestinal
permeability
values.

that L:M was not
associated with
“growth status.”

There were some
unexpected
findings: the
duration of
breastfeeding, and
not the timing of
introduction of solid
foods, was
correlated with L:M,
and the correlation
was direct, not
inverse. Authors
speculate that this
could be due to
higher mean age of
their cohort
compared to
another study that
demonstrated
beneficial effect of
duration of
breastfeeding on
reduced L:M in
Guatemala [205].

Appendix 7. Evidence table of all studies included in the review.

Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Children with
diarrhea had
significantly higher
L:R ratios by both
blood and urine
testing compared
with controls
without GI illness.

Authors used
data from nondiarrheal
controls from
their clinical
practice to
derive cut-points
for L:R ratios
used in this
study:
• Blood L:R:
• Low= <7
• Intermediat
e= 7-12.5
• High=
>12.5
• Urinary L:R:
• Low= <10
• Intermediat
e= 10-18
• High= >18

32

Mean lactose:lactulose ratio
by feeding mode:
• Breastfed: 2.76
• Non-breastfed: 0.31,
p<0.0001 corrected for
infant age
Mean L:M by feeding mode:
• Breastfed: 0.23
• Non-breastfed: 0.28, nonsignificant, p-value not
specified
2000

Darwin, Australia

Case-control

Haase A et al.

Cases were >4
mo olds admitted
to Royal Darwin
Hospital with
diarrhea. Controls
were patients
admitted with nonGI illness.

n=264;

Dual sugar
permeability testing in
diarrheal disease
Lactulose:rhamnose
ratio (L:R) as a marker
of intestinal
permeability in
children with or
without diarrhea. Also
directly compared
blood and urine
methods of L:R testing
in a subset of
subjects.

More than 75% of
cases and
controls were
Aboriginal.

n=150 cases
with AD
n=114 controls
with no
diarrhea

Blood Test:
L:R
Urine Test:
L:R
Among cases:
• 24 had both blood
and urine L:R
• 98 had blood L:R only
• 28 had urine L:R only
Among controls:
• 25 had both blood
and urine L:R
• 36 had blood L:R only
• 53 had urine L:R only
A total of 49 subjects
were tested with both
blood and urine L:R
methods to allow direct

32

Geometric mean.
Geometric mean.
34
Geometric mean.
33

Among the subset with both
blood and urine specimens:
• Urine L:R:
33
• Mean (CI):
• Cases: 12.4 (9.3,
16.5)
• Controls: 6.7 (5.0,
8.8), p=0.004
• Distribution across
ratios:
• Low: n=31
• Intermediate: n=9
• High: n=9
• Blood L:R:
34
• Mean (CI):
• Cases: 9.4 (6.7, 13.1)
• Controls: 5.9 (4.4,
7.8), p=0.04
• Distribution across
ratios:
• Low: n=27
• Intermediate: n=11
• High: n=11

There was
substantial
agreement
between urine and
blood L:R tests in
the same subjects.
Urine has been an
established
substrate for sugar
excretion
assessment as an
indication of
intestinal
permeability.

Controls were
significantly
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker
comparison of values.

Results
Among subjects with only
urine tested:
35
Mean urine L:R (CI):
• Cases: 15.7 (12.6, 19.6)
• Controls: 6.7 (5.7, 8.0),
p<0.0001
Among subjects with only
blood tested:
36
Mean blood L:R (CI):
• Cases: 12.8 (10.3, 16.0)
• Controls: 3.7 (2.8, 4.9),
p<0.0001
Even though blood L:R was
consistently lower than urine
L:R by a geometric mean (CI)
of 1.09 (1.02, 1.16), there
was strong correlation
between L:R ratios in blood
and urine as measured by:
• Concordance correlation
coefficient for agreement
(CI) of 0.76 (0.64, 0.88)
• Kappa statistic (CI) of 0.71
(0.51, 0.92) (when L:R
ratios are divided into 3
ordered categories)
• Sensitivity and specificity of
blood tests of 81% (25/31)
and 89% (16/18),
respectively, when using
the urine testing as the
standard.
The failure rate* for serum

35
36

Geometric mean.
Geometric mean.

Conclusion

Comments

However, timed
collection of urine
is not a trivial task,
especially among
female children,
and contamination
with stool is
problematic,
especially in
children with
diarrhea. However,
the much lower
concentrations of
probe sugars in
blood compared to
urine had posed a
challenge to
sensitive detection
in blood. High
performance liquid
chromatography
(HPLC) methods,
as used in this
study, now provide
a more sensitive
method of
assessing blood
specimens.

older than the
cases, but
authors suggest
that age
differences do
not impact L:R
test
performance.

The failure rate of
L:R blood testing
was significantly
lower than that of
urine testing.

Numbers of
subjects do not
always match
up (e.g.
numerator in
test failure rate
calculations
does not match
other such
reported
numbers).
Analyses of
those subjects
who had both
blood and urine
testing were
conducted on
combined cases
and controls.
Analyses of
those with and
without diarrhea
would have
been of interest.
One would
expect children
with diarrhea to
have higher
rates of urine
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Reference and Study
Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

L:R testing (20/197, 10%)
was lower than for urine
testing (86/234, 37%)
(p<0.0001).

Comments
test failure due
to contamination
with stool and to
have higher
failure rates
using either
analytes due to
higher rates of
emesis.

* Defined as emesis with
rhamnose/lactulose oral
challenge (same dose for
urine and serum testing),
urine leakage or
contamination with stool, or
plasma quantity from blood
draw of insufficient quantity
for analysis.

Spot blood
testing might be
more feasible
than timed urine
collections, but
HPLC might not
be feasible in
resource-poor
settings.
This study
appears to
report on the
same population
as two other
studies in this
review which
also assessed
serum L:R as a
marker of
intestinal
permeability [43,
58].

2000
Hafeez A et al.
An audit of pediatric
upper gastrointestinal
endoscopies

Islamabad,
Pakistan
2 mo-12 yr olds
referred from
various hospitals
to KRL Hospital
Islamabad for

Case-series
n=41;
• 28 with PD
• 9 with FTT
• 4 with short
stature

Endoscopic duodenal
Biopsy:
• Gross endoscopic
visualization
• Histopathology

Positive histopathologic
findings were identified in:
• 21/28 with PD
• 7/9 with FTT
• 3/4 with short stature

75% of the PD and
77% and the short
stature/FTT
patients had
abnormalities by
endoscopy.

More abnormalities were
found via histology than

Authors assert the

There was
possible bias in
the manner of
selection for
endoscopy. 14
biopsies were
unable to be
analyzed (from
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Reference and Study
Outcomes of
Diagnostic Interest
Duodenal biopsy
among children with
PD or growth
problems

Location and
Target Population
abdominal pain,
PD, short stature,
FTT, GI bleeding,
or anemia. The
subjects of
interest for this
review were those
with PD or growth
problems.

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

visualization, and findings did
not necessarily correlate.

importance of
biopsies among
children with
indications for
endoscopy, due to
lack of correlation
between them and
increased
identification of
abnormalities by
biopsy.

100
endoscopies).
Authors did not
report the
endoscopic
appearance of
the mucosa.
Histology
findings were
reported by
specimen (with
multiple
specimens from
some patients),
not by condition
or by patient, so
specific results
could not be
interpreted in
regards to this
review.
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Reference and Study
Outcomes of
Diagnostic Interest
2007
Jain S et al.
Fecal occult blood
screening in children
with severe
malnutrition

Fecal occult blood
among severely
malnourished children
compared to healthy
controls

Location and
Target Population

Design and
Sample Size

Delhi, India

Case-control

Children (ages
unspecified)
admitted with
severe
malnutrition and
age-matched
healthy controls
recruited from an
immunization
clinic.

n=80;
n=50 cases
with severe
malnutrition
n=30 healthy
controls

Biomarker

Results

Conclusion

Comments

Stool Test:
Occult blood

Fecal occult blood test was
positive in 30/50 (60%) cases
and 0/30 controls.

Blood Test:
Hemoglobin

Among cases positive for
fecal occult blood, 20 (66.7%)
were found to have
hemoglobin <8 g/dL.

A high proportion of
severely
malnourished
children had a
positive fecal occult
blood test,
compared with no
positives among
healthy controls.

Among cases,
half had a
presenting
complaint of
diarrhea
(duration not
specified), but
the authors did
not report
results stratified
by diarrhea
duration.

Enteric infections:
• Parasitic infections were
detected in 14/50 (28%) of
cases, 12 (85.7%) of whom
tested positive for fecal
occult blood.
• Bacterial infections were
detected in 18/50 (36%) of
cases, 13 (72.2%) of whom
tested positive for fecal
occult blood.
• Of the remaining 18 for
whom an enteric pathogen
was not identified, 5
(27.8%) tested positive for
fecal blood.
Among the 30 cases with
fecal occult blood, 16 were
breastfed, 11 were fed cow’s
milk, and 3 were fed formula.

Malnourished
children with
identifiable
pathogens more
often tested
positive for fecal
occult blood,
although
approximately 25%
of those without an
identifiable
pathogen also
tested positive.
Presence of fecal
blood did not
appear to vary by
feeding mode (e.g.
breast milk, cow’s
milk, or formula),
although data
presented were
limited.

Authors did not
provide
differences in
proportions of
occult blood
among those
with and without
specific enteric
pathogens.
Statistical
analysis was not
provided; data
were reported
as proportions
only.
Matching
scheme was not
defined.
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Reference and
Study Outcomes of
Diagnostic Interest
2002

Location and
Target Population

Design and
Sample Size

New Delhi, India

Case-series

2-12 yr olds
selected from
hospitalized
patients with
symptoms
suspicious for
protein-losing
enteropathy
(hypoalbuminemia
and edema).

n=3 <5 yr old

2001

New Delhi, India

Case-control

Kapoor S et al.

<12 yr olds
admitted to
hospital with PD
and Giardia.

n=40;

Controls had no
diarrhea and were
hospitalized for
non-GI conditions.

n=10 controls
without diarrhea

Blood Tests:
• IgG
• IgM
• IgA

Case-control

Blood Test:
Mannose-binding
lectin (MBL)

Kapoor S et al.
Detecting protein
losing enteropathy
by Tc-99m dextran
scintigraphy: A
novel experience
Tc-99m dextran
scintigraphy as a
marker of proteinlosing enteropathy
or intestinal
inflammation

Giardiasis--clinical
and diagnostic
perspective
Immunoglobulin
concentrations in
duodenal fluid and
serum among
children with PD
and Giardia
infection compared
to those without
diarrhea
2006
Kirkpatrick BD et al.
Serum mannosebinding lectin
deficiency is
associated with

Biomarker

Results

Conclusion

Comments

Tc-99m dextran
scintigraphy

Abnormal Tc-99m dextran
uptake was positive in one
child found to have subtotal
villous atrophy on biopsy
and another thought to have
abdominal tuberculosis.

Scintigraphy
might be a useful,
noninvasive
method for
detecting
intestinal
pathology.

This pilot study had
a small sample
size of 8 children,
and only 3 were
younger than 5
years.

Differences in
immunoglobulin
concentrations
were limited
among children
with PD infected
with Giardia
compared to
children without
such conditions.

The number of
controls was small
due to constraints
in obtaining
duodenal aspirate
from children
without GI
symptoms.

While
cryptosporidiosis
was associated
with MBL
deficiency, MBL
concentrations
were not
significantly

MBL deficiency
was defined as
concentrations <70
ng/mL.

The child with the negative
scan had marasmus and
partial villous atrophy on
biopsy.

n=30 cases with
PD and Giardia

Duodenal secretion
aspirates:
• IgG
• IgM
• IgA

Higher mean concentrations
of IgM were found in
duodenal aspirates of cases
compared to controls
(p<0.05).
Mean concentrations of
duodenal IgA and IgG did
not differ between cases
and controls.

Most cases were
<7 yr old, with
n=19 <3 yr old.
Ages of controls
were not specified.
Port-au-Prince,
Haiti
<36 mo old innercity residents
recruited from the
rehydration unit at
the State

n=99;
n=49 cases with
Cryptosporidium
infection
(22 with PD)

Serum MBL concentrations
were lower in cases than in
healthy controls (p=0.002)
and diarrhea controls
(p=0.045).
Percentage MBL-deficient:
• 36.7% cases
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Reference and
Study Outcomes of
Diagnostic Interest
cryptosporidiosis in
young Haitian
children

Location and
Target Population
University Hospital
or from GHESKIO
37
HIV Center .

Mannose-binding
lectin as a marker of
innate immune
response among
children with and
without
Cryptosporidium
infection

All subjects were
HIV-negative.

2006

Port-au-Prince,
Haiti

Kirkpatrick BD et al.
Childhood
cryptosporidiosis is
associated with a
persistent systemic
inflammatory
response
Fecal cytokines and
lactoferrin as
markers of intestinal
37

<36 month olds
recruited from
GHESKIO HIV
39
Center with
Cryptosporidium
infection and
healthy controls.
Subjects were
followed-up at 6
and 9 months after

Design and
Sample Size

Biomarker

n=9 diarrhea
controls negative
for
Cryptosporidium

n=73;
n=42 cases with
diarrhea and
Cryptosporidium
infection
(18 with PD)

• 9.8% healthy controls
• 0 diarrhea controls

associated with
mean duration of
diarrhea or history
of PD.

Comments

Among cases, the
proportion of those with PD
was nearly double among
those with MBL deficiency
compared to those without
MBL deficiency, but these
results were not significant
(p=0.13). MBL deficiency
was not associated with
duration of diarrhea
(p=0.37) among those with
cryptosporidiosis nor with
anthropometric status
among either cases or
controls.
Stool Tests:
• Lactoferrin
• Cytokines:
• IFN-γ
• TNF-α
• TGF-β
• IL-4
• IL-8
• IL-10

n=31 healthy
controls without
diarrhea and
Cryptosporidium-

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.
Reported results were adjusted for confounding variables, unless otherwise noted.
39
The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.
38

Conclusion

Cryptosporidiosis was
associated with MBL
deficiency (odds ratio=22.4;
38
CI: 3.1, 160.8 ).

n=41 healthy
controls without
diarrhea and
Cryptosporidiumnegative

Cohort

Results

Proportion lactoferrinpositive at enrollment:
• Cases: 51.2%
• Controls: 4.0%
Cases had higher
concentrations of TNF-α
than controls at enrollment
(p=0.04), but no difference
was observed at follow-up.
Controls had almost 2x
higher fecal IFN-γ at
enrollment (p=0.1); the

Lactoferrin was
present among
half of subjects
with
cryptosporidiosis
and uncommon
among those
without such
infection.
Fecal TNF-α was
higher among
cases at
enrollment but did

Cut-off values for
lactoferrin positivity
were not provided.
Breastfed children
(>85% of cases
and controls) were
included in testing.
Proportions at
follow-up were not
reported.
The association of
fecal cytokines and
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Reference and
Study Outcomes of
Diagnostic Interest
mucosal
inflammation among
children with and
without
Cryptosporidium
infection

Location and
Target Population

Design and
Sample Size

infection resolved.

negative

Biomarker

HIV status of
subjects varied.
There was a high
prevalence of
malnutrition in the
study population.

Results

Conclusion

Comments

magnitude of difference
increased (to almost 3x) and
was statistically significant
at the 6- and 9-month
follow-up (p=0.01 and
p=0.03, respectively).

not persist when
infection resolved.

lactoferrin with
growth parameters,
history of PD, and
HIV status were
not reported, nor
was their
association with
each other.

No differences in fecal
concentrations of TGF-β, IL8, IL-4, or IL-10 were noted
between groups.

Paradoxically,
controls’
comparatively
higher fecal IFN-γ
increased in both
magnitude and
degree of
statistical
significance at
follow-up.
Of the remaining
fecal cytokines
assessed, there
were no
differences
between cases
and controls.

2002
Kirkpatrick BD et al.
Cryptosporidiosis
stimulates an
inflammatory
intestinal response
in malnourished
Haitian children
Stool lactoferrin,
reducing
substances,
leukocytes and
cytokines as
markers of intestinal
inflammation of
40

Port-au-Prince,
Haiti
<18 mo olds from
a low SES setting
recruited from the
rehydration unit of
GHESKIO HIV
40
Center with
diarrhea and
Cryptosporidium
infection. Controls
recruited from an
outpatient clinic
without
Cryptosporidium
infection included
those with and

Case-control
n=49;
n=17 cases with
Cryptosporidium
and diarrhea (5
with PD)
n=32 controls
without
Cryptosporidium;
• 17 with diarrhea
(5 with PD)
• 15 healthy

Stool Tests:
• Reducing
substances (RS)
• Lactoferrin
• Cytokines:
• TNF-α receptor I
• IL-4
• IL-8
• IL-10
• IL-13
• IFN- γ
Blood Test:
WBC

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Proportion RS-positive:
• 33.3% cases
• 64.7% diarrhea controls
• 46.7% healthy controls,
(p=0.2)
Proportion lactoferrinpositive:
• 83.3% cases
• 60.0% diarrhea controls
• 28.6% healthy controls,
(p=0.01)
IFN-γ was not recovered in
any stools.
All other fecal cytokines
were significantly

Fecal lactoferrin
was identified
most often in
children with
diarrhea,
especially in
those with
Cryptosporidium.
While some fecal
cytokines were
detected in as
many as 40% of
healthy controls
and 70% of
controls with
diarrhea, they
were generally
associated with

Various markers of
systemic
inflammation,
including serum
cytokines, were
measured but their
relationship with
markers of
intestinal
inflammation was
not reported.
Reported results
were not stratified
by persistent vs.
acute diarrhea
status.
Cut-off values for
lactoferrin positivity
were not
described.
Stools from
children who were
breastfeeding were
not tested for
lactoferrin.
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Reference and
Study Outcomes of
Diagnostic Interest
children with and
without
Cryptosporidium
infection

Location and
Target Population

Design and
Sample Size

Biomarker

without diarrhea.

Results

Conclusion

associated with
Cryptosporidium cases
compared to diarrhea and
healthy controls.

Cryptosporidium
infection. The
other stool tests
did not
discriminate by
diarrhea or
Cryptosporidium
status.

Additionally, TNF-α receptor
I, IL-8, and IL-13 were found
in diarrhea and healthy
controls, while IL-4 and IL10 were not.

Comments

Fecal lactoferrin was
associated with the
presence of TNF-α receptor
I (point estimate not
provided, p=0.03).
Mean WBC counts were
within normal range in all 3
groups.
2008
Kohli A et al.
Giardia duodenalis
assemblage, clinical
presentation and
markers of intestinal
inflammation in
Brazilian children
Fecal lactoferrin as
a marker of
intestinal
inflammation in
Giardia-infected
children and its
association with
persistence of
diarrhea

Goncalves Dias
favela in Fortaleza,
Brazil
All newborns from
an urban
shantytown were
recruited at birth
and followed for up
to 4 yr. Those with
Giardia recovered
from stools were
included in this
study.

Cohort
n=108 stool
samples from 47
children
Stools were
collected at
regular intervals
as well as during
episodes of
diarrhea.

Stool Test:
Lactoferrin

Proportion of positive
lactoferrin results decreased
with each new Giardia
infection, p=0.015:
st
• 1 infection: 74.0%
(15.2% of those testing
positive had high titers)
nd
• 2 infection: 40.0% (5.3%
of those testing positive
had high titers)
rd
• 3 infection: 1 (20.0%)
tested positive (at a high
titers)
Increasing titers of
lactoferrin were associated
with longer duration of
diarrhea, p=0.017:
• Negative: 2.2 days
• Low: 9.7 days
• High: 14.6 days

Increased
concentrations of
lactoferrin were
observed more
frequently with
first time Giardia
infections.
Concentrations
were associated
with longer
duration of
diarrhea, although
these results were
not presented
separately for first
and recurrent
infections.
Stool lactoferrin
might be useful in
predicting

Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution; the
following scale was
used:
• High = positive
at 1:400-1:3200
dilution
• Low = positive at
1:25-1:200
• Negative = no
reaction at 1:25
Stools from
children who were
breastfeeding were
not tested.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
Lactoferrin results did not
differ between symptomatic
and asymptomatic children
at first infection, but those
with symptoms had positive
results with recurrent
infections with greater
frequency (75.0% vs. 0 in
asymptomatic repeat
infections, p=0.017.)

2003
Kukuruzovic RH et
al.
Increased nitric
oxide production in
acute diarrhea is
associated with
abnormal gut
permeability,
hypokalemia and
malnutrition in
tropical Australian
aboriginal children
Nitric oxide (NO) as
a marker of
intestinal
permeability and
inflammation, and
lactulose:rhamnose
ratio (L:R) as a
marker of intestinal
permeability and the
relationship

Darwin,
Australia
1-6 yr old
Aboriginal and
non-Aboriginal
hospital inpatients.
Subjects were
grouped as
follows:
1. Children with
AD
2. Children with no
diarrhea but with
non-GI infectious
conditions
3. Children without
GI or infectious
conditions

Case-control
n=318;
n=169 cases with
AD
(154 Aboriginal)
n=149 controls:
• 73 with non-GI
infections (49
Aboriginal)
• 76 with no
infections (29
Aboriginal)

Urine Test:
Nitric Oxide (NO)*
Blood Tests:
L:R
Mean corpuscular
volume (MCV)
Stool Test:
Reducing substances
(RS)**
(169 cases tested)

* NO is an unstable
free radical and is
converted to nitrite
and nitrate. Urine
nitrate (NO3)+ nitrite
(NO2) was expressed
as a ratio with urine
creatinine (NO2 +
NO3:Cr) in order to
account for

NO among Aboriginal
children with diarrhea was
>3x higher than any other
group and >5x higher than
in non-Aboriginal controls.
• NO was >3x and >2x
higher among Aboriginal
than non-Aboriginal
children in the diarrhea
(p<0.001) and no
infections groups
(p<0.001), respectively,
but there was no
difference between them
in the non-GI infections
group.
• NO was >3x and ~2x
higher in the diarrhea
compared to the no
infections group among
Aboriginals (p<0.001) and
non-Aboriginals (p<0.03),
respectively.
• NO was virtually the same
among the Aboriginal nonGI infections and no

Conclusion

Comments

duration of
diarrheal illness in
G. duodenalisinfected children.

Data were part of a
larger study; similar
data on lactoferrin
in Cryptosporidiuminfected children
were published by
O.Y. Bushen, et al.
(also included in
this review);
however, Bushen
et al. used a
slightly different
grading scale for
reporting lactoferrin
results [108].

NO2 + NO3:Cr
ratio, as a
measure of
endogenous nitric
oxide production,
was used as a
marker of gut
permeability and
inflammation, with
an attempt to
identify how much
more it reflects as
response to
inflammation from
GI vs. non-GI
infections.

Positive stool RS
was defined as
>0.5%.

Among nonAboriginal
controls, NO
production was
the same among
those with
diarrhea and nonGI infections (and
higher compared

Abnormal L:R was
defined as >7.6; no
reference or
derivation was
provided for this
cut-point.
Study population
appears to be the
same as in another
Kukuruzovic, et al.
study also included
in this review which
assessed serum
lactulose:rhamnose
as a marker of
intestinal
permeability [58].
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Reference and
Study Outcomes of
Diagnostic Interest
between NO and
L:R, growth
parameters, mean
corpuscular volume
(as a surrogate of
iron deficiency), and
stool reducing
substances among
children with and
without diarrhea

Location and
Target Population

Design and
Sample Size

Biomarker
differences in urine
concentration.
** Measured only
among children with
profuse diarrhea.

Results
infections groups, as well
as among the nonAboriginal diarrhea and
non-GI infections groups.
112/152 (74%) and 31/169
(18%) of children with AD
had abnormal L:R ratios and
positive stool RS,
respectively.
NO and L:R were measured
at “convalescence” on Day
5 among those with
diarrhea: the mean
improvement in NO was
21.7% compared with
54.6% for L:R (p=0.01).
NO and L:R were correlated
41
(n=193, r=0.37, p<0.001) ;
the correlation was stronger
for lactulose (effect
ratio=1.47, p<0.001) than
for rhamnose (effect
42
ratio=0.80, p=0.02 ).
NO was not correlated with
43
stool RS or MCV, but was
correlated with lower WAZ
score (effect ratio=0.88,
p=0.05).

41

Reported results appear to have been adjusted for age and race.
Reported results were adjusted for age and race.
43
Reported results among children with diarrhea were adjusted for age and race.
42

Conclusion
to controls). NO
was highest by far
among Aboriginal
children with
diarrhea
compared to any
other group.
Authors suggest
that high basal
concentrations of
NO among
Aboriginal
children due to
(clinically silent)
enteropathy could
explain the
concentrations
seen among
Aboriginal
controls in this
study.
NO appeared to
decrease
significantly more
slowly than L:R
among children
recovering from
diarrhea.
NO was found to
correlate with L:R.
NO was more
strongly
correlated with
lactulose than
rhamnose.

Comments
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Reference and
Study Outcomes of
Diagnostic Interest
2002
Kukuruzovic RH et
al.
Milk formulas in
acute gastroenteritis
and malnutrition: a
randomized trial
Lactulose:rhamnose
ratio (L:R) as a
marker of intestinal
permeability among
children with
diarrhea and/or
malnutrition treated
with milk formulas of
varying composition
and osmolality

44

Geometric mean.

Location and
Target Population

Design and
Sample Size

Darwin, Australia

RCT

Inpatient
Aboriginal children
<3 yr old with AD
and/or WAZ score
<-2.

n=177;

60% of subjects
had low WAZ
score and 90%
had diarrhea.

n=60 received
De-Lact formula
n=65 received OLac formula
n=52 received
Alfaré formula
Subjects were
treated with one
of three lowlactose formulas:
• De-Lact, lowosmolality
lactose-free
formula
• O-Lac, lactosefree formula
• Alfaré, partially
hydrolyzed
formula

Biomarker

Results

Blood Test:
L:R

Baseline mean L:R (CI) in
De-Lact group was 14.9
(10.4, 21.5), with no
difference between groups.

L:R testing was
repeated in 150
subjects at day 5:
• De-Lact: n=48
• O-Lac: n=52
• Alfaré: n=50

44

The mean improvement* in
L:R (CI) was 13.0 (9.3, 16.6)
with some significant
differences between the
various formulas:
• De-Lact: 18.6 (10.6, 26.6)
• O-Lac: 12.0 (7.5, 16.6),
p=0.15 compared to DeLact
• Alfaré: 8.5 (2.1, 14.9),
p=0.049 compared to DeLact
* Improvement in L:R was
calculated as baseline L:R
minus repeat L:R.

Conclusion

Comments

Authors noted
that treatment
with all of the lowlactose formulas
studied resulted in
improved L:R
among this
population at risk
for enteropathy
and growth
failure.
Improvement was
most marked with
the low osmolality
formula, De-Lact.

Reported results
did not appear to
be harmonized with
the method
described for
calculating
improvement in
L:R.
Fully breastfed
children were
excluded.
The study did not
include a control
arm (of standard
care) to which
change in L:R
could be
compared.
Authors reiterate
the advantages of
serum over timed
urine collection for
assessment of L:R
as discussed in
another publication
in this review [125].
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Reference and
Study Outcomes of
Diagnostic Interest
2002
Kukuruzovic RH et
al.
Small bowel
intestinal
permeability in
Australian
Aboriginal children
Serum lactulose:
rhamnose ratio
(L:R), serum
lactose, and stool
reducing
substances as
markers of intestinal
permeability among
Aboriginal and nonAboriginal children
with and without
diarrhea

Location and
Target Population

Design and
Sample Size

Darwin, Australia

Case-control

Cases were
Aboriginal and
non-Aboriginal
children admitted
to hospital with
diarrhea. Controls
were Aboriginal
and non-Aboriginal
children admitted
without GI
illnesses.

n=375
admissions for
306 children;
n=285 case
admissions for
AD (264
Aboriginal)
n=90 control
admissions with
no diarrhea (74
Aboriginal)

Biomarker

Results

Conclusion

Comments

Blood Tests:
• Lactose
45
• Lactulose
• Rhamnose
• L:R
• Hemoglobin
• Mean corpuscular
volume (MCV)

27/75 (36%) of Aboriginal
controls and 0 nonAboriginal controls had
abnormal L:R ratios.

Mean L:R ratios
of Aboriginal
children were
approximately
double those of
non-Aboriginal
children both
among those with
and without
diarrhea,
consistent with
authors’
suggestion that
clinically silent
enteropathy is
prevalent among
Aboriginal
children.

Positive stool RS
was defined as
>0.5%.

Stool Test:
Reducing substances
(RS)*
L:R testing was
repeated on day 5 for
a subset of Aboriginal
subjects:
• 174/264 admissions
for acute diarrhea
• 25/74 control
admissions
* Measured only
among children with
profuse diarrhea
when “clinically
indicated." Number
tested not provided.

46

Mean L:R at baseline:
Cases:
• Aboriginal: 16.4
• Non-Aboriginal: 7.9,
p=0.002 compared to
Aboriginal cases
Controls:
• Aboriginal: 4.6
• Non-Aboriginal: 2.5,
p=0.02 compared to
Aboriginal controls
47

Mean improvement in L:R
(CI) at day 5 among those
with repeat testing:
• Aboriginal cases: 14.6
(11.2, 18.0)
• Aboriginal controls: -0.63
(-4.0, 2.7)
48

Mean lactulose recovery :
• Cases day 1: 0.085
(0.070–0.103)
• Cases day 5: 0.039
(0.033–0.046)
• Controls: 0.024 (0.019–
0.029)
All 3 values significantly
differed from one another.
Mean rhamnose recovery:

45

Mean L:R
significantly
improved over 5
days among
Aboriginal cases.
Children with
severe diarrhea
had higher mean
L:R.
Higher case L:R
was driven more
by high lactulose
than by low
rhamnose.
Similarly,
improvement in

Abnormal L:R was
defined as >5.6,
derived from 2 SD
above the
arithmetic mean for
non-Aboriginal
controls in this
study. The
rationale for the
choice of 2 SD
above the
arithmetic, instead
of the geometric,
mean is not clear.
Proportions of
cases with
abnormal
concentrations
were not reported.
Analysis included
data for 69 children
with repeat
admissions; this
might violate
independence
assumptions for
their statistical
analysis methods.
Repeat L:R testing
was conducted on

Lactulose and rhamnose results were expressed as % of dose administered.
Geometric mean.
47
Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated.
Reference 134. Kukuruzovic, R.H. and D.R. Brewster, Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6): p. 571-577.
48
Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.
46
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

• Cases day 1: 0.479

L:R among cases
was primarily due
to decreased
lactulose.

controls of both
racial groups, but
among cases it
was only
conducted on
Aboriginal cases.

(0.424–0.542)
• Cases day 5: 0.555
(0.498–0.616)
• Controls: 0.585 (0.500–
0.685)
These values did not
significantly differ from one
another.
Confidence intervals (CIs) in
the authors' graphical
representation of mean L:R
at admission did not
overlap, and the difference
in means was particularly
evident between Aboriginal
and non-Aboriginal subjects.
Factors associated with L:R
49
among cases were :
• Acidosis (p=0.007)
• Hypokalemia (p=0.035)
• Diarrhea severity
(p=0.001)
Age and malnutrition were
not associated with L:R.
38% and 27% of Aboriginal
cases had positive serum
lactose and stool RS,
respectively. 12% of
Aboriginal and nonAboriginal controls
combined had lactosemia.
Presence of lactosemia was
associated with L:R,

49

Reported results were adjusted for confounding variables, unless otherwise noted.

Stool RS and
serum lactose
were found in
approximately
one-quarter and
one-third of
Aboriginal cases,
respectively. The
latter was weakly
associated with
increased
lactulose.

This study appears
to report on the
same population as
in the Kukuruzovic,
et al. 2003
reference also
included in this
review, which
assessed nitric
oxide excretion
[43].
Authors reiterate
the advantages of
serum over timed
urine collection for
assessment of L:R,
as discussed in
another publication
in this review [125].
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
adjusted relative risk
50
(CI)=1.06 (1.03, 1.10) .
Stool RS, anemia, and MCV
were not associated with
L:R.

50

Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

Conclusion

Comments
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Reference and
Study Outcomes of
Diagnostic Interest
2004
Laadhar L et al.
Determination of
antitransglutaminase
antibodies in the
diagnosis of celiac
disease in children:
results of a five year
prospective study
Duodenal biopsy
among patients with
suspected CD

Location and
Target Population

Design and
Sample Size

Sfax, Tunisia

Case-control

Children admitted
for endoscopic
biopsy for
symptoms of CD
(not specified).

n=99

Subjects of interest
for this review
were those who
tested negative for
CD-specific
serology and who
did not meet the
study diagnostic
criteria for CD-subtotal or total
villous atrophy
consistent with
Marsh stages 3 or
4.
Controls were
aged 3 mo-17 yr
(mean 4.5 yr).

Biomarker

Results

Conclusion

Comments

Endoscopic duodenal
biopsy:
Histopathology

Of 99 subjects not meeting
diagnostic criteria for CD,
endoscopic biopsies
revealed:
• 76 had normal
morphology of the
intestinal mucosa
• 7 had elevated densities
of intraepithelial
lymphocytes
• 10 had partial villous
atrophy (Marsh stage 2)
• 6 had various other
conditions such as
giardiasis or gastritis

Among 169
children with
symptoms of CD,
41% had subtotal
or total villous
atrophy, 10% had
partial villous
atrophy or
inflammatory
findings, and 45%
had normal
biopsies.

Article in French.
Prevalence of CD
antibodies did not
clearly align with
case/control
designation.
Because of the
way the results
were reported, we
could not extract
data on those who
tested negative for
CD-specific
serology and who
had Marsh stages
3 or 4
histopathology.
Methods section
described obtaining
duodenal biopsies,
while results and
conclusion sections
specify that jejunal
specimens were
obtained.
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Reference and
Study Outcomes of
Diagnostic Interest
2006
Leite CA et al.
Functional,
microbiological and
morphological
intestinal findings
among human
immunodeficiency
virus infected
children
Small intestinal and
rectal biopsy to
assess morphology
and D-xylose as a
marker of
malabsorption
among HIV-infected
children

Location and
Target Population

Design and
Sample Size

Sao Paulo, Brazil

Cohort

5 mo-12 yr old
(median 24 mo)
HIV-infected
subjects recruited
from a hospital and
clinic.

n=11;

All subjects had
some degree of
protein-energy
malnutrition.

n=6 patients with
no diarrhea in the
30 days
preceding
enrollment

n=5 patients with
current or recent
episode of
diarrhea

Biomarker

Results

Conclusion

Comments

Blood Test:
D-xylose
(9 tested)

100% had low D-xylose
absorption:
• Mean: 15.6 mg/dL
• SD: 5
• Range: 8.9-24.4
• Median: 14.2

There was a high
prevalence
(100%) of
abnormal Dxylose results
among HIVinfected children,
regardless of
diarrhea status.

Portuguese
language article.

Biopsy of small
intestine by tethered
capsule or
endoscopy:
Histopathology
(10 tested)
Rectal biopsy:
Histopathology
(6 tested)

Small intestinal biopsy:
• 100% had some degree
of villous atrophy based
on a I-IV grading system:
• Grade I: 3
• Grade I/II: 2
• Grade II: 1
• Grade II/III: 1
• Grade III/IV: 1
• 2 samples were too
superficial to assess
• Intraepithelial
lymphocytes were
increased in half of the
biopsies.
• Lymphocytic and
polymorphonuclear
(PMN) infiltration of the
lamina propria were
present in 10/10 and 7/10
biopsies, respectively.
Rectal biopsy:
• 100% had normal
architecture
• Lymphocytic and PMN
infiltration were present in
6/6 and 4/6, respectively.

All patients also
had cellular
infiltration of the
lamina propria
and varying
degrees of villous
atrophy.
There was no
correlation
between D-xylose
and degree of
villous atrophy on
biopsy.

D-xylose <25
mg/dL was defined
as indicative of
malabsorption.
This value is higher
than what some
references have
noted as a cutpoint [186].
Investigators used
a well-articulated
system of grading
villous atrophy.
Results were not
presented by
diarrhea status,
perhaps due to
small sample size.
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Reference and
Study Outcomes of
Diagnostic Interest
2010
Lima AA et al.
Effects of vitamin A
supplementation on
intestinal barrier
function, growth,
total parasitic, and
specific Giardia spp
infections in
Brazilian children: a
prospective
randomized, doubleblind, placebocontrolled trial
L:M as a marker of
intestinal barrier
function, and stool
lactoferrin and
specific intestinal
immunological
cytokines as
markers of intestinal
inflammation among
nutritionally at-risk
children who
received either
vitamin A or placebo

51

Location and
Target Population

Design and
Sample Size

Fortaleza, Brazil

RCT

2 mo-9 yr olds
(mean 43 mo) from
an impoverished
urban community,
eligible if HAZ
score was
<median for their
community.

n=79;

Subjects were
screened for
intestinal
parasites, and
longitudinal
anthropometrics
were assessed.

n=40 received
placebo
(tocopherol)
n=39 received
vitamin A (retinyl
palmitate)
Subjects were
treated every 4
mo.

Biomarker

Results

Conclusion

Comments

Urine Tests:
51
• Lactulose
• Mannitol
• L:M

Median L:M at baseline was
0.089. There was no
significant change in L:M at
4 mo follow-up within either
treatment group.

Frequency of
stool lactoferrin
varied between
23%-32%.

Stool Tests:
• Lactoferrin
• Cytokines:
• IFN-γ
• TNF-α
• IL-4
• IL-10

No significant difference in
L:M was observed between
treatment groups.

Authors did not
report testing for
associations
between urinary
markers of
intestinal
permeability and
concentrations of
fecal cytokines, or
between these
markers and
growth parameters
or parasitosis.

For lactulose and mannitol results, excretion measurement was not specified.

Both median lactulose and
mannitol excretions
decreased at 4 mo follow-up
among the vitamin A
compared to the placebo
group:
• Lactulose: 0.21 to 0.74,
p=0.042
• Mannitol: 3.06 to 8.25,
p=0.008
Overall proportion of
lactoferrin was 23% initially.
At 1 mo follow-up, there was
no difference in prevalence
between vitamin A (33%)
and placebo (31%) groups.
Cytokine concentrations did
not significantly differ
between placebo and
vitamin A groups.

While vitamin A
supplementation
was associated
with reduced
lactulose
excretion, it was
also associated
with reduced
mannitol
excretion, with no
overall effect on
L:M.
Vitamin A
supplementation
was not
associated with
presence of
lactoferrin or
intestinal cytokine
response.

Cut-point values for
lactoferrin positivity
and abnormal L:M
were not
described.
Exclusively
breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.
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Reference and
Study Outcomes of
Diagnostic Interest
2005
Lima AA et al.
Intestinal barrier
function and weight
gain in
malnourished
children taking
glutaminesupplemented
enteral formula
L:M as a marker of
intestinal
permeability and
various stool tests
among children with
malnutrition or PD
who received either
glycine or glutamine
supplemented
formula or placebo

Location and
Target Population

Design and
Sample Size

Fortaleza, Brazil

RCT

2-60 mo olds
hospitalized with
WAZ score <-2,
~70% of whom
had PD.

n=80;
n=53 received
supplemented
formula
• 27 with glycine
• 26 with
glutamine
n=27 received
nonsupplemented
formula

Biomarker

Results

Urine Tests*:
52
• Lactulose
• Mannitol
• L:M

Mean L:M (SE):
• Glutamine group:
• Baseline: 0.31 (0.10)
(similar in all three
groups)
• Day 10: 0.10 (0.02);
significant decrease,
(p=0.01)
• No significant decrease in
L:M in glycine and
nonsupplemented formula
groups at day 10

Stool Tests**:
• Lactoferrin
• Leukocytes
• Occult blood
• Reducing
substances (RS)
* n=80 tested at
enrollment, n=65
tested at day 10.
** n=60 tested.

53

Mean lactulose (SE):

• Glutamine group:

• Baseline: 0.97 (0.46)
(similar in all three
groups)
• Day 10: NS decrease
in all 3 groups

Mean mannitol (SE):

• Glutamine group:

• Baseline: 3.42 (0.64)
(similar in all three
groups)
• Day 10: NS decrease
in all 3 groups

Proportion of stool markers
at baseline among all
subjects:
• Lactoferrin: 53.3%
• Leukocytes: 11.7%
• RS: 3.3%
• Occult blood: 5.0%

52
53

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.

Conclusion

Comments

L:M significantly
improved in the
glutamine group
only.

The relationship
between stool
markers and L:M
was not reported.

>50% of subjects
had intestinal
inflammation by
stool lactoferrin.
Fecal leukocytes,
RS, and occult
blood were
detected in fewer
subjects than
lactoferrin.

Data were not
stratified by history
of PD.
Fecal fat was
assessed, but
results were not
reported.
Cut-off values for
lactoferrin positivity
were not
described.
Exclusively
breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.
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Reference and
Study Outcomes of
Diagnostic Interest
2007
Lima NL et al.
Wasting and
intestinal barrier
function in children
taking alanylglutaminesupplemented
enteral formula

Location and
Target Population

Design and
Sample Size

Parque
Universitario,
Fortaleza, Brazil

RCT

6 mo-8 yr olds
(mean age 3.5 yr)
from an urban
setting with HAZ,
WAZ, or WHZ
scores <-1.

n=51 received
alanyl-glutamine
treatment

n=107;

Biomarker

Results

Conclusion

Comments

Urine Tests:
54
• Lactulose
• Mannitol
• L:M

L:M median (range) at
baseline:
• Treatment: 0.0385
(0.8922 [sic])
• Placebo: 0.0302 (5.5812
[sic])

Even though
lactulose
excretion
improved in the
treatment group,
mannitol excretion
worsened with
overall L:M not
changing.

Authors state that
L:M median and
range values were
within the
confidence interval
for values of
healthy children in
the study
community; no
reference was
cited.

Lactulose and mannitol
excretion both significantly
decreased in the treatment
group only (p=0.05 for both
55
sugars) . L:M did not
change significantly within
or across groups days after
treatment.

n=56 received
glycine placebo

L:M as a marker of
intestinal
permeability in
assessing alanylglutamine
supplement to
improve intestinal
barrier function in
malnourished
children compared
to glycine-containing
placebo supplement

2006
Long KZ et al.
The effect of vitamin
A supplementation
on the intestinal
54

Lactulose excretion was not
associated with WHZ, WAZ
or HAZ scores in either
56
group . Mannitol was not
associated with growth
parameters in the control
group, but was associated
2
with WHZ (r =-0.386,
2
p=0.027) and WAZ (r =0.385, p=0.027) scores in
the supplemented group.
Data for L:M and growth
parameter association was
not provided.
Mexico City,
Mexico
All 5-15 mo olds
within a periurban
community were
eligible to be

RCT
n=505 stool
samples from 127
children;

Stool Tests:
Cytokines:
• IL-4
• IL-6
• IFN-γ

n=243 stool

For lactulose and mannitol results, excretion measurement was not specified.
Reported results were adjusted for age and season.
56
Reported results were adjusted for age and season.
55

Lactulose,
mannitol and L:M
did not change
significantly in the
placebo group.

Positive tests for fecal
cytokines:
• IL-4: ~55%
• IFN-γ: ~50%
• IL-6: ~40%
There were no significant

Although the
authors defined
persistent and
chronic diarrhea in
their methods, they
did not report data
stratified according
to these conditions.
Authors provide
2
negative R values
when reporting
Pearson’s
correlation analysis
results; these likely
actually represent r
values.

Differences in
fecal cytokine
concentrations
due to vitamin A
supplementation
were observed
only in the subset

Pre-intervention
fecal cytokine
concentrations
were not reported.
Differences in fecal
cytokines between
all subjects with
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Reference and
Study Outcomes of
Diagnostic Interest
immune response in
Mexican children is
modified by
pathogen infections
and diarrhea

Location and
Target Population

Design and
Sample Size

screened for
participation.

samples from 57
who received
vitamin A
supplementation

Biomarker

n=262 stool
samples from 70
who received
placebo

Fecal cytokines as
markers of intestinal
mucosal immune
activation in children
with and without GI
pathogens receiving
vitamin A or placebo

Results

Conclusion

Comments

differences in proportions of
these fecal cytokines
between vitamin Asupplemented and placebo
subjects.

of subjects with
GI infection or
diarrhea.

and without GI
infections or history
of diarrhea were
not directly
reported; all
differences were
described in terms
of vitamin A
interaction.

Despite a
reduction in FAZ
with increasing
fortification, TAZ
increased as
more zinc was
consumed and
with increasing
concentrations of
zinc fortification.

Intestinal function
could play a role in
zinc (or other
micronutrient)
absorption; such
factors were not
explored in this
study.

Vitamin A-supplemented
children with diarrhea had
lower median IFN-γ
concentrations (odds
57
ratio =0.51; CI: 0.26, 0.99)
and higher IL-4
concentrations (odds
ratio=2.14; CI: 0.94, 4.87)
compared to children with
diarrhea in the placebo
group in a nonrandomized
analysis. IL-6
concentrations did not differ
in this analysis. There were
no differences between the
two groups among those
without diarrhea.

Participants were
followed
regularly;
diarrhea history
was tracked and
stool samples
were tested.

Differences in median
concentrations of fecal
cytokines by types of enteric
pathogens were also
observed.
2005

Lima, Peru

RCT

López de Romaña
D et al.

3-4 yr olds residing
in a poor
community at the
periphery of Lima
with stunting and
moderate anemia
as a surrogate risk
factor for zinc

n=41;
(31 completed
both initial and
follow-up
absorption assay
at 2 mo)

Longitudinal
measurements of
zinc absorption in
Peruvian children
consuming wheat
57

Group 1:

Urine Test:
Zinc excretion to
measure fractional
absorption of zinc
(FAZ) and total
absorbed zinc (TAZ)
following radiolabeled
zinc administration

Mean zinc parameters (SD)
at initial assessment:
• FAZ:
• Group 1: 0.34 (0.11)
• Group 2: 0.24 (0.05)
• Group 3: 0.13 (0.04)
• TAZ (mg/d):
• Group 1: 0.71 (0.18)
• Group 2: 1.11 (0.21)
• Group 3: 1.34 (0.47)

The principal aim

The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children.
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Reference and
Study Outcomes of
Diagnostic Interest
products fortified
with iron only or iron
and 1 of 2 amounts
of zinc
Zinc absorption
among stunted,
anemic children
receiving zinc as
well as iron and/or
iron/zinc-fortified
foods

Location and
Target Population

Design and
Sample Size

deficiency.

n=14 received
wheat flour with
iron fortification
only
(10 completed
follow-up)
Group 2:
n=12 received
wheat flour with
iron and 3mg
zinc/100g flour
(9 completed
follow-up)
Group 3:
n=15 wheat flour
with iron and 9mg
zinc/100g flour
(12 completed
follow-up)

Biomarker

Results

Conclusion

Comments

Neither mean FAZ nor TAZ
changed significantly at
subsequent assessments in
any treatment group.

Authors speculate
that reduction in
FAZ with
increasing
fortification could
be due to factors
such as saturation
kinetics.

of this study was to
determine
appropriate extent
of zinc fortification
of a staple food in
a specific
community; we
present only results
relevant to this
review.

In both the initial and
subsequent assays, mean
TAZ from zinc-fortified
meals increased with
increasing amounts of
fortification (p< 0.001).
However mean FAZ was
inversely related to zinc
intake from these meals
(p<0.001).
Nonfortified dinner FAZ and
TAZ were significantly lower
in the group receiving the
most zinc-supplementation
at the initial assay (p=0.015
and p=0.012, respectively)
despite no difference in zinc
intakes from the unfortified
dinner by treatment group.
This relationship between
groups was not observed at
the second assay; however,
a significant decrease of
16% in mean FAZ and TAZ
from the unfortified dinners
was observed between
initial and subsequent
assays (p<0.001).
Mean plasma zinc
concentrations did not differ
between treatment groups
throughout the study period.
The proportion with low
fasting plasma zinc
concentrations (<65μg/dL)

Authors described
a unexpected
finding:
subjects
consuming more
zinc from the zincfortified breakfast
and lunch meals
absorbed less
zinc from the
unfortified
dinners during the
initial absorption
assay.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Fecal IgE was
detected 3 times
more frequently
during episodes
of PD than AD
and 5 times more
frequently in PD
stools than in
stools from those
without diarrhea.

Sampling was
based on episodes
of diarrhea within a
cohort of infants;
individual infants
could have
contributed more
than one diarrheal
episode.
Additionally, it
appears that an
individual could
also have been
included as a case
of PD, a control
with AD, or a nondiarrhea stool
within the same
analysis.

was lower at the end of the
study (3.3% vs. 20.5%
initially, p=0.046).
2001

Bilbeis, Egypt

Mahmud MA et al.

Newborns
recruited at birth
from a rural village
and followed for
the first year of life.

Sociodemographic,
environmental and
clinical risk factors
for developing
persistent diarrhea
among infants in a
rural community of
Egypt
Stool IgE as a
marker of
gastrointestinal
allergy and its
association with
persistent vs. acute
diarrhea

Surveillance of
diarrhea symptoms
identified 392
episodes of
diarrhea, 41 (11%)
of which were
persistent.

Nested casecontrol within a
cohort study
n=392 episodes
of diarrhea
(including 41
episodes of PD)
among 152
infants* )

Bilbeis, Egypt

Cohort

Mahmud MA et al.

Newborns
recruited at birth

n=152
followed for

Fecal IgE was detected
more frequently in stools
from episodes of PD
compared to episodes of
58
AD: odds ratio (CI) =3.3
(1.0, 10.9).
Fecal IgE was detected
more frequently in stools
from episodes of PD than in
stools from children without
diarrhea: odds ratio
(CI)=4.84 (1.1, 21.7).

* Stool samples
from each PD
episode were
counted as a
case for analysis
and compared to
randomly
selected AD
episodes and to
non-diarrheal
samples.

2001

58

Stool Test:
IgE

Study population
appears to be the
same as in another
Mahmud, et al.
study also included
in this review which
reported the
prevalence of fecal
IgE by gender and
age within the
cohort [143].
Stool Test:
IgE

Reported results were adjusted for confounding variables, unless otherwise noted.

Overall incidence of fecal
IgE: 0.39/child-year
By age group:

Substantial
incidence of fecal
IgE was observed
in this setting in

Study population
appears to be the
same population as
in another
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Reference and
Study Outcomes of
Diagnostic Interest
Increased fecal IgE
among infants in a
rural community of
Egypt: an analysis
of associated risk
factors

Location and
Target Population

Design and
Sample Size

from a rural village
and followed for
the first year of life.

29,036 infant
days

Fecal IgE as a
marker of intestinal
inflammation among
children with
diarrhea

Stools were
collected during
episodes of
diarrhea.

2002

Blantyre, Malawi

Case-series

Manary ML et al.

2–5 yr olds (mean
age 43.6 mo, SD
7.7) from rural
area attending
immunization
clinic.

n=10

Zinc homeostasis in
Malawian children
consuming a highphytate, maizebased diet
Zinc absorption in a
sample of 10
asymptomatic
children

There was a high
prevalence of
stunting and low
plasma zinc in this
series.

Biomarker

Results

Conclusion

Comments

• < 3 mo: 0.28/child-yr
• 3-6 mo: 0.42/child-yr
• 6-9 mo: 0.16/child-yr
• >9 mo: 0.12/child-yr

infants.

Mahmud, et al.
reference also
included in this
review which
assessed the
relationship
between fecal IgE
and PD [142].

Relative risks (CI):
• 3-6 compared to >9 mo
olds : 3.28 (1.03, 13.60)
• Male gender: 1.82 (0.83,
4.18)

Stool Test:
Endogenous fecal
zinc (EFZ)
Urine Test:
Zinc excretion to
measure fractional
absorption (FAZ) and
total absorption (TAZ)
following radiolabeled
zinc administration.

Mean (SD):
• FAZ: 0.24 (0.04)
• TAZ (mg/d): 1.30 (0.33)
• EFZ (mg/d): 1.15 (0.33)
Language in the discussion
section strongly suggests,
but does not explicitly state,
that TAZ and EFZ were not
correlated. Correlation
analysis for these
parameters was not
reported.

IgE incidence
peaked at 3-6 mo
of age.
Male gender was
associated with
fecal IgE.

EFZ was higher
than would be
expected for a
zinc deficient
cohort, and EFZ
was not
correlated with
TAZ as would
have been
expected. While
high-phytate diets
leading to poor
zinc absorption
might explain
these findings, the
authors note that
in a previous
study (among a
somewhat older
age group) there
were no
differences in EFZ
among children
consuming highor low-phytate
diets [187]. They
note that such
perturbations in
EFZ have also

Authors note that
the lack of
comparable
data from children
of the age range in
this study limits
data interpretation.
They also provide
results per body
weight due to
presumed
relationship;
validity of such
measures has not
been established.
Authors comment
that the methods
used for calculating
absorption
measures are
sensitive and
accurate, but quite
difficult to conduct,
especially among
children.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

been reported in
children with
enteropathy due
to cystic fibrosis
[188] and suggest
that a similar
process could be
going on in these
Malawian children
due to TE.
2001

Varanasi, India

Case-series

Mishra OP et al.

1-5 yr olds with PD
selected randomly
from an outpatient
population in an
urban setting.

n=30 with
endoscopy
performed

Endoscopic and
histopathological
evaluation of
preschool children
with chronic
diarrhea
Duodenal biopsy
among patients with
chronic diarrhea

A high proportion
of the children had
varying degrees of
protein energy
malnutrition.

Endoscopic duodenal
biopsy:
• Gross endoscopic
visualization
• Histopathology

7 (23.3%) had grossly
abnormal endoscopic
findings:
• 5 (16.7%) with chronic

duodenitis

• 1 with duodenitis with

multiple erosions

• 1 with duodenitis with

hemorrhagic gastritis

22 (73.3%) had abnormal
histopathology:
• 17 (56.7%) with villous
atrophy with mononuclear
cell infiltration
• 1 (3.3%) with villous
atrophy and eosinophilic
infiltration
• 2 (6.7%) with villous
atrophy and mononuclear
and eosinophilic
infiltration
• 2 (6.7%) with only
mononuclear cell
infiltration
Mean duration of diarrhea
(SD) was not associated
with gross endoscopic

Grossly abnormal
endoscopic
appearance was
found in onequarter of children
with chronic
diarrhea
assessed by
endoscopy.
Three-quarters
had abnormal
histology. More
than half had
villous atrophy
with mononuclear
cell infiltration;
these patients
had >1 month
longer duration of
diarrhea than
those with either
normal histology
or mononuclear
cell infiltration
without villous
atrophy.
Age,
enteropathogen
recovery, and
WFA were not

Authors do not
report assessing
relationship
between gross
endoscopic
findings and
histopathology.
Number of patients
with villous atrophy
and both
mononuclear and
eosinophilic
infiltration was very
small (n=2), yet
authors report a
significant
difference in their
duration of diarrhea
relative to those
with normal
histopathology.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

findings but did vary by
histopathology:

associated with
gross endoscopic
or
histopathological
findings.

• Normal histopathology:

9.0 wk (6.0), n=8

Comments

• Mononuclear cell

infiltration: 9.0 wk (6.0),
n=2
• Villous atrophy with
mononuclear cell
infiltration: 14.9 wk (5.3),
n=17, p<0.02 compared
to normal histopathology
• Villous atrophy with
mononuclear and
eosinophilic infiltration:
21.5 wk (2.1), n=2,
p<0.02 compared to
normal histopathology
• Villous atrophy with
eosinophilic infiltration:
6.0 wk, n=1
No consistent pattern was
observed between gross
endoscopic findings or
histopathological lesions
and age, degree of
malnutrition, or type of
enteropathogen recovered
in stools.
2001
Mittal SK et al.
Tropical sprue in
north Indian children
D-xylose and
duodenal biopsy as

New Delhi,
India
0-15 yr old
gastroenterology
clinic patients with
PD.
Those with

Case-series
n=94;
(38 with repeat
biopsies)
<5 yr old: n=44

Duodenal biopsy,
method not specified:
Histopathology

36 (38.3%) were diagnosed
with TS including 14/44
(31.8%) who were under 5
years of age.

Blood Tests:
• Hemoglobin
• D-xylose*

18 (19.1%) were diagnosed
with CD.
Degree of villous atrophy

More than half of
the GI clinic
patients with PD
had some degree
of villous atrophy.
More than onethird and almost
one-fifth of

Biopsy results were
not provided for
patients without TS
or CD.
It was unclear if
there were patients
with abnormal Dxylose and
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Reference and
Study Outcomes of
Diagnostic Interest
markers of TS

Location and
Target Population

Design and
Sample Size

abnormal
morphology on
biopsy, abnormal
D-xylose test, and
clinical response to
antibiotics were
diagnosed as
having TS.

Biomarker

Results

Conclusion

Comments

* Not specified
whether from urine or
serum, and units of
measurement not
provided.

among TS vs. CD patients:
• Mild in 8/36 (22.2%) vs. 0
• Moderate in 23/36
(63.9%) vs. 4/18 (22.2%)
• Severe in 5/36 (13.9%)
vs. 14/18 (77.8%)

subjects were
diagnosed with
TS and CD,
respectively.

histology who did
not respond to
antibiotic therapy
and therefore were
not diagnosed with
TS.

Mean hemoglobin
concentration (range)
among TS patients was 8.3
g/dL (5.5-11) and did not
differ from values of those
with CD.

Those with
abnormal
morphology and
response to
gluten-free diet
were diagnosed
with CD. We
include data on
these subjects for
comparative
reasons.

Among the 22 TS patients,
repeat biopsies showed:
• 16 with normalization
• 5 with improvement
• 1 worsened despite
marked clinical
improvement
The D-xylose test was
abnormal in all TS patients
by diagnostic definition.

2002
Moya-Camarena SY
et al.
Effects of
asymptomatic
Giardia intestinalis
infection on
carbohydrate
absorption in wellnourished Mexican
children

59

Hermosillo,
Sonora, Mexico
3-6 yr olds in a
periurban setting
attending
preschool centers
meeting inclusion
criteria of no GI
symptoms, no
antibiotics in the
preceding 3 wk,
and no SBBO by
lactulose HBT and

Case-control
n=13;
<5 yr old:
n=5
n=7
asymptomatic
cases infected
only with G.
intestinalis
n=6 controls

D-xylose results were expressed as % of dose administered.

Breath Tests*:
• Lactose HBT
• D-Xylose HBT**
Urine Test:
, 59
D-xylose**
* Reported as parts
per million (ppm) postsubstrate ingestion
after subtraction of
baseline, pre-

Mean lactose HBT (SE):
• Cases pre-treatment: 3.6
(0.75) ppm
• Cases post-treatment: 0.85 (0.75) ppm (p<0.05
compared to pretreatment)
• Controls: 0.19 (0.81) ppm
(p<0.05 compared to pretreatment cases)
Mean xylose HBT (SE):

• Cases pre-treatment: 2.2

(0.69) ppm for infected

By study
diagnostic
definition, all TS
patients improved
with treatment.
Among those who
had repeat
biopsies, almost
three-quarters
showed
normalization of
histology, while
23% had partial
improvement and
1 patient had
worsened
pathology.

Lactose HBT
concentrations
were normal
according to
established cutpoints among all
subjects.
However, lactose
HBT was
significantly
higher among
cases compared
to controls and

Cut-off points used
to define abnormal
D-xylose tests
were not provided.

Statistical methods
might not have
been adequate to
account for intrasubject correlation
when comparing
the same group of
subjects (cases)
before and after
treatment.
Investigators
wished to exclude
children with
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Reference and
Study Outcomes of
Diagnostic Interest
Lactose hydrogen
breath test (HBT) as
a marker of lactose
absorption, and
xylose breath test
and urinary
excretion as
markers of xylose
absorption in wellnourished children
with asymptomatic
giardiasis and noninfected controls

Location and
Target Population

Design and
Sample Size

Indican test.

without Giardia
Cases were
evaluated before
and 3 wk after
treatment with
tinidazole. Posttreatment stools
were verified for
absence of
parasites.

2002

Kingston, Jamaica

Case-series

Murphy JL et al.

5-23 mo olds
admitted to the
Tropical
Metabolism
Research Unit of
the University of

n=24

Maldigestion and
malabsorption of
dietary lipid during
severe childhood

Subjects were
divided into 3
groups of 8

Biomarker
substrate H2
concentrations. A
positive HBT is
considered to be a
rise of >20ppm in
breath H2 above
baseline H2
concentration.

Results
group

• Cases post-treatment: -

4.16 (0.69) ppm (p<0.05
compared to pretreatment)
• Controls: 1.13 (0.74) ppm
(NS compared to pretreatment cases)

** Investigators did
not specify the xylose
enantiomer used,
however test
functionality
characteristics lead us
to assume that it was
the dextrorotary (D)
enantiomer.

Mean urinary excretion of
xylose (SE) among cases
pre-treatment and posttreatment was 34% (3) and
46% (11), respectively (NS),
well above cut-offs
indicative of malabsorption.

Stool Tests:
• Total and
13
fractionated C
following ingestion
13
of one of three C
labeled triglycerides
(TG): trilaurin,
triolein, or trilinolein*

Median total stool excretion
13
of C in phase 1 was 9%
(range: 1%-29%) and did
not vary between TG
groups.
13
Median C excretion
dropped 33%-99% in phase
2 and 86%-95% in phase 3

Conclusion

Comments

there was also a
significant
decrease in
lactose HBT
among cases
after treatment.
The clinical
relevance of such
mildly elevated
HBT results in
asymptomatically
infected children
is unclear.

SBBO. As such,
inclusion criteria
restricted
participants to
those with
adequate
production of H2
following ingestion
of lactulose and
with minimal
urinary indoxyl
sulfate excretion.
The number of
children excluded
due to failure to
meet these criteria
was not reported.

Results did not
demonstrate
xylose
malabsorption by
either urinary or
breath measures
among any group.
While urinary
results did not
differ before and
after treatment,
case xylose HBT
was significantly
lower after
treatment; again
the clinical
significance of
such results is not
apparent.
High
concentrations of
13
C (compared to
healthy UK
children) [190]
were observed in
half of the
subjects at

Authors state that
the study was not
powered to
compare the
different TGs, but
they contend that
medium chain
trilaurin did not
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Reference and
Study Outcomes of
Diagnostic Interest
malnutrition

Stool recovery of
radiolabeled
products as markers
of lipid digestion and
absorption, and bile
salt deconjugation
as a marker of
SBBO among
children with severe
malnutrition

Location and
Target Population

Design and
Sample Size

the West Indies
with severe
malnutrition.

children, each
group receiving a
different labeled
triglyceride.
Data were
collected in three
separate phases
as described
above in JL
Murphy et al.
2001 [149].

Biomarker
13

• C stool assay
following
administration of
13
labeled fatty acid C
glycocholate**
* To assess fat
excretion as a % of
dose administered.
Also assessed
13
proportion of C in
triglyceride (TG) and
fatty acid (FA)
fractions to distinguish
excretion caused
impaired digestion
(presence of TG) vs.
poor absorption
(presence of FA).
** To assess bile salt
deconjugation in the
bowel caused by
SBBO; conducted
after the TG
assessment and a 3
day washout period.

Results

Conclusion

Comments

compared to phase 1
(p<0.05 each).

admission,
reflecting
impaired digestion
or absorption.

appear to be
processed
differently than the
longer chain TGs
triolein and
triolinolein.

Over the study period, there
were significant
associations between total
13
lipid and the amount of C
labeled TGs in stool for
some groups, but not for
others.
13

Median C in TG and FA
was similar across TG
groups in all phases. 13C
FA recovery was similar and
reduced by ~2/3 compared
13
to Phase 1. C TG was not
detectable in Phases 2 or 3.
Statistical comparisons
between phases were not
reported.
13

C after radiolabeled
glycocholate administration
was detected in stool at
quantities considered to be
in excess of the 7%
recovery of dose
administered upper limit of
normal in U.S. adults in
[189]:
• Phase 1: 13/24 (54%)
• Phase 2: 5/24 (20.8%)
• Phase 3: 3/24 (12.5%)

The differences in
13
stool C were
wide but not as
extreme as in a
previous study by
same
investigators (also
examined in this
review) using a
different TG
(tripalmitin)
substrate [149].
13

C excretion did
not significantly
differ between TG
groups and
declined with
improving clinical
course.
Similar to their
previous study,
significantly more
13
C in stool was
recovered as FA
than TG,
reflecting
impaired
absorption over
poor lipid
digestion/
hydrolysis. Unlike
in their previous
study, there was
evidence of
SBBO as

Authors did not
describe the
method used to
assign subjects to
different TG
groups.
While it was noted
that some subjects
had positive stool
cultures, details
were not provided
on the nature of the
enteric infections.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

measured post13
ingestion of C
glycocholate.
2001

Kingston, Jamaica

Case-series

Murphy JL et al.

7-23 mo olds with
malnutrition
admitted to the
University of the
West Indies.

n=8

Gastrointestinal
handling and
metabolic disposal
13
of C-labelled
tripalmitin during
rehabilitation from
childhood
malnutrition
Fecal fat, stool
recovery of
radiolabeled
products, and
breath tests as
markers of lipid
digestion and
absorption and bile
salt deconjugation
as a marker of
SBBO among
children with severe
malnutrition

Data were
collected in three
separate phases
(each lasting 9
days):
1. Within 48
hours of
admission
2. During early
rehabilitation
3. During late
rehabilitation

Stool Tests:
• Fecal fat*
• Total and
13
fractionated C
assay after
administration of
13
C tripalmitin
(TP)**
13
• C assay after
administration of
13
C glycocholate
(GCA)***
Breath Tests:
13
• CO2 after
administration of
13
C glycocholate
(GCA)***
13
• CO2 after
administration of
13
C TP****
* In 72 hour stool
collection (measured
as total grams and as
% of dietary fat
intake).
** To assess fat
excretion as a % of
dose administered.
Also assessed
13
proportion of C in
triglyceride (TG) and
fatty acid (FA)
fractions to distinguish

Mean fecal fat (SD):
• Phase 1: 2.4 g/day (3.6)
or 5.9% (9.4) of dietary
lipid intake
• Phase 2: 1.7 (0.9) g/day,
or 3.3% (2.4) of intake
• Phase 3: 0.9 (0.6) g/day,
or 1.4% (0.7) of intake
• Differences between
phases were not
statistically significant.
13

Total excretion of C in
stool also varied widely
across patients (0%-44%)
and did not differ between
study phases.
Correlation between fecal
13
fat and C (r=0.48; p<0.05)
was observed.
Lack of lipid digestion and
absorption were assessed
by measuring TG and FA
fractions, respectively.
13
Mean C TG recovery (SD)
(% of administered dose),
number of patients excreting
TG:
• Phase 1: 0.7% (1.6), n=3
• Phase 2: 0.9% (2.8), n=1
• Phase 3: no recovery
from any subjects,
differences between
phases were NS
13

C FA fraction in stool

Mean fecal fat
was not elevated
compared to
published norms
[191, 192] during
any study phase.
There was wide
variation in fecal
fat at
presentation, and
wide variations in
13
stool C across
subjects. Authors
indicate that this
is the first such
assessment in
malnourished
children; previous
studies on healthy
children from the
UK demonstrated
average excretion
of 6% [190].
The majority of
13
excreted C was
in the form of FA
rather than TG.
Authors
interpreted this to
reflect failure of
lipid absorption in
the face of
adequate
digestion/
hydrolysis. Each
form (FA and TG)

Statistical methods
might be
inappropriate for a
small sample.
All subjects were
treated with
antibiotics including
metronidazole for
presumptive
SBBO; this might
have affected GCA
testing.
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Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

excretion caused by
impaired digestion
(presence of TG) vs.
poor absorption
(presence of FA).

declined during
rehabilitation.
13
Mean C FA recovery (SD):
• Phase 1: 6.0% (7.3)
• Phase 2: 4.8% (3.7)
• Phase 3: 3.3% (3.8),
differences between
phases were NS

was found in
decreasing values
as the study
phases
progressed,
suggesting
improved
digestion and
absorption,
although results
did not differ
significantly.

*** To assess bile salt
deconjugation in the
bowel caused by
SBBO; conducted
after the TG
assessment and a 3
day washout period.
**** Expressed as a
percentage of
absorbed label (dose
administered - label
recovered in stool) to
assess oxidation for
acute energy needs.

Mean FA values were ~9x
(NS), 5x (p<0.001), and 3x
(p<0.05) higher than mean
TG values in Phases 1, 2,
and 3, respectively.
Following administration of
13
labeled TP, absorbed C
label by breath analysis was
~5% (range 0%-21.2%) and
similar across study phases.
Following the administration
of labeled GCA, there was
either no or minimal
13
recovery of C in stool and
13
CO2 on breath (as % of
dose administered) in all
phases.

Fecal fat was
correlated with
concentrations of
13
C in stool.
There was no
evidence of
SBBO or bile acid
malabsorption.
13

CO2 excretion
following
administration of
13
C TP was
minimal,
suggesting a
propensity for
deposition in
adipose tissues
rather than
oxidation for
immediate energy
needs. The
authors report
that this breath
test has not been
widely used, but
that healthy UK
children have
breath excretion

Comments
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

values from 15%43% [190],
compared to a
mean of 5% and
range 0%-21% in
this cohort; the
latter findings
were more similar
to results from
kwashiorkor
patients where
13
C-labeled oleic
acid was used as
substrate [193].
2000

Sao Paulo, Brazil

Case-control

Nichols B et al.

Cases were
children (mean
age 9.9 mo, SD
8.1) hospitalized
with malnutrition
refractory to
dietary
rehabilitation.

n=33;

Contribution of
villous atrophy to
reduced intestinal
maltase in infants
with malnutrition
Jejunal biopsy,
maltase activity, and
enzyme messenger
RNAs among
malnourished and
well-nourished
children. Assessed
association between
maltase and villous
atrophy and other
mucosal intestinal
markers indicative
of loss of
enterocytes and
enterocytic function.

Controls were
children (mean
age 3.6 mo, SD
1.0) with HAZ and
WAZ scores >-2
and normal
intestinal mucosa
on biopsy,
hospitalized for
Kasai procedure
for biliary atresia.

n=24 cases
n=9 controls
Subjects were
matched on
height and
weight; ages
differed within
matched sets.

Jejunal capsule
biopsy:
• Histopathology*
• Maltase activity
• Intestinal messenger
RNA (mRNA)
abundances:
• Maltaseglucoamylase
(MGA)
• Sucraseisomaltase (SI)
• Villin, a
structural
protein
expressed only
in enterocytes
• Sodiumactivated
luminal glucosegalactose
transporter 1
(SGLT), a
functional
protein
expressed only
in enterocytes

Mean villous atrophy score
(SD):
• Cases: 2.6 (0.8)
• Controls: 1.2 (0.5),
p=0.006)
WAZ score was correlated
with villous atrophy (r=0.65,
p- value not reported).
13/25 [sic] cases and 0/5
controls had subnormal
(defined as <94 U/g protein)
of maltase activity; mean
maltase was 34% lower
among cases (p=0.11).
Maltase activity did not
appear to decrease with
WAZ score (further details
not provided).
However, in sub-analyses
among those samples with
an adequate β-actin, a
housekeeping gene
message, (n=10 cases, n=9
controls), cases’ findings

The malnourished
children had
significantly
greater villous
atrophy than the
younger controls.
Among the subset
tested for mRNA
messages,
maltase activity
as well as the
mRNA
abundances for
MGA, villin and
SGLT were
significantly
correlated with
case status and
were correlated
with villous
atrophy.
While maltase
deficiency has
been reported in
malnutrition in

Tissue from
patients requiring
intestinal resection
as part of their
biliary atresia
management
provides an
opportunity to
assess presumably
“normal” intestinal
architecture.
However, unless
they mocked up ex
vivo mucosal
biopsies in these
controls, resections
will have lower
proportions of
villous to
submucosa tissue
compared to cases’
samples derived
from mucosal
biopsies. While this
probably doesn’t
affect histology, it
might affect
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker
• β-actin
* Mucosal atrophy
was scored on a scale
of 1 (absence of
atrophy compared to
an organ donor) to 4
(similar to children
with active CD).
Histology among
controls was on
surgically resected
tissue.

Results

Conclusion

Comments

expressed as a mean
percent of controls' (SD)
included:
• Villous length (reciprocal
of atrophy score): 38.9
(41.6), p=0.004
• Maltase activity: 37.1
(23.2), p=0.001
• MGA mRNA: 45.1 (36.4),
p=0.016
• Villin mRNA: 52.5 (22.6),
p=0.003
• SGLT mRNA: 66.6 (23.1),
p=0.057
• β-actin: 88.2 (15.8),
p=0.189

other studies,
authors assert
that these are the
first results that
directly support
the hypothesis
that reductions in
maltase activity
are due to villous
atrophy. This
study also nicely
correlates mRNA
relative
abundance with
function.

enterocyte
functional assays
and mRNA
determination, as
transmural tissue
will bring in more
diverse populations
of cells; only some
of them might have
transcripts of
interest. However,
the bias is likely in
a direction that
would reduce effect
size.

Both villous length and
maltase activity in a subset
of cases were less than
40% of control values.
MGA, villin, and SGLT
mRNA abundances were
correlated with villous
atrophy score (r=0.73),
(r=0.76), and (r=0.54),
respectively (p-values not
60
reported) .
MGA mRNA abundance
was correlated with maltase
activity (r=0.32).

60

Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin.

It was unclear if
control inclusion
criteria included
absence of atrophy
or if all potential
controls lacked
atrophy.
Statistical methods
might not have
adequately taken
into account the
small sample size
and matching
scheme.
Subsets of subjects
were investigated
for various tests.
For example, 10
cases had mRNA
analyses based on
β-actin adequacy.
Another instance of
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments
selected testing
was the subset of
22 and 15 cases
that had WAZ
score to histology
and mRNA
correlation
analyses,
respectively.
Rationale for
subset selection
was not thoroughly
described.

2001
Northrop-Clewes
CA et al.
Anthelmintic
treatment of rural
Bangladeshi
children: effect on
host physiology,
growth, and
biochemical status
L:M as a marker of
intestinal
permeability, and α
1-antichymotrypsin
as a marker of
inflammation and
immune response to
treatment among
children randomized
to bimonthly
antihelminthics or
placebo.

61

Geometric mean.

Jamalpur district,
northern
Bangladesh

RCT*

2-5 yr olds from
poor rural villages,
sampled randomly
from a larger
cohort study.

n=54 received
bimonthly empiric
antihelminthic
treatment

Stools were
assessed for
helminthiasis and
giardiasis. Growth
was followed
longitudinally.

n=109;

n=55 received
placebo
* Randomized at
the village level.

Blood Tests:
• α 1antichymotrypsin
(ACT)
• Albumin
• Total protein
Urine Test:
L:M
Among 93 subjects
with L:M at baseline:
• 46 received
treatment
• 47 received placebo
Among 66 subjects
with repeated L:M
testing:
• 34 received
treatment
• 32 received placebo

61

Mean L:M at baseline:
• Treatment: 0.22
• Placebo: 0.25
Seasonal variation in L:M
was observed, with highest
values following the
monsoon season.
Within-subject L:M analysis
showed no significant
association with intestinal
helminthiasis and no
significant improvement in
treatment or placebo groups
over 1 yr. L:M was generally
not associated with
giardiasis (with the
exception of one group at
one study interval).
L:M was inversely
correlated with ∆HAZ and
∆WAZ scores at some of
the follow-up intervals (r=0.22, p<0.02 and r=-0.21,

L:M ratios were
high overall and
demonstrated
seasonal
variation.

Baseline study
data were lost, so
analysis began
with samples taken
at month 2.

Intra-individual
L:M values did not
change
significantly over
time, nor were
they associated
with helminthiasis
or consistently
associated with
giardiasis.

The relationship
between the serum
markers and
intestinal
permeability was
not reported.

Inverse
correlations were
seen between
L:M and growth
parameters.
Serum markers
were within
normal range.
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Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

p<0.05, respectively, at 12
mo follow-up visit).

The only
significant change
in these markers
was a decrease in
total protein in the
treatment group
without
concomitant
change in
albumin; this
suggested a
decrease in
globulins (not
directly
measured),
perhaps due to
decreased
inflammation.

Mean serum ACT, albumin
and total protein were within
normal ranges and were not
associated with growth
parameters. ACT and
albumin concentrations did
not significantly change with
treatment, whereas total
protein concentrations did
(p<0.001).

2009

Kathmandu, Nepal

Cohort

Panter-Brick C et al.

3-18 mo olds in
two cohorts:
1. All children in
target age range
from four
squatter
settlements
2. Randomly
selected, agematched cohort
from lower
middle-class,
periurban
households

n=86;

Pathways leading to
early growth
faltering: An
investigation into the
importance of
mucosal damage
and
immunostimulation
in different socioeconomic groups in
Nepal
Lactose:creatinine
ratio (Lactose:Cr) as
a marker of
intestinal
permeability and
62

Geometric mean.

n=48 in squatter
cohort
n=38 in lower
middle-class
cohort

Urine Test:
Lactose:Cr
Blood Test:
• Hemoglobin

62

Mean Lactose:Cr (CI):
• Squatter: 0.14 (0.12,
0.16)
• Middle Class: 0.08 (0.07,
0.10)
• Statistically significant
difference between the 2
groups among the 6-12
mo olds (p=0.007) and
18-24 mo olds (p=0.002),
but not among 12-18 mo
olds.
• For both SES groups,
Lactose:Cr values
decreased with increasing
age (p<0.001).
HAZ, WAZ, WHZ, and
∆WAZ scores were strongly
associated with mean
Lactose:Cr (p<0.001 each)

Authors speculate
that Lactose:Cr
accounted for less
of the
deterioration in
nutritional status
among the
squatter children
because of
several factors,
including poorer
nutritional intake,
that impact the
nutritional status
of children with
lower socioeconomic status.

Comments

Specific sugar
excretion was
normalized to
urinary creatinine
to control for
variation in renal
function.
Authors suggest
that while
Lactose:Cr might
not be as accurate
as L:M, it might be
a more fieldfriendly
assessment of
mucosal damage
compared to L:M,
requiring only spot
urine collection and
no substrate
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Diagnostic Interest
hemoglobin,
albumin, α-1-acid
glycoprotein, and
IgG as markers of
immunostimulation.
The latter were also
assessed for their
relationship to
nutritional status.

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

as was ∆HAZ score
(p=0.004); ∆WHZ score was
not. The strength and
magnitude of association
between ∆WAZ score and
Lactose:Cr was most
pronounced among the
wealthier cohort and there
was no association between
∆HAZ score and Lactose:Cr
among the squatter
children.

dosing. However,
L:M was not
assessed in this
study; direct
comparison of the
two tests was not
possible.
While hemoglobin
concentration was
inversely related to
Lactose:Cr, testing
for associations of
other measured
blood markers
(IgG, AGP and
albumin) with
Lactose:Cr were
not reported.

Hemoglobin concentrations
were inversely related to
2
Lactose:Cr (r =0.018,
p<0.001).

2001
Perin NM et al.
Intestinal absorption
of D-xylose in
children infected
with the human
immunodeficiency
virus
D-xylose as a
marker of intestinal
absorption among
HIV-infected
children with and
without GI
symptoms

Florianopolis,
Brazil
18 mo-14 yr old
HIV-infected
children with GI
and non-GI
symptoms of HIV
infection recruited
from a pediatric
AIDS center.

Cross-sectional
n=104

Blood Test:
D-xylose

Prevalence of an abnormal
D-xylose result was 7.7%.
Mean D-xylose (SD, range):
42.8mg/dL (14.4mg/dL, 1673 mg/dL)
D-xylose was not
associated with age.
Of the 8 children with
abnormal results, 1 had
diarrhea. Of 19 with
diarrhea, 1 had an abnormal
result.
Of those with abnormal
results, 50% had
Cryptosporidium infection.
Of the 33 subjects with
Cryptosporidium infection, 4
had abnormal D-xylose

Comments

D-xylose showed
substantial
variation across
individuals.

Portuguese
language article.
D-xylose <25
mg/dL was defined
as indicative of
malabsorption.
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Design and
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Biomarker

Results

Conclusion

Comments

results.

2003
Pires AL et al.
Digital
morphometric and
stereologic analysis
of small intestinal
mucosa in wellnourished and
malnourished
children with
persistent diarrhea
Computerized
morphometric and
stereologic
assessments in
proximal small
intestine biopsy in
subjects with PD

Porto Alegre,
Brazil

Cross-sectional,
retrospective

6 mo-5 yr old
inpatients from an
urban setting who
underwent biopsy
as part of a workup for PD.

n=65

There was a high
proportion of
children with
malnutrition in this
study population.

Small intestinal
biopsies, site and
method not specified*:
• Mucosal
morphometric
assessment by
computer analysis
(62 tested):
• Villous height
• Crypt depth
• Villous:crypt
ratio
• Mucosal
thickness
• Digital assessment
(500x magnification)
(65 tested):
• Enterocyte
height
• Enterocyte
nucleus height
• Brush border
height
• Stereological
analysis to assess
mucosal surface
area
(62 tested)

Computerized mucosal
measures were similar to
those by micrometer and
were not associated with
nutritional status.
Digitally assessed
enterocyte height,
enterocyte brush border,
and enterocyte nucleus
height correlations:
• WAZ score: r=0.25
(p=0.038), r=0.26
(p=0.03), and r=0.24,
(p=0.05), respectively
• WHZ score: r=0.29
(p=0.02), r=0.27 (p=0.03),
and r=0.16 (p=0.19),
respectively
• HAZ score: r=0.16 (0.18),
r=0.23 (p=0.06), r=0.23
(0.06)

Enterocyte
measures show
some correlation
with WAZ and
WHZ scores, but
not with HAZ
score. However,
surface area and
villous:crypt ratios
were not
correlated with
any growth
parameter.

There was no correlation
between mucosal surface
area and growth
parameters.

* From stored
specimens previously
assessed by
micrometer.
2008

Chandigarh, India

Case-control

Poddar U et al.

<14 yr (mean age

n=28 controls;

Endoscopic duodenal
biopsy:
Histopathology

Duodenal biopsy of those
with giardiasis showed
nonspecific chronic

Duodenal biopsy
demonstrated
histological

Authors did not
report the biopsy
findings in the TS
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Is tissue
transglutaminase
autoantibody the
best for diagnosing
celiac disease in
children of
developing
countries
Duodenal biopsies
in controls with
giardiasis, TS, and
SBBO

Location and
Target Population

Design and
Sample Size

6.9 yr) presenting
with symptoms
consistent with CD
(PD, FTT, and/or
pallor)

• 22 with
giardiasis
• 1 with TS
• 5 with SBBO

Chandigarh, India

Case-control

Poddar U et al.

18 mo-14 yr olds
with PD, FTT, or
pallor from a
hospital pediatric
gastroenterology
unit.
Subjects with
normal
crypt:villous ratio
on biopsy were of
interest for this
review.

n=47

Duodenal biopsy, Dxylose, and fecal fat
in children with
symptoms of CD but
normal mucosal
biopsy results

Results

Conclusion

Comments

inflammation of lamina
propria; there was no
evidence of villous atrophy.

changes
accompanying
Giardia infection.

or SBBO patients.

38% had chronic
inflammatory cell infiltrates
in the lamina propria.

Among controls
with normal
mucosal
architecture by
biopsy, more than
one-third had PD.

Relationships
between fecal fat,
D-xylose and
biopsy results were
not reported.

Subjects negative
for CD were of
interest for this
review.

2002

Celiac disease in
India: Are they true
cases of celiac
disease?

Biomarker

Endoscopic duodenal
biopsy:
Histopathology
Stool Tests:
• Fecal fat*
• D-xylose**
* In 72-hour stool
collection.
** Not specified
whether from urine or
serum, and units of
measurement not
provided.

55% had abnormal D-xylose
concentrations.
20% had abnormal fecal fat
test.
No results beyond
proportion positive were
reported for any of the
above markers.

D-xylose and
fecal fat might not
correlate well with
duodenal biopsy
results.

While 38% of
controls had PD,
results for the
markers studied
were not stratified
by PD for this
group.
Seven children with
biopsies consistent
with CD did not
respond to glutenfree diet and were
excluded from the
study.
Cut-off points used
to define abnormal
D-xylose tests
were not provided.
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2000
Quadro L et al.
Retinol and retinolbinding protein: gut
integrity and
circulating
immunoglobulins
L:M as a marker of
small intestinal
permeability, and its
correlation with
serum retinol among
mildly malnourished
children

63

Location and
Target Population

Design and
Sample Size

Goncalves Dias
favela in Fortaleza,
Brazil

Cross-sectional

1-9 yr olds with
mild malnutrition
selected from a
large cohort of
children from an
urban slum. They
were recruited at
birth and followed
longitudinally.

n =30

Biomarker

Results

Conclusion

Comments

Urine Tests:
63
• Lactulose
• Mannitol
• L:M

80% of subjects had
abnormal L:M, defined as
>=0.030.

Children with low
serum retinol had
higher L:M,
apparently
mediated by
mannitol
excretion.

The L:M normal
cutoff was defined
lower than for most
other L:M studies,
as 0.030. The
authors reference
several studies
regarding use of
this cut point.

19 (63%) had
some degree of
vitamin A
deficiency—all of
these had mild
deficiency, except
for 2 with
moderately low
concentrations.

Lactulose and mannitol results were expressed as % of dose administered.

Serum retinol was:
• Inversely correlated with
L:M (r=0.46, p=0.012)
• Directly correlated with
mannitol (r=0.66, p<0.01)
• Not correlated with
lactulose (data not
reported)
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2004
Rabbani GH et al.
Green banana and
pectin improve small
intestinal
permeability and
reduce fluid loss in
Bangladeshi
children with
persistent diarrhea
L:M as a marker of
intestinal
permeability among
infants with PD who
are treated with
green banana,
pectin, or rice diet

Location and
Target Population

Design and
Sample Size

Dhaka,
Bangladesh

RCT

5-12 mo old males
admitted to the
hospital of the
International
Centre for
Diarrhoeal Disease
Research with PD
but without other
concurrent
illnesses.

n=57;
n=19 received
green banana
and rice

Biomarker

Results

Urine Tests:
64
• Lactulose
• Mannitol
• L:M

Mean L:M (SD) by
treatment group, pre- and
post-treatment:
• Banana: pre=0.50 (0.14),
post=0.21 (0.12), p<0.01
• Pectin: pre=0.54 (0.17),
post=0.23 (0.09), p<0.01
• Placebo: pre=0.41 (0.11),
post=0.45 (0.13), p>0.6

n=17 received
pectin and rice
n=21 received
rice alone
(placebo)

Conclusion
65

Lactulose and mannitol
excretion did not differ
between groups at baseline.
Lactulose excretion was not
significantly reduced after
intervention in the placebo
group. Mean (SD):
• Pre-treatment: 1.45 (0.12)
• Post-treatment: 1.35
(0.15)
Both treatment groups had
70-80% reduced lactulose
excretion following
treatment (p<0.01).
Mannitol excretion
increased in all groups
compared to their pretreatment values, but only
significantly so in the
banana and pectin groups
(p<0.05).
Mean mannitol % excretion
(SD), pre- vs. posttreatment:
• Banana: 1.82 (0.13) vs.

64
65

Lactulose and mannitol results were expressed as % of dose administered.
Type of mean not specified.

L:M values were
high at baseline
among the study
population of
inpatient young
children with PD.
Mean L:M
significantly
improved with the
green banana or
pectin intervention
but were still
above normal
range following 7
days of treatment.
The
improvements in
L:M were driven
by both mannitol
and lactulose,
with the latter
having an impact
of greater
magnitude.
Authors cite
studies
postulating that
the effectiveness
of green banana
in reducing
diarrheal fluid loss
is due to its high
content of
amylase-resistant
starch, which
undergoes
bacterial
fermentation into

Comments
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Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
3.21 (0.16)

• Pectin: 1.91 (0.12) vs. 3.2

(0.18)

• Placebo: 2.10 (0.11) vs.

2.33 (0.18)

The banana and pectin
groups stopped having
diarrhea more often
compared to controls (e.g.
p<0.01 by day 4). Among
the banana and pectin
groups, stool reductions
were associated with
percent change in L:M
before and after treatment
2
(R =0.84 for pectin and
2
R =0.86 for banana; p<0.05
for each).

2001
Rabbani GH et al.
Increased nitrite and
nitrate
concentrations in
sera and urine of
patients with cholera
or shigellosis
To assess and
compare nitric oxide
as a marker of
intestinal
inflammation among
children with cholera

Dhaka,
Bangladesh
2-6 yr olds with
cholera or
shigellosis
admitted to the
hospital.
Controls were
recruited from the
healthy attendants
of patients or from
children of hospital
staff.
Mean age (SD) in

Case-control
n=63;

Urine Test:
Nitric Oxide (NO)*

• 24 with cholera
• 21 with

Blood Tests:
• Nitrite (NO2)
• Nitrate (NO3)
• WBC

n=18 healthy
controls

Stool Test:
Leukocytes

Samples were
collected from
cases on
admission

* Nitric oxide (NO) is
an unstable free
radical that is

n=45 cases:

shigellosis

In children with shigellosis,
median serum NO was ~8x
higher at baseline than in
controls and significantly
differed from convalescent
concentrations (p<0.01).
Concentrations declined by
52% of baseline during the
recovery period but did not
return to values found in the
controls (measure of
statistical significance not
reported).
In children with cholera,
median serum NO
concentrations at baseline

Conclusion

Comments

short-chain fatty
acids in the colon,
stimulating
colonic salt and
water absorption.
Pectin is thought
to work by a
similar
mechanism.
Authors also
suggest that short
chain fatty acids
might affect
entero-hormones
and growth
factors, resulting
in the observed
changes in
intestinal
permeability
[206].

NO as measured
by both serum
and urinary NO2
and NO3
concentrations
was significantly
elevated at
presentation
during acute
illness compared
to 7-10 days after
hospitalization in
both cholera and
shigellosis.
Median serum NO
concentrations in

Some values
reported in table
format conflict with
the text; columns of
data appear to be
transposed.
Assessment for NO
correlation with
fecal leukocyte
counts was not
reported, nor was
the correlation
between urinary
NO and total blood
WBC.
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Reference and
Study Outcomes of
Diagnostic Interest
or shigellosis or
healthy controls.
Evaluated to assess
nitric oxide
production during
infection of small
bowel without
inflammatory lesion
(e.g., cholera) and
during infection
causing colon
inflammation (e.g.,
shigellosis).

Location and
Target Population

Design and
Sample Size

yr:

and upon
discharge (after
7-10 days of
treatment).

• Shigellosis

cases: 3.8 (1.2)

• Cholera cases:

4.2 (1.4)

• Controls: 4.7

(1.8)

Biomarker

Results

Conclusion

converted to nitrite
and nitrate. Urine NO2
+ NO3 were
expressed as a ratio
with urine creatinine in
order to account for
differences in urine
concentration.

were ~4x higher than in
control subjects. Recovery
concentrations decreased
52% from baseline (p<0.01);
convalescent values did not
differ from the values in
controls (p<0.4).

cholera patients
were ~half of
those with
shigellosis both
upon admission
and upon
discharge and
concentrations
were much higher
in cases than in
controls, Such
striking
differences were
not observed for
urinary NO
results.

Median urinary NO ratios
were similar among those
with Shigella and V.
cholerae infection, both
upon admission and
discharge. Initial values
were ~2x higher than upon
discharge (p<0.05 and 0.01,
respectively). Control
median NO was of an
intermediate concentration
between cases’ admission
and discharge median
concentrations; the
difference between control
and case admission values
was NS.
Mean blood WBC counts
(SD):
• Shigellosis: 19.6 (3.3)
• Cholera: 8.3 (2.8)
• Controls: 7.1 (1.8)
Mean fecal WBC/high
power field (SD):
• Shigellosis: 38 (17)
• Cholera: 5 (2)
• Controls: 3 (1)
Serum NO correlated with
blood WBC count in
shigellosis cases at baseline
2
(r =0.92, p<0.01), but only

Serum NO
concentrations
correlated with
total blood WBC
in shigellosis
cases.

Comments
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Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

SBT values were
significantly lower
and L:R values
were significantly
higher among
Aboriginal
children with
diarrhea than
among those
without GI
symptoms. SBT
was also
significantly lower
among Aboriginal
controls than
among nonAboriginal
children without
diarrhea. This is
consistent with
previous reports
of high
prevalence of
clinically silent TE
in this population.

Abnormal L:R
ratios were defined
as >16; no
reference or
derivation was
provided for this
cut-point.

to a slight degree upon
2
discharge (r =0.26, no pvalue reported) and there
was no correlation among
the cholera cases. Serum
NO correlated with stool
volume at presentation
2
(r =0.85, statistically
significant per authors, pvalue not reported).
2009
Ritchie BK et al.
13C-sucrose breath
test: novel use of a
noninvasive
biomarker of
environmental gut
health
Sucrose breath test
(SBT) as a marker
of small bowel
mucosal damage vis
a vis sucrase
activity among an
Australian
Aboriginal
population. Also
compared SBT with
serum
lactulose:rhamnose
ratio (L:R)

66

Geometric mean.

Darwin and
Adelaide, Australia
4 mo-5 yr old
Aboriginal children
admitted to
hospital with
diarrhea.
Two control
groups:
1. Aboriginal
controls
admitted to
hospital with
non-GI
symptoms (50%
had pneumonia)
2. Healthy, nonAboriginal
controls
recruited from
community

Case-control
n=43;
n=18 Aboriginal
cases with AD
n=25 controls:
• 18 Aboriginal,
without diarrhea
• 7 nonAboriginal,
healthy

Blood Tests:
• L:R
(32 Aboriginal cases
and controls tested)
• C-reactive protein
(CRP)
• Mean Corpuscular
Volume (MCV)
• Hemoglobin
Breath Test:
13
C sucrose breath
test (SBT)

20/32 (63%) of Aboriginal
children had abnormal L:R
ratios.
66

Mean L:R (CI):
• Diarrhea cases: 31.8
(24.9, 40.7)
• Aboriginal controls
without diarrhea: 11.4
(8.5, 15.5),
significant difference
(p<0.0001)
SBT Mean (CI):

• Diarrhea cases: 1.9%

(0.9, 3.0), p<0.0001
compared to nonAboriginal controls and
p=0.004 compared to
Aboriginal controls
• Aboriginal controls: 4.1%
(3.0, 5.2), p=0.032
compared to nonAboriginal controls
• Non-Aboriginal controls:
6.1% (4.8, 7.3)
Significant differences were
observed between all three
groups.

SBT was
significantly
inversely

L:R test was not
conducted among
the non-Aboriginal
controls.
SBT/L:R
correlation analysis
was based on data
for Aboriginal
cases and controls
combined; stratified
analysis was not
reported and could
be of interest
considering the
large difference in
L:R observed
between these
groups.
Associations of
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Location and
Target Population

Design and
Sample Size

Biomarker

Results
SBT results were not
associated with wasting or
with patient age or
breastfeeding status.

Conclusion

Comments

correlated with
L:R.

MCV, CRP, and
hemoglobin with
SBT after adjusting
for potentially
confounding
variables were not
reported.

L:M was generally
normal (compared
to UK values) for
non-HIV-infected
infants, but
significantly
increased among
HIV-infected
subjects,
especially after 6
weeks.

Assessment of
association
between L:M and
neopterin was not
reported.

SBT and L:R were inversely
correlated (r=0.67; CI: 0.42,
0.62; p<0.0001). L:R
explained 45% of the
variance in SBT; diarrhea
explained 28% of variance.
SBT was associated with
increased MCV, relative risk
(CI)=3.9 (2.8, 5.0). SBT was
not associated with
hemoglobin or CRP.
2001
Rollins NC et al.
Feeding mode,
intestinal
permeability, and
neopterin excretion:
A longitudinal study
in infants of HIVinfected South
African women

Durban, South
Africa
1, 6, and 14 wk old
infants born to
HIV-infected
mothers.

Cohort
n=272

L:M as a marker of
gut mucosal
integrity and urinary
neopterin excretion
as a marker of cellmediated immunity
in infants with and
67
68

Lactulose and mannitol results were expressed in mg.
Geometric mean.

Urine Tests:
67
• Lactulose
• Mannitol
• L:M
• Neopterin

68

Mean L:M (CI):
• HIV-infected subjects:
• 1 wk: 0.12 (0.06, 0.27)
• 6 wk: 0.24 (0.15, 0.38)
• 14 wk: 0.24 (0.14,
0.44)
• Uninfected subjects:
• 1 wk: 0.13 (0.09, 0.19)
• 6 wk: 0.08 (0.06, 0.11)
• 14 wk: 0.09 ( 0.07,
0.13)
HIV-infection by 14 wk of
age was significantly
associated with increased
L:M.
A non-significant, positive
trend in neopterin excretion
was observed among HIV-

The increased
L:M in HIVinfected infants
was primarily
driven by
lactulose rather
than mannitol.
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without HIV infection

2000
Rollins NC et al.
Vitamin A
supplementation of
South African
children with
diarrhea: optimum
timing for improving
biochemical and
clinical recovery and
subsequent vitamin
A status
L:M as a marker of
intestinal
permeability and
urinary neopterin,
serum α-1 acid
glycoprotein, and Creactive protein as
markers of
inflammation among
children with severe
diarrhea

69
70

Location and
Target Population

Durban, South
Africa
6-60 mo old
inpatients or
outpatients with
severe diarrhea.

Design and
Sample Size

RCT
n=139;
n=66 received
vitamin A on
admission (group
1)
n=73 received
vitamin A after
clinical
improvement
(group 2)
Treatment
involved vitamin
A
supplementation
either on the day
of
admission or after
acute diarrheal
symptoms had
resolved.

Biomarker

Urine Tests:
69
• Lactulose
• Mannitol
• L:M
• Neopterin
Blood Tests:
• C-reactive protein
(CRP)
• α-1 acid
glycoprotein (AGP)
49 subjects received
urine testing:
• Group 1: n=25
• Group 2: n=24
Blood and urine were
tested on days 0 and
3.

For lactulose, mannitol, and neopterin results, excretion measurement was not specified.
Geometric mean.

Results

Conclusion

infected infants.

Higher neopterin
excretion by HIVinfected infants
was observed but
this was not
statistically
significant.

70

There were no differences
in mean L:M between
groups or within groups
between days 0 and 3,
although there was a
significant difference in
paired analysis within
individuals at the two time
points (data not presented,
and direction, magnitude
and degree of significance
not reported).

Mean L:M ratios
were very high
(~10x) (at
baseline and at
day 3 in both
groups) compared
to other studies in
this review. Study
authors
suggested (via
personal
correspondence)
that this could
have been due to
the severity of
illness in the
sample population
(children
hospitalized for
diarrhea).

Lactulose and mannitol
excretion were assessed
only in the paired analysis.
Lactulose excretion
decreased between days 0
and 3 (magnitude of effect
and degree of significance
not reported), while mannitol
excretion showed no
change.

Vitamin A
administration did
not result in
significant
improvement in
L:M, neopterin, or
AGP regardless
of timing of
vitamin A
administration.

Mean L:M:
• Group 1:
• Day 0: ~1.8
• Day 3: ~2.4
• Group 2:
• Day 0: ~1.2
• Day 3: ~0.7

Comments

Urine testing could
only be conducted
in the laboratory on
certain days; hence
only a subset of
subjects underwent
those tests.
Group 2 patients
had significantly
higher CRP, nonsignificantly higher
WBCs and AGP,
and lower retinol
and retinol-binding
protein
concentration
compared to group
1 at baseline.
Authors note that
these parameters
suggest that Group
2 patients might
have been more ill
at baseline. For the
subset of 49
patients
undergoing urine
72
testing, the mean
L:M and neopterin
concentrations
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
71

Mean neopterin and AGP
concentrations did not differ
between groups or within
groups on the different
study days or in the paired
analysis. When initial CRP
(~2x higher in Group 2
compared to Group 1,
p<0.004) was taken into
account, mean CRP on day
3 did not differ between the
2 groups. However in the
paired analysis, CRP
concentrations were
significantly different
between days 0 and 3.

Conclusion

Comments
were lower among
Group 2 than
Group 1 subjects
(NS). However,
baseline
differences in acute
phase and vitamin
A markers at
baseline were not
reported separately
for these 49
subjects.
Data for lactulose
and mannitol
excretion were not
reported
separately.
Rationale for
additional analyses
of these molecules
expressed as ratios
with creatinine was
not explained.
Authors suggest
that their 3-day
testing period
(based on their
previous work in a
different setting
[207] might have
been too short to
identify effect as
demonstrated by
McCullough et al.
at 10 days after
presentation [208].

72
71

Geometric mean.
Geometric mean.
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Study Outcomes of
Diagnostic Interest
2006
Samie A et al.
Cryptosporidium
species: preliminary
descriptions of the
prevalence and
genotype
distribution among
school children and
hospital patients in
the Venda region,
Limpopo Province,
South Africa

Location and
Target Population

Design and
Sample Size

Vhembe, South
Africa

Cross-sectional

0.1-88 yr olds from
semi-urban
community
included patients
hospitalized with
diarrhea or other
GI complaints as
well as students
attending nearby
schools.

n=26 <5 yr old:
• 22 hospitalbased subjects
• 4 school-based
subjects

Biomarker

Results

Conclusion

Comments

Stool Test:
Lactoferrin

16/22 patients and 0/4
students were lactoferrin
positive.

Lactoferrin
prevalence was
high among
children
hospitalized with
diarrhea or other
GI symptoms,
regardless of
Cryptosporidium
status.

Among the entire
study cohort of all
ages, lactoferrin
results were similar
among hospitalized
patients regardless
of Cryptosporidium
status (influence of
HIV infection was
not reported).
Among school
children, lactoferrin
was more
frequently found to
be positive among
those infected with
Cryptosporidium;
statistical testing
was not reported.

While examination of
lactoferrin association with
history of diarrhea or with
Cryptosporidium infection
was not reported, only 3/22
and 16/22 hospitalized
patients and 2/4 and 3/4
school children were
positive for Cryptosporidium
and had a history of
diarrhea, respectively.

Stool lactoferrin as a
marker of intestinal
inflammation among
hospitalized patients
and school children

Lactoferrin was
not found among
school-recruited
children, most of
whom did have a
history of
diarrhea. Two of
the four school
children were
Cryptosporidiumpositive.

Lactoferrin results
were graded based
on agglutination
reaction positivity
with increasing
dilution and was
considered
negative if there
was no reaction at
1:25.
Some subjects
were breastfed and
were tested for
lactoferrin.

2004
Sarker SA et al.

73

Geometric mean.

Dhaka,
Bangladesh
2-5 yr old

Case-control
n=25:

Blood Test:
Iron (absorption test)

73

Mean iron absorption from
ferrous (Fe) sulfate and Fe
fumarate:
• Uninfected children:

Iron absorption
from Fe fumarate
was significantly
lower than from

Data on iron
absorption among
2-5 yr olds are
limited, making
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Reference and
Study Outcomes of
Diagnostic Interest
Helicobacter pylori
infection, iron
absorption, and
gastric acid
secretion in
Bangladeshi
children

Location and
Target Population

Design and
Sample Size

apparently healthy
children from a
periurban setting,
screened for iron
deficiency and H.
pylori.

n=13 cases
infected with H.
pylori

Xi-Chou (town) &
Yun-Nan
(province), China

Cross-sectional

Biomarker

Results

Conclusion

Comments

15.6% and 5.4%,
(p<0.001)
• Infected children before
treatment: 19.7% and
5.3%, (p<0.0001)
• Infected children after
treatment: 22.5% and
6.4%, (p<0.0001)
• H. pylori treatment did not
significantly affect
absorption (Fe sulfate or
fumarate), p=0.3

Fe sulfate.

comparison of
results from this
study setting
difficult.

Stool Test:
Endogenous fecal
zinc (EFZ)

Mean (SD):
• FAZ: 0.35 (0.12)
• AZ (mg/d): 0.63 (0.24)
• EFZ (mg/d): 0.67 (0.23)

Urine Test:
Zinc excretion to
measure fractional
absorption of zinc
(FAZ) and total
absorbed zinc (TAZ)
following radiolabeled
zinc administration

The quantity of absorbed
zinc was lower than
physiologic requirements.

Zinc absorption
was lower than
physiologic
requirements and
EFZ was higher
than expected.

n=12 controls not
infected with H.
pylori

Iron absorption
among children with
iron deficiency
anemia with and
without H. pylori
infection
2006
Sheng XY et al.
Major variables of
zinc homeostasis in
Chinese toddlers
Differences in zinc
absorption in
healthy toddlers with
a high prevalence of
zinc deficiency.

n=43

19-25 mo olds
recruited from a
remote small town
and 2 surrounding
rural villages.
48% of children
had plasma zinc
concentrations
below 2.5th
percentile. Dietary
zinc intake was
low.
There was a high
prevalence of
stunting among
the subjects.

2008

Aligarh, India

Cross-sectional

Sherwani K et al.

1-12 yr olds (mean
age 51.2 mo) from

n=19

Duodenal biopsy,
method not specified:
Histopathology

Results do not
support the
hypothesis that H.
pylori infection
influences
absorption of
water-soluble (Fe
sulfate) or nonwater-soluble (Fe
fumarate) iron
compounds.

Zinc absorption was ~80%
of estimated physiologic
requirement and equivalent
to the amount of
endogenous zinc excreted
via the intestine; it was
expected that absorbed zinc
would exceed excreted zinc
[144, 187, 194, 195].

The authors note
that the results
are difficult to
explain and
specifically state
that they do not
think (though
without clear
justification) that
enteropathy is
prevalent in the
population and
therefore could
not be a
contributing
factor.

Six patients had partial
villous atrophy and nonspecific duodenitis by
biopsy.

Biopsy identified
abnormal
histopathology in
approximately 1/3

There was no statistically
significant difference in any
laboratory value between
the town and village groups.

The 6 children with
partial villous
atrophy were
thought to have
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Reference and
Study Outcomes of
Diagnostic Interest
Prevalence of iron
deficiency anemia in
chronic diarrhoea
and celiac disease A western UP
experience
Duodenal biopsy in
patients with PD

Location and
Target Population

Design and
Sample Size

Those with
negative CD workup were subjects
of interest for this
review.
Cairo, Egypt

Case-control

Soliman SM et al.

6-24 mo olds with
diarrhea were
recruited from AlSahel teaching
hospital
malnutrition clinic.

n=30;

Blood cell and
albumin markers
among infants with
acute, persistent or
no diarrhea, and
effects on these
markers after 10
days of
supplementation
with micronutrient
mixture (containing
vitamin A, zinc and
other
micronutrients)
among subjects with
and without diarrhea

Results

an urban setting
with PD recruited
from pediatric
outpatient and
inpatient units.

2003

Role of
micronutrient
mixture in acute and
persistent diarrhea
in infants and its
impact on nutritional
status

Biomarker

5/6 PD cases and
10/14 AD cases
had some degree
of malnutrition.
Infants with PD
had significantly
lower vitamin A
and zinc stores
compared to
controls. Those
with AD had
significantly lower
vitamin A stores.

n=20 cases:
• 6 with PD
• 14 with AD
n=10 healthy
controls*
* Controls were
age- and sexmatched to
cases.

Blood Tests:
• Complete blood
count and
differential
• Red cell measures:
• Mean
corpuscular
volume (MCV)
• Mean
corpuscular
hemoglobin
(MCH)
• Mean
corpuscular
hemoglobin
concentration
(MCHC)
• Transferrin
saturation
• Albumin

Mean baseline hemoglobin
was significantly lower in
infants with AD and PD
(p<0.05 for each group)
than in controls
Mean MCV and MCH were
lower in those with AD
(p<0.025 and p<0.01,
respectively) and PD
(p<0.01 for both markers)
compared to controls.
Mean lymphocyte counts
among PD cases were low
compared to those of
controls (p<0.01).
Other markers did not vary
significantly at baseline.
However, among infants
with PD, mean albumin was
abnormally low, although it
was not significantly
different compared to
controls or those with AD.
Mean albumin (g/dL) (SE):
• PD: 2.9 (0.27)
• AD: 3.29 (0.25)
• Controls: 3.37 (0.21)

Conclusion

Comments

of patients who
did not have CD,
but did not identify
PD etiology in the
remainder who
did not have CD.

SBBO as they
recovered after
treatment with
broad spectrum
antibiotics.

Albumin and
many hematologic
markers were low
at baseline
among infants
with diarrhea,
especially in
those with PD,
compared to
those without
diarrhea; some of
these differences
were statistically
significant.
Parameters
generally
normalized after
micronutrient
supplementation.

Information on
control recruitment
and
anthropometrics
were not specified.
Sample size was
small when
stratified by
case/control
groups, especially
for PD cases (n=6).
Controls were
reported to have
been matched to
cases, yet there
were half the
number of controls
than cases and
statistical testing
(student’s t-test)
was not
commensurate with
matched casecontrol
methodology.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Biopsy results
might show
inflammatory
damage in cases
with no
macroscopic
damage visible.

Spanish language
article.

Following micronutrient
supplementation, mean
hemoglobin, MCV,
lymphocyte counts and
albumin increased in both
diarrhea groups to
concentrations on par with
control baseline
concentrations (albeit
increases were NS except
within the PD group). MCH
improved to concentrations
on par with the control
group only among the
infants with AD.
2003

Santiago, Chile

Cross-sectional

Tassara O et al.

0-12 yr old
(median 9 mo)
HIV-infected
children treated in
hospital. A high
proportion had PD.

n=11

Gastrointestinal
diseases in children
infected with the
human
immunodeficiency
virus

Endoscopic
upper GI biopsy
including esophagus,
stomach, and/or
duodenum:
• Gross endoscopic
visualization
• Histopathology

Endoscopy and
biopsy among HIVinfected children

Biopsies of esophagus,
stomach or duodenum
showed inflammatory
changes of varying degree
in all 11 subjects.

Inflammatory
changes identified
in the digestive
system were not
specified by site
(i.e. esophagus,
stomach or
duodenum).
Results were not
stratified by
presenting
symptoms,
including PD.

2000

Orissa State, India

RCT

Thurnham DI et al.

Subjects were
recruited from 2
sources:
1. Hospital-based
infants admitted
for “diarrheal or

n=174;

Innate immunity, gut
integrity, and
vitamin A in
Gambian and Indian

Macroscopic inflammatory
changes were observed on
endoscopy in the
esophagus, stomach or
duodenum in 2 subjects.

n=94 hospitalbased
• 31 received
vitamin A at day

Urine Test:
L:M
For hospital-based
subjects, L:M was
assessed at baseline,
discharge from

Mean L:M was ~3-fold
higher among hospitalized
compared to clinic patients
at baseline. Within the
allocation groups, mean
baseline L:M did not differ
for either the hospitalized or
clinic subjects.

Mean L:M values,
including postintervention
values, were 2-5
times higher than
those observed in
the UK [209].

Precise numerical
values were not
reported, rather
L:M results were
portrayed in figures
with units
expressed in mg,
making it difficult to
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Reference and
Study Outcomes of
Diagnostic Interest
infants
L:M as a marker of
intestinal integrity
among children
receiving vitamin A
supplementation

Location and
Target Population

Design and
Sample Size

respiratory
disease,” mean
age 9 mo
2. Clinic-based
infants with
“minor
ailments”, age
not specified

1
• 32 received
vitamin A at
discharge (up to
day 5)
• 31 received
placebo
n=80 clinicbased*
Clinic-based
subjects were
randomized to
receive vitamin A
weekly for 8 wk
or placebo.
* Number of
subjects in each
treatment group
was not specified.

Biomarker
hospital, and 10 or 30
days after discharge.
For clinic-based
subjects, L:M was
assessed at baseline,
4, and 8 wk.

Results

Conclusion

Comments

Among the hospital cohort,
mean L:M declined
significantly in the two
vitamin A groups compared
to the placebo group, and
remained lower at day 30
among the treatment
groups, but the difference
was no longer significant
compared to the placebo
group.

L:M reduction was
accelerated
among vitamin Asupplemented
children, but endof-study mean
values did not
differ statistically
between
allocation groups
in either the clinic
or the hospital
cohorts.

compare these
results to those of
other studies.

Among the clinic cohort,
mean L:M reduction was
accelerated in vitamin Asupplemented children.
However, mean L:M did not
significantly differ between
treatment groups at any
time point.
The rate of decline in L:M
was most steep among the
vitamin A-treated
hospitalized patients, in
whom the mean L:M value
decreased by 63% over 30
days, followed by placebotreated hospitalized
patients, with a decrease of
38% over 30 days. Mean
L:M decreased by 57% in
the vitamin A-treated clinic
patients, while there was no
change in L:M among the
clinic placebo group.

Information on
study design, such
as randomization
scheme, was
limited.
The article also
reported reanalyzed data from
a 1991 report from
The Gambia [209].
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Study Outcomes of
Diagnostic Interest
2009
Trehan I et al.
A randomized,
double-blind,
placebo-controlled
trial of rifaximin, a
nonabsorbable
antibiotic, in the
treatment of tropical
enteropathy
L:M,
sucrose:lactulose,
and
sucralose:lactulose
as markers of small
intestinal, gastric,
and colonic
permeability,
respectively, among
those receiving
rifaximin or placebo

Location and
Target Population

Design and
Sample Size

Limela, Malawi

RCT

All 3-5 yr olds from
the village were
recruited.

n=144;
n=72 received
rifaximin for 7
days
n=72 received
placebo
It was presumed
that if SBBO is
the etiology for
enteropathy,
treatment with
rifaximin would
result in improved
intestinal
integrity.

Biomarker

Results

Conclusion

Comments

Urine Tests
74
• Lactulose
• Mannitol
• Sucrose (SUC)
• Sucralose (SCL)
• L:M
• Sucrose:lactulose
ratio (SUC:L)
• Sucralose:lactulose
ratio (SCL:L)

At enrollment:
• Mean mannitol (SD):
• Treatment: 9.57 (5.24)
• Placebo: 10.29 (6.62)
• Mean lactulose (SD):
• Treatment: 0.30 (0.18)
• Placebo: 0.34 (0.25)
• Mean SUC (SD):
• Treatment: 0.062
(0.04)
• Placebo: 0.074 (0.058)
• Mean SCL (SD):
• Treatment: 0.51 (0.29)
• Placebo: 0.58 (0.53)
75
• Mean L:M (SD):
• Treatment: 0.18 (0.12)
• Placebo: 0.17 (0.09)
• Mean SUC:L (SD):
• Treatment: 0.50 (0.34)
• Placebo: 0.64 (0.90)
• Mean SCL:L (SD):
• Treatment: 0.42 (0.32)
• Placebo: 0.39 (0.23)
• For both groups
combined:
• 76% had L:M >0.10
• 34% had L:M >0.20

There was a high
proportion with
elevated L:M
which did not
change with
rifaximin
treatment.

Methodological
differences in
specimen
collection and
testing, in particular
for SCL excretion,
might account for
some differences in
values compared
to other studies.

Subjects were tested
before and after
treatment.

No significant postintervention differences
were observed in any
fractional sugar excretion or
dual sugar test, including
among children with
elevated pre-intervention
L:M.

74
75

Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.
Type of mean for sugar ratios not specified.

Baseline L:M
measurements in
this study
resembled those
of another
Malawian
population in
similar
environmental
conditions [120].
SCL excretion in
this population
was similar to that
found in healthy
American children
(0.4%), while
SCL:L was
comparatively
lower (0.8) and
driven by
lactulose [210].
SCL:L might be a
better marker of
colonic
permeability [211213]. Results from
this study
potentially
indicate that
colonic

This was the first
use of SCL for sitespecific absorption
testing in a
developing country
setting.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

permeability was
normal.
Few data exist on
SUC excretion.
Results in this trial
are similar to
those found in
another Malawian
population (0.06%
SUC excretion)
[120] and high
compared to
healthy older
children from
developed
country settings
(0.02-0.03%)
[210, 212].
2008

Fortaleza, Brazil

Cross-sectional

Vieira MM et al.

2 mo-9 yr olds
(mean age 41 mo)
from an
impoverished
urban community,
eligible if HAZ
score <median
for their
community.

n=102

Carotenoids, retinol,
and intestinal barrier
function in children
from northeastern
Brazil
L:M as marker of
intestinal barrier
function, fecal
lactoferrin and
leukocytes as
markers of intestinal
inflammation, and
CRP and AGP as
acute phase
reactants among
76

Urine Tests:
76
• Lactulose
• Mannitol
• L:M
(97 tested)

48.5% had abnormal L:M.

Stool Tests:
• Lactoferrin
(93 tested)
• Leukocytes

L:M was associated with
levels of common dietary
carotenoids, primarily driven
by lactulose. However, the
association was not always
statistically significant, and
the direction of association
varied depending on
precursor.

Blood Tests:
• C-reactive protein
(CRP)
• α-1-acid
glycoprotein (AGP)

Lactulose and mannitol results were expressed as % of dose administered.

L:M and excretion of each
sugar separately did not
vary with retinol
concentration.

40% of stool samples were
positive for lactoferrin.

Almost half of
subjects had
increased L:M,
and ~40% of
subjects had
increased
lactoferrin.
While serum
retinol
concentrations
were not
associated with
L:M, serum
carotenoids were;
authors suggest
that these retinol
precursors might
be more sensitive
predictors of

L:M threshold for
abnormal values
was defined as
>0.0864 [214]. Cutoff values for
lactoferrin positivity
were not
described.
Relationships
between acute
phase proteins and
measures of
intestinal
permeability or
inflammation were
not reported.
Relationships
between L:M and
lactoferrin or fecal
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Reference and
Study Outcomes of
Diagnostic Interest
children with varying
vitamin A status

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

1% of stool samples were
positive for fecal leukocytes.

impaired intestinal
function.
However, the
reported direction
of association
varied, making
interpretation of
these results
unclear.

leukocytes as well
as those between
retinol or
carotenoids and
lactoferrin or fecal
leukocytes were
not reported.

L:M values were
elevated in this
population, with
no significant
change after the
intervention.

The relationships
between L:M and
growth parameters,
immuno-globulins,
and acute phase
proteins were not
reported.

30% of stool samples were
positive for parasites but
this had no impact on L:M
results, lactoferrin, or acute
phase reactants.

2007
Williams EA et al.
A double-blind,
placebo-controlled,
glutaminesupplementation
trial
in growth-faltering
Gambian infants
L:M and plasma
immunoglobulins
and acute phase
reactant proteins
(albumin, C-reactive
protein, and alpha1-antichymotrypsin)
in community-based
Gambian infants
enrolled in a
glutamine trial

77

Geometric mean

West Kiang region,
Gambia
4-10 mo olds from
a rural area
followed during the
5-month rainy
season and for 6
months afterward.

Cohort
n=72
Glutamine or
placebo of
nonessential
amino acids was
orally
administered
twice daily during
rainy season; L:M
ratio was
measured
monthly, and
plasma samples
were collected 3
times.

Urine Tests:
76
• Lactulose
• Mannitol
• L:M
Blood markers
• C-reactive protein
(CRP)
• Alpha-1
antichymotrypsin
(ACT)
• IgA
• IgG
• IgM
• Albumin

77

Mean L:M (CI):
• Baseline:
• Glutamine group: 0.33
(0.25, 0.43)
• Placebo group: 0.33
(0.26, 0.41)
• Post-intervention:
• Glutamine group: 0.29
(0.23, 0.35)
• Placebo group: 0.26
(0.21, 0.32)
Mean excretion of lactulose
(CI):
• Baseline:
• Glutamine group: 0.21
(0.16, 0.28)
• Placebo group: 0.20
(0.15, 0.26)
• Post-intervention:
• Glutamine group: 0.17
(0.13, 0.21)
• Placebo group: 0.14

None of the
plasma markers
differed
significantly
between
treatment and
placebo groups,
either at baseline
or at the end of
supplementation.
Growth outcomes
did not differ
significantly
across treatment
groups.

Exclusively
breastfed children
were excluded
from study
participation due to
assessment of
stool lactoferrin.
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results
(0.11, 0.18)
Mean excretion of mannitol
(CI):
• Baseline:
• Glutamine group: 2.65
(2.02, 3.48)
• Placebo group: 2.50
(1.87, 3.36)
• Post-intervention:
• Glutamine group: 2.48
(1.99, 3.11)
• Placebo group: 2.14
(1.62, 2.82)
L:M values did not differ
significantly between
treatment groups before or
following intervention.
However, a repeated
measures ANOVA showed
that during supplementation,
L:M values were borderline
elevated among the
glutamine-supplemented
group relative to the placebo
group (p=0.05), counter to
expectation.
Neither ACT, CRP, albumin,
nor immunoglobulins IgA,
IgG, or IgM differed
significantly between
treatment and placebo
groups, either at baseline or
at the end of
supplementation.
Mean levels of IgA and IgG
increased during the study
(p <0.001), while IgM levels

Conclusion

Comments
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Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

Comments

Subclinical
mastitis was not
associated with
magnitude of L:M.

Actual L:M values
were not reported
but are found in a
companion study,
also included in
this review [119].

did not. Concentrations of
each of these
immunoglobulins did not
differ between treatment
and placebo groups.
Plasma albumin, ACT,
and CRP values showed no
change over the course of
the study.
Proportions of children with
elevated CRP ranged from
30-41% at different
collection time points. The
glutamine intervention had
no effect on proportion of
children with elevated CRP.
Treatment and placebo
groups experienced
decreases in WAZ, HAZ,
and MUAC coinciding with
the rainy season; however,
there was no significant
difference observed
between the groups for any
of these parameters.
Treatment and placebo
groups did not differ in
morbidity indices (i.e.
percentage of time reported
with a particular illness or
illness overall).
2000
Willumsen JF et al.
Subclinical mastitis
as a risk factor for

Durban, South
Africa
HIV-infected
breastfeeding
mothers and their

Cross-sectional
analysis of
baseline data
prior to
randomization for
an RCT

Urine Test:
L:M

There was no significant
association between L:M
and subclinical mastitis as
measured by milk Na/K.
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Reference and
Study Outcomes of
Diagnostic Interest
mother-infant HIV
transmission

Location and
Target Population

Design and
Sample Size

infants followed up
to 14 wk of age.

n=104 mothers

L:M as a marker of
infant intestinal
permeability and its
relationship with
subclinical maternal
mastitis

Women recruited
from antenatal
clinic via a vitamin
A supplementation
trial to reduce
mother-to-child
HIV transmission.

n=108 infants (4
pairs of twins),
(26 were HIVinfected by 3 mo
of age)

2000

Lima, Peru

Case-control

Zhang Y et al.

0-36 mo olds with
watery diarrhea
admitted to oral
rehydration unit of
hospital.

n=36;

Lactulose-mannitol
intestinal
permeability test in
children with
diarrhea caused by
rotavirus and
Cryptosporidium
L:M as a marker of
intestinal
permeability in
children with
diarrhea

n=29 cases:
• 15 with C.
parvum alone
• 7 with rotavirus
alone
• 7 with bacteria
(alone or with
rotavirus or
Cryptosporidiu
m)
n=7 controls with
unknown etiology

Biomarker

Results

Arithmetic mean.

Comments
The study group in
Willumsen, et al.
represents a
subsample of the
study population
reported in the
companion study.

Urine Test:
L:M
Enrollment and
convalescent (at day
20) L:M ratios were
assessed.

78

Mean L:M (SE) at day 1,
day 20:
• Rotavirus only: 0.67
(0.38), 0.19 (0.09)
• Cryptosporidium only: 0.76
(0.43), 0.28 (0.14)
• Bacterial infection: ranged
from 0.2-0.87, 0.11-0.99
• Unknown etiology: 0.26
(0.12), 0.29 (0.18)
Mean L:M ratios
significantly differed
between the unknown
etiology and both the
rotavirus (p< 0.01) and
Cryptosporidium groups
(p<0.05) at baseline, but
not at day 20.
Mean L:M ratios decreased
between baseline and day
20 for both the rotavirus
(p<0.001) and
Cryptosporidium (p<0.05)
groups.
Among the group of
subjects with enteric
bacterial infections, the

78

Conclusion

L:M ratios were
significantly
elevated in
children with
rotavirus or
Cryptosporidium
infection
compared to
those with
diarrhea not
caused by
rotavirus,
Cryptosporidium,
or identifiable
bacteria.
Mean L:M did not
change
significantly
among those with
diarrhea of
unknown
etiology, but did
significantly
decrease among
those infected
with rotavirus or
Cryptosporidium,
reaching ratios

Appendix 7. Evidence table of all studies included in the review.
Reference and
Study Outcomes of
Diagnostic Interest

Location and
Target Population

Design and
Sample Size

Biomarker

Results

Conclusion

causative agents identified
and mean L:M ratios
(baseline, day 20) were:
Campylobacter jejuni and
rotavirus infection (0.86,
0.18), C. jejuni and
Cryptosporidium infection
(0.87, 0.53), Salmonella sp.
(0.2, 0.11), C. jejuni (0.69,
0.99), and Aeromonas sp.
(0.38, 0.11). The L:M ratios
of this group of seven
infants were not included in
the statistical analyses.

similar to those
with diarrhea of
unknown
etiology.

Comments

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these
studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.
Further details on L:M studies can be found in Table 14.
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval,
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins,
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G,
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium
99, T3=triiodothyronine, T4 = thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score),
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)
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